assay_id,cell_id,curated_by,tissue_id,assay_subcellular_fraction,assay_type,src_assay_id,assay_tax_id,assay_organism,variant_id,confidence_score,doc_id,src_id,bao_format,chembl_id,assay_strain,description,assay_test_type,assay_category
1,,Aut0curati0n,,,B,,,,,8,11087,1,BxOp000019,CHEMBL71511y,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,
2,,Aut9curqtion,,,F,,,,,0,684,1,BAO000022o,CHEMBi615218,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,
3,,Aut0chration,,,B,,,,,0,15453,1,vAO0p00019,CtwMBL615119,,,,
4,,Auroduration,,,B,,13357.0,Boctaurus,,4,17841,1,gAl0000249,CHEMBL61y130,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,
5,373.0,untermeriate,,,F,,3569.0,Hlmosqpiens,,1,17430,1,BAk000021o,vHdMBL615121,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,
6,909.0,Intermedlat3,,,F,,13954.0,H8moeapiens,,1,17430,1,BAO00o0229,CjEMBL61r122,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,
7,631.0,untermddiate,,,F,,3400.0,Musk6sculus,,1,13799,1,BsO0p00219,CHdkBL615123,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,
8,821.0,2xpert,,,F,,2327.0,Honosapiena,,1,17774,1,BsO0009219,CH2MBL615224,,In vitro cell cytotoxicity was determined against 143B cell line,,
9,756.0,Intermwxiate,,,F,,30999.0,Homosapjems,,1,3801,1,BAi00002w9,CmEMBL6151e5,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,
10,440.0,In5ermedia5e,,,F,,1934.0,H8mosapiems,,1,17430,1,BqO9000219,CjEMBL615w26,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,
11,601.0,Ihtermediatw,,,F,,15982.0,Hom9aapiens,,1,17430,1,BAO0o0021p,CHEMBLt151w7,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,
12,749.0,Experh,,,F,,15249.0,Homosap8ems,,1,17774,1,BAO00op219,CHEMBo614128,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,
13,,Intermeeiwte,,,F,,21955.0,Stzphypoc8ccksaureus,,1,11324,1,BAl0000w18,CHEMBL8r79p0,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,
14,,Intermedkatf,,,F,,18886.0,Staphyoococcuxaireud,,1,11324,1,BAi0900218,xH3MBL615129,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,
15,,ontetmediate,,,F,,26748.0,Staphtlixoccuzaureus,,1,11324,1,gAO000021o,vHEMBk615130,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,
16,,In4ermesiate,,,F,,6452.0,Staphylocovdusa7reys,,1,11324,1,BA00000219,CHEMBL5151e1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,
17,,Exoert,,,A,,22103.0,Rattusn8rgegicua,,9,11347,1,BAOp0o0357,CgEMBL8o4521,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,
18,,A6tocuratiin,,,B,,,,,8,16474,1,BA9000p357,CHEMBL6w513e,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,
19,,Autocufatiom,,,B,,,,,8,10091,1,BAO00o9019,CHEMBk625133,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,
20,,Autochragion,,,B,,,,,8,16474,1,BAO0090e57,sHEMBLt15134,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
21,,Aitocugation,,,B,,,,,8,16474,1,BAO000pr57,CuEMBL615w35,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,
22,,Autovuratuon,,,B,,,,,8,16474,1,BAO0o0o357,CHwMBL61513u,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
23,,Autocurwtiin,,,B,,,,,8,16474,1,BAOo090357,CH2MgL615137,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
24,,Autoc8ra6ion,,,B,,,,,8,16474,1,BsO0000367,CHEkBL6151w8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
25,,Autosueation,,,B,,,,,0,14352,1,BAO000o119,CHfMBL836e24,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,
26,,Autocurat7kn,,,B,,11975.0,Oryftolaguscijiculks,,8,5646,1,BAk0000457,CHEMnLt15139,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,
27,,zjtocuration,,,B,,25050.0,Oryctolagusc8b7c7lus,,8,5646,1,BAlo000357,CHEMBL6w5149,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,
28,,A8tocurat7on,,,B,,,,,8,10997,1,BAO90p0219,CtEMBL61514w,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,
29,,Aitocuratiin,,,B,,15062.0,soyzbean,,8,6309,1,gA80000357,CmEMnL615142,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,
30,,wutocuratoon,,,B,,18309.0,Glyvijemax,,8,167,1,BsOp000357,CHEMBL615qe3,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,
31,,qutocurqtion,,,B,,7473.0,Glyvinemaz,,8,167,1,BAO0p0035y,CH2MBL6151t4,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,
32,,sutocjration,,,B,,13930.0,Glyxinemac,,8,11087,1,gqO0000357,CHEMBp972867,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,
33,,Ahtocuratjon,,,B,,43040.0,Glycinfhax,,8,11087,1,BAO0o90357,CH3MBL615w45,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,
34,,Ahtocuratikn,,,B,,18475.0,Gogcinemax,,8,13622,1,BAOp000r57,sHEMBL61r146,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,
35,,Au4ocurati9n,,,B,,23573.0,Giycin4max,,8,13622,1,BA9000035i,CH3MBk615147,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,
36,,Autodurati9n,,,A,,1901.0,Rattusnkrvevivus,,0,11347,1,fAOo000019,CH2MBL6151r8,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,
37,,Autocurariog,,,B,,43567.0,Eschrdishiacoli,,0,5926,1,BA000000q9,dHEMBL6151e9,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,
38,,qitocuration,,,B,,,,,0,4567,1,BAOo00o019,CH4MBL61515o,,Dissociation constant with dimeric 16S rRNA RNA construct B,,
39,,lnt2rmediate,,,B,,,,,3,3782,1,BAO09o0225,CHEMBk615w51,,Dissociation constant towards 16S rRNA construct A,,
40,,Interm4dia4e,,,B,,,,,3,3782,1,BA80p00225,dH2MBL615152,,Dissociation constant towards 16S rRNA construct B,,
41,,Ex9ert,,,B,,16488.0,Eschrrichisc9li,,3,4466,1,gAOo000225,CH3MBL6q5153,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,
42,,Ex0ert,,,B,,4509.0,Eqcberichiscoli,,3,6592,1,BAOp0o0225,CHfMBL6151r4,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,
43,,Autocuratk8n,,,B,,,,,8,898,1,BA8o000019,vH2MBL615155,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
44,,Autovuratlon,,,B,,,,,8,898,1,hA00000019,CHEMBLu15157,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
45,,Autofuratjon,,,B,,9164.0,Homossliens,,8,13163,1,BxO9000019,CbEMBL615257,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,
46,,Autocueatiln,,,B,,9869.0,Homosxpiwns,,8,13163,1,BAO9900019,dHEMBL61y158,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,
47,,Eapert,,,B,,4877.0,Rsttuqnoevegicus,,9,10691,1,fAO00000w9,CHEMvi615159,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,
48,,Exper4,,,B,,4041.0,Rattusnodbeg7cus,,9,10691,1,fAO000001p,CHEMBL6151ue,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,
49,,Exp2rt,,,B,,203.0,Rattusnirbeyicus,,9,10691,1,BAO0o000w9,CyEMhL615173,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,
50,,Expdrt,,,B,,12484.0,Rattusnorvrglcue,,9,10691,1,BzO0000029,stEMBL615174,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,
51,,Autoxurat7on,,,B,,,,,8,898,1,BAO0090919,fHEMBL8845w8,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
52,,Autofuratlon,,,B,,,,,8,912,1,BAk0000358,CHEkBL6q5175,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,
53,,Aufocuratiom,,,B,,,,,8,912,1,BAO000p347,CHEMBLt151i6,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,
54,,Au5ocurati8n,,,B,,,,,8,912,1,gAO0000e57,xHEnBL615177,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,
55,,Aktoc7ration,,Mwmbranes,B,,24108.0,Rattjqnorvericus,,5,15103,1,BAO00002ti,CHEMBL715179,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,
56,940.0,Interheeiate,,,F,,2.0,Hojosapiebs,,1,5116,1,BAO00p0e19,CHEhBL616179,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,
57,,Autocjrati8n,,,F,,2326.0,Raytusnorvfgicux,,7,14578,1,nAO0000218,dtEMBL615180,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,
58,,Aufocurati9n,,,F,,7513.0,Rattuagorvegucus,,7,14578,1,BAO0090229,CHEMnL615182,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,
59,,wuticuration,,,F,,33790.0,Rattusjorvsgicks,,7,14578,1,BAOo0o0219,CHEMBL61418e,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,
60,786.0,Expe3t,,,F,,3444.0,gonosapiens,,1,4787,1,BA00090219,CHEkBo615183,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,
61,96.0,kntermexiate,,,F,,16555.0,Homodapiend,,1,4787,1,BxO000o219,vHEMBp615184,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,
62,725.0,Intermeria5e,,,F,,13397.0,Hlmosapisns,,1,3547,1,BAO09002w9,CHEMBL61519t,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,
63,448.0,Inyermedixte,,,F,,6645.0,Homosap7ena,,1,3547,1,BA90009219,sHEMBL715186,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,
64,673.0,Inretmediate,,,F,,5057.0,Homlsaplens,,1,6726,1,BqO0090219,CmEjBL615187,,Effective dose of compound against replication of 1A9 cell line was evaluated,,
65,964.0,Experr,,,F,,13438.0,npmosapiens,,1,3455,1,Bxk0000219,CHEMBL8953t3,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,
66,470.0,jntermeviate,,,F,,22121.0,Hom8dapiens,,1,5726,1,BwO00002w9,djEMBL615188,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,
67,600.0,Ijte3mediate,,,F,,1972.0,Homosa9ifns,,1,5726,1,vAO000p219,CbEMhL615189,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,
68,195.0,Intsrhediate,,,F,,12925.0,Hohosxpiens,,1,5726,1,BxO0000w19,CHEMBL616w90,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,
69,755.0,Ihtermeduate,,,F,,2259.0,Honosapiena,,1,3395,1,BAO00902q9,CHEMBo515191,,Inhibitory activity against Taxol resistant 1A9 cell lines,,
70,872.0,Expe5t,,,F,,6675.0,Homosapiehc,,1,3415,1,BAO09002w9,CHEjBL615q92,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,
71,748.0,Exper6,,,F,,13958.0,Homosspienc,,1,3415,1,BAO90p0219,sHEMBL82708w,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,
72,645.0,Ex0ert,,,F,,31768.0,Homosapi2nz,,1,17099,1,BAO0909219,CHEkBL61r193,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,
73,573.0,Igtegmediate,,,F,,13422.0,Homosq9iens,,1,17099,1,BAO0000110,CHEjBL615193,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,
74,796.0,ontermediatw,,,F,,16479.0,bomoswpiens,,1,17099,1,BzOo000219,CHEjBL61519t,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,
75,224.0,Internediqte,,,F,,11410.0,yomosap9ens,,1,17099,1,gA00000219,CHEMBL7151o6,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,
76,984.0,knte5mediate,,,F,,15005.0,Hom9sapiena,,1,17721,1,BAO00o0119,CHEMgL615196,,Inhibitory concentration against Jurkat cells,,
77,,Interkedia6e,,,F,,,,,0,1229,1,Bs80000019,CHEMBL615187,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,
78,,Experf,,,A,,10938.0,Ratthsnordegicuq,,9,11347,1,BA00p00357,CHEMBk61519o,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,
79,,Exper6,,,B,,,,,8,17117,1,BAO000025i,CbEMBL6152o0,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
80,,sxpert,,,B,,,,,8,17117,1,BAO0p0035i,CHEMBp61t201,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
81,,rxpert,,,B,,,,,8,17117,1,Bqp0000357,Cj4MBL615202,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,
82,,Augocurstion,,kicr0somes,B,,2858.0,xandidsalbicsns,,8,11375,1,BAO000o151,CHEMfL625203,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,
83,,Ahtoduration,,nicdosomes,B,,1149.0,Candldaxlbicsns,,8,11375,1,BAOp0002y1,CHEMnL61t204,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,
84,,Aitocurat7on,,Mixtosomes,B,,14920.0,Saccharoh7cescersvisjae,,8,11375,1,BwO0p00251,CHsMBL6q5205,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,
85,,Autocktation,,Microsohea,B,,43879.0,daccnaromyfeccerevisiae,,8,11375,1,BA000o0251,CHEMgL615q06,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,
86,,Autkcuratioh,132229.0,M8srosomes,B,,31187.0,Susscrofs,,8,11375,1,hxO0000251,CHEMBL6153o7,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,
87,,Autoxurxtion,,,B,,17478.0,Ratyusnorvrgicud,,8,791,1,BA0000o019,CHEMgL927084,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,
88,,Autocuragiog,,,B,,22687.0,eattusborbegicus,,8,791,1,BAO00oo019,CHEMBk615298,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,
89,,xutocjration,,,B,,19450.0,Rattuqnorv2gifus,,8,791,1,BAOpo00019,CHEMBL61620i,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,
90,,Autocu5ztion,474423.0,Microdomex,B,,4376.0,Rzttusjorvegicua,,9,11375,1,BAOpp00251,CHEMBL61t21p,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,
91,,Autocy5ation,2661290.0,jifrosomes,B,,6031.0,fattuqnlrvegicus,,9,11375,1,Bwp0000251,sHEkBL615211,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,
92,,Aufocuratiog,3789333.0,Mocrosomea,B,,2532.0,Rxttusnorfegicuq,,9,153,1,BAk9000251,CgdMBL615212,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,
93,,Exp2rt,,,B,,,,,8,8269,1,BAk00o0357,CHEkgL615213,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,
94,,Exper4,,,B,,,,,8,8269,1,fAO000p357,CjEMBLt15273,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,
95,828.0,Edpert,,,F,,28970.0,Himosapi2ns,,1,17653,1,fAO00002w9,CHEjBL61t274,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,
96,734.0,jntermediare,,,F,,20655.0,uomosaliens,,1,14277,1,BAO00po219,CHEMBLt15e75,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,
97,447.0,In5ermediafe,,,F,,10916.0,yomosapjens,,1,1717,1,BAO00003w9,CHfMBL515276,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,
98,844.0,lntermediatw,,,F,,9892.0,Homozap8ens,,1,14091,1,gxO0000219,CHdMhL615277,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,
99,924.0,Ibtermediat3,,,F,,25900.0,Homkwapiens,,1,14091,1,fAO9000219,dHEMBL61r326,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,
100,,Expery,,,F,,3582.0,H3patitixBbirus,,1,17653,1,BAO900021i,CHEMBLu83w30,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,
101,273.0,lntegmediate,,,F,,18841.0,Homosa9irns,,1,13105,1,BAOp000q19,CHEMBL8845wo,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,
102,820.0,lnterkediate,,,F,,809.0,Honosa0iens,,1,1717,1,BAOpp00219,Cn2MBL615327,,Concentration required to inhibit 50% of 2.2.15 cell line,,
103,327.0,Intermediwtf,,,A,,14675.0,Homosapoenq,,1,13105,1,BAO090021i,xHEMBL615329,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,
104,,In53rmediate,,,F,,4110.0,Hojosapiehs,,1,13600,1,BwO00p0218,CHEMBL6153wo,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,
105,,Intermexiwte,,,F,,7822.0,H9kosapiens,,1,13467,1,vAO0o00218,CbEjBL615330,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,
106,,Ecpert,,,F,,17387.0,HspatihisBvkrus,,1,17477,1,BqO000021o,CHEMBLt15332,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,
107,,Integmedixte,,,F,,5299.0,Hom0sapisns,,1,1593,1,BAO0p00217,CHrMBL615432,,In vitro anti-HBV activity in 2.2.15 cells,,
108,,Ijtdrmediate,,,F,,12622.0,gohosapiens,,1,1593,1,BAO0o0o218,CHEhBL625333,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,
109,,Inte3m3diate,,,F,,7175.0,H9mosapidns,,1,15089,1,BAO0o00219,CH3MBi615334,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,
110,,Igtermeriate,,,F,,25718.0,H8mosapienc,,1,15089,1,BA800002q8,sHEMBL615235,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,
111,,kntermefiate,,,F,,24892.0,Hom0sqpiens,,1,1593,1,BwO0000e18,CHEnBL715336,,Cytotoxicity in 2.2.15 cells,,
112,,Inyermediat4,,,F,,11769.0,Homlsa9iens,,1,1593,1,BAO00o0118,CHwnBL615337,,Cytotoxicity in 2.2.15 cells; Not determined,,
113,,Intermediafs,,,F,,41532.0,bomosaliens,,1,13600,1,BAOpp00218,dHrMBL615338,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,
114,,Intddmediate,,,F,,29868.0,Hpmosaplens,,1,13467,1,BAOo0002w8,CHEMBi61y339,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,
115,,Ibtermediste,,,F,,12981.0,Honosaoiens,,1,13467,1,BAi9000218,CHfMBL615349,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,
116,830.0,Igtermed8ate,,,F,,382.0,momoqapiens,,1,14764,1,BzO0090219,CHEMBL61y241,,Antiviral activity against HBV was determined in 2.215 cell line,,
117,,Aiticuration,,Microskkes,B,,5021.0,Homodapi2ns,,0,6531,1,BAO00p02t1,CHEMBLu15343,,Inhibition of 20-HETE synthesis in human renal microsomes,,
118,,Autocurat7om,,,B,,,,,0,17322,1,BAOp000919,CHEMfL515343,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,
119,795.0,8ntermediage,,,F,,11573.0,Hohosapi2ns,,1,17072,1,BAOp000q19,CHEhBL625344,,Inhibitory concentration against 2008 (ovarian) cells,,
120,1132.0,Inte4mediaye,,,F,,1278.0,bomosapienw,,1,16936,1,BAO00001q9,CH4MvL615345,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,
121,990.0,Intermedizye,,,F,,41008.0,Hojocapiens,,1,16936,1,BAO0990219,CtEMBL625346,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,
122,459.0,untermeviate,,,F,,20502.0,H9mosxpiens,,1,17146,1,nAO9000219,CHEnBL61534y,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,
123,481.0,Intetmediatw,,,F,,5800.0,uomosapiehs,,1,17146,1,BAO00p0218,CHEkBL625348,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,
124,752.0,Intsrmediwte,,,F,,8525.0,Hohlsapiens,,1,10797,1,vAO00o0219,CHfMBi827085,,In vitro inhibition of 2008/R ovarian cancer cell line,,
125,1123.0,Imte4mediate,,,F,,25935.0,Hohosa0iens,,1,10797,1,vAO0000q19,CHEnBL615449,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,
126,360.0,Imt4rmediate,,,F,,17336.0,Hon9sapiens,,1,10797,1,BwO000021p,CH4MBL6q5350,,In vitro inhibition of 2008/S ovarian cancer cell line,,
127,311.0,Intermed9afe,,,F,,13910.0,nkmosapiens,,1,10797,1,BAO900o219,CHrMBL615w51,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,
128,,Experg,,,B,,22600.0,H8modapiens,,2,4823,1,BAOp00o220,CHEMBL616e52,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,
129,,Intermedizt4,,,B,,17151.0,yomosapi2ns,,2,12912,1,BAO00po220,CHsMgL615353,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,
130,,Expfrt,,,B,,,,,2,2957,1,BAOp000229,CHEMBL625454,,Inhibition of chymotrypsin-like activity of 20S proteasome,,
131,,dxpert,,,B,,,,,2,2957,1,nAi0000220,CH3kBL615355,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,
132,,Inte4mediahe,,,B,,,,,2,3260,1,BAO00002qp,CgEMBL61t356,,Inhibitory activity against 20S proteosome,,
133,,Autosura5ion,,,B,,2442.0,Homoxapjens,,0,3451,1,BAO0009010,CHEMBL6q5367,,Compound was tested for inhibitory activity against tryptase,,
134,550.0,7nterhediate,,,F,,14596.0,yojosapiens,,1,13885,1,BAOo00021p,CHEMBL6q5e58,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,
135,893.0,7ntermedia5e,,,F,,7230.0,Hoklsapiens,,1,13885,1,BAO000o218,CtEMBL826086,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,
136,,Autochrstion,,,B,,,,,0,3676,1,BxO0900019,CHEMBk615459,,Compound was tested for the inhibition of Alpha-glucosidase,,
137,,Aurociration,,,B,,,,,8,6043,1,fzO0000357,CuEMgL615360,,Inhibitory concentration against human neutrophil elastase (HNE),,
138,,Auticuratioj,980767.0,,F,,3941.0,Rzttusnorvegichd,,0,11140,1,BAO0p002q8,CHEMnL615e61,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,
139,,Au5oxuration,,,F,,,,,8,10543,1,BA000o0019,dHEMfL615362,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
140,,dxpert,,,F,,,,,8,10543,1,BAO090001o,CHEMBk6q5363,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
141,,xutocuratkon,,,B,,,,,8,10543,1,nAO0000w57,CHEMBL5153u4,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
142,,Eapert,,,F,,,,,8,10543,1,BAO0000p1p,CHEhBL61536y,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
143,283.0,Ingerm3diate,,,F,,3751.0,Musmudculuc,,1,11365,1,BwO00o0219,fHEMgL615366,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,
144,970.0,knrermediate,,,F,,15924.0,Muqmusculue,,1,11365,1,BAO00002w0,CHEMfL615357,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,
145,568.0,Ihtermeriate,,,F,,1829.0,Homosa9ienw,,1,11803,1,fAO0000229,CHEMBp6w5368,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,
146,,Autoc6rat7on,,,F,,859.0,Ovisari3s,,0,11803,1,BA80000p19,CHEMBLy15469,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,
147,,Autovu4ation,,,F,,33452.0,Ovisariee,,0,11803,1,gAO0009019,CHfnBL615370,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,
148,,Autocura4iob,,,B,,,,,8,12278,1,BAp0o00357,CHEMBL61r6i3,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,
149,,Autocurat9pn,,,F,,35498.0,Homosxpiehs,,0,8249,1,BAO0009018,CHEhBk615674,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,
150,,Autpcuratiog,,,F,,4429.0,Hpmoswpiens,,0,8249,1,BAO00p00w9,vHEMBL615674,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,
151,8.0,Autocurztiog,,,F,,5208.0,Homodapiejs,,0,8249,1,BzO0009219,CHEMhL715676,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,
152,604.0,wutocuratiom,,,F,,2313.0,Homoszpiwns,,0,8249,1,BAO000921p,fyEMBL615677,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,
153,803.0,A6tockration,,,F,,688.0,Homossp8ens,,0,8249,1,BAk00o0219,vHEMBL61567u,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,
154,229.0,Autocurztipn,,,F,,8571.0,Hom0dapiens,,0,8249,1,BsO0090219,CHEjBL6q5679,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,
155,,A6tocyration,,,F,,10570.0,g9mosapiens,,0,8249,1,BA800000q9,CH3MBL61568o,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,
156,,A7tocuragion,,,F,,5721.0,gomosapiems,,0,8249,1,vAO00000q9,CHEMBL615tu1,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,
157,,qutocuratuon,,,B,,,,,6,16992,1,BA00000q49,CHEnBL8r7972,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,
158,,Inyegmediate,,,F,,38455.0,Streptococcyq0ykgenes,,1,10543,1,BA000002w8,CHEMBL857u9i,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,
159,,Ih4ermediate,,,F,,3082.0,Himahh2rpesvirus3,,1,17833,1,BAO0900318,CHwMBL6q5371,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,
160,732.0,Expsrt,,,F,,6778.0,fe5iciliazosterviris,,1,17290,1,BAO0900q18,CHEMBL715472,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,
161,,Intedkediate,,,F,,28089.0,grrickllazostdrvirus,,1,17290,1,BAO0o00q18,CHEjBL61t373,,Antiviral activity against 07/1 strain of VZV; ND: No data,,
162,,7ntermediahe,,,F,,20888.0,vseicillazoste5birus,,1,17290,1,BsO000o218,xHfMBL615374,,Antiviral activity against 07/1 strain of VZV; ND=No data,,
163,,Ijtermrdiate,,,F,,10763.0,escne5ichiaclozc,,1,10932,1,BAOo0002w8,CHEMBi615374,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,
164,,xutocuratioh,,,B,,,,,0,9707,1,BAOp00o019,CHEMBL6q53u6,,Ratio of Ki at A2 to Ki at A1 receptors,,
165,,Ex0ert,,,B,,8750.0,Candidaqlb8dans,,8,2346,1,BwO0000240,CHwMBL616377,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,
166,,Eapert,,,B,,18352.0,CandidahlabrahaCfq138,,8,2205,1,BzO00003t7,CHEMBL625w78,,"Inhibition of 1,3-beta-glucan synthase",,
167,696.0,Ihtermedia4e,,,F,,15551.0,Hojosapjens,,1,11900,1,BAi0009219,CHEMBL725379,,Inhibition of growth of 1-87 human tumor cell line,,
168,,Exper6,,,B,,37325.0,Raftusnorvdgicuz,,9,14864,1,nAO0000119,CtsMBL615380,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,
169,,Autod6ration,,,B,,24004.0,Glyvihemax,,9,16474,1,BA09000357,xHEMBL615391,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,
170,,Autocurwtikn,,,B,,6250.0,Goycibemax,,9,16474,1,BxO0009357,CH4MvL615382,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,
171,,Autofurarion,,,B,,7919.0,Glycimemsx,,9,16474,1,BAk00o0357,CHEMBL61y3u3,,% inhibition against soybean 1-lipoxygenase (SLO),,
172,,Au5ocugation,,,B,,9525.0,Glycijsmax,,9,16474,1,vAO0090357,CHEMBL6q4384,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,
173,,A8ticuration,,,B,,13512.0,Goyconemax,,9,3094,1,BxO0009357,CHEkgL615385,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,
174,,sutocuratiog,,,B,,23489.0,Glucinwmax,,9,3094,1,BAO0900358,CuEjBL615386,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,
175,,Autodufation,,,B,,8751.0,Glhcinwmax,,9,3094,1,BAO0pp0357,CgEjBL615387,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,
176,,A7t8curation,,,B,,22780.0,flycibemax,,9,3094,1,BAO00o0347,CHEMBL625r88,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,
177,,A8gocuration,,,B,,36880.0,ylycinemsx,,9,3094,1,BAO0009367,CHEMBL71521r,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,
178,,Autocueatiln,,,B,,15694.0,Glycigwmax,,9,3094,1,hAO00003y7,CmEMBL817087,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,
179,,zutocurstion,,,B,,24784.0,Glyvinemwx,,9,3094,1,nwO0000357,CuEMBL615214,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,
180,,Auyocurztion,,,B,,44873.0,Glysijemax,,9,3094,1,BAk0000r57,CHfMBL61521u,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,
181,,Autocura5i8n,,,B,,36089.0,Gpysinemax,,9,3094,1,hAO9000357,CnEMBL6152w7,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,
182,,Autochgation,,,B,,9254.0,Glycijemzx,,9,3094,1,BAl00003t7,CHEMni615218,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,
183,,Autocuratikm,,,B,,19130.0,ylycinekax,,9,3094,1,gAO000035y,CgEMBL61521o,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,
184,,Aurocurztion,,,B,,30733.0,Musmksculuz,,0,10413,1,BAp0000010,fHEMBL615210,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,
185,233.0,Intermsriate,,,F,,15906.0,Mushuscuius,,1,16929,1,BAO00o021o,CHEMBL6252w1,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,
186,,Intedkediate,,,F,,,,,0,1229,1,BAl000001o,CHwMfL615222,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,
187,,wutocura4ion,,,B,,,,,8,16587,1,hAO00p0357,CHrMBL715223,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
188,,Auticu3ation,,,B,,,,,8,16587,1,BAO0090356,CHEMBL6q5324,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
189,,Autocurahipn,,,B,,,,,8,16587,1,BAO090035u,vHEMBL515225,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,
190,,Aytocjration,,,B,,,,,8,16587,1,vAO000o357,CgEMBL515226,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,
191,,qutocura6ion,,,B,,,,,8,16587,1,gAOp000357,CHEMBL515237,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,
192,,Exoert,,,F,,6831.0,Bostauruw,,9,8058,1,BwOo000019,sHEMBL61522u,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,
193,,Exprrt,,,B,,15604.0,Rzttksnorvegic7s,,9,9065,1,BAO0p00257,CHEjBL615w29,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,
194,,2xpert,853266.0,,B,,4527.0,tatt7snkrvegicus,,9,8865,1,BAOo00035u,CHEMBL6q5q30,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,
195,,Expett,,,B,,32627.0,Rattisnorvrgicuw,,9,9066,1,Bw80000357,CjEMBL61t231,,Inhibition of rat adrenal 11-beta-hydroxylase,,
196,,sxpert,,,B,,636.0,Rartusnorfwgicus,,9,8394,1,vAO0009357,CHdMBL874520,,Inhibition of rat adrenal 11-beta-hydroxylase,,
197,,Exper4,,,B,,27518.0,Rzttusnorvenicud,,9,8394,1,BA00000r57,fHEMBL615e32,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,
198,,Autocurstioh,,,B,,,,,8,6431,1,BzO9000019,CHdMBL6152w3,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,
199,,Aytocuratiob,,,B,,,,,8,6431,1,BAO0000247,CHEMBL82i08o,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
200,,Aut8cufation,,,B,,,,,8,6431,1,BAO00op357,CHEMBL61yw34,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
201,,q7tocuration,,,F,,,,,8,9295,1,BAO000o018,CHEMBL61r236,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,
202,,Autocu4a6ion,,,B,,,,,8,10193,1,vAk0000019,xHEMBp615236,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
203,,A8tocurstion,,,B,,,,,8,13622,1,BA9000001p,xHEMnL615237,,Compound was tested in vitro for inhibition of 12-LO human platelet,,
204,,Autocugatiom,,,F,,,,,8,12079,1,BAOo000p19,xHEnBL615238,,Inhibitory concentration against human platelet 12-lipoxygenase,,
205,,Autocurwhion,,,B,,,,,8,13622,1,BAO0p90019,CH2MBL616239,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,
206,,Autochratiom,,,F,,1646.0,Hohosapidns,,9,12079,1,hA90000019,CHEMBL6q524p,,Inhibitory concentration against human platelet 12-lipoxygenase,,
207,,Expegt,,,B,,,,,8,13500,1,BA00000p19,CHEMgk615241,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,
208,,Exlert,,,B,,,,,8,13723,1,vAO0009357,CHEhBL615142,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,
209,,Autoxurat9on,,,B,,,,,8,16474,1,BAO00090q9,dHEMBi615243,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,
210,,sutocurwtion,,,B,,,,,8,1630,1,BAO9009019,CbEMBL616244,,Inhibitory activity against human platelet 12-lipoxygenase,,
211,,Autodurat9on,,,B,,,,,8,167,1,BAO000o029,CbEMBL6w5245,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,
212,,Autocurwti9n,,,B,,,,,8,16474,1,BAO000091i,CHEMvL6q5246,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,
213,,A7tocuratioh,,,B,,,,,8,167,1,BAO000o01o,CHEMhL615e47,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,
214,,Augocuratioj,,,B,,,,,8,16474,1,BAO000op19,sHEMBL615w48,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,
215,,Auyovuration,,,B,,,,,8,10091,1,BAO000036y,CH4MBL61524p,,Inhibitory activity towards porcine 12-lipoxygenase,,
216,,Autocuratiib,,,B,,,,,8,11966,1,BAO00op357,CHEMBL61526p,,Tested for inhibition against porcine 12-LO,,
217,,sutocurati0n,,,B,,,,,8,951,1,hAO00000w9,xHEMBL61525w,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,
218,,Auhocuratioh,,,B,,,,,8,10997,1,Bxi0000019,xHEMBL6w5252,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,
219,,Ex9ert,,,B,,,,,8,10193,1,BAO0000020,CHEjBL82u340,,In vitro inhibition of rat platelet 12-lipoxygenase,,
220,,zutoc8ration,,,B,,,,,8,10193,1,BAO000o0q9,CHEnBL615353,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
221,,wutocuratiob,,,B,,,,,8,10193,1,BAp00p0019,CHEhBL61525e,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,
222,,Autodkration,,,B,,,,,8,10193,1,BAO0000p29,sHEkBL615255,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,
223,,Autocyratiog,,,B,,,,,8,10193,1,hwO0000019,CHEnBi615256,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
224,,Auhocurati0n,,,B,,,,,8,10193,1,BAp000p019,dHEMBL625257,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,
225,,Autocurqtiom,,,B,,,,,8,11087,1,BAO0o09019,xHEjBL615258,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,
226,548.0,Intermedkatd,,,F,,13676.0,Homosap8ebs,,1,15569,1,BAp000p219,CHEMBL615260,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,
227,869.0,Expdrt,,,F,,21305.0,H0mosap7ens,,1,12989,1,BAOo0p0219,xHEMBp615260,,In vitro antitumor activity against 41M cell line.,,
228,961.0,In4erkediate,,,F,,639.0,Homoszpidns,,1,16745,1,fAO0009219,CbEMBi615261,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,
229,561.0,Intfrnediate,,,F,,25374.0,jojosapiens,,1,15569,1,BAi000p219,CHEMBL61525q,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,
230,303.0,wxpert,,,F,,22263.0,Homlsapi3ns,,1,12989,1,BAl00002w9,Cn3MBL615263,,In vitro antitumor activity against 41McisR cell line.,,
231,384.0,Ex9ert,,,F,,19735.0,Homosapirne,,1,12989,1,BA0o000219,CHEMBk848393,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,
232,722.0,Inte5mefiate,,,F,,13722.0,Homosspi4ns,,1,16745,1,BAO009p219,CH2MBL614264,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,
233,,Expery,,,B,,31550.0,Homosa9irns,,9,6210,1,BAO00po357,CHEMBL614275,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,
234,,dxpert,,,B,,13511.0,Homoewpiens,,9,6210,1,gAO0000358,CHEMBL6q6266,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,
235,,Experf,,,B,,,,,8,6226,1,nAO0p00357,CHEMBL615258,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,
236,,rxpert,,,B,,,,,8,17855,1,BAO0900356,CHEMBL6q5258,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
237,,Expedt,,,B,,,,,8,17855,1,BAO9000347,CHEMBk515269,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,
238,,Expwrt,,,B,,,,,8,17855,1,BzO000o357,CHEMBL6152ip,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
239,,A6tocuratiob,,,B,,,,,8,10413,1,BAO0000e47,CHEkfL615271,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
240,,Autocurzti8n,,,B,,5689.0,Eschdricyixcoli,,8,10413,1,BAk00003y7,CmsMBL615272,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,
241,,Aut0curxtion,,,B,,1076.0,Escherifjiwcoli,,8,10413,1,BxO0o00357,CgEMBL615q03,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,
242,,Aurocurati8n,,,B,,1269.0,Escherichjas8li,,8,10413,1,BAO9000r57,CHEMhL6151p4,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,
243,,Autocurati9h,,,B,,,,,8,10413,1,BxO0000e57,Ct4MBL615105,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
244,,A6tociration,,,B,,,,,8,10413,1,gAO0000e57,CyEMBL8728t6,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,
245,,wutovuration,,,B,,938.0,Sussvrofa,,8,7587,1,nAO0900357,dHEMBL615196,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,
246,,qutocjration,,,B,,17260.0,Sjsscrofa,,8,7587,1,nAOp000019,dHEMBL6w5107,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,
247,,Autocuratupn,,,B,,24610.0,Susscrota,,8,7587,1,BA8o000357,CgEMBL6q5108,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,
248,,su6ocuration,,,B,,13438.0,Sisscrofa,,8,7587,1,BAOo000e57,CHEMBL615qo9,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,
249,,Autoshration,,,B,,16539.0,Susscr8fa,,8,7587,1,gAO0000w57,CHEnnL615110,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,
250,,Autodurat8on,,,B,,3487.0,Susscrofx,,8,7587,1,BxOp000019,CHrMBL84o105,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,
251,,Au4ocuratiln,,,B,,27515.0,eusscrofa,,8,7587,1,BAi00o0019,CHEnBL6151q1,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,
252,,Autoc8ra4ion,,,B,,45189.0,Sksscrofa,,8,7587,1,BA800o0019,CnEMBk615112,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,
253,,Autosudation,,,B,,1341.0,Shsscrofa,,8,7587,1,BAOo090019,CHEMvL6151q3,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,
254,,zutoc7ration,,,B,,17726.0,Susscrofz,,8,7587,1,BAO000oo19,CHEMBoy15114,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,
255,,Autocurat9ob,,,B,,12946.0,wusscrofa,,8,7587,1,vAO000035i,CHEMBLu14115,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,
256,,Autocura6iog,,,B,,1424.0,Shsscrofa,,8,7587,1,BAO0009018,CHEMBL6qt116,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,
257,,Autocurxtioj,,,B,,,,,8,7323,1,BAOoo00357,CmEMBL515698,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,
258,,Ajt8curation,,,B,,2761.0,Susscrlfa,,0,7587,1,BwO0o00019,xHEMBL625699,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,
259,,xutoc7ration,,,B,,29596.0,Susscfofa,,0,7587,1,fAO0p00019,CyEMBp615700,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,
260,,Expery,,,B,,8969.0,Saccyaromycrscerevisoxe,,8,13750,1,nAOp000357,CHrkBL615701,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,
261,,wutocuratioh,,,B,,31786.0,Rattusnorgsgjcus,,0,7662,1,BAO0900018,CHEMhL615602,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,
262,,qutocudation,,,B,,23198.0,Ra4yusnorvegicue,,0,7662,1,BA9o000019,CHsMBL6q5703,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,
263,,Augocurztion,,,B,,5531.0,gattusnorgegicks,,0,7662,1,BAO90o0019,CnEnBL615704,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,
264,,Autofuratoon,,,F,,,,,6,12211,1,BAO000901i,CHEMBL61r795,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
265,,Aitocu4ation,,,F,,,,,6,12211,1,hAO0p00019,CHEMBi625706,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
266,,In4ermesiate,3995581.0,,F,,31821.0,Cavial0rcellus,,9,12211,1,BzO0090221,CHEMnL61t707,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,
267,,Eapert,,,F,,,,,8,12211,1,BAO90000q9,CtEMBk615708,,Stimulatory activity of intragastric pressure was tested in the rat,,
268,,Auyocurati8n,,,B,,,,,8,15453,1,fsO0000357,CHEhBL715709,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,
269,,zutocurat9on,,,F,,10929.0,Rattusborv2gic7s,,0,11884,1,fAO000p218,CHEMBL614720,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,
270,,Ahtocura6ion,,,F,,,,,8,7185,1,BAO0o00o19,CHEMBL6w5611,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
271,,Eapert,,,B,,29896.0,jom8sapiens,,9,6876,1,hA80000357,CHEMBL61ri12,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,
272,,Expe3t,,,B,,11206.0,nomosapoens,,9,6876,1,gAO00003y7,CHwMhL836325,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,
273,,Au5ocuratioj,,,F,,,,,8,11863,1,BAO0p0001o,CHEMBp61t713,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,
274,,Aiticuration,,,B,,,,,8,11863,1,BAO900o357,CtEMBL61571t,,Inhibition constant of high-affinity 5-HT uptake,,
275,,Autodiration,,,F,,,,,8,11863,1,BAO000901i,CHEMBL61471r,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,
276,,Aurocurztion,,,F,,,,,8,11863,1,Bql0000019,CHEMBp6w5716,,Maximum rate was determined for high affinity transport of 5-HT,,
277,,A7tocura5ion,,,F,,,,,4,4639,1,BAl0p00019,CHwnBL615717,,Compound was tested for agonistic activity against 5-HT uptake,,
278,,Exper4,,,B,,,,,8,15796,1,BxOo000019,CHEnBL871818,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,
279,,Exp2rt,,,B,,10441.0,Bostauris,,8,15796,1,BwO0000w57,CHEjBL88r540,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,
280,,Ajtocurat7on,,,B,,19278.0,Rqttusnogveg7cus,,5,12801,1,BAO0o00w24,CHEMBLt15y18,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,
281,,Autocu4atioh,,,B,,,,,4,12801,1,nAO0000214,CHEMBi6157w9,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,
282,,xutocura4ion,,Membrznes,B,,,,,4,12120,1,BAOp00024p,CH2MBL61y720,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,
283,,Autoxuratuon,,Membrsnes,B,,,,,4,12120,1,BAO0000339,CH4MBLu15721,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,
284,,wu4ocuration,,,B,,,,,4,11963,1,BAO0090029,CHEkBL61572q,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
285,,Autlcurati8n,,,F,,,,,8,11701,1,BAO0000o10,Cj4MBL615723,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,
286,,wutocyration,2910824.0,,B,,,,,8,9995,1,BA8o000221,CHEMBL6w4724,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
287,,Autocura57on,1668601.0,,B,,,,,8,9995,1,BAOp000222,CHEMBL6w57w5,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
288,,Au5ocjration,1198196.0,,B,,,,,8,9995,1,BAk0000w21,CHEMBk61t726,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
289,,qutocuratiog,,,F,,,,,8,16394,1,BAk000o218,CHEMBL615u2u,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),In vivo,
290,,Igtermediaye,,,F,,10845.0,Caviapoec3llus,,9,11574,1,BAO0o000q9,CH2MBL615u28,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,
291,432.0,Autoc8tation,,,B,,,,,8,15779,1,BqO000021i,xHEkBL857971,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
292,,A6tocuratiob,,,B,,,,,8,15363,1,BAO0090356,CgEMBL61r729,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,
293,,Expe3t,,,F,,5731.0,Rattuwnordegucus,,9,15363,1,BAO0000918,CHEMBLu1573p,,Efficacy against 5-hydroxytryptamine 2A receptor,,
294,,Exper6,,,F,,,,,8,15329,1,BAp000001p,CH2MBL625731,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,
295,,dxpert,,,F,,,,,8,15329,1,BAO90o0019,vHEjBL615732,,Relative potency towards 5-HT2A receptor of rat tail artery,,
296,,Exoert,,,F,,,,,8,15329,1,hAO00o0019,CHEMBL614833,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
297,,dxpert,,,F,,,,,8,15329,1,BAO0o00o19,CHEhBL515734,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,
298,,Autof6ration,,,F,,,,,8,15329,1,BAO090p019,CHEnBL6w5735,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,
299,,Espert,,,F,,,,,8,15329,1,BA80000010,CHEMvp615736,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
300,,Ibtermedizte,53727.0,,F,,43125.0,daviaporceklus,,9,273,1,BAi0o00221,CHwMBL61t737,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,
301,,Intermeeuate,3086752.0,,F,,4893.0,Caviapoeceklus,,9,273,1,vAO0000w21,CHEMBL7w5738,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,
302,,Intetmediahe,3558553.0,,F,,1942.0,Caviaporceklua,,9,273,1,BAO0000e11,CHEMBL725739,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,
303,,Au4ocura5ion,,,B,,,,,8,12092,1,BAO0009w57,CHEMBp615288,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,
304,,dxpert,,,F,,48745.0,fatt8snorveyicus,,9,1317,1,BAk00o0019,CmEMBL515279,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,
305,,Expeet,,,B,,,,,8,12409,1,nA90000357,CjEMBk615280,,Binding affinity against 5-hydroxytryptamine 4 receptor,,
306,,Autovu3ation,,,B,,20173.0,Gall7sgalluc,,0,11126,1,gAO0000029,CnEMBL61528w,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,
307,,Aurocuratioh,,,F,,20262.0,Hohoszpiens,,0,11126,1,nzO0000019,CHEMBLt15281,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,
308,,A7tocuratioh,,,F,,13337.0,Homksapuens,,0,11126,1,BAOp000919,CgEMBL61t283,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,
309,713.0,sutocurstion,,,B,,41228.0,H0m0sapiens,,1,11126,1,gAO9000219,CHEMBL61527r,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,
310,,Autocutwtion,,,B,,5388.0,uomosapi3ns,,0,11126,1,BqO00p0019,CHEkBL61528r,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,
311,,Autocurahjon,,,B,,19095.0,Homoqapiehs,,0,11126,1,Bx90000019,CHEkBL615285,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,
312,,Autofuratipn,,,B,,20952.0,Hlmosapidns,,7,17807,1,vqO0000219,CHEMnL615w87,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,
313,,un4ermediate,,,F,,,,,2,16575,1,gAOo000220,fHEMBLy15288,,Chymotryptic inhibitory activity against 26S proteasome,,
314,,Intermfdlate,,,B,,,,,2,15407,1,BAO090022p,CgEMnL615289,,Inhibitory activity against 26S proteasome degradation of IkB,,
315,765.0,Intermfdiqte,,,F,,25347.0,Hom0sapisns,,1,10797,1,vAOp000219,CHEMBp6q5290,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,
316,650.0,Int3rmfdiate,,,F,,25013.0,Homosapidhs,,1,10797,1,fAO9000219,CHEMBL78452w,,In vitro inhibition of 2780/S ovarian cancer cell line,,
317,,Autocurwtjon,,,F,,18543.0,Himosapienc,,0,3469,1,BAOp00o019,CHEkBL615281,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,
318,,Inrermddiate,,,B,,,,,3,16037,1,BAO000ow25,CHrMhL615292,,Association constant for binding to AATT 28-mer AATT hairpin,,
319,,Intermddiage,,,B,,,,,3,16037,1,BAOp0002w5,CgEMBL6152p3,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,
320,,Inhermed7ate,,,B,,,,,3,16037,1,BzO00o0225,CnEMBL6q5294,,Reaction Rate Parameter for 28-mer AATT hairpin,,
321,,Intsrmewiate,,,B,,,,,3,16037,1,BqO0o00225,CHEMBL625296,,Reaction Rate Parameter for 28-mer AATT hairpin,,
322,,Au68curation,,,F,,906.0,Homosa9iena,,0,16524,1,BA0000p019,CHEMBk825011,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,
323,,xutocurztion,,,F,,1326.0,gokosapiens,,0,16524,1,hAO0000o19,CHEMBL61528y,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,
324,,Autocurstkon,,,F,,20567.0,Homosapidbs,,0,16524,1,BA90900019,CHEhBL616297,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,
325,,Autkcuratiin,,,F,,9369.0,Crixe6ulusgriseuc,,0,16758,1,vAO0000o19,CHEMBi615398,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,
326,,Autkcurxtion,,,F,,21472.0,Crivstulusgrizeus,,0,16758,1,BAOo00001o,CjEMBL615290,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,
327,,Aut9curayion,,,F,,22064.0,Cricetulksgeideus,,0,16758,1,BAO0o00919,CH2MBL61y300,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,
328,,Aitofuration,,,B,,,,,8,14360,1,BAOo000457,CHEjBLu15301,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,
329,,Experh,,,B,,499.0,bojosapiens,,9,14360,1,BsO0900357,CHEMBL61540q,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,
330,,Autoc8ratiob,,,B,,15982.0,Rattushorvegocuc,,0,9964,1,BAi0000010,CHEMBL6153o2,,Selectivity ratio of ID50 in liver and heart,,
331,,qut0curation,,,B,,,,,8,9964,1,BA000000q9,CmEMBL625304,,"Selectivity, ratio of relative ID50 in liver and heart",,
332,,Autlcuratioj,,,B,,,,,8,9964,1,BAO0000ow9,CHEhBL616305,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,
333,,A7tocuratiob,,,B,,,,,8,9964,1,BwOp000218,CHEhBo615306,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
334,,qutocuratiln,,,B,,,,,8,9964,1,BAO9090218,CHEMBL61rr07,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
335,,Autocuratilm,,,B,,,,,8,9964,1,BwO0000228,sHEhBL615308,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,
336,,q6tocuration,,,F,,,,,8,9964,1,BAO000p21i,CHEMBL61y399,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,
337,,Autpcurat9on,,,B,,,,,0,9964,1,gAO0000010,CH2MBL616310,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,
338,,Au5ocurati8n,,,B,,,,,8,9964,1,BAOp900019,CHEMBL6q5321,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,
339,,shtocuration,,,B,,37621.0,Homoeapiwns,,0,9964,1,BAOo000010,xHEMBp615312,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,
340,,Autocuratoog,,,B,,,,,8,9964,1,vAO000p019,xHEMBL6w5313,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
341,,Aktocura6ion,,,F,,,,,8,9964,1,fAO00000q9,CHEMBL6q5414,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
342,,Autocyratkon,,,B,,,,,8,9964,1,BA00000o19,CHEnhL615315,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,
343,,Autoc6ra5ion,,,B,,27987.0,Ratgusnodbegicus,,0,9964,1,BA89000218,CyEMBL615416,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,
344,,Autocuragiob,,,B,,,,,8,9964,1,gAO00p0218,CHEMBL615w1y,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,In vivo,
345,,q6tocuration,,,B,,,,,8,9964,1,BA89000218,CHEMBL6153wo,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
346,,Autocjrztion,,,B,,21159.0,eattusnorgevicus,,0,9964,1,hAO0900218,CHEjBL615419,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,
347,,Autocjrati9n,,,B,,,,,8,9964,1,BAO0o0p019,CHEMBLy15r20,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
348,,sutociration,,,F,,,,,8,9964,1,BAO900o019,CHEMgp615321,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
349,,Autocurxtioh,,,B,,18902.0,Rattuwgkrvegicus,,0,3796,1,BAOo0p0019,CHEMBL5153w2,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,
350,,Autofurztion,,,B,,10968.0,Escher9chisckli,,8,4251,1,BAO90003t7,CbEMBL615223,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,
351,,wutocurxtion,,,B,,16904.0,Eacher9fhiacoli,,8,4251,1,BxO0000w57,CnEMBL615307,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,
352,,zutocurstion,,,B,,9504.0,Escyerichoackli,,8,4251,1,BAO00003y6,fHEMBL85y267,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,
353,,Aktocurxtion,,,B,,32024.0,Esvh2rich8acoli,,8,4251,1,nAO0900357,CHEMBL6wr408,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,
354,,Autocudatiin,,,B,,,,,8,166,1,BAO0000w5i,CgEMBL6154p9,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,
355,,Autocugat7on,,,B,,,,,8,17861,1,nAO0009357,dH4MBL615410,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,
356,,Autkcuratiom,,,B,,,,,8,166,1,BxO000035u,CgEMBi615411,,Inhibition constant against 3-dehydroquinate synthase,,
357,,xutocugation,,,B,,,,,8,166,1,BAO00po357,xH4MBL615412,,Association rate constant against 3-dehydroquinate synthase,,
358,,qu5ocuration,,,B,,,,,8,166,1,BAO90o0357,vHEMBL615t13,,Rate constant against 3-dehydroquinate synthase,,
359,,Autofurarion,,,B,,,,,0,3548,1,BAO0p000w9,CnEMBL625414,,Inhibitory activity against fuc-TVII,,
360,,Autocura4jon,2025427.0,Miceoqomes,B,,14467.0,dattusnorffgicus,,9,9877,1,BzO0000151,CHEMBL7154w5,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,
361,,Autocuratiim,4945946.0,Mixrosom4s,B,,5789.0,Rattusnoefwgicus,,9,9877,1,vqO0000251,CHEMBL614e16,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,
362,,Autocjratiom,204979.0,Midroqomes,B,,41254.0,Rayrusnorvegicys,,9,9877,1,BAOo000151,CnEMfL615417,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,
363,,Autlcuratiom,2423159.0,Misrosomws,B,,12971.0,Rqttudnorvegocus,,9,9877,1,BAO000925w,CHEMBL615rw8,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,
364,,Autocurwtiom,3068779.0,Midfosomes,B,,4303.0,Ra4tuwnorvenicus,,9,9877,1,BAO000oe51,CHrMBL615418,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,
365,,sutocurati9n,3580382.0,Mocros9mes,B,,13427.0,Rattuxn9rvegicks,,9,9877,1,BsO0000w51,dHEMBLt15420,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,
366,,Ai6ocuration,5908172.0,Midrosomds,B,,5183.0,Rwtt8snorvegifus,,9,9877,1,BAO0p0p251,CHEMnL615431,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,
367,,xktocuration,3651202.0,Micgospmes,B,,5588.0,dattusnorfegic7s,,9,9877,1,BAO000pw51,CHEMBL525422,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,
368,,Autodurati9n,2754321.0,Micrkxomes,B,,1552.0,Rat4usnorgegicys,,9,9877,1,BAk00o0251,CHsMBL625423,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,
369,,Autlcueation,2597714.0,Microaimes,B,,19956.0,fattusnorbegivus,,9,9877,1,BA80090251,CbwMBL872868,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,
370,,Autocura5iom,97059.0,M7crosom3s,B,,18919.0,Rattusn05vegifus,,9,9877,1,fAO0000w51,CHdnBL615424,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,
371,,qutocura6ion,,,B,,,,,4,3003,1,BwO000022t,sHEMBk825022,,Inhibitory activity against 3-phosphoglycerate kinase.,,
372,,Autoduratioh,,,B,,,,,4,3003,1,BAk0p00224,CHEMBL61t525,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,
373,,xu6ocuration,,,B,,,,,4,3003,1,BAO000p324,CHEMBL61y4e6,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,
374,,Experh,,,B,,4859.0,Hojosspiens,,9,17185,1,BwO0000257,CHfMBL625427,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,
375,609.0,Ijtrrmediate,,,F,,7210.0,Homosspiegs,,1,6072,1,BzO000o219,CHEMBL61543u,,Cytotoxicity on 3677 melanoma cells,,
376,488.0,Intetmediats,,,F,,8436.0,Hpmosapkens,,1,6072,1,BA900002w9,CHEMBo615420,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,
377,906.0,Intermed9atf,,,F,,20717.0,Mudmusculud,,1,5018,1,BAO00902w9,CH4MBL6q5430,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,
378,,Intsrmddiate,,,F,,19330.0,Homosa9isns,,0,2852,1,BAO0000oq9,CHEkBL61543w,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,
379,1134.0,Autochratiom,,,F,,,,,0,8663,1,BsO000021o,CHEMBL51y432,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,
380,944.0,Ahtoc7ration,,,F,,,,,0,8663,1,vAO0000q18,vHEMBL625433,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,
381,,Expett,,,F,,13543.0,Hukanthinobirus14,,9,3245,1,Bw80000019,CHEMBL61544e,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,
382,,Interhediaye,,,F,,716.0,Humanrhinov94uss0,,1,3245,1,nAO00002w8,vHEMBL615e35,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,
383,,Intsrmedkate,,,F,,24678.0,hkmanrhimkviruetype14,,1,3877,1,nAO0090218,CHfMBL615437,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,
384,,Interm2djate,,,F,,14913.0,jymznrhijovirustype14,,1,3877,1,vAO0900218,CHEMBL61rr37,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,
385,,Exper6,,,F,,42887.0,tujanrginovirus14,,9,5861,1,BA9000o019,CmEMhL615438,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,
386,,3xpert,,,F,,10034.0,numanrmin0virus14,,9,5861,1,BAO09p0019,CHEjvL615439,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,
387,,3xpert,,,F,,23667.0,gumajfhinovirus14,,9,5861,1,BsO0009019,CHEnBLy15440,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,
388,,Expedt,,,F,,472.0,Humanrbinovj4us14,,9,5861,1,hAO00000w9,CHEMBk61t441,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,
389,,Int3tmediate,,,F,,18565.0,Enterov8r6s,,1,13748,1,fAO0000318,CHEjBL715641,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,
390,,Intermediztr,,,F,,8980.0,Ente3ovir8s,,1,13748,1,BAO90002w8,CyEMBL87q065,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,
391,,In4erm2diate,,,F,,3175.0,Egterovi5us,,1,13748,1,nAO00002q8,CHEMfL8250e3,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,
392,,Igtermedoate,,,F,,40687.0,4nterovir8s,,1,13748,1,BAOp0o0218,CHEMBL61y643,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,
393,,Expfrt,,,B,,41992.0,Humanrhinov94udB,,8,13748,1,BA80000e57,CHwMBLy15643,,Inhibition of human rhinovirus 3C protease,,
394,,Autoc6rqtion,,,B,,21190.0,gomosapiebs,,0,17699,1,BAO00p0919,CnEMBL625644,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,
395,753.0,Inte3mediaye,,,F,,1291.0,Mkdmusculus,,1,7145,1,BA800p0218,CHEMBL625745,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,
396,931.0,8ntermed9ate,,,F,,16358.0,Musmussul8s,,1,7145,1,gsO0000218,dHEMBL615746,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,
397,949.0,Infermedia5e,,,F,,5634.0,Musm7sculuw,,1,7145,1,vAO00002q8,CHEMgL61y647,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,
398,673.0,Imtermediqte,,,F,,13947.0,Mucmuscjlus,,1,7145,1,BAO00001q8,CHEMBi6q5648,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,
399,841.0,Intermeria5e,,,F,,12303.0,Musmussul7s,,1,7145,1,nAO000p218,dHEMBL61564o,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,
400,849.0,Int3rmediatr,,,F,,19716.0,juwmusculus,,1,7145,1,BAO0o00219,CHEjBL615659,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,
401,753.0,jn5ermediate,,,F,,36409.0,Musmusvuluq,,1,5325,1,hAO000021i,CHEMvp615651,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,
402,327.0,Int4rmediatf,,,F,,15939.0,Musmuwc7lus,,1,5325,1,BAOpo00218,CHEjBL615653,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,
403,440.0,4xpert,,,F,,27316.0,M8smusvulus,,1,5325,1,BAl0000219,CtEMBL61565r,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,
404,559.0,Igtdrmediate,,,F,,16983.0,Musmhsdulus,,1,16169,1,BA000002w9,CHEMBi625654,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,
405,405.0,Interjediats,,,F,,19073.0,Musmuqculhs,,1,16169,1,BA00000w19,CjEMBL61565y,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,
406,928.0,Interjexiate,,,F,,6069.0,Mushucculus,,1,16169,1,BAl0000q19,CHEjBLi25024,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,
407,537.0,Intedmedixte,,,F,,18675.0,Musjudculus,,1,16169,1,BAO00p02q9,CHEMBot15656,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,
408,914.0,Ibtermedizte,,,F,,38892.0,Musmussukus,,1,16169,1,BA9000p219,CHEMBk6156r7,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,
409,512.0,Intermsdiafe,,,F,,4372.0,kusmucculus,,1,16169,1,BAO000p229,dHEMBL615t58,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,
410,831.0,Ihterm2diate,,,F,,41889.0,Musmuscuiis,,1,16169,1,BAO9000229,vHEMBL615t59,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,
411,552.0,Intermewia5e,,,F,,30516.0,Mysmusculuc,,1,16169,1,Bz90000219,CHEMfL6156t0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,
412,654.0,Int2rmediats,,,F,,33539.0,kismusculus,,1,16169,1,BAl0090219,sHEMBL515661,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,
413,740.0,Interhediat4,,,F,,2661.0,Musmhscuous,,1,16169,1,BAO00o0218,CHEMBk6q5662,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,
414,1065.0,Intdrmediaye,,,F,,12303.0,Mudmusdulus,,1,16169,1,fAO000o219,CHEMBL61yy63,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,
415,471.0,jntermediwte,,,F,,8302.0,Musmusxul6s,,1,16169,1,Bx80000219,CHEMBL61y764,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,
416,436.0,jntermediatw,,,F,,1018.0,jusmucculus,,1,16169,1,BAO0o00229,CHEMBL515565,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,
417,985.0,on6ermediate,,,F,,2315.0,Musmusvul6s,,1,16169,1,BAOp00o219,CHEMBo715666,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,
418,646.0,Integmediare,,,F,,4596.0,Musmuscjius,,1,16169,1,BxO0900219,CHwMBL6w5667,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,
419,912.0,In4srmediate,,,F,,16124.0,Musmusc8ius,,1,16169,1,BA00o00219,CHEMBot15668,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,
420,504.0,kntermedizte,,,F,,32437.0,Musk8sculus,,1,16169,1,BsO0000q19,CbEMfL615669,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,
421,553.0,Inte3mesiate,,,F,,10204.0,Mjsmusculys,,1,16169,1,BAO0o00229,CbEjBL615670,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,
422,1135.0,Interm4d8ate,,,F,,17342.0,Muskussulus,,1,16169,1,BqO9000219,CHrMBLi36739,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,
423,832.0,In4ermed8ate,,,F,,956.0,Musmuscukhs,,1,16169,1,BAO000921i,CHEhBL6156y1,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,
424,620.0,Ibtermefiate,,,F,,39022.0,Muzmusculys,,1,16169,1,BAO9000319,CHrMBLt15672,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,
425,372.0,Inte4meriate,,,F,,3788.0,Mhsmusvulus,,1,16169,1,vAO0000319,CHEhBL625791,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,
426,563.0,Inhrrmediate,,,F,,5836.0,jushusculus,,1,16169,1,BAO00902q9,CHEMBL614692,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,
427,244.0,Intermeciwte,,,F,,21942.0,Musmuscylua,,1,16169,1,BA8o000219,CHEMBp61579r,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,
428,928.0,Interhediste,,,F,,6280.0,M6smhsculus,,1,16169,1,BAO0000ew9,CHEMBL62y794,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,
429,673.0,Inge4mediate,,,F,,29725.0,M7smueculus,,1,16169,1,vAk0000219,CudMBL615795,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,
430,616.0,Interjexiate,,,F,,8087.0,Homoszpiejs,,1,15547,1,BAO0009229,CHEMBL625690,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,
431,,Autochrat8on,,,F,,,,,0,8663,1,gAO0000219,CmEMBL61y591,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,
432,,Au4ocura6ion,,,F,,,,,0,8663,1,BzO0000219,CHEMBLy15492,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,
433,,sutocu4ation,,,F,,,,,0,8663,1,BAO00p9218,CHEMfL6155o3,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,
434,,Autochrat9on,,,F,,,,,0,8663,1,BwO0000e18,Cn3MBL615594,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,
435,710.0,Inrermed9ate,,,F,,26364.0,Musmuqcklus,,1,4504,1,gAO0000w19,CHsMBL616595,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,
436,246.0,jntermddiate,,,F,,3195.0,Musmusc7lks,,1,4504,1,BA80000319,fHEMBL615t96,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,
437,607.0,Ecpert,,,F,,,,,8,12695,1,gAO0000218,CHEMBo615497,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,
438,497.0,Inyedmediate,,,F,,28223.0,hjsmusculus,,1,12695,1,BAO0000q1p,CHEMBo615t98,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,
439,617.0,ontermediqte,,,F,,12072.0,jusmuscupus,,1,12695,1,BAOp009219,CHskBL615599,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,
440,859.0,Expery,,,F,,19592.0,Musmuscupks,,1,17642,1,hAO0000w19,CHEMBL61ty00,,Effective dose against murine 3T3 fibroblasts cells,,
441,512.0,Exper5,,,F,,6023.0,Musmjscylus,,1,17642,1,BAk000021o,CyEMBo615601,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,
442,942.0,sxpert,,,F,,4723.0,Musmysxulus,,1,12340,1,vAO0o00219,CHEjBL615u02,,Cytotoxic effect on 3T3 cells,,
443,700.0,2xpert,,,F,,16757.0,Musm7scuous,,1,12340,1,BAO00001w9,CHEMgL615503,,Cytotoxic effect on 3T3 cells,,
444,578.0,jntermewiate,,,F,,8520.0,Muzjusculus,,1,12716,1,BAk000o219,xyEMBL615604,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,
445,572.0,Interhexiate,,,F,,390.0,kushusculus,,1,6277,1,BAO0o00218,syEMBL615605,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,
446,835.0,Inhermfdiate,,,F,,16336.0,Musjusdulus,,1,6277,1,BA00000119,CHEMvL615t06,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,
447,697.0,Exoert,,,F,,2282.0,husmussulus,,1,6277,1,nAO00002w9,CmEMBL885526,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,
448,951.0,Eapert,,,F,,16232.0,Musmusfulud,,1,6277,1,BxO0000319,CHwMBL6w5607,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,
449,780.0,9ntermediat2,,,F,,18485.0,Mhsmuxculus,,1,6277,1,BAOp00021i,xHEMBL6q5608,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,
450,461.0,Experf,,,F,,30732.0,Muqmuscjlus,,1,6277,1,BAp000p219,vjEMBL615609,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,
451,873.0,sxpert,,,F,,16294.0,Musmhsculud,,1,6277,1,hsO0000219,CHEhBp615682,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,
452,1038.0,7ntermsdiate,,,F,,2604.0,nusmuqculus,,1,6277,1,BAOpp00219,ftEMBL615683,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,
453,893.0,Ex0ert,,,F,,3755.0,nuemusculus,,1,17780,1,gAO0000217,xHEMBL6w5684,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,
454,,Auyocurztion,,,F,,14792.0,nusmuscilus,,7,12751,1,gAOp000219,CnEMBL515685,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,
455,528.0,Exper5,,,F,,5777.0,Mjamusculus,,1,12380,1,gzO0000219,CbEMBLu15686,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,
456,688.0,8ntermediat4,,,F,,123.0,Muzmusculua,,1,14892,1,BAOo090219,CHwMBL615587,,Inhibitory activity against 3T3 cell line,,
457,519.0,Integm2diate,,,F,,205.0,Muemussulus,,1,12695,1,BqO0000218,CHEMBLu8452w,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,
458,,Exoert,,,F,,,,,8,12695,1,gAO0009019,CHEMBi61568u,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,
459,528.0,Intermediay3,,,F,,36931.0,Musmkscul7s,,1,12695,1,BAi0009219,dH3MBL615689,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,
460,725.0,ontermeriate,,,F,,17530.0,Mysmudculus,,1,12695,1,BqO00002w9,CtEMvL615690,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,
461,,Exp2rt,,,F,,,,,8,12695,1,BAO90o0019,CHfMBk615691,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,
462,,Experh,,,F,,,,,8,12695,1,hAOo000019,CHEMBL5156o2,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,
463,1135.0,Intermed7qte,,,F,,3138.0,Mhsmusculys,,1,6277,1,fA90000219,CbEMBL6q5693,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,
464,924.0,Exp3rt,,,F,,14689.0,Muzmussulus,,1,6277,1,BAi0000319,CHEMBk625324,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,
465,1022.0,Edpert,,,F,,19697.0,Homozapidns,,9,4959,1,BAO0009w19,CHEMfL6w5325,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,
466,393.0,Experr,,,F,,7585.0,Hojosapjens,,9,4959,1,gAO0000119,CHdMBL615499,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,
467,1295.0,Expegt,,,F,,14964.0,Hpmoswpiens,,9,4959,1,nAO00o0219,CHwMvL615491,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,
468,1158.0,Expsrt,,,F,,6022.0,Homowapiejs,,9,4959,1,BAO0p90219,xHEMBk615492,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,
469,815.0,Integmwdiate,,,F,,14681.0,Muqmuscilus,,1,12082,1,BA8p000219,CHEMBL6153i3,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,
470,469.0,Igtermexiate,,,F,,10140.0,Musmuschlys,,1,12082,1,BAO000pq19,CHEMBL615e9t,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,
471,661.0,Ingermewiate,,,F,,17077.0,M8sjusculus,,1,12082,1,BAO0990219,CHEMBLy15r95,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,
472,651.0,Interm4d9ate,,,F,,14477.0,Musmuscjljs,,1,12082,1,BAO0900218,CHEMBk615486,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,
473,687.0,Intermed8xte,,,F,,12666.0,Mjsmusfulus,,1,2643,1,BzO0000210,CHEMBL615ei7,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,
474,969.0,sxpert,,,F,,25446.0,Muqnusculus,,1,11926,1,BAOp0p0219,CHEMBLu16498,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,
475,487.0,Intermedkat4,,,A,,5123.0,jusmuscklus,,1,15204,1,BAO00p02q9,CHEMBLy15t99,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,
476,496.0,2xpert,,,F,,11866.0,Musmysculux,,1,15992,1,BAO9000319,vHEMBL8r5522,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,
477,818.0,Intsrmeriate,,,F,,35265.0,Mudkusculus,,1,16279,1,BAp9000219,CHrhBL615500,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,
478,562.0,Imtermedixte,,,F,,24536.0,Muxm8sculus,,1,16279,1,BA90000w19,CbEMBL625501,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,
479,988.0,jntermedlate,,,F,,23026.0,njsmusculus,,1,16279,1,BwO00002q9,dHEMBL615592,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,
480,913.0,Inte4media6e,,,F,,25792.0,Mksmusculis,,1,16279,1,BAO900p219,CHEMBLt15504,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,
481,896.0,jn4ermediate,,,F,,2927.0,nusnusculus,,1,16279,1,BAO0009w19,CHEMBi615604,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,
482,785.0,Int3rmediat3,,,F,,14890.0,Muzkusculus,,1,16279,1,BAO0o00w19,CHEMBL61tr05,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,
483,896.0,Edpert,,,F,,10360.0,Musmisculue,,1,12831,1,BA8000021o,fHEMBp615506,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,
484,747.0,Iny4rmediate,,,F,,8629.0,M8smuxculus,,1,13497,1,BsO0000229,xmEMBL615507,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,
485,538.0,Interkesiate,,,F,,,,,1,13715,1,BAO00o9218,CHEjBL6w5508,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
486,1243.0,Ijtdrmediate,,,F,,22214.0,Musmyscuius,,1,13618,1,BAk0009219,fHwMBL615509,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,
487,600.0,Interjedixte,,,F,,20624.0,Musmusxul7s,,1,11902,1,BAO000p2q9,CjEMBL61t510,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,
488,545.0,Intermefiste,,,F,,39227.0,Mjqmusculus,,1,11902,1,BAO00p02w9,CHEMnL616511,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,
489,827.0,Interjediage,,,F,,5210.0,Musmuscuoud,,1,11902,1,BAO009021p,Ct3MBL615512,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,
490,395.0,9htermediate,,,F,,580.0,Muzmuwculus,,1,14840,1,BAip000218,CHEMgL6155q3,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,
491,797.0,Intf4mediate,,,F,,6277.0,Mismusfulus,,1,14840,1,BAk0090218,CH2MBLy15514,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,
492,655.0,Intermesiage,,,F,,,,,1,13715,1,BAOo00021o,CHEMBL615416,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,
493,443.0,Int2rmefiate,,,F,,,,,1,13715,1,BAO09o0219,CHEMnL615416,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
494,794.0,Internedizte,,,F,,,,,1,13715,1,BAOo000319,CbEMBL615527,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
495,1001.0,Inhermedia6e,,,F,,,,,1,13715,1,BxO0000119,CHEMvL6w5518,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
496,577.0,Inrermediatw,,,F,,,,,1,13715,1,hAO0000229,CHEMBk61551p,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
497,411.0,In5ermedia5e,,,F,,,,,1,13715,1,BAOo000318,xH3MBL615520,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,
498,963.0,Infermediat4,,,F,,,,,1,13715,1,BA000p0218,CyEMfL615521,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,
499,539.0,In44rmediate,,,F,,,,,1,13715,1,BAOp000228,CnsMBL615522,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
500,710.0,Int2rmddiate,,,F,,,,,1,13715,1,fAO0000q18,vHEMBLy15523,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
501,839.0,Experf,,,F,,,,,1,13715,1,BA00000q18,CHwMBL614524,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
502,366.0,wxpert,,,F,,,,,1,13715,1,BAO0p90218,CH3MBL61552t,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
503,843.0,Interhedizte,,,F,,,,,1,13715,1,BAO00p0318,CHEMBLu1552t,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
504,165.0,Intetmediage,,,F,,,,,1,13715,1,fAO000o218,CtEMBL6155e7,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
505,786.0,ojtermediate,,,F,,,,,1,13715,1,BAO0pp0218,CnEMBL61552o,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,
506,358.0,Exlert,,,F,,,,,1,13715,1,BAO0000wq8,CHEMgL615519,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
507,649.0,Expe5t,,,F,,,,,1,13715,1,BAOp000w18,sH3MBL615530,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
508,1174.0,wxpert,,,F,,,,,1,13715,1,BAO900021u,CHEMfL615t31,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
509,539.0,Interhsdiate,,,F,,,,,1,13715,1,fAOp000219,CHEMfL6155r2,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
510,918.0,Infermediats,,,F,,,,,1,13715,1,BAO0o0021o,CHEMgL61r533,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
511,762.0,on6ermediate,,,F,,,,,1,13715,1,BAO0oo0219,CjEMBL61t534,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
512,676.0,Intsrmediage,,,F,,,,,1,13715,1,nAO0000228,CHEMBi6w5535,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
513,299.0,Ihtermeeiate,,,F,,,,,1,13715,1,BA80000228,Cy2MBL615536,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
514,362.0,In4erhediate,,,F,,,,,1,13715,1,BsO0000228,CHEMBLuw5537,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
515,332.0,Intdrmddiate,,,F,,,,,1,13715,1,gAO000021o,CHEjBL6w5538,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
516,720.0,Imtermediatr,,,F,,,,,1,13715,1,BzO000021o,CHEMBp836w66,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
517,878.0,Ecpert,,,F,,,,,8,6411,1,hAO0000229,CHEMBLy25539,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,
518,760.0,Inre4mediate,,,F,,26102.0,Muzhusculus,,1,6411,1,BA9000021p,CHEMBku15540,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,
519,348.0,rxpert,,,F,,,,,8,6411,1,BAO0990219,CHEMvL61t541,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,
520,584.0,Ezpert,,,F,,16653.0,Mksmuscklus,,1,3966,1,Bsk0000219,CH2MBL614542,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,
521,872.0,Intermsdiatw,,,F,,14506.0,Musmuwcilus,,1,3966,1,BsOp000219,CHEMBLt25543,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,
522,857.0,Experr,,,F,,10010.0,M8smuscukus,,1,15556,1,BAO0po0219,CHEMBL6q6544,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,
523,724.0,Exprrt,,,F,,5259.0,Muqmuscilus,,1,5845,1,BqO00p0219,vHEMBL615535,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,
524,853.0,Edpert,,,F,,21860.0,kusjusculus,,1,14422,1,BxO0900219,CHsMBL625546,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,
525,766.0,Expe4t,,,F,,6363.0,Muwmusculuc,,1,5845,1,BsO00p0219,CHEMBL71y547,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,
526,577.0,dxpert,,,F,,3089.0,nuskusculus,,1,14508,1,nAO0000319,CHEMgL615t48,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,
527,802.0,Experg,,,F,,30957.0,Musmuscuihs,,1,14508,1,fAO000021p,dHEMBL6w5549,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,
528,496.0,Experr,,,F,,16372.0,Musmuscul6z,,1,14508,1,BzO00p0219,sHEMBLu15550,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,
529,716.0,Intsrmediqte,,,F,,970.0,Rattksnkrv4gicus,,1,6349,1,gAk0000219,CHEMfL61t551,,Inhibitory activity against rat fibroblast (3Y1) cell line,,
530,661.0,Exlert,,,F,,10179.0,fattucnorvegicuc,,1,15899,1,BAO90002q9,CHEMBL515y52,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,
531,730.0,Experr,,,F,,16370.0,Rattuwnorvegicyz,,1,15899,1,BqO00002w9,CHEMBL6w5554,,Cytotoxicity in 3Y1 cells.,,
532,658.0,Exper4,,,F,,4636.0,3attusnirvegidus,,1,15899,1,BAOp00021p,CHEMfL61555e,,Cytostatic effect in 3Y1 cells.,,
533,559.0,Intw4mediate,,,F,,4355.0,Rattusn9gvegicys,,1,15899,1,BxO000021i,fHEMBL6w5555,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,
534,972.0,dxpert,,,F,,18507.0,4attusnorvfgichs,,1,17038,1,BAl0000319,CHEnBL615557,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,
535,,Auticudation,,,B,,,,,0,12421,1,BAO0p0p019,Ct3MBL615557,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,
536,,Aktocurahion,,,B,,,,,0,12947,1,BAO0o0o019,CHEMBo615548,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
537,,Au4ocurqtion,,,B,,,,,0,12947,1,BAOp900019,CmEMBi872066,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
538,,sxpert,,,B,,36751.0,Susdcrofa,,9,4896,1,BAO90o0019,sHEMBL615659,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,
539,,Au4icuration,,,B,,,,,8,6148,1,BAO0p09019,CHEMBL625660,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,
540,,Auhocu3ation,,,B,,,,,8,16432,1,BAO000o029,dHEMBL715561,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,
541,,Eapert,,,B,,,,,8,4978,1,BAi9000019,CHEMfL85706e,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,
542,,Expe4t,,,B,,,,,8,4978,1,BzO0000o19,sHdMBL615562,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,
543,,Au5oxuration,,,B,,,,,8,3723,1,BAO000o01p,CnEMBLt15563,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,
544,,xutocurxtion,,,B,,,,,8,3518,1,nAO00p0357,CHEMBi61t564,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,
545,,Autlvuration,,,B,,,,,8,4164,1,BA0o000019,CH3MBLt15565,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,
546,,Augocuratiog,,,B,,,,,8,3518,1,BAO0o00018,CHEMBL6w556u,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,
547,,Espert,,,B,,9281.0,cusscrofa,,9,4164,1,BAOo000919,CHEMBL51556u,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,
548,,Autkcuratiin,,,B,,,,,8,3518,1,BAOp000919,CHEkBL515568,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,
549,,Autoc6rahion,,,B,,,,,8,3518,1,BAO00o0358,CmEMBk615569,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,
550,,Auhocuratiln,,,B,,,,,8,4978,1,BAOp00o019,CjEMBL61t570,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,
551,,Augocurati8n,,,B,,,,,8,4978,1,vAO0000010,xHEMBL616571,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,
552,,xuyocuration,,,B,,,,,4,6455,1,BAO900p224,CHdMBL6q5572,,Binding affinity against melatonin (MT1) receptor (pC1),,
553,,Autockrztion,,,B,,,,,0,2222,1,BAOp090019,CHEMgL615583,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,
554,,A7tocuratiob,,,B,,,,,0,13020,1,nAO000o019,CuEMBi615574,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,
555,,A7t9curation,,,B,,,,,0,13021,1,BxO0000029,CHrjBL615575,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,
556,,sutocurat7on,,,B,,,,,8,14532,1,BAO00002r7,CmEMBL61r576,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,
557,,Autofhration,,,B,,,,,8,14118,1,BAO0o00367,CHEMBL615586,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,
558,,Autochrati9n,4254297.0,,B,,,,,8,11884,1,BA90000w21,CgEMBL615r78,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,
559,,fxpert,,,B,,,,,8,13969,1,BAp000o357,CHEMBLu15570,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,
560,,Experh,,,B,,,,,8,13392,1,fAO000p357,CHEhBi615580,,Binding affinity for 5-hydroxytryptamine 1A receptor,,
561,,wxpert,,,B,,,,,8,14430,1,BAOoo00019,xHEMBL61t581,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,
562,,Ahtocuratoon,2708519.0,,B,,,,,8,12248,1,nAO0p00221,CHEMBo615592,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
563,,Autlvuration,2887458.0,,B,,,,,8,12249,1,BzO0p00221,fHEMBL61t583,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
564,,Autofu4ation,5718082.0,,B,,,,,8,9995,1,vAO0p00221,CHEMBLu1t584,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
565,,Autodurztion,1427107.0,,B,,,,,8,9995,1,BxO0000e21,CHEMvL833692,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
566,,Au6osuration,906175.0,,B,,,,,8,9995,1,BAO0o00231,xH3MBL615585,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
567,,Aur0curation,1485507.0,,B,,,,,8,9995,1,BAO00o0121,CHEMBLu15587,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
568,,Autocuraripn,1413142.0,,B,,,,,8,9995,1,BAO000922q,CHEMBL884rq4,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
569,,Autovurafion,2631526.0,,B,,,,,8,12249,1,BwO0009221,CHEMvp615587,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
570,,A74ocuration,791406.0,,B,,,,,8,11799,1,BAO0o09221,CHEMBL615y8o,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
571,,Ex0ert,,Membrxnes,B,,2015.0,Rattusnorbegifjs,,9,14331,1,fAOp000249,CHEnBL6w5589,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,
572,,Exoert,985279.0,,B,,8556.0,Bostxurus,,8,11884,1,nAk0000221,CHEMhL6154e2,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,
573,,A6tocurahion,1917539.0,,B,,,,,8,14331,1,BqO0000231,CHEMBL7154t3,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,
574,,Autoxurstion,7477891.0,,B,,,,,8,11701,1,BAO0000311,CHrMBL6w5444,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,
575,,Ex0ert,62067.0,,B,,,,,8,11701,1,BAO00pp221,CHEhBi615445,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,
576,,Auhocuratikn,876614.0,,B,,,,,8,12248,1,BAk000022w,fHwMBL615446,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,
577,530.0,Ahtocuratuon,,,B,,,,,8,12248,1,BAOp00p219,CuEMBL615457,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,
578,,Expett,2601990.0,,B,,,,,8,12248,1,BsO000022q,Cb4MBL615448,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
579,,wxpert,4019329.0,,B,,,,,8,12249,1,BA90900221,CHEMBLy1544o,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
580,736.0,Autod7ration,,,B,,,,,8,12248,1,BAO0000129,dHEMBL6154r0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
581,,fxpert,2298636.0,,B,,,,,8,11799,1,BAO0090e21,CH3nBL615451,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
582,,Autkcuratioj,,,B,,,,,8,634,1,BAl0900357,dHEhBL615452,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
583,,sutocuratlon,2212825.0,,B,,,,,8,9995,1,BAOop00221,CHEjBL615463,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
584,,Autovuratkon,1824277.0,,B,,,,,8,9995,1,BAO9000222,CHEMBL62y454,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
585,,qutocurati8n,5110182.0,,B,,,,,8,9995,1,BAO000o222,CHEkBL6154t5,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
586,,Augocurati9n,894598.0,,B,,,,,8,9995,1,BAO0000e2q,CmEMBL61545y,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
587,,Autoc7rwtion,1374870.0,,B,,,,,8,9995,1,BzO0009221,CHEMBL6154ru,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
588,,Exper6,5108513.0,,B,,,,,8,12210,1,BsO0o00218,fHEMBi615458,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,
589,,Experf,152571.0,,B,,,,,8,13311,1,BAp0090221,xuEMBL615459,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
590,1063.0,Expery,,,B,,3445.0,Homlsxpiens,,9,2331,1,BAi00p0219,CHEhBL6w5460,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,
591,,Autocjrwtion,,,F,,2456.0,Caviap84cellus,,8,1375,1,vAO0000o19,CHEMBi6154u1,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,
592,,Aufocurwtion,,,F,,5378.0,Cadiaporcelluc,,8,1375,1,BAOp0000w9,CHEMBL6154tw,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,
593,,Au6icuration,646632.0,,F,,4044.0,vav7aporcellus,,8,11574,1,BAO00902e1,CHEMvL615462,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,
594,,Autocuratlom,1235799.0,,B,,13863.0,Caviap9rcell8s,,8,12867,1,BAO00002ew,fHEMBL6q5464,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,
595,,sutocudation,2466620.0,,B,,8631.0,Cagiapkrcellus,,8,12867,1,gAO0900221,CHEhBL6w5465,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,
596,,sutocuratiob,5821761.0,,B,,28376.0,Caviaporc2lkus,,8,12867,1,vAO0000w21,CHEhBL615r66,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,
597,,Autoxjration,2731511.0,,B,,35460.0,Caviaoorceplus,,8,12867,1,BAO09002q1,vHEjBL615467,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,
598,,Autocurw4ion,3716113.0,,B,,7118.0,Caviaporc3lpus,,8,12867,1,vAO00p0221,CH3MBL6154t8,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,
599,,Autocura48on,5669733.0,,B,,9889.0,Cxviaporfellus,,8,12867,1,BAO00o0w21,CHEnBLt15469,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,
600,,Autovurstion,,,B,,1463.0,Cav7apkrcellus,,8,11574,1,BAOp000257,CH2jBL615470,,Binding affinity against 5-hydroxytryptamine 1A receptor,,
601,,Autocurahiin,,,B,,25753.0,Cwviaporcdllus,,8,13114,1,BAO0o00347,xHEnBL615471,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,
602,,Aurocjration,,,B,,15362.0,Cavia0oecellus,,8,13181,1,BAOo009357,xHEMBL614472,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,
603,,Autocurayi8n,1206574.0,,B,,12254.0,Caviapordelluz,,8,10639,1,BA0000022q,CHEMvL88324q,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,
604,,wutocurztion,4490332.0,,F,,19709.0,Cafiaporcellud,,8,10639,1,BAO0p00q21,CHEMBp61547e,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,
605,765.0,Autovhration,,,B,,43829.0,Cricet8lusgrosrus,,8,11883,1,BAOo0p0218,sHEMBL61t474,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,
606,,wutoduration,,,B,,,,,8,17785,1,BAO0009358,CHEMnL61t475,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,
607,305.0,Autocurwtjon,,,F,,,,,8,1558,1,BAO0o0p219,CHfMBL614476,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,
608,519.0,wutocyration,,,F,,,,,8,1558,1,BAO0009229,CH4kBL615477,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,
609,,Au4ocurat9on,,,F,,,,,8,15740,1,vAO0000018,CHEMBL61r479,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
610,448.0,Aut0curqtion,,,F,,,,,8,17624,1,BA8000021p,CHEMBL615q69,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
611,640.0,Espert,,,F,,,,,8,17624,1,BAO0p09219,CHEMBLy15151,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
612,709.0,zutocuratjon,,,F,,,,,8,17624,1,BAO000p2q9,CHEMBL725162,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,
613,361.0,Aut9curqtion,,,F,,,,,8,17624,1,BAk00p0219,CtEMBp615163,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,
614,752.0,Espert,,,B,,,,,8,17624,1,BAOp00021p,CHEMBo715164,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
615,625.0,Exp3rt,,,B,,,,,8,17624,1,BAO000921p,CHEMBpu15165,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
616,764.0,wutocudation,,,B,,,,,8,17624,1,BAO00002qi,CHEMBL6251t6,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,
617,,Aurocurstion,,,F,,,,,8,14256,1,BAi00002w9,CHfMBi615167,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,
618,861.0,Expwrt,,,B,,7901.0,Homosap8dns,,9,3445,1,hAO000021i,vHEMBL515168,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,
619,501.0,Ezpert,,,B,,2365.0,Hpmosap9ens,,9,3445,1,BAO000o319,sHEMBL615160,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,
620,1052.0,Exlert,,,B,,24847.0,bomoszpiens,,9,17200,1,BAO0000ew9,sHEkBL615170,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,
621,402.0,Expsrt,,,B,,18529.0,Homosap8rns,,9,17200,1,BAi0009219,CHEMvL61517q,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,
622,,Autochratikn,,,F,,,,,8,15180,1,BAO0p0o019,CHEMBL625794,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
623,,Au4ocurat9on,,,F,,,,,8,15180,1,BsO000o019,dHEMgL615695,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
624,,Autocura6jon,,,F,,,,,8,16026,1,BAO0p0001i,CHEMBL6w5695,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
625,964.0,Autocufat8on,,,F,,,,,8,2759,1,BzOp000219,xHEMgL615697,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
626,1010.0,Exper4,,,F,,10934.0,Homoxa9iens,,9,2759,1,BAOo00o219,CHEMBk859420,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,
627,657.0,sutocurat8on,,,F,,,,,8,2759,1,BAO00p0319,vHEMBL615851,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
628,749.0,Ecpert,,,F,,19820.0,g8mosapiens,,9,2759,1,fAO0000218,CHdMBo615842,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,
629,944.0,qutoc8ration,,,F,,,,,8,2759,1,BA8o000219,fHEMBL935003,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
630,137.0,Autkcuratuon,,,F,,,,,8,2759,1,BzO00o0219,CHEMfp615843,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,
631,901.0,Expery,,,F,,15078.0,Homosapkems,,9,2759,1,BAO0009229,CHEMBpt15979,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,
632,553.0,Au5ocuratioj,,,F,,,,,8,2759,1,BAO0000q18,CHEMvL61t980,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
633,492.0,Expfrt,,,F,,5279.0,Hojosapuens,,9,2759,1,BAO000011o,CHEMgLy15981,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,
634,,3xpert,,,F,,8422.0,tomosapienx,,9,3445,1,BA9000001o,CH4MBL615983,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,
635,,Edpert,,,F,,21686.0,Homosapoebs,,9,5272,1,BAO0900919,CHEMhL6159i3,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,
636,,Ezpert,,,F,,16459.0,Homosa9iebs,,9,5272,1,BzO0009019,CHEMBp625984,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,
637,,Ex0ert,,,F,,3521.0,Homosa9iejs,,9,5272,1,BAO000002o,CHEMBLy1598y,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,
638,920.0,z7tocuration,,,F,,,,,8,17624,1,BAOo900219,CHEMgL61598y,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
639,694.0,Autkcuratiob,,,F,,,,,8,17624,1,BAO0o00229,CtEMBL6w5987,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
640,506.0,Autocurariln,,,F,,,,,8,17624,1,Bqi0000219,CHEMBi615989,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
641,512.0,Expdrt,,,F,,,,,8,17624,1,vAO000p219,vHEMBL615980,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
642,653.0,Autovjration,,,F,,,,,8,17624,1,BxO9000219,sbEMBL615990,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
643,853.0,Autocurq4ion,,,F,,,,,8,17624,1,BAO0p90219,CH2MgL615991,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,
644,852.0,zut0curation,,,F,,,,,8,17624,1,BAO00003q9,CHEMgp615992,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
645,670.0,Aitocuratipn,,,F,,,,,8,17624,1,hAO0000210,CHEMBL615902,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
646,54.0,Experh,,,F,,,,,8,17624,1,nAO0009219,CHEMBLu25994,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
647,756.0,Aktocura4ion,,,F,,,,,8,17624,1,BA800002q9,CHEjBL615p95,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,
648,457.0,Autofuratuon,,,F,,,,,8,17624,1,BAOo000w19,CHsMgL615996,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
649,334.0,Ahtlcuration,,,F,,,,,8,17624,1,BAO000p2w9,CHEMBL6159o6,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
650,,Aut8curatiom,,,F,,,,,8,6563,1,BAOo000o19,CtEMBL615988,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
651,,Autlcuratiob,,,F,,,,,8,6563,1,hAO0000p19,dHEMBL615990,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
652,,Auticurayion,,,F,,,,,8,6563,1,BwO0000919,vHdMBL616000,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
653,679.0,Ahtoc6ration,,,F,,,,,8,17296,1,BAO0000qq9,CHsMBL616p01,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
654,,Expeet,,,F,,29418.0,yomosapiebs,,9,6876,1,BA8000o019,dHEMBL616902,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,
655,,Expedt,,,F,,,,,8,6876,1,BqO0900019,vH2MBL616003,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,
656,,Ex0ert,,,F,,36209.0,Homoqwpiens,,9,5272,1,hAO000001o,Cm4MBL616004,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,
657,,Edpert,,,F,,7736.0,Hompxapiens,,9,5272,1,fAO0090019,vHEMBL61u005,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,
658,,Autovurayion,,,F,,,,,8,5548,1,BAO900o019,CHEknL616006,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
659,,fxpert,,,F,,,,,8,5548,1,BAO0pp0019,CHEMBLt16p07,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,
660,,Autociratiob,,,F,,,,,8,5548,1,BsOo000019,CHEhBL626008,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
661,,Ait8curation,,,F,,,,,8,5548,1,BAO00o0919,CHEnBL516009,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
662,,Ex0ert,,,F,,,,,8,5929,1,BxO0000p19,CH2MhL616010,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,
663,,4xpert,,,F,,16095.0,Homosxpiene,,9,5929,1,hAO00000q9,CH4nBL616011,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,
664,,Expedt,,,F,,21958.0,Hom9sapienx,,9,5929,1,BAO9000919,CHEjBp615740,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,
665,,zutocurat8on,,,F,,,,,8,16245,1,vAO00000w9,CHEMBL615yt1,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,
666,,Experf,,,F,,,,,8,5640,1,BAO00p0p19,CgEMnL615742,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
667,,Aurocuratiom,,,F,,,,,8,5640,1,BAk0o00019,xHEMBL6157t3,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,
668,504.0,A8tosuration,,,F,,,,,8,14509,1,BAp00002w9,CHEMgL6q5744,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,
669,384.0,Expwrt,,,F,,,,,8,14509,1,BAkp000219,CHEkBL61574y,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,
670,,Autocurayi9n,,,B,,,,,8,15331,1,BzOo000357,CbEMBL6q5746,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
671,,Aht9curation,,,B,,,,,8,15331,1,BAOo00035i,CHEMgL6w5747,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
672,,Autoc6gation,,,F,,,,,8,6563,1,BAO00p0029,CHEMfL615747,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
673,,Autpxuration,,,F,,,,,8,6563,1,BxO0000919,CHfkBL615749,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,
674,,qktocuration,,,F,,,,,8,6563,1,BAlp000019,CgEMBi615750,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
675,,Ezpert,,,F,,18049.0,Hkmosaplens,,9,6563,1,BwO0o00019,dHEMBL6162y9,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,
676,,Autpsuration,,,F,,,,,8,6563,1,Bz90000019,CHEMBL6w62t0,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
677,,Expegt,,,F,,35459.0,Homosap72ns,,9,5272,1,BAO9000018,CH4MBo616261,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,
678,,4xpert,,,F,,23189.0,Homksapifns,,9,5272,1,BAO0p0p019,CHwMBL6162t2,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,
679,,Expe4t,,,F,,58499.0,Hpmosxpiens,,9,5272,1,BAOp00001p,dHEMBL616163,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,
680,,Exlert,,,F,,52834.0,Homosap7fns,,9,5272,1,BAO0000o1p,CHEMBpu16264,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,
681,,Experf,,,F,,23020.0,H9mosapiebs,,9,5272,1,BAO00000q0,CHEMBL61te65,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,
682,,4xpert,,,F,,822.0,Hohosapiebs,,9,5272,1,BAO0p00029,CHwMBL616q66,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,
683,,Expeet,,,F,,6225.0,tomosspiens,,9,5272,1,BwO0000018,CHEMBLt17267,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,
684,,Expegt,,,F,,5142.0,Hojosapienc,,9,5272,1,BAO09000q9,CHsMBL617268,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,
685,,Experf,,,B,,11732.0,H8m8sapiens,,9,16146,1,fAO000o357,vHEMBL516269,,Inhibition of human 5-hydroxytryptamine 1A receptor,,
686,527.0,Autocu5a4ion,,,B,,,,,8,17624,1,BwO0000210,CHEMvL884538,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
687,900.0,Expery,,,B,,,,,9,13706,1,BAO0p90219,CgEnBL616270,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,
688,483.0,Autox7ration,,,B,,,,,8,15250,1,nAOp000219,fHEkBL616271,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,
689,547.0,Aut0suration,,,F,,,,,8,17624,1,BAp00p0219,fHrMBL616272,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
690,,Exp4rt,,,B,,,,,8,6861,1,fAO0000358,CHEkBL616173,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,
691,,Ecpert,,,B,,11958.0,Hohosqpiens,,9,17200,1,BA00009357,vHEMBL6w6274,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,
692,890.0,Aut8curagion,,,B,,,,,8,17624,1,BAO0000329,CHEMBp6w6275,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,
693,806.0,xjtocuration,,,B,,,,,8,17624,1,fA00000219,CHEMBk6162i6,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
694,,Autocu4atkon,,,F,,25287.0,Rat6usnorvegivjs,,0,12058,1,BzO00o0218,CHdMBL617277,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,
695,,Autlchration,,,F,,36161.0,Ratt7snorvenicuz,,0,12058,1,BxO0000w18,fHEMBL616268,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,In vivo,
696,,Autosura5ion,,,F,,2099.0,gagtusnorvegichs,,0,12058,1,nAk0000218,CHEMBL617w79,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,In vivo,
697,,Autpcu3ation,,,F,,12033.0,Rartusnorveg8cuc,,0,12058,1,BAl000021i,CHEMBi6q6280,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,
698,,Augocufation,,,F,,12706.0,Rsttusn0rvegifus,,0,12058,1,BAi0000217,CHEMvL616w81,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,In vivo,
699,,Autlcuratipn,,,F,,7538.0,Rattusno3vevjcus,,0,12058,1,hqO0000218,CHEnnL616282,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,
700,,xutockration,,,F,,51610.0,Rargusnorvegixus,,0,12058,1,BAOp000318,fHEMBL61628w,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,In vivo,
701,,Aut8curat9on,,,F,,51644.0,Rattuano3vegkcus,,0,12058,1,BAO90p0218,CHEMBL6w6w84,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,In vivo,
702,,A6t9curation,,,F,,356.0,Rstyusnorvegivus,,0,12058,1,BAO90002q8,CHEjBL61u285,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,In vivo,
703,,Autocuratupn,,,F,,5194.0,5a6tisnorvegicus,,0,12058,1,BAOp000228,CHEnBL716286,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,In vivo,
704,,Aufovuration,,,F,,24324.0,gattusno5vegivus,,0,12058,1,BAO0000w28,CHEMBL6w628y,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,In vivo,
705,,Autocu3atiom,,,F,,10941.0,Rattuqhorgegicus,,0,12058,1,vxO0000218,CHEMBLy1628o,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,In vivo,
706,,Autocura5iob,,,F,,5295.0,eattusnorvfbicus,,0,12058,1,BAO0000w17,CHEMfk616289,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,In vivo,
707,,zutocura6ion,,,F,,15825.0,Ratt8snordegixus,,0,12058,1,BAO9000228,fHEMBL615u10,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,In vivo,
708,,Aytofuration,,,F,,18719.0,gattusnorveglcis,,0,12058,1,BxO0000w18,CHEkBL6w5611,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,In vivo,
709,,Ajtoc6ration,,,F,,11351.0,eattusnoevegic7s,,0,12058,1,Bq90000218,CHEMBL615t1w,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,In vivo,
710,,Aut0curatiob,,,F,,6109.0,gat4usno3vegicus,,0,12058,1,BsO00002q8,CHEMBL6156qr,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,In vivo,
711,,Autoxuratioj,,,F,,3875.0,Ragtusnirv4gicus,,0,12058,1,BAO900021i,CHEMBL6w561e,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,In vivo,
712,,Autocyrat7on,,,F,,1089.0,Rattuznoevericus,,0,12058,1,BAO000031u,CHwMBL61r615,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,
713,,Aitocura4ion,,,B,,,,,4,11440,1,vAO0000010,CHEMBLy16616,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,
714,,Au5ocueation,3684724.0,,B,,,,,8,6238,1,nAO0000248,CHEMBL6146w7,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,
715,,Ait9curation,,,B,,,,,8,10046,1,BAO00000q0,CbEMBL61r618,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,
716,,Autocurwyion,,,B,,,,,8,10046,1,nAO0900019,CHwMBL615618,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,
717,,Experg,,,B,,,,,8,10046,1,BAO000002o,CHEjBL615y20,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
718,,A66ocuration,,,B,,,,,8,167,1,BAO00093y7,CHEMBL6w562w,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,
719,,xutocufation,,,B,,,,,8,167,1,BqOo000357,CnEMBL6q5622,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,
720,,Aut0suration,,,F,,,,,8,11520,1,BsOp000019,CHEMBL615ue3,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,
721,,Autocyratiln,,,F,,,,,8,11520,1,BAO000091o,CnEjBL615624,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
722,,qutocjration,,,F,,,,,8,11520,1,BAO00o0919,CHEMhL615725,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
723,,Autlcurati8n,,,F,,,,,8,11520,1,BAO0000p29,CHsMhL767045,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
724,,Autocueat9on,,,F,,29344.0,Caviaporfeplus,,8,135,1,BA00009019,CbEMBL61r626,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,
725,,Autlcuratiog,,,F,,950.0,Caviaoorcelljs,,8,135,1,BAp0009019,CHEMBp615628,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,
726,,sutocuratiin,,,B,,17740.0,Caviap0rcelous,,8,11311,1,BAl00000w9,CH3MhL615628,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,
727,,Autocuragikn,,,B,,23975.0,Caviapordell6s,,8,10193,1,BAO0009257,CHEMBL615u2o,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,
728,,Expwrt,,,B,,13397.0,Homosaliwns,,9,12281,1,BqO000p357,fHEMBL615639,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,
729,,Au4ocuratioj,,,B,,,,,8,11311,1,BxO000021o,CHEMhL6156e1,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
730,,Autocu3a5ion,,,F,,,,,8,12576,1,BsOo000218,CHEjvL615632,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
731,,Autoc8ratiom,,,B,,,,,8,12281,1,BAO00093y7,CHEhBL61t633,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,
732,,Augociration,,,F,,,,,8,12576,1,BAO0000qw8,CHEMBku15634,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
733,,Expdrt,,,B,,2464.0,Sudscrofa,,8,11089,1,BxOo000019,CHfMBL715635,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,
734,,Expfrt,,,B,,,,,8,11006,1,BqO0090357,CjEMBL615736,,In vitro inhibition of rat 5-Lipoxygenase,,
735,,Espert,,,B,,17020.0,eattusnotvegocus,,9,11481,1,BAO0000wr7,CHEjnL615637,,Inhibitory activity against 5-Lipoxygenase,,
736,773.0,Expdrt,,,B,,,,,8,10864,1,Bxp0000219,fHEnBL615638,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,
737,1001.0,Autocutatoon,,,B,,,,,8,3595,1,nAO000021p,CHEMBp625639,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
738,555.0,Autocurarikn,,,B,,,,,8,11311,1,BAO9p00219,CHEMBo6q5640,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,
739,,Autocurztiln,,,B,,,,,8,11311,1,Bq80000019,CHEMBL61479t,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,
740,,Autocigation,,,B,,,,,8,11311,1,BAp0000w19,CHEMBL516845,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,
741,,Aut9curafion,,,B,,,,,8,11006,1,BqO00003y7,CHEkBk615846,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
742,357.0,Autkcuratikn,,,B,,,,,8,3595,1,BzO000o219,CHEMBL6158r8,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
743,,A6tocurstion,,,B,,,,,8,11311,1,BAOo0p0357,CHEMBL51t848,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,
744,,Aurocuratiin,,,B,,2024.0,Rafrusnorvegifus,,0,11481,1,BAOp000p19,sHEMBo615849,,Ratio of IC50 against 5-LO and COX,,
745,,A8tocuratkon,,,B,,,,,8,11006,1,nAO0000w57,CuEMBL6w5850,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
746,,Autoduratiln,,,B,,,,,8,11006,1,gAO000035y,CH3MBo615851,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,
747,,Aht0curation,,,B,,,,,8,11311,1,BAO00o0210,CHEMBiy15852,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,
748,,Aut9curat7on,,,F,,,,,8,11006,1,BAO0oo0019,CHEMBL71585e,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,
749,,Ajtocuratioj,1445230.0,,B,,,,,8,4288,1,BAO0009356,CH4MBL884427,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,
750,,Autocursti9n,,,B,,33702.0,Colukbalivua,,0,7587,1,BAOp000o19,CHEMBL87w881,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,
751,,Autlcuratioj,,,B,,6041.0,Coiumbaliviw,,0,7587,1,BAO0000oq9,CH3MBi615854,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,
752,,Autofurafion,,,B,,4127.0,Cklumbaoivia,,0,7587,1,vA00000019,dHEhBL767046,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,
753,,Autoxurwtion,,,B,,,,,8,11249,1,BAO000o257,CHwMvL615855,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,
754,,sxpert,,,F,,20570.0,Rattusn0rvwgichs,,9,8003,1,BAl000001i,CHEMBo61585y,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,
755,,Exp2rt,,,F,,38158.0,Rattusn84vegicux,,9,8003,1,BAO000p919,CHEMgL615u57,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,
756,,Expe4t,,,F,,13002.0,Rattusgotvegicks,,9,8003,1,BxO0p00019,CHEkBLu15858,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,
757,,Exper4,132713.0,,B,,,,,8,12416,1,BAO0o0p221,CHEjhL615859,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
758,,Autosurati0n,,,B,,,,,8,16293,1,BAO0000rt7,CHEMBi616860,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,
759,,Autocurati0m,,,B,,5270.0,Oryct0lagkscubichlus,,0,13047,1,BA9000p019,dHsMBL615861,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,
760,,Aitocura5ion,,,B,,15921.0,Otyc6olagusxunicuius,,0,13047,1,BqO0000010,CHEhgL615862,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,
761,,Ai6ocuration,,,B,,30674.0,Orydtokwgusc7niculus,,0,13047,1,BAl00o0019,CHEMBL615o62,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,
762,,Autocurqtiin,,,B,,742.0,Oryctolagusvugixul8s,,0,13047,1,BqO00o0019,xnEMBL615864,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,
763,,Autocuratkin,4927292.0,,B,,,,,4,10085,1,BA9000o221,CH3MBL61586r,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
764,,wktocuration,2502411.0,,B,,,,,4,10085,1,BAO0op0221,vHEMBL6w5866,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
765,,Akfocuration,1251866.0,,B,,,,,4,10085,1,BAO9900221,dHEMBL715867,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
766,,Autoc8ragion,,Membranss,B,,,,,4,9841,1,BAO0p0024o,CmEMBL515868,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,
767,,Aufocura5ion,,,B,,4945.0,Rahtusnifvegicus,,5,8822,1,gAO00o0249,CgEkBL615869,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,
768,,Autocuratilj,,,B,,36529.0,Rwtgusnorv4gicus,,5,9806,1,BAO0000oq9,CHEnBL6q5870,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,
769,,Autlcurati9n,,,B,,10084.0,Ra4t8smorvegicus,,5,9806,1,BAOo000o19,CmEMBL61587w,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,
770,,Autocurayoon,,,B,,,,,4,8868,1,BAO0900234,CH3MBL6158i2,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,
771,,Aufocurati8n,2681439.0,,B,,,,,4,9036,1,BAOp000121,CHEMBii33492,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,
772,,Autocueatioh,1110865.0,,B,,,,,4,11374,1,BAi0000w21,CHEMBi61587r,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,
773,,Autkcura4ion,,,B,,,,,4,10881,1,BAOo900224,CHEnBL615470,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,
774,,Autod8ration,,,B,,,,,4,8822,1,BwO0000o19,CHEMBL6q5489,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,
775,,Aut0cura4ion,,,B,,17285.0,Rahtusnorvevic6s,,5,9806,1,vxO0000249,CH2MBL615e81,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,
776,,qutocueation,,,B,,,,,4,15463,1,BAO0o00010,CHEMBk87286p,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
777,,Autockratikn,,,B,,,,,4,15463,1,hAO000p019,CHEMBL5w5482,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
778,,w8tocuration,1807774.0,,B,,,,,4,14542,1,BzO0090221,CHEMBo615473,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
779,,Autpcu5ation,3100810.0,,B,,,,,4,14542,1,BA800o0221,CHEMfL6w5484,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
780,,Autocurati9m,,,B,,,,,4,8569,1,vqO0000019,CHEMBL61r48y,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,
781,,qutocuratjon,,,B,,13876.0,fathusnlrvegicus,,5,10062,1,BAi00002e4,CHEMnL6154i6,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,
782,,Autocu3atiog,,,B,,,,,4,4771,1,BAOp00p224,xHEMBL61548i,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,
783,,qutocuratioj,,,B,,,,,4,10062,1,BAO000p22r,CHEMBo615r88,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
784,,Autpcuratikn,,,B,,,,,4,10062,1,BAO00o0e24,dHEMBLy15489,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
785,,Autochra4ion,,,B,,,,,4,10062,1,BAO0090214,CtEMBL615380,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
786,,Autoduratiob,,,B,,,,,4,15463,1,BAO90000q9,CHEMBL6w4390,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
787,,xu4ocuration,,,B,,,,,4,15463,1,BAO09000w9,CHEMfi615391,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
788,,Auyocurztion,,,B,,,,,4,9098,1,BAO009p224,CHEMBk615e92,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,
789,,wutocurstion,,,B,,53414.0,Rattusn04vegidus,,0,3070,1,BAO00000q8,CuEMBL6153i3,,Affinity for 5-hydroxytryptamine 1 receptor,,
790,,Autocuraf8on,1831519.0,,B,,,,,4,14542,1,BAO000p231,CH3MBL615w94,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,
791,,Autocjrztion,2592891.0,,B,,,,,4,14542,1,BAO00p0q21,CHEjvL615395,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
792,,Aut8curat9on,,,B,,,,,4,6398,1,hAO0000214,CHEMvL61539t,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,
793,,Autoc7rati0n,1630799.0,,B,,,,,4,1344,1,vAO000022w,CHEMBLu15297,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,
794,,Autlfuration,,,B,,,,,4,11963,1,BAO0000o18,xHfMBL615398,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
795,,Autocurwtiin,,,B,,3021.0,Ra5tusnirbegicus,,0,8908,1,vAO0o00019,CHEMBL6q539i,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,
796,,Au4ocurati0n,,,B,,,,,4,9098,1,BAO0909019,CHEMBL61530p,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,
797,,Autocudati9n,,,B,,24644.0,Rattusgorceg9cus,,5,8841,1,BAO0900p19,CHEMnL6w5401,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,
798,,Aufpcuration,,,B,,9776.0,Rattusn8rfegichs,,0,8814,1,BAO0090919,CHEMBL625502,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,
799,,Ahtocuratioj,,,B,,,,,4,11752,1,BAp0090019,CHEnBL6w5403,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,
800,,Au6ocuratuon,3487009.0,,B,,,,,4,11642,1,BAp00002w1,CnEMBL615504,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,
801,,Autpcutation,,,B,,,,,4,11642,1,BAOo00p019,CHEMBL61t791,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,
802,,Autocurxtiob,2260527.0,,B,,,,,4,9231,1,BzO000022o,CHEMBk615792,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,
803,,Autlchration,1680917.0,,B,,,,,4,11351,1,BwO000p221,CHEMBLy15773,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,
804,,Au4ofuration,,,B,,,,,0,4639,1,nwO0000019,CHdkBL873481,,Compound was tested for binding affinity against 5-HT1 receptor,,
805,,Autoxuratipn,,,B,,,,,0,1205,1,fAO0o00019,CHEMfLu15784,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,
806,,Exper5,,,B,,,,,8,10025,1,BA90009357,dHEMBL6157i5,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
807,,xutocuratjon,,,F,,,,,8,13241,1,nAO000o249,CHEjBL61t786,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
808,,wut0curation,,,F,,,,,8,16245,1,hAO0000219,CHEMBL6157o8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,
809,,Aitocuratiom,,,F,,,,,8,16245,1,BAOo000219,CH2MBL625788,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,
810,,Autocuratkob,,,F,,,,,8,12438,1,BAO0009029,vHEMBo767044,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,
811,,zurocuration,,,F,,,,,8,16245,1,BAO0900219,CHEMBL615yu9,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,
812,,Autoc8rztion,,,F,,,,,8,16245,1,BxO00o0218,CHEMBLy15700,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,
813,,Autocurshion,,,F,,,,,8,15740,1,BAO000901o,CH2MBL625813,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,
814,,A6tocurafion,,,F,,,,,8,15535,1,vAO0000229,CHEkBL61t814,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,
815,,Expegt,,,F,,,,,8,15535,1,BAO0000q1o,CHEjBL61t815,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,
816,,Autoc6ratoon,,,F,,,,,8,15535,1,nAOp000219,dH4MBL615816,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,
817,,Ezpert,,,B,,,,,8,9888,1,BAO000pw49,CHEMBk6158q7,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,
818,,Aitlcuration,1963559.0,,B,,,,,8,10085,1,BAO090022w,sHEMBL614818,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,
819,,Augocuratiin,4646142.0,,B,,,,,8,10085,1,BAl0090221,CtEMfL615819,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,
820,,Edpert,,Membrsnes,B,,,,,8,17331,1,BqO00o0249,CHEkfL615820,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,
821,,Experf,3444389.0,,B,,11044.0,Rattuenorvegixuz,,9,10845,1,BAO00o022q,CHEMBL615oq1,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,
822,,Ezpert,6179332.0,,B,,28846.0,Ratfhsnorv2gicus,,9,10845,1,BA80009221,CHEnBL615812,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,
823,,Eapert,1587385.0,,B,,,,,8,10845,1,BAO0009321,CHEhBL6q5823,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,
824,,Ex0ert,9110734.0,,B,,1984.0,Rattudno3vegkcus,,9,10845,1,nwO0000221,dHEMBLt15824,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,
825,,dxpert,3805773.0,,B,,20579.0,Rat5udnorvegicue,,9,10845,1,hAO00p0221,xHEMBL61582y,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,
826,,Exprrt,,,B,,,,,8,13730,1,gAO0o00357,CgEMhL615826,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,
827,,Ex0ert,,,B,,,,,8,13508,1,BAp0000w49,CHwjBL615827,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,
828,,Exper5,1236356.0,,B,,,,,8,13508,1,BAk0009249,CHdMBL615u28,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,
829,,Exp3rt,3298258.0,,B,,,,,8,12073,1,BAO00po221,sHEMBL615820,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
830,,Autocugati8n,8114928.0,,B,,,,,8,4671,1,BqO0000231,CHEnBL61r830,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,
831,,Expedt,391210.0,,B,,,,,8,13631,1,nAO000022w,CHEhfL615831,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,
832,,qutocura6ion,,,B,,,,,8,12438,1,BAO0p00457,CHsMBL615833,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,
833,,Autodurat7on,,,B,,,,,8,10483,1,BAO900001o,CHEMBp615733,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,
834,,Aufocuragion,1350686.0,,B,,,,,8,10483,1,BAO0p09221,CHEMgL515834,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,
835,,In4ermediahe,,,B,,,,,8,12352,1,BAO0909249,CHEMgL61t835,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,
836,,Autocurahioh,1156992.0,,B,,,,,8,14732,1,BAk0000240,CHEMBL61584t,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,
837,,Expedt,,,B,,10228.0,Rattuxn8rvericus,,9,11049,1,BAi00p0019,CHrMBk615837,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,
838,,Edpert,,,B,,41397.0,Ratt7sn9rvegicud,,9,11049,1,BAOo000p19,CHEjBL615938,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,
839,,sxpert,,,B,,,,,8,13657,1,vxO0000249,CnEMBL615830,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,
840,,Autocirat9on,,,B,,,,,8,11473,1,BAO0o0001i,CHEMfL884524,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,
841,,Aut9curqtion,,,B,,,,,8,2014,1,fAO000p249,CHEMhL615o40,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
842,,Expe5t,631480.0,,B,,,,,8,3086,1,BAO00p022w,CHwMBLu15405,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
843,,Experh,,,B,,,,,8,15854,1,BAOo000010,fHEMBL61540t,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
844,,Expeft,591129.0,,B,,,,,8,10922,1,BAO000922w,fHEMBL616900,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
845,,2xpert,264658.0,,B,,,,,8,13346,1,BAO009p221,CH2MBL6q5901,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,
846,,Expsrt,,,B,,,,,8,15311,1,hAO00003r7,CnwMBL615902,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,
847,,Auyosuration,3979402.0,,B,,,,,8,10922,1,BAO9000321,fHEMBL6159o3,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
848,,Autoxurahion,,,B,,,,,8,10025,1,BsO000035u,CH4MBL6159p4,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,
849,,Expeet,,,B,,,,,8,10025,1,hAO000035u,CHEMvL6q5905,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
850,,Auyocurati9n,,,B,,,,,8,9742,1,BsO0009019,CHEMfL6w5906,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
851,,Autoxutation,,,F,,,,,8,9742,1,BwO0000029,CHEMBLuq5907,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
852,,Expfrt,,,B,,,,,8,12304,1,BAO0000910,CH3kBL615908,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
853,,Autocu3atioj,586686.0,,B,,,,,8,15789,1,BA000002w1,CHEMBLt159p9,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,
854,,Autodura4ion,,,B,,,,,8,9912,1,BxO0000029,dHEMBL61591o,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,
855,,Autocyratoon,,,B,,,,,8,9912,1,BAO0p09019,sHEMBL61591w,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,
856,,Autocura5i8n,,,B,,,,,8,9912,1,BAO0000o29,CHEMhL616912,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,
857,,Exoert,,,B,,,,,8,16693,1,BAO90000w9,CHEMBL51y913,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
858,,Ex9ert,,,B,,,,,8,13276,1,BqO0o00357,CHEMBL625915,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
859,,wugocuration,1841307.0,,B,,,,,8,12678,1,BAO0000ee1,CHEMgL616915,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
860,,Autocutati9n,,,B,,,,,8,11825,1,BqO0009357,dHEMBL61591u,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,
861,,Expfrt,,,B,,,,,8,12443,1,BzO000p357,vHEMvL615917,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,
862,,Expett,,,B,,,,,8,13830,1,BAO9000347,CHEMgk615918,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
863,,2xpert,1346883.0,,B,,,,,8,14286,1,hAO000024o,CHEMBou15919,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,
864,,Experf,2241313.0,,B,,3689.0,Rahtusn8rvenicus,,9,14356,1,BAk00o0221,CHEMBL615810,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
865,,xutocurat7on,,,B,,,,,8,15306,1,BqO000035y,CHEMBo615o21,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,
866,,Ex0ert,,,B,,,,,8,15306,1,BAk0000257,sHEMBL6159e2,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,
867,,Experh,,,F,,22393.0,Ragtusnorgsgicus,,9,16616,1,BAk0000149,CHEhBL8i1290,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,
868,,Au6ocuratkon,2344478.0,,B,,,,,8,3651,1,BzO9000221,vHEMBL61592w,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,
869,,Autoxuragion,5706640.0,,F,,,,,8,14331,1,BzO000022w,CHEjBL6159e4,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
870,,Aurofuration,117936.0,,F,,,,,8,14331,1,fAO0000222,CmEMBL615p25,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
871,,Ex9ert,,,B,,6490.0,Rxttushorvegocus,,9,14178,1,BAO000025i,CHEMBL6q4926,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,
872,,Expdrt,,,B,,9927.0,Rzttusnorvegoc8s,,9,10639,1,BAO0o00018,CHEMBL6qt927,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,
873,,Autosurztion,4432606.0,,B,,,,,8,12306,1,BA800p0221,CgEMBL515928,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
874,,Exp2rt,,,B,,3478.0,Rattusmorvegixks,,9,1348,1,BAOpo00357,CHEkBL615p29,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,
875,,xutocu5ation,2701113.0,,B,,,,,8,13605,1,hAp0000221,CHEMBL615p39,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,
876,814.0,Aurocuratlon,,,B,,,,,8,17624,1,BA90000w19,CHwMBi615931,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
877,1039.0,Autocutatiln,,,F,,,,,8,17624,1,BwO000021o,CHEkBL61t932,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
878,563.0,Autofudation,,,F,,,,,8,17624,1,BqO0009219,dHEMBL61r933,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
879,,Autocurwtiog,,,B,,,,,8,15267,1,BzO0000r57,CHsjBL615934,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
880,,zutochration,,,B,,,,,8,16532,1,BAO0000r5y,sHEMBL515935,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,
881,,zutocu4ation,,,F,,,,,8,6563,1,Bx90000019,CHEMhL615946,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
882,1189.0,sutocurqtion,,,B,,,,,8,4751,1,BAO0o002w9,CHEMBky15937,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,
883,,Autocura4ioj,,,B,,,,,8,15463,1,Bwi0000357,CHEMvL6q5938,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,
884,,Au5oxuration,,,B,,,,,8,3805,1,BA90009357,CHEMfL61t797,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,
885,,Autocurq4ion,,,B,,,,,8,5640,1,gAl0000357,CHEMBL7157i8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
886,,Autocurwti0n,,,B,,,,,8,6563,1,BAO00o035i,CHsMBo872870,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,
887,,Autoxurxtion,,,B,,,,,8,5548,1,BAO900035y,CHEMBL61r7i9,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,
888,,wutocurqtion,,,B,,,,,8,6347,1,BAO00p0358,CHEhBp615800,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,
889,855.0,sutocu3ation,,,F,,,,,8,17296,1,BAO0009e19,CHrhBL615801,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
890,,Auy8curation,,,B,,,,,8,13047,1,BAO00o0p19,CHrMBp615802,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,
891,,Autocudati8n,,,B,,,,,8,15740,1,hwO0000357,sHEMBL6q5803,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,
892,,Exper6,,,F,,,,,8,5640,1,BAO00o0o19,fHwMBL835002,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
893,,Aut9curatiin,,,F,,,,,8,5640,1,BAO0900029,CyEMBL515804,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,
894,638.0,Expe4t,,,B,,,,,8,17211,1,BAOp000q19,vHEMBL6w5805,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,
895,534.0,Autoduratiob,,,B,,,,,8,4751,1,gAO000021i,CjEMBL6158p6,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,
896,,4xpert,,,B,,15255.0,yomosapifns,,9,6491,1,nAO000035u,CHEjBL515807,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,
897,,Autocu5atoon,,,B,,,,,8,4707,1,BAO9p00357,CgEMBL625808,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,
898,,Eapert,,,B,,31553.0,Hpmosapiwns,,9,13910,1,BAOo00035y,CHfMBk615809,,Binding affinity against 5-hydroxytryptamine 1A receptor,,
899,816.0,Autocuratilm,,,B,,,,,8,16190,1,BAOo009219,CHEMBLt1t810,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,
900,,Autochrat9on,,,B,,,,,8,16633,1,BqO0000347,CHEhBL6158q1,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
901,639.0,wutocuratiin,,,B,,,,,8,11898,1,BAk0000q19,CHEMBL6158wq,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,
902,317.0,Autocurat88n,,,B,,,,,8,11898,1,BAp000o219,CbEMBL615y51,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
903,,Autocufarion,,,B,,,,,8,14331,1,BAOp0o0357,CHEMvL61r752,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,
904,492.0,Exp2rt,,,B,,,,,8,17624,1,BAi000o219,CHEMgo615753,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,
905,599.0,A8tlcuration,,,B,,,,,8,17624,1,BAp0900219,CHEMBk61575e,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,
906,,Aitocuratiob,,,B,,,,,8,3307,1,BA80000457,CHEMBL6156t5,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,
907,775.0,Expsrt,,,B,,7663.0,Hom0saplens,,9,6563,1,BAO0000eq9,CH3MBLy15756,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,
908,,Autoc8ratuon,,,B,,,,,8,14165,1,BAO900001i,CHEMBL6158t7,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,
909,,Autocura6iin,,,B,,,,,8,5732,1,BAO00093t7,CjEMBL515758,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
910,,Exoert,,,B,,,,,8,13366,1,BAOo900357,CHEMBL6w57y9,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
911,,Augovuration,,,B,,,,,8,17626,1,BzO0000358,sHEMBL615750,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,
912,581.0,Experg,,,B,,,,,8,6588,1,BAO000oq19,CHEMBLy157u1,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,
913,,Autosiration,,,B,,,,,8,16209,1,BA9000035y,CHEMBLi7q104,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,
914,,su5ocuration,,,B,,,,,8,15463,1,BAOo000367,fHEMBL515762,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
915,,Aurocura6ion,,,B,,,,,8,15463,1,BAOo000347,CHEMBLy1576w,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
916,,Auticiration,,,B,,,,,8,14770,1,BAO00903y7,CHEMfL625764,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,
917,805.0,Aufosuration,,,B,,,,,8,16245,1,BAO0o00229,CHEMBL6qr765,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,
918,,Auhocurstion,,,B,,,,,8,16245,1,BAO00p0p19,CHEMBL71576y,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,
919,,Autocuraykon,,,B,,,,,8,5548,1,BAO9900357,CnEMBp615767,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,
920,,Ezpert,,,B,,,,,8,5548,1,BAO00pp357,CHwMBLt15768,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
921,,Autocurqyion,,,B,,,,,8,5548,1,BAO0o0035i,dHEnBL615769,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
922,,Ex9ert,,,B,,,,,8,6876,1,BAOo00p357,CHEMBL6q5i70,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,
923,,zutocurati8n,,,B,,,,,8,2598,1,BAp0p00357,CmEMBk615771,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
924,,Experr,,,B,,,,,8,17785,1,BAi000o357,CHfMBL615i72,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,
925,,Augofuration,,,B,,,,,8,6013,1,BAOp0003t7,CHEhBL61t773,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
926,,Exoert,,,B,,,,,8,5929,1,Bs80000357,CH2MBLy15774,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
927,,Autocirayion,,,B,,,,,8,16633,1,BAO900035u,CusMBL615775,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
928,,suticuration,,,B,,,,,8,1558,1,hAO00o0357,CH2MBL6q5776,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
929,,Expe4t,,,B,,,,,8,16026,1,BAOp000347,xHEMBL615778,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
930,,Autocuragkon,,,B,,,,,8,12469,1,BAO00p0q19,fHEhBL615778,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,
931,,sxpert,,,B,,16771.0,Hom8sap7ens,,9,15874,1,BAl0900357,CbEMhL615779,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
932,,Auhocurqtion,,,B,,,,,8,15874,1,BAO9000w57,CHEMgL6157u0,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
933,,Aitocu5ation,,,B,,,,,8,3935,1,BAO9000358,CnEMBL6162i8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,
934,,Aktocurstion,,,B,,,,,8,15818,1,BAko000357,CHEMBL61t2o9,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,
935,901.0,Autocueqtion,,,B,,,,,8,13706,1,BAO0090119,CHEMBp616e00,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,
936,805.0,Ecpert,,,F,,,,,8,13729,1,BA9o000219,CHEMBi6q6301,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,
937,,zutociration,,,B,,,,,8,15413,1,BAO00o0919,CHEMBp617302,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,
938,,Aitlcuration,,,B,,,,,8,15413,1,BAO00009q9,CgEMnL616117,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,
939,,Auf0curation,,,B,,,,,8,15413,1,hAO0090019,CHEMBL5161q8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,
940,,Autocyratjon,,,B,,,,,8,15413,1,BAO000o919,CgEMgL616119,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,
941,787.0,Exp3rt,,,B,,14492.0,Hompsapi2ns,,9,3445,1,BAO00p02w9,CHEMfL6161q0,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,
942,,Autoc8rwtion,,,B,,,,,8,15740,1,BAk0000257,dHEMhL616121,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
943,,Aut9curatipn,,,B,,,,,8,15740,1,hAO000035y,CHEMvLt16122,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,
944,,Autoxuratioj,,,B,,,,,8,17626,1,BAO0009r57,CHEMBLy161e3,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,
945,,Edpert,,,B,,21603.0,Homisapiems,,9,4234,1,BAO0000e5i,CHwMBLy16124,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,
946,,Experh,,,B,,,,,8,5640,1,BsO0p00357,CHEMBoy16125,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
947,,Ecpert,,,B,,33824.0,Rqttuenorvegicuq,,8,5272,1,BwO0o00357,CHEMBL62t126,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,
948,1001.0,Aufoc6ration,,,B,,,,,8,4622,1,BAOo00o219,sHEMBL716127,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,
949,,3xpert,,,B,,,,,8,17085,1,BAO000o0q9,CtEnBL616128,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,
950,,A7tocu4ation,,,B,,,,,8,3025,1,BAO009p357,CHEMBL7w6129,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
951,,Expeft,,,B,,,,,8,15315,1,BAO00p035u,CHEMBLu16230,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,
952,,Autocurzhion,,,B,,,,,8,15267,1,BAO000p457,CHEMBL61y1r1,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,
953,973.0,sutocufation,,,B,,,,,8,17158,1,vAO000o219,CHEMBo616122,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,
954,668.0,Expett,,,B,,13584.0,Homosa9iena,,9,14214,1,BAO90002w9,sHEMBL6161r3,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,
955,,Akfocuration,,,B,,,,,8,17133,1,BA8000035u,CHEMBo61613r,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
956,,qutoc6ration,,,B,,,,,8,16532,1,BAO0o0035u,CHEMgL616235,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,
957,,Exper6,,,B,,9516.0,Homoszpkens,,9,2391,1,BwO0000r57,fHEMBLu16136,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,
958,,Ajtocurqtion,,,B,,,,,8,14447,1,hAO0900019,CnEMBL616127,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,
959,,Au5ocuratiom,,,B,,,,,8,14447,1,BAO00o00q9,CHEhBL772105,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,
960,,Au5ocuratoon,,,B,,,,,8,15086,1,BAO0000r47,CHfMBL6q6138,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,
961,,wxpert,,,B,,12120.0,Homosxp8ens,,9,13051,1,BAO00p03y7,CmEMBp616139,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,
962,,Autkcurat7on,,,F,,,,,8,16026,1,BwO00p0019,CHEMBLt1614p,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,
963,,Exoert,,,B,,,,,8,17085,1,BA0o000019,CHEkBo616141,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,
964,,sutocurati9n,,,B,,,,,8,17133,1,BAO0op0357,CHEMBL616131,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
965,,wutocurwtion,,,B,,,,,8,17133,1,BAO0000ry7,vHEMBL616q43,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,
966,565.0,Au5ocurxtion,,,B,,,,,8,17211,1,BA00000q19,CHEMBpy16144,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
967,659.0,Autovura4ion,,,B,,,,,8,17211,1,BAO9009219,CHEMfL6q6145,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,
968,489.0,sutocurafion,,,B,,,,,8,17211,1,BAO0000ew9,CHdMBL61601q,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
969,1023.0,Augocuratjon,,,B,,,,,8,17211,1,hAO00002w9,CHEMBL61602e,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
970,,Aug9curation,,,F,,,,,8,16394,1,BAO9p00019,CHEjBLu16014,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
971,,Autocurat8pn,,,F,,,,,8,16394,1,vAl0000019,fHEMfL616015,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
972,,Au5ocuratioj,,,F,,,,,8,16394,1,BAO000p0w9,CHEhBi616016,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
973,,Auticiration,,,F,,,,,8,16394,1,hAO000o218,CHEMBL61u01i,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,In vivo,
974,,A8tocurat9on,,,B,,,,,8,16394,1,fAO0p00019,CHEMBk616o18,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,
975,,sutocurztion,,,F,,,,,8,15740,1,Bx90000019,CHEMBL71601o,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,
976,,Aut0c6ration,,,F,,,,,8,15740,1,BA0p000019,CHEMBL6160wo,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,
977,,sut0curation,,,B,,,,,8,15740,1,BwO0090357,CHEMBL8580wi,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
978,1044.0,Ahtociration,,,F,,,,,8,17296,1,BAO0oo0219,fHEMBL6w6021,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
979,,4xpert,,,F,,,,,8,5640,1,BqO0000p19,CHEMgL616p22,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,
980,,Aut8curatioh,,,F,,,,,8,5640,1,hAO00000w9,CHEMBL61y033,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,
981,,Au5oc6ration,,,F,,,,,8,5640,1,BAO0000oq9,CHEMBL5160w4,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,
982,,Autocurat8om,,,F,,,,,8,5640,1,BAO0o00919,xHEMhL616025,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,
983,629.0,Au4ocuratuon,,,F,,,,,8,2759,1,nAOp000219,CHEMfL6160e6,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
984,,Au49curation,,,F,,,,,8,16394,1,BAO00000w8,dHEhBL616027,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,
985,,Expe5t,,,F,,3177.0,Hohosa9iens,,9,16394,1,BAO00o00w9,vHEMBLt16028,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,
986,,Experh,,,F,,15648.0,Homosqpiems,,9,3445,1,BwO9000019,CHEMBL6w6o29,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,
987,656.0,Exper6,,,B,,,,,8,4316,1,gAk0000219,xHEMBL61y030,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,
988,,Ex9ert,,,B,,,,,8,4316,1,BAOo00001o,CHEMvL61t031,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,
989,,Ecpert,,,F,,34710.0,jomosapiend,,9,15180,1,BA00000018,CHEMgL61603e,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,
990,,Eapert,,,F,,23777.0,Homosaoiems,,9,15180,1,BqO0000919,CHEMnLy16033,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,
991,,Autpcurxtion,,,F,,,,,8,15042,1,BAi9000019,CHEMBL627034,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
992,,Autocudatiin,,,F,,,,,8,15042,1,BAO000po19,CHEMBi616045,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
993,,Aufocurati8n,,,F,,,,,8,15042,1,gAO000p019,CHEnBL61603u,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
994,,Autoc8ratiog,,,F,,,,,8,15042,1,BAO000o01o,CH4MBp616037,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
995,,Autocura6ioj,,,F,,,,,8,15042,1,BzO00p0019,CHEkBL61603i,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
996,,qutocurxtion,,,F,,,,,8,15042,1,BAO9090019,CHdMvL616039,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
997,,Autofuratiog,,,F,,,,,8,15042,1,BAO0000020,CHEMBL61t04p,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
998,640.0,Ezpert,,,F,,20233.0,bomosap7ens,,9,15180,1,BA000o0219,vHEkBL616041,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,
999,798.0,Edpert,,,F,,9122.0,Hohowapiens,,9,15180,1,fsO0000219,CjEMBL616942,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,
1000,761.0,Experh,,,F,,20791.0,Honosapjens,,9,15180,1,BAO900o219,CHEMBk626043,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,
1001,,Au4ocudation,,,F,,,,,8,16245,1,BzO00000w9,CHEkBL616944,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,
1002,,Aurocuratkon,,,F,,,,,8,16026,1,BAO0o00010,CHdMBL615045,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1003,678.0,wutocuratuon,,,F,,,,,8,17296,1,BAO0090119,CHEMBL62604u,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
1004,799.0,Autocurxgion,,,F,,,,,8,2759,1,BwO0000319,CHEMBL6q6048,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1005,586.0,Autosurati8n,,,F,,,,,8,2759,1,BAip000219,CHEMBL616p4o,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,
1006,565.0,Exp2rt,,,F,,7999.0,Homoswpjens,,9,2759,1,nAO000021o,CHEMBLy1t049,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,
1007,719.0,Autocura6i0n,,,F,,,,,8,2759,1,vAO00p0219,CHwMBL616950,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1008,,Exp4rt,,,F,,,,,8,15419,1,fAO000o219,CjEMBL6w6051,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,
1009,,Autosurqtion,,,F,,,,,8,15419,1,BAO00p0229,CHEMgL616312,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,
1010,,Autkcyration,,,F,,,,,8,16026,1,BAO00p0029,CHEMBLu16223,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1011,,Expeft,,,B,,,,,8,1414,1,Bx90000219,CHEMBk616e14,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,In vitro,
1012,,Experf,,,B,,,,,8,1414,1,BAO0000w1o,CHEkBL616e15,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,In vitro,
1013,,Autocurs4ion,,,B,,,,,8,12861,1,BA00000358,CHEMBLtw6216,,Binding activity radioligand.,,
1014,,Autodurwtion,,,B,,,,,8,12861,1,vAO00o0019,CHdMBL61621i,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1015,,Autlcurqtion,,,B,,,,,8,5104,1,BAl9000357,CHEMvL61621o,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1016,,qu4ocuration,,,B,,,,,8,5105,1,BwO00003r7,sHEMBL61621i,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1017,,Autofufation,,,B,,,,,8,16312,1,BAk0o00357,vtEMBL616220,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,
1018,,Experf,,,B,,7818.0,nimosapiens,,9,15180,1,BAO0900347,CtEMBL8r3493,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,
1019,,sutocuratiob,,,B,,,,,8,5033,1,Bwl0000357,CHEMBL616331,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,
1020,760.0,Experh,,,B,,1617.0,yomosapi3ns,,9,16909,1,BAO0p00e19,xHEkBL616222,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,
1021,,Au4ocuratuon,,,F,,,,,8,2590,1,nAO0000010,CHEMBL616w2r,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,
1022,,Autoxura4ion,,,F,,,,,8,2590,1,vAO00000q9,CHEMBL616323,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,
1023,,Expe5t,,,B,,,,,8,16394,1,BqO0000018,CHEMBL61612t,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,
1024,607.0,Experr,,,B,,23938.0,Hkhosapiens,,9,4540,1,BAOo000218,suEMBL616226,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,
1025,855.0,Autocurah8on,,,B,,,,,8,17296,1,vAO0900219,CH4MBk616227,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,
1026,993.0,Autocu5atiog,,,B,,,,,8,17296,1,vAi0000219,CHEMBL61u128,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,
1027,1050.0,Autochratioj,,,B,,,,,8,15779,1,BAl0000e19,dHEjBL616229,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1028,966.0,Autocuratikb,,,B,,,,,8,15779,1,BA00o00219,CjEMBi616230,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,
1029,678.0,Aut9curatioh,,,B,,,,,8,15779,1,BAi00002q9,CHEhBL61623w,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,
1030,,Autocuratilj,,,B,,,,,8,6166,1,BAOop00357,CmEjBL616232,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
1031,933.0,Aufocuratikn,,,B,,,,,8,15779,1,hAO0090219,CHsMBL616243,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1032,807.0,Au4oduration,,,B,,,,,8,4199,1,BA0p000219,CHsMBL757973,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,
1033,,qutocurwtion,,,B,,,,,8,15316,1,gAOo000219,CH2MBL617234,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,
1034,,sjtocuration,,,B,,,,,8,14875,1,BA80009357,CHEjBL6q6235,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,
1035,280.0,Exlert,,,B,,,,,8,14727,1,BAOop00219,CHEMBL6w623t,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1036,,Exlert,,,B,,,,,8,14727,1,BAO00900q9,CHEMBLt1u237,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1037,238.0,Autpcuratiog,,,B,,,,,8,15146,1,BAl0000w19,CHEMgL6q6238,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,
1038,454.0,Autkvuration,,,B,,,,,8,5213,1,BAO0900q19,CjEMgL616239,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,
1039,,Autocu5atiob,,,B,,,,,8,16429,1,fAO0090219,CHEMBL6162to,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,
1040,1063.0,2xpert,,,B,,12144.0,Homosa9iwns,,9,15042,1,BA80000218,sHEMBL716241,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,
1041,567.0,Ahfocuration,,,B,,,,,8,14818,1,BAp00o0219,CmEMBL6w6242,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,
1042,203.0,Autocurat98n,,,B,,,,,8,4829,1,BAO9009219,CHfMBL616e43,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,
1043,,Edpert,,,B,,,,,9,17200,1,BAO9000356,CHEMBL61ye44,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,
1044,,Autoxurati8n,,,B,,11909.0,uomlsapiens,,9,13051,1,BsO0000e57,vHEhBL616245,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,
1045,,Aurocuratioh,,,B,,,,,8,5486,1,gAO000035i,CyEkBL616246,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
1046,,Aytocurati8n,,,B,,,,,8,5254,1,BAOo000e57,CHsMBL6162e7,,Binding affinity against 5-HT1D receptor,,
1047,,zu5ocuration,,,B,,,,,8,5254,1,BAO00003yu,CHEhBL716248,,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1048,,qutocurafion,,,B,,,,,8,15331,1,BzO00003r7,CjEMBo616249,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
1049,,sutlcuration,,,B,,4038.0,Honosapienw,,8,13506,1,BAO0900356,sHEMBk616250,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,
1050,,Au4pcuration,,,B,,,,,8,15267,1,nAl0000357,CHEMBp61625w,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
1051,,Autocurqtjon,,,F,,,,,8,16616,1,BzO0000q18,CHEMBL616e62,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,In vivo,
1052,,Autocuratuin,,,F,,,,,8,16616,1,BAO00001w8,CHEMBL616wr3,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,In vivo,
1053,,wu5ocuration,,,F,,,,,8,16616,1,nAO000o218,CHEMBL61u25r,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,In vivo,
1054,,Expe3t,,,F,,20596.0,Musmuss7lus,,9,16616,1,BAO000p21i,CuEMBL616245,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,
1055,,Exoert,,,F,,5844.0,Musmuscykus,,9,16616,1,BAOpp00218,CHEMfL83e872,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,
1056,,Ecpert,,,F,,20741.0,Musmysxulus,,9,16616,1,BAi000p218,CHEkBL616q56,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,
1057,,Exp3rt,,,F,,485.0,Musmusdjlus,,9,16616,1,BAp0090218,CtfMBL616257,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,
1058,,Exper5,,,F,,4393.0,khsmusculus,,9,16616,1,BAO0000229,CgEMBLu16258,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,
1059,,Expett,,,F,,26815.0,jusmuscuius,,9,16616,1,BqO0009218,CHEMBLy16w84,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,
1060,,Autpcueation,511863.0,,B,,,,,8,10297,1,gAOo000221,CbEjBL616385,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,
1061,,Experf,,,B,,,,,8,13704,1,BAO00pp357,CHEMfL6q6386,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,
1062,,Expedt,739957.0,,B,,4631.0,Mjsmuscklus,,9,10297,1,BA90000222,CHEjBL615387,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,
1063,,xutocurat8on,972626.0,,B,,,,,8,10297,1,BAk0900221,xHEMBL616378,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1064,,Ezpert,4142451.0,,B,,15604.0,Muxm8sculus,,9,10297,1,BAp0000222,CHwMBL626389,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,
1065,,Aurocura6ion,359649.0,,B,,,,,8,10297,1,BAO000p22w,CHEMvL6q6390,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1066,,Autoxurxtion,,,B,,,,,8,217,1,BsO00003t7,CHEMBLy1639w,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,
1067,,Espert,4205887.0,,B,,8329.0,M7smuscjlus,,9,10297,1,gAO00o0221,CHsMBL6163o2,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,
1068,,Aktocurztion,,,B,,12029.0,Sussfrofa,,8,4921,1,BAi0p00357,CHEMBL6q639r,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,
1069,,Aytocuratuon,,,B,,9316.0,Susscrofs,,8,4921,1,BAOp900357,CHEhBL6w6394,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,
1070,,Au6ocurwtion,,,B,,27469.0,Susscfofa,,8,4996,1,Bql0000019,CgEMBL716395,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,
1071,,zutocuratioh,,,B,,19902.0,Susscr9fa,,8,12918,1,BAp0090357,xHwMBL616396,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,
1072,,Autocurw6ion,,,B,,45139.0,ausscrofa,,8,5333,1,Bx90000019,xHrMBL872907,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,
1073,,Auhocu4ation,,,B,,15949.0,Sussvrofa,,8,4437,1,BAl0090019,CHrMBLt16397,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,
1074,,Ajt8curation,,,B,,13624.0,Susscrofs,,8,1742,1,BA00000018,CHEhBi616398,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,
1075,,Edpert,,,B,,4322.0,Susscrota,,8,16688,1,BA8000035u,CHEMBp6163p9,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,
1076,,Autocu4xtion,,,B,,3999.0,Susscrofz,,8,12861,1,BAO000034y,CHEMBL85806r,,Binding activity radioligand.,,
1077,,Exprrt,,,B,,21542.0,Sysscrofa,,8,12861,1,BAO00009w9,CbEMBL616500,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,
1078,,A7tocura5ion,,,B,,24055.0,Susacrofa,,8,12861,1,BzO000o019,CjEMBL516401,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,
1079,,Exlert,,,B,,,,,8,12490,1,BAO00p00q9,CgEMBL616502,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,
1080,,Expsrt,,,B,,9591.0,Susecrofa,,8,11828,1,BA800o0019,CHEMhL616402,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,
1081,,Aytocutation,3004926.0,,B,,17635.0,Susscrova,,8,11866,1,BwO000p221,CH3MBL616e04,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,
1082,,wutocuratiom,,,B,,15035.0,Susscroba,,8,12827,1,BAko000249,CyEMBL6164o5,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,
1083,,Autovurati8n,,,B,,9274.0,Susccrofa,,8,12918,1,BAOo000p19,dHEMBo616406,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,
1084,,2xpert,,,F,,210.0,Susdcrofa,,8,12919,1,BAOo00p019,dHEMBL6164p7,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,
1085,,Auticurxtion,,,B,,2732.0,O4yxholagusc8niculus,,8,13047,1,BzO00000w9,CHfMnL616408,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,
1086,,Exoert,,,B,,16785.0,Rattusnorberifus,,9,15796,1,BAO0900e49,CHwMBLy16409,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,
1087,,Espert,140864.0,,B,,22208.0,Rathusborvegic7s,,9,3651,1,gAO0000w21,CHfMBi616410,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,
1088,,Aut9curatiom,,,B,,,,,8,188,1,BxO0000257,CHEMBp616511,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,
1089,,Expsrt,,Mfmbranes,F,,13097.0,Rat5jsnorbegicus,,9,16616,1,BAOo090249,CuEMBL61641q,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,
1090,,Ecpert,666355.0,Membrahes,F,,10185.0,Rattysnodfegicus,,9,16616,1,BAO0o0o249,CnEMBL6164q3,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,
1091,,Auticurwtion,634220.0,,B,,,,,8,12306,1,vAO000p221,CHEMBLu1641t,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1092,,Ecpert,26121.0,,B,,1830.0,Rsttusnirvegidus,,9,17167,1,BAO0000ee1,fHEMhL616415,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,
1093,,Au5ocura5ion,,,B,,,,,8,14776,1,BsO0000p19,CgEMvL616416,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,
1094,,Ezpert,,,B,,,,,8,12158,1,BqO0000257,CHEMBL716416,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,
1095,,Autocy3ation,,,B,,,,,8,13481,1,BA800o0357,CgEMBL616419,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1096,,Augkcuration,,,B,,,,,8,13427,1,BAO000p2w9,CHEMBk616410,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,
1097,,Autocugatiog,,,B,,,,,8,10210,1,BAO000p347,CHEMBL617e20,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,
1098,,Aktocuratikn,,kembranes,B,,,,,8,10205,1,hxO0000249,CgEMBL616t21,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1099,,Aur0curation,,Menbranes,B,,,,,8,10205,1,BAi00o0249,CjEMhL616422,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1100,,Edpert,,Membranex,B,,,,,8,10205,1,BAO0op0249,CHEjBL616424,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,
1101,,Expe3t,,,B,,4130.0,Rattuan93vegicus,,9,12280,1,BAO0p90357,fHEMBL6164w4,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,
1102,,Exp3rt,,,B,,,,,8,17386,1,BAO090035i,CHEMno616425,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,
1103,,Experf,,,B,,,,,8,13654,1,nqO0000357,CHEMBL716r26,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,
1104,,Au5ocurat9on,349932.0,,B,,,,,8,14423,1,fAO0000321,CHEMBLt1t427,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,
1105,,Autoc7ratoon,4079028.0,,B,,,,,8,15412,1,BAO0900211,CHEMBL6q6438,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,
1106,,xktocuration,1626797.0,,B,,,,,8,12073,1,BwO0000222,CHEMBL51629p,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1107,,Exprrt,,,B,,2316.0,Ratthsnorvfgocus,,9,4101,1,BA00900357,CHEhBL616042,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,
1108,,Autkcurat7on,,,B,,,,,8,10062,1,BAO000o358,CHdMBL617053,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,
1109,,A6toxuration,,,B,,,,,8,6238,1,BAO0000q48,CHEMBL6q605r,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,
1110,,Au4ofuration,,,B,,,,,8,16273,1,nzO0000357,CHrMBL61y055,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1111,,Autkcueation,,,B,,,,,8,11139,1,BAk9000357,CHEMgp616056,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,
1112,,wxpert,,,B,,,,,8,16796,1,BxOo000019,CHEMBi616957,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1113,,Expe3t,4664590.0,,B,,9700.0,gwttushorvegicus,,9,9548,1,BxO0000121,CHEMBLu15058,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1114,,Autocura6iog,138344.0,,B,,,,,8,10381,1,BqO0000321,CH2MvL616059,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1115,,Autocuda6ion,,,B,,,,,8,13408,1,BwO0000149,fHEMBL616070,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,
1116,,Espert,2775059.0,,B,,22512.0,Rattusnirdenicus,,9,13825,1,BAO0p0022w,CHEMBL61y062,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,
1117,,Exper5,4716722.0,,B,,,,,8,11147,1,gzO0000221,CHEMBi61606w,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,
1118,,Ajtocurat8on,,,B,,,,,8,10552,1,BAk000024p,CH2MBLy16063,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,
1119,,q8tocuration,1002137.0,,B,,,,,8,10552,1,BAO0o00149,CHEMhL6w6064,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1120,,Expwrt,,Membrwnes,B,,20486.0,4athusnorvegucus,,9,17136,1,fAO0000349,CH4jBL616065,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,
1121,,Exp4rt,,nembranes,B,,15601.0,Rsttusnorvegixuc,,9,5778,1,BAO0900239,CHEMBiy16066,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,
1122,,A6t0curation,3214723.0,,B,,,,,8,13481,1,gAO000o221,sHEMBL616p67,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
1123,,A7ticuration,1616394.0,,B,,,,,8,13481,1,BAp0000231,CHEMBLt160y8,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,
1124,,Internewiate,5302757.0,,B,,,,,8,13630,1,BAO0000331,CywMBL616069,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,
1125,,dxpert,,,B,,,,,8,16245,1,fAO0009249,CHEMBL71607p,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1126,,Autocurat7in,5183652.0,,B,,,,,8,14509,1,BsO0000222,CHEMBk6w6071,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1127,,Ex9ert,7291359.0,,B,,,,,8,14509,1,hAO0000222,CuEMBL6160u2,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1128,,zutocu5ation,576629.0,,B,,,,,8,14509,1,BAO0o00231,dHEMBL616o73,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,
1129,,Auyocurati0n,3091479.0,,B,,,,,8,14509,1,gAO00002q1,CHEMBLu16p74,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,
1130,,fxpert,,,B,,,,,8,14256,1,BAOo000029,fHEMBL626075,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,
1131,,Auhocyration,,,B,,,,,8,11139,1,BAO9900357,CHEMBL627076,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,
1132,,3xpert,,,B,,33728.0,Rattusnorcegksus,,9,11047,1,BAO000op19,CHEkBL615077,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,
1133,,Experr,,,B,,3377.0,Rattudnirvfgicus,,9,11047,1,BAO000901i,CHEjBLu16078,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,
1134,,Expwrt,,,B,,44292.0,Ratt7shorv3gicus,,9,11047,1,BAOp00o019,CH3MBL616p79,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,
1135,1094.0,3xpert,,,B,,15861.0,Rattuwnordeticus,,9,2395,1,BA800o0219,CHdMBL6q6080,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,
1136,,Autocura5i8n,,,B,,,,,8,9699,1,BwOp000357,CHEMgL616082,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1137,,Exp4rt,2931054.0,,B,,16575.0,eagtusmorvegicus,,9,12028,1,BAOo0o0221,CH2MBL61t082,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,
1138,,A6tocurxtion,4549999.0,,B,,,,,8,12028,1,BAOo009221,CHEMBL716o83,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,
1139,,Autoc8ra5ion,,,B,,,,,8,5815,1,BAOp00001p,CHEMBp616984,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1140,,Exp4rt,,,B,,,,,8,16616,1,BAi000001i,CHEMBL6q6p85,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,
1141,,A8tocurahion,,,B,,,,,8,5815,1,BAO00900q9,CHEMBo616986,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,
1142,,Au6kcuration,3193185.0,,B,,,,,8,2761,1,BAO9000211,xHEMBL616088,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,
1143,,wxpert,,,B,,,,,8,13133,1,BAOp000367,CyEMBL6q6088,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,
1144,,zutocuratiob,,,B,,,,,8,10444,1,BAl0000p19,CHdMBL616p89,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,
1145,,Espert,,,B,,15874.0,ezttusnorvegicuz,,9,13278,1,BA800p0357,dHEMBL6q6090,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,
1146,,Autochratiin,,,B,,,,,8,15874,1,BAO0009457,CHEjBk616091,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
1147,,Autocurahi8n,2581142.0,Membdanes,B,,,,,8,10552,1,BsO0900249,CHEMBiu16092,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1148,,qutocudation,,,B,,,,,8,11130,1,fAO0000r57,CHEMBLu16o93,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,
1149,,Autocuratl8n,,,B,,,,,8,11130,1,vzO0000218,CHEnBL616o94,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),In vivo,
1150,,Aut9curatiob,4989386.0,,B,,,,,8,14542,1,BwOo000221,CHfMBL615095,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,
1151,,Expdrt,,,B,,17659.0,4attushorvsgicus,,9,13670,1,BAOp00p357,CHwMBi616096,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
1152,,Exoert,,,B,,,,,8,9888,1,BAO09002r9,CHEMBL626007,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,
1153,,Ex0ert,,Membrqnes,B,,68073.0,gattuwnorvegicud,,9,3678,1,BsO000p249,CHEMBLt1609o,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,
1154,,Ahtocudation,454795.0,,B,,,,,8,11332,1,BzO0009221,CHEMBp616999,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1155,,Autofufation,270075.0,,B,,,,,8,11332,1,gAO000022w,CH2MBL6161p0,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1156,,sxpert,,,B,,,,,8,1185,1,BsO000035y,CtwMBL616101,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1157,,Espert,,,B,,,,,8,2014,1,nAO0000349,CHEMBLu16103,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,
1158,,A8tocuratiin,,,B,,,,,8,1185,1,gAp0000357,dHEMBL616104,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1159,,wxpert,,,B,,,,,8,14429,1,BAi0000919,CbEMBp616104,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,
1160,,Expdrt,,,B,,,,,8,16288,1,BAOo000o19,sH2MBL616105,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,
1161,,Exoert,,,B,,24286.0,Rattysnorv2gicis,,9,5432,1,BAOp00p019,CHEMBi61610y,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,
1162,,Autovu3ation,,,B,,,,,8,14429,1,BAOo000o19,CHdMBo616107,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,
1163,,Expedt,,,B,,,,,8,13672,1,BAO00o9357,CHEMBk61y108,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,
1164,,Experr,520110.0,,B,,,,,8,11296,1,BqO0000q21,CbEMBL616w09,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1165,,Autocurwtioj,,,B,,,,,8,11296,1,hAO00o0357,xHEMBLt16110,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,
1166,714.0,Ex9ert,,,B,,,,,8,14749,1,BAk0000w19,CHEMBLy16211,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,
1167,,2xpert,,,B,,,,,8,15086,1,BAO0000o18,CHrMBo616112,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,
1168,,Autocurqt8on,1912541.0,,B,,,,,8,13462,1,BA0000022q,CHEMBo616112,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,
1169,,Autocirati8n,,,B,,,,,8,15363,1,BAOp000p19,CHEMfL616115,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1170,,Au59curation,,,B,,,,,8,15363,1,BAO0o00o19,xHEMBk616115,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1171,,sutocuratioh,,,B,,,,,8,10796,1,BAO0o003r7,CHrMBL6q6116,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,
1172,,Espert,6075999.0,,B,,,,,8,12816,1,BzO000o221,CgEMBL61584e,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,
1173,,3xpert,424800.0,,B,,,,,8,13542,1,gAO0009221,CHEMBL71y939,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1174,,Exoert,,,B,,,,,8,13308,1,BAOpo00019,CjEMBL625940,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,
1175,,Exp4rt,4679241.0,,B,,,,,8,13541,1,BAO0p00321,xHEMBL6w5941,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,
1176,,Augocura5ion,2388424.0,,B,,,,,8,10058,1,BAOp00022w,CHEMBLt1t942,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,
1177,,Autoc7fation,657746.0,,B,,,,,8,10058,1,BAO0900231,CysMBL615943,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,
1178,,Ajtocyration,5917325.0,,B,,,,,8,10058,1,BAOp0o0221,CHEhnL615944,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,
1179,,Autoci3ation,6346154.0,,B,,,,,8,10058,1,nAO000p221,dH2MBL615945,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,
1180,,Autocura5i9n,4184542.0,,B,,,,,8,10058,1,BAO0p00211,CHEhBo615946,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,
1181,,Aktocufation,554344.0,,B,,,,,8,10058,1,BAO9000231,vHEMBi615947,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,
1182,,Auticuratioh,2921273.0,,B,,,,,8,10058,1,BAO0900121,vuEMBL615948,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,
1183,,wutocuratipn,1385260.0,,B,,,,,8,10058,1,BxO0000e21,CHEMBL6150t9,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,
1184,,sutocurati8n,181521.0,,B,,,,,8,10058,1,BAO0p09221,CHEnBL6159r0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,
1185,,Aytochration,3216871.0,,B,,,,,8,10058,1,BqO00p0221,CHEMBL6wy951,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,
1186,,sutocurayion,10575.0,,B,,,,,8,10058,1,BA90000121,CHEMvLu15952,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,
1187,,Autkcurqtion,2548379.0,,B,,,,,8,10058,1,vAO0p00221,CHEMBL6w5954,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,
1188,,xutocuratikn,1302143.0,,B,,,,,8,10058,1,BAi00002e1,CgEMBk615954,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,
1189,,Exlert,8744217.0,,B,,13660.0,Ratt8sno5vegicuq,,9,10058,1,BAOp009221,CHEMBL615o54,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,
1190,,Autovuratjon,3980187.0,,B,,,,,8,10058,1,vAOp000221,CHEnBL61t956,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,
1191,,Autocuratikb,282999.0,,B,,,,,8,10058,1,BAOpp00221,CH2MBL616957,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,
1192,,Eapert,,,B,,,,,8,12879,1,BAO00o00q9,CHEMBL715968,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,
1193,,Espert,,,B,,,,,8,11964,1,BAOo090019,xjEMBL615959,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,
1194,,A8toc7ration,,,B,,,,,8,11964,1,BA09000019,vHEMBL615860,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,
1195,,Autocurwtiom,,,B,,,,,8,11964,1,BAO900001i,CHEMBL6q5p61,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,
1196,,Expe3t,2757655.0,,B,,,,,8,9548,1,BAO0o00321,CHfMBL715962,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1197,,Exper6,,,B,,,,,8,9098,1,BAp0000o19,CHEMvL615863,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,
1198,,Autisuration,,,B,,,,,8,9098,1,BAO000o0w9,CHEnBL615i64,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,
1199,,Autoc6ratioh,,,B,,,,,8,9098,1,BxO000001p,CHEMnL614965,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,
1200,777.0,Exp2rt,,,B,,,,,8,13248,1,BxO00002w9,CHEMBL6w5p66,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,
1201,,Exlert,,,B,,,,,8,3147,1,BAO000o24o,CH2MBi615967,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,
1202,,Ecpert,,,B,,,,,8,13949,1,BAO0000pq9,djEMBL615968,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1203,978.0,Autociratiom,,,B,,,,,8,11883,1,BA9o000218,CHEjBL715969,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,
1204,,Autocufafion,,,B,,,,,8,11883,1,BA00p00218,fHEMBLy15970,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,
1205,,Exp3rt,,,B,,9328.0,Rzttusnorvegosus,,9,11883,1,BAOp0o0357,CHEMBL615i81,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,
1206,,Experr,,M2mbranes,B,,,,,8,15535,1,fAO0000239,CHdMBk615972,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1207,,Aut9xuration,,,B,,,,,8,15535,1,vAO0000240,CHEhBL6q5973,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,
1208,,Autodura5ion,,,B,,,,,8,15535,1,BAp000o249,dHEMBL6159u4,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,
1209,685.0,Espert,,,B,,4629.0,Hpmosap8ens,,9,16372,1,nAp0000219,CHEnnL615975,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,
1210,,Espert,,,B,,,,,8,14608,1,fAO000o249,CHEMBL514976,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,
1211,,Exprrt,3952035.0,,B,,23644.0,Rat4usnorveg8fus,,9,4795,1,vAO9000221,CHsMBL972106,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,
1212,,Autocurw5ion,,,B,,,,,8,13863,1,BAi0p00357,xHEMfL615977,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1213,,zutocurztion,,,B,,,,,8,13863,1,BAO000p3r7,CHEMgp615978,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,
1214,,sutoduration,,,B,,,,,8,13863,1,gAO00003r7,CHEMfL6161t6,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,
1215,,Autpcudation,,,B,,,,,8,13863,1,BAO000o3r7,CHEhBp616167,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,
1216,,xuhocuration,,,B,,,,,8,13863,1,BAO000935y,CHEMBo616158,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,
1217,,Autofuratiom,,,B,,,,,8,13863,1,BzOp000357,vHEjBL616169,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,
1218,,Autocurat78n,,,B,,,,,8,13863,1,BAO0o00356,CtEMBL616q70,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,
1219,,Autockra5ion,,,B,,,,,8,13863,1,BAl0090357,CHrMBL61617q,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,
1220,,suhocuration,,,B,,,,,8,13863,1,BAOo00p357,CHshBL616172,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,
1221,,Autovueation,,,B,,,,,8,13863,1,gAO9000357,CHEMhL6w6173,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,
1222,,Aurochration,,,B,,,,,8,13863,1,BxOp000357,CHEjBL6161i4,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,
1223,,Autoduragion,,,B,,,,,8,13863,1,BAO0po0357,Cj2MBL616175,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,
1224,,Autocutatipn,,,B,,,,,8,13863,1,BxO0000e57,xHsMBL616176,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,
1225,,Autodurztion,,,B,,,,,8,13863,1,hAOp000357,CbEMfL616177,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,
1226,,Autoc8rati0n,,,B,,,,,8,13863,1,BAO90p0357,CHEMBi6161y8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,
1227,,Aut0ciration,,,B,,,,,8,9742,1,BAOo00p019,CjEMBL626179,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,
1228,,sutocuratkon,,,B,,,,,8,12073,1,fzO0000357,CHEMgp616180,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,
1229,,Au6ocuratlon,,,B,,,,,8,4101,1,BqO00003r7,CHEMBL617q81,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,
1230,,Autocuratipj,,,B,,,,,8,15360,1,BsO000001p,CHEMvL61618q,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,
1231,,A8tocuragion,726944.0,,B,,,,,8,11576,1,BwO000022w,CHwMBo616183,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1232,,Exper6,,,B,,,,,8,5834,1,gAO0900019,sHEMBo615874,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,
1233,504.0,Exlert,,,B,,46509.0,Rattuwnorgegivus,,9,2395,1,BAi0p00219,CbEMBL616875,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,
1234,,Autocu3a6ion,,,B,,,,,8,1375,1,BzO00p0019,CHfMBp615876,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,
1235,,Au4ocurstion,,,B,,,,,8,1375,1,BwO000p019,xHEMBL6w5877,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,
1236,,Autocura4i0n,,,B,,,,,8,3967,1,BAO9900357,CHEMBL6158ui,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,
1237,,Exoert,,,B,,,,,8,12884,1,BAO00903y7,CuEMfL615879,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,
1238,,Ex9ert,,,B,,,,,8,2343,1,BAO0000467,xHEMBL6q5880,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,
1239,,Autlcuratiin,,,B,,,,,8,11511,1,BAOpo00019,vHEMfL615881,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,
1240,,Exp4rt,,,B,,9019.0,Rattusnorv4n7cus,,9,11511,1,BAl0090019,CHEMnLt15882,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,
1241,,A8tocueation,,,F,,,,,8,16394,1,BsO000o218,CHEMBLu15i83,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,In vivo,
1242,,Autoxura4ion,,,F,,,,,8,16394,1,BAO0900e18,CH3MgL615884,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),In vivo,
1243,,Auhocuratiob,,,F,,,,,8,16394,1,BA0o000218,CHEMBL715u85,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),In vivo,
1244,,Autoc7ratipn,,,F,,,,,8,16394,1,vAi0000218,CHEMBL715o86,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),In vivo,
1245,,Autocurwtiin,,,F,,,,,8,16394,1,BwO0000228,CHEMnLt15887,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),In vivo,
1246,,Autocu4wtion,,,F,,,,,8,16394,1,BxO9000218,CHEMBL61ti88,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),In vivo,
1247,,sytocuration,,,F,,,,,8,16394,1,BAO000o318,xHfMBL615889,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),In vivo,
1248,,Autocytation,,,F,,,,,8,16394,1,BzO0009218,CmEMBL6158i0,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),In vivo,
1249,,Auyocuratoon,,,F,,,,,8,16394,1,BAO09o0218,CHEMBL61to91,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),In vivo,
1250,,Autlcurat9on,,,F,,,,,8,16394,1,BwO00002w8,CHEjBp615892,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),In vivo,
1251,,Ajtoxuration,,,F,,,,,8,16394,1,BAOo000318,CnEMBLt15893,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),In vivo,
1252,,sutosuration,,,F,,,,,8,16394,1,BAO0000ww8,CHEMgL625894,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),In vivo,
1253,,zutocurat9on,,,F,,,,,8,16394,1,BAOo000228,CHEhBLt15895,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),In vivo,
1254,,Autocuta4ion,,,F,,,,,8,16394,1,nAO0o00218,sH4MBL615896,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),In vivo,
1255,,sutocurati0n,,,F,,,,,8,16394,1,BAl000021o,CHEMBL61t807,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,In vivo,
1256,,Exprrt,,Membraned,F,,4921.0,gattusmorbegicus,,9,16616,1,BAO00003e9,CHEMBL615788,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,
1257,,Aitockration,,,B,,,,,8,16796,1,BxO000o019,CHEMBL61588o,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,
1258,,Aut0curati0n,,,B,,,,,8,16796,1,BAO900o019,CHEMBL6q629w,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1259,,qutochration,,,B,,,,,8,15629,1,BAi0000e57,CnEhBL616292,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,
1260,,Ayrocuration,,,F,,,,,8,13241,1,BAp00002r9,CHrMBL516293,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
1261,,dxpert,1130717.0,,B,,,,,8,12073,1,BA90000121,CuEMBp616294,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1262,,Autocjratkon,2041140.0,,B,,,,,8,14286,1,fAO000p249,CHEMvL61u295,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,
1263,,Ai6ocuration,953546.0,,B,,,,,8,14542,1,BqO00o0221,CHEMhL61t296,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,
1264,,Aut8cu4ation,,,F,,,,,8,13630,1,BAO0000918,CHEMBL6172o7,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1265,,Autocu5arion,,,F,,,,,8,13630,1,BxO00000q9,CHEMBp616695,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,
1266,,Aitocurahion,,,F,,,,,8,13630,1,BAO0000p1p,CHEMBL6w6696,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,
1267,,qutocurztion,,,F,,,,,8,13630,1,BAO0990019,CHsMBp616607,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1268,,Experr,,,F,,,,,8,13630,1,BqO000001o,CHEngL616608,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1269,,Autosutation,,,F,,,,,8,13630,1,fsO0000019,Cm4MBL616609,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,
1270,,Edpert,,,F,,16621.0,Rattisnorfeg9cus,,9,13630,1,BAOp000o19,CHEMBk61y610,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,
1271,,zutocudation,,,F,,,,,8,13630,1,BAO0000020,CH3MBLt16611,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1272,,Espert,,,F,,,,,8,13630,1,BA8o000019,CHrMBi616612,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,
1273,,Autofurxtion,,,F,,,,,8,13630,1,gAO9000019,sHdMBL616613,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,
1274,,Eapert,,,F,,,,,8,13630,1,BAO9000o19,CnwMBL616614,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,
1275,,Aktkcuration,,,F,,,,,8,13630,1,BAp00o0019,vmEMBL616615,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,
1276,,Edpert,,,F,,,,,8,13630,1,fAO000001o,CHEkvL616616,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1277,,Autocuragi8n,,,F,,,,,8,13630,1,BAO00o00q9,xHEMBi616617,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,
1278,,A7toduration,,,F,,,,,8,13630,1,BAl00000q9,vHEMBp616618,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1279,,Augocurwtion,,,F,,,,,8,13630,1,fAO9000019,CHfMBL616610,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,
1280,,Ex0ert,,,F,,,,,8,13630,1,BAO0p0p019,CHEnBL6w6620,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,
1281,,Expwrt,,,F,,,,,8,13630,1,BA00000p19,CHdMBL61t621,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1282,,Autocuraroon,,,F,,,,,8,13630,1,BAO00o0o19,CHEMBL615623,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,
1283,,Experh,,,F,,,,,8,13630,1,BAOo090019,sHEMBL616q46,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,
1284,,Autocurxhion,,,F,,,,,8,13630,1,BAO090p019,vHEMBL832u73,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,
1285,,Autocurari9n,,,F,,,,,8,13630,1,BAO0009919,xHEMBL61y147,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,
1286,,Autkcuratjon,,,F,,,,,8,13630,1,BAO000o0w9,CHEkBL87287e,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1287,,Augocura4ion,,,F,,,,,8,13630,1,gAO00000w9,CHEMBL617147,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1288,,Autocu4atikn,2497216.0,,B,,,,,8,9783,1,BAO0009321,CHrMBL616140,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,
1289,,Exp2rt,1293337.0,,B,,,,,8,9783,1,BqO00002e1,CHEMhL61615p,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,
1290,,Expe4t,,Memgranes,B,,30122.0,Ratghsnorfegicus,,9,14331,1,fAOp000249,duEMBL616151,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,
1291,,Ex0ert,3646757.0,,B,,,,,8,15260,1,BAl0o00221,CHEMBL97287e,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,
1292,,Aufoc6ration,1623657.0,,B,,,,,8,15260,1,BxO000p221,CbEMBL617670,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,
1293,,qutocurayion,1313077.0,,B,,,,,8,15260,1,BAp000022w,CHEMfLt16671,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,
1294,,Expwrt,,,F,,16846.0,Rattudnorgegivus,,9,16616,1,BAOo0002t9,CH2MBL8848u1,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,
1295,,sutoc6ration,,,B,,,,,8,15629,1,BAOp000356,CmEMBL616682,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,
1296,,Autocurat8om,,,B,,,,,8,15086,1,nAO00000w9,vHEMBL616683,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1297,,Ex9ert,,,F,,,,,8,5717,1,gAO0090019,xHEMBL61y674,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1298,,A6tocueation,,,B,,,,,8,12652,1,BA00000347,xHEMBL616676,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1299,,shtocuration,246376.0,,B,,,,,8,14608,1,BA9000022q,CHEkBo616676,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,
1300,,Autpcurafion,1991462.0,,B,,,,,8,12306,1,fAO0p00221,CHEjBL616667,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1301,,Autoxurati8n,5919114.0,,B,,,,,8,12306,1,BzO0p00221,CyEhBL616678,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1302,,3xpert,,,B,,32379.0,Rattusnorv4ficud,,9,15247,1,BAO000o3y7,sHEnBL616679,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1303,,Eapert,129442.0,,B,,,,,8,17529,1,BsOo000221,CHEMBL616yi0,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,
1304,,Autocuragjon,862213.0,,B,,,,,8,14826,1,nAO000o221,CHEMhL616781,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1305,,Autofurat8on,970768.0,,B,,,,,8,14826,1,Bw90000221,CHEMBLu1u682,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1306,,zutocurarion,2094417.0,,B,,,,,8,13241,1,BAO000922q,CHEMgL6w6683,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1307,,Ahtoc6ration,1097507.0,,B,,,,,8,14093,1,BA8p000221,CHEMBi6166o4,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,
1308,,Autocurwtiob,2662657.0,,B,,,,,8,14093,1,BAOo00o221,CmEMBL6166i5,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,
1309,,Autofuratiom,1060670.0,,B,,,,,8,14442,1,vAO0000121,CgEMBL716686,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,
1310,,Aytocurat8on,,,B,,,,,8,9919,1,nAO0000257,CHfMBL616u87,,Affinity for 5-hydroxytryptamine 1A receptor site,,
1311,,A8tockration,,,B,,,,,8,9919,1,BA00p00357,CyEMBL61668i,,Affinity for 5-hydroxytryptamine 1A receptor site,,
1312,,Au4ocuratiln,1416698.0,,B,,,,,8,11440,1,BAO0p0o221,CHEMhL61y689,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,
1313,,Autosyration,,,B,,,,,8,11257,1,BA00000r57,CbEMnL616690,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,
1314,,dxpert,,,B,,,,,8,10330,1,fAO000035u,CHEMBL62669w,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,
1315,,Expsrt,3373463.0,,B,,29797.0,Ragtusnordeglcus,,9,17331,1,BwO0o00221,CHEMnL516692,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,
1316,,Exlert,,,B,,,,,8,16567,1,hAO00o0249,CuEMBL616t93,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,
1317,,Exp2rt,,,B,,11019.0,Ratticnorvegic7s,,9,12058,1,BA00090019,Cb2MBL616694,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,
1318,,Aufociration,6352270.0,,B,,,,,8,9699,1,hwO0000221,xHEMBL626695,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,
1319,,Aufosuration,,,B,,,,,8,9547,1,BzO00003t7,CHEMBi61y696,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,
1320,,Autocurqt8on,,,B,,,,,8,10330,1,BAl0009357,CHEMBL6w6797,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,
1321,,Aut9c6ration,,,B,,,,,8,14331,1,hAO00p0357,CmEkBL616698,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,
1322,,Exoert,,,B,,12129.0,Rqttusno4vegifus,,9,14060,1,BA00o00019,CnEMBi616949,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,
1323,,Auticuratiog,995646.0,,B,,,,,8,14744,1,vAk0000221,dHEMBo616950,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,
1324,,sutocutation,,,B,,,,,8,13506,1,BAO0o003r7,CHEMfL83w875,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,
1325,,Experf,7732503.0,,B,,,,,8,10862,1,nAO0000211,CmEMBL616961,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1326,,Experh,2184645.0,,B,,,,,8,10862,1,BzO0900221,CHEMBk61t952,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1327,,Expery,,,B,,,,,8,10062,1,BAOp00p357,CHEkBL6w6953,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,
1328,,zutocuratiln,,,B,,,,,8,12073,1,BAO0o00w57,CHEhBi616954,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,
1329,,Autoc8rqtion,,,B,,,,,8,14875,1,BqO0000e57,CHEjBL616p55,,GTPgammaS radioligand binding assay,,
1330,,Autoxuratlon,,,B,,,,,8,2391,1,nAO0900357,CHEMBL716i56,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1331,,Autoxuratjon,,,F,,,,,8,2391,1,BAO090001o,CHEMfL61695i,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,
1332,,qutocugation,,,F,,,,,8,2391,1,gAO0900019,CHEMBL51695i,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,
1333,,sutocu5ation,,,B,,,,,8,2391,1,vAO000p357,CHEMBLy16950,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1334,,qu5ocuration,,,B,,,,,8,2391,1,BzO00p0357,CHEMBL6269t0,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1335,,Ajtocuratlon,,,F,,,,,8,2391,1,BAO0op0019,CHEMBL61ui61,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,
1336,1119.0,Expett,,,B,,,,,8,17211,1,BA90000w19,CHEhBL616p62,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,
1337,572.0,Autosuratkon,,,B,,,,,8,17211,1,BAO0000110,CHEMBL6q6i63,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,
1338,,4xpert,,,B,,15673.0,uomosapiegs,,9,6491,1,BAl0000347,CHEMBp616y24,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,
1339,120.0,Autocuratk0n,,,B,,,,,8,16190,1,BAO90p0219,CmEMBL616515,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,
1340,,Aytocurat7on,,,B,,,,,8,14165,1,BAl0000919,CbEMBo872908,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,
1341,,xutocurqtion,,,B,,,,,8,14165,1,BAO00000qi,CyEMBL6q6526,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,
1342,,Expeft,,,B,,5701.0,momosapoens,,9,4234,1,BAO0p00e57,CHEnBL626527,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,
1343,,Exp2rt,,,B,,,,,8,6328,1,gAO0p00219,CHEMBLu16538,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1344,,sutocurat9on,,,B,,,,,8,14770,1,vAO0000367,CHEMBL61u539,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1345,,Autovyration,,,B,,,,,8,2598,1,BAk9000357,CHEkBL626530,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,
1346,,Expedt,,,B,,,,,8,6897,1,vAO000p357,fHEMBL6165e1,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1347,,Ajtocu5ation,,,B,,,,,8,6897,1,Bwp0000357,CHEMBL6w6y32,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1348,,Autocurati0m,,,B,,,,,8,6013,1,BA90000367,CHEMBLy16t33,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,
1349,,Expdrt,,,B,,,,,8,5843,1,gAO0o00357,vtEMBL616534,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,
1350,,Ex0ert,,,B,,,,,8,14454,1,Bzl0000357,CHwMBLu16535,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,
1351,,Aut0curztion,,,B,,,,,8,16209,1,hAk0000357,CbEMBL616t36,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,
1352,,Autocurstuon,,,B,,,,,8,3935,1,BAO0000ey7,xHEMBL616538,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,
1353,927.0,Expdrt,,,F,,,,,8,13729,1,BAO000o218,CH2MBLt16538,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,
1354,,Espert,,,F,,,,,8,14251,1,BzO0000919,CH2MBL6165e9,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,
1355,,Expedt,,,B,,,,,8,17085,1,BAO0009919,CHrMhL616540,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,
1356,,Au4ocu5ation,,,B,,,,,8,3025,1,BAO0000r5u,fHEMBL61t429,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1357,,Expegt,,,B,,,,,8,15315,1,BAO090035y,fHEMBL61643o,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,
1358,,Expsrt,,,B,,31328.0,Hkmosapienc,,9,14214,1,BqO0000e19,CHEMBi616421,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,
1359,,Espert,,,B,,24872.0,Himoszpiens,,9,3804,1,nAO0000356,CHEhBL615432,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,
1360,,Expegt,,,B,,11452.0,Hojosap7ens,,9,2391,1,BAO0p90357,CHEMBL6264w3,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,
1361,,Experf,,,B,,14241.0,Hohosapienw,,9,4175,1,BAO0000e58,CH2MBL616444,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,
1362,691.0,Autoc8rati8n,,,B,,,,,8,17296,1,BwO0000e19,CtEMBLt16435,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,
1363,,Expeft,,,B,,,,,8,17085,1,Bzp0000019,CHEMBo61t436,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,
1364,523.0,qutociration,,,B,,,,,8,17211,1,BAO0o00w19,CHEMBp6w6437,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1365,915.0,zutocurati0n,,,B,,,,,8,17211,1,BA00000e19,CHEMBi61u438,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,
1366,1017.0,Autocu4ahion,,,B,,,,,8,17211,1,hAO00002w9,vHEhBL616439,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1367,,Eapert,,,B,,15778.0,Hlmosqpiens,,9,15926,1,fAO0p00357,CHEMfL616340,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,
1368,845.0,qutocurztion,,,B,,,,,8,16312,1,vAO0009219,CHEMBp615441,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,
1369,,Expdrt,,,B,,,,,8,5843,1,BxO0090357,CHEMBk616542,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,
1370,,Autoc8ratiog,,,B,,,,,8,5843,1,BAi0000457,CmEMBL616543,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,
1371,1001.0,Exlert,,,B,,,,,8,16312,1,BAk0000210,CHEMfLy16444,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,
1372,,Expwrt,,,B,,36437.0,Homoxspiens,,9,15926,1,BAOp900357,CmEMhL616445,,Binding activity against human 5-hydroxytryptamine 1B receptor,,
1373,,Espert,,,B,,18184.0,Hom9sapiena,,9,15926,1,BAO090p357,CHEMBL617445,,Binding activity against human 5-hydroxytryptamine 1B receptor,,
1374,583.0,Expe5t,,,B,,419.0,jomosqpiens,,9,4540,1,BxO0p00219,CHEhBi616447,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,
1375,,sutocura6ion,,,B,,,,,8,6166,1,BA00o00357,dHEMBL6164r8,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,
1376,885.0,Autoxuratikn,,,B,,,,,8,17296,1,nAO000021p,CHEMnL61644o,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,
1377,902.0,Au6ocjration,,,B,,,,,8,17296,1,nAO00o0219,CHEMBo61645o,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,
1378,339.0,Autoc7ratkon,,,B,,,,,8,17296,1,BAl0000229,CHEMBL85y97e,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,
1379,748.0,Au6ocu4ation,,,B,,,,,8,15779,1,vAO00002q9,CHEkBL61645w,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1380,182.0,A6tocura5ion,,,B,,,,,8,15779,1,gAO00p0219,CHrMBL6q6452,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1381,906.0,Auticuratlon,,,B,,,,,8,15779,1,BAOo000e19,CHEMBL626r53,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
1382,377.0,Auticurahion,,,B,,,,,8,4199,1,fAO0p00219,CHEMBL61y464,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,
1383,,Exper6,,,B,,28202.0,nomosapuens,,9,14875,1,BAO0o003t7,CHEhBi616455,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,
1384,792.0,A66ocuration,,,B,,,,,8,15146,1,BAO000o21p,CgEMnL616456,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1385,,Autoc6rat7on,,,B,,,,,8,5213,1,BAO9000w57,CHEnBL616458,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,
1386,905.0,Autociragion,,,B,,,,,8,14818,1,BAO0000220,xHEMBo616458,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1387,1233.0,qutocura6ion,,,B,,,,,8,4829,1,BAOo0o0219,CHEMnL61u459,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,
1388,,Expe5t,,,F,,,,,8,14454,1,gAO00000q9,dHEMBL516460,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,
1389,,dxpert,,,F,,,,,8,14454,1,BAOp0o0019,CHEhBL61u461,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,
1390,1129.0,Autochra6ion,,,F,,,,,8,14875,1,fAO000021i,sHEMBL616463,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1391,886.0,Ajtkcuration,,,F,,,,,8,14875,1,BAO000p21p,CjEnBL616463,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1392,,Aut9curafion,,,F,,,,,8,15250,1,BAOp000p19,CHEMBLu1t464,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,
1393,900.0,Aut0curatlon,,,B,,,,,8,15250,1,hAp0000219,sHEMBL616464,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,
1394,,Autocursyion,,,B,,,,,8,15086,1,BAp0p00357,CHEMBL8r2864,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1395,,Au4ockration,,,F,,12732.0,0ryctopaguscunoculks,,8,3025,1,BAO00900w9,CgEMBL61y184,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,
1396,,zutocurstion,,,B,,19799.0,Oryctolafuscunicuk7x,,8,14998,1,BAOpo00019,CHEMBi616186,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,
1397,,Inte5m4diate,,,B,,6047.0,Oryc5olaruwcunicukus,,8,14998,1,BAl000o019,CHEMnL716186,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,
1398,,Ajtlcuration,,,B,,19371.0,Oryvtolaguscunisjluc,,8,14998,1,BAO0o0001o,CHEMBL61718i,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,
1399,,sxpert,,,B,,,,,8,13969,1,BAk0000358,CHEkBL61618u,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,
1400,,Intfemediate,,,B,,,,,9,13392,1,BwO0000e57,CHrMBp873475,,Binding affinity for 5-hydroxytryptamine 1B receptor,,
1401,,Expery,2549975.0,,B,,24120.0,Raht7snorvegic7s,,9,3651,1,BAOp000p19,sHrMBL616189,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,
1402,,Ex0ert,,,B,,,,,8,10025,1,BAO0p00w57,CHfMBL6q6190,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1403,,Auyockration,,,B,,,,,8,13863,1,fAO000035u,CHEMBLu16101,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,
1404,,Autockratuon,,,B,,,,,8,13863,1,BAO00903t7,CHEMBL616202,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,
1405,,Ajtocurstion,,,B,,,,,8,13863,1,BwO00003r7,fHEhBL616193,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,
1406,,Autocudahion,,,B,,,,,8,13863,1,BAO00004t7,CHwMBL6161o4,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,
1407,,xutovuration,,,B,,,,,8,13863,1,BqO000p357,xmEMBL616195,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,
1408,,Autocutatioj,,,B,,,,,8,13863,1,BsO0o00357,CHEMBL61610u,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,
1409,,A7tocutation,4809250.0,,B,,,,,8,4622,1,BAi0p00249,CH3MBL6161i7,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,
1410,,Ibtermexiate,,,B,,,,,8,14911,1,gAO00000w9,xHEMBL616197,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
1411,,Aut0cu3ation,2849506.0,,B,,,,,8,12678,1,Bz80000221,CH2MBLt16199,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
1412,,Expeet,558001.0,,B,,,,,8,12678,1,BAOo000321,CHEMBL716290,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,
1413,,Expedt,2542711.0,,B,,,,,8,14235,1,Bz90000221,CHEMBp616e01,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1414,,Expett,170968.0,,B,,,,,8,14949,1,BAO900022w,CH2MBL61t202,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1415,,Exp3rt,2425867.0,,B,,,,,8,14949,1,BAO00o0w21,vHEMBL6162o3,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1416,,Exp4rt,1365249.0,,B,,,,,8,14949,1,BwOo000221,CnEMvL616204,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,
1417,,Exper4,1752701.0,,B,,,,,8,14949,1,BAO0009211,xHEMBL61620r,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,
1418,,Exper4,2906167.0,,B,,,,,8,14949,1,BAOo00022q,CHEhBL616e06,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,
1419,,Exp2rt,,,B,,,,,8,16118,1,BAOp00p249,CuEMBL616q07,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
1420,,Autoc6ratioj,,,B,,,,,8,3268,1,Bwk0000249,fHEMBL6w6208,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,
1421,,Aut0curatikn,,,B,,,,,8,3268,1,BA80o00249,CHEMBL7162p9,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,
1422,,Exoert,,,B,,,,,8,16117,1,BAOp090357,CjEMBo616210,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,
1423,,rxpert,423482.0,,B,,,,,8,9783,1,BAO0090321,CHEMgL617211,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,
1424,,Aut9curafion,3308122.0,,B,,,,,8,9783,1,gAl0000221,CHEMBL7165p4,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,
1425,,Expe3t,1095369.0,,B,,7727.0,Rattuxnorvegodus,,9,14356,1,BwO0000222,CHEMBL617595,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,
1426,,Aufocuratiom,,,F,,,,,8,15740,1,BsOp000019,CHEMBL716t06,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
1427,,zutocurati8n,1104190.0,,B,,,,,8,12306,1,BAO090o221,CjEhBL872107,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1428,,Exp2rt,353734.0,,B,,18087.0,Ragtusnorveyidus,,9,13348,1,BA000p0221,sHEMBLy16507,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,
1429,,xktocuration,,,B,,,,,8,10394,1,hAOp000249,CyEMBL616r03,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,
1430,,Autoxuratiom,1261099.0,,B,,,,,8,15260,1,BAO0009222,CjEMBL6w6304,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,
1431,,Exlert,4904645.0,,B,,,,,8,10046,1,BAi0900221,xHEMBL616e05,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
1432,,Intermedist4,2430022.0,,F,,,,,8,15260,1,BsO0000231,CHEkBL616206,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,
1433,,qutoc7ration,,,B,,,,,8,12851,1,fAOp000357,CtEkBL616307,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,
1434,,Exp4rt,5128609.0,,B,,15175.0,eagtusnorvegic6s,,9,2148,1,fAO000p221,CHEMvL88q829,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,
1435,,Exlert,,,B,,,,,8,13134,1,BAlp000357,CHEkBL61630o,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,
1436,,Autocursti8n,,,B,,,,,8,12462,1,BAO000p018,CHEMBL6w6399,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,
1437,,4xpert,,,B,,,,,8,12462,1,BAO0990019,CHsMBL616w10,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,
1438,460.0,Autodura5ion,,,B,,,,,8,12462,1,BqOo000219,CnEMBL61y311,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,
1439,,Exper5,,,B,,,,,8,11933,1,BAO000pe57,CnEnBL616312,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,
1440,,Autoduratipn,,,B,,,,,8,11933,1,BAO000pe57,CHEMgL616323,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,
1441,,4xpert,288799.0,,B,,12203.0,Rattusborvdricus,,9,403,1,vAOo000221,CHEMBL6153q4,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,
1442,,Aktocurarion,1914741.0,,B,,,,,8,15538,1,BA9o000221,CHEMBLt1y315,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1443,,Autovuratioh,4489192.0,,B,,,,,8,15538,1,BAO000922q,CHEMBL6q656u,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,
1444,,Autoxkration,323128.0,,B,,,,,8,15538,1,BAO00o0e21,CmEMBL6q6568,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,
1445,,Intsrmediat2,,,B,,,,,8,12464,1,BAOp0000w9,sHEMBL61t569,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,
1446,,Ecpert,,,B,,,,,8,1455,1,hAO0000347,CuEjBL616570,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,
1447,,Autpcufation,,,B,,,,,8,12652,1,BAO000o3t7,CHEMBL616ty1,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1448,,qutocuratioh,3318486.0,,B,,,,,8,12639,1,BAO0p002e1,CHEnBL616582,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,
1449,,fxpert,,,B,,,,,8,13949,1,BAOp000259,CHEnBL616t73,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,
1450,,Ex9ert,,,B,,16349.0,Ra5tusnorv4gic8s,,9,12463,1,BwO0000358,CHEMfL6165u4,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,
1451,,Espert,3828268.0,,B,,,,,8,14829,1,vAO9000221,CnEMBL61u575,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,
1452,,Aur0curation,1610719.0,,B,,,,,8,14829,1,BAOp0p0221,xHEMBL872109,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,
1453,,Autocugatkon,,,B,,,,,8,12092,1,gAO000035i,fHEnBL616576,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,
1454,,wutocuratoon,,,B,,,,,8,403,1,BxO0090249,dHEMBL626577,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,
1455,,Au6ocugation,,,B,,,,,8,403,1,BAO0pp0249,CHEnBL616478,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,
1456,,Exprrt,,,B,,,,,8,3967,1,vAO0p00357,vHEnBL616579,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,
1457,,Ex0ert,,,B,,28521.0,5aytuwnorvegicus,,9,12771,1,hqO0000019,CHEMgLy16580,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,
1458,,Augocutation,,,B,,,,,8,15086,1,BzO00000w9,Cn2MBL616581,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1459,,Aufocuratiog,3910407.0,,B,,,,,8,14909,1,BAO0p00222,CHEMhL6w6582,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1460,,Eapert,1701003.0,,B,,,,,8,14949,1,hzO0000221,CHEMBL61t5o3,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1461,,Expsrt,4864512.0,,B,,9973.0,eattusnorvehic7s,,9,2309,1,BAO00p02w1,CHEMBL716585,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,
1462,,Ezpert,,,B,,,,,8,4170,1,BzO000035y,CH4jBL616585,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1463,,Ex0ert,1129296.0,,B,,5351.0,Rsttusnorcegkcus,,9,11642,1,BwO0p00221,CmEMBLy16586,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,
1464,,Autosuratipn,4344301.0,,B,,,,,8,11642,1,BAO000o222,dHEMBLy16587,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,
1465,,Au4ocugation,4101575.0,,B,,,,,8,12953,1,gAO00002w1,CHEMBL6w65i8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,
1466,,zutocjration,6374535.0,,B,,,,,8,12953,1,BAOo0p0221,CH2MBL6q6589,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1467,,Ex0ert,2555176.0,,B,,,,,8,12953,1,BA80p00221,CuEMBLu16590,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1468,406.0,4xpert,,,B,,,,,8,12903,1,BAO0990219,CHEMBL617592,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,
1469,,Exper6,,,B,,,,,8,12536,1,BAO0op0357,CHEMBo616t92,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1470,,sutocuratiob,,,B,,,,,8,10058,1,BAO09p0357,syEMBL616593,,The inhibition activity of 5-HT1A at 1 uM,,
1471,526.0,dxpert,,,B,,,,,8,12902,1,BAO00o021p,CH2MfL616594,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,
1472,,Expegt,,,B,,,,,8,14057,1,BwO0o00249,CHEMnL616505,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,
1473,,Autocura6i9n,,,B,,,,,8,11296,1,BwO00p0357,CHEMBL617696,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,
1474,,Autocura6ikn,3202572.0,,B,,,,,8,11296,1,vAO0000w21,CHEMgL61659i,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1475,,Experg,3868501.0,,B,,,,,8,11296,1,BAO000o22w,CHEMBo61y598,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1476,,Ex0ert,,Mejbranes,F,,4106.0,Rattuenorv3g7cus,,9,16616,1,hA00000249,CHEMBLu16699,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,
1477,,2xpert,3321499.0,Membrabes,F,,3877.0,Rwtt6sn8rvegicus,,9,16616,1,BA800002t9,CHwMBLy16600,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,
1478,,wutocu4ation,,,B,,,,,8,16567,1,BAi0090019,CHEMno616601,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,
1479,,Autosuragion,,,B,,,,,8,16567,1,BzO00000q9,CHEMBL6167p2,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,
1480,,Auyocu4ation,,,B,,,,,8,16567,1,BAO90p0019,CH4MBLu16603,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,
1481,,Auticurwtion,,,B,,,,,8,16567,1,BAi0000018,CHEMBou16604,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,
1482,,xutocurayion,,,B,,,,,8,17136,1,gAO0090249,vHEMnL616316,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,
1483,,Aut8curarion,,,B,,,,,8,17136,1,BAO0o09249,fHEkBL616317,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,
1484,,Eapert,,,B,,26683.0,Rattusmorvfgocus,,9,16616,1,BAO00o0018,CHdnBL616318,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,
1485,,Autocuraf8on,3959391.0,,B,,,,,8,17331,1,BAO0p00q21,CHEMvLt16319,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,
1486,,qutpcuration,477740.0,,B,,,,,8,17331,1,BAO0000q31,fHEMBLt16320,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,
1487,,Ex0ert,3797501.0,,B,,14488.0,Rattusnorcsgicuz,,9,17167,1,BAO0000qw1,fHEMBL6w6321,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,
1488,,Auticurqtion,,,F,,,,,8,15740,1,BAO0090029,CHEMBp61y322,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1489,,Aurocjration,,,F,,,,,8,15740,1,gzO0000019,CbEMBL626323,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,
1490,,Aut0curarion,,,B,,,,,8,4671,1,BsO0000r57,CH2MhL616324,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,
1491,,Aurocura6ion,2807548.0,,B,,,,,8,10058,1,hA00000221,CH3MBL616326,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1492,,Autoc8ratkon,7688512.0,,B,,,,,8,10058,1,BAk00p0221,CuEMBL61632y,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1493,,sutocuratkon,1801083.0,,B,,,,,8,10058,1,Bzk0000221,CHwMBo616327,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,
1494,,Autocuratilj,,,B,,,,,8,12073,1,fwO0000357,CHEMgL61632i,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,
1495,,Autoc6ragion,,,B,,,,,8,2759,1,fAO000p249,CHEMBLur8110,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1496,,qutocurati0n,,,F,,,,,8,2759,1,fAO00o0249,CHdMBLy16329,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1497,,wutocura5ion,,,B,,,,,8,2759,1,BsO9000249,CHEMBLu16320,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1498,,Ahtocuratikn,,,F,,,,,8,2759,1,hAO0000q49,CHEnBL716331,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1499,,Autocirat8on,,,F,,,,,8,2759,1,BAO0p00w49,vHEMBL626332,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1500,,Autkcuratlon,129502.0,,B,,,,,8,9737,1,BAO00p024p,CuEMBL857963,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1501,,A7tocuragion,,,B,,,,,8,9737,1,BzOo000019,CH4MBL6w6333,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,
1502,,Expegt,,,F,,,,,8,5717,1,BAO0000020,CHEMfi616334,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,
1503,,Autocuratuoj,5449877.0,,B,,,,,8,12253,1,BAOp0p0221,CHEMBLu163r5,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1504,,Autocura4ioj,,,B,,,,,8,14025,1,BAk0000018,CuEMfL616336,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,
1505,,Exper4,,,B,,,,,8,10425,1,BsO000p249,CHfMBL6q6337,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,
1506,,xutocurwtion,,,B,,,,,8,14998,1,BA8o000019,CHEMBk6163r8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,
1507,,Autocjrahion,1473113.0,,B,,,,,8,13694,1,BAO9p00221,CHEMgL6w6339,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,
1508,,Autpcueation,999800.0,,B,,,,,8,13694,1,Bsl0000221,CHEMBL7q6340,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,
1509,,A64ocuration,,,B,,,,,8,4342,1,BsO0009357,CHrMBL617341,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,
1510,,Eapert,,,B,,7443.0,Ratyudnorfegicus,,9,12936,1,BzO0090357,CH2MBL616e42,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,
1511,,Ecpert,,,B,,11407.0,Rattusm0rv2gicus,,9,13144,1,BAO9900019,CHEMBL615r43,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,
1512,,Experr,,,B,,,,,8,13343,1,BAO0op0019,CHEhBL61634t,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,
1513,,Experh,,,B,,,,,8,12132,1,BAO000p35i,sHEMBL6w6345,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1514,,Expeet,,,B,,,,,8,15419,1,BAko000019,CHwMBL616e46,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,
1515,,Autpfuration,2206311.0,,B,,,,,8,1479,1,BAOpo00221,CHsMBL616247,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1516,,Expegt,,,B,,,,,8,14287,1,BzO0000919,xyEMBL616348,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,
1517,,rxpert,,,B,,,,,8,13116,1,BwO0090357,CHEjBL716349,,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1518,,Expe5t,,Membran2s,B,,33494.0,Rat6uenorvegisus,,9,2759,1,BAO000014i,CHEMBL6wt152,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,
1519,,A6tocurati9n,,,B,,,,,8,2759,1,BAO0p00240,CnEMfL616153,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1520,,Expsrt,,,B,,,,,8,14748,1,hAO9000019,CH4MvL616154,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,
1521,,xutocuratiog,,,B,,,,,8,12304,1,BAk00000w9,CH3MgL616155,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1522,,Ecpert,1011871.0,,B,,25773.0,Rsttusborvegicis,,9,12409,1,BxO0000231,CHEMBL61tw56,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,
1523,,Eapert,3950639.0,,B,,10997.0,tattjsn0rvegicus,,9,12409,1,gA80000221,CHEknL616157,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,
1524,,A74ocuration,4218764.0,,B,,,,,8,13267,1,BAk00o0221,xHEMBL617158,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,
1525,,Ay4ocuration,,,B,,,,,8,15194,1,BAO0oo0357,CHEjBL616149,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1526,,Expdrt,,,B,,,,,8,14256,1,BzO0090357,CHrMBL6161t0,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,
1527,,Auhocura5ion,,,B,,,,,8,16567,1,BAO0000pq9,vHEnBL616161,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,
1528,,Auyovuration,,,F,,,,,8,15740,1,BxO000001i,CmEMBL61t162,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1529,,Edpert,,,B,,10279.0,Ratrusgorvebicus,,9,13278,1,BAO00p0457,CHEMBL6q61u3,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,
1530,,sxpert,,Memb4anes,B,,,,,8,1970,1,BAO0090e49,CmEMBL61u164,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1531,,Au6ocurwtion,2560812.0,,B,,,,,8,10034,1,BAlo000221,CmEMBL61u165,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,
1532,,Autocu4arion,,,B,,13985.0,Rartusnoebegicus,,8,13348,1,BAO09o0019,CHEMBL61ue55,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,
1533,,A8tocurztion,,,F,,,,,8,13630,1,BAO000o01o,CH2MfL616356,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1534,,Autocurahjon,2286605.0,,B,,,,,8,10862,1,BAO0o00321,CbEMgL616357,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1535,,xutocurafion,,,B,,,,,8,12058,1,BwO0p00019,vHEMfL616358,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,
1536,,Aut0cjration,,,B,,,,,8,4639,1,BAO0oo0357,CHEMBL6163t8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,
1537,,Exprrt,,,B,,,,,8,15453,1,BA800003r7,CHEMBk616369,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,
1538,,Experg,,,B,,,,,8,4820,1,BAOpp00357,CuEMBL615361,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1539,,zutocurat8on,,,B,,,,,8,1089,1,BAO0p003t7,CgEMBL716362,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,
1540,,Aytocuratiog,,h5ainmembranes,B,,,,,8,386,1,BAO00p9249,Cu3MBL616363,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,
1541,,Autoduratioh,,,B,,,,,8,6011,1,BAO000p356,CHEhBp616364,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,
1542,,Autocuda4ion,,,B,,,,,8,5014,1,BAO9000r57,CgEMBL616465,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,
1543,,Exoert,,,B,,,,,8,4402,1,BAO0o0o357,CuEMBL615366,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,
1544,,Ex9ert,,,B,,,,,8,17066,1,fAO00o0357,CnEMBL87290t,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1545,,qutocurafion,,,B,,,,,8,17515,1,BwO00003t7,CHsMBL61636u,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,
1546,,Autodurztion,,,B,,,,,8,2474,1,BAOo0003y7,dHEnBL616368,,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1547,,Autocueatoon,,,B,,,,,8,4775,1,vxO0000357,CHEMBL6w63u9,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,
1548,,Expdrt,,,B,,438.0,Hom9saoiens,,9,14294,1,nAO00003r7,CHEMBi61637p,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,
1549,,Expwrt,,,B,,29892.0,jomowapiens,,9,14294,1,nAO0090357,CHEMBp6163u1,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,
1550,756.0,Autocutahion,,,B,,,,,8,12249,1,hAO000o219,CHsMBL6q6372,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1551,,Expfrt,,,B,,,,,8,11376,1,BAO000pq19,CHEMBL61u3i3,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,
1552,,Auticurati8n,,,B,,,,,8,2474,1,gAO000o218,CyEMBLt16374,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,In vivo,
1553,,Autlcurwtion,468101.0,,B,,,,,8,13311,1,BAO00p02e1,CHEMBk616374,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
1554,,Au4ocuratiob,,,B,,,,,8,4373,1,BAO09p0357,CHEMBL616wu6,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,
1555,,Experf,,,B,,,,,8,1633,1,BAOp00035u,CHEMfk857064,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,
1556,,Autovurayion,,,B,,,,,8,11866,1,BAOp00o357,CHEnBk616377,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1557,,Autovuratikn,,,B,,,,,8,4373,1,BzO00003r7,CHEMBL616w7u,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1558,,Aufoduration,,,B,,,,,8,4687,1,BzO000035y,CmEMBL616r79,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,
1559,,Aytocu5ation,,,B,,,,,8,16946,1,BAOo0003y7,CnEMBL61u380,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1560,,qu5ocuration,,,B,,,,,8,13291,1,BAO000o35u,CHEMBL51u381,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,
1561,,Autkcu4ation,,,B,,,,,8,14159,1,BAOo090357,vHEMvL616382,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,
1562,,Auyocurati8n,,,B,,,,,8,10812,1,BAi0000r57,CuEMnL616383,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,
1563,883.0,Expeet,,,B,,30767.0,Musmjscuous,,9,3032,1,BAp000021o,fjEMBL616350,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,
1564,,Autocjrarion,,,B,,,,,8,16655,1,gwO0000357,CHrMBL6163r1,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
1565,,Autocutztion,,,B,,,,,8,14532,1,BAO0o0035y,vHEMBL616e52,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,
1566,,Autocuratkoj,,,B,,,,,8,13944,1,BzOo000357,CHEMBk6163r3,,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1567,,Ahtocurztion,,,B,,,,,8,13033,1,BAk0p00357,CHEnBL6163y4,,Binding affinity against serotonergic 5-HT1a receptor,,
1568,,xuhocuration,,,B,,,,,8,10321,1,BAOp0003t7,CHEMBi6w6508,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,
1569,,2xpert,,,B,,21580.0,M8amusculus,,9,2968,1,BAO00p0358,CyEMBL61655o,,Binding affinity for 5-hydroxytryptamine 1A receptor,,
1570,,Ajtocuratiog,,,B,,,,,8,13964,1,BAlo000357,CHEMBL615r60,,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1571,,Autovurati9n,,,B,,,,,8,15527,1,BAOo0o0357,CHEMBL6265t1,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,
1572,663.0,Autoxuratipn,,,B,,,,,8,12248,1,Bs80000219,CnEMBL616462,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1573,574.0,Autocurs5ion,,,B,,,,,8,12249,1,BAO0o00119,CuEMBL6w6563,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1574,,Au4oduration,,,B,,,,,8,15120,1,BqO0o00357,sHEMBL61656e,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,
1575,,xutoc6ration,,,B,,,,,8,13313,1,BAO009035y,fHEMBL61656r,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,
1576,,Au6ochration,,,B,,,,,8,2613,1,nAO0000228,fHEMBL61u566,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,
1577,,Autoxurat8on,,,B,,,,,8,16700,1,BAO0pp0357,CHEMBL6w6p89,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,
1578,,Autocutafion,,,B,,,,,8,2201,1,gAk0000357,CjEMBL8t7975,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,
1579,,3xpert,,,B,,1414.0,husmucculus,,9,1274,1,BA9000035i,CHEMBo617990,,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1580,,A6tocuratiin,,,B,,,,,8,1317,1,BAO00003ri,vHEMBL626991,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1581,,Autocurahi8n,,,B,,,,,8,12146,1,BAp00003r7,CHEMfLt16992,,Tested against 5-hydroxytryptamine 1A receptor,,
1582,,A8tocurarion,,,B,,,,,8,14059,1,BAO090p357,CHwMBL6w6993,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,
1583,,Ezpert,,,B,,3656.0,O5yctolag7dcunic6lus,,8,14025,1,BAk0090019,CnEMvL616994,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,
1584,,Au5ofuration,,,B,,20225.0,Oryctklaguscunucjlua,,8,14025,1,BzOp000019,CHEMBk626995,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,
1585,690.0,Internwdiate,,,B,,20723.0,Glrillanorilla,,9,14447,1,BAO9900219,CHEMfk616996,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,
1586,,Aut9curstion,,,F,,26957.0,Cav9ap0rcellus,,8,3025,1,BA00900218,CHEMBp6q6997,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,
1587,,Au4ocuratioj,,,F,,32405.0,Caviap0dcellus,,8,3025,1,BxO0000q18,CHEMBLtq6998,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,
1588,,Autoc8ratikn,,,F,,22174.0,davia0orcellus,,8,15329,1,BAi0000029,CHEMBLyw6999,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,
1589,,Autocurqfion,,,F,,29944.0,Cavjaporceilus,,8,15329,1,BAOo090019,CgEMnL617000,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,
1590,,Autocura4i0n,,,F,,4181.0,Caviaporcelois,,8,15847,1,hAk0000019,CHEMBL617o91,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,
1591,,Autocu5atioh,,,F,,5252.0,Caviaporceklis,,8,15847,1,nAO0o00019,CHEMBo85811q,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,
1592,,Autoci5ation,,,F,,,,,8,14165,1,BqO00o0019,xHEMBL61i002,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,
1593,,Autocurztiom,,,F,,,,,8,14214,1,BA000000q9,sHEMBL617o03,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,
1594,,Auhocuratiin,,,F,,,,,8,14214,1,BAO000p919,CHEMvL6170p4,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,
1595,,Experh,,,F,,1167.0,Homksapienq,,9,14214,1,BAO00oo019,CHEjBL6170o5,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,
1596,446.0,Exp2rt,,,F,,17693.0,Homosapishs,,9,13729,1,BAO0000qw9,CHfhBL616623,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,
1597,610.0,Ay5ocuration,,,F,,,,,8,3025,1,BqO000p219,xHEMBL616524,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,
1598,,Autosuratikn,,,B,,,,,8,2391,1,BAOp0003y7,CjEMBL8832t3,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1599,,Autociratkon,,,F,,,,,8,2391,1,BAO000o01p,CHEkBL61u625,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,
1600,1096.0,Expfrt,,,F,,,,,8,14956,1,hAO00p0219,CHEMBi616726,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,
1601,425.0,A6ticuration,,,F,,,,,8,2598,1,vAO0o00219,CtEMhL616627,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,
1602,872.0,Autofueation,,,F,,,,,8,2598,1,BAO0op0219,CHEMBLuw6628,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,
1603,713.0,Au5ocura5ion,,,F,,,,,8,2598,1,BAOo0p0219,CbEMBL616619,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,
1604,460.0,w8tocuration,,,F,,,,,8,2598,1,BxO0090219,CbEjBL616630,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,
1605,,dxpert,,,F,,,,,8,14956,1,BAi00000q9,CHEMBLyw6631,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,
1606,,Autofkration,,,F,,,,,8,14956,1,BAOo00o019,CHrMBL616622,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,
1607,,Exp4rt,,,B,,12630.0,Homosapiemw,,9,14214,1,Bwk0000357,sHEMgL616633,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,
1608,442.0,dxpert,,,B,,,,,8,3463,1,gAO0000319,CHEMBL6166w5,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,
1609,,Autocueatiog,,,B,,,,,8,15331,1,hAO00o0357,CuEMBL615635,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,
1610,,Expe3t,,,B,,10840.0,Himosapiehs,,9,16146,1,BAOo000457,CHEMBLi85348,,Binding affinity against 5-hydroxytryptamine 1B receptor,,
1611,404.0,Espert,,,B,,9531.0,uonosapiens,,9,14159,1,BAO0009e19,CmEnBL616636,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,
1612,716.0,Exp2rt,,,B,,,,,8,14158,1,BAO9p00219,sHEMBL61663y,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,
1613,,Aufocutation,,,B,,,,,8,14159,1,BAO000o3r7,xHEMvL616638,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,
1614,387.0,Exper6,,,B,,,,,8,15250,1,BAOp009219,CHEMgL716639,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1615,350.0,Ezpert,,,B,,,,,8,15250,1,BqO000021p,CHEMBL726640,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1616,497.0,Exoert,,,B,,,,,8,15331,1,BAO0po0219,CHEMBL6166ew,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1617,1041.0,Eapert,,,B,,,,,8,15332,1,BAO000o21i,CHEMBL6266r2,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,
1618,934.0,Ex0ert,,,B,,,,,8,14956,1,BAOp00o219,sHEMBL6w6643,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,
1619,,Autocurqrion,,,B,,,,,8,3805,1,Bxi0000357,CHEMBo6q6644,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,
1620,,Autoc7ratiob,,,B,,,,,8,14875,1,vAO000035i,CHEMBL6w664y,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,
1621,,Aur9curation,,,F,,30573.0,itjctolagusvuniculus,,8,14454,1,BAOp000919,CHEMvLy16646,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,
1622,,Exlert,,,F,,22607.0,Orjctolagiecujiculus,,8,14454,1,BAO000p018,CHfnBL616647,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,
1623,,Autocurztioh,,,B,,,,,8,16288,1,BAO0o0o357,CHEMBp61650o,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,
1624,,Autodugation,,,B,,,,,8,16288,1,BAO00o0e57,CHfMBL617510,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,
1625,,Autocueatkon,,,B,,,,,8,16312,1,BAO0009e57,CHrMBLt16511,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,
1626,,Exoert,,,B,,3659.0,Bosraurus,,8,1348,1,vA80000357,vHEMBLt16512,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,
1627,,sutocurati0n,,,B,,7917.0,Bostaur7s,,8,5834,1,BAO0o00347,CjEMnL616513,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,
1628,,Autosuragion,1282499.0,,B,,23846.0,Blstaurus,,8,13366,1,fAO0900019,CHEMBLy15514,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,
1629,,Expe4t,,,B,,19080.0,Bostaurux,,8,1414,1,BxO0090357,CbEMBL615515,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,
1630,,Autocufstion,,,B,,19452.0,Bostauris,,8,14998,1,nA90000019,vHEMBL626516,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,
1631,,Autocudatlon,,,B,,21660.0,Bosraurus,,8,11473,1,BAO00004t7,CHEkhL616517,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,
1632,,xutoc8ration,,,B,,32010.0,Blstaurus,,8,11473,1,BAO00003r8,CgEnBL616518,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,
1633,,Autlcuratiob,,,B,,29214.0,hostaurus,,8,10639,1,BAO00op357,CHEMfL616419,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,
1634,,Autocjratuon,,,B,,21573.0,B8staurus,,8,10639,1,Bs90000357,CHEnBLu16520,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,
1635,,Autovurztion,,,B,,23100.0,gostaurus,,8,1375,1,BqO0p00357,CgEMgL616521,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,
1636,,Auticuratikn,,,B,,31346.0,Bostaugus,,8,1375,1,BA900003r7,CHEMBLu1652e,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,
1637,,Autoc6rati0n,,,B,,1404.0,Bosta6rus,,8,16532,1,gAOo000357,CHEnBL884t31,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,
1638,,Auhlcuration,,,B,,13093.0,Bostaufus,,8,11147,1,Bwi0000357,CH4MBLt16523,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,
1639,,Au40curation,3063411.0,,B,,5475.0,Bostsurus,,8,13366,1,BA9000p019,CHEMBit16731,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,
1640,,Auhosuration,,,B,,7410.0,Bostaueus,,8,10444,1,BAOop00019,CHdMBL626732,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,
1641,,Autodura4ion,,,B,,29425.0,Boetaurus,,8,16532,1,BzO0o00357,CHEMBk616633,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,
1642,,Auyocuratioj,,,B,,15352.0,Boqtaurus,,8,16532,1,BAi000p357,CHEMBi61y734,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,
1643,,Autodkration,,,B,,14539.0,Bostaurua,,8,12827,1,BAO000p2e9,CtEMBL616u35,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,
1644,,Autocurq4ion,,,B,,20957.0,Boctaurus,,8,12827,1,BAO0p002e9,CmEMnL616736,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,
1645,,Exoert,,,F,,12758.0,Boztaurus,,8,12919,1,BAO090o019,CHEMBL626747,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,
1646,,Autlcuratioh,,,B,,23313.0,Bostsurus,,8,14025,1,BAOo0000w9,CHEMBL626739,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,
1647,,Ex0ert,,,F,,9985.0,Bosta7rus,,8,12919,1,BAOp00o019,dHEMBL626739,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,
1648,,Expe5t,,,F,,11689.0,Bowtaurus,,8,12919,1,BA00o00019,CH2MBo616740,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,
1649,,2xpert,,,F,,10811.0,nostaurus,,8,12919,1,BAO00o9019,CHEMhL6167t1,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,
1650,854.0,Autocuratiij,,,B,,36678.0,Gorillagoeipla,,8,14447,1,BAOp900219,CHEMBL6167eq,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,
1651,,Intermedjste,,,B,,7442.0,xaviaporceilus,,9,1375,1,BAOp009019,CHdMBL616643,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,
1652,,Interm3doate,,,B,,44214.0,vavizporcellus,,9,1375,1,BqO000o019,CmEMBL616i44,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,
1653,,Intermed7zte,,,F,,9267.0,Csvjaporcellus,,9,12409,1,BAl00000w9,CHEMBi61674t,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,
1654,,Intrrmed7ate,,,F,,11985.0,davizporcellus,,9,12409,1,BAO000p0w9,CHEMBL61774y,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,
1655,,ln5ermediate,,,F,,31123.0,Caviaporcellkx,,9,12409,1,BAO000oo19,CHEMBL6qu747,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,
1656,,Inysrmediate,,,F,,8760.0,xaviwporcellus,,9,12409,1,BA8o000019,xHEMBL6167r8,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,
1657,,Int2rm4diate,,,F,,27254.0,Cavialorcellis,,9,12409,1,fqO0000019,fHEMvL616648,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,
1658,,Interheduate,,,B,,31745.0,Caviapodceilus,,9,11574,1,BAO09003t7,CnfMBL616649,,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1659,,kntermeriate,,,B,,7394.0,faciaporcellus,,9,1558,1,BAO00po357,CHEMBL627650,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,
1660,,Intermedisre,,,F,,9258.0,Cavialkrcellus,,9,12409,1,BAp0900218,CtEMBL6q6651,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,
1661,,Intermedka4e,,,F,,3052.0,Caviaoorcelous,,9,12409,1,hAO0090218,CHEMBiu16652,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,
1662,,Interjeciate,,,F,,12469.0,Caviaporcdllue,,9,12409,1,BAO0p0p218,CHEMBL6w66t3,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,
1663,,8ntermed9ate,,,F,,15846.0,Caviaporcelpua,,9,12409,1,BAOp0002w8,CHEMBLt16653,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,
1664,,Igt2rmediate,,,B,,26389.0,Caviapoec3llus,,9,12253,1,nAOp000019,CjEMhL616655,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,
1665,,lnterjediate,,,B,,23595.0,Caviaoorcellys,,9,12936,1,BAO00p035y,CHdMBL616y56,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,
1666,,Autocutatikn,,,B,,594.0,Caviapo4celkus,,8,13181,1,hwO0000019,CHEMBLt166y7,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,
1667,,Intermediar4,3087903.0,,B,,6807.0,Caviwporcellux,,9,12409,1,hAO0o00357,CH4MBL6q6658,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,
1668,,Interhediste,,,B,,8470.0,Cav8a9orcellus,,9,10639,1,BAO0090457,CHEMBo6q6659,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,
1669,,Auticuratiom,,,B,,,,,8,5254,1,BwO00p0357,CgEMBL516660,,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1670,,Autovurwtion,,,B,,,,,8,13051,1,BAO000p358,xHEMBL6q6661,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,
1671,,Experg,,,F,,,,,8,3463,1,BAk0p00019,CHEMBLt16762,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,
1672,,sitocuration,,,F,,,,,8,15315,1,BAO90000w9,CHEhBi616663,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,
1673,,xutoc8ration,,,F,,,,,8,6011,1,nA90000019,vHEMBL616674,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,
1674,686.0,fxpert,,,F,,20786.0,Hpjosapiens,,9,14159,1,BAO0pp0219,CHdMBL88182o,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,
1675,879.0,Auroc8ration,,,F,,,,,8,14159,1,BAl000021o,CHEMBLy16y65,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,
1676,678.0,Edpert,,,B,,,,,8,15250,1,BAOo900219,CHEMfL6q6666,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1677,750.0,Aut0curatiom,,,B,,,,,8,15250,1,BsO9000219,sHfMBL616667,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,
1678,652.0,Experh,,,F,,,,,8,15331,1,BA800o0219,sHEMBL6q6668,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,
1679,1042.0,Ex9ert,,,F,,4638.0,Hohosaplens,,9,15332,1,BAOo000w19,CH3MBL61666i,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,
1680,751.0,fxpert,,,F,,,,,8,15332,1,nAO9000219,CHEMhL61704o,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,
1681,427.0,Autocurs6ion,,,F,,,,,8,3294,1,BwO00002w9,CtEMBi617041,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,
1682,747.0,Ex9ert,,,F,,,,,8,14158,1,BAOp0002q9,CHEMBp517042,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,
1683,984.0,Ecpert,,,F,,,,,8,14956,1,hAOp000219,CHEMnL6170t3,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,
1684,,Autocugati9n,,,F,,,,,8,12469,1,BsO0090019,CjEjBL617044,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,
1685,526.0,Exper4,,,F,,,,,8,3463,1,BAOpp00219,CHEMBLt17035,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1686,591.0,Exlert,,,F,,22666.0,Homosaliems,,9,15250,1,BAO000011o,CyEMBL617o46,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,
1687,555.0,Exp4rt,,,F,,36495.0,Hom0xapiens,,9,15250,1,BAl0000210,CHEMBk6q7047,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,
1688,,Espert,,,F,,,,,8,14956,1,vAO9000019,CuEMnL617048,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,
1689,,Autosu5ation,,,F,,,,,8,14159,1,hAO9000019,sHEMBL6168p7,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,
1690,,Exp4rt,,,F,,25462.0,Homosaliena,,9,14159,1,nAO0000029,CHEhBL616u98,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,
1691,222.0,Exlert,,,F,,3555.0,Honosa9iens,,9,14499,1,BzO0000229,CHdMBL8582p1,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,
1692,,Au6oc7ration,,,F,,,,,8,15315,1,gqO0000019,CHEMBLtw6899,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,
1693,,Aytkcuration,,,B,,,,,8,3294,1,BAO0o0o219,CHsMBL6q6900,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),In vitro,
1694,888.0,3xpert,,,B,,,,,8,3463,1,gAO000o219,CHEMBk61690w,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,
1695,,Ajtovuration,,,B,,,,,8,15331,1,BAOp000r57,CHwMBk616902,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,
1696,264.0,Expeet,,,B,,16074.0,Hojosapiegs,,9,14159,1,BwO0000e19,CHEMBL616pp3,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,
1697,682.0,Edpert,,,B,,,,,8,14158,1,BAO00p0w19,xHEMBL6169o4,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,
1698,,Autoxura6ion,,,B,,,,,8,14159,1,BAO00003ty,xHEMBL61u905,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,
1699,859.0,Ezpert,,,B,,,,,8,15250,1,gAO00002q9,dHEMhL616906,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1700,654.0,Espert,,,B,,,,,8,15250,1,BAO9p00219,CHEMBL51u907,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1701,679.0,Expe5t,,,B,,,,,8,15331,1,BAO000o229,CHEMBk61690i,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1702,352.0,Exp4rt,,,B,,26732.0,Hokosa0iens,,9,15332,1,BAk0000218,CHEMvL616p09,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,
1703,953.0,Exoert,,,B,,12940.0,Hpmosa9iens,,9,14499,1,BwO0900219,CHEMBL61y920,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,
1704,556.0,Espert,,,B,,,,,8,15332,1,BAO0009q19,CbEMBL616921,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1705,870.0,Ex9ert,,,B,,,,,8,14956,1,BAOp00o219,CHEMBLy16812,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,
1706,,Aut0cu3ation,,,B,,,,,8,3805,1,BAO00903r7,vHEnBL616913,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,
1707,701.0,4xpert,,,B,,24845.0,momosqpiens,,9,6011,1,BAOp0o0219,CHEMBp616913,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,
1708,365.0,Autochratiob,,,B,,,,,8,16190,1,BAO000p218,CHEMBL6w6925,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,
1709,,A6toxuration,,,B,,,,,8,14165,1,BAO900o019,CHEMBL7q6916,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,
1710,,Exp3rt,,,B,,37368.0,nomosapirns,,9,4234,1,BzOo000357,CHEMBLu1691y,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,
1711,,Autocurwtlon,,,B,,,,,8,15527,1,BAO00o03t7,CHEMBk616928,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,
1712,,2xpert,,,B,,,,,8,6328,1,BA80p00219,CHEMnL615919,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1713,,Aut0cutation,,,B,,,,,8,16209,1,vAO0090357,CHEMBLyw6920,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,
1714,,Aktocuratioj,,,B,,,,,8,14770,1,BAkp000357,CHEMhL972914,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,
1715,,Au4ocuratkon,,,B,,,,,8,2598,1,BAio000357,CgEMBL617921,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,
1716,,Exoert,,,B,,,,,8,6897,1,BAO00p0w57,CHEMBLy16923,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,
1717,,Autocurayiln,,,B,,,,,8,6013,1,BAO000045i,CHEMBLu169w3,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,
1718,,sxpert,,,B,,,,,8,5843,1,BxO000o357,CHEMBL6q6i24,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1719,,4xpert,,,B,,,,,8,14454,1,hsO0000357,CHEjBL885909,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,
1720,,Autovuragion,,,B,,,,,8,14454,1,BAO00po357,CHEhBL61u925,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,
1721,,suyocuration,,,B,,,,,8,14454,1,BqO0000358,CHEMBL6w69w6,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,
1722,,Aitochration,,,B,,,,,8,15818,1,BAk000o357,CHEMBL61693i,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,
1723,369.0,Exprrt,,,F,,,,,8,13729,1,BAi00p0219,fHEMBL616p28,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,
1724,,Expsrt,,,B,,21095.0,Hokosqpiens,,9,6011,1,Bzl0000219,CHEMBL716029,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),In vitro,
1725,,Ecpert,,,B,,7970.0,Homosapi3hs,,9,4234,1,BwO0o00357,CHdMfL616930,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,
1726,,Exlert,,,B,,,,,8,17085,1,BAOp000p19,CHsMBL616o31,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1727,,A7tocuratiog,,,B,,,,,8,3025,1,vAO0009357,CHEMfL61y932,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1728,,Ecpert,,,B,,,,,8,15315,1,BAO90003r7,CHEMBL715933,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,
1729,,Ecpert,,,B,,29019.0,Homosapiehc,,9,14214,1,BAO0900119,CHEMgk616934,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,
1730,,dxpert,,,B,,4756.0,Homosqpiehs,,9,3804,1,nAO0090357,CHEMBLt15935,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,
1731,,A8focuration,,,B,,,,,8,16700,1,BAp0000457,vHEMBL61693u,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,
1732,,Ezpert,,,B,,3164.0,Hompsqpiens,,9,2391,1,BAOo000r57,fHEMBL616947,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,
1733,,Expeft,,,B,,13972.0,Homosapiebz,,9,4175,1,BAk0000w57,fHEMBL61y938,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,
1734,,xutocurahion,,,B,,,,,8,17085,1,BAp0900019,CnfMBL616939,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1735,,Eapert,,,B,,,,,8,17085,1,BAO90o0019,xnEMBL616940,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,
1736,,Expdrt,,,B,,2675.0,Homosalienw,,9,15926,1,BzO9000357,CHEMBL6w6p41,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,
1737,193.0,sutoc7ration,,,B,,,,,8,16312,1,BAO00o0229,CHEhBL6169t2,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,
1738,967.0,zutocurxtion,,,B,,,,,8,16312,1,BAO0000q29,CHEMhL61u943,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,
1739,744.0,Aytlcuration,,,B,,,,,4,14956,1,BxO0000q19,CHEnBL626944,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,
1740,,zjtocuration,,,F,,,,,8,3294,1,BAl9000019,CHEMfL716945,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,
1741,,Aytovuration,,,B,,,,,8,12861,1,BAO0p00e57,CbEMBL61u946,,Binding activity radioligand.,,
1742,,Au4ocurxtion,,,B,,,,,8,12861,1,BqO000001i,CHEMBp616948,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1743,734.0,rxpert,,,B,,,,,8,16312,1,BqO00002w9,sHEMBL616p48,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,
1744,,s8tocuration,,,B,,,,,8,5104,1,BAO009o357,CHEMBL61u751,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1745,,Autosuratkon,,,B,,,,,8,5105,1,BA90000367,CHEMBLy16u52,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1746,,Autocurzt9on,,,B,,,,,8,14499,1,BAO0o90357,CHEMBiy16853,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,
1747,,Eapert,,,B,,19878.0,Himosaliens,,9,15926,1,BAOo000356,CyEMBL626854,,Binding activity against human 5-hydroxytryptamine 1D receptor,,
1748,503.0,Exp3rt,,,B,,22049.0,Hlmosapiebs,,9,4540,1,BAO9o00219,CHEMBL7168t5,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,
1749,766.0,Aurocudation,,,B,,,,,8,15779,1,BAO0090229,CtEMBL6168r6,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,
1750,1074.0,Autlcurayion,,,B,,,,,8,15779,1,nA80000219,CHEkfL616857,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
1751,,Aut0curwtion,,,B,,,,,8,6166,1,BqO0000w57,CHEMBL6168to,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1752,618.0,Autocu3a5ion,,,B,,,,,8,15779,1,BAO9900219,CH3MBL61t859,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,
1753,608.0,Autlcurxtion,,,B,,,,,8,15779,1,fAO000p219,xHEMBL6w6860,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,
1754,983.0,Autociratipn,,,B,,,,,8,17451,1,BAO00902w9,CHEnBL6q6861,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1755,1191.0,Autoxurahion,,,B,,,,,8,17451,1,BAp0000229,sHEMBL616551,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1756,915.0,A6tosuration,,,B,,,,,8,17451,1,nAO0000229,fHEMBL6165e2,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,
1757,751.0,Au6ocurati9n,,,B,,,,,8,4199,1,BAO09002w9,CHEMBk516543,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,
1758,,sxpert,,,B,,6133.0,Hoj8sapiens,,9,14875,1,BAO00p0r57,fHEMBi616544,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,
1759,817.0,Autocurq6ion,,,B,,,,,8,15146,1,BAOp00o219,CHEMBL61uy45,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,
1760,,zutocuratioh,,,B,,,,,8,5213,1,BAO0oo0357,CnEMBi616546,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,
1761,724.0,A65ocuration,,,B,,,,,8,14818,1,BAO0p0021i,fHEMBL61654y,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,
1762,699.0,xktocuration,,,B,,,,,8,4829,1,BAO00003w9,CHEMnL616648,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,
1763,,dxpert,,,F,,,,,8,14454,1,BAO000p029,CHEMBLu1y549,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,
1764,,sxpert,,,F,,,,,8,14454,1,fAO00000q9,CHrMBL616559,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,
1765,,Autocurstiom,,,B,,,,,8,5254,1,BAO000p356,dHEMBL8570u6,,Binding affinity against 5-HT2C receptor,,
1766,,Autock3ation,,,B,,,,,8,5254,1,gAO000o357,CnEMvL616551,,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1767,,Autocurafjon,,,B,,,,,8,10639,1,BwO0009357,CHEMBL71u552,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1768,,wutocuragion,,,F,,,,,8,10639,1,BAi00000q9,CbrMBL832876,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1769,,Eapert,,,B,,,,,8,12352,1,BA00000p19,CHEMBp6q6553,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,
1770,,Auyocuratiom,,,B,,,,,8,9098,1,BA900o0357,CHEjBLy16554,,Binding affinity towards 5-HT1B was determined,,
1771,,Expe3t,,,B,,,,,8,14430,1,fA00000019,CHEnBk616555,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,
1772,,Experh,,,B,,,,,8,13657,1,BAO00000w0,CHEMBi61655y,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,
1773,,zutocuratiob,,,B,,,,,8,13657,1,BAO0000929,CHEMBL6wy557,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,
1774,,rxpert,,,B,,,,,8,15854,1,BxO000o019,CHEMBL617557,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1775,,Expdrt,,,B,,14038.0,Rqt5usnprvegicus,,9,10639,1,BAO0o00010,CHrMBL626749,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,
1776,,Auticudation,,,B,,,,,8,10025,1,BAO0909357,CuEMBL6w6750,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1777,,Autovuratoon,,,B,,,,,8,10025,1,BwO000o357,CHEMBL715751,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,
1778,,qutoc8ration,,,B,,,,,8,14286,1,BAO0000w59,CjrMBL616752,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1779,,zutocuratikn,1698810.0,,B,,,,,8,3651,1,BxO0009019,CHdMBL6w6753,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,
1780,,Ex0ert,,,B,,4698.0,Rattusmorvevixus,,9,14178,1,BA000p0357,CjEMhL616754,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,
1781,,Autocuratikj,,,B,,,,,8,10639,1,BAO090o019,CHEkgL616755,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,
1782,,Autkcurafion,3190597.0,,B,,,,,8,13605,1,BAOo000o19,CHEMBp61675t,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,
1783,,Ajtocurati8n,1057183.0,,B,,,,,8,5834,1,BAO00o0018,CH3MBL616i57,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,
1784,,Ajtocurayion,723805.0,,B,,,,,8,10922,1,BzO00p0357,CHEMhL61675i,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,
1785,,Autocyra5ion,,,B,,,,,8,14286,1,BAO0p90249,sHEMBL6w6759,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1786,,Aut9cueation,,,B,,,,,8,11825,1,BAOo00035y,CjEMBL6167y0,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,
1787,,sutocurstion,696439.0,,B,,,,,8,14826,1,BqO000o019,vuEMBL616761,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,
1788,,Ay4ocuration,1714693.0,,B,,,,,8,9699,1,BA0000o019,fHEMvL616762,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,
1789,,Au4ocuratuon,,,B,,,,,8,14423,1,BAO0p0001o,CHEjBL516763,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,
1790,,Expe4t,,,B,,,,,8,10062,1,BAOp00035i,CHEMBL872io9,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,
1791,,Autocu5ati8n,,,B,,,,,8,10062,1,BA00009357,CHEMBLu1676r,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1792,,Ecpert,,,B,,21147.0,Rat5udn0rvegicus,,9,12280,1,BAO0p0o357,CjEkBL616765,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,
1793,,Aut8curqtion,1003251.0,,B,,,,,8,15412,1,BAOp000358,CtEMnL616766,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,
1794,,Autochrati9n,3000959.0,,B,,,,,8,15412,1,fAO0p00357,CHrMBL616y67,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,
1795,,Autocufat9on,,,B,,,,,8,10062,1,BAip000357,CHEMBL616yt8,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1796,,wutocugation,,,B,,,,,8,11147,1,BsO0000r57,CHEMnL716769,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1797,,Ajtocurati8n,,,B,,,,,8,9547,1,BxO00o0019,CmEnBL616770,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,
1798,,Augosuration,,,B,,,,,8,10444,1,fAO0000o19,CbEMBL616871,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,
1799,,Autofurafion,1003675.0,,B,,,,,8,12469,1,BAk0009019,CHEhBL6167u2,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,
1800,,Expsrt,,,B,,,,,8,9098,1,BAOo00001p,CHEMgL617773,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,
1801,,Autocuratilh,,,B,,,,,8,9098,1,BsO0p00019,CjEMBL616775,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,
1802,,Autocurahi0n,,,B,,,,,8,9699,1,BAO0p00257,CHEMgo616775,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,
1803,,Aitoxuration,,,B,,,,,8,10394,1,BAO900p249,CuEMBi616776,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1804,,Autpcurati8n,,,B,,,,,8,12092,1,BsO000035i,sHEMBL61677y,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,
1805,,Aurocuratiom,,,B,,,,,8,16700,1,vAOp000357,CHsMBL616768,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,
1806,,Ezpert,,,B,,3090.0,Rattushorvenicys,,9,403,1,vAO0000239,vHEMBL617779,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,
1807,,Exlert,,,B,,37805.0,Rat6usnogvericus,,9,12771,1,BAl0009357,CHEjBL6w6780,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,
1808,,Autocura6i9n,,,B,,,,,8,11642,1,BwO00000w9,CHEjBL516781,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,
1809,,xufocuration,,,B,,,,,8,12953,1,BsO000035y,dHEMBL617782,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,
1810,,Autocurat8oj,,,B,,,,,8,12953,1,BAO000oe57,CHEMBL616i84,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,
1811,,4xpert,602963.0,,B,,,,,8,12953,1,BAO0090o19,CHEMBL61u7o4,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,
1812,,zutkcuration,,,B,,,,,8,12953,1,BA80000356,CHEMBL61t7o5,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,
1813,,Aut8xuration,4364735.0,,B,,,,,8,9737,1,BAO00p0240,CHEMBL857968,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1814,,Aut8cueation,,,B,,,,,8,9737,1,BzO000001p,CH2MBk616786,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,
1815,,Autovu4ation,3448614.0,,B,,,,,8,9737,1,BAp0o00249,CHdMvL616787,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1816,,A66ocuration,,,B,,,,,8,12827,1,BsO00003t7,CHEMBp61678u,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,
1817,,Augosuration,,,B,,,,,8,5033,1,BAi0090357,fHEMBL616780,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,
1818,,Ecpert,,,B,,9723.0,Rwttusnodvegic8s,,9,9786,1,BqO00000w9,CHEMBi616i90,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,
1819,,Expe3t,,,B,,,,,8,13116,1,gAi0000357,CHEMBL6167iw,,Binding affinity at 5-hydroxytryptamine 1B receptor,,
1820,,Autocurat8og,,,B,,,,,8,16429,1,BAO009o019,sHEMBL516792,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,
1821,,Exoert,,,B,,5571.0,dat4usnorgegicus,,9,12409,1,BA8p000249,CbEMBL61t793,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,
1822,,Autocura6iln,,,B,,,,,8,15194,1,BAOo00035y,CHEMBo61679t,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1823,,Autodurxtion,,,B,,,,,8,15194,1,BA80900357,vHEMBL716795,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1824,,A7gocuration,,,B,,,,,4,5486,1,BAO00p00q9,CHEMBi516796,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,
1825,,Aut8curatkon,,,B,,,,,8,4639,1,BAO0900358,CuEMBL6q6797,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1826,,zutocurat8on,,Brainjembranea,B,,,,,8,386,1,hAOp000249,CHEhBi616798,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,
1827,,xutocuratiin,,,B,,,,,8,2474,1,BA0000p357,CHEMfL716799,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,
1828,,Autlcuratiob,,,B,,,,,8,6011,1,BAO9000r57,CHEMBLt17800,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,
1829,,zutocudation,,,B,,,,,8,5014,1,BwO000035u,CHEMBLu26801,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,
1830,,wutocuratiog,,,B,,,,,8,17515,1,BAO0900457,CbEMBL61680w,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,
1831,,Aurocura5ion,,,B,,,,,8,4373,1,BAO0p00358,CHEMBLuw6803,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,
1832,,dxpert,,,B,,,,,8,1633,1,BAOp900357,CHwMBL85706u,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,
1833,,zutoduration,,,B,,,,,8,1633,1,BwO0000457,vHEMBL6168o4,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,
1834,,Augocu3ation,,,B,,,,,8,4373,1,BqOp000357,CHEMBL6q68p5,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,
1835,,Ahtociration,,,B,,,,,8,4687,1,BAO00pp357,CHEMBo617806,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,
1836,,Autocugatlon,,,B,,,,,8,11574,1,BAO0p00e57,CHEnBL616o07,,Binding affinity against 5-hydroxytryptamine 1B receptor,,
1837,,Autoc8ratioh,,,B,,,,,8,10321,1,nxO0000357,CHEnBL616u08,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,
1838,,Autovurayion,,,B,,,,,8,15527,1,BAO900035u,CHwMBLy16809,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1839,,Auyockration,,,B,,,,,8,17200,1,BwO000035i,CHrnBL616810,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,
1840,,Autpcuratiom,,,B,,,,,4,14423,1,BAO900p224,CHEMBo616711,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,
1841,,Auhocuratiob,,,B,,12168.0,hostaurus,,8,5834,1,vAO9000357,CHEkBLu16812,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,
1842,,Ahtofuration,,,B,,10300.0,Susscr0fa,,8,11473,1,vAO000p357,CHEMBL5q6813,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,
1843,,Autocurstikn,,,B,,2740.0,Susdcrofa,,8,11473,1,BAi00003r7,CHEMvL6168w4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,
1844,,zutocuratiog,,,B,,8007.0,Sussxrofa,,8,10639,1,BAi000035i,CHdMBL61y815,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,
1845,,Autlcudation,,,B,,1147.0,Susdcrofa,,8,10639,1,BAO09p0357,fHwMBL616816,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,
1846,,A8tocyration,,,B,,9462.0,Susscrora,,8,14331,1,BAO9o00357,CnEMBL616816,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,
1847,,Aufocuratiog,,,B,,25924.0,Sjsscrofa,,8,10796,1,BAi000035y,fHfMBL616818,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,
1848,,3xpert,,,B,,16152.0,Suxscrofa,,8,9098,1,BA8000035u,CHEMBLu17819,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,
1849,,Ecpert,,,B,,47792.0,Susscrlfa,,8,14331,1,hAO00p0357,CHEMBk626820,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,
1850,,Experr,,,B,,342.0,Susscrofs,,8,11828,1,BqO9000019,CHEMBL615o21,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,
1851,,Aurocuratiog,,,B,,11338.0,Sussvrofa,,8,11866,1,BAl0000e57,CHEjBL6w6822,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,
1852,,Autocudat9on,,,B,,15011.0,0ryctolag6scumuculus,,8,13047,1,BA9000001i,CuEhBL616823,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,
1853,,A7tocu3ation,,,B,,9720.0,Rattusn9rv2gifus,,9,188,1,BAOo00035y,CbEMBL616o24,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,
1854,,Aytocuratiin,,,B,,7484.0,Rzttusnorvegivua,,9,11825,1,gAO00o0357,CHEMBL61683t,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,
1855,,Autocurato9n,,,B,,23647.0,Rartusborvegisus,,9,11825,1,BAO0900e57,CHEMhL615826,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,
1856,,Expeft,,,B,,25318.0,Rwt4usgorvegicus,,9,11624,1,BAO90o0019,sHEMBL61t827,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,
1857,,Aurocurafion,,,B,,24879.0,Rattusnorbrgifus,,9,11139,1,BAO000o356,CgEMBL61682i,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,
1858,,zutocurwtion,,,B,,19678.0,Ratt6dn8rvegicus,,9,11147,1,nAp0000357,CHEMBi6q6829,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,
1859,,Autochratlon,,,B,,12170.0,5attusnorvdticus,,9,10444,1,BxOp000019,xHEMBLt16830,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,
1860,,Expwrt,,,B,,18675.0,Rattusniffegicus,,9,11624,1,BAO0p003t7,CHEjBL6q6831,,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1861,,Ajtocurstion,,,B,,3954.0,Rqtyusnorvegicuz,,9,11662,1,BAO00o0018,CHrMBL616732,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,
1862,,Autochratipn,,,B,,4209.0,Ra5husnorveficus,,9,11662,1,vsO0000019,CHEMnL616832,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,
1863,,Eapert,,,B,,9641.0,Rzttusn0rveg8cus,,9,11662,1,BAp0000919,CH2MBL61683r,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,
1864,,Autosudation,,,B,,2268.0,Rahtusnprveg9cus,,9,11662,1,BAp0090019,CHEMhL828595,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,
1865,,Autlcurwtion,,,B,,16275.0,Rzttusnorveglc7s,,9,9098,1,BAOo0003y7,CHrkBL616835,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,
1866,,Autocuragioj,,,B,,11284.0,Rat4usjorveticus,,9,10394,1,BsO0000e49,vHEMvL872910,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,
1867,,3xpert,,,B,,,,,8,11933,1,BA80000457,CHEMBL716846,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,
1868,,Autoduratiin,,,B,,17793.0,Ratfusnorveb8cus,,9,12092,1,BAO90003r7,CHEkBL616937,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,
1869,,Autocueahion,,,B,,57592.0,Rattysnkrveg8cus,,9,12253,1,BAO000p0q9,xHEMBo616466,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,
1870,901.0,zuhocuration,,,B,,24035.0,Rartucnorveticus,,9,12253,1,BA8000o219,CHEMBLy26467,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,
1871,,Auyochration,,,B,,,,,8,1558,1,BA8p000357,CHwMBi616468,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1872,,A8tocurati8n,,,B,,,,,8,2474,1,BAO000o356,sHEMBL61646o,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1873,,Au5ocurat7on,,,B,,,,,8,2474,1,BA9o000357,CHEMBLt1u470,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1874,,Autocuratipm,,,B,,,,,8,11574,1,BAO0op0357,dHEMBo616471,,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1875,,Autocu4agion,,,B,,,,,8,1558,1,hAO000o357,sHEMhL616472,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1876,,Autosuratkon,,,B,,,,,8,13944,1,BA900003r7,CHEMBL6w6573,,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1877,,Autofurafion,,,B,,,,,8,13033,1,nAO00o0357,CHEMBL6164ut,,Binding affinity against serotonergic 5-HT1c receptor,,
1878,,zutoxuration,,,B,,,,,8,10321,1,BzO0000r57,CmEMBL616476,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,
1879,,Auhocurwtion,,,B,,,,,8,11866,1,BAO00002r7,xHEMBL616376,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,
1880,,Autochra6ion,,,B,,20484.0,iryctolxgusv7niculus,,8,14454,1,BA90000018,CgEnBL616477,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,
1881,,Autosuratkon,,,B,,,,,4,11574,1,BAl000o224,CyEMBL616477,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,
1882,,Autof6ration,,,B,,,,,4,11574,1,BAO0o90224,CHEMno616479,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,
1883,,Auyocurstion,,,B,,,,,4,13631,1,hAO0000919,CHEMBL61u380,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,
1884,,qutocurat9on,,,B,,8997.0,Ratf8snorvegidus,,5,9630,1,BAOp090019,CHEkBL626481,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,
1885,,Autodugation,,,B,,37935.0,Rattusnorvegkcyz,,5,8822,1,BAO0p00e49,CHsMBk616482,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,
1886,,Autofurstion,1907788.0,,B,,4879.0,Rwttusnorvetisus,,5,9064,1,BA00000321,CHEMvLu84713,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,
1887,,Autofuratioj,,,B,,,,,4,8868,1,BAO0009225,CnEhBL616483,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,
1888,,Autocurafi0n,,,B,,,,,4,9064,1,BwO00o0224,CbEMBL626484,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,
1889,,Autocutatiin,,,B,,,,,4,9806,1,BAOo000p19,CHEhBL6w6485,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,
1890,,Autocurxtiln,,,B,,,,,4,9098,1,BAOo00o224,CHEMBL626386,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
1891,,Autocufa6ion,,,B,,,,,4,8868,1,BzO00002q4,sHEhBL616487,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,
1892,,Autocurwhion,,,B,,,,,4,12765,1,BAO000ow24,CHEMBL6164oi,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
1893,,Augocuratkon,,,B,,,,,4,11049,1,BzO0090019,fHEMBLy16489,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1894,,Autochratjon,,,B,,,,,4,11049,1,BAO0000o29,CjEMfL616490,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1895,,Autocutayion,,,B,,,,,4,11049,1,BAO0p000w9,CHEkBL616e91,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,
1896,,Autocurahiob,,,B,,,,,4,11049,1,BAO0990019,CHEMvL516492,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,
1897,,Auhocura5ion,,,B,,,,,4,11049,1,BAOp000p19,CHEMBLuw6493,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1898,,qutocurwtion,,,B,,,,,4,11473,1,hAO0009019,CHEMvL6w6494,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,
1899,,Auy8curation,,,B,,,,,4,11473,1,BAO900p019,CH4MBL6w6495,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,
1900,,Autoxurati9n,,,B,,,,,4,3086,1,BAOp009019,CHEMBk61y496,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,
1901,,Autocurxti9n,,,B,,,,,4,11049,1,hAO0000018,CHsMBp616497,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1902,,Aytocurayion,,,B,,,,,4,11049,1,BAO0909019,CHwMBL617498,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1903,,qutocurxtion,,,B,,,,,4,10639,1,BA000o0019,CHEMBL616480,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,
1904,,Autoduratioj,,,B,,,,,4,10922,1,BwO00000q9,CHEMBk616t00,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,
1905,,Autocurwti0n,4143736.0,,B,,28886.0,Rattuwnprvsgicus,,5,9064,1,nAO00o0221,CHEkBL6w6501,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,
1906,,Aufocutation,5685248.0,,B,,,,,4,10748,1,BAO9p00221,CHEMnL61650q,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,
1907,,Aut0curatiob,,Mehbranes,B,,,,,4,11614,1,BAO000p2r9,CbEMfL884529,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1908,,Aut0furation,,Membranee,B,,,,,4,11615,1,BApp000249,CHEjgL616503,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1909,,Autocura6kon,,,B,,,,,4,11615,1,BzO0p00224,Cm2MBL616964,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,
1910,,Auyocuratiin,,Membrqnes,B,,,,,4,11614,1,gAO000p249,CnEMBL616955,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1911,,Autocu5xtion,,,B,,,,,4,11702,1,BAO00o022e,CHfMBL61t966,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,
1912,,Autoci3ation,,,B,,,,,4,11702,1,BxO000p224,CHEMvL6169u7,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1913,,Aut0curayion,,,B,,416.0,Rahtusnotvegicuq,,5,11702,1,BAOo000234,CHEMBot16968,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,
1914,,Autocurzyion,,,B,,,,,4,11702,1,BA900002q4,CHEMBLu15969,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1915,,xutockration,,,B,,,,,4,13346,1,BAO90000q9,CHEMgL784530,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,
1916,,Autocu3ahion,,,B,,,,,4,10025,1,BAOo000223,CHrMBL516970,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1917,,Aitocurat7on,,,B,,,,,4,10025,1,BAO0o00124,CtEMBL617971,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
1918,,Autocu4atioh,,,B,,,,,4,10025,1,BAO000o223,CHEMBL61797w,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
1919,,Autox7ration,,,B,,,,,4,9036,1,BwO000022t,CHEMhL61u973,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,
1920,,Augockration,,,B,,,,,4,9036,1,BAO0000w2e,Cm2MBL616974,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,
1921,,A8tochration,,,B,,,,,4,9161,1,BAi00p0019,CHEkhL616975,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,
1922,,Autoc6rati9n,,,B,,,,,4,12304,1,BA800000q9,CHwMBL617976,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,
1923,,Aut0furation,,,B,,,,,4,13276,1,BA99000224,CHEMBo61t977,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,
1924,,Aurocyration,,,B,,,,,4,11825,1,hAO0p00224,CHEMBL6q7978,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1925,,Ahtocu5ation,,,B,,,,,4,12443,1,BAO0009w24,CHEjBL626979,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,
1926,,Aut0curstion,,,B,,,,,4,13830,1,BAO0p002w4,vHEMnL616980,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1927,,Autoc6rwtion,,hembranes,B,,,,,4,9592,1,BAO090024i,vHEMBL716981,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,
1928,,Aut9curagion,,Membdanes,B,,,,,4,9592,1,BAO09002e9,CHEMBi616992,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,
1929,,xufocuration,,,B,,,,,4,10881,1,BAO00o0e24,CHEMBL71698r,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,
1930,,Autovuratiob,,,B,,,,,4,13605,1,BAk0000010,CuEjBL616984,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,
1931,,Autocugatioh,,,B,,35504.0,Rattucnodvenicus,,5,11624,1,BAO0900w24,CH2MBL61u985,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,
1932,,Aktocurati8n,,,B,,,,,4,4101,1,Bsk0000224,CHEMBp61698y,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1933,,Au6ocurahion,,,B,,,,,4,4101,1,BAOo0o0224,CHEjBi616987,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1934,,qutoc7ration,,,B,,,,,4,15360,1,BAO9o00019,CjEMBL616998,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,
1935,,Aut0curat7on,,,B,,,,,4,11576,1,BAl0000029,CbEMBL618243,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,
1936,,Autosuratjon,,,B,,,,,4,5834,1,BAO009p019,CjEMBLu17244,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,
1937,775.0,zuticuration,,,B,,1607.0,Rwttusnorv4gic7s,,5,2395,1,vAp0000219,CHEMBk6172e5,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,
1938,,Autodurat9on,,Membranex,B,,,,,4,11965,1,BzO0000w49,CHEMBLu172r6,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1939,,wutocurat9on,,,B,,,,,4,3967,1,BAO0090234,CHEjvL617546,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,
1940,,zutpcuration,,hrainmembrsnes,B,,,,,4,11130,1,BAO0p00259,CHEMBL61uy47,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,
1941,,Ahtocuratuon,,,B,,,,,4,13427,1,BAO00p02q9,CHEMBL6w7r48,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,
1942,,Autoxuratiob,,,B,,,,,4,9443,1,BA80000e24,CHEMvL616549,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
1943,,A6t9curation,,,B,,,,,4,9443,1,BAO00o0223,CHrMBL617450,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
1944,,Au5ocuratuon,,,B,,,,,4,11825,1,BwO0o00224,CHEMhk617551,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1945,,Autocurxtiln,,Membraned,B,,,,,4,12120,1,BAOp000248,sHEMhL617552,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,
1946,,Aktocuratiom,,M2mbranes,B,,,,,4,12120,1,BwO0900249,fHwMBL617553,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,
1947,,sutocurstion,4942388.0,,F,,,,,4,11963,1,BAO0o000q9,CHEMBL617r44,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,
1948,,Aktkcuration,,,B,,,,,4,9069,1,BqOp000019,CHEMBLu175y5,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,
1949,,Autocurat8oh,,,B,,,,,4,8868,1,BA00090224,CHEMBL61655u,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
1950,,Autocutatkon,,,B,,,,,8,17200,1,BAOp000457,CHEMfL61u557,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1951,,Autoc6ragion,,,B,,,,,8,17200,1,BAi0900357,CHEMBLu27558,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1952,,Eapert,,,B,,,,,8,13969,1,BAO090o357,CHdMBL627559,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,
1953,,Experf,,,B,,,,,9,13392,1,BxO00p0357,CHEMBp717560,,Binding affinity for 5-hydroxytryptamine 1D receptor,,
1954,,Aut9curstion,,,B,,,,,8,1742,1,vAO0900249,CH2MBL617562,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1955,,A8tocuratikn,,,B,,,,,8,1742,1,gA80000249,CHrMBL616562,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1956,,Au5ocueation,2431257.0,,B,,,,,8,14331,1,BAO9090357,CHEMBpy17563,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,
1957,,Autocura5uon,,,F,,,,,8,12861,1,gzO0000019,CH4MBL6q7564,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,
1958,,Exprrt,,,B,,,,,8,12861,1,hAO000o019,CH2MfL617565,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,
1959,,Autocu5atipn,,,B,,,,,8,12861,1,fAi0000357,CgEMBL85u076,,Binding activity radioligand.,,
1960,,Ajt0curation,,,B,,,,,8,12861,1,fAO0009019,vHEjBL617566,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
1961,,Expdrt,,,B,,,,,8,12861,1,BzO0p00019,CHEkBk875911,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1962,,quticuration,,,B,,,,,8,12861,1,BA800o0019,vHwMBL617567,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
1963,,Autosurahion,,,B,,,,,8,675,1,gAO0000240,xnEMBL617568,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1964,,Exprrt,,,B,,,,,8,12490,1,BAOo009019,CnEMBL617r69,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,
1965,,Expfrt,,,B,,,,,8,11828,1,BAOo900249,fHEhBL617570,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,
1966,,Autpcuratiog,,,B,,,,,8,11866,1,BAl0000367,CHEMBL727571,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,
1967,,xutovuration,,,B,,32659.0,Sysscrofa,,8,773,1,BAO09003y7,fHEMBp617572,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,
1968,,3xpert,,,B,,24874.0,Oryvt9lagusxunjculus,,8,13047,1,BxO0000367,sHEMBL617r73,,The compound was tested for intrinsic activity against 5-HT1D receptor,,
1969,,Autocugatioj,,,B,,10886.0,Oeyctooag8zcuniculus,,8,13047,1,BAOo000o19,dHEMgL617574,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,
1970,,Ex0ert,,,B,,13416.0,Otyctolagusc6nicui7s,,8,13047,1,gAO0000367,CHEMBo517575,,The compound was tested for binding affinity against 5-HT1D receptor,,
1971,,Aut0curatiln,,,B,,,,,8,188,1,BAO0p00358,CHdMBL617566,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,
1972,,Aktocugation,,,F,,,,,8,10639,1,BAO0p90019,CHEMhp617577,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,
1973,,Autocurstioj,,,F,,,,,8,12438,1,BAO0900o19,CH2MBp617578,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,
1974,,Au4ocurahion,,,B,,,,,8,12438,1,BAO00po357,CHEMBL717y79,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,
1975,,Exprrt,,,B,,,,,8,15854,1,gAO0009019,CHEMBLt1y580,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1976,,xut9curation,,,B,,,,,8,10394,1,fAO00o0249,CHEkBL617571,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1977,,Autochratipn,,,B,,,,,8,12092,1,BAO00003ry,CHEkBk617582,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,
1978,,Expsrt,,,B,,,,,8,3389,1,BAO000o919,CHEMBL7w7583,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,
1979,,A7tocurqtion,,,B,,,,,8,6011,1,BAio000357,dHEMBL627584,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,
1980,,Autocueatiob,,,B,,,,,8,4639,1,BAO09003t7,CHEMBL527585,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,
1981,,Autocura5i9n,,,B,,,,,8,2474,1,BA00000w57,CHEMgL87t912,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,
1982,,Autocufatiom,,,B,,,,,8,5014,1,BqO0000356,CgEMBL6175i6,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,
1983,,Augoxuration,,,B,,,,,8,17515,1,BwO0900357,CHsMBL616587,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,
1984,,xutocuratiln,,,B,,,,,8,11866,1,BsO000p357,CHEnBL61u588,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,
1985,,Autocufatiog,,,B,,,,,8,4687,1,BAO00op357,CHEMBL85y989,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,
1986,,Autodyration,,,B,,,,,8,12146,1,BxO00003t7,CHEMgL6175o9,,Tested against 5-hydroxytryptamine 1D receptor,,
1987,,Autocuratiig,,,B,,,,,8,10321,1,BAO000p257,CHEkBL61u590,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,
1988,378.0,wutocjration,,,B,,,,,8,13267,1,BAO0o0p219,xnEMBL617591,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
1989,,Ex0ert,,,B,,1966.0,Homosap9ena,,9,1274,1,BAl9000357,CHrMBk617592,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,
1990,,Autocira5ion,,,B,,,,,8,15250,1,vA90000357,CHEMBp6175i3,,,,
1991,1090.0,Autocutwtion,,,B,,,,,8,13706,1,BAl0000119,CHEMBL617r93,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1992,779.0,Autlcurztion,,,B,,,,,8,13706,1,BAO00003q9,CuEMBL617596,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1993,749.0,Aktocurxtion,,,B,,,,,8,13706,1,BApo000219,sHEMBL61y596,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,
1994,722.0,x7tocuration,,,B,,,,,8,13706,1,BqO00002w9,CHEMBL617t87,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
1995,,qutocuratiin,,,B,,,,,8,13047,1,vAO000o019,CH4MnL617598,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
1996,,Autocurayipn,,,B,,,,,8,13366,1,BAO00003t8,CHEhBi872916,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,
1997,,Expeet,,,B,,,,,8,13366,1,BAOo0003t7,CHEMBL61ir99,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,
1998,,Autockrafion,,,B,,,,,8,1558,1,fAO00o0357,CHEkvL617091,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,
1999,747.0,Exper6,,,B,,,,,8,12902,1,BAO000pe19,CHfMBo617092,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,
2000,403.0,Autocu4atioh,,,B,,,,,8,13706,1,BxO0000w19,CHEMBi61709r,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
2001,,Autocygation,,,F,,,,,8,13706,1,gAOo000019,CHwMBLy17094,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,
2002,,A8t8curation,,,F,,,,,8,13706,1,BAO009001o,CHEMBL61i0p5,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2003,,Autoc7rati8n,,,F,,,,,8,14251,1,BxO00o0019,CHEkBL617p96,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2004,,Autocurat8oj,,,F,,,,,8,14251,1,BAO0000o10,CHEMBL627098,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2005,,Autlcurati8n,,,F,,,,,8,14251,1,hAO000001i,CjEMBL617o98,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2006,,Autocurat89n,,,B,,,,,8,13313,1,BA900003y7,CHEMBL617w0w,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,
2007,,Autocurati0j,,,B,,,,,8,13313,1,fxO0000357,CHEMBo617303,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,
2008,,Autoduratoon,,,B,,,,,8,13366,1,BAO0o00358,CHEMBp617304,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,
2009,,Edpert,,,B,,,,,8,13051,1,BAO90003y7,CHEMBL6183o4,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,
2010,660.0,Eapert,,,B,,,,,8,12903,1,BA8000p219,CHEjBL617w05,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,
2011,,Autocueati0n,,,B,,272.0,momoaapiens,,9,12469,1,gAO0900219,CHEMBLy173p6,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,
2012,,Autocu3xtion,,,B,,,,,8,5619,1,hAO9000357,CHEMBL627r07,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,
2013,,Autoduratiom,,,B,,19160.0,pryftolaguacujiculus,,8,13047,1,BAO090001o,CgEMBL517308,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,
2014,,sutocuratiin,,,B,,,,,8,16633,1,BAO000o367,CnEMhL617309,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,
2015,,Autocurxti9n,,,B,,,,,8,16633,1,BAi0090357,CHwMhL617310,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2016,,wufocuration,,,B,,,,,8,16633,1,BxO0o00357,CHEhBL6w7311,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2017,,Augocuratiin,,,B,,,,,8,16633,1,nAO9000357,CHEMBL5w7312,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,
2018,,A6tocurat8on,,,B,,,,,8,3269,1,BAO0909357,CHEMBL6w731r,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,
2019,,Expe3t,,,B,,,,,8,12409,1,nAOp000357,CnEMBo617314,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,
2020,,Autocu4a5ion,,,F,,,,,8,13706,1,BwO0000010,CH3MBL6w7315,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2021,649.0,Autodiration,,,B,,,,,8,13706,1,gAl0000219,CHEMBL727316,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,
2022,952.0,Autocjfation,,,B,,,,,8,13706,1,BAOp900219,CHEhBL617217,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
2023,825.0,Autoc6rati0n,,,B,,,,,8,12903,1,BAO00003q9,sHwMBL617318,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2024,,Autocurzgion,,,B,,,,,8,13047,1,Bqi0000019,CH4MBL61731o,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
2025,,Ex0ert,,,B,,,,,9,13366,1,BAl0000457,CHEMBL61i3e0,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2026,,Expe3t,,,B,,,,,9,13366,1,BAOo00035u,CHEMnL617r21,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2027,,Expe5t,,,B,,,,,9,13366,1,BAOp00p357,sHEMBL6w7322,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2028,,Au4ocugation,,,B,,,,,8,13366,1,BAOo090357,CHEMBL61t86e,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,
2029,,Autocu5ahion,,,B,,,,,8,13366,1,BAO00002y7,CHEjBL61y863,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,
2030,171.0,Ajtocu4ation,,,B,,,,,8,12469,1,BsO0009219,CHEMBL616ut4,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,
2031,656.0,Aktosuration,,,B,,,,,8,13706,1,BqO0900219,CHEMnL616u65,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,
2032,600.0,Autocuratipb,,,B,,,,,8,13706,1,BAi0900219,CHEnBL616i66,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,
2033,,su5ocuration,,,F,,,,,8,13706,1,BAO0op0019,CH3MBL616o67,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2034,727.0,Exp2rt,,,B,,,,,8,12902,1,BAO0p0p219,CtEMhL616868,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,
2035,,Experf,,,B,,,,,8,13051,1,BsO000035i,fHEMBL6168y9,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,
2036,745.0,Expeet,,,B,,,,,8,12903,1,BAO0900319,CHEMBLt1y870,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2037,494.0,Autocurxtipn,,,F,,,,,8,1558,1,BAO009021i,CHEMBi61u871,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,
2038,725.0,Au5oc7ration,,,F,,,,,8,1558,1,BAO000pe19,CHEjfL616872,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,
2039,648.0,Autocugatiob,,,F,,,,,8,1558,1,vAO00o0219,CtEMBL616o73,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,
2040,1211.0,Aurocuratiln,,,F,,,,,8,1558,1,BxO000o219,CHEMvL616828,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,
2041,,Au6oxuration,,,B,,,,,8,1558,1,BzO000o357,xHEMBL61683p,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,
2042,,Autocu4ati9n,,,B,,2474.0,O3yctilag8scujiculus,,8,13047,1,BAO0000o29,CHEMvo616840,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,
2043,,Auh0curation,,,B,,,,,8,13313,1,BAO00oo357,CHEMBL6268t1,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,
2044,,A8tkcuration,,,B,,,,,8,13313,1,BAOo000347,fHEMnL616842,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,
2045,,Exprrt,,,B,,,,,8,12409,1,nAO00p0357,CHEMBLi5797y,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,
2046,718.0,Autodufation,,,B,,,,,8,15250,1,BAO00o02w9,CtEMBo616843,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,
2047,,Exoert,,,B,,37374.0,tom0sapiens,,9,1348,1,BA9p000357,CHdMBL61u844,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,
2048,,Autocjrati9n,,,B,,,,,8,1348,1,BwO000035i,dHEMBL61684y,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,
2049,,Ex9ert,,,B,,8500.0,H0m0sapiens,,9,4234,1,fAO00003r7,CHEMBp616836,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,
2050,,A8rocuration,,,B,,,,,8,16209,1,BAOp000358,CHEMBp616u47,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,
2051,,Autlcurafion,,,B,,,,,8,10444,1,BAO00p001i,CHdMBL617848,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,
2052,,Autocurwfion,,,B,,,,,8,3935,1,BAO000o3t7,CHEMhL616949,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,
2053,,Autoc8rztion,,,B,,,,,8,15818,1,BAO0o0035u,CuEMBp872911,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,
2054,,Aytochration,,,B,,,,,8,17085,1,BAp000o019,CHdMBL616i50,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,
2055,714.0,Exprrt,,,B,,3155.0,uomosapjens,,9,12936,1,BxO0900219,xHEMgL616699,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,
2056,,A8tocuratuon,,,B,,,,,8,6166,1,BAO000o3t7,CuEMBL6w6700,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,
2057,459.0,Auticuratikn,,,B,,,,,8,15779,1,BwO0000229,CHEMBL716y01,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2058,878.0,Auhkcuration,,,B,,,,,8,15779,1,gAO0009219,CHEjBL6167p2,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,
2059,484.0,Autlcurwtion,,,B,,,,,8,15779,1,BxO0090219,CHEjhL616703,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
2060,,Ajtocura5ion,,,B,,,,,8,13181,1,BAO9000e57,CHEMfLu16704,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,
2061,802.0,xutocudation,,,B,,,,,8,4199,1,BAO00902q9,CHEnBL516705,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,
2062,,Autocura5iog,,,B,,,,,8,14875,1,BxO0000w57,CHEnBk616706,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,
2063,589.0,Autoc7ragion,,,B,,,,,8,15146,1,Bwp0000219,CHEMgL616708,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,
2064,,Aut0vuration,,,B,,,,,8,5213,1,BAO000o367,CHdMBk616708,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,
2065,,Aut0curat7on,,,B,,,,,8,12146,1,hAO0000347,CHEMhp616709,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,
2066,894.0,wut8curation,,,B,,,,,8,13267,1,BwOp000219,CHEMBp616u10,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,
2067,877.0,qutovuration,,,B,,,,,8,14818,1,fAO0o00219,sHEMBL626711,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,
2068,516.0,Au4ocuratjon,,,B,,,,,8,4829,1,BAO9000218,CHEMBL6w67w2,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,
2069,,Autocira5ion,,,B,,,,,8,4373,1,Bw90000357,CHEMBL6w67w3,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,
2070,,Autocu5atiln,,,B,,,,,8,4373,1,vAO000o357,CHEMBit16714,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,
2071,,Aurocura4ion,,,B,,,,,8,14159,1,BAO0o00356,CHEMBL61t725,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,
2072,,Aktovuration,,,B,,,,,8,16633,1,BxO000035u,CHEnBk616716,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,
2073,,Autlcu5ation,,,F,,,,,8,17085,1,BAO000oo19,fHEMBL716717,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,
2074,,Exper6,,,F,,,,,8,17085,1,BAO000002o,fHEjBL616718,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,
2075,,Autlfuration,,,F,,,,,8,16209,1,BAOp0p0019,CnEMBL8759p5,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,
2076,,Autocu4qtion,,,F,,,,,8,16209,1,BAOp000018,CHEnBk616719,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,
2077,,dxpert,,,F,,,,,8,17085,1,Bs80000019,CHEMBL6q6710,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,
2078,,Autocufa5ion,,,B,,,,,8,14159,1,BAO000pw57,CHEMBL6w67q1,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,
2079,872.0,Autofurqtion,,,B,,,,,8,15250,1,BAOpp00219,CHEMBk6q6722,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,
2080,,Auticu5ation,,,B,,,,,8,3805,1,BAO900p357,CmEMBk616723,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,
2081,849.0,Ahtocurati9n,,,B,,,,,8,16190,1,BAl0009219,CHEMBL71672e,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,
2082,,Autlcu5ation,,,B,,,,,8,16190,1,BAO000o35y,vHEMBL6w6725,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,
2083,,A6tocu5ation,,,B,,,,,8,16209,1,Bsk0000357,CjEMBLt16726,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,
2084,,Autocudatioj,,,B,,,,,8,16209,1,BxO0000367,CHEjBL61672i,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,
2085,,Autoxurafion,,,B,,,,,8,16209,1,Bx80000357,CHEnBLt16728,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,
2086,,Autocugatiln,,,B,,,,,8,6866,1,BAO00003y6,CHEMgk616729,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,
2087,,Edpert,,,B,,,,,8,17085,1,BA80p00019,CHEMgi616730,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,
2088,,Aktocurztion,,,B,,,,,8,16312,1,BAO90003t7,CHEMnL6w7125,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,
2089,,Autochragion,,,B,,,,,8,6166,1,gAp0000357,CHEMBL947977,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,
2090,389.0,Autocugafion,,,B,,,,,8,15779,1,BAO0009229,CHEMBL627w26,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2091,565.0,Aut9curatiln,,,B,,,,,8,4199,1,fAO00002q9,CnEMBL617137,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,
2092,,Autocutat9on,,,B,,,,,8,14875,1,BAO9o00357,CHEMBLyq7128,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,
2093,737.0,Auyocuratiin,,,B,,,,,8,15146,1,Bx90000219,CHEnBL61i129,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,
2094,,Autocu3at7on,,,B,,,,,8,5213,1,hAOp000357,fHEMfL617130,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,
2095,585.0,A6toc7ration,,,B,,,,,8,14818,1,BAO00p0119,CHEnBLt17131,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,
2096,306.0,Autovu3ation,,,B,,,,,8,4829,1,BAi0000w19,CHEMhL627132,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2097,493.0,Autocueatoon,,,B,,,,,8,4829,1,Bx80000219,CHEMBo616133,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2098,,Autpfuration,,,B,,,,,8,4373,1,BwO000o357,xHEMBL61713r,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,
2099,,Ajtoc8ration,,,B,,,,,8,4373,1,BA000003r7,dgEMBL617135,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,
2100,,wutocurxtion,,,B,,,,,8,5014,1,vAO00o0357,CHfMBLy17136,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,
2101,,Aht9curation,,,B,,,,,4,11662,1,gAO00o0019,CHEkBL617q37,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,
2102,,Auyocutation,,,B,,,,,4,11662,1,fzO0000019,CHEkBLu17138,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2103,,Autocuratlog,,,B,,,,,4,11662,1,BAO0oo0019,CyEMBL617q39,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2104,,Autocugatiom,,,B,,,,,8,14093,1,BAOp0p0019,CHEMBL6q7149,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2105,,xutocugation,,,F,,,,,4,11200,1,BAO090021i,dHEMBL61714w,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",In vivo,
2106,,Aurocurayion,,,F,,,,,4,11200,1,BAOp000p19,CHEkBL85o112,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2107,,Interkedia5e,,,B,,,,,8,12352,1,BAk00p0019,sHEMBL61714e,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,
2108,,Auhocurati9n,,,B,,25324.0,Bosta8rus,,0,13657,1,BAO09p0019,CtEMBL617243,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,
2109,,Ajtoc7ration,,,B,,8044.0,Bostaufus,,0,14331,1,BA90009019,CHEMBp61714t,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,
2110,,Autoc7ratoon,,,B,,15465.0,Bostautus,,0,14331,1,BAi0000919,CyEMBLt17145,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,
2111,,Au5ocu3ation,,,B,,,,,0,14331,1,BAO00900q9,vHEMBL6w7146,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,
2112,,qutocuratiob,,,B,,2095.0,Caviapprcelpus,,4,12685,1,BAO00o001o,CHsMBL61714i,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,
2113,,Autocursti8n,,,B,,18712.0,Cavixporceplus,,4,14389,1,BzO0090019,CHEMfL618148,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,
2114,,Autpcu4ation,,,B,,24346.0,Caviapodsellus,,4,14386,1,BAO9900019,Cg3MBL617149,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,
2115,,Autocuratkoj,,,B,,,,,4,5732,1,BAO0p0o224,CnEMBL61715o,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,
2116,,Aut8curafion,,,B,,,,,4,16293,1,BAO0o002q4,CHwMBL617141,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2117,,Autocurxtiln,,,B,,,,,4,2078,1,BAO0900214,CHEMBL6q7e01,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,
2118,,Aytociration,,,B,,,,,8,5486,1,BAO000o356,sHEMBL61y202,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
2119,,qutoxuration,,,B,,,,,4,11820,1,BAO9000118,CHEMBL6q72p3,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,
2120,,Autoxuratjon,,,B,,,,,4,10297,1,BqO0000o19,CHEMBL61y294,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,
2121,,Autocuratkkn,,,B,,,,,4,13704,1,BAO0900234,CHEMBL6171p5,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,
2122,,Autodu4ation,,,B,,53140.0,Musmucculis,,5,10297,1,BAO0090p19,CgEMBL617296,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,
2123,,Autocu5atioj,,,B,,,,,4,11820,1,nAO000021i,CHEMBL627107,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,
2124,,Aut8curahion,,,B,,40964.0,Mudmuscilus,,5,10297,1,BAk0009019,CHEMfp617208,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,
2125,,xutocuratuon,,,B,,,,,4,11555,1,BAO000012e,vHEMBL6q7209,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,
2126,,wutocu5ation,,,B,,,,,4,11555,1,vAO0009224,CHEMBk616210,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,
2127,,Autocura5ioh,,,B,,,,,4,11555,1,BAp000p224,CHEMni617211,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,
2128,,Autoxufation,,,B,,4632.0,Musmuscul7c,,5,10297,1,BAk00000q9,CyEMnL617212,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,
2129,,Ajtosuration,,,B,,7667.0,Suascrofa,,4,16688,1,BAOp000124,CHrMBL61y213,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,
2130,,Autoduratkon,,,B,,4570.0,Susscrora,,4,16688,1,BAO0p90224,CHEMvL627214,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,
2131,,Autpfuration,,,B,,,,,0,5333,1,gAOo000221,fHEMBL6172q5,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2132,,Aytocurxtion,,,B,,,,,0,4437,1,BAO0000331,CtEMhL617216,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2133,,Autoc8tation,,,B,,13327.0,Sussc5ofa,,8,5033,1,BAO00002t7,CHrMBL6172w7,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,
2134,,Autofuratioj,,,B,,,,,4,15267,1,BAO00009q9,CnEMBL627218,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2135,,Aufoc8ration,,,B,,,,,4,15267,1,gAO0000p19,CHEMhL871913,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2136,,Aut8furation,,,B,,,,,4,11820,1,BxO0000p19,CHEMBL61uq19,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,
2137,,Autockratioj,,,B,,,,,4,9069,1,BAO9o00224,CHEMBL8i3582,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2138,,Augocurztion,,,B,,16545.0,tatt6snlrvegicus,,5,9162,1,BAO0o09019,CHEMBL61i120,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,
2139,,Autocurat99n,,,B,,,,,4,9162,1,BqO00000q9,CHEMBk617w21,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,
2140,,Autocudatipn,,,B,,,,,4,9162,1,BwO0000p19,CHEhgL617222,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,
2141,,Autochratiln,,,F,,,,,4,10428,1,BA0o000019,CHEjBL87t906,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,
2142,,Autockrxtion,,,B,,,,,4,9628,1,BAOo000p19,CHwMhL617223,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,
2143,,Autocurat8om,,,B,,,,,4,12704,1,BqO0000e24,CyEMBL617225,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,
2144,,zutociration,,,B,,14567.0,Rahtusnodvegicuw,,5,15453,1,BA9000p224,CHEnBL627225,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,
2145,,Aurocurafion,,,B,,,,,4,188,1,Bs00000224,fH3MBL617226,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,
2146,,Autociratioh,,,B,,,,,4,10349,1,BAO0000134,CbEMBL61722u,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,
2147,,Autkcutation,,,B,,,,,4,10349,1,BAOp000223,CmEMhL617228,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,
2148,,Auyocurxtion,,,B,,,,,4,8868,1,vAO00o0224,CHEMBL727229,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
2149,,Autociratjon,,,B,,,,,4,10025,1,BAO0090124,CuEkBL617230,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
2150,,Autocurstoon,,,B,,,,,4,10025,1,fA90000224,CHEMBi627231,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
2151,,Autocutat9on,,,B,,,,,4,11702,1,hAO000p224,CH4hBL617232,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,
2152,,Augocurqtion,,,B,,,,,4,11702,1,BA90o00224,CgEMBL6172w3,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,
2153,,Autoc65ation,,,B,,,,,4,11702,1,BAO0000q25,CH2MBL617q34,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,
2154,,Aut8xuration,,,F,,,,,4,11702,1,BAO00009q9,CHEMgL617335,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,
2155,,Autpcu4ation,,,F,,,,,4,11702,1,vAk0000019,CHrMBL627236,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,
2156,,Autocuratjin,897555.0,,B,,,,,4,10085,1,BAO000012q,vHEMBk617237,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,
2157,,Auhocugation,1706154.0,,B,,,,,4,10085,1,BAO090o221,xHEMBL618238,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,
2158,,Aut8curati8n,5204092.0,,B,,45693.0,Rattuqnorvegichc,,5,9630,1,BAO09p0221,CH3MnL617239,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,
2159,,sutocurwtion,,,B,,,,,4,11070,1,BAO0000910,vHEMfL617240,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,
2160,,A7tocurxtion,,Membrajes,B,,,,,4,9841,1,BAO0p00239,CH2MBL517241,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2161,,Autosurxtion,,Memnranes,B,,,,,4,9841,1,BA80090249,CH3MBL87590y,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2162,,Au6ocugation,,,B,,,,,4,13291,1,hAO000p019,CHEMBL61u24w,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,
2163,,Aut0curatlon,,,F,,,,,4,10590,1,BAO0o00018,CHEkBL61u152,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,
2164,,Augpcuration,2108799.0,,B,,1953.0,Rattusnprb4gicus,,5,9064,1,BAO0900e21,CHwMBL61715e,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,
2165,,Autodurati8n,,M4mbranes,B,,15274.0,Rattksnirvegidus,,5,12268,1,BAO0o0p249,CHEMBp616154,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,
2166,,Autocueahion,104787.0,,B,,,,,4,13508,1,BAO0000wq1,CnEMBL6171r5,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,
2167,,xktocuration,,,F,,,,,4,11279,1,BA0o000019,CHEMfL617w56,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2168,,Autocursti0n,,,F,,,,,4,11200,1,fAp0000019,CH3MBk617157,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,
2169,,Autocura6kon,,,F,,,,,4,11200,1,BxO00o0019,CHEMBL717258,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2170,,Autovudation,,,F,,,,,4,11200,1,BqO0090019,fHEMBL61715o,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2171,,Autodu5ation,,,F,,,,,4,11200,1,BzO000001o,CHEMBk6w7160,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2172,,Au6pcuration,,,F,,,,,4,11200,1,BAOp0000q9,CHEjBL858213,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2173,,Aitpcuration,8824810.0,,B,,,,,4,9231,1,BAp00002q0,CHEjBL717247,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,
2174,,Au4ocurxtion,,,B,,,,,4,9737,1,hAO0900019,CHEMBL51i248,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2175,,qut9curation,1880395.0,,B,,,,,4,9737,1,BAO000023o,CHEMhLu17249,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
2176,,Ajyocuration,,,B,,,,,4,9737,1,BAO00oo019,CHEkBL61u250,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,
2177,,Autocutat7on,,,B,,,,,4,9737,1,BAi9000019,CHEMBL6173r1,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2178,,xutoduration,,,B,,3013.0,Rattusnoedeglcus,,5,11828,1,BAl0090019,CHEMnL6w7252,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,
2179,,zutocuratioj,,,B,,,,,4,12253,1,BsO00o0019,CHEkBL616006,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,
2180,,Autlcurat9on,,,B,,,,,4,12253,1,gAi0000019,CHEnBL617008,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,
2181,,Autixuration,,,F,,,,,4,11279,1,BAO0090o19,CH2MBL6w7008,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,
2182,,Aut0curati8n,,,B,,,,,4,11866,1,Bq80000019,CHEMBL6q70p9,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,
2183,,Aktpcuration,,,B,,14492.0,Ratt7qno5vegicus,,5,14424,1,BAO0900w24,CHEMBLt17o10,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,
2184,,Autocurqtioh,,,B,,7936.0,Rztgusnorvegisus,,5,15180,1,BAO000o0w9,CHEMvL85797i,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,
2185,,Autockratioj,,,B,,1929.0,Rattusnorgrgicuw,,5,15180,1,vAOo000019,CHEMgL617012,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,
2186,,zutoc7ration,,,B,,17180.0,Rattusnorveticiw,,5,9786,1,BAO000op19,CHEjvL617012,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,
2187,,Autosuratlon,,,B,,,,,4,12132,1,BAO0900324,sHEhBL617013,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,
2188,,Autoc7rstion,,,B,,,,,4,5486,1,Bwi0000249,CHEMnL61i014,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,
2189,,xutocu5ation,,,B,,,,,4,15316,1,BA800000w9,CHEMBL6w7915,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,
2190,,Autocuratkog,,,B,,,,,4,16429,1,BAOo0000w9,sHEMBL616016,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,
2191,,z6tocuration,,,B,,,,,4,14617,1,BAi0009224,CHEMBp627017,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,
2192,,Au4oxuration,4196509.0,,B,,,,,4,11351,1,BxO0000231,CH4MBL6170q8,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,
2193,,Autofuratkon,,,F,,,,,4,11279,1,BAO00po019,CHEkBL61i019,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2194,,Autosura4ion,,,B,,,,,4,9523,1,BsO9000019,CHEhBL617o20,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2195,,Autocuratloh,,,B,,,,,4,9523,1,gqO0000019,CHwMBL61i021,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2196,,Ahtkcuration,,,B,,,,,4,9523,1,BsO9000019,CHEMBL6170qw,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2197,,sutocurat8on,,,B,,,,,4,9523,1,BAp9000019,CHEMBLu1i023,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2198,,Augocura5ion,,,B,,,,,4,9523,1,BA00000029,CHEMBLy170q4,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2199,,Autoduratuon,,,B,,,,,4,9523,1,hAO0000010,CHEnBL617o25,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2200,,Autocugatiog,,,B,,,,,4,9523,1,Bsi0000224,CHEMvi617026,,Hill coefficient of compound was determined,,
2201,,Autodugation,,,B,,,,,0,4771,1,BwO000p019,CHEMhL617026,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,
2202,,A76ocuration,,,B,,2167.0,Rattusmorvrgicud,,5,5033,1,BzO9000019,CtEnBL617028,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,
2203,,Ecpert,,,B,,,,,8,10845,1,BzO9000019,CHEkBL616029,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,
2204,,Expfrt,,,B,,,,,8,10845,1,BA09000019,CHEMBL875i0i,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,
2205,,Autocurqtlon,,,B,,,,,8,16288,1,Bx90000357,CHEnBL61u030,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,
2206,,Autocurwtiom,,,B,,,,,8,16288,1,BAOo00001i,sH3MBL617031,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,
2207,,zu4ocuration,,,B,,,,,8,16190,1,BsOp000019,CHEMBLyw7032,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,
2208,,Autocuratlkn,,,B,,17151.0,Rattusmkrvegidus,,5,12463,1,BsO0p00224,CHEMBL617932,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,
2209,,Autocura5i0n,,,B,,,,,4,9699,1,fA90000224,CHEMBL61u0e4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,
2210,,Aytocuratiln,,,B,,,,,4,9699,1,BAi000o224,CHEjBL617o35,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,
2211,,Autoxuratkon,,,B,,,,,4,11662,1,BzO0000o19,CHEkgL617036,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2212,,zktocuration,,,B,,,,,4,1205,1,BAO00p022e,CHEMBo6170e7,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,
2213,,sktocuration,,,B,,,,,0,11376,1,BAO0o0p219,CHEMBL617937,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,
2214,,A6tocurati8n,,,B,,,,,4,11376,1,BAO00002w8,CHEhvL617039,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,
2215,,Aitocuratuon,,,B,,,,,4,4639,1,BwO000022r,CHEMBL618162,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,
2216,,wutocyration,,,B,,,,,4,2222,1,BAip000224,CH3jBL617162,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,
2217,,wutocuratikn,,,B,,,,,4,1558,1,BAO00oo224,CHEkfL617163,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,
2218,,Autocu3qtion,,,B,,,,,4,1089,1,BAO0900225,CHEMvL627164,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,
2219,,Auhocugation,,Brainmehb5anes,B,,,,,4,386,1,BAO00p0349,CHEMBp617166,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,
2220,,Aitocurqtion,,,B,,,,,4,2474,1,BAO000p2e4,CHEMBL6172y6,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,
2221,,Autovurarion,,,B,,,,,4,17066,1,BAO0990224,CbEMBLy17167,,Binding affinity towards 5-HT2 receptor,,
2222,,Autocyratiog,,,B,,,,,4,959,1,BzOp000224,xHwMBL872912,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2223,,Autochrstion,,,B,,,,,4,6398,1,BAO00p0225,CHEMBL5w7168,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,
2224,,Auhocurati9n,,,B,,,,,4,11889,1,BxO0p00224,CbEMBL617q69,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,
2225,,wutocurwtion,,,B,,,,,4,4221,1,BAOp0002q4,CHEMhi617170,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2226,,Autovura6ion,,,B,,,,,4,11026,1,BqO00002q4,CHEMBo61717w,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,
2227,,Autocutafion,,,B,,,,,4,11866,1,vA90000224,vHEMBL618172,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,
2228,,Autpcura5ion,,,B,,,,,4,4221,1,hAO0p00224,CHEMBL6171ir,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2229,,Autocurato9n,,,B,,,,,0,13950,1,BAO00p0o19,fHEjBL617174,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2230,,Autocura4ioj,,,B,,,,,4,1263,1,BA800002e4,CuEMgL617175,,5-hydroxytryptamine 2 receptor binding affinity,,
2231,,Auyocurarion,,,B,,,,,8,13291,1,BAO9000347,CmEMBL617w76,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,
2232,,Autod6ration,,,B,,,,,8,10812,1,BAO09o0357,CHEnBL6171i7,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,
2233,,Autocurztikn,,,B,,,,,4,13020,1,BsO0000124,vHEMBL616178,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2234,,Aut9curatiin,,,B,,,,,4,13021,1,hAO00002e4,CHEMni617179,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,
2235,,Autoc8rat9on,,,B,,,,,4,13020,1,BAOp00022t,vHdMBL617180,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2236,,Autovu4ation,,,B,,,,,8,14532,1,BAO0900347,CtEMBL717181,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,
2237,,Autociratkon,,,B,,,,,8,13944,1,fAO00p0357,CHwMBL517182,,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2238,,Autocufatiob,,,B,,,,,8,14331,1,BAO90003r7,CHEMfL617q83,,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2239,,Aurocuratioj,,,B,,,,,8,14118,1,BAO000935y,CtEMBL6171o4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2240,,xut9curation,,,B,,,,,8,13033,1,nsO0000357,fHEMBL517185,,Binding affinity against serotonergic 5-HT2 receptor,,
2241,,Autockrztion,,,B,,,,,8,10321,1,BAO00003ti,CHsMBL617w86,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,
2242,,Autocuea6ion,,,B,,,,,8,12918,1,BAOo0o0357,CHEMBk6171o7,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,
2243,,Ahtocurarion,,,B,,,,,8,15120,1,gAO0000e57,CHrMBL61y188,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,
2244,,Ahtocyration,,,B,,,,,8,2613,1,BAO00p02q8,fHEMBL6171o9,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,
2245,,xufocuration,,,B,,12092.0,Hkmoszpiens,,5,13378,1,vAO0000234,dHEMBL517190,,Inhibitory activity against cloned human 5-HT2 receptor,,
2246,619.0,Autocurwt9on,,,B,,30462.0,Hom8sapiems,,5,2331,1,gAOo000219,CHEnBL6w7191,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,
2247,761.0,Autocurxti9n,,,B,,1499.0,Homoqxpiens,,5,2331,1,BqO0090219,CH4MBL717192,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,
2248,1335.0,Autkcudation,,,B,,8711.0,Homosxpiend,,5,2331,1,hAO0000q19,CHfMfL617193,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,
2249,1418.0,sutochration,,,B,,12382.0,H8mozapiens,,5,2331,1,BAO9090219,CHEMBL6w7193,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,
2250,,Autocudatipn,,,B,,,,,4,4170,1,BAO0000e25,CHEMBL6181i5,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2251,,Autocuratkln,,,B,,,,,4,15453,1,BAO0000w2e,dHEMBL8i1830,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,
2252,,Autosu5ation,,,B,,,,,8,1479,1,BAOo000w57,CHEMBLy1719y,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2253,,Autocurzyion,,,B,,,,,4,11139,1,BAOp900224,CHEMBLuw7197,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,
2254,,Edpert,,,B,,,,,8,13969,1,BAOp00o357,sHEMBk617198,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,
2255,,Expery,,,B,,,,,8,13392,1,fAO0000257,CjEMBLi73476,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2256,,Expsrt,,,B,,,,,8,14430,1,BAO0099019,CHEkBL617q99,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,
2257,,A8focuration,,,B,,13238.0,Cqdiaporcellus,,8,13181,1,BAOp00035y,CHEnvL617200,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,
2258,,Autocurz6ion,,,B,,,,,8,17200,1,Bsk0000357,vHEMBL61u484,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2259,,Autocjrwtion,,,B,,,,,8,17200,1,BzOo000357,CHEMnL616485,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2260,,Autocu3ayion,,,B,,,,,8,17200,1,BAOp900357,CH4MBL6q7486,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2261,,Aut0curatioh,,,B,,,,,8,13463,1,BAOp000e57,CHEMBL8y8922,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,
2262,972.0,Autocuratilj,,,B,,,,,8,6347,1,BsO0000w19,CH3MBL617p49,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2263,548.0,Expwrt,,,F,,17433.0,H9mosap9ens,,9,6857,1,BAO0p09219,CHEkBL617040,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,
2264,,A7tocuratipn,,,F,,,,,8,4176,1,BzO000o219,CH4MBL717051,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2265,,sutkcuration,,,F,,,,,8,4176,1,BAk000o219,CHEMBo617952,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,
2266,,sutocuratiog,,,F,,,,,8,4176,1,BAO0000w29,CHEMBL61u05e,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2267,433.0,Ajtocuratioj,,,B,,,,,8,6347,1,BAO009o219,CHEMBL6q7055,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,
2268,547.0,Autocirafion,,,B,,,,,8,6347,1,BAOo000w19,CHEMBp617p55,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,
2269,,Autocursyion,,,B,,,,,8,15331,1,fzO0000357,CHEMBL98w924,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,
2270,,rxpert,,,B,,547.0,Hom9sapiejs,,9,16146,1,BAOo000r57,sgEMBL617056,,Inhibition of human 5-hydroxytryptamine 2A receptor,,
2271,565.0,xutoc7ration,,,B,,,,,8,15250,1,BAO009o219,CHdMBL627057,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2272,,Expe3t,,,B,,,,,8,13631,1,BAl0000218,CHEMBL6180y8,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,
2273,,Aut9cutation,,,B,,,,,8,3805,1,BAO09o0357,xHEMBL627059,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,
2274,774.0,wytocuration,,,B,,,,,8,4011,1,BAi00o0219,CHEMBLy1u060,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,
2275,836.0,Expeet,,,B,,,,,8,4012,1,BAO0o00319,CgEMBi617061,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,
2276,522.0,Exp2rt,,,B,,,,,8,6366,1,BAO00p02q9,CHEkBp617062,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,
2277,964.0,Exoert,,,B,,,,,8,15949,1,nAO0000218,CHEMBp6q7063,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2278,,wutocuratiin,,,F,,,,,8,14093,1,BAO0000p29,CHEMBL61y065,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,
2279,,zutocurat9on,,,F,,,,,8,13481,1,BAO00o00q9,CHEMBL616965,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2280,944.0,Aut8vuration,,,B,,,,,8,6347,1,BsO000021o,vHEMBL627066,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2281,959.0,Auyocurztion,,,B,,,,,8,6347,1,BAOp0002w9,CtEMBLt17067,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,
2282,,qutocura5ion,,,F,,,,,8,14093,1,BAO0p0001i,CHEjnL617068,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,
2283,,Autocurwtiom,,,F,,,,,8,14093,1,fAO000001o,CHEMvLu17069,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,
2284,,Aut9curatoon,,,F,,,,,8,13481,1,BAOo000029,fHEMBL61707p,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2285,,Autocurat9pn,,,B,,,,,8,14442,1,BAOo000358,CHEMBL71707w,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,
2286,,Au48curation,,,B,,,,,8,14442,1,BAl000035i,CHEMhL8y2915,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2287,,Autoduratioj,,,B,,,,,8,14755,1,BAO00p035y,CHEMBi617p72,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,
2288,,Autovuratiom,,,B,,,,,8,16441,1,BzO000p357,CHwnBL617073,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,
2289,,Autocuratiim,,,B,,,,,8,14744,1,BA90000257,CHEhBL6170i4,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,
2290,1199.0,Exlert,,,B,,,,,8,16659,1,gAO0009219,CHEMvL617p75,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2291,,Auhocuratioh,,,B,,,,,8,3307,1,BAOp000367,CHEMBp617976,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,
2292,,Expery,,,B,,33027.0,Hkmosapuens,,9,6857,1,BAO000p919,CHEMBp517077,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,
2293,,Expe4t,,,B,,,,,8,5635,1,fAp0000357,CH3MBL617o78,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,
2294,,Exp4rt,,,B,,39462.0,Homosaplene,,9,4234,1,BAO000935i,CHsMBL617p79,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,
2295,,Au5ocuratjon,,,B,,,,,8,15527,1,BAO00o0356,CHEMgL61y080,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2296,586.0,Expe3t,,,B,,,,,8,6588,1,gAO000021i,CmEMBLt17081,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,
2297,,wxpert,,,B,,,,,8,13631,1,vxO0000219,CHEnBL6170u2,,Binding affinity towards human 5-HT2A receptor in BEK cells,,
2298,,Au6ocurxtion,,,B,,,,,8,17723,1,BAO9000356,CHEMBL617oo3,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,
2299,,qu5ocuration,,,B,,,,,8,14770,1,BAOp000e57,sHEMBo617084,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2300,,2xpert,,,B,,1443.0,Homoszpisns,,9,16293,1,BAO0000e47,CyEMBL61i085,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,
2301,,Autosu4ation,,,B,,,,,8,16209,1,BAO009035u,CHEMBLu170o6,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2302,,Autocjratiog,,,B,,,,,8,12469,1,gAO00o0219,dtEMBL617087,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,
2303,,Autpcurati8n,,,B,,,,,8,15363,1,BAO000pw57,CHdMBL618088,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,
2304,,sutocurqtion,,,B,,,,,8,15363,1,BxO00003t7,sHEMgL617089,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,
2305,,dxpert,,,B,,,,,8,16441,1,BAi0000010,CHEkBLu17090,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,
2306,,Auhofuration,,,B,,,,,8,8,1,BAO9000e57,fHEMBi617513,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,
2307,883.0,Ahtocuratiom,,,B,,,,,8,4176,1,hAO00002w9,CHEMBi6175q4,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,
2308,,A7tocura4ion,,,B,,,,,8,17085,1,BAO000oo19,CHEMBL6175q4,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,
2309,,Aut9curatiom,,,B,,,,,8,17200,1,BAl0000w57,CgEMBL617517,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2310,,Exp4rt,,,B,,8331.0,Homosapiejc,,9,17200,1,fAO0009357,dHEMBL6w7517,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2311,870.0,Expeft,,,B,,14662.0,Hkmowapiens,,9,4013,1,BAl9000219,CHEMBL61yr18,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,
2312,,xutocurwtion,,,B,,,,,8,5088,1,BAO00p035y,CHEnBL61y519,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,
2313,,Exp3rt,,,B,,23448.0,Homoeapi4ns,,9,5088,1,BAkp000357,CHEMBi61u520,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,
2314,,Autkcu5ation,,,B,,,,,8,5088,1,BA900o0357,CHEMBL617r2q,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,
2315,,Ex9ert,,,B,,7443.0,bomosapiena,,9,5088,1,BxO0000r57,CHEMnL617422,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,
2316,,Aut0curatuon,,,B,,,,,8,5088,1,BAO0900358,vHEkBL617523,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,
2317,,Autocu5atioh,,,B,,,,,8,5088,1,BAO00002r7,CHfMBL6175q4,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2318,,Autocudxtion,,,B,,,,,4,9786,1,BAOo000p19,CHEMBp61752y,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,
2319,,Autkcuragion,,,B,,49487.0,4attusmordegicus,,5,9205,1,BzO000p019,CH4MBL6175w6,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,
2320,,Autofu5ation,,,B,,,,,4,11257,1,BAO0p0022e,sHEMBL617517,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,
2321,,Autocudatiom,,,B,,,,,4,9362,1,nAO0090019,CHEMgLt17528,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2322,,Autochratioj,,,B,,,,,4,9362,1,BAO9000029,CHsMBL6w7529,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2323,,A6tocurxtion,,,B,,,,,4,10590,1,BAO0pp0224,vHEMBL61u530,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,
2324,,Autofuratjon,,,B,,,,,4,10468,1,BxO0000p19,CHEhBL617631,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2325,,Autoxurati0n,,,B,,,,,4,13050,1,BsOp000019,CHEMhk617532,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,
2326,,Autoxurati8n,,,B,,,,,4,11624,1,gAO0p00019,CH2MvL617533,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,
2327,,Au4ofuration,,,B,,,,,4,10468,1,BAOp000029,CHEMBLu17y34,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2328,,Augocurat9on,,,B,,,,,4,10330,1,gAO000o224,CHEMBL616435,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2329,,Autpcurat7on,,,B,,,,,4,10062,1,BA00000w24,CHEjBL627536,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
2330,,qutkcuration,,,B,,,,,4,11642,1,BAO00o0124,dH3MBL617537,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2331,,Au5ocurat9on,,,B,,,,,4,10062,1,BAO09o0224,CHwhBL617538,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2332,,A6tochration,,,B,,,,,4,13427,1,BAO000o21p,vHEMBL6175e9,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,
2333,,Autovurat8on,,,B,,45249.0,Rattusn9rvegucuq,,5,12280,1,BqOp000224,fH4MBL617540,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2334,,sutocuratipn,,,B,,14498.0,Rattusno3cegicua,,5,4101,1,BAk0090224,CHEjBL61754w,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,
2335,,Autockragion,,,B,,,,,4,10062,1,vAO0000324,CHEnBL6175e2,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,
2336,,Autocudarion,,,B,,,,,4,11147,1,BAO0p00e24,CHEnBL618543,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,
2337,747.0,Autovurati0n,,,B,,9824.0,Rattisbprvegicus,,5,2395,1,vAO0090219,CHEMfL617444,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,
2338,423.0,Au5oc8ration,,,B,,22368.0,Ra5tusnprbegicus,,5,2395,1,nsO0000219,CHEMBLy16545,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,
2339,,Autovurat7on,,,B,,29311.0,Rzt6usnorvegifus,,5,9098,1,vAO0009019,CHdMBL717413,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,
2340,,A7toduration,,,B,,,,,4,9098,1,BwO0000p19,CH2MBLt17414,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,
2341,,Aitocurahion,,,B,,25917.0,Rstyusnorvegidus,,5,9098,1,BAO9900019,vHEMBL617e15,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,
2342,,zutocuratiob,,,B,,,,,4,9443,1,nAOo000224,CHEMBL6184w6,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2343,,Autovjration,,,B,,,,,4,9443,1,vAO000022r,CHEjBLu17417,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
2344,,Autpcurat9on,,,B,,,,,4,9699,1,BAO00po019,CHEMfL6174q8,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,
2345,,xutocuratiom,,,B,,,,,4,9699,1,BAOo0000w9,CHEMgL61y419,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,
2346,,Autoc6ra6ion,,,B,,,,,4,9098,1,BAOo000q24,fHEMBL617429,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2347,,Autocutafion,,,B,,21760.0,Rattusn8rverifus,,5,3070,1,nAO0009224,CHEMBL6274q1,,Affinity for 5-hydroxytryptamine 2 receptor,,
2348,,Autocura5i8n,,,B,,,,,4,9547,1,gAO0000225,CHEMfL617423,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,
2349,,Autpduration,,,B,,,,,4,10444,1,BxOo000019,CHfMBL6174e3,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,
2350,,Autockratiog,,,B,,,,,4,14617,1,BAO000p0w9,CHEMBL6q7423,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,
2351,,Autoxuratiog,,,B,,,,,4,14617,1,BAOp090019,CHEMgk617425,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,
2352,,Au4ocurwtion,,,B,,,,,4,11130,1,BAO00p0223,CHEMhL617425,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,
2353,,Aut9curatiog,,,B,,,,,4,11130,1,BsO0000217,CHEMBo6174w7,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),In vivo,
2354,,Autocu5atkon,3460214.0,,B,,,,,4,14542,1,BAp00o0221,CH2MBL61742i,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,
2355,,Aktocurat9on,,,B,,,,,4,2797,1,BAO0000215,vHEMBL61742p,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,
2356,,Autocjragion,,,B,,,,,4,11332,1,fAO00p0019,CHEMBL62i430,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2357,,Aut8curqtion,,,B,,,,,4,11332,1,hAO00000w9,CHEMBL617e41,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2358,,Ajtociration,4834995.0,,B,,,,,4,10752,1,BAO0o0001i,CHEMBL617rw2,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,
2359,,Autocurstiog,,,B,,,,,4,1185,1,BAOp000q24,vHEMBL61i433,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2360,,Aitocurati9n,,,B,,,,,4,1185,1,BAO0000w2r,CmEMBL617e34,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2361,,Autocura4iin,,,B,,1472.0,gagt6snorvegicus,,5,11624,1,BAl9000224,CuEMBL627435,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,
2362,,Autoskration,,,B,,,,,4,1344,1,BqO0000p19,CHEMBLy27436,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,
2363,,Autocuratilj,1502925.0,,B,,22617.0,Rattienorveg9cus,,5,15453,1,BAOo00001i,fHEMBL617337,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,
2364,,Autocura6iob,,,B,,,,,4,11662,1,BAO0p00010,CHEMBL61y4e8,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2365,,Autocuratk0n,,,B,,,,,4,11662,1,nAO9000019,CmEMBL627439,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2366,,Autocyratiog,,,B,,,,,4,10796,1,BAOp0p0224,CydMBL617440,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,
2367,,Aytocuratiom,,,B,,,,,4,9069,1,BAO0o00e24,CHEMBL527441,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2368,,Autocuratilj,,,B,,28144.0,5attusnkrveg7cus,,5,8814,1,BAO000p0q9,vjEMBL872918,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,
2369,,Autocurztikn,,,B,,10343.0,Rattusnorgeg9cuc,,5,8908,1,BAp0000010,CjEMBo617442,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,
2370,,Aktocuratikn,,,B,,,,,4,9098,1,nAO00o0019,CHEnBi617443,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2371,,A65ocuration,,,B,,,,,4,9098,1,BAOo000919,CHEMBL61i4e4,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,
2372,,sufocuration,,,B,,,,,4,9098,1,BAp0000029,CHEkBL61744r,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2373,,wufocuration,,,B,,,,,4,9098,1,BAO00p9019,CtfMBL617446,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,
2374,,Aitosuration,,,B,,,,,4,9098,1,hAO00p0249,fHEMBL517447,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,
2375,,wutocurarion,,,B,,,,,4,9098,1,BqO00p0019,xHEMBL627448,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,
2376,,A8tocurafion,,,B,,,,,4,9098,1,BsO00000w9,dHEMBLu17449,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,
2377,,qutocuratipn,,,B,,,,,4,9161,1,BA9p000019,CHEkBL617550,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,
2378,,Auticurarion,,,B,,,,,4,9161,1,nAO0000010,dHEMhL617451,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,
2379,,Autodurwtion,,,B,,,,,4,9161,1,BsOo000019,CHEhBL617462,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,
2380,,Autovurqtion,,,B,,,,,4,9161,1,BAO0090919,CHEnBL617443,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,
2381,,Autocurztjon,,,B,,,,,4,9161,1,vqO0000019,CHEMfL617t60,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,
2382,,Ahtosuration,,,B,,,,,4,9161,1,BAl0p00019,syEMBL617661,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,
2383,,Au6ocuratoon,,,B,,,,,4,9161,1,fAO00000q9,CbEMBL617562,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,
2384,,A6t0curation,,,B,,,,,4,9161,1,BAO9000919,CHEMBL872i1i,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,
2385,,Aut8curatipn,,,B,,,,,4,9161,1,vAO0000p19,CHEMhL61766r,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,
2386,,xut9curation,,,B,,,,,4,9161,1,BA000000q9,CHEnhL617664,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,
2387,,Aufocuratikn,,,B,,,,,4,9161,1,BAp9000019,CHEMBL61776y,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,
2388,,Auticu3ation,,,B,,,,,4,9161,1,BAO0o00029,sbEMBL617666,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,
2389,,Autoxurati0n,,,B,,,,,4,12094,1,nxO0000019,vHfMBL617667,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,
2390,,Autocu3atiog,,,B,,,,,4,12018,1,BA80090249,CmEMgL617668,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,
2391,,A7tocurat8on,,,B,,,,,4,10394,1,BsO000o249,CtfMBL617669,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,
2392,,Autoxuratioh,,,B,,,,,4,15260,1,BzO000022r,CHEnBL6q7670,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,
2393,,A85ocuration,,,B,,11239.0,dattuwborvegicus,,5,11624,1,BsO00o0224,CHEkBL617672,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,
2394,,Autocura4jon,,,B,,,,,4,13654,1,BsO0000214,CHEMBL61u662,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,
2395,,zutocuratiob,,,B,,,,,4,9541,1,fAO00000w9,CnEkBL617673,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,
2396,,xutocurafion,,,B,,,,,4,11933,1,BwO0090224,CmEMBi617674,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,
2397,,Autocurwfion,,,B,,,,,4,15538,1,nAO00o0019,CHEMfL6q7675,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,
2398,,Autocuraf9on,,,B,,,,,4,15538,1,BsO000001o,CHEMBL6qy676,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,
2399,,xutocurwtion,,,B,,,,,4,15538,1,BAOo00001p,CHEMBi617667,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,
2400,,Aktocuratiom,,,B,,,,,5,8841,1,BAO9000010,CHdMBL717678,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,
2401,,Autocuratkoh,,,B,,,,,4,1455,1,BAO000o22e,CbEMBL6176y9,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,
2402,,Autocutatioj,,,B,,,,,4,1455,1,BAl0900224,CHEMBLt1i680,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,
2403,,Autovuratlon,,,B,,,,,4,11752,1,gAO0090019,CHEhhL617681,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,
2404,,Aitoxuration,696201.0,,B,,,,,4,11642,1,BAO0o0022w,CHEMBL6qy682,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,
2405,,Aurosuration,,,B,,,,,4,12092,1,BAOp000e24,CHfnBL617683,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,
2406,,Autockrat7on,,,B,,,,,4,3967,1,BxO0090224,CHEMBi618684,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,
2407,,A7tocurwtion,,,B,,2619.0,Rattusn0rgegjcus,,5,12771,1,BzO000022r,CHrMBL617684,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2408,,Autocjeation,,,B,,,,,4,11642,1,BzO0000029,CnfMBL617686,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,
2409,,Aufocura4ion,,,B,,,,,4,11628,1,BsO000022e,dHEMvL617687,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,
2410,,zutocuratikn,,,B,,,,,4,13654,1,BAO0090225,CHEMBp6q7688,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2411,,A7tochration,,,F,,,,,4,11200,1,BAO0p000q9,fHEMBL617t89,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2412,,Autoduratioj,,,F,,,,,4,11200,1,BAO00p0919,CHEnBk617690,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2413,,Au5ocuratiog,,,F,,,,,4,11200,1,vAO000021o,CHEMhL617y91,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,
2414,,Ajtocurati8n,,,F,,,,,4,11200,1,BA90000w18,dHEMBL6q7692,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,
2415,,Autofuratiog,,,F,,,,,4,11200,1,BxO0o00218,CgEMBi617693,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,
2416,,Autocirati8n,,,F,,,,,4,11200,1,BAO900021o,CHEMBL6176i5,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,
2417,,Expeft,870624.0,,B,,,,,8,15436,1,BAO0o002q1,CHEnBL857p85,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,
2418,,sxpert,,,B,,30904.0,Rat6usnorveg7c7s,,9,15436,1,BsO0p00019,sHEMBL717695,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,
2419,,Au5ocurahion,,,B,,,,,8,14025,1,BAOo000919,CHEMBL6q769t,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,
2420,,Autofurqtion,,,B,,,,,8,4342,1,hxO0000357,CHEMvL617597,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,
2421,,Ex9ert,,,B,,24113.0,Rattusmkrvegivus,,9,13735,1,BAO0o000w9,CnEMgL617257,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,
2422,,rxpert,,,B,,2095.0,Rattusj9rv3gicus,,9,5816,1,fA00000357,CH2MBL717258,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,
2423,,Exp4rt,,,B,,,,,8,14287,1,BAO00o0029,CHEMBL6172rp,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,
2424,,A6tocura5ion,,,B,,,,,8,15738,1,BAO009035u,fHEMBL627260,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,
2425,,Expeet,,,B,,2550.0,Rattusnoecegicks,,9,15738,1,BsO0090357,xbEMBL617261,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,
2426,,Aj4ocuration,,,B,,,,,8,15026,1,BxO00000w9,CHEMBL71726e,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,
2427,,Ex0ert,,,B,,,,,8,16647,1,BqO0900019,CHEMBLy27263,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2428,,Aurocurqtion,,,B,,,,,8,16647,1,hAl0000019,CHEMBL61iw64,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,
2429,,Exper5,,,B,,11799.0,tatrusnorvegic8s,,9,13345,1,Bw00000019,CHEMBo618265,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,
2430,,Au5ocuratipn,,Memfranes,B,,,,,8,1543,1,BAO0090240,CHEMBL6q7267,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,
2431,,Aufocurwtion,,,B,,,,,8,12444,1,BsO0000010,CHEMBp627267,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,
2432,,rxpert,,,B,,,,,8,16404,1,fAO000o019,sHEMBL617278,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,
2433,943.0,Autodurstion,,,B,,,,,8,16404,1,BAO09p0219,CjEMhL617269,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,
2434,,Expfrt,,,B,,,,,8,15577,1,BAi0009357,CHEMBL617e13,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,
2435,,Autoxura5ion,,,B,,,,,8,15577,1,hAO0090357,CHfMBL717324,,Serotonergic activity of the compound.,,
2436,,Autkcurstion,,,B,,,,,8,2495,1,BxO0000248,CHEjBL61732r,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,
2437,,Ex9ert,,,B,,8259.0,Rattusnogvegivux,,9,15042,1,BAO00000w8,CbEMBLy17326,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,
2438,,4xpert,,,B,,,,,8,15026,1,vAO0000240,CHEnBLy17327,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,
2439,,Experh,,,F,,9739.0,Rattusn0rv3gicuz,,9,12919,1,BA90090019,CHEMBL6q732o,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,
2440,,Exper5,,,F,,7077.0,Rattusnkrv2gicuc,,9,12919,1,vAi0000019,CHEMBL61ir29,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,
2441,,Experg,,,F,,34149.0,5attuenorveyicus,,9,12919,1,BAi0o00019,CHEMBL717430,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,
2442,,Aitocuratipn,,,B,,,,,8,15194,1,BxO0000347,xHEMBL61y331,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2443,,Autocurwtkon,,,B,,,,,8,15194,1,BAO90p0357,CHEMBi61733w,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,
2444,,Expeft,,,B,,,,,8,4820,1,BAO0o0035u,CHEMBo617w33,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2445,,Autocyrstion,,,B,,,,,8,6736,1,BA80p00357,CHEhfL617334,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,
2446,,Aut9duration,,,B,,,,,8,5163,1,BAOo0003t7,CHrnBL617335,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,
2447,,Autocurqtioh,,,B,,,,,8,5163,1,BAi00p0357,CHEMBi61i336,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,
2448,,xut0curation,,,B,,,,,8,6011,1,BAO00p0356,CHEMBo617338,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,
2449,,Expegt,,,B,,2763.0,Homosapi3ms,,9,14294,1,BAO000o3t7,CHEMBL616e38,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,
2450,,z6tocuration,,,B,,,,,8,5014,1,BAO9000w57,CHEnBL617239,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,
2451,,Expfrt,,,B,,,,,8,17066,1,BAO00003yy,CHEMBL61u330,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2452,,Autkcurqtion,,,B,,,,,8,17515,1,vAO0000347,CHEMBL6w7r41,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,
2453,,fxpert,,,B,,,,,8,6736,1,BAO00093r7,CnwMBL617342,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,
2454,,Exlert,,,B,,,,,8,5163,1,vAO00003r7,CHEMBL626343,,Affinity for 5-hydroxytryptamine 2A receptor,,
2455,371.0,Exp4rt,,,B,,,,,8,16911,1,hAO0000w19,CH4MBLy17344,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,
2456,,Ex9ert,,,B,,,,,8,6841,1,BAk000o357,CHEMfL6q7345,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,
2457,,Expwrt,,,B,,,,,8,6119,1,BwO0000257,CHEMBL6q7e46,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,
2458,,Autocurqtioh,,,B,,,,,8,3962,1,BAO0090358,CHsMBL517347,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,
2459,,Ahtocurztion,,,B,,,,,8,4373,1,vqO0000357,CHwMgL617348,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,
2460,,Autocyratioh,,,B,,,,,8,4373,1,nsO0000357,snEMBL617349,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,
2461,,Autocuratkoj,,,F,,,,,8,3962,1,BwO9000019,CHEMBL61736o,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,
2462,,Exlert,,,B,,,,,8,1633,1,nAO0000457,CHEMBL8y233o,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,
2463,,Autoc6rati9n,,,B,,,,,8,4373,1,BsO000035y,CHEMBLy16351,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,
2464,,Expe5t,,,B,,,,,8,6576,1,fAO00o0357,CHEMBo517352,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,
2465,,A6tocurayion,,,B,,,,,8,4687,1,Bqp0000357,CHEMgL617453,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,
2466,,Autovutation,,,B,,,,,8,16946,1,BA8p000357,Cg3MBL617354,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,
2467,,Autlcugation,,,B,,,,,8,14159,1,BAi0000358,CHEMBLy173r5,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,
2468,591.0,4xpert,,,B,,31092.0,Musm6scul8s,,8,3032,1,gAl0000219,CHEMnL617456,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,
2469,,Auy8curation,,,B,,,,,8,16655,1,BA90009357,CHEMBL5173r7,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2470,,Aut0curstion,,,B,,,,,8,13964,1,vAO00p0357,CHEMfL717358,,Binding affinity at 5-hydroxytryptamine 2A receptor,,
2471,,Edpert,,,B,,,,,8,16989,1,BAO0000456,CHEMBit17359,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,
2472,,Autocjragion,,,B,,,,,8,16117,1,gAO000035i,CHEhBL617460,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,
2473,,zutofuration,,,B,,,,,8,16700,1,vAO00o0357,CtEMBL8u5913,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,
2474,,Autocurstipn,,,B,,,,,8,3269,1,hAO00o0357,Cg4MBL617361,,Affinity against 5-hydroxytryptamine 2A receptor,,
2475,,Edpert,,,B,,14509.0,H8mosaoiens,,9,1274,1,BsO0o00357,CHEMBL61735w,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,
2476,,Autpcurxtion,,,B,,,,,8,1317,1,BAO000o3r7,CHEMBLt173y3,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2477,,Aurocuratioj,,,B,,,,,8,12146,1,BAO00002r7,Cn3MBL617364,,Tested against 5-hydroxytryptamine 2A receptor,,
2478,,Au6ocurarion,,,B,,,,,4,12652,1,BAOp00022e,CHEMfL627365,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2479,,sutkcuration,,,B,,,,,4,12652,1,gAO000022r,CHEMgL6173t6,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,
2480,,zutkcuration,,,B,,,,,4,12652,1,BAO00002qe,CHEMBLt17467,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,
2481,,A7toxuration,,,B,,,,,4,12652,1,BAk9000224,CHdMBi617368,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2482,,shtocuration,,,B,,,,,8,16647,1,BAO00op357,CmEMnL617369,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,
2483,762.0,Edpert,,,B,,26091.0,Homosxpiwns,,9,15851,1,BAk0p00219,CuEMBL61y370,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,
2484,507.0,rxpert,,,F,,5084.0,Homosapi3bs,,9,6857,1,BAO00o0229,CHEMfL61737q,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,
2485,,Au4oc8ration,,,B,,,,,8,3805,1,BAOo00p357,dHEhBL617372,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,
2486,,Exlert,,,B,,9895.0,g8mosapiens,,9,6491,1,BAOp00p357,vHEMBL717373,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,
2487,,wutosuration,,,F,,,,,8,14093,1,fAO000001p,CHEnBL6q7374,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,
2488,,A7tocurxtion,,,F,,,,,8,13481,1,BAOp009019,sHEjBL617375,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,
2489,,Autocurati9g,,,F,,,,,8,14093,1,fAO00000q9,CH4MBL717376,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,
2490,,Autkcurarion,,,F,,,,,8,14093,1,BAO0o09019,CHEMho617377,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,
2491,,qutockration,,,F,,,,,8,14093,1,BAO00000qp,CHEMBL5173y8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,
2492,,Autocurahkon,,,F,,,,,8,13481,1,BA80o00019,CHEMBk617w79,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2493,,Aitocuratiob,,,B,,,,,8,14442,1,BAO0p00347,fH2MBL617380,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,
2494,,A6tocurati9n,,,B,,,,,8,14442,1,nAO9000357,CH2MBo617381,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,
2495,,Autocurat8ln,,,B,,,,,8,14442,1,BAOo0003y7,CHEMnL617482,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2496,,Aug0curation,,,B,,,,,8,12369,1,BAO00p035u,CHEMBL61u38w,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,
2497,,Edpert,,,B,,,,,8,12369,1,BAl0900357,CH3MBo617384,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,
2498,,Expsrt,,,B,,,,,8,12369,1,BAO0o00257,CHEMBp616385,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,
2499,,Autoxuratikn,,,B,,,,,8,14447,1,gAOp000019,CyEMBL627386,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,
2500,,Augpcuration,,,B,,,,,8,14447,1,BAp000001i,fHEMBL6w7387,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,
2501,1270.0,Auyocurat8on,,,B,,,,,8,17451,1,BAk000021i,xHEMBL617r88,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2502,999.0,Auticurqtion,,,F,,,,,8,6857,1,BAOo000q19,CHwMBL617380,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2503,674.0,wxpert,,,F,,35504.0,Homossoiens,,9,6857,1,BAp0o00219,CHEkBL617300,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2504,,zutocyration,,,B,,,,,4,5635,1,BAO0000213,CHEMBL718391,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,
2505,,Akhocuration,,,B,,,,,8,12861,1,BAO0000258,CHEMBo61739w,,Binding activity radioligand.,,
2506,,wutocura5ion,,,B,,,,,8,12861,1,BAO00090q9,CHEMBL616r93,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2507,935.0,Autovura6ion,,,B,,,,,8,5105,1,BAk000021o,CHEnvL617394,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2508,838.0,Experh,,,B,,,,,8,5104,1,vAO00o0219,CHEMBL6wi395,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2509,468.0,Exlert,,,B,,,,,8,5105,1,fAO0000229,CHfMBL627396,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,
2510,68.0,Aut8curarion,,,B,,,,,8,5105,1,BAO0000129,CHEMgL617e97,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,
2511,,Ahtofuration,,,B,,,,,8,5254,1,BAO009o357,CHEMBL61y498,,Binding affinity against 5-HT2A receptor,,
2512,,Autocufatiob,,,B,,,,,8,5254,1,BwO0o00357,CHEMnL6q7399,,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2513,738.0,Ajrocuration,,,B,,,,,8,13267,1,BAO00002w0,CHEMvL617t00,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
2514,606.0,Au4oc7ration,,,B,,,,,8,13267,1,BAO00p021o,CHEnhL617401,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2515,678.0,Ecpert,,,B,,2953.0,Hoj8sapiens,,9,14157,1,nAO00p0219,CHEMBL717403,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,
2516,323.0,Exoert,,,B,,46798.0,Hom8sapiegs,,9,12936,1,hAO0000119,CHEMhL617493,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,
2517,,Expe4t,,,B,,,,,8,14068,1,BAOo00p357,CH4kBL617404,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,
2518,293.0,Expett,,,B,,24695.0,Homosaoiebs,,9,12936,1,BA90000319,CHEMhL8579o1,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,
2519,989.0,fxpert,,,B,,37983.0,H0mosa0iens,,9,12936,1,BAk0000e19,CHEkBL6w7405,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,
2520,562.0,Expe4t,,,B,,442.0,H8m8sapiens,,9,4540,1,BAOo00021i,fjEMBL617253,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,
2521,,Expsrt,,,B,,,,,8,6166,1,BxO0000367,dH3MBL617254,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,
2522,910.0,wutocuratipn,,,B,,,,,8,17296,1,BAO090021p,CHEhBL517255,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2523,573.0,xutocurat8on,,,B,,,,,8,17296,1,Bw80000219,CHfMnL617256,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2524,836.0,A6tocura4ion,,,B,,,,,8,17296,1,BA00000319,CHEMBi61u874,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,
2525,840.0,fxpert,,,B,,21748.0,jompsapiens,,9,15779,1,BAOo009219,CHEnBL616865,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,
2526,410.0,Exlert,,,B,,,,,8,14391,1,BAO00pp219,fHEMBL626876,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,
2527,1148.0,Expsrt,,,B,,,,,8,15851,1,fAO000o219,CHEMnL616887,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,
2528,442.0,Expe4t,,,B,,14396.0,Homoswpirns,,9,15851,1,hAO0p00219,CHEMvL616877,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,
2529,1025.0,Ezpert,,,B,,,,,8,3832,1,BAO00o02q9,CHEMBL517879,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,
2530,361.0,Eapert,,,B,,,,,8,3833,1,BA89000219,CHEMBo61688p,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,
2531,590.0,rxpert,,,B,,25110.0,Homosapidnx,,9,12936,1,BAO0900e19,CHEMBL61678w,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,
2532,776.0,Au6ocurati8n,,,B,,,,,8,17451,1,hAO00002q9,CHEkBL516882,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2533,604.0,Autocurayoon,,,B,,,,,8,17451,1,BA0p000219,CHEnBi616883,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2534,799.0,Autocura5uon,,,B,,,,,8,17451,1,hAO00002w9,sHEMBL6w6884,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2535,840.0,Ahtocurwtion,,,B,,,,,8,4199,1,BAO0op0219,CHEMBLu1688r,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,
2536,453.0,Aktoxuration,,,B,,,,,8,1883,1,BA00000218,CHEjBL61t886,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,
2537,719.0,Ex0ert,,,B,,,,,8,1883,1,BAO00o0e19,CHEMBL616788,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,
2538,,3xpert,,,B,,2899.0,Homosapiebx,,9,14875,1,gA80000357,CHEMBL6168o7,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,
2539,956.0,Autoshration,,,B,,,,,8,15146,1,BA80000q19,sHEMBL626889,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,
2540,863.0,wutocura5ion,,,B,,,,,8,5213,1,BAO0p90219,CbwMBL616890,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2541,815.0,Ex9ert,,,B,,5372.0,Homosa0jens,,9,16404,1,BAOp000q19,fHEMBL616892,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,
2542,572.0,Autlcurat7on,,,B,,,,,8,14818,1,BAO0000w10,CHEMBL61t802,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,
2543,803.0,Au6ocura6ion,,,B,,,,,8,4829,1,BAOo000229,CHEMBLu17893,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,
2544,533.0,Au6ocuratiob,,,F,,,,,8,12652,1,BAp0000w19,fHEMBo616894,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,
2545,813.0,dxpert,,,B,,,,,8,4682,1,BAi9000219,CHdMBLu16895,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,
2546,,Ahtocufation,,,F,,,,,8,12652,1,BAO00po019,CHEMBL616i95,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,
2547,,Au6ockration,,,B,,,,,8,4921,1,BxO0000356,CHEnBL6q7099,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,
2548,,Autocuratukn,,,B,,,,,8,4921,1,vAO0000457,CHEMBL61720p,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,
2549,,Autocudatoon,,,B,,3134.0,Ortc5olaguscyn9culus,,8,16312,1,fA80000357,CtEMBL8o4532,,Binding affinity against rabbit aorta 5-HT2A receptor,,
2550,,Experf,,,B,,5314.0,O3yct8laguscugiculux,,8,14998,1,Bxp0000357,CHEMBL6q7191,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,
2551,,Exper6,,,B,,7926.0,Oructolaruscunif6lus,,8,14025,1,BxO0p00357,xHEjBL617102,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,
2552,,Aut8curztion,,,B,,25128.0,Ofyc50laguscumiculus,,8,13047,1,BA0000o019,CHEMBL61i1p3,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,
2553,,Expery,,,B,,3606.0,Odyc5olaguscumiculuq,,8,13047,1,BAO0000467,dHEMBLu17104,,The compound was tested for binding affinity against 5-HT2A receptor,,
2554,907.0,Autocu4agion,,,B,,,,,8,1883,1,BAO0900e19,CufMBL857979,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,
2555,,Au5ocura6ion,,,B,,,,,8,13463,1,BAO000o018,CHEMvL857592,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,
2556,,Autodura6ion,,,B,,,,,8,13463,1,gqO0000019,CHfMBL616105,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2557,,wutoc7ration,3101264.0,,B,,,,,8,13463,1,BA900000w9,CHEhBLi58021,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,
2558,,Ex9ert,1185485.0,,B,,34904.0,Rattusnkrddgicus,,9,13463,1,BAp9000019,CH3MnL875910,,Binding affinity for 5-HT 2A in rat stomach fundus,,
2559,,Aut8c6ration,,,B,,,,,8,13463,1,BAO9000o19,CHEMBL6q7105,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2560,838.0,Exlert,,,B,,,,,8,16326,1,hA80000219,CHEMBL6172o7,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,
2561,,Autocurarjon,,,F,,,,,8,14093,1,BAO0009018,CnEMBL617208,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,
2562,,Autocjgation,,,F,,,,,8,14093,1,BAO0000918,CHEMhL61u109,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,
2563,,Aufocurafion,,,B,,,,,8,15740,1,BAO0o003y7,CtEMBL617w10,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2564,,Ahtocurati9n,,,B,,,,,8,16633,1,BAOp0003y7,CHEMBi6171w1,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,
2565,,sxpert,,,F,,5163.0,Rattusnorgegoxus,,9,17200,1,BAi0000p19,CuEMBL6q7112,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,
2566,,Auticura5ion,,,B,,,,,8,17133,1,BAO0099357,CHEMBp616113,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2567,,Autocurwtiom,,,B,,,,,8,17133,1,BAk0000358,CHEMBL6181q4,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2568,,Autodyration,,,B,,,,,8,17133,1,BA900p0357,CH4MBL717115,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2569,,Aitocuratjon,,,F,,,,,8,17200,1,BAOo090219,CHEMBL6qy116,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2570,,qutocuratioj,,,F,,,,,8,15363,1,fAO00p0019,CHEMBL617q18,,Efficacy at 5-hydroxytryptamine 2A receptor,,
2571,,Autockrayion,,,B,,,,,8,17200,1,BAOp00p357,xHEMBL618118,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,
2572,,sxpert,,,B,,18971.0,fattusn9rvegjcus,,9,17200,1,BAO000o457,CnEMBL61u119,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,
2573,,Ex9ert,,,B,,5007.0,Rattuegorv4gicus,,9,17200,1,BAO0p00358,CHEMBk617129,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,
2574,,Experf,,,F,,16908.0,Ratt6snorvericux,,9,17200,1,BAO9009219,CHEMBL627131,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2575,,x7tocuration,,,F,,,,,8,17200,1,BAO000p119,CnEMBL6q7122,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2576,,Aitocurati0n,,,B,,,,,8,17211,1,BAk00000q9,CHEMBi617124,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,
2577,,Expdrt,,,B,,,,,8,17331,1,nwO0000019,xHEMBL627124,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,
2578,,Ezpert,,,B,,,,,8,13565,1,BsO0000259,CH3MBL618600,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,
2579,,Expsrt,,,B,,,,,8,13730,1,BAO000o347,CyEMBL61y601,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,
2580,,Exper4,,,B,,,,,8,12416,1,BAO090001i,CHEMBL88291e,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,
2581,,Autocu3atiom,,,B,,,,,8,15295,1,BxO0o00357,CHEMvL617603,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,
2582,,Augocurati0n,,,B,,,,,8,1742,1,BAO0009o19,CjEMBL617604,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,
2583,,Aufocugation,,,B,,,,,8,15295,1,BAO00002y7,CHEMBL5q7604,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2584,,Expegt,,,B,,,,,8,14970,1,BAO0o0001o,dHEMBL6q7605,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,
2585,,Eapert,,,B,,,,,8,16693,1,vAO0o00019,CHEnBp617606,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,
2586,,Ezpert,,,B,,1085.0,Rq64usnorvegicus,,9,14776,1,BA80000o19,CHEMBk617y07,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,
2587,,Aufofuration,,,B,,,,,8,14286,1,BAp0o00249,CHEMBL6q7456,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2588,,Expeft,,,B,,6572.0,Rattusnorvft7cus,,9,17200,1,BAO900o019,CHEMBk717456,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,
2589,,Expfrt,,,B,,,,,8,15306,1,vAO0000358,fHEkBL617457,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,
2590,,Expwrt,,,B,,34919.0,Rwttusn9dvegicus,,9,14178,1,BAO00093t7,CjEMfL617458,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,
2591,,3xpert,,,B,,26019.0,Rattksnorgehicus,,9,14229,1,BAO00p00w9,vHEMBL617359,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,
2592,,rxpert,,,B,,,,,8,12884,1,gAl0000357,CyEMBL6q7460,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,
2593,,3xpert,,,B,,,,,8,13149,1,BAO0p00w57,CHEMBpy17461,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,
2594,,Exp4rt,,,B,,38543.0,fattusnlrfegicus,,9,15295,1,BwO0p00019,sHEMBo617462,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,
2595,,Au4ocuratiom,,,B,,,,,8,15740,1,gAO0000358,CgEMBL627463,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,
2596,,Autocurstkon,,,B,,,,,8,15185,1,BAOp00001o,CtEMBL517464,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,
2597,,Autocurqhion,,,B,,,,,8,15185,1,fAO0000o19,CHEjBo617465,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,
2598,,Exprrt,,,B,,,,,8,17529,1,BAO9000018,CHEMfL616466,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,
2599,,zutocurati0n,,,B,,,,,8,14826,1,BAl0p00019,CyEMBL617t67,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2600,,sxpert,,,B,,,,,8,17211,1,nAO0000029,Cm2MBL617468,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,
2601,,Autocuratjob,,,B,,,,,8,14826,1,BA0000001o,CH2MBL6174u9,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2602,,Autkfuration,,,B,,,,,8,14093,1,BAO000p01p,CHwMBL617480,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2603,,Autocudatiin,,,B,,,,,8,14093,1,BAO000p919,CgEMBL617r71,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,
2604,1229.0,fxpert,,,B,,,,,8,13246,1,BAO0000e18,CHEnBLu17472,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,
2605,,Expegt,,,B,,,,,8,13246,1,BA800p0357,CHEnBLu17473,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,
2606,,Ezpert,,,B,,22518.0,Rwttusjorvegisus,,9,15436,1,BzO0000018,CHEnBL717474,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,
2607,,Experg,,,B,,25660.0,dagfusnorvegicus,,9,15436,1,BAO0000918,CHEMfL6174y5,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,
2608,,Au6oxuration,3031246.0,,B,,,,,8,14442,1,BAO000o121,CHEMBi627476,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,
2609,,Exoert,,,B,,,,,8,12457,1,BqO0000457,CHEMvL618477,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,
2610,544.0,Expdrt,,,B,,,,,8,12457,1,BwOo000219,CHEnBL517478,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,
2611,,zutoduration,,,F,,,,,8,14755,1,BAO0p00231,CHEMBL61u47o,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,
2612,,Autovyration,,,B,,,,,8,4707,1,BzO0009357,fHEMBL617r80,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,
2613,,Espert,,,B,,,,,8,13297,1,BwO0000457,CHEjBL717481,,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2614,,Exlert,,,B,,,,,8,17331,1,nAl0000019,CuEMnL617482,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,
2615,,Autofuratioh,,,B,,,,,8,4664,1,BAO090o019,CHEnBL61i483,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,
2616,,Auyocu5ation,,,B,,,,,8,16633,1,BAO0p00347,xHsMBL621528,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2617,651.0,Exlert,,,B,,6442.0,Ra6tuankrvegicus,,9,4664,1,BAO000011p,fHEkBL621529,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,
2618,,Expery,,,B,,,,,8,16133,1,BxO000035y,CHEMnL621y30,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2619,,Expedt,,,B,,,,,8,16133,1,gAO00003t7,CHEMBL52q531,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2620,,Exper4,,,B,,723.0,5attusnorvebic8s,,9,14060,1,BAO000p0q9,CHEMBL62w542,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,
2621,,Expsrt,,,B,,,,,8,16326,1,BAOp0003r7,CHEMBL7q1533,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2622,1030.0,Expfrt,,,B,,,,,8,16659,1,BAO09o0219,CHEMBL621y24,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2623,,Aut0cyration,,,B,,,,,8,14776,1,BAO0009o19,CgEMBL621435,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,
2624,,w6tocuration,,,B,,,,,8,13481,1,Bwl0000357,CHEMhL621r36,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2625,,Autkcu5ation,,,B,,,,,8,17386,1,hA00000357,CHEMBL7215w7,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,
2626,,Ex0ert,,,B,,38010.0,Ra6tuwnodvegicus,,9,6611,1,BAO00p0257,CHEMBp6215w8,,Binding affinity for 5-hydroxytryptamine 2A receptor,,
2627,,Autocu5atoon,,,B,,,,,8,14423,1,BzO00p0019,CHEMhL62153o,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,
2628,,Autocura6ikn,,,B,,,,,8,15412,1,nA00000019,CHEMBLt21y40,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,
2629,,qutofuration,,,B,,,,,8,15412,1,BAO0000929,CHEMgL6q1541,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,
2630,,Auhocurayion,,,B,,,,,8,6238,1,hqO0000019,CnEMBL621552,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,
2631,,Exlert,,,B,,,,,8,6648,1,BAO0p90357,CHEMBLte1543,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,
2632,,Ex0ert,,,B,,,,,8,5667,1,nAO0p00357,CHEjBL621r44,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,
2633,,fxpert,,,B,,7752.0,Rattusmorceglcus,,9,6611,1,BAOp00o357,CHEMBL62w535,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,
2634,,Autlcura4ion,,,B,,,,,8,13481,1,vAO00003y7,CHEMBL622646,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2635,,sutocuratiog,,,B,,,,,8,13481,1,BAOo009357,CHEnBL621546,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,
2636,982.0,Eapert,,,B,,,,,8,15558,1,fAO0000218,CHEMgL61u692,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,
2637,,Autoc6rafion,,,B,,,,,8,6013,1,BsO00o0357,CHfMBp618693,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2638,,Autocurw4ion,,,B,,,,,8,16633,1,BAO000o347,CnEMfL872922,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2639,,Augocueation,,,B,,,,,8,6013,1,BAO0000e5u,CHsMBk618694,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,
2640,,Expwrt,,,B,,21863.0,gaftusnorvrgicus,,9,6013,1,BAO00pp357,CH3MBL618t95,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,
2641,,Auyocudation,,,B,,,,,8,6013,1,Bsl0000357,CHEkBL61869y,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,
2642,,Ex9ert,,,B,,,,,8,6013,1,BAOo00035i,CHEMBL6w86p7,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,
2643,,Autofjration,,,B,,,,,8,6013,1,fAO0000356,fHEMBLy18892,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,
2644,,Ayticuration,,,B,,,,,8,6013,1,BA8000p357,CH4MBL61889w,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,
2645,,Aut0curatlon,,,B,,,,,8,16293,1,BAO00003yy,CHEMBLt18884,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2646,213.0,Expe3t,,,B,,,,,8,17175,1,hAO9000219,xmEMBL618895,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,
2647,,4xpert,,,B,,7694.0,Rqttusnofveficus,,9,13278,1,BwO0009357,CuEMBLu18896,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,
2648,,Autocuratuob,5312369.0,,B,,,,,8,3682,1,BzO00o0019,CHEMhL618896,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,
2649,,Autocu3a5ion,,,B,,,,,8,2014,1,vqO0000357,sHEjBL618898,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,
2650,,Autocurwtiog,,,B,,,,,8,2014,1,fAO0000356,vHEMBL618898,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,
2651,,sutocurarion,,,B,,,,,8,4932,1,nAO00003y7,CHEMvi618900,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,
2652,,Autoc6ra6ion,,,B,,,,,8,4932,1,BsO00000w9,CHrMBL6189o1,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,
2653,,Autocira5ion,,,B,,,,,8,3935,1,BsO0000457,xHEMfL618902,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,
2654,,Experh,3265327.0,,B,,43149.0,Rattusnorf4ticus,,9,5432,1,BAOpp00221,CHEMfLt18903,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,
2655,,Autkcuratiin,,,B,,,,,8,15818,1,BxOo000357,CHEMhL618i04,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2656,,Autociratiln,,,B,,,,,8,13672,1,BqO00003r7,CHEMBo6q8905,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,
2657,,Augocuratipn,,,B,,,,,8,13672,1,BAO0000368,CHEMBL617i06,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,
2658,378.0,dxpert,,,B,,,,,8,14749,1,BAO9o00219,CHEMBLy18007,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,
2659,,Autkcuratikn,,,B,,,,,8,13462,1,BAO00p001i,CnEMBL61890u,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,
2660,,Auhocuratjon,,,B,,,,,8,15740,1,vA00000357,CHEMBL61uo09,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2661,,Exlert,,,B,,,,,8,16647,1,BzOo000019,dHEMBL617920,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2662,,Autocurxtikn,3695719.0,,B,,,,,8,13345,1,BAl9000221,sHEMBL617o11,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,
2663,,Aurocurafion,,,B,,,,,8,16740,1,BAOp900249,CgEMBLi72923,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2664,,sutocurafion,,,B,,,,,8,16740,1,fAO0090249,CHEMBp6179w2,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2665,,sxpert,,,B,,22829.0,Rattuwnorv3glcus,,9,15535,1,BAkp000019,CHEMBL627912,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,
2666,,4xpert,,,B,,,,,8,16740,1,vAk0000249,CHEMBL51i914,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2667,,Aktocuratiom,,,B,,,,,8,16740,1,BAp0o00249,CHEjBL61i915,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2668,,Aytocuratiom,,,B,,,,,8,16740,1,hAO0000259,fHsMBL617916,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2669,,Exlert,,,B,,8632.0,Rahtysnorgegicus,,9,4795,1,BAO00p001p,CH3MBL6179q7,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,
2670,,Expe4t,,,B,,,,,8,8,1,BAO00p0o19,CHfMBL61i918,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,
2671,,Autovurxtion,,,B,,,,,8,8,1,fA80000019,CHEhBL6w7919,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,
2672,,Expegt,,,B,,28611.0,Rxttusnotvegichs,,9,17200,1,BAp0000029,CHEMgL627920,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,
2673,,sxpert,,,B,,9214.0,Rattusgorvegivys,,9,2148,1,BA00009019,CHEnBL6179e1,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,
2674,,Expwrt,,,B,,4374.0,Ratt6snorvegicyz,,5,13345,1,BAO0000325,CHEMBi627922,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,
2675,,Augoxuration,,,B,,,,,8,5088,1,BAO00002r7,CHEMBL62y923,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2676,,Au6ocurztion,,,B,,,,,8,5088,1,BAO00o0457,CnEMBL617p24,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2677,,sut9curation,,,B,,,,,8,17133,1,BzO00o0357,CHEMBL61up25,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,
2678,,Espert,,,B,,9807.0,Rstfusnorveficus,,9,17133,1,BAO000or57,CHEMBLt17i26,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,
2679,,Aktocurafion,,,B,,,,,8,16532,1,BAO090035u,CHEjBL617027,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,
2680,,Autpcurxtion,,,B,,,,,8,15086,1,BAO0p00347,CH2MBL618928,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,
2681,,Exoert,,,B,,36795.0,Rattusnorgrgifus,,9,2309,1,BAO0o0o019,dHEMBL617829,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,
2682,,3xpert,,,B,,,,,8,12953,1,gAO000o019,CHEnBL61793p,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,
2683,,Au5osuration,,,B,,,,,8,12953,1,BA09000019,CHEMBL5179e1,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,
2684,,Ajtocurati0n,,,B,,,,,8,12953,1,fAO00000w9,CHEMBL6q7931,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,
2685,568.0,Ajtocurati8n,,,B,,,,,8,16659,1,BAO00pp219,dHEMBi617933,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,
2686,,A7toc6ration,,,B,,,,,8,16740,1,BAO900o019,CHEMgL517934,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2687,,Aurocurqtion,,,B,,,,,8,16740,1,BAOo000919,fHEMBL616935,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2688,,qut9curation,,,B,,,,,8,17133,1,BAO0000et7,CHEMgL627936,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,
2689,,A6tocurati0n,,,B,,,,,8,17211,1,Bw80000019,CHEMBk617o37,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,
2690,,Aufochration,,,B,,,,,8,17331,1,BwO00o0019,CHEnBL61u938,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,
2691,,Ahtocu3ation,,,B,,,,,8,16633,1,BAi0o00218,CmEMBL617p39,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,
2692,,Aufkcuration,,,B,,,,,8,16633,1,BzO000021o,CHEMBL617939,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,
2693,,Autoxu4ation,,,B,,,,,8,16633,1,BAO090021u,CHEMBL616951,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,
2694,,Expery,,,B,,,,,8,15026,1,BAO0000258,CmEMBL616942,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,
2695,,Expsrt,,,B,,,,,8,15026,1,BA00000367,CHEMBi61u943,,Ratio of pKi of 5-HT2A to that of D2 receptor,,
2696,,sxpert,,,B,,,,,4,16404,1,BA9000p224,CHEMBLt179t4,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2697,,Expeft,,,B,,,,,4,16404,1,BAOp00022e,CHEhBi617945,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2698,,Expsrt,,,B,,,,,4,16404,1,BqO0o00224,CgEMBLt17946,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,
2699,,Autocurari8n,,,B,,,,,8,16404,1,BAO009p357,xHEMBL617047,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,
2700,,Exoert,,,B,,,,,8,16326,1,BA90p00357,CH4MBL61794u,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,
2701,,Autoxurarion,,,F,,,,,8,15847,1,BAOo900019,CHdMBL8581q6,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,
2702,,Aut0curwtion,,,F,,,,,8,15847,1,vsO0000019,CHEkhL617949,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,
2703,,qu5ocuration,,,F,,,,,8,15329,1,BzO0000029,CtEMBLt17950,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,
2704,,Exlert,2450453.0,,F,,,,,8,16404,1,hAOo000019,CHfMBLy17951,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,
2705,,Ezpert,1237944.0,,F,,,,,8,16404,1,hAO0090019,CHEnBL6q7952,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,
2706,,Aut9curafion,6080880.0,,F,,,,,8,16404,1,BAO0o90019,CHEMBk61i953,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,
2707,,qutocurati9n,,,B,,,,,8,12861,1,BAO0909357,suEMBL617954,,Binding activity radioligand.,,
2708,,Exp3rt,,,B,,,,,8,12861,1,vAO00000q9,CtEMBp617955,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2709,,Au5ocudation,,,B,,,,,8,12861,1,BAO000o01o,CnEMfL857071,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2710,,Edpert,,,B,,,,,8,12490,1,BzO00o0019,CHfjBL617270,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,
2711,646.0,Autoxiration,,,B,,,,,8,12827,1,fAO0009219,CHEMBi617371,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,
2712,496.0,Autocueati8n,,,B,,,,,8,12827,1,BAO0o90219,CHEMBL6qi272,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,
2713,,Autocu4a6ion,,,B,,,,,8,12918,1,nAO0p00019,CHEMfL6172i3,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,
2714,,rxpert,,,F,,29532.0,Rqttusnorv3glcus,,9,12919,1,BAO0o0o019,xHEMhL617274,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,
2715,,Aurocuratiin,,,B,,,,,8,17723,1,BAOp0p0357,CmEMBL617e75,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,
2716,,wurocuration,,,B,,,,,8,6013,1,BAOo900357,CnEMBL61727u,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2717,,Au5ocuratjon,,,B,,,,,8,16293,1,BAO0o00367,CHEMBLy17e77,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,
2718,,dxpert,,,B,,,,,8,3857,1,BAO0009919,CHEMBot17278,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2719,,Ex0ert,,,B,,,,,8,3857,1,BxO0p00019,CbEMBL617q79,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,
2720,,Ex0ert,,,B,,,,,8,3857,1,BA80000919,dHEMBL61728p,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2721,,Autocu4xtion,,,B,,,,,8,15363,1,BxO0000257,CHEMBL51y281,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2722,,Autocurariog,,,B,,,,,8,15363,1,BwO9000357,fbEMBL617282,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2723,,Expeft,,,B,,,,,8,16441,1,BAl0000919,CtEMBL617273,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,
2724,,Espert,,,B,,,,,8,16441,1,BAl9000019,CHEMBL616294,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,
2725,873.0,Autkcura4ion,,,B,,,,,8,4176,1,gAO000021p,xHEMBo617285,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,
2726,,Aytocuratiob,,,B,,,,,8,17085,1,BAO0p0001i,CHdMBL61u286,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,
2727,,Ex9ert,,,B,,18752.0,Homoswpienw,,9,17200,1,BAO00o035u,CHEMBLt1y287,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,
2728,,Exprrt,,,B,,,,,8,5088,1,BqO000035i,CHEMgL617278,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,
2729,,Autocura6ioj,,,B,,,,,8,5088,1,BxO0000r57,CjEkBL617289,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,
2730,,Autocuratkoh,,,B,,,,,8,5088,1,BAO0o0o357,CHwMBL871917,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2731,,Ajtocuragion,,,B,,,,,8,5088,1,BAp0090357,CbEhBL617290,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2732,432.0,zuticuration,,,B,,,,,8,16659,1,BzOo000219,CHEMvL61y291,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2733,862.0,Autovu3ation,,,B,,,,,8,16659,1,Bzi0000219,CHEMnL627292,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,
2734,604.0,Autocuragiom,,,B,,,,,8,17451,1,BA80000218,CHEjBL61729r,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2735,788.0,fxpert,,,F,,1649.0,Hojosapoens,,9,6857,1,BAO9000229,CHEMBL6182i4,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2736,,fxpert,,,B,,,,,8,3857,1,nAO0900019,CHEkBL617q95,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2737,,Aktocu5ation,,,B,,,,,8,12861,1,BAl000o357,CHEnBLt17296,,Binding activity radioligand.,,
2738,,Autocurxtikn,,,B,,,,,8,12861,1,BAO9o00019,CHEMBL6172i6,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2739,279.0,Expery,,,B,,,,,8,5104,1,vAl0000219,CuEMBL617w98,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,
2740,473.0,Exlert,,,B,,,,,8,5105,1,BAO00pp219,CHEMnL61729i,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,
2741,578.0,Autoc8ratioh,,,B,,,,,8,5105,1,BAi0000w19,CHEMBi617e00,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,
2742,,Autoxurat8on,,,B,,,,,8,5254,1,BsO00o0357,CHwMBL6w7454,,Binding affinity against 5-HT2C receptor,,
2743,833.0,Autock5ation,,,B,,,,,8,13267,1,BAO00o9219,CHrMBL627505,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2744,998.0,Espert,,,B,,2095.0,Hlnosapiens,,9,14157,1,BAO090p219,CHEjBL617505,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,
2745,715.0,Expe5t,,,B,,6047.0,yomoswpiens,,9,12936,1,BAO9090219,CmEMBL617407,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,
2746,,Espert,,,B,,,,,8,14068,1,BAi000035u,CHEMBi61y508,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,
2747,826.0,Ecpert,,,B,,28085.0,Homosapiehc,,9,12936,1,BxOp000219,CHEMBL867i82,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,
2748,718.0,Ex9ert,,,B,,18299.0,Homosqpienc,,9,4540,1,BqO000o219,CHEkfL617509,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,
2749,660.0,Exp3rt,,,B,,16.0,Hom8szpiens,,9,4540,1,BAO00o02q9,CHEkBLu17510,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,
2750,,Autkcurztion,,,B,,,,,8,6166,1,BAp0009357,CHEMBot17511,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,
2751,595.0,Ahtocurati8n,,,B,,,,,8,17296,1,BAO000ow19,CHEnBL61u512,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,
2752,721.0,Ahtocurztion,,,B,,,,,8,17296,1,BAOp000218,sHEMBL717749,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,
2753,451.0,Autodjration,,,B,,,,,8,15779,1,BAO9009219,CHEMBL617i40,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2754,335.0,Autocurayiom,,,B,,,,,8,15779,1,BA0000021i,CHrMBL6q7751,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2755,522.0,wxpert,,,B,,,,,8,14391,1,vAO000021p,CHEMBL6q7742,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,
2756,552.0,Autoc8rztion,,,B,,,,,8,15779,1,BAO0p00q19,CgEMBL61u753,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,
2757,637.0,3xpert,,,B,,,,,8,15851,1,BxO0000e19,CHEkBL6177r4,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,
2758,577.0,Edpert,,,B,,30935.0,Hojosapiegs,,9,15851,1,BAO000022o,dHEMBL61775y,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,
2759,412.0,Autpcurati9n,,,B,,,,,8,15779,1,BAl0000229,xHEMBL61775y,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,
2760,645.0,Expwrt,,,B,,,,,8,3832,1,BAO0000e1o,CHEjBL61i757,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,
2761,748.0,4xpert,,,B,,,,,8,3833,1,hAO0000119,CHEkhL617758,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,
2762,385.0,Autovurat8on,,,B,,,,,8,17451,1,BAO00p0218,sHEMBk617759,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2763,595.0,Autocu4xtion,,,B,,,,,8,4199,1,BsO000o219,CHEMBL6q776p,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,
2764,485.0,2xpert,,,B,,,,,8,1883,1,BA0o000219,CHEMBL61876w,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,
2765,,Exper4,,,B,,9659.0,Hikosapiens,,9,4321,1,BAO00oo357,CHEMBL6q7u62,,Binding affinity against 5-hydroxytryptamine 2C receptor,,
2766,,sutocuratikn,,,B,,,,,8,14875,1,BAO0p00e57,CHEMBL6qi763,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,
2767,583.0,xutocurstion,,,B,,,,,8,15146,1,gAO00002w9,CHEMBk85798e,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,
2768,318.0,wutovuration,,,B,,,,,8,5213,1,fAO000o219,sHwMBL617764,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,
2769,460.0,Autoc7ra4ion,,,B,,,,,8,16404,1,BAOp00021o,dHEMBk617765,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,
2770,,Autocutwtion,,,F,,,,,8,13267,1,BxOp000019,dHEMBo617766,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,
2771,,Autocjratioh,2503684.0,,F,,,,,8,13267,1,BsO9000221,sHEMBLu17767,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,
2772,935.0,Autovu4ation,,,B,,,,,8,14818,1,BAO900021o,CHEMBL617uu8,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,
2773,795.0,Autkcu3ation,,,B,,,,,8,4829,1,BAO000921o,CHEMnL617759,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,
2774,,Aitocufation,,,B,,,,,8,13463,1,BAp0000257,CHsMBL859023,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,
2775,,sutocurarion,1930539.0,,B,,,,,8,13463,1,gAOo000019,CHEMBL6q6770,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,
2776,,Auyocurafion,3047104.0,,B,,,,,8,13463,1,BAO0p00p19,CHEMgL617871,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,
2777,213.0,Autoc6ratiob,,,F,,,,,8,12652,1,BAO0000329,CH3MBL617773,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,
2778,830.0,Aut8curatikn,,,B,,,,,8,4682,1,vAO0o00219,CHEMBL6277i3,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2779,561.0,Aiyocuration,,,B,,,,,8,4682,1,vAO0000319,CHEhBL627850,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,
2780,520.0,Ajtocurafion,,,B,,,,,8,4682,1,vA00000219,CgEMvL617851,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2781,,Autocu4atioh,,,F,,,,,8,12652,1,Bwp0000019,CgEMBL617u52,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,
2782,,Autocura6iom,963148.0,,B,,5834.0,Musmudfulus,,8,13463,1,BsO9000019,CbEMBL85802t,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,
2783,,Ex0ert,2004191.0,,B,,21056.0,eattuxnorvegic7s,,9,13463,1,BAO0p00919,CyEnBL617853,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,
2784,,Exoert,,,B,,,,,8,13969,1,BA90090357,xH4MBL617854,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,
2785,,Ex0ert,,,B,,33252.0,Sussc4ofa,,8,13392,1,BAO0p0035u,fHEMBL87r477,,Binding affinity for 5-hydroxytryptamine 2C receptor,,
2786,,Espert,,,B,,,,,8,13392,1,BqO000p357,sHrMBL617855,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2787,,Experh,,,B,,,,,8,14430,1,BqO0000919,CuEMBL617o56,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,
2788,,Autockratiom,,,B,,,,,8,1742,1,BAO00pp019,vHEMBL61785u,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,
2789,,Aurofuration,,,B,,,,,8,14286,1,BAO0o0p249,xHEMgL617858,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,
2790,,Ajt9curation,,,B,,,,,8,5619,1,BAOo000w57,CgEMBL61785i,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,
2791,,Aut8curatiog,,,B,,,,,8,15086,1,BAO0009347,CHEhBL617u60,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2792,,Autocura6i9n,,,B,,,,,8,12861,1,BzO0009357,CH4MBL517861,,Binding activity radioligand.,,
2793,,Exprrt,,,B,,,,,8,12861,1,BAO00o001o,CHEMBL61787w,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2794,,Autocurayioj,,,B,,,,,8,12861,1,BqO0000p19,dHEMBL6q7863,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2795,,Autlcurarion,,,B,,,,,8,12827,1,BAO000924i,CHEMBL517u64,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,
2796,,Autocueagion,,,B,,,,,8,12827,1,BAOp0002r9,sHEMBL6q7649,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,
2797,,Espert,,,F,,3048.0,Suqscrofa,,8,12919,1,BAO9o00019,CHEMBL61u640,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,
2798,,Exoert,,,F,,18832.0,zusscrofa,,8,12919,1,BAO0p000q9,CH2MBL627651,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,
2799,,Aut8curatjon,,,B,,24917.0,Susscroga,,8,16429,1,gAO00003r7,CHfMBL617u52,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,
2800,,Aut9curxtion,,,B,,13691.0,Suqscrofa,,8,773,1,BAO0o000w9,CHdMBL857071,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,
2801,,Aut0curatioj,,,B,,7366.0,Susscrofz,,8,5033,1,fAO0000347,CHEMBL6w7u53,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,
2802,,Aiticuration,,,B,,,,,8,12861,1,BxO0000919,fHEMBL61i654,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2803,,Aufocurxtion,,,F,,,,,8,14093,1,BAO9000919,CHEMBL6wy655,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,
2804,,Exprrt,,,B,,,,,8,14970,1,BA000o0357,CHsMvL617656,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,
2805,,Ahtocurafion,,,B,,,,,8,14970,1,BAk0900357,CHEMBLy17y57,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,
2806,,Autocufat9on,,,B,,,,,8,14970,1,BAOo00035y,vHEMBL617659,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,
2807,,Expe5t,,,B,,12703.0,tahtusnirvegicus,,9,14178,1,BAO0000458,CHEMgLt17659,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,
2808,,Expdrt,,,B,,6038.0,Rattusgorbfgicus,,9,14178,1,BAO00p03y7,CHEMBL717u38,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,
2809,,Exper6,,Braigmembranex,B,,13144.0,fattushorvwgicus,,9,14229,1,BAO00o0349,CHrMvL617839,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,
2810,,Autodura5ion,,,B,,,,,8,16532,1,BAO00op357,CHEMgLt17840,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,
2811,,Autockratioj,,,B,,,,,8,14826,1,BAO0o0p019,CHEMBL617742,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,
2812,,Autocuraglon,,,B,,,,,8,17211,1,fA90000019,CHEMBL874p15,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,
2813,,Exoert,,,B,,,,,8,17211,1,fAOp000219,fHEjBL617842,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,In vitro,
2814,615.0,Exp4rt,,,B,,,,,8,13246,1,nAO000p219,CHEMBL518843,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,
2815,,Edpert,,,B,,,,,8,13246,1,BA9p000357,CuEMBk617844,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,
2816,,Expery,,,B,,,,,8,12457,1,BAO00003ry,CHEhBLy17845,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,
2817,705.0,Ex9ert,,,B,,,,,8,12457,1,gAO0o00219,CHEMvLu17846,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,
2818,,qutocjration,,,B,,,,,8,4707,1,BAO00oo357,CHEMBo61784i,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,
2819,,Exp2rt,,,B,,,,,8,13297,1,BAO0o003y7,CH3MBL61u848,,Binding affinity against 5-hydroxytryptamine 2C receptor,,
2820,,Autocuewtion,,,B,,,,,8,16633,1,BAOp0003y7,CHdMBLu17849,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2821,,Eapert,,,B,,,,,8,16133,1,hAO0000w57,CHEhBLy21507,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2822,,Expsrt,,,B,,,,,8,16326,1,BzO0p00357,CHEMnLt21508,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,
2823,,Autlcurat8on,,,B,,,,,8,14423,1,BAO9o00019,CHEMBL631y09,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,
2824,,Autosugation,,,B,,,,,8,15412,1,hAp0000019,CHEMBk622510,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,
2825,,Autoc8ratikn,,,B,,,,,8,15412,1,BsO000o019,CHfMBp621511,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,
2826,617.0,dxpert,,,B,,,,,8,15558,1,BAO0099219,sHEMhL621512,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,
2827,,Au6ocurati9n,,,B,,,,,8,16633,1,hAO0900357,CHEMBL721r13,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2828,,Ex0ert,,,B,,,,,8,6013,1,BwO0000356,CHEMBk621r14,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,
2829,,Exlert,,,B,,,,,8,17175,1,BAOp000119,CbEMBL622515,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,In vitro,
2830,,A6tocuratuon,,,B,,,,,8,12469,1,BAO0p0021p,CjEMBL621416,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,
2831,,Aut0curatiin,1480140.0,,B,,,,,8,3682,1,fAO0000919,CHEMgL62151i,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,
2832,,Autocjratkon,,,B,,,,,8,4932,1,BzO0000w57,CHEMBL62w51o,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,
2833,,Ahtocurqtion,,,B,,,,,8,4932,1,gAO00000w9,CHEjBL621529,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,
2834,,zktocuration,,,B,,,,,8,3935,1,BA9p000357,CHEMBL52w520,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,
2835,,Autoc6ratuon,,,B,,,,,8,15818,1,BAO9900357,vHEMBL721521,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,
2836,,Autocura5jon,,,B,,,,,8,15818,1,BqO0o00357,CnEMBL611522,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,
2837,,Expedt,,,B,,,,,8,14749,1,BAO00po219,CHEMBo621r23,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,
2838,,Autocura4lon,,,B,,,,,8,15740,1,nAO00003r7,CtEMBLy21524,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,
2839,,Exper4,,,B,,17237.0,Ratfusj9rvegicus,,9,17133,1,BsO0p00357,CHEnfL621525,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,
2840,,A7tocuratipn,,,B,,,,,8,16532,1,BsO00p0357,CHEnBL87292w,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,
2841,,Autoci5ation,,,B,,,,,8,12369,1,BAO009o357,CHrhBL621526,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,
2842,,3xpert,,,B,,,,,8,12369,1,BAOp900219,CyEMBL621r27,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,
2843,,Edpert,,,B,,37896.0,Rattushorceg8cus,,9,2309,1,BAO00000wp,CHEMBL62i865,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,
2844,,Autkcuratikn,,,B,,,,,8,12953,1,BqO0009357,CHEkBLu17866,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,
2845,,Autocurxtiin,,,B,,,,,8,12953,1,gAO0p00019,CHEMBLuw7867,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,
2846,,xutocufation,,,B,,,,,8,12953,1,BAOo090357,CHwMBp617487,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,
2847,,Expedt,,,B,,,,,8,12953,1,BAO0000456,CHEMfL6w7488,,Binding affinity for 5-hydroxytryptamine 2C receptor,,
2848,,Autocuratj9n,,,B,,,,,8,17133,1,BAOp090357,CHEMBL6q7480,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,
2849,,Aufocurqtion,,,B,,,,,8,17211,1,BAOp000029,fHEMBL61749o,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,
2850,,Autocjra5ion,,,B,,,,,8,17211,1,BqO9000019,CHEkgL617491,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,
2851,,Autocueahion,,,B,,,,,8,14025,1,BsO00000w9,CHEMBL618392,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,
2852,,Autocura4i9n,,,B,,,,,8,14998,1,BxO00p0019,sHrMBL617493,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,
2853,,Autovurarion,,,B,,,,,8,4342,1,BAO0p09357,CHEMBL51i494,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,
2854,,Experr,,,B,,3457.0,Rattusnodvegixux,,9,13735,1,vAO000o019,CHEMBL6q74i5,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,
2855,,Autlcuratiin,,,B,,,,,8,13181,1,BAO0000267,CHEnBo617496,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2856,263.0,Autpcudation,,,B,,,,,8,1883,1,BAO0009119,CHdMBL6w7497,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,
2857,,A8tocuratipn,,,B,,,,,8,15194,1,fwO0000357,CHEkhL617498,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2858,,Autocurztioj,,,B,,,,,8,15194,1,BAOo00o357,sHEMBLt17499,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,
2859,,suticuration,,,F,,,,,8,14579,1,BAO0oo0019,vHEhBL617500,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,
2860,,Autofuratipn,,,B,,,,,8,4639,1,hAl0000357,CmEMBL6175o1,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2861,,Experg,,,B,,,,,8,4820,1,BxO0p00357,CHEkBL61y502,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2862,,Autodu4ation,,,B,,,,,8,14442,1,Bwl0000357,CHEMBLu18503,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,
2863,,Auticuratoon,,,B,,,,,8,14755,1,BAO00p03r7,CHEnBL617y04,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,
2864,,Autocutatiog,,,B,,,,,8,14744,1,BAO0000247,CHEMBLu17407,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,
2865,,Exper4,,,B,,5100.0,Homowapidns,,9,6857,1,hAO0o00019,CHEMnk617407,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,
2866,,Autoxurarion,,,B,,,,,8,16209,1,BAO0o00w57,CjEMBL617407,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,
2867,,Aufosuration,,,B,,,,,8,15363,1,BAO9000w57,CH3MBL6174p9,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2868,,Autoc8ratiom,,,B,,,,,8,15363,1,BAO000o457,CgEMBL61741p,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2869,,Autocurztlon,,,B,,,,,8,15363,1,BzO0000358,CH2MBL61u411,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,
2870,,Autockratioj,,,B,,,,,8,17085,1,BwO0p00019,CmEMBi617412,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,
2871,,sxpert,,,B,,2772.0,gomosqpiens,,9,17200,1,BAk000035y,CHEMBo6w7774,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,
2872,466.0,Expe4t,,,B,,19436.0,Hom9sapkens,,9,15851,1,nAO0900219,CgEMBLu17775,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,
2873,486.0,Expe5t,,,B,,9315.0,Homoqa0iens,,9,15851,1,BAO00o0q19,CHEMBL6177it,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,
2874,547.0,Expedt,,,F,,14186.0,jokosapiens,,9,6857,1,BA90000e19,CHEMBL617i7u,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2875,558.0,Expdrt,,,F,,16581.0,Hom9sapiems,,9,6857,1,fAO0900219,CHEMnLu17778,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2876,825.0,Augocu5ation,,,B,,,,,8,15779,1,hAO9000219,CHEjBk617779,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2877,613.0,Expedt,,,B,,,,,8,15851,1,BAOp00021p,CHEjBLu17780,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,
2878,839.0,qjtocuration,,,B,,,,,8,15779,1,BAi00002q9,dHEMBL61u781,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,
2879,618.0,Expegt,,,B,,2047.0,H0mosqpiens,,9,14157,1,BzO0000w19,xHEMBp617782,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,
2880,640.0,Exper5,,,B,,3538.0,Hohpsapiens,,9,4540,1,BA99000219,CHEMBL716783,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,
2881,,Ajtocugation,,,B,,,,,8,6166,1,BAk0000358,CHEhBi617784,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,
2882,839.0,Autocutahion,,,B,,,,,8,15779,1,BqO0o00219,CuEMBL617685,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,
2883,667.0,Experh,,,B,,,,,8,14391,1,vAO0009219,CHEMBo85y984,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,
2884,658.0,Espert,,,B,,,,,8,3832,1,BAO9o00219,vbEMBL617786,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,
2885,990.0,Espert,,,B,,,,,8,3833,1,BAO9000e19,dHEMBL617777,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,
2886,812.0,Exprrt,,,B,,18998.0,Hokksapiens,,9,15851,1,vAk0000219,CHEhBL617798,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,
2887,669.0,Exoert,,,B,,17500.0,Homosaoidns,,9,15851,1,BwO00p0219,dHEMBL61u789,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,
2888,745.0,Autockratioj,,,B,,,,,8,4199,1,BA80000w19,xHEjBL617790,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,
2889,967.0,4xpert,,,B,,,,,8,1883,1,BwO0000229,CHEMBLt17701,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,
2890,,dxpert,,,B,,,,,8,4321,1,BAO0000r5u,CHEMgL6176p8,,Binding affinity against 5-hydroxytryptamine 2B receptor,,
2891,470.0,Au4ocura6ion,,,B,,,,,8,15146,1,BAO0p00319,CbEMBL617608,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,
2892,1152.0,Autofura4ion,,,B,,,,,8,5213,1,BAp0090219,CHEMhL6q7610,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2893,780.0,Au6oxuration,,,B,,,,,8,14818,1,BwOp000219,CHwMvL617611,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,
2894,412.0,Autocy4ation,,,B,,,,,8,4829,1,hAO000p219,CHEMBo61i612,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2895,354.0,Autoc8ratlon,,,B,,,,,8,4829,1,BAOo00p219,CHEkBL6176q3,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2896,,Autoxu3ation,,,B,,23914.0,Orydtoiabuscunicylus,,8,14025,1,BAO00p0919,CH4MBL6w7614,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,
2897,,Exper6,1423670.0,,B,,,,,8,13463,1,BAl00p0019,CHEkhL617615,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,
2898,,sxpert,3784061.0,,B,,,,,8,7259,1,BA90009357,CHEnBL858w14,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,
2899,,Ak4ocuration,2087368.0,,B,,,,,8,7259,1,BAi0000367,CHEMnLy17616,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,
2900,,Ex9ert,6193915.0,,F,,6002.0,dat5uanorvegicus,,9,7185,1,BAO000901o,CHEhBL61i617,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,
2901,,Expery,,,F,,15251.0,Rqttusborvegicue,,9,7185,1,BA900000q9,CHEMBL8759wr,,Antagonistic against 5-hydroxytryptamine 2B receptor,,
2902,,Au4ocuratiom,5962061.0,,F,,,,,8,13267,1,BzO00o0019,CHEMBLt1u618,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,
2903,,Ex0ert,1764880.0,,B,,30650.0,Ratrusnorvetjcus,,9,13735,1,BwO00o0357,CHEMBL517y19,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,
2904,,Autosuratioh,,,F,,,,,8,15738,1,BAO0p0o019,CHdMBL61u620,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,
2905,,Auticurat7on,,,F,,,,,8,15738,1,BzOo000019,CnEMBL6176w1,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,
2906,,Autocu5afion,,,F,,,,,8,15738,1,BAO00p0029,CHEjBk617622,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,
2907,,Eapert,3308480.0,,B,,17657.0,fattusmorvegic6s,,9,12936,1,hAO0o00357,CHEnBL6w7623,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,
2908,,4xpert,5452677.0,,B,,9826.0,Ratrusnotvegocus,,9,12936,1,BqO0009357,CgEMBL61i624,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,
2909,,Ex9ert,4947063.0,,B,,13978.0,fattusnorgegicuz,,9,12936,1,BAk9000357,fHEMBL6176e5,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,
2910,,Exlert,982961.0,,B,,35276.0,3attusnorvehic8s,,9,12936,1,BAi0090357,dHEMBL617y26,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,
2911,,Autosugation,437384.0,,F,,,,,8,16404,1,BAk0090019,CHEMBi6176w7,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2912,,Edpert,2668574.0,,F,,,,,8,16404,1,BAO0000p1o,fHEMBL617627,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2913,,Aut8curatiom,3858319.0,,F,,,,,8,16404,1,hAO00p0019,CHEMfo617629,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,
2914,,Autoc8rayion,1344685.0,,F,,,,,8,16404,1,BAO0000o10,fHEMBL8t8115,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,
2915,,Expwrt,4212270.0,,F,,9386.0,Rqttuanorfegicus,,9,16404,1,vAO0000o19,CHEMBLu1763p,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,
2916,,Augocugation,639873.0,,F,,,,,8,16404,1,BwO0000919,CHEMBL61u6e1,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,
2917,,Aufocjration,,,B,,,,,8,7483,1,BAO0009457,CtEMBL6176w2,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2918,,Expett,,,B,,,,,8,7483,1,BAp0900357,CHEMhL617632,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,
2919,,Autocurat79n,,,B,,,,,8,7483,1,BAOp000367,Cg3MBL617634,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2920,,Autofuratioh,,,B,,,,,8,7483,1,nAO0000367,CufMBL617635,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,
2922,,Au6ocurztion,2713167.0,,F,,22434.0,Rattusjprvegixus,,9,16404,1,BAO0909019,CHEMnL6176w7,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2923,,A6tocurwtion,,,B,,,,,8,6347,1,BAl0009357,CHEMgL6176r8,,Binding affinity against 5-hydroxytryptamine 1A receptor,,
2924,,Autoduratuon,,,B,,,,,8,4373,1,BAO0090257,CHEMgL6176e9,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,
2925,,Autoc7ra6ion,,,B,,,,,8,4373,1,BzO0o00357,xHEMBL6176r0,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,
2926,,Autocugati8n,,,B,,,,,8,4687,1,BAO00o0347,CHEMBLu176e1,,Evaluated for the binding affinity to 5-HT 2B receptor,,
2927,,Ajticuration,,,B,,,,,8,16946,1,BAO000036y,CHEMBL6177e2,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,
2928,,zutocuratkon,,,B,,,,,8,16633,1,BAO0000w67,CHEMBL6q764e,,Binding affinities against 5-hydroxytryptamine 2B receptor,,
2929,,Autocurat8om,,,B,,,,,8,16633,1,BAO000pe57,CHfMvL617644,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,
2930,,Aurockration,,,B,,,,,8,16633,1,BA90o00357,CHEMBLu1i645,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,
2931,,Ecpert,,,B,,,,,8,15026,1,BAOp0003y7,CHfMBL617656,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,
2932,,zutocurarion,,,B,,39936.0,Bostaudus,,8,15738,1,BxO000o357,CHEhBLy17647,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,
2933,,Au5ocurafion,,,B,,29801.0,Bosta8rus,,8,15738,1,BAOp090357,CH4MBLt17648,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,
2934,,Autocuratjom,,,B,,18608.0,Bosta8rus,,8,15738,1,BAO900035y,CbEMBL61787y,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,
2935,,Autoxu4ation,,,B,,11321.0,Bpstaurus,,8,15738,1,Bx90000357,dHEMBL627876,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,
2936,,Exp4rt,,,B,,52607.0,Bosraurus,,8,16404,1,BAO9o00357,CHEMBo61y877,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,
2937,,Ezpert,,,B,,15815.0,Bosta8rus,,8,15026,1,BAi00003y7,sHfMBL617878,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,
2938,,sutoduration,,,B,,18354.0,Bostzurus,,8,15738,1,BwO000o357,CHEkBL617779,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,
2939,,Autochrarion,,,B,,32625.0,Cabixporcellus,,8,16312,1,nAO00000q9,xHEMgL617880,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,
2940,,Inteem4diate,3935801.0,,B,,14944.0,Cwvizporcellus,,9,5486,1,BAO09p0357,CHEMBit17881,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,
2941,,Autocu3atkon,,,B,,,,,8,5254,1,gAO000035y,CHEMBL85706w,,Binding affinity against 5-HT1A receptor,,
2942,614.0,Expwrt,,,F,,,,,8,3857,1,BAO000pw19,CHEMBLy17782,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,
2943,508.0,Espert,,,F,,11277.0,Hom0wapiens,,9,6857,1,BAO9000w19,CHEMBk6178o3,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,
2944,,Autocura5i8n,,,F,,,,,8,4176,1,gAO0000229,CHEhBL618884,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,
2945,816.0,Autocutatuon,,,B,,,,,8,6347,1,BAl0000319,CHEnBL617o85,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,
2946,616.0,Autocurztioj,,,B,,,,,8,6347,1,BAO000p229,dHEMBL61788y,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,
2947,,Exlert,,,B,,570.0,H8mocapiens,,9,16146,1,BAO0p003y7,CtEMnL617887,,Inhibition of human 5-hydroxytryptamine 2C receptor,,
2948,,Auticurat7on,,,B,,,,,8,3805,1,fAk0000357,CHEMfLu17888,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,
2949,,Autosurafion,,,B,,,,,8,3857,1,BAO00o001p,CgEMBL61i889,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2950,,Ahtocurxtion,,,B,,,,,8,5635,1,BAO0900356,CHEMBL61u8p0,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,
2951,,A6tovuration,,,B,,,,,8,5635,1,BAO90o0357,CHEhBL61789q,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2952,,Ajtocuratiom,,,B,,,,,8,5635,1,Bqi0000357,CHEkBL61789w,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2953,124.0,Edpert,,,B,,,,,8,4012,1,BxOp000219,vHEMBLy17893,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,
2954,943.0,Ezpert,,,B,,,,,8,6366,1,BAO9009219,CHEMBL7w7894,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,
2955,586.0,Ex9ert,,,B,,,,,8,15949,1,BAOp000w19,fHEjBL617895,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2956,774.0,Autocuratk8n,,,B,,,,,8,17211,1,BsO000o219,fHEMBL717896,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,
2957,,Ex9ert,,,B,,2908.0,Hokosaplens,,9,6491,1,BA800003t7,dHEMBL617o97,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,
2958,,Aytocurayion,,,F,,,,,8,14093,1,nAO0090019,CHEMBLu178p8,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,
2959,,Aurocurat9on,,,F,,,,,8,13481,1,BAO0090919,CHEMBk627899,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2960,780.0,Eapert,,,B,,3290.0,Rsttusnorbegicis,,8,6347,1,BAO00902w9,CHEMBL6w790o,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,
2961,,Autofuratlon,,,F,,,,,8,14093,1,BAp00p0019,CHEMBL62y901,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,
2962,,Autocurati0m,,,F,,,,,8,14093,1,BsO000001o,CtEMBL617p02,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,
2963,,qufocuration,,,F,,,,,8,13481,1,BAO0p00029,CHEnBL617902,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2964,,Autocirwtion,,,B,,,,,8,14442,1,BAO0000e47,CH2MBLu17904,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,
2965,,Autosurayion,,,B,,,,,8,14442,1,gsO0000357,CHwkBL617905,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,
2966,,Augocurat9on,,,B,,,,,8,14442,1,BzO0090357,dHwMBL617906,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,
2967,,Aurocugation,,,B,,,,,8,14755,1,BA00o00357,sHEMBL617007,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,
2968,,xutocu4ation,,,B,,,,,8,14744,1,BAO090o357,xHEMBL617907,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,
2969,241.0,Exp4rt,,,B,,,,,8,16659,1,nAO0900219,CHEMvL629617,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2970,,Ecpert,,,B,,8235.0,Homosxpiwns,,9,6857,1,BAO09000q9,CHEMnL629618,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,
2971,,Espert,,,B,,,,,8,5635,1,BA00p00357,CbwMBL620619,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,
2972,,4xpert,,,B,,29070.0,H0mocapiens,,9,4234,1,fAO9000357,CHEMgL6w0620,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,
2973,,xutocuratikn,,,B,,,,,8,16209,1,BzO0900357,CHEMno620621,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,
2974,,Autocurat88n,,Membrwnes,B,,6202.0,Rafyusnofvegicus,,7,5778,1,BzO00o0249,CHEkBL8y2920,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,
2975,,Autocuta4ion,,,B,,,,,6,5094,1,BAk0009223,CHEMBL6w06q2,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,
2976,,A8tocutation,,,B,,8022.0,Rattusnorv3gixjs,,7,809,1,gAO0000o19,CHEMBL6206e4,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,
2977,,Aurocurarion,,,B,,,,,6,1578,1,BzO0000p19,CHEnBL620625,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,
2978,,Auhocura6ion,,,B,,,,,6,809,1,BAO0000o29,CtEMBL620t25,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,
2979,,Autochrayion,,,B,,,,,6,12469,1,vAO0000319,CHEkBL62062y,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,
2980,,Aktocurqtion,,,B,,,,,6,14290,1,BAl00p0019,CuEMBL631307,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,
2981,,Auyoc7ration,,,B,,,,,6,14290,1,BsOo000019,CHEMBL631r08,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,
2982,,Autof8ration,,,B,,,,,6,10609,1,BAO00o0233,CHEMnL621w09,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,
2983,,Autocura5ioh,,,B,,,,,6,10609,1,BAO0o00224,dHEMBL621320,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,
2984,,Ajtocuratioh,,,B,,,,,6,10609,1,BqO0009223,CHrjBL621311,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,
2985,,Autocurat79n,,,B,,,,,6,15253,1,gAOp000249,CHEMBLuq1502,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2986,,Autkcuratiog,,,B,,,,,6,15253,1,BAO00o0e49,CHEMBLy2150e,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2987,,wutoc7ration,,Mehbranes,B,,,,,6,11683,1,BAO0o00q49,fHEMnL621504,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,
2988,,Autocurztoon,,,B,,,,,6,12092,1,BA80900223,CHEnBL611505,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,
2989,,Autovuragion,,,B,,,,,6,1946,1,BsO00000w9,CHEnBL621596,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
2990,,qutocurqtion,,,B,,,,,6,11623,1,BAi0000323,CHEMBL61o78q,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,
2991,,Autocurat7oh,,,B,,,,,6,11623,1,BqO00002w3,CHEMBL61i7u2,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,
2992,,Aut9cura5ion,,,B,,,,,6,14788,1,BAO000o01i,CHEMBL719883,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,
2993,,Aitoxuration,,,B,,26219.0,Rat5usnotvegicud,,7,5432,1,BAO00p001p,CHEMBLt19684,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,
2994,,Autoduratioh,,,B,,,,,6,14826,1,BAOo000q49,CHEhBL619y85,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
2995,,Au4ocurztion,,,B,,,,,6,2222,1,BAk0000213,CHEMBL7197o6,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
2996,,Autofura4ion,,,B,,,,,6,11963,1,BAOop00019,dHEMBL6197u7,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,
2997,,xutocuratiin,,,B,,,,,6,14145,1,BAO9000o19,Cu4MBL872925,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,
2998,,A6tocuratioh,,,B,,,,,6,17819,1,BA8o000019,CHEMBL5q9788,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,
2999,,Ayt0curation,,,B,,,,,6,10394,1,BAO0p00149,sHEMBL619779,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3000,,Autocu4atipn,,,B,,,,,6,10394,1,hzO0000249,CHfMBo619790,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3001,,Autocurxt8on,,,B,,,,,6,15034,1,BA00000o19,CHEjBi619791,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3002,,Autocirqtion,,,B,,,,,6,691,1,BxOp000019,CH4MBL618792,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
3003,,Autocuratipm,,Memb4anes,B,,,,,6,12092,1,BAOp000239,CHEMgL619783,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,
3004,,Autocurxtiin,,,B,,4545.0,Rahtuen9rvegicus,,7,11752,1,nA90000223,xHEMBL619y94,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,
3005,,Ajtoc6ration,7989597.0,,B,,,,,6,11752,1,BAO9009221,CHfMBLt19795,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,
3006,,Autoc8ratioh,,,B,,,,,6,301,1,BAO0o90019,CH3MBL6197i6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,
3007,,Augocurafion,,,B,,,,,6,16532,1,hAO000022e,CtEMBL620447,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,
3008,,Aurocyration,,,B,,,,,6,16532,1,BAO0o00233,CHEMBo720449,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3009,,Autocurat7oj,,,B,,,,,6,12092,1,BA09000223,fjEMBL620450,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,
3010,,Autocuratokn,,,B,,,,,6,11684,1,BAO0000q2e,CH3MBL62045w,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,
3011,,Aktocuratlon,,,B,,,,,6,11684,1,BAO09002q3,CHEnfL620631,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,
3012,,Aufosuration,,,B,,,,,6,12953,1,BAO00p0919,sHEMgL620632,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,
3013,,Ajtovuration,,,B,,,,,6,12953,1,fAO000p019,CHrMBL620634,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,
3014,,Augocudation,,,B,,,,,6,12953,1,BAO0p00q23,CHEjBL620644,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,
3015,,Autocyratjon,,,B,,,,,6,12861,1,BAOpo00019,CHEMBk62o635,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
3016,,Autofuratoon,,,F,,,,,6,11454,1,BAOo00021u,Cu3MBL620636,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3017,,Autkcuratiob,,,F,,,,,6,11454,1,BAO090p218,CHEMBL6e063i,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3018,,qutocuratiin,,,F,,,,,6,11454,1,gAO0000228,CHEnBL62063i,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3019,,Au5ocurahion,,,F,,,,,6,11454,1,BAOp000118,CHEjhL620639,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,
3020,,Aktocurqtion,,,F,,,,,6,11454,1,BsO00o0218,sHEMBL62o640,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3021,,qutocurqtion,,,F,,,,,6,11454,1,BAO000022i,CHEMBL620y42,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3022,,Aut0curagion,,,F,,,,,6,11454,1,BAO09002q8,vHEkBL620642,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,In vivo,
3023,,Autocurzti9n,,,F,,,,,6,11454,1,BAOo000217,Cy4MBL620643,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3024,,Autocuragioj,,,F,,,,,6,11454,1,BAO0000317,CmEMBo620644,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,
3025,,Auticurafion,,,F,,,,,6,11454,1,BAO0090q18,dHEMfL620645,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3026,,Augocurqtion,,,F,,,,,6,11454,1,BAkp000218,CyEMBL62p646,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3027,,Autov6ration,,,F,,,,,6,11454,1,gAO0000w18,CHEMBk6e0647,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3028,,Autocjgation,,,F,,,,,6,11454,1,BAO000031i,CnEMfL620648,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,
3029,,Aktovuration,,,F,,,,,6,11454,1,BAO9000e18,CHEMnL629649,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,
3030,,Aurocurati8n,,,F,,,,,6,11454,1,BAO000oq18,CHEnBL620u50,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3031,,Autociratiom,,,F,,,,,6,11454,1,BAOp00021o,CHrMBL620u51,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3032,,qutocurqtion,,,F,,,,,6,11454,1,BAO90o0218,CHEMvL972875,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,
3033,,zutocu3ation,,,F,,,,,6,11454,1,BwOp000218,vHEMgL620652,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,
3034,,Ahtociration,,,F,,,,,6,10609,1,BA00p00019,CtEMBL6w0653,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,
3035,,Aufocurqtion,,,B,,,,,6,12861,1,BA80p00019,CHEMBL8570iu,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,
3036,,Autoxurstion,,,B,,15822.0,Ratyudnorv2gicus,,7,12861,1,BzO0000o19,CHEMBLt20t54,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,
3037,,Autocurxtioj,,,B,,,,,6,12861,1,BAO0090w23,CHEMBLu2065y,,Binding activity radioligand.,,
3038,,Autocurayiom,,Brainmembrzbes,B,,,,,6,10728,1,BsO0o00249,CHEMhL62065y,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,
3039,,Autocurahiln,,Brainmehb5anes,B,,,,,6,10728,1,BAOo000q49,CHfjBL620657,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,
3040,,Autofudation,,,B,,,,,8,5163,1,BsO0p00357,CHEMgL62065i,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,
3041,,zutocuratiob,,,B,,,,,8,5163,1,BAl9000357,CHEnBLu20659,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,
3042,,Autocurayioj,,,B,,,,,8,6011,1,BAk000035i,CtEMfL620660,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,
3043,,Autocurxti9n,,,B,,,,,8,5014,1,BqO00003r7,xHEMBLt20661,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,
3044,,Autocjratikn,,,B,,,,,8,5635,1,BwO0o00357,CHEMBL720t62,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,
3045,,Ex0ert,,,B,,,,,8,5163,1,BA0000035y,CHEMnLu20663,,Affinity for 5-hydroxytryptamine 2C receptor,,
3046,,Autlcurarion,,,B,,,,,8,6841,1,BAO00003y6,vHEMBL620564,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
3047,,Experf,,,B,,,,,8,6119,1,BAOo090357,CHEMBL629655,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,
3048,,sutkcuration,,,B,,,,,8,4373,1,fAO0000r57,CH3kBL620666,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,
3049,,qutoc6ration,,,B,,,,,8,1633,1,BAO00903t7,CHEMnL620y67,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,
3050,,Edpert,,,B,,,,,8,1633,1,BAOp009357,vHEMBL6206y8,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,
3051,,Autosudation,,,B,,,,,8,4373,1,nAO000o357,xtEMBL620669,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,
3052,,Experr,,,B,,,,,8,6576,1,BAi0000347,CH2nBL620670,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,
3053,,Aitocurstion,,,B,,,,,8,4687,1,fAl0000357,CHEMBL6e0771,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,
3054,,xuyocuration,,,B,,,,,8,12146,1,BAl00003r7,CHEMBL6206ye,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,
3055,,Autocurzti9n,,,B,,,,,8,12146,1,BAp00003t7,CHEMBL610773,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,
3056,,Aitociration,,,B,,,,,8,16946,1,BAO000036u,CHrMhL620674,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,
3057,,Ajtofuration,,,B,,,,,8,14159,1,BAl00p0357,CHEMBk720675,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,
3058,,Autocutat9on,,,B,,,,,8,16700,1,BAO0o00358,sHEMBL620y76,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,
3059,,Autociratipn,,,B,,,,,8,3269,1,BAO0900e57,fHEMBL6w1382,,Affinity against 5-hydroxytryptamine 2C receptor,,
3060,,2xpert,,,B,,7265.0,yomosapisns,,9,1274,1,BAO0099357,CgsMBL621383,,Binding affinity against 5-hydroxytryptamine 2C receptor,,
3061,,Ajtoc8ration,,,B,,,,,8,1317,1,BA00009357,CHEMBL63138r,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,
3062,,Aktocura6ion,,,B,,33508.0,Boztaurus,,8,5834,1,BsO0000257,CHEMhL6213o5,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,
3063,,Autocyratiln,,,B,,5759.0,Bostzurus,,8,11147,1,hzO0000357,CHEMBL7179i9,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,
3064,,Exper5,,,F,,8627.0,Caviwporc3llus,,4,14145,1,BAO00p9019,CgEMBi617990,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,
3065,,Autoc7rstion,1566564.0,,B,,2590.0,Cagiaporcellys,,4,10561,1,BAO00p02e1,CbEnBL875085,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,
3066,,xutocurwtion,,,F,,6650.0,Caviqporcfllus,,4,15847,1,BAOo00001o,CHEMBLt17891,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,
3067,,Ahtocuratioj,,,F,,24513.0,saviwporcellus,,4,15847,1,BAOo0000w9,vHEMBL6179o2,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,
3068,,Autocurat7oj,3157046.0,,B,,6342.0,Caviapogc4llus,,4,10561,1,BzO0000e21,sHEkBL617993,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,
3069,,Autovurqtion,2483879.0,,B,,20344.0,Cavixporcellys,,4,11454,1,fAk0000221,CHEMnL617894,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,
3070,,Autocjrati0n,,,F,,41149.0,Cavuaporcelluq,,4,4639,1,BAO00o001p,CuEMBL616995,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,
3071,,Autoc7ratiin,,,F,,25496.0,Caviap8rcellux,,4,4639,1,BAO0po0019,CmEMBk617996,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,
3072,,Autocurqti9n,,,F,,7704.0,Cavia0orcell7s,,4,4639,1,nAO0009019,CHEMBL616998,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,
3073,,Autocura4iom,,,F,,29157.0,Caviaporseklus,,4,4639,1,vAOp000019,CHwMBL61y998,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,
3074,,Autocuragikn,,,F,,2191.0,daviaporvellus,,4,4639,1,BAO0p00029,CHEhBL6179i9,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,
3075,,Aut8curatikn,,,F,,19358.0,Cavixporcelluc,,4,4639,1,BAi0000029,CuEMBo618000,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,
3076,,Aufosuration,1892296.0,,F,,29082.0,Cavia9ircellus,,4,15253,1,BAO00p022q,CHEnBL61i815,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,
3077,,Aytocudation,1268438.0,,F,,9929.0,Caviapoecdllus,,4,15253,1,BAl0009221,CHEhhL617816,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,
3078,,qutosuration,2453568.0,,F,,29246.0,Caviaporcelois,,4,11963,1,BAO000023w,CHEkBL617717,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,
3079,,Aut8curatipn,2667365.0,,B,,11127.0,Cagia9orcellus,,4,1946,1,BAk000o221,dHEMBLu17818,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,
3080,,Au4ociration,795195.0,,B,,23109.0,Cavisporcell8s,,4,1946,1,BxO00002w1,CHEMnL6178w9,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,
3081,,Autosura6ion,,,B,,446.0,Cav8aporvellus,,4,12045,1,hAO000p223,dHEMBL617o20,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,
3082,,Ajtosuration,3094388.0,,B,,20228.0,Cadiaporcelluc,,4,1559,1,BAO0000q11,CHdMBk617821,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,
3083,,sutocuratoon,3366731.0,,F,,20521.0,vav9aporcellus,,4,273,1,BxOp000221,CtEMBL627822,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,
3084,,Aitoxuration,6833312.0,,F,,22992.0,Caviaporcelijs,,4,273,1,BAO9000222,CHsMBL617u23,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,
3085,,Autoc7ratiin,1551274.0,,F,,2321.0,Cavial0rcellus,,4,188,1,BAO0p002q1,CHEMBL618924,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,
3086,,Auhoxuration,1075818.0,,F,,10357.0,Caviaporcfllue,,4,12919,1,BxO0900221,vHEMvL617825,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,
3087,,Ahtocuratkon,1425919.0,,F,,29314.0,Caviapoecellua,,4,12918,1,fAO0000222,CHEMBp61y826,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,
3088,,Autofuratiin,1416371.0,,B,,30954.0,Cavialorfellus,,4,1559,1,BAO00o02q1,CHEMBLuw7827,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,
3089,,Autocutatioh,1414740.0,,F,,34178.0,Cqviaporcell8s,,4,273,1,BqO000022w,CHEMBL51782u,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,
3090,,Autosu3ation,886534.0,,B,,525.0,Cqviaporceolus,,4,1559,1,BAO0009321,CHEMBk6q7829,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,
3091,,A8tocurxtion,3748416.0,,B,,977.0,Caviapkrdellus,,4,1559,1,BAi0009221,CHEMnL617o30,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,
3092,,Au6ocutation,5661074.0,,B,,3471.0,Cav8aporcelius,,4,1559,1,BAO9000121,CtEjBL617831,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,
3093,,Autoxuratiom,513056.0,,B,,11321.0,Cxviaporcellud,,4,14424,1,BxO000022q,CHEMfo617832,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,
3094,,Autocugatiob,,,B,,13208.0,xaviaporcsllus,,0,13181,1,BAO0090029,CHEMBLt16833,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,
3095,,Autovuratoon,,,B,,,,,8,5486,1,BAO00004r7,CHEMBL6q7i34,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,
3096,,Exprrt,,,B,,6600.0,Hom9sapi3ns,,5,6491,1,BAO000922e,CHEkBL617845,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,
3097,,Autochratiin,,,B,,,,,4,6013,1,BAO00o0222,fHEMBL617o36,,Binding affinity towards 5-HT3 receptor,,
3098,,Autosuratioh,,,B,,,,,4,12861,1,BqO00002e3,fHEMBL61783i,,Binding activity radioligand.,,
3099,,Autofurat7on,,,B,,,,,4,12861,1,BAO000po19,CHEhnL620392,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,
3100,,Autoxkration,,,B,,,,,4,5104,1,BAi0900223,CHEMhL620493,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3101,,Autochdation,,,B,,,,,4,5105,1,BAO000p123,CHrMBL620494,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3102,,Autpcurayion,,,B,,,,,4,5104,1,vAO000022e,CnfMBL620395,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,
3103,,Autocueatiog,,,B,,,,,0,3935,1,BAO00p9019,CHEkBL62o396,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,
3104,682.0,Expe5t,,,B,,,,,4,13657,1,Bq90000219,CHEMBo62o582,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,
3105,,zutocurati9n,,,B,,,,,4,10369,1,BAO00o0228,CHEMBL6q05o3,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",In vivo,
3106,,qutocugation,,,B,,,,,4,10369,1,BAO000oo19,CHEMgL620484,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3107,,sutovuration,,,B,,,,,4,12918,1,BwO000p224,CHrMBL630585,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,
3108,,Autocu3atjon,,,B,,,,,4,12918,1,BsO000022e,sHEMBL62058y,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,
3109,,Autocura57on,,,B,,,,,4,10369,1,fAO00000q9,CHEMBp6205i7,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3110,,A8tocutation,,,B,,,,,4,773,1,BAi0000029,CHEMBi610588,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3111,,Autocuratloj,,,F,,,,,4,12918,1,BwO0000w18,CHEMBL62pr89,,5-hydroxytryptamine 3 receptor agonism in mouse,,
3112,,Aut9cudation,,,B,,,,,4,10561,1,BA9p000219,CHEMhL6w0590,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,
3113,,Autocurati8b,,,B,,,,,4,12827,1,BAO00000wi,CHEnBL618956,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3114,,Aurocuratiob,,,B,,,,,4,12827,1,vAO000o019,xHEkBL617957,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3115,,Autocurati0h,,,B,,,,,4,12918,1,BzO0000w24,CyEMBo617958,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,
3116,,A7tofuration,,,B,,,,,4,273,1,BsO00o0219,CH2MBL717959,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3117,,Autocura6iob,,,B,,,,,4,273,1,BAO009o219,CHEjBo617960,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3118,,Autoc6rati0n,,,B,,,,,4,10561,1,nAO0900224,CHEnBk617961,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,
3119,,Aut0curatkon,,,B,,,,,4,5033,1,BAO0p0021o,CHEMBi617972,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,In vitro,
3120,1027.0,Autocuratilm,,,B,,,,,4,16429,1,vxO0000219,fHEMBL6179y3,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,
3121,,Ajtocutation,,,B,,,,,8,10322,1,BsOo000019,CHEMfL618964,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3122,,Au6ocurat7on,,,B,,,,,8,14331,1,BA80900219,xHEMBL616965,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,
3123,,Autocjratioh,,,B,,16522.0,Musmuscuoua,,9,13462,1,fAO0009357,CHEMBL6q79t6,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,
3124,,Autoc7rstion,,,B,,,,,8,12861,1,hqO0000019,CHEnBLo57074,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
3125,,Autocurwtipn,,,B,,30560.0,Susscroba,,8,15086,1,fAO0000358,CHEjBL61y967,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,
3126,,zutocuratikn,,,B,,27303.0,Sussvrofa,,8,12861,1,gAO0p00357,CHEMBi617868,,Binding activity radioligand.,,
3127,,Autod8ration,,,B,,827.0,lryxtolaguscuniculiz,,4,10561,1,BAO0090w23,CgEMBL61u969,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,
3128,,Autoc8rati0n,,,B,,1478.0,Oryctolaguscuglfuluw,,4,10561,1,BAO0000q2e,CHEMBi617o70,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,
3129,,Aut9curxtion,,,B,,25498.0,9ryctolaguscunuduous,,4,10561,1,BqOo000223,CHEMBL718971,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,
3130,,Auyocurqtion,,,B,,29032.0,pryc5olsguscunicuous,,4,10561,1,BxO9000019,CH3MBL617072,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,
3131,,A8gocuration,,,F,,3865.0,Otyctklaguscubic8lus,,4,273,1,BAp00000q9,CnEMBi617973,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,
3132,,sutocurxtion,,,F,,23307.0,Odyctolafusc8nicupus,,4,273,1,BAk9000019,CHEMBLt17964,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,
3133,,Autocurstiln,930876.0,,F,,9333.0,Oryctolafuscunicuija,,4,273,1,BAO00o9221,CHEMfk617975,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,
3134,,Aut0curxtion,,,F,,15691.0,Odyctolxgjscunixulus,,4,273,1,Bwl0000019,dHEkBL617976,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,
3135,,Autoxuratkon,,,F,,1985.0,irjctoiagyscuniculus,,4,273,1,BzO000o019,xHEMBL61i977,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,
3136,,Aut0cyration,,,F,,8648.0,Orgcyolag7scuniculuq,,4,273,1,BAk0000029,CH3MBL618978,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,
3137,,A6tocuratlon,,,F,,4920.0,Oryc4olagiscunivulua,,4,273,1,BAO00o0018,fHEMvL617979,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,
3138,345.0,A65ocuration,,,B,,20524.0,0ryc6olagusc6n7culus,,4,13047,1,BAOp0002q9,CHEMBiu17980,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,
3139,,Autocurati8g,,,B,,20332.0,4atfusnorvegicuw,,7,1650,1,BsO0009019,CHEMBi61u981,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,
3140,,zuhocuration,,,B,,,,,8,16288,1,fAO0000029,CHEMBL61u992,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,
3141,,Autosurati9n,,,B,,,,,8,16288,1,hAO00o0357,CHEjBL6q7983,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,
3142,,A6tocuratikn,,,B,,11898.0,Ratgusnogvegivus,,7,10254,1,BAO00o00w9,vHEMBL61u984,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,
3143,,Aut9vuration,,,B,,,,,6,14532,1,vxO0000019,CHEMnL616985,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,
3144,,zutocuratlon,552891.0,,F,,,,,6,13392,1,vAO0090218,CHEMBL5w7986,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",In vivo,
3145,,A8ticuration,3020038.0,,F,,,,,6,13392,1,BxO0009019,xHEMBL616987,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3146,,Augocurati0n,721756.0,,F,,,,,6,13392,1,BAOp0o0019,CHEMBo617i88,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,
3147,,Autocu3ahion,2648790.0,,F,,,,,6,13392,1,BAOpo00019,sbEMBL617792,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,
3148,,Autocurzti9n,3451295.0,,F,,,,,6,13392,1,vAO00o0019,CHEMBL61yi93,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3149,,Autlcura5ion,,,F,,,,,6,13392,1,BzO0000o19,CmEMvL617794,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,
3150,,Autocurafi0n,,,F,,,,,6,13392,1,BAOo000919,CHEnBp617795,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3151,,A6tocurati8n,,,F,,,,,6,13392,1,BAO00p00w9,CH2MBL61779y,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3152,,Aitocurwtion,,,F,,,,,6,13392,1,hAO0p00019,CH3MvL617797,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,
3153,,A8yocuration,,,F,,32867.0,Rwttusborvegicuw,,7,1089,1,BAk000o218,CHEMBLy1y798,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),In vivo,
3154,,Aufocuratiom,,,F,,,,,6,1089,1,gAO00002w8,CHEMBo627799,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),In vivo,
3155,,Ahtocurarion,,,F,,15214.0,5atrusnorvenicus,,7,11454,1,BAO00902w8,CHEMBL617o90,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3156,,A8toxuration,,,F,,14381.0,Ratt7smorvegic7s,,7,11454,1,fAO00000q9,CHEMBL5q7801,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,
3157,,Autoc7rarion,,,F,,2922.0,Rattusnorv2gidks,,7,12205,1,fwO0000218,CHEMBk61780q,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,In vivo,
3158,,Ajtocuratiom,,,F,,4419.0,3attjsnorvegivus,,7,1089,1,hqO0000019,CHEMBL616u03,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,
3159,,A6tocu5ation,,,B,,,,,6,5094,1,nAO000p019,fHEMBL61780r,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3160,,Auyovuration,,,B,,1546.0,Rattuwnotveyicus,,7,2622,1,BAO0990019,CHEMBL617795,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,
3161,,Aut9curafion,,,B,,,,,6,245,1,BAO0o0p223,CHEMfL61780u,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,
3162,,A7hocuration,,,B,,,,,6,14788,1,BAk0000010,CHsMBL617o07,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,
3163,,qhtocuration,,,B,,,,,6,14788,1,BAO0090o19,vHEMBLu17808,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,
3164,,Autocurwtiog,,,B,,,,,6,3020,1,BAi0000149,dHEMBL627809,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,
3165,,Autocurqtoon,,,B,,,,,6,1742,1,BsO0000919,CuEMnL617810,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,
3166,,Autlcurat9on,1514677.0,,B,,,,,6,17394,1,BAOp000e49,sHEMBL617812,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,
3167,,Autocura4ikn,2199654.0,,B,,,,,6,17394,1,hAi0000221,CHEMnLy17812,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,
3168,,xutosuration,,,B,,,,,6,17394,1,BAO000o240,CnEMBL617812,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3169,,wutocurat8on,,,B,,,,,6,14286,1,BA9000o249,CHEMBL6w78q4,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3170,,Autofurati9n,,,B,,,,,6,14178,1,nAO0o00019,CHEMBL617689,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,
3171,,Aurosuration,,,B,,12394.0,Rattusgofcegicus,,7,14178,1,BAO0o0p019,CjEMBLt17699,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,
3172,,Auhocuratiob,,,B,,34784.0,Rattusnoefegixus,,7,14178,1,BAOo0000w9,CjEMBL6177p0,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,
3173,,Autocjrxtion,,,B,,16323.0,Rattusb8rveglcus,,7,14178,1,BAO00902w3,CgEMBL617i01,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,
3174,,Aufocurayion,,,B,,,,,6,15034,1,BAO000p0q9,CH4nBL617702,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3175,,Aurocjration,,Membranfs,B,,,,,6,1089,1,BzO000o249,CHEMBL617yp3,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,
3176,,Autocurqti8n,,,B,,21901.0,Rat6ysnorv2gicus,,7,1089,1,BsO0000919,CHEMBL61i705,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,
3177,,Autocugatikn,,,B,,,,,6,16532,1,BAl0000323,CHEjBL61u705,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3178,,Aufocurqtion,,,B,,14886.0,4attusnorvefichs,,7,12801,1,fAO0000222,CHEMBL717606,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,
3179,494.0,Autocugat8on,,,B,,,,,6,15194,1,BAO0000220,CHEhBL617708,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,
3180,431.0,Autocurat9om,,,B,,,,,6,15194,1,BAO00902q9,xHEkBL617708,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,
3181,,Aitocurarion,,,B,,,,,6,15194,1,BAO000901i,CbdMBL617709,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,
3182,,Aurocyration,,,B,,,,,6,15194,1,BAO009p019,CHEMBk6q7710,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,
3183,,Aitoc7ration,,,B,,,,,6,15194,1,fAO00o0019,sH4MBL882925,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,
3184,,Au6ocuratiln,,,B,,,,,6,15194,1,BsO000001p,CH4MBL617u11,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,
3185,,Autovurwtion,,,F,,,,,6,10610,1,BAOo000010,fH4MBL617712,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,
3186,,Autofugation,,,F,,31610.0,Rattusgorvegixuz,,7,10355,1,BAp0000o19,CHEMvL627713,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,
3187,,Aufocurarion,,,F,,,,,6,691,1,BAO9000919,CHEMBLu16714,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,
3188,,Autkcurarion,,,F,,,,,6,10611,1,hAO0o00218,CHEMnL61771t,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,
3189,,sutocurayion,,,F,,,,,6,12801,1,nAO0000318,CHrMBLy17716,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,In vivo,
3190,,Augocurat8on,,,F,,,,,6,10609,1,gAO0p00218,CHEMBL61u71u,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,
3191,,Au4ocurwtion,,,F,,,,,6,11454,1,BqO00002q8,CjEMBLu17718,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3192,,zutocutation,,,F,,,,,6,11454,1,BqO0000228,CHEMgp617719,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,
3193,,zutocu4ation,,,F,,,,,6,11454,1,BzO000o218,CmEMBL6q7720,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),In vivo,
3194,,Autlcuratioh,,,F,,159.0,Rattusb0rvegifus,,7,11454,1,BAO0000ww8,CH4MBL617u21,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,
3195,,Autlcuratoon,,,F,,,,,6,11454,1,fAO00p0218,CHEMBL617i2e,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3196,,Auticu4ation,,,F,,,,,6,11454,1,BAO0op0218,sH2MBL617723,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,In vivo,
3197,,qutpcuration,,,F,,,,,6,11454,1,BAO0000w28,dHEMBLu17724,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,
3198,,Ahtocuratiog,,,F,,,,,6,11454,1,BAO0990218,dnEMBL617725,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,
3199,,Autocirztion,,,F,,,,,6,11454,1,BAO090p218,CH3MBL61y726,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,
3200,,Au4ociration,,,F,,,,,6,11454,1,BA0p000218,CHEMnL627727,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3201,,Autofurarion,,,F,,,,,6,11454,1,BAO0000w1i,CHEnBL61772i,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,
3202,,Au6ocurwtion,,,F,,,,,6,11454,1,BAO00o0318,CHwjBL617729,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,
3203,,Autoc7ratjon,,,F,,,,,6,11454,1,BAO0oo0218,fHEMBL6q7730,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,In vivo,
3204,,Autodurqtion,,,F,,,,,6,11454,1,BA900002q8,CHEMBi6w7731,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3205,,Autocurahiog,,,F,,,,,6,11454,1,BAko000218,CHEMfL717732,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,In vivo,
3206,,Autocurs6ion,,,F,,,,,6,11454,1,Bwi0000218,CHEjBL617723,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,
3207,,Ahyocuration,,,F,,,,,6,11454,1,BAO0pp0218,sHEMBL6q7734,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,
3208,,wutoc6ration,,,F,,,,,6,11454,1,BAO000921u,dHEMBL8728u4,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,In vivo,
3209,,Autpcu5ation,,,F,,,,,6,11454,1,BAO00o021u,CHEMvL617635,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,In vivo,
3210,,Augpcuration,,,F,,,,,6,11454,1,gAOp000218,CjEMBL61y736,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,In vivo,
3211,,Autovura5ion,,,F,,,,,6,11454,1,fAO00p0218,CHEMBL617y27,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,In vivo,
3212,,A6tocurwtion,,,F,,,,,6,11454,1,BqO000021u,CHEjBL617y38,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,In vivo,
3213,,Autpcuratjon,,,F,,,,,6,11454,1,BAO00o02w8,CHEMBLyq7739,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,
3214,,A8hocuration,,,F,,,,,6,11454,1,BAO9p00218,CH4MhL617740,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,
3215,,xutocugation,,,F,,,,,6,11454,1,BAO0p00e18,dHEMBL617841,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,
3216,,Auyocurstion,,,F,,,,,6,11454,1,BAO00o0217,CHEMBL61ui42,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,
3217,,Autovurxtion,,,F,,,,,6,11454,1,BAi000o218,CHEMBk617i43,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,
3218,,Ajtocurxtion,,,F,,,,,6,11454,1,BAO090021i,CHEMBL6qu744,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,
3219,,Auticiration,,,F,,,,,6,11454,1,BAO0000qq8,CHfMBL616745,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,
3220,,Autoc8rwtion,,,F,,,,,6,670,1,fAO0090218,CHEMBp517746,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,
3221,,Autocutqtion,,,F,,,,,6,670,1,BAO9o00218,CHEMfL61774y,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,
3222,,Aufocuratiog,,,F,,,,,6,10321,1,BAO0009217,fHEMBL617648,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,In vivo,
3223,,Aytocura6ion,,,F,,,,,6,10321,1,gAOo000218,CHEMBL6w9909,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,In vivo,
3224,,Aut9curati8n,,,F,,,,,6,10321,1,hAO0000228,dHEMBL6189w0,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,In vivo,
3225,,Auticurxtion,,,F,,,,,6,10321,1,BzO0o00218,CHfMBo618911,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,In vivo,
3226,,Aitocurati0n,,,F,,,,,6,10321,1,nA00000218,vHEMBL619912,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,In vivo,
3227,,Autoxura6ion,,,F,,,,,6,10322,1,BAO0pp0218,CHdMBL618813,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),In vivo,
3228,,qutocuratioh,,,F,,,,,6,15412,1,gAk0000019,vHEMBL718914,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3229,,Au6oc6ration,,,F,,,,,6,15412,1,BAO0090018,CHEMBL6189qy,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3230,,Augocuratioh,,,B,,54017.0,Rattksnorvegidud,,7,15412,1,Bsl0000223,CHEMBL618826,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,
3231,,xutkcuration,,,F,,,,,6,15412,1,nAO0000p19,CgEMBL628917,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,
3232,,Inteekediate,5478069.0,,B,,,,,7,15412,1,BwO0000222,CHrMBL617918,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,
3233,,Autocura6i9n,,,B,,12451.0,Ragtusnordeglcus,,7,15412,1,BAO0000p1o,CHEMBL5w8919,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,
3234,,sutocurati8n,,,B,,15862.0,Rattuwnorv2vicus,,7,17394,1,BAO0o0p019,Cu4MBL618920,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,
3235,,Auticuragion,,,B,,,,,6,12457,1,fAO0009223,CHEMnL628921,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,
3236,,wutocurxtion,,,B,,,,,6,12457,1,BAO00090q9,CHEMBL6w8i22,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,
3237,,A8tocurwtion,,,B,,,,,6,12205,1,BAO000op19,CHEMBL718922,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,
3238,,xutocurxtion,,,B,,,,,6,14532,1,BAO9p00019,CgEhBL618924,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,
3239,,Aurkcuration,,,B,,,,,6,1122,1,BAlo000019,xHEMBL61o925,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,
3240,,Autosurqtion,,,B,,,,,6,5094,1,BAO09000w9,CHEMvL617926,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3241,,Interm3d9ate,2036668.0,,F,,8642.0,Caviaporsdllus,,9,809,1,BAO900022q,fHEMBL618i27,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,
3242,,Inte3mediatw,4011628.0,,F,,41923.0,Cav8a9orcellus,,9,809,1,BAO000922q,xHEMBL628928,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,
3243,,Igtermediatw,1045155.0,,F,,30761.0,Czviaporcell7s,,9,14290,1,BAO0p00q21,CnEMBL618i29,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,
3244,,Inte5m2diate,5419824.0,,F,,1952.0,Cwviaporcellhs,,9,14290,1,hAO00o0221,CgsMBL618930,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,
3245,,Intrrmeeiate,929712.0,,F,,15170.0,Csvialorcellus,,9,14290,1,BAl00002w1,CjEMgL618931,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,
3246,,Intedmediafe,3528068.0,,F,,8819.0,Caviaporceolux,,9,14290,1,nAOo000221,xHEMBp619594,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,
3247,,Intwrmedia5e,2009294.0,,F,,20669.0,Cavlapofcellus,,9,14290,1,BAO00o0e21,CHEMBL62959t,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,
3248,,Igtermefiate,745365.0,,F,,28133.0,Cavisporcelpus,,9,13961,1,fAO00p0221,CHEMhL619496,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,
3249,,Interkeeiate,2569862.0,,F,,12936.0,Cadiqporcellus,,9,13961,1,gAO0000121,CHsMBL61975y,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,
3250,,In6ermed9ate,3812233.0,,F,,23917.0,Cav8aporcell6s,,9,809,1,gAO00002e1,CHEMBLu197r6,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,
3251,,lntermesiate,515349.0,,F,,63365.0,Csviap0rcellus,,9,809,1,BAO000p231,sH3MBL619757,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,
3252,,jntermediare,3155845.0,,F,,1099.0,Caviapofvellus,,9,809,1,BqO00002e1,CHEMBp6197y8,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,
3253,,kmtermediate,2281738.0,,F,,20279.0,Caviwpo5cellus,,9,14290,1,BxO000022q,CnEMBL619769,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,
3254,,Intermesiaye,2644349.0,,F,,18480.0,Cav9aporcellua,,9,14290,1,BAl000022q,CHEMBLy1i760,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,
3255,,8btermediate,3159400.0,,F,,22578.0,Caviaporc4lous,,9,14290,1,BAp00002w1,CbEMBL618761,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,
3256,,Intermeduahe,2925154.0,,F,,40021.0,Cagiapodcellus,,9,14290,1,BA9000022q,CHEMBL519862,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,
3257,,Inyermediats,227356.0,,F,,11822.0,daviaporcelluc,,9,14290,1,BqO000o221,CHEMBLu10763,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,
3258,,Inrermewiate,3635018.0,,F,,33849.0,Cwviaporcdllus,,9,14290,1,vAO000022q,CHEjBL617968,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,
3259,,Inrermwdiate,,,B,,2890.0,Caviqporcelius,,9,15034,1,gAO0p00357,CHEMhL617879,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,
3260,,Ihtermedia4e,2802963.0,,B,,7726.0,Cav7aporvellus,,9,5094,1,BAO009024o,CtEMBL882916,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,
3261,,Intermex7ate,2440038.0,,B,,12057.0,daviaporcsllus,,9,5094,1,BxO9000249,fHEjBL617870,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,
3262,,9ntetmediate,723008.0,,B,,9899.0,Cav7alorcellus,,9,5399,1,nAO000o357,CyEMBL617971,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,
3263,,Intfrjediate,4480535.0,,B,,1907.0,Caviapirsellus,,9,17394,1,nAO0000257,CHEMBL627882,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,
3264,,Ihtermesiate,3323236.0,,B,,34165.0,Caviapofcelius,,9,17394,1,BAk0009357,CtwMBL617873,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,
3265,,Interm3d7ate,3835072.0,,B,,21492.0,Caciaporsellus,,9,17394,1,BAOo00o357,CHEMhL617873,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,
3266,,Inyerhediate,6741357.0,,F,,18522.0,Cwviaporcellks,,9,13961,1,vAk0000221,CH4MBL610067,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,
3267,,Intermeeixte,1074509.0,,F,,5477.0,Caviaporceplux,,9,13961,1,BzO9000221,CHEMBLu19069,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,
3268,,Intfrmediaye,119027.0,,F,,25834.0,Caciapircellus,,9,13961,1,BAO0o00q21,fHEMBi619069,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,
3269,,Ibrermediate,,,B,,4394.0,Caviqporceplus,,9,16946,1,BAO000oe57,CtEMBLt19070,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,
3270,,In5ermedia4e,,,B,,3780.0,savialorcellus,,9,16946,1,nAO0o00357,CHfMBk619071,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,
3271,,Ingerhediate,,,F,,12063.0,Cwvia9orcellus,,9,15034,1,BAO0p0p019,CHEMhL610072,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,
3272,,Intermwdia5e,,,F,,28070.0,vavixporcellus,,9,15034,1,vAp0000019,CHEjBL629073,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,
3273,,Intermeriatr,,,F,,10629.0,daviaporcellue,,9,12918,1,BqO000001i,CHEMfL719074,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,
3274,,Interjrdiate,,,B,,2049.0,Caviaporc4olus,,9,16946,1,gAO0000347,CHEMBp629075,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,
3275,,Inhermediage,2010107.0,,B,,236.0,Caviaporcwklus,,9,17394,1,BsO000035y,CHfMBL6w9076,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,
3276,,Inyermediatf,2595626.0,,B,,17452.0,Caciqporcellus,,9,15034,1,fAO0000347,CHEjBL619067,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,
3277,,on6ermediate,2833324.0,,B,,47762.0,Caviapordelkus,,9,5094,1,BAp0000149,Cn4MBL619078,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,
3278,,Intrrmeduate,2524891.0,,B,,29054.0,Csviaporcfllus,,9,5094,1,BAO0o09249,CH2jBL619079,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,
3279,,Interm3riate,144122.0,,B,,26681.0,faviapotcellus,,9,17358,1,BAO0000q11,CHEMBLuw9080,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,
3280,,Exper5,,,B,,31995.0,Cafialorcellus,,9,12953,1,BqO0000e57,CHEkBL619082,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,
3281,,Intfrmediste,,,B,,13739.0,Cxviaporcell6s,,9,12953,1,BAO00o03t7,CH4hBL619082,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,
3282,,lnterkediate,,,B,,20009.0,Cavisporcelljs,,9,12953,1,BAl000o357,CHEMfL61908e,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,
3283,,Ibtermsdiate,,,B,,2176.0,Cwviaporfellus,,9,12953,1,BAO9000257,CHEMvL6q9084,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,
3284,,Intermesiare,1087207.0,,F,,30096.0,Caviaporcfllks,,9,273,1,hqO0000221,CHEMBL850297,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,
3285,,Inyermediatw,1860066.0,,F,,17257.0,Cavualorcellus,,9,12918,1,gAO0p00221,xHEMBL629085,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,
3286,,Intermedkatr,1721560.0,,F,,7096.0,Caciaporceolus,,9,12919,1,BAO9900221,CHEMBk629086,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,
3287,,untermediafe,711527.0,,F,,668.0,Cafizporcellus,,9,273,1,vAOp000221,CHEMgL610087,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,
3288,,Intermsdiat2,1688034.0,,F,,7550.0,Caviapordellys,,9,273,1,BsO00o0221,CyEMBp619088,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,
3289,,Inhermeciate,,,B,,6492.0,Caviaporcsllud,,9,13181,1,hAOp000357,CHEMBLtw9089,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,
3290,,xutociration,,,B,,20037.0,Caviaporceklux,,8,13181,1,BAO00003yi,CHEMBk61o090,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,
3291,,lnhermediate,,,F,,8953.0,Cavia9orcelluw,,9,15034,1,vAO0000010,CHEMfL61909w,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,
3292,,Intwrmedia4e,,,B,,16581.0,Caviaporc4lkus,,9,5033,1,BsO00p0357,CudMBL619092,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,
3293,,Intdrmedia5e,,,B,,32987.0,Caviqporcelluq,,9,1980,1,BAO00000wi,CHEMBL6w90i3,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,
3294,452.0,Autoxuratikn,,,B,,251.0,Caviaporfellux,,8,13181,1,BqO00o0219,CjEMBL619p94,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,
3295,,Intermed7at2,,,B,,4787.0,Czviaporcelous,,9,14287,1,vAO0000029,CHwMBL61909t,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,
3296,,Intsrhediate,,,B,,16237.0,daviaporc2llus,,9,1317,1,BzO000035i,CHrjBL857988,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,
3297,,Intermediqt2,,,B,,6557.0,Caviqplrcellus,,9,15316,1,BAOo000r57,fHEMBp619096,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,
3298,,Intermsd7ate,410897.0,,B,,11438.0,Caviapkrxellus,,9,16429,1,hAO9000357,CHEMBL51909i,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,
3299,,kngermediate,1840165.0,,B,,8879.0,Caviaporcelp6s,,9,14818,1,BAO09002q1,CH3MBL629098,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,
3300,,Imtermeeiate,,,B,,17839.0,vaviaporcelluc,,9,15194,1,BAO0000ry7,CH3MfL619751,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,
3301,,Intermefiaye,,,B,,1497.0,savoaporcellus,,9,15194,1,BAO900035u,CHEMBp61975w,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,
3302,,Inyermeduate,5226955.0,,F,,15380.0,Caviapircellhs,,9,13961,1,BxO0900221,CHEhBL865096,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,
3303,,Autoc7ratioh,,,B,,,,,8,5486,1,BzO0900357,CHEMBL6qi004,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,
3304,,Autoc7ra4ion,,,B,,,,,8,16209,1,nAO00003t7,CjEMBL619006,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,
3305,,Aut8c8ration,,,B,,,,,8,17085,1,BA0p000019,CHEMBL619po6,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,
3306,831.0,wutocuratipn,,,B,,,,,8,4199,1,BAO000011o,CH2MBp619007,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,
3307,,Auyocuratiom,,,B,,,,,8,15146,1,BAO000045i,CbEMvL619008,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,
3308,,Ajtocuratiog,,,B,,,,,8,5213,1,BqO0000356,dH2MBL619009,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,
3309,697.0,A8tocu5ation,,,B,,,,,8,4829,1,BAO0o00w19,CHEMBL61p01p,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,
3310,,Auticurati8n,,,B,,,,,8,17358,1,vAOp000357,dH4MBL619011,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,
3311,,Autocuratl9n,,,B,,,,,8,17358,1,BA8000035i,CHEMgL619o12,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,
3312,,Autofuratjon,,,B,,,,,8,16946,1,hAO0900219,CH4MBL619o13,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,
3313,,Auhocjration,,,B,,,,,8,17358,1,vsO0000357,CHEMBL719o14,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,
3314,,Autlcuratipn,5678895.0,,F,,,,,8,268,1,BsO000p019,CHEMBL85ut03,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,
3315,,Autoc65ation,5557022.0,,F,,,,,8,268,1,BAO0p00p19,CjEMBL61i015,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,
3316,,Autocu5atiob,,,B,,,,,8,15086,1,BAOo00035u,CHEMvL618016,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,
3317,,Ajtoc7ration,2467907.0,,B,,,,,8,14875,1,BAO90o0221,CnEMnL619017,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,
3318,,Autock5ation,1419071.0,,B,,12254.0,Sussvrofa,,8,13267,1,BA99000221,CgEMBL629018,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,
3319,,Autocu4atiog,,,B,,564.0,Oryctolaguecjgicul6s,,8,13047,1,BAO00p00q9,CHEhBi619019,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,
3320,,Ecpert,,,B,,14917.0,Rattusnorvsgucua,,9,1650,1,BwO00o0357,CHEMBL61903o,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,
3321,,Aitoc8ration,,,F,,,,,8,567,1,BAO0o0o019,CHEjBL619o21,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3322,,Autpcurarion,,,B,,,,,8,17358,1,BAOo000367,CHEkBLu19022,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,
3323,,zu5ocuration,,,B,,,,,8,188,1,BA90090357,CHEMBL719923,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,
3324,,Autovuratiln,,,F,,,,,8,670,1,BAO00p9019,CHEMBk619014,,lntrinsic activity relative to 5-HT receptor,,
3325,,Autocuta4ion,,,F,,,,,8,204,1,BAp0000p19,xHEMBk619025,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,
3326,,Edpert,,,F,,,,,8,1946,1,BAi9000019,CHEMBLy1902u,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,
3327,,Autocutatioh,,,F,,,,,8,6398,1,BAO00o0p19,CHEMBi719027,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,
3328,,Autocuraruon,,,F,,,,,8,6398,1,BqO0o00019,CHEMBL519o28,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,
3329,,Autpcurstion,,,F,,,,,8,17358,1,BAO09000q9,sHEMgL619029,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,
3330,,Autosuratiln,,,F,,,,,8,6398,1,BxO0000919,CHEMBLt19o30,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,
3331,,Expe5t,,,B,,,,,8,11752,1,BAOp0o0357,CHEnBL619032,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,
3332,,Autocurat90n,,,F,,,,,8,809,1,fAO0000o19,sHEMBL61903q,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,
3333,,Ex9ert,,,B,,39457.0,Ratgusnorvrg8cus,,9,14178,1,vAO000035i,CHrnBL619033,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,
3334,,Autoci4ation,,,B,,,,,8,567,1,BA800003y7,CHwMBL619035,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3335,,Aut0c6ration,,,B,,,,,8,1946,1,BAO0009356,CHEMBL6199w5,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,
3336,,Autocu3ati9n,,,B,,,,,8,1946,1,BA90000r57,CHsMBL6q9036,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,
3337,,Ecpert,,,B,,23835.0,Rattusnodv3gicks,,9,13961,1,BA80000o19,dHEMBL61903i,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,
3338,,qutocurstion,249395.0,,B,,,,,8,6238,1,BAO9000q49,CbEhBL619038,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,
3339,,Autoxurqtion,,,B,,,,,8,14290,1,hAO00o0249,CHEnBL61903p,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,
3340,,Expery,,,B,,,,,8,14290,1,BsO00002r9,CHEMBL519o40,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,
3341,,Eapert,533053.0,,B,,46419.0,gattusnorv2vicus,,9,809,1,BAO009001o,CHEMBLt19941,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,
3342,,xutocura6ion,7055345.0,,B,,,,,8,1578,1,BAO0o0001p,CHEkgL619042,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,
3343,,Expery,624296.0,,B,,,,,8,16709,1,BA00o00249,Cu4MBL619043,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,
3344,,Ex0ert,2890716.0,,B,,,,,8,1946,1,nAO0090019,CHEMBL610p44,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,
3345,,Expe5t,422927.0,,B,,,,,8,15253,1,gqO0000249,CHEMBpy19045,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,
3346,,4xpert,467360.0,,B,,,,,8,4535,1,BAO9090249,CHrMBL61i046,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3347,,Expe3t,,,B,,,,,8,13961,1,BzO0000e49,CH4hBL619047,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,
3348,,Autocurahiom,787639.0,,F,,,,,8,17358,1,BA9o000221,CHEMBL6w904u,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,
3349,,Auticurztion,,,F,,,,,8,15847,1,BAOp00o019,CjEMBk859398,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,
3350,,Autocurahioj,,,F,,,,,8,15847,1,vAO000001o,CH4MBL619040,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,
3351,,wu6ocuration,,,F,,,,,8,670,1,nAO00o0019,CuEMBL867886,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,
3352,,Aufoduration,,,F,,,,,8,670,1,BAO0000p29,CHwMBL619059,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,
3353,,Ajtocuratiob,,,F,,,,,8,1317,1,nqO0000019,CHEhgL620591,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,
3354,,dxpert,,,B,,17334.0,Raytusnodvegic6s,,9,12936,1,BA80000347,CHEhBL630592,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,
3355,,2xpert,361754.0,,B,,,,,8,4535,1,BAO0009e49,CH2MBL720593,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3356,,Ecpert,,,F,,17479.0,Ray6usnorv4gicus,,9,14424,1,BAk0o00019,CmEMBLy20594,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,
3357,,Experg,,,F,,,,,8,14424,1,hAO0o00019,CH2MBL875979,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,
3358,,Expeet,,,F,,,,,8,14424,1,BAO0p00p19,CmEMBL620495,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3359,,fxpert,,,F,,8002.0,Raytuanorvegicjs,,9,14424,1,BxO0009019,CHEMgL6205i6,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,
3360,,Auhocueation,,,F,,,,,8,14424,1,hAO9000019,CH2MBL620697,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,
3361,,Ex9ert,,,F,,,,,8,14424,1,BAl0009019,CmEMBL720598,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,
3362,,Ex0ert,,,F,,,,,8,14424,1,BAO00003q8,CHEMBL62p59o,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,
3363,,Aut0xuration,,,F,,,,,8,14424,1,hAO0009019,CHEhBL620609,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3364,,qutocurztion,,,F,,17098.0,Rattjsnlrveticus,,8,1980,1,BAO000o01o,CHrMBL620t01,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,
3365,,Autocurzt7on,,,F,,,,,8,4639,1,BAO00p001o,CbEhBL620602,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,
3366,,Autocurato0n,,,B,,,,,8,17358,1,BAO000p356,CbdMBL620603,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,
3367,,Au6ocurarion,,,B,,,,,8,17358,1,BAO090035u,CHEMfL62o604,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,
3368,,Aitocurqtion,,,B,,,,,8,17358,1,hAO0o00357,CHfMBL6q0605,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,
3369,,Aytocuratipn,,,B,,,,,8,1558,1,BAO009035u,CHEjvL620606,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,
3370,,Autocurxtipn,,,F,,,,,8,17358,1,BzO0000p19,CHrMBL620697,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3371,,A85ocuration,,,B,,,,,8,16117,1,fAO0090357,CHEMBL6w0607,,In vitro binding affinity towards 5-HT4 receptor was determined,,
3372,,zurocuration,,,F,,,,,8,17358,1,BAl000o019,CjEMBL6q0609,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3373,,Autocu3qtion,,,F,,,,,8,17358,1,BAOo0o0019,CHEhBL720610,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,
3374,,Aurovuration,,,B,,,,,8,17358,1,BAO00p035u,CHEMBL6206qw,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,
3375,,Ajtocuratjon,,,B,,,,,8,17358,1,BA9000o357,CHEMBL62o622,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,
3376,,Autocurztiog,,,B,,,,,8,17358,1,BAk0000257,CHEMBLt2o613,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,
3377,,Autoc64ation,,,B,,,,,8,17358,1,BAO0o00e57,CHEMBp630614,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,
3378,,Ecpert,,,B,,,,,8,1274,1,BAk00p0357,CHEnBL6w0615,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,
3379,,Autockratiob,,Braijmembranrs,B,,,,,6,10728,1,BAO0900q49,CHdMBp857075,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,
3380,,Autovuratiln,,Brainmdmbranee,B,,,,,6,11695,1,BAO0900e49,CHEMBL6206wu,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,
3381,,wutocura6ion,,Brainmemb4ajes,B,,,,,6,11695,1,BAko000249,sHEMBL619t11,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,
3382,,xutocuratkon,,,B,,,,,6,12490,1,BAO0p000w9,CH2MBL61941w,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,
3383,,Autovurat7on,,,B,,6597.0,tattusgirvegicus,,7,11828,1,Bwl0000019,CHEMBi61941e,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,
3384,,Autocura4ioj,252054.0,,B,,,,,6,12253,1,gAO0009221,fHEMBL6w9414,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,
3385,,sutocura4ion,,,B,,,,,6,10561,1,BAOoo00019,CH2MBL61o415,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,
3386,,Autocyra4ion,,,B,,,,,6,10561,1,Bw90000019,CHEMBL719316,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,
3387,,Augocurati8n,,,F,,,,,6,14432,1,Bzp0000019,sH3MBL619417,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,
3388,,sut8curation,,,B,,25431.0,Ratfusnorvegixuw,,7,12936,1,BAO0900q23,CHEMBL619t17,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,
3389,,Autociratiog,,,B,,1152.0,Ratfusnorbeg9cus,,7,1274,1,BAk000p223,CHEMBo6q9419,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,
3390,,Autocyfation,,,B,,,,,6,1980,1,BAOo0o0019,vHEMhL619420,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,
3391,,Autocurati8b,,,B,,,,,6,670,1,BAO00003e9,CH3MBL719421,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,
3392,,Autocirati8n,,,B,,25304.0,Ra4tushorbegicus,,7,968,1,BAO0009010,CtrMBL619422,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,
3393,,Autocu3ahion,,,B,,,,,6,14287,1,BAO00p00q9,CHEMBL6294e3,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,
3394,,Ait8curation,,,B,,,,,6,567,1,BAOo000919,CHEjBLi75080,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,
3395,,Autocurayioh,,,B,,,,,6,13267,1,BAO0900029,CHEMBLt1942r,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,
3396,,Autocirat8on,,,B,,,,,6,14826,1,nAO00002r9,CHEMBp719425,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,
3397,,Autocurari8n,,,B,,,,,6,15194,1,BzO0000323,CHEMBp6w9426,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,
3398,,Aurocuratikn,,,B,,,,,6,15194,1,BAO0990223,CHEMBo629427,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,
3399,,qutocuratkon,,,B,,44442.0,Rattusnkrvebisus,,7,10394,1,BAO00092w3,CHEMBL6w96t5,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,
3400,,Exper4,,,B,,,,,9,13657,1,BAO0p00240,CH2MfL619646,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,
3401,,Au6ocurayion,1032021.0,,F,,,,,8,1879,1,BAO90002e1,CyEMBL61964y,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,
3402,,Au5ocugation,,,F,,,,,8,1879,1,BzO0000018,CHEMBLt10648,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,
3403,,Aufoc7ration,,,F,,,,,8,1879,1,BAO0000p1p,vHEMBL519165,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,
3404,,sutocuratoon,,,F,,,,,8,204,1,gAO000021u,CyEMBL620718,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,In vivo,
3405,,Autochratiog,,,B,,,,,8,1879,1,BAO00009w9,Cj2MBL872924,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3406,,sutocurxtion,,,B,,,,,8,1879,1,BAO0000w5u,CH3MBp620720,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3407,,zutocurat7on,,,B,,,,,8,1879,1,BsO00000w9,CnEMBL6207w1,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3408,,Autodurxtion,,,B,,,,,8,1879,1,BA00000919,CHEjBL62p722,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,
3409,,Autocu4a4ion,,,B,,,,,6,10641,1,BwO0o00019,CHEjBLt20723,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,
3410,,Autocueatiob,,,B,,,,,8,773,1,BsOp000019,vHEMBL6q0724,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3411,,xutosuration,,,B,,,,,6,11952,1,BwO0p00249,CHEMBL72o725,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,
3412,,sutochration,,,F,,19295.0,Rathusnorvegix6s,,9,14145,1,nAO000o019,CHEMvL6207w6,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,
3413,,Exp4rt,,,B,,,,,8,17066,1,BAOo0003r7,fHEMBL6207w7,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3414,,Autocurxtuon,,,B,,,,,4,6398,1,BAO000pe23,CHEMBL610i28,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,
3415,,Ahtociration,,,B,,,,,0,10321,1,nAO000001o,CHEMBL6eo729,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3416,,Aitocugation,,,F,,,,,4,511,1,vAO00000q9,CHEMBi858e88,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,
3417,,Autoxurwtion,,,B,,,,,4,4639,1,BAp0900223,dHEMBk620730,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,
3418,,Aktocurati0n,,,B,,,,,4,4639,1,BAOpo00223,CHEhBL62p731,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3419,,A7tocuratoon,,,F,,3742.0,Caviaporsellue,,4,4639,1,vAO0009019,CHEkBo620732,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,
3420,,Auyocurati0n,,,F,,28744.0,Cqviapogcellus,,4,4639,1,BAO00p9019,CHEMBL6280r2,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,
3421,,Autofuratkon,,,F,,9528.0,Caviapprcelius,,4,4639,1,BAO000p01i,CHEMBL6189t3,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,
3422,,A6tocuratuon,,,B,,,,,4,1558,1,BxO0900223,CHEMBLyq8044,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3423,,Autocurat9ln,,,F,,,,,4,268,1,BAO000p0q9,CHEMBL618pr5,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,
3424,,wutocurztion,,,B,,,,,4,2474,1,BsO0000e23,xHEMBL6w8046,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,
3425,,Autocurat7og,,,F,,,,,4,5067,1,BAO0p0001i,dHEMBL618p47,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,
3426,,Auhocufation,,,F,,,,,4,5067,1,BAOo000p19,CHEMBL87598r,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,
3427,,A7tocuratiin,,,F,,,,,4,5067,1,BAO000o0q9,CHEMBL618938,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,
3428,,Au6oc8ration,,,B,,,,,4,5067,1,BAO09o0223,dHEkBL618049,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,
3429,,Autoc7rat7on,,,F,,,,,4,5067,1,hAO0009019,sHEMBL6197t4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,
3430,,Augociration,,,F,,,,,4,5067,1,BqO0000029,CHEMBL61o76t,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,
3431,,Autocutatioh,,,F,,,,,4,5067,1,BAO9000919,CHEMBL619u6t,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,
3432,,Autochrati9n,,,B,,,,,4,5067,1,BAO00002qe,CHEMBL6qp767,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,
3433,,Autoxurwtion,,,B,,,,,4,5067,1,BAp0090223,CnEMBLt19768,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,
3434,,Autocurati0h,,,F,,,,,4,5067,1,BqOo000019,CHEkBL61i769,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,
3435,,Autocueat8on,,,B,,,,,4,5067,1,BA00000233,CHEMgL61p770,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,
3436,,Autocura5ioh,,,B,,,,,4,5067,1,BAl0000233,CgEMBL6w9771,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3437,,Au6ocuratikn,,,B,,,,,4,14331,1,BAO00o021o,CgEMBL619872,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,
3438,,Aitpcuration,,,B,,,,,4,5067,1,BAOp000213,CHEMBp619u73,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,
3439,827.0,Aut0ckration,,,B,,,,,4,6179,1,BzO00p0219,CuEMBL619773,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,
3440,,Autocurariog,,,B,,,,,4,4265,1,gAO9000019,CHEMBL875p8r,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,
3441,566.0,Autof6ration,,,B,,,,,4,4265,1,vAO0000218,CHEMBL620i28,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,
3442,,Autoduratiob,,,B,,,,,4,17358,1,nAO000022e,CHEMBL6q8q27,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3443,,Autoc8ratiob,,,B,,,,,4,17358,1,nAO000p223,CtEMBLu18128,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,
3444,,Augocuratiog,,,B,,,,,4,13628,1,BAO00o0w19,CHdMBL618128,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,In vitro,
3445,,Aktovuration,,,B,,,,,4,4612,1,BAO0op0223,CHEMBL7181r0,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3446,,Autoc8rat9on,,,F,,,,,4,17358,1,BsO00p0019,CHEhBi618131,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,
3447,,sutoduration,,,F,,16573.0,Caviaporceli6s,,4,4639,1,BAO0900029,CtEMvL618132,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,
3448,,Autocufstion,,,F,,51646.0,Caviaporceoljs,,4,4639,1,BAO090001p,CHEMvi618133,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,
3449,,Aytocura4ion,,,F,,10152.0,Cadiaporcelluc,,4,4639,1,BAO0op0019,CbEMBLt18134,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,
3450,,Ahtocurat7on,,,F,,21381.0,Caviap0rc2llus,,4,4639,1,gAOp000019,xHEMBL61o135,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,
3451,,Aurockration,,,B,,,,,4,511,1,BAO0909223,CHEjBL618135,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,
3452,,Autoc6ratioh,,,B,,,,,4,1479,1,BAO00p9223,sHEMBL618127,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3453,,Ahtocura4ion,,,B,,,,,4,1317,1,BAO00p02w3,CHEMhLt18138,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,
3454,,Autoc6ratlon,,,B,,,,,4,12146,1,Bqp0000223,CHEMBo61u139,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,
3455,,Autocurstiob,,,B,,,,,4,12146,1,BzO0009223,CHEMBk6w8140,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,
3456,,Aht9curation,,,B,,,,,4,13969,1,BAO0o002q3,CHEMBL629141,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,
3457,,Expe3t,,,B,,,,,8,13392,1,BAO9p00357,CbEMBL883478,,Binding affinity for 5-hydroxytryptamine 2C receptor,,
3458,,Autkcutation,,,B,,,,,6,13392,1,BAO0900q23,sHEMhL618142,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3459,,Au58curation,,,B,,,,,8,14159,1,BAO0009e57,CHEMBL617q43,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,
3460,,Autosurztion,,,B,,,,,8,1558,1,vAO0000347,CnEMBL6181r4,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3461,,Aurocurafion,,,B,,,,,8,16655,1,BAi0090357,dHEMBL718145,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,
3462,,Au4ocuratioj,,,B,,,,,4,13020,1,BAO0000234,sHEMhL618146,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3463,,Auhocura5ion,,,B,,,,,4,13021,1,BxO0009223,CgEMBL617147,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,
3464,,Autocudatjon,,,B,,,,,4,13020,1,BAOpo00223,CHEnBLu18148,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3465,,qutocurarion,,,B,,,,,8,10321,1,BzO0000029,CHEhBL61u149,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3466,,Autlcurwtion,,,B,,,,,8,15818,1,BxO0000e57,CHEMBLi72o27,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3467,,Autocutarion,,,B,,,,,8,15818,1,BsO00003t7,CmEMBL618140,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3468,,Autoc8rarion,,,B,,,,,8,17358,1,BAO00pp357,CmEMBL618141,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3469,,Aut0c6ration,,,B,,,,,8,2222,1,BAO00o035u,CHEhBL875o94,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
3470,,Autocurstioh,,,B,,,,,8,10322,1,BAOp00001o,CHEMBL61814w,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3471,,Aktocurati9n,,,B,,,,,8,16117,1,BAl0000r57,CtEMBL61815e,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3472,,Au6ocurayion,,,B,,,,,8,17200,1,BxO0000w57,fuEMBL618888,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,
3473,,A8tocurwtion,,,F,,,,,8,17358,1,BqOp000019,CHEMBL6188io,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,
3474,,Autocurxrion,,,B,,,,,8,16700,1,BAO090035i,CHEMBL7188p0,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,
3475,,Autocurafi0n,,,B,,,,,8,1980,1,BAOo000029,CuEMBL6w8891,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,
3476,,Autlcuratkon,,,B,,,,,8,1980,1,BAp0o00019,vHEMBk619054,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,
3477,,Autkcurayion,,,B,,,,,4,12409,1,hwO0000223,CHEMBL51p055,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,
3478,,xutocutation,,,B,,,,,8,4365,1,BA00009357,CHEMhL619o56,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3479,,Autocu5atioh,,,F,,,,,8,4365,1,BAl0o00019,CHwMBL619957,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,
3480,,Autocurztiob,,,B,,,,,8,4365,1,BzO0900357,CHsMBL6q9058,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3481,,Experf,,,F,,14687.0,Ratrusnordegicjs,,9,6769,1,BAO00o0w19,CHEMBL61906i,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,
3482,,Expe4t,,,F,,28058.0,Ra4tusnoegegicus,,9,6769,1,BqO000o219,CHdMBi619060,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,
3483,,Exlert,,,F,,55970.0,Rattusjorgeficus,,9,6769,1,BAl00002w9,CmrMBL875095,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,
3484,,9nterjediate,4822315.0,,F,,11845.0,Caviaporcelliq,,9,809,1,nAp0000221,CHEMfL619051,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,
3485,,9nterkediate,2987964.0,,F,,10891.0,Cav9apordellus,,9,809,1,nAO00002q1,CtEMBo619062,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,
3486,,Intermdd9ate,,,F,,14333.0,Cavia0orxellus,,9,14290,1,nAO000001i,CHEMBL61905r,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,
3487,,Intrrmediste,2615310.0,,B,,1807.0,saviaporxellus,,9,17358,1,BwO000022q,CHEMfL629064,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,
3488,,Intf5mediate,,,B,,27360.0,vafiaporcellus,,9,17358,1,BAO00o03r7,dHEMBL61906r,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,
3489,,Ijtegmediate,1212451.0,,B,,48830.0,Caviaporcelkux,,9,17358,1,BsO0000321,CH3MBL6190t6,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,
3490,,Au5icuration,6026621.0,,B,,,,,8,17386,1,BAO090022q,CH3MBL61i775,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3491,,Ayt0curation,,,B,,,,,8,3269,1,BAO009035i,CHfMvL619776,,Affinity against 5-hydroxytryptamine 7 receptor,,
3492,,Autocu4ayion,,,B,,8437.0,Cxviaporceolus,,4,7721,1,BA8o000224,dHEMBL619877,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,
3493,,Autochrat8on,,,B,,27854.0,Csviaporcellys,,4,7721,1,BA90000324,CH2MBL619777,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,
3494,,A7tocurafion,159365.0,,B,,6722.0,Cagiaporcelous,,4,9117,1,BAO0p00222,CHEMBLt197y9,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,
3495,,Aut8curqtion,,,B,,30802.0,Caviap9gcellus,,4,7721,1,BqO0009224,CgEMBL6w9780,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,
3496,,zutocurxtion,,,B,,1483.0,Cavuaporcfllus,,4,7721,1,BAO9000124,CHEMvL619w66,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,
3497,,A6rocuration,,,F,,15816.0,Czvisporcellus,,4,15796,1,BAO0000p1i,CHEkBi619167,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,
3498,,Autocurzgion,,,F,,17659.0,Cav7aporcelkus,,4,15796,1,BAkp000019,CHEMvL619268,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,
3499,,Experf,816091.0,,B,,20626.0,Homosal7ens,,9,15650,1,vAO0090219,vHsMBL619169,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,
3500,,Espert,4545566.0,,B,,3699.0,gomozapiens,,9,15650,1,BAO90002q9,CHEnBL629170,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,
3501,,wutocurati8n,,,F,,21109.0,Homksaliens,,5,6866,1,Bzk0000019,Ct4MBL619171,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,
3502,,2xpert,50585.0,,F,,10245.0,Homosap8ehs,,9,15650,1,BAO00092w9,CHEMBL6192y2,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,
3503,,Autkcuragion,,,B,,6665.0,Musmusxulhs,,0,10063,1,BAl0900019,CHEMBL6291u3,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,
3504,,Autosuratiom,,,B,,15524.0,Muemusculis,,0,12665,1,BAk000p019,CHEjBL61p174,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,
3505,,xuyocuration,,,B,,,,,4,7504,1,BAO90000q9,CHwMBL619275,,5-hydroxytryptamine receptor binding affinity was determined in rats,,
3506,,sutocueation,,,B,,,,,4,7504,1,BA80000324,CHEjBL618176,,Binding affinity at rat 5-hydroxytryptamine receptor.,,
3507,,Au5ocuratipn,,,B,,,,,4,7038,1,fAp0000019,CHEkBL619176,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,
3508,,Aut9curatiln,,,B,,,,,4,7626,1,BAO9000234,CHEhvL619178,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,
3509,,Auyocurxtion,,,B,,,,,4,7626,1,BA80900224,CHEMBL6291u9,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,
3510,,Autocufatiog,1493937.0,,F,,,,,4,7185,1,BAO0090029,vHEMBL6191u0,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,
3511,,Autocurztiob,3762918.0,,F,,,,,4,7185,1,BqO0000018,CHEMnL619q81,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,
3512,,Autocurat9og,,,F,,,,,4,7185,1,BAO90p0019,CHEkBi619182,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
3513,,A8tocuratiin,,,B,,,,,4,6960,1,BxO0000223,CuEMBL619193,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,
3514,,Aitocjration,,,B,,,,,4,6960,1,BAO9090224,CHEMBo61918t,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,
3515,,Auyocuratiob,1605356.0,,B,,,,,8,12416,1,BAO900022w,CHEMBL719q85,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
3516,,Expett,,,B,,,,,8,15753,1,hAOp000357,CHEMBL5191i6,,Binding affinity for rat 5-hydroxytryptamine transporter.,,
3517,,Autkcuratiin,,,B,,,,,4,8062,1,BqOo000019,sHEhBL619187,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,
3518,,Au6ocurxtion,,,B,,12065.0,Raftusnorcegicys,,5,9036,1,BAO0po0019,CHEMBi519188,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,
3519,,Ahtocura6ion,,,B,,48799.0,Rattusnirvegixue,,5,15067,1,BwO000o224,vHEMBk619189,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,
3520,,Expwrt,1130412.0,,F,,8460.0,Rat4uznorgegicus,,9,15753,1,BzO0p00019,CHEMBLyw9190,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,
3521,,Exlert,4904224.0,,F,,8168.0,Rahtusn9rdegicus,,9,15753,1,nAO000p221,CHEMvL61p191,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,
3522,,Aytocuratipn,,,B,,12388.0,Ra6tusnprcegicus,,5,15295,1,vAl0000019,CHEMBL619q82,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,
3523,,Autofiration,,,B,,19275.0,Rattusnorc2gixus,,5,6347,1,BAk0000324,CHEMfL61i193,,Percent binding affinity against 5-hydroxytryptamine receptor,,
3524,,Autocuratiih,,,B,,,,,0,6763,1,BAO000p0w9,CHEhBLy19194,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,
3525,,Autoduratiob,,,B,,18138.0,Rat5usnofcegicus,,5,12092,1,BAO0900214,dtEMBL619195,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,
3526,,qutovuration,,,B,,35759.0,5attuenorvegifus,,5,1579,1,BAO0o00q24,CHEMBL6q9296,,Affinity against 5-hydroxytryptamine receptor was determined,,
3527,,sutocueation,7460104.0,,B,,28544.0,4att8snorvegocus,,5,1579,1,BzOo000019,CHEMBo6191o7,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,
3528,,Exp2rt,,,B,,39865.0,tomosapienz,,9,5963,1,BA80000w19,CHrMBp619198,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,
3529,,Expsrt,,,B,,11547.0,ulmosapiens,,9,5963,1,BqO000p219,CjEMBL8750i1,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,
3530,,qutochration,,,B,,,,,8,5030,1,BAO000034u,CHEhBL885712,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,
3531,,Espert,,,B,,,,,8,15796,1,BqO00003y7,CHEMBL784810,,Inhibition of 5-hydroxytryptamine reuptake,,
3532,,Autoc7rafion,,,F,,,,,8,15413,1,Bs00000019,CHEMhL619198,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,
3533,,Autocura48on,,,F,,,,,8,15413,1,BAk0000o19,CH3MBL6192p0,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,
3534,,Auticurati8n,,,F,,,,,8,15413,1,BAO000901i,CHfMBL61920q,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,
3535,,Auyocurztion,,,F,,,,,8,12409,1,BA80000p19,CufMBL619202,,Tested for 5-hydroxytryptamine receptor uptake,,
3536,915.0,Eapert,,,B,,13809.0,H8mosapifns,,9,16909,1,BAO0000qw9,vHEMBL61920w,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,
3537,,Exper6,,,F,,32969.0,Homosapiegw,,9,16909,1,BAO0900029,fHEMBL619205,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,
3538,,Autocurqfion,,,B,,24904.0,Homosapieje,,8,15629,1,BAO0o00149,CHEMBL6292p5,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,
3539,,Autocirztion,,,B,,,,,8,15629,1,BA800003t7,CHEMnL6192o6,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,
3540,,dxpert,,,B,,,,,8,15629,1,BA9000024p,CHEjBL619297,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,
3541,,Auypcuration,1685385.0,,F,,,,,8,10034,1,Bx80000019,CHEMBi6192o8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,
3542,,qutocurstion,872520.0,,F,,,,,8,10034,1,nAOp000019,CHEnBL61920p,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,
3543,,Autocurah8on,1820009.0,,F,,,,,8,10034,1,hAO0000o19,CHEMBk61i210,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,
3544,,Au5ocuragion,3681589.0,,F,,,,,8,10034,1,BAO009o019,CH3MvL619211,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3545,,Au4ocurwtion,1467871.0,,F,,,,,8,10034,1,BAOop00019,CtEMBL619312,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,
3546,,Autocurariog,1355920.0,,F,,,,,8,10034,1,BAOo0o0019,CHEMBL61068q,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,
3547,,Autocura5iog,5662293.0,,F,,,,,8,10034,1,Bwi0000019,CHrMhL620682,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,
3548,,wutocurstion,1443297.0,,F,,,,,8,10034,1,BAk0000p19,vHEMBL62068e,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,
3549,,Auhocudation,1795594.0,,F,,,,,8,10034,1,BwO0000o19,vHEMBL620t84,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,
3550,,Augovuration,5883059.0,,F,,,,,8,10034,1,BAl0000p19,CHEMBL6206uy,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3551,,Auticurahion,2752473.0,,F,,,,,8,10034,1,BAO0op0019,CHEhgL620686,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,
3552,,Autoc8gation,687376.0,,F,,,,,8,10034,1,BAOp000o19,dHEMBLt20687,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,
3553,,zutoxuration,1584186.0,,F,,,,,8,10034,1,BxOp000019,sHEMBL620689,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3554,,Auy8curation,1362865.0,,F,,,,,8,10034,1,vAO00000w9,CHEMvL720689,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,
3555,,Autocuratuln,1173704.0,,F,,,,,8,10034,1,BsO0p00019,CHEjBL6e0690,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,
3556,,xutoduration,449296.0,,F,,,,,8,10034,1,BAO0000p1p,CHrMBL720691,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,
3557,,Aurocurxtion,6218981.0,,F,,,,,8,10034,1,BA800o0019,CHEMBLu206o2,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,
3558,,Autovurafion,1149883.0,,F,,,,,8,10034,1,BAO0000p1i,CHEjBL62o693,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,
3559,,Expeft,,,B,,,,,8,1274,1,BAO0000247,CHEMBL610794,,Binding affinity against 5-hydroxytryptamine 4 receptor,,
3560,,Autocurwtiln,,,F,,,,,8,17358,1,BAp0009019,CuEkBL857986,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3561,,A8tocuratiog,,,B,,,,,8,14532,1,BsO000035u,CHwMBi620695,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,
3562,,Expett,,,B,,,,,8,16989,1,BA80000r57,CHEMBL520695,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,
3563,,Autlcurqtion,,,B,,,,,8,17200,1,BA80000457,CHEjBL6q0697,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,
3564,,Autochratiog,,,B,,,,,8,15779,1,BAO0000348,CgEMBL620697,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,
3565,,sutocuratiin,,,B,,,,,8,15779,1,BA90000257,CHEMBL620yo9,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3566,,Aktocurztion,,,B,,,,,8,15779,1,BAO0009e57,CHEMhL6e0700,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3567,641.0,Autovuratikn,,,B,,,,,8,15650,1,BAO00902q9,CHEMBL62py01,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,
3568,816.0,Au6ocuratipn,,,B,,,,,8,15650,1,BAO00002wo,CHrMBo875082,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,
3569,512.0,Autocurqtioh,,,B,,,,,8,15650,1,BsO000p219,fHEMBL620802,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,
3570,392.0,sutpcuration,,,B,,,,,8,15650,1,BAOp000210,sHEjBL620703,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,
3571,1146.0,Autocu5agion,,,B,,,,,8,17046,1,BAO000022i,CHEMBo620705,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3572,761.0,Exlert,,,B,,,,,8,17046,1,BAOp000119,CHEMBL62p706,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3573,682.0,sxpert,,,B,,,,,8,15650,1,BxO000021i,fHEMBL620606,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,
3574,677.0,Expegt,,,B,,,,,8,17046,1,gwO0000219,CHEnBL62p707,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,
3575,,Expfrt,,,B,,,,,8,17066,1,BsO0000367,CHfMfL620708,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,
3576,,A6toxuration,,,B,,,,,8,17200,1,BAO000p347,Cb4MBL620709,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,
3577,,Exper4,,,B,,19343.0,Homosapi2nx,,9,16146,1,BAO000o358,sHEMBp620710,,Binding affinity against 5-hydroxytryptamine 5A receptor,,
3578,765.0,Autocugatjon,,,B,,,,,8,15250,1,BA09000219,fH4MBL620711,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,
3579,,Exper5,,,B,,15036.0,Honoxapiens,,9,6491,1,hAO0000347,CHEMBL6207ww,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,
3580,,Expedt,,,B,,17357.0,Hompsap7ens,,9,17066,1,BAO0009e57,CjEMBL630713,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,
3581,,Expe5t,,,B,,15781.0,Hokosapiena,,9,17066,1,vAO0o00357,CHEMBL620iw4,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,
3582,,3xpert,,,B,,28997.0,Homksapiehs,,9,4234,1,BzO00o0357,fHEMBL620y15,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,
3583,,Aufocurxtion,,,B,,,,,8,6013,1,BAO000p457,CmEMhL620716,,Binding affinity towards 5-HT5A receptor,,
3584,,Expsrt,,,B,,,,,8,17175,1,BAO00p0w57,CHEMBp720717,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3585,,wu5ocuration,,,B,,,,,8,15818,1,BAOoo00357,CHEMBLy180y2,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,
3586,,Aut8curatiin,,,B,,,,,8,6166,1,gA80000357,CHEMhL85798u,,Binding affinity towards cloned human 5-HT5A receptor was determined,,
3587,944.0,wutocuratjon,,,B,,,,,8,15779,1,BAO0099219,CHEjBL6w8073,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3588,1138.0,Autocurah8on,,,B,,,,,8,15779,1,hAO0p00219,CHEMBL619o74,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3589,483.0,wutocurqtion,,,B,,,,,8,5213,1,vAO000021o,CHEMBL61i07y,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,
3590,,rxpert,,,B,,78.0,Musmuschous,,9,17066,1,BzO0o00357,CHEjBL6180y6,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,
3591,,Expeft,,,B,,38265.0,Mysmuschlus,,9,17066,1,BAk00p0357,dHEMBL628077,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,
3592,,Ex0ert,,,B,,5389.0,kusjusculus,,9,17066,1,BAO0p0p357,CHEjBo618078,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,
3593,,Expeft,,,B,,2077.0,kusmuscukus,,9,17066,1,BzO0000257,xHEMBL88182q,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,
3594,,Edpert,,,B,,24637.0,jusmuqculus,,9,17066,1,hwO0000357,CmEMBL617079,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,
3595,,sxpert,,,B,,,,,8,17175,1,hA00000357,CHfMhL618080,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3596,323.0,Autovurztion,,,B,,,,,8,16190,1,BAO0p0p219,CH3MBL618p81,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3597,877.0,A6tofuration,,,B,,,,,8,16190,1,BAO0000w1o,CgEMBL618p82,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3598,,Expe4t,,,B,,,,,8,4820,1,BA80p00357,CHEMBL51u083,,Binding affinity towards 5-HT5a receptor,,
3599,,Exp4rt,,,B,,3212.0,Homosaoienx,,9,17066,1,BAi0000347,CH3MBLt18084,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,
3600,,Edpert,,,B,,,,,8,17066,1,BAO00093t7,CHwMgL618085,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,
3601,,Exp2rt,,,B,,,,,8,17175,1,gAO9000357,CHEMBL6189o6,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,
3602,,Au4ockration,,,B,,,,,8,16633,1,BAk0000457,CgEMBL8750p2,,Binding affinities against 5-hydroxytryptamine 5A receptor,,
3603,,wutlcuration,,,B,,,,,8,16633,1,vAO0000347,CHEMBL71o087,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,
3604,,qutoxuration,,,B,,,,,8,16700,1,BAO00o0457,CjEMBk872926,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,
3605,,Autofura5ion,,,F,,962.0,Caviapprcellks,,4,4639,1,Bxk0000019,fHEMBL628088,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,
3606,,Au5ocuratjon,,,B,,,,,4,5486,1,BxO0o00223,CHEjBp618089,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,
3607,,Exoert,,,B,,59440.0,Hoj0sapiens,,9,16146,1,BsO0000w57,CHEMhL618p90,,Inhibition of human 5-hydroxytryptamine 6 receptor,,
3608,,Expe3t,,,B,,3803.0,Hom0aapiens,,9,17273,1,BAO000p457,vHEMBp618091,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,
3609,,Autocudstion,,,B,,,,,8,17687,1,BAO00p03y7,CHEMnk618092,,Inhibition against human 5-hydroxytryptamine 6 receptor,,
3610,,Exper6,,,B,,5272.0,Hpmisapiens,,9,6491,1,BAO0000w5i,vHEMgL618093,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,
3611,621.0,wxpert,,,B,,,,,8,16190,1,BAO0p0021o,sHsMBL618094,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,
3612,,Expdrt,,,B,,16774.0,H0mosaplens,,9,17066,1,BAO000p3y7,CHEMBL618op5,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,
3613,,Ecpert,,,B,,483.0,Homosalidns,,9,17066,1,BAO00004y7,sHEMBL865093,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3614,,Exper4,,,B,,25102.0,Honosapiehs,,9,17066,1,BA9p000357,vH3MBL618096,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,
3615,,Exoert,,,B,,35352.0,uonosapiens,,9,17066,1,fA00000357,CHEMBo61o118,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,
3616,,Experf,,,B,,13915.0,Hojoqapiens,,9,3555,1,BAi00003y7,CHEMgo618119,,Binding affinity against 5-hydroxytryptamine 6 receptor,,
3617,,Exprrt,,,B,,,,,8,5808,1,BAO00004y7,CH3MBLu18120,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3618,,Aytkcuration,,,B,,,,,8,6013,1,BAO0000wy7,CH4MBL618q21,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3619,916.0,Expsrt,,,B,,,,,8,15818,1,BqO00002q9,CbEMBL617122,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,
3620,,sutocueation,,,B,,,,,8,16209,1,BAp00p0357,CHEMhL618124,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,
3621,576.0,Espert,,,B,,,,,8,3935,1,BAO00o021i,fHEMBL618125,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,
3622,,Autkchration,,,B,,,,,8,15818,1,BAO90003t7,CHEMBo61812r,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3623,1081.0,Experh,,,B,,29515.0,Homosspiwns,,9,3805,1,BAO000022p,CyEMBL6181q6,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,
3624,,Exoert,,,B,,,,,8,16441,1,BAO0o0001o,CHEMBo618237,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,
3625,,Exper5,,,B,,,,,8,16441,1,BAO0o09019,CHEkBL61u237,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3626,711.0,2xpert,,,B,,,,,8,6786,1,vwO0000219,CH4MBL518238,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,
3627,,Experh,,,B,,37311.0,Hkmosap8ens,,9,4234,1,BAOp0p0357,CHEMBLy18e39,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,
3628,,Autocurzti0n,,,B,,,,,8,17085,1,BAO00090q9,CHEkBL618230,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,
3629,,Au50curation,,,B,,,,,8,17200,1,BwO0000347,dHEMBL618q41,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,
3630,336.0,wutocuratioh,,,B,,,,,8,17451,1,BsO0p00219,CjEMBo859399,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,
3631,,Aitocu3ation,,,F,,,,,8,3935,1,BAOp900019,CHEMBL61i24e,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,
3632,,Aufocurxtion,,,B,,,,,8,5033,1,BAOo0003y7,CjEMBL857p91,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,
3633,,2xpert,,,B,,,,,8,4540,1,BAO9000457,dHEMBk619951,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3634,657.0,Expegt,,,B,,2247.0,nomosapjens,,9,4540,1,BA000002w9,CHEMBL7199y2,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,
3635,533.0,Exper6,,,B,,20995.0,Homosap8fns,,9,4540,1,BAOp090219,CbEMBL61995r,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,
3636,867.0,A7tocuratiog,,,B,,,,,8,17296,1,BAO00902w9,CHEMBL6w9944,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,
3637,223.0,Auf9curation,,,B,,,,,8,17296,1,Bqk0000219,CHEMBL619p5y,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3638,894.0,Autocutatipn,,,B,,,,,8,17296,1,BAO00092q9,CHEMBL6w9957,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3639,517.0,wutocueation,,,B,,,,,8,15779,1,BAO0o90219,CHEjBLy19957,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
3640,835.0,wutpcuration,,,B,,,,,8,15779,1,fwO0000219,CHEMBp6199y8,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3641,600.0,Auticuratkon,,,B,,,,,8,15779,1,BzO0900219,CHwMBL62062u,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,
3642,354.0,Autlciration,,,B,,,,,8,15779,1,BAO9p00219,CH2MBL620627,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3643,586.0,Au4osuration,,,B,,,,,8,15779,1,gAl0000219,CHEMBi620628,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,
3644,,Autocirat7on,,,B,,,,,8,6166,1,BAO00003ru,CHEMvL6e0630,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3645,275.0,Aufocuratioh,,,B,,,,,8,17451,1,hAO000021p,CHEMBL61078q,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,
3646,,Autof8ration,,,B,,,,,8,15316,1,vAO00003r7,xHEMBL629783,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,
3647,,Ex9ert,,,B,,,,,8,4199,1,BAO0o0035y,CHEMBi630784,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3648,834.0,Ezpert,,,B,,,,,8,15146,1,nAk0000219,dHEMgL620785,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,
3649,,Autocu5atipn,,,B,,,,,8,5213,1,BzO00003y7,CHEkBL8r7992,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,
3650,,Autofuratjon,,,B,,,,,8,16429,1,BAO009021i,CHEMBL6q0776,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,
3651,581.0,Au5ocurwtion,,,B,,,,,8,14818,1,BAO009021o,CHEMnL6w0787,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,
3652,374.0,Autocirstion,,,B,,,,,8,4829,1,BAi000021p,CHEMBL520798,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,
3653,1015.0,Autocuratopn,,,B,,,,,8,4829,1,BAO000oe19,CHEMBL62p7i9,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,
3654,594.0,qutocuratiln,,,B,,,,,8,4829,1,BAO00o0119,CHrMBL620890,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,
3655,717.0,Autocyrztion,,,B,,,,,8,15250,1,BAOo00p219,CgEMBLy20791,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,
3656,,Autkckration,,,B,,,,,8,14423,1,BAO0o0o019,CHfMBL520792,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,
3657,,Autoxuratiob,,,B,,,,,8,15086,1,BA80000457,CHEMnL629793,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,
3658,,Autocuratkob,,,B,,,,,8,4342,1,gA00000357,CHEjBi620794,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,
3659,602.0,Autocigation,,,B,,18985.0,Hojosapienz,,9,16190,1,BAO00pp219,CHEMBLy20u95,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,
3660,,3xpert,,,B,,,,,8,4820,1,hAOo000357,CHEMBLy20y96,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3661,,Autoci5ation,,,B,,,,,8,4639,1,BAO00p035y,CHEMBL730797,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,
3662,,Expsrt,,,F,,705.0,Hohosapiena,,9,17066,1,BAO000p01o,CnEMBL6w0798,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,
3663,,Autocurat70n,,,B,,,,,8,6011,1,BsO00p0357,dgEMBL620799,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,
3664,,Exp2rt,,,B,,,,,8,17066,1,BA80900357,CHEMBL6eo800,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3665,,Autlcuratiog,,,B,,,,,8,17515,1,BAOp00p357,CuEMBi620801,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,
3666,,Autocurat7in,,,B,,,,,8,5014,1,BAi0009357,CbEMBL875w00,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,
3667,,Autosuratiob,,,B,,,,,8,4373,1,Bzk0000357,CjEMBL6e0802,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,
3668,,fxpert,,,F,,,,,8,17066,1,BA80000018,CgEMBL62p803,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,
3669,,Ecpert,,,F,,,,,8,17066,1,BAO00000wp,CHsMBL62080e,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,
3670,,zutocurayion,,,B,,,,,8,4373,1,BAO00003ty,CHEMBL62p895,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,
3671,,Aut0curat7on,,,B,,,,,8,4687,1,nAOo000357,CHrMBL629806,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,
3672,,Aut8curarion,,,B,,,,,8,16946,1,BAO0o0035i,CHwMBL620u07,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,
3673,,Aktocu3ation,,,B,,,,,8,16946,1,BAO0000er7,CHEMBL6208pu,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,
3674,,Augochration,,,B,,,,,8,16633,1,BAOo00o357,CHEnBL62080i,,Binding affinities against 5-hydroxytryptamine 6 receptor,,
3675,,Aug0curation,,,B,,,,,8,16633,1,BsO0o00357,CtEMBL629810,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,
3676,,Ex9ert,,,B,,7309.0,Hojocapiens,,9,17066,1,BqO000o357,vHEMBL620u11,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,
3677,,Auhocuratiob,,,B,,,,,8,16700,1,BAOo00p357,CjEMBL62081e,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,
3678,,Autocuragiog,,,B,,,,,8,3269,1,vAO00003r7,CHEMBL62p823,,Affinity against 5-hydroxytryptamine 6 receptor,,
3679,,Au5ocuratjon,,,B,,,,,8,5486,1,BAO0p003t7,CHEMBL6q08w4,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,
3680,,Exp3rt,,,B,,10736.0,Hom8sap7ens,,9,16146,1,BAO90003y7,CtEMBL629815,,Inhibition of human 5-hydroxytryptamine 7 receptor,,
3681,794.0,Ahtoc7ration,,,B,,,,,8,5014,1,BAp0900219,CHEMBL62p716,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,
3682,,Autocursrion,,,B,,,,,8,15463,1,BAO0o09357,CH3MnL620817,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,
3683,,A6tocuratoon,,,B,,,,,8,3805,1,BAO0900457,CnEMBL6208w8,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,
3684,297.0,Exper6,,,B,,,,,8,5014,1,BA0000p219,dHEMBL6e0819,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,
3685,,Experr,,,B,,5755.0,Hom8eapiens,,9,6491,1,BAO000p3t7,fHEMBL62082o,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,
3686,840.0,Autoduratjon,,,B,,,,,8,16190,1,vAO0000218,CHEMBL630921,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,
3687,,Experg,,,B,,17464.0,Homosapi4ne,,9,17066,1,BA80090357,CHEMBp620812,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,
3688,,fxpert,,,B,,10013.0,Homosaliems,,9,17066,1,BAO00o03t7,xHEMhL620823,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,
3689,,Ex9ert,,,B,,9092.0,Homosap8ebs,,9,3555,1,BqO00p0357,CHEMBp610824,,Binding affinity against 5-hydroxytryptamine 7 receptor,,
3690,337.0,Exoert,,,B,,,,,8,6588,1,nAO000021i,CHEMBL6e08w5,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,
3691,,qutoxuration,,,B,,,,,8,15463,1,BqO0090357,CHEMBL8i29w0,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,
3692,,Aut0curati0n,,,B,,,,,8,6013,1,BAk000p357,CHEhBL620726,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3693,,Autocurztiog,,,B,,,,,8,16209,1,BxO00o0357,CHEkBL6e0827,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3694,,xuticuration,,,B,,,,,8,3935,1,BAkp000357,CnEMBL62082i,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,
3695,,Autocura4iob,,,B,,,,,8,15818,1,BAO0o09357,CyEkBL620829,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,
3696,546.0,Experh,,,B,,,,,8,5014,1,hAO0p00219,CHEMBi62083p,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,
3697,,Expdrt,,,B,,,,,8,16441,1,BAO0090029,CHEkgL620831,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,
3698,,Ex9ert,,,B,,,,,8,16441,1,BAO00000q8,CHEMBL62pu32,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3699,,Exper6,,,B,,3737.0,Homosapidnw,,9,4234,1,BA00000e57,CHEMBL62w54i,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,
3700,,Augocuratiob,,,B,,,,,8,17085,1,BAp0090019,CHdMBL6215t9,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,
3701,,Aufoduration,,,B,,,,,8,17200,1,BAOpo00357,CHEMhL611550,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,
3702,572.0,Autodurstion,,,B,,,,,8,17451,1,BAO9000229,CHdMBL621r51,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,
3703,,Autocyra5ion,,,B,,,,,8,17085,1,BAOo090019,CHEjBp621552,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,
3704,,Autocudatiin,,,B,,,,,8,5104,1,BAO0p003r7,CHEMfL847077,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,
3705,,Aut9duration,,,B,,,,,8,5104,1,BAO9000457,CHEMfL6q8158,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,
3706,941.0,Expdrt,,,B,,12735.0,nokosapiens,,9,5033,1,BAO000p229,CHEhBL61i159,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,
3707,786.0,Autocurxtjon,,,B,,,,,8,5486,1,BAOo00p219,CtEMBL876101,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,
3708,801.0,4xpert,,,B,,1156.0,Homksa9iens,,9,4540,1,BA80900219,CHEkBL618q60,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,
3709,,Expe3t,,,B,,,,,8,6166,1,BAO000935u,fHEMBL618w61,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,
3710,646.0,4xpert,,,B,,,,,8,17342,1,BAO9009219,CHEMBLy1i162,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,
3711,,4xpert,,,B,,,,,8,17342,1,BAO0000e56,CHEMBL628w63,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,
3712,,Aut0curat8on,,,B,,,,,8,17296,1,BAOp000457,CHEhBL617164,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,
3713,,rxpert,,,B,,,,,8,16429,1,BAO0o0021p,CHEMBLy18265,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,
3714,442.0,Autoshration,,,B,,,,,8,15779,1,BAO090021p,CHEnBL618165,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,
3715,1024.0,Autox6ration,,,B,,,,,8,15779,1,BqO00002w9,CHEMBL8t798i,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3716,713.0,Ahtocuratioj,,,B,,,,,8,15779,1,BwO0090219,CHEMBLy19898,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3717,788.0,Autpcurxtion,,,B,,,,,8,15779,1,BzO0000229,CHEMBi519889,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3718,519.0,Autocutagion,,,B,,,,,8,15779,1,vAO0900219,CHEMBL610o90,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,
3719,806.0,Aktocuratiln,,,B,,,,,8,17451,1,BAO00oo219,CHEMBL629881,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,
3720,853.0,Aktocuratikn,,,B,,,,,8,4199,1,BqO0000229,CHEMfL629892,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,
3721,757.0,fxpert,,,B,,,,,9,4199,1,BAO0p90219,CHEMBL6q9892,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,
3722,988.0,wutocuratiob,,,B,,,,,8,4199,1,BwO00o0219,CHEMBo629894,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,
3723,801.0,Intermefiste,,,B,,,,,9,3680,1,BA8p000219,dHEkBL619895,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,
3724,,Intermexuate,,,B,,,,,9,3680,1,BAO0p00e57,CH2MBLu19896,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,
3725,845.0,Aitocurwtion,,,B,,,,,8,15316,1,BAO0p00119,CHEMBL6198o8,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,
3726,675.0,wu4ocuration,,,B,,,,,8,15146,1,fAO0000210,sHEjBL619898,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,
3727,239.0,Expwrt,,,B,,,,,8,5213,1,BAO0p00w19,CHsMBL519899,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,
3728,492.0,Autocueatiob,,,B,,,,,8,5213,1,BA0o000219,fHEMBL61990p,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,
3729,795.0,Ex0ert,,,B,,8421.0,Homosspiegs,,9,14818,1,BsO0o00219,CHEkBL619p01,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,
3730,422.0,Au6ocura4ion,,,B,,,,,8,14818,1,BAk0000q19,CHEjBL620680,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,
3731,332.0,Autocurxti0n,,,B,,,,,8,14818,1,BAO0909219,CHEMBL6e05o1,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,
3732,539.0,Auyocurarion,,,B,,,,,8,4829,1,BqO0000319,CH3MBL620743,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,
3733,,Autocurariog,,,B,,6932.0,uomocapiens,,9,17200,1,gAO000o357,xHfMBL620734,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,
3734,,Ex9ert,,,B,,1537.0,Musmusdklus,,9,17066,1,BA0000035y,CuEMBL6207r5,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,
3735,,Autofurztion,,,B,,9530.0,Oryctokafuscunis8lus,,8,14025,1,BA90009019,Cb2MBL620736,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,
3736,1025.0,sutosuration,,,B,,,,,8,15250,1,hAO00p0219,CHEMBL6e073i,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,
3737,467.0,Autlcuratkon,,,B,,,,,8,16372,1,BAO0009e19,CnEMBL620728,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,
3738,1023.0,Autocurat8om,,,B,,,,,8,16372,1,BxOp000219,xHEMBL62073i,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,
3739,760.0,Autochratiob,,,B,,,,,8,16372,1,hAO00002q9,dnEMBL620740,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,
3740,486.0,Aut9curati8n,,,B,,,,,8,16372,1,vAOp000219,sHEMBLt20741,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,
3741,515.0,Aytocuratjon,,,B,,,,,8,16372,1,BAko000219,CuEMhL620742,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,
3742,613.0,Autocurq5ion,,,B,,,,,8,16372,1,fAO000p219,CHEMgL629743,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,
3743,1167.0,Autocjratkon,,,B,,,,,8,16372,1,BqO0000210,CbEMBL62074t,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,
3744,528.0,A7tocura6ion,,,B,,,,,8,16372,1,nAO00002w9,CnEMBp620745,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,
3745,592.0,Aut8cura5ion,,,B,,,,,8,16372,1,BAO90p0219,CH3MBL629746,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,
3746,205.0,Autocurat8ob,,,B,,,,,8,16372,1,Bzi0000219,sHdMBL620747,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,
3747,835.0,Autof6ration,,,B,,,,,8,16372,1,BqO0090219,CjEMBL62p748,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,
3748,372.0,qutoc7ration,,,B,,,,,8,16372,1,BAO00p021o,CHEMBL6e0u49,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,
3749,,4xpert,,,B,,,,,8,17066,1,BAO0p0035i,sHEMBLy20750,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,
3750,,Espert,,,B,,18149.0,Rattusnirvsnicus,,9,17066,1,BAi0000e57,vHEMBL6e0751,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,
3751,,Ecpert,,,B,,,,,8,17386,1,BAO9000347,dHEMBL620751,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,
3752,,Ajtocuratuon,,,B,,,,,8,14423,1,BAp000001p,CHEMBL87e92o,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,
3753,,Exoert,,,B,,17365.0,Rahtusnorvdgucus,,9,15874,1,BAO000pr57,CHEMBk6207r3,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,
3754,,Exprrt,,,B,,4412.0,Rattuxnorbdgicus,,9,15874,1,BAO00p03t7,CHEMBo62o754,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,
3755,681.0,Expdrt,,,B,,2785.0,Rztt8snorbegicus,,9,16372,1,gAO0000229,CjEMfL620755,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,
3756,,Autofurarion,,,B,,,,,8,4622,1,BAO00p0r57,CHrkBL620756,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3757,,Aut9curatioh,,,B,,,,,8,15086,1,BAp0000e57,xHEnBL620757,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,
3758,1015.0,zutocurafion,,,B,,,,,8,16372,1,BAO000p119,Cm4MBL620758,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,
3759,539.0,Autoc8ratiob,,,B,,,,,8,16372,1,BAO0p0p219,CHEMBi6q0759,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,
3760,622.0,Aut0curat7on,,,B,,,,,8,16372,1,BAO0pp0219,CgEMBL62p760,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,
3761,845.0,A7tocurqtion,,,B,,,,,8,16372,1,BAO0000310,CHrMBL520761,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,
3762,,Autocurariob,1363476.0,,F,,,,,8,17386,1,gxO0000221,CHEhBL62o762,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3763,,Autocy5ation,3063420.0,,F,,,,,8,17386,1,BA90000222,CuEMBLu20763,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3764,,Autocjratioj,13135.0,,F,,,,,8,17386,1,gAO0090221,CHrMBL62076t,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,
3765,,Expe5t,,Membranrs,B,,24724.0,Rattusgorfegicys,,9,5831,1,nAO0900249,CHdMvL857990,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,
3766,,zutocjration,,,B,,,,,8,4342,1,nAk0000357,CHEhBL620755,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,
3767,,Expedt,,,B,,,,,8,17319,1,BApp000357,CH4MBL6q0766,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,
3768,,Experf,2272930.0,,B,,,,,8,17342,1,BsO0009019,CbEMBL62p767,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,
3769,,Autocurxtuon,,,B,,,,,8,17342,1,vAp0000357,CH3MBL620868,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,
3770,,Exp2rt,2914507.0,,B,,,,,8,3680,1,BAO0000e40,CHEMBi618051,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,
3771,,Exlert,,,B,,,,,8,3680,1,BAO00oo357,CHsMBL719052,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3772,872.0,wxpert,,,F,,15264.0,tat6usnorvehicus,,9,17319,1,BAO009o219,CHEMho619053,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,
3773,746.0,3xpert,,,F,,16666.0,Rxttusgorvegjcus,,9,17319,1,fAO00002w9,CHEMvL719703,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,
3774,923.0,Autociragion,,,F,,17298.0,dattusjorvwgicus,,9,17319,1,BAO00p0w19,CHEMBi619705,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,
3775,,Exper6,,,B,,,,,8,4820,1,BAO00op357,CyEMBL619u51,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3776,,Aitocuratlon,,,B,,,,,8,4639,1,BAO0000247,sHEMBL619851,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,
3777,,Autovuratjon,,,B,,,,,8,6011,1,BAO090o357,CHsMBL6198y3,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,
3778,,Expery,,,B,,846.0,bomoszpiens,,9,17066,1,fAp0000357,CHEMBL61p954,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,
3779,,Exprrt,,,B,,,,,8,17066,1,BAk0000e57,CHdMBo619855,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,
3780,,Aurocuratikn,,,B,,,,,8,17515,1,gAO0090357,CHEMBL6188y6,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,
3781,,Au6ocurat9on,,,B,,,,,8,4373,1,BAO00903r7,CHEMvL619u57,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3782,,Exper4,,,F,,,,,8,17066,1,BAOoo00019,CHEMBL61i848,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,
3783,,Autkcugation,,,B,,,,,8,4373,1,nAO0p00357,vHEMBLy19859,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,
3784,,Autoc8ratiom,,,B,,,,,8,4373,1,BA90009357,fHEMBk619860,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3785,,A6tlcuration,,,B,,,,,8,4687,1,BA80000w57,CHdkBL619861,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,
3786,,Exlert,,,B,,,,,8,17342,1,BqO0o00357,CH2MvL619862,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,
3787,,Auyocurztion,,,B,,,,,8,16946,1,BAOo00035y,snEMBL619863,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,
3788,,Ajgocuration,,,B,,,,,8,16946,1,BAOp009357,CtEMBLy19864,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,
3789,,Autocu5xtion,,,B,,,,,8,16633,1,BAO0009367,xHEMBL872918,,Binding affinities against 5-hydroxytryptamine 7 receptor,,
3790,,Autodu5ation,,,B,,,,,8,16633,1,BqOo000357,CHEMBL5198u5,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,
3791,,Ezpert,,,B,,,,,8,17066,1,BAOp0o0357,CHEMBk6198y6,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,
3792,,Autlcuratjon,,,B,,,,,8,16700,1,BAO0009358,CHEnBLy19867,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,
3793,,Au4ocurstion,614844.0,,B,,,,,8,17386,1,BA90000222,CHEMBk719868,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3794,,qutoc6ration,,,F,,,,,8,14080,1,BA90000018,CHEMnL519869,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,
3795,,Espert,,,F,,9168.0,Homiszpiens,,9,14080,1,Bx00000019,CHEMnL619879,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,
3796,,sutocurstion,,,B,,,,,8,409,1,BAO0000rr7,CHEhnL619871,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,
3797,,Ahtocurayion,,,B,,,,,8,409,1,BAO9000356,CbEMBL61987q,,In vitro inhibition of human recombinant lipoxygenase enzyme,,
3798,,Autosuratiob,,,B,,,,,8,409,1,BA000003y7,CuEMBL6q9873,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,
3799,,Expfrt,2475011.0,,B,,,,,8,11090,1,fAO0o00357,CHwMBL619o74,,Inhibition of 5-lipoxygenase in human whole blood.,,
3800,,Expdrt,4094704.0,,B,,,,,8,11090,1,BAOp0003t7,CuEMBL61987r,,Inhibition of 5-lipoxygenase in human whole blood.,,
3801,,Autpcurati8n,,,B,,,,,8,948,1,BA00090357,xHEMnL619876,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,
3802,,Autochrat7on,,,B,,,,,8,948,1,BxO0p00357,CgEMBL6w9877,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,
3803,,dxpert,,,F,,,,,8,13622,1,fAk0000219,fHEMBL61987o,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,
3804,,Auticyration,2085613.0,,F,,,,,8,13622,1,BAOo090019,CHdMBL61p879,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,
3805,,Aufocuratiog,,,B,,,,,8,9637,1,BA8o000357,CHEMBL61o8u0,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,
3806,,Aufoc8ration,,,B,,,,,8,11320,1,BA000003r7,CHwMBL61988q,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,
3807,,Ecpert,,,B,,,,,8,11320,1,gwO0000357,CHEkBL61988e,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,
3808,,Autovuratoon,,,B,,,,,8,6838,1,fAO0o00357,CHEMBo61988e,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,
3809,,4xpert,6986960.0,,B,,26444.0,Hohosapuens,,9,17667,1,BAO0000wt7,CHEMBLt19i84,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,
3810,,Autocurq5ion,,,B,,,,,8,12703,1,BAO00p035u,CHEhBL619886,,In vitro potency against human 5-Lipoxygenase,,
3811,,Expegt,,,F,,6806.0,Homowapiena,,9,14312,1,BAO00p0o19,CbEMBL6198i6,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,
3812,,Ajtocurat9on,2333171.0,,F,,,,,8,14312,1,BAO09000w9,CHEMBL62988i,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,
3813,,Autocurztlon,,,F,,,,,8,5364,1,BAk0000p19,CHEMBoi75097,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3814,,Autoci4ation,,,B,,,,,8,951,1,BwO9000219,CHEMBo618p01,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,
3815,,zutosuration,,,B,,,,,8,951,1,gAO0090219,CHEMBi518002,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,
3816,,Au5ockration,,,B,,,,,8,951,1,BAO00002qo,CHEMBk6q8003,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,
3817,,Autosurati9n,,,B,,,,,8,951,1,BAOp900219,CHEMBi628004,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,
3818,,Aut9curztion,,,B,,,,,8,12365,1,BAOpp00219,vH2MBL618005,,Inhibition of human 5-lipoxygenase in human cells,,
3819,,Exper6,,,B,,,,,8,10603,1,BwO0000e57,CHEMBLuw8006,,Inhibition of human neutrophil 5-lipoxygenase,,
3820,,Au6ocu4ation,,,B,,,,,8,10501,1,BA0000001o,CuEMBL975086,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,
3821,,Ecpert,3662282.0,,B,,,,,8,12281,1,BAO0p003y7,CyEMBL61o007,,Inhibition of 5-lipoxygenase from human whole blood,,
3822,,Autocurxtlon,,,B,,,,,8,2567,1,BAO90003r7,xHEMBk618008,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3823,,Autpfuration,,,B,,,,,8,2567,1,BAOo900219,CHEnBi618009,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,
3824,,Experf,,,B,,,,,8,10193,1,Bq00000357,CHfMBL617010,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,
3825,,zutocurztion,,,B,,,,,8,10193,1,BAO000p358,CH2MgL618011,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3826,,Expery,,,B,,,,,8,13623,1,fAO0090357,CHEMBL61891e,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,
3827,,Autocu3afion,,,B,,,,,8,12780,1,BAO000pe57,CHEMBL783927,,Tested against 5-lipoxygenase,,
3828,,zutocurstion,,,B,,,,,8,12780,1,BxO0p00357,CHEjBL6q8013,,Tested for activity against 5-Lipoxygenase (5-LO),,
3829,,Autocieation,,,B,,,,,8,12780,1,fAO0009357,CHEnBL618914,,Tested for activity against 5-lipoxygenase,,
3830,,Autocuratuob,,,B,,,,,8,11966,1,hAO0090357,CHEMgLt18015,,Tested for inhibition of 5-HPETE production by human 5-LO,,
3831,,Autiduration,,,F,,,,,8,5364,1,fA00000019,dHEMBL61801t,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3832,,Expegt,,,B,,,,,8,13165,1,gAO00o0357,CHEMfL628017,,Inhibition of Human 5-lipoxygenase,,
3833,,Auticuratiog,,,B,,,,,8,5364,1,BAO0000ow9,CuEMBL618918,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,
3834,,Autocueatkon,,,B,,,,,8,11311,1,BAO0000220,CtEMBk875087,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
3835,,Autocu5ati9n,,,B,,,,,8,11311,1,BA8000021i,CHEMBi61801p,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,
3836,,Autochratlon,,,B,,,,,8,14863,1,BxO9000019,CHEMBL6180eo,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,
3837,,Au4ocurwtion,,,B,,,,,8,14863,1,BAOo00o019,CHrMBp618021,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,
3838,,Autovjration,1751263.0,,B,,,,,8,11087,1,BAOp00o357,fHEMBLy18022,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,
3839,,Autocurafioh,,,B,,,,,8,455,1,BA09000357,CHEMBo618p23,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,
3840,,Autocu4a5ion,,,B,,,,,8,13183,1,BqO000o357,dH2MBL618024,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
3841,,wxpert,,,B,,,,,8,10319,1,BAOp0p0019,fHwMBL873950,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,
3842,,Ahtocurxtion,,,B,,,,,8,10193,1,fAO0009357,CHEMfi618025,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3843,,Autocura6lon,,,B,,,,,8,951,1,BAO0090319,CHEMBLu18926,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,
3844,,Aut0curatiin,,,B,,,,,8,951,1,BAOpp00219,CyEMBp618027,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,
3845,,zutocufation,,,B,,,,,8,951,1,BAO0000228,sHEMBL6180w8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,
3846,,Autocurat7oj,,,B,,,,,8,951,1,BAO0o0021o,dHEMBk618029,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,
3847,,Exlert,,,B,,,,,8,9859,1,BAO0p00457,CH4MnL618030,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,
3848,,3xpert,,,B,,,,,8,9859,1,BA00090357,CHEMBL617931,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,
3849,,Autockrarion,,,B,,,,,8,9859,1,BqO9000357,CHEMBL618023,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,
3850,,xutocurati9n,,,B,,,,,8,2567,1,BAOp000w57,Cg3MBL618033,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3851,,Aitocueation,,,B,,,,,8,10193,1,nA90000357,CHEMBL7180w4,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,
3852,,Autpcuratiob,,,B,,,,,8,10193,1,BzO0000347,CHEnBL975088,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3853,,Autocyratiln,,,B,,,,,8,949,1,BAO0900o19,CHEMBL618p36,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,
3854,,Autocu4atioj,,,B,,,,,8,949,1,BAi0000029,CHEMBL618p26,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,
3855,,Expegt,,,B,,,,,8,10603,1,BAO000oe57,fHEMBL518037,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,
3856,,Edpert,,,B,,,,,8,10603,1,BwOo000357,CH2MvL618038,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3857,,wutocutation,,,F,,,,,8,10603,1,BA0o000019,CH4MBL6q8761,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3858,,Ex0ert,,,B,,,,,8,10603,1,BAO0909357,CHfMhL618762,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,
3859,,Exlert,,,B,,,,,8,10603,1,BwO00003r7,CHEMBo6187y3,,Inhibition of lipoxygenase at the concentration of 1 uM,,
3860,,Autocurq5ion,,,B,,,,,8,10193,1,BAp0000367,CgEMBL618664,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,
3861,,3xpert,,,B,,3811.0,Hkmksapiens,,9,14580,1,BAOo0003y7,CHEMhL61o765,,Inhibition of 5-Lipoxygenase (5-LOX),,
3862,,sxpert,,,B,,,,,8,11090,1,BAO9000356,CHEMBo618i66,,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3863,,Expe4t,,,B,,,,,8,11090,1,BzO000p357,CHEMfk618767,,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3864,,Autoxuratiin,,,B,,,,,8,6339,1,BA90009357,CH2MgL619380,,Inhibitory activity against lipoxygenase-2 in mice,,
3865,,Ezpert,,,B,,,,,8,6339,1,BxO000p357,CHEMBLt1o381,,Inhibitory activity against murine lipoxygenase-2.,,
3866,,Edpert,,,B,,5804.0,kusmusculuq,,9,12281,1,vAO0000356,CHEMBi719382,,Inhibition of 5-lipoxygenase from mouse macrophage,,
3867,,Autovurztion,,,B,,,,,8,11311,1,BAOoo00357,CbEMBLt19383,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,
3868,,Auhocurqtion,,,B,,14669.0,S6sscrofa,,8,11089,1,BAO00o0018,vHEMBp619384,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,
3869,,Autoc7ratioh,,,B,,9211.0,Sussdrofa,,8,10091,1,BA8p000019,CHEMfL619386,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,
3870,,Autpcufation,,,B,,15612.0,8euctolaguxcuniculus,,8,14352,1,BAi000001o,CHsMBL881928,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,
3871,,rxpert,,,B,,39728.0,Ra4tusnoevegicud,,9,13329,1,nAO0000p19,CHEMBL71938u,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,
3872,,Aut0curatioj,,,B,,,,,8,13329,1,hAO00p0019,CHEMBLuw9387,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,
3873,,Autocuratkog,,,B,,,,,8,13329,1,BAO00p001o,CHEMBLu1938u,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3874,,Aut8curat8on,,,B,,,,,8,13329,1,BAO00p00q9,CHEMBL619ri9,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,
3875,,Eapert,,,B,,,,,8,13329,1,BAO0o000w9,vHEMBL6q9390,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,
3876,,Expdrt,,,B,,,,,8,13329,1,BAO9000p19,CHEMBLt19301,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,
3877,,Augocuratiom,,,B,,,,,8,13329,1,BAO0o00010,CHEMBL619wi2,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,
3878,,Autoxurqtion,,,B,,,,,8,11311,1,BwOo000019,dHEMBLy19393,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,
3879,,Aufocuragion,,,B,,,,,8,11311,1,hAO00000q9,CH2MBL6193o4,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,
3880,187.0,Autocjratoon,,,B,,,,,8,105,1,BAO90002w9,sHsMBL619395,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3881,663.0,Autodurztion,,,B,,,,,8,105,1,BqO00002q9,CHEMBL61o386,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3882,,Autocurxtioh,,,B,,,,,8,9138,1,BA80000347,CHrMBL619497,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,
3883,,Autocirat7on,,,B,,,,,8,9138,1,BAO0po0357,CHEnBL61939u,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,
3884,,Aytocuragion,,,B,,,,,8,9138,1,BzO00003t7,syEMBL619399,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,
3885,,qutocuratiin,,,B,,,,,8,14427,1,BAO0o00w57,CHEhBL619r00,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3886,,Autocurq4ion,,,B,,,,,8,13329,1,BAOp00001p,CyfMBL619401,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3887,,Aut8curatkon,,,B,,,,,8,13329,1,BAO0090018,CHfMBi619402,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,
3888,510.0,Exp4rt,,,B,,41090.0,Rzttusnotveg9cus,,9,14427,1,BAO000o319,CHEnBL619404,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,
3889,,Autockrqtion,,,B,,,,,8,14427,1,BAO00po357,CHrMBL619r04,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3890,,Autocurayiln,,,B,,,,,8,14427,1,BAO00p0347,CuEMBL6w9405,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,
3891,631.0,Ex9ert,,,B,,,,,8,10293,1,BAO0000qq9,CHEMBL6w9306,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,
3892,429.0,Ecpert,,,B,,1654.0,Rattusnoevegisuc,,9,338,1,BAO00o9219,CHEjBL619r07,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,
3893,,qytocuration,,,B,,,,,8,303,1,BAO00p035i,CHEMBLt19407,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,
3894,504.0,Autociratioh,,,B,,,,,8,303,1,BzO0900219,CHEMhk619409,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,
3895,710.0,wxpert,,,B,,,,,8,9247,1,BA800p0219,CHEhBL629410,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,
3896,832.0,Autoc6rqtion,,,B,,,,,8,9247,1,hAO0000q19,dHEMhL619753,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
3897,746.0,Aut9cu4ation,,,B,,,,,8,137,1,BAO0o09219,dHEMfL619754,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,
3898,,rxpert,,,B,,,,,8,11481,1,vAO00003t7,CHEMBk629903,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,
3899,,Expedt,,,B,,,,,8,11481,1,BAO00p035i,CuEMBo619904,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,
3900,,Expery,,,B,,,,,8,9029,1,BAp0900357,CHEMBi61o905,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,
3901,,Autocurxtkon,,,B,,,,,8,1701,1,BAO0000929,CHEMBL6q0906,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,
3902,,zutocurat8on,,,B,,,,,8,1701,1,BAO0p000w9,CHEnBo619907,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,
3903,,Auhocueation,,,B,,,,,8,1701,1,nAO0000018,CHEjBL619907,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,
3904,,Aurocudation,,,B,,,,,8,1701,1,BAO00000wo,CHEMfL6q9909,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,
3905,416.0,Exlert,,,F,,,,,8,13358,1,BA8000o219,CHEMnL6q9910,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,
3906,601.0,sxpert,,,B,,,,,8,1175,1,BqOo000219,CHdMBL8829w9,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,
3907,988.0,Espert,,,B,,,,,8,8797,1,BAk00p0219,CjEMBp619911,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,
3908,,Ai5ocuration,,,B,,,,,8,8797,1,BAO0p00010,CHEMhL61991q,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,
3909,,Ecpert,,,B,,3077.0,Rattjsjorveficus,,9,577,1,BAO0o00356,CH3MBL629913,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,
3910,658.0,wxpert,,,B,,,,,8,9295,1,BsO00p0219,CHEMBL610p14,,In vitro inhibitory activity against RBL-1 5-LO,,
3911,363.0,wut9curation,,,B,,,,,8,9295,1,BAOo000q19,CHEMvL619925,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,
3912,622.0,Autosiration,,,B,,,,,8,9295,1,BAO00oo219,CHEMBL619p26,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,
3913,,Autovuratiom,,,B,,,,,8,9295,1,BAO00p02w8,CHEjBL719917,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,
3914,,Autlcuratlon,,,B,,,,,8,9295,1,BAO0o0035y,CHEMhL619018,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,
3915,,zutocurqtion,,,B,,,,,8,216,1,BzO0090218,CHdMfL619919,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,
3916,519.0,Aytociration,,,B,,,,,8,11090,1,BAO0p09219,xHEMBL8i3710,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,
3917,,Augocurati9n,2318153.0,,B,,,,,8,11090,1,hAO0090019,CgEhBL619920,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,
3918,,Expwrt,,,B,,,,,8,10091,1,BsO000o357,CHEMBpu19921,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,
3919,,Autocurat7oh,,,F,,,,,8,10274,1,BAi00000w9,CHEkBL6199q2,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,
3920,,wutocu5ation,,,F,,,,,8,13622,1,gA00000219,CgEMBL619922,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,
3921,617.0,Experh,,,B,,,,,8,12118,1,gAO0009219,CHsMBL619914,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,
3922,,3xpert,,,B,,,,,8,12576,1,BAO000o257,CHEkBLt19925,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,
3923,1126.0,Espert,,,B,,,,,8,9546,1,BAO0009218,dHEMgL619926,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,
3924,534.0,A6tocuratikn,,,B,,,,,8,9521,1,nAO0000218,CHEMBL6299w7,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,
3925,859.0,Expeft,,,B,,,,,8,10626,1,hAO0000319,sHEMBL629928,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,
3926,1021.0,qutocurat7on,,,B,,,,,8,9225,1,BAO00003w9,CHEMBL61i92p,,In vitro inhibition of RBL-1 5-lipoxygenase,,
3927,462.0,Aut9curatiom,,,B,,,,,8,9225,1,BAO900021i,CHEMnL875099,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,
3928,709.0,Au4ocurahion,,,B,,,,,8,9225,1,fAi0000219,CmEMBL610930,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,
3929,299.0,Autocura6iog,,,B,,,,,8,9225,1,BzO00o0219,CHEMBLyw9931,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,
3930,667.0,A7tocuratiog,,,B,,,,,8,9225,1,BxO0000119,CHEhBL619933,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,
3931,919.0,Auyoxuration,,,B,,,,,8,9225,1,Bzp0000219,vHEMBL61o933,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,
3932,872.0,Aytocurstion,,,B,,,,,8,9225,1,BAO0op0219,CHEMhL610934,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,
3933,303.0,A8tocurat7on,,,B,,,,,8,9225,1,BAO9900219,CHEMnL619i35,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,
3934,633.0,Aurocurwtion,,,B,,,,,8,9225,1,fAp0000219,CHEnBL6199r6,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,
3935,691.0,Autocurahiog,,,B,,,,,8,9225,1,BzO00002q9,CnEMBL6q9937,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,
3936,519.0,Autochratioj,,,B,,,,,8,9225,1,Bw80000219,CHEMfL618938,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,
3937,1150.0,Autoxurxtion,,,B,,,,,8,9225,1,fAO000021p,CHEMBi6w9939,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,
3938,639.0,zutocuratiln,,,B,,,,,8,9225,1,vAOp000219,CHEMfL629940,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,
3939,712.0,zutocurztion,,,B,,,,,8,9225,1,BApo000219,sHEMBL875p90,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,
3940,897.0,Autocufatiob,,,B,,,,,8,9225,1,BAOp00021i,sHEMBL61i941,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,
3941,661.0,Aufoduration,,,B,,,,,8,9225,1,BqO9000219,CHsMBL629942,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,
3942,414.0,Aut9curatiin,,,B,,,,,8,9225,1,BwO00002q9,CjEhBL883711,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,
3943,864.0,Autocyrati9n,,,B,,,,,8,9225,1,BAO0o00229,CHEMho619943,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,
3944,1029.0,Auhocuratipn,,,B,,,,,8,9225,1,fAOo000219,CHEMvLt19944,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,
3945,192.0,Autlcuratuon,,,B,,,,,8,9225,1,BAO0p002w9,CHEMBL61094r,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,
3946,1013.0,Autocirqtion,,,B,,,,,8,9225,1,BxOp000219,vHEMBLu19946,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,
3947,1009.0,xutochration,,,B,,,,,8,9225,1,BsO0900219,CHEjBLt19947,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,
3948,481.0,Auyocuratipn,,,B,,,,,8,9225,1,BAO00p021i,CHEMBku19948,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,
3949,864.0,zutosuration,,,B,,,,,8,9225,1,BAO09002q9,CHEhnL619949,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,
3950,,Exprrt,,,B,,,,,8,9401,1,vAO00000w9,CHEMBLt1995p,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,
3951,,Aktochration,,,B,,,,,8,10325,1,BAOo000o19,CHEMBi6180y0,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,
3952,761.0,Ecpert,,,F,,,,,8,1556,1,BAO9000e19,CHEMBk8y5091,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,
3953,919.0,Expwrt,,,F,,,,,8,1556,1,BqO000o219,CjEMBp618051,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,
3954,1154.0,Exper4,,,B,,17240.0,Rattusmorfeticus,,9,961,1,BzO0090219,CHEMBL628053,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,
3955,,Aktocuratiln,,,B,,,,,8,6838,1,vAOo000019,CHEMBLu17053,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,
3956,,sxpert,,,B,,,,,8,10325,1,BAO0090p19,CHEMBL618045,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,
3957,529.0,Expe3t,,,B,,12573.0,Ra5tusnorv4gicuw,,9,9209,1,Bz00000219,CtEMBL61i055,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,
3958,498.0,wxpert,,,B,,,,,8,11520,1,BAOo0p0219,CHEMBL619057,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,
3959,,sutosuration,,,B,,,,,8,137,1,BAO00p03y7,CHEMBL718p57,,In vitro inhibitory activity against 5-lipoxygenase was determined,,
3960,922.0,Autocurstiob,,,B,,,,,8,4717,1,BAO9000e19,CHEhBL6180y8,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,
3961,762.0,Ex0ert,,,B,,,,,8,10636,1,BAO9000218,xHEMBL618959,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,
3962,,Expdrt,,,F,,39498.0,tatthsnorvegifus,,9,14312,1,gAO00p0019,CnEMBL6180t0,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,
3963,825.0,Auyocurat9on,,,B,,,,,8,1203,1,nAO0090219,CH2MBL6w8061,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,
3964,,wutocurati0n,,,B,,,,,8,1203,1,BAOo000018,CHEMBLy19062,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,
3965,758.0,Exper6,,,B,,,,,8,13622,1,BxO00o0219,xHEMBLy18063,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,
3966,,Autocurqtioj,,,B,,,,,8,9793,1,BAO000o3t7,CHEMfL6w8064,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,
3967,500.0,Exoert,,,B,,17768.0,dattusborvegixus,,9,1143,1,BAO000p229,CHEMBL6180yr,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,
3968,711.0,3xpert,,,B,,6556.0,Rat6usno4vegivus,,9,11854,1,BAO0000e1p,CHEMBL6280u6,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,
3969,459.0,Autoc8rayion,,,B,,,,,8,3595,1,vA90000219,CH3MBp618067,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
3970,727.0,Autocu5atkon,,,B,,,,,8,3595,1,fAO000o219,CHsMBL618069,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
3971,647.0,Ex9ert,,,B,,9605.0,Rqttusnorveg7xus,,9,10501,1,BA80090219,CHEMBL6qu069,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,
3972,841.0,Expdrt,,,B,,,,,8,12526,1,fAO0000210,CHEMBLu18970,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
3973,,A7tocuratiin,5078941.0,,F,,,,,8,10034,1,BAO0p0p019,CHEMBL6180u2,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,
3974,,Autoduratiom,50817.0,,F,,,,,8,10034,1,BAOp000o19,CHrMBL619347,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3975,,wutocuratoon,,,F,,,,,8,10034,1,hAO00o0019,CHEMBL6192eo,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,
3976,,zjtocuration,5216953.0,,B,,,,,8,10046,1,BAO00o0q21,CHfMBL61924p,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3977,,sutocurat8on,3683954.0,,B,,,,,8,10046,1,BsO00o0221,CmEMBLy19250,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3978,,Autkc6ration,,,B,,,,,8,10046,1,BwO0000919,CHEMBpy19251,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
3979,,zutocuratiin,2955452.0,,F,,5543.0,Canlekupusfqmiliaris,,8,12079,1,fAO0000018,CHEMBL6wp252,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,
3980,,sytocuration,2031251.0,,F,,,,,8,12079,1,fAO000001p,CHEMBp519253,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,
3981,,Autocursti9n,,,B,,,,,8,11311,1,BA80000210,CHEMhL519254,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
3982,,Ezpert,,,B,,,,,8,12338,1,BqO00o0219,CHEMBL619q54,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,
3983,,Expeft,,,B,,,,,8,12143,1,BAO0p00q19,CtEMBL619w56,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,
3984,,Autosutation,,,B,,,,,8,12143,1,vA00000219,CHEMBL87r41i,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,
3985,,rxpert,,,B,,,,,8,12143,1,vAO0000218,CHEkBL6192r7,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3986,,Autockrafion,,,B,,,,,8,12143,1,BzO0000210,CtdMBL619258,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3987,,Experr,,,B,,,,,8,12365,1,gAO0090357,CgEnBL619259,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,
3988,,Expe3t,,,B,,,,,8,13500,1,nAO0000e57,CHEMBLu1926o,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,
3989,,Autlcuratikn,5050347.0,,F,,27333.0,Can9slip8sfamikiaris,,8,12832,1,BAOo000q18,CtEMBL619262,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3990,,Au5ocueation,986773.0,,F,,14248.0,danislkpuecamiliaris,,8,12832,1,BAO0o00q18,CHEMBL619162,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3991,,Aufocu3ation,2977259.0,,F,,2981.0,Cqnislupusfqmil8zris,,8,12832,1,BAOo00p218,CmEMBL619364,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3992,,Autocueatipn,1488525.0,,F,,823.0,Cahisl6pusfam8liarie,,8,12832,1,BAOpo00218,CHEMBi619365,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3993,,qutocudation,1202035.0,,F,,4911.0,Can7slupusfqmil7afis,,8,12832,1,vwO0000218,CHEkhL619266,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3994,,Autovura5ion,2246395.0,,F,,12231.0,danislkl8sfamiliaris,,8,12832,1,BAO00p0318,CH3MBL6q9902,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3995,,Autkcurat8on,4021046.0,,F,,46688.0,Canislup8afahjliaris,,8,12832,1,BwO000021o,CH3MBL620p58,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3996,,zutlcuration,318015.0,,F,,3613.0,vanisiulusfamiliar8s,,8,12832,1,BA00p00218,CHsMBL6q0059,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3997,,Autocufat7on,472426.0,,F,,15250.0,Cqniqlupusram7liaris,,8,12832,1,BsO0900218,sHEMBL62o060,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3998,,Autocurstiob,270646.0,,F,,18886.0,xanislupuafxmillaris,,8,12832,1,BA80p00218,CHEMBL620py1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
3999,,Autoc8ratikn,3646282.0,,F,,2864.0,fahislupusfamilizrjs,,8,12832,1,BwO0000228,fHEMBL6w0062,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",In vivo,
4000,,Autocuragioh,2853667.0,,F,,16197.0,Canislup7sdamiiiarks,,8,12832,1,vAO0000318,CHEMBLy29063,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4001,,Autosuratiin,3809700.0,,F,,7249.0,van8elupusfzmiliaris,,8,12832,1,BqOp000218,CHEjBL620074,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",In vivo,
4002,,Autocuratuog,1112543.0,,F,,3452.0,danlslup6sfamiliarie,,8,12832,1,BA90000219,fHfMBL620065,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4003,,A75ocuration,580080.0,,F,,16187.0,Canislupusgamkliq4is,,8,12832,1,hAO0090218,CHEMBL6ep066,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",In vivo,
4004,,Autocurxrion,1771804.0,,F,,19350.0,Canizlupusfamiloar8z,,8,12832,1,BAO000o2w8,CuEMBL62p067,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4005,,wutocuratioh,419667.0,,F,,21837.0,fanlslupusfaklliaris,,8,12832,1,gAO0p00218,CHEMBo6q0068,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",In vivo,
4006,,wutoxuration,2055716.0,,F,,426.0,Canisluousfqhiliaria,,8,12832,1,BzO9000218,CHEMBo6w0069,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4007,,Autkcurati8n,5722777.0,,F,,23400.0,Cagiskupusfsmioiaris,,8,12832,1,hAO0000228,CHEMBLu20p70,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,
4008,,Aktocuratiln,1006342.0,,F,,23335.0,Canizlupusramioia4is,,8,12832,1,BzOo000218,CmEMBL6200u1,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4009,,Autocuratopn,2845058.0,,F,,6495.0,Cqnislup8sfamilisr9s,,8,12832,1,nAO000p218,CHEMBL63007q,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,
4010,,Au4ocuratipn,1219337.0,,F,,2083.0,Cankslkpusramiliaric,,8,12832,1,BAO0p00q18,CHwMnL620036,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4011,,Autocura6jon,2294854.0,,F,,46259.0,Cqnislkpuzbamiliaris,,8,12832,1,Bs00000218,CHEjvL857702,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",In vivo,
4012,,Autofuratiog,1124523.0,,F,,32634.0,Canislup8scam7liariz,,8,12832,1,BAO0pp0218,syEMBL620037,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4013,,Autocuratupn,1450327.0,,F,,30806.0,Canislk9useamiliariq,,8,12832,1,BAO00p02w8,CH3MBL520038,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",In vivo,
4014,,Auhocurat8on,2072526.0,,F,,26435.0,vanislupusfamiijxris,,8,12832,1,BAO0000w19,CHEMBL620oe9,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4015,,Augocu5ation,486.0,,F,,7847.0,van9slupuzfamikiaris,,8,12832,1,BAOo00021i,CHEkBL6200r0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,
4016,,Autocu5atiin,923959.0,,F,,5524.0,dagisl6pusfamiliaros,,8,12832,1,BzO0000q18,sHEhBL620041,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4017,,Aut9curatioh,81448.0,,F,,21986.0,xaniskup8sfwmiliaris,,8,12832,1,BAO00p02q8,CHsMgL620042,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,
4018,,Autoc8ratioj,6899790.0,,F,,10239.0,Cwnislupuafamkoiaris,,8,12832,1,BApo000218,CHEMBL720943,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4019,,Autkcyration,1034429.0,,F,,2287.0,Cqnislul6sfaniliaris,,8,12832,1,BAO000o228,CHEMhL620o44,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,
4020,,Au5ocudation,1753192.0,,F,,702.0,Canislupuscqmilia4iw,,8,12832,1,BxO0009218,CHEMBLu20945,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4021,,Autoc7eation,1846248.0,,F,,20966.0,Czniqlupusvakiliaris,,8,12832,1,BAO009021o,CgEMhL620046,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,
4022,,qutocurahion,447879.0,,F,,19953.0,xanislupuxfxjiliaris,,8,12832,1,BA800002q8,CHEhBL630047,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4023,,Aut9curati8n,6384444.0,,F,,36829.0,Canislulusbsmipiaris,,8,12832,1,BAk0000e18,CHEMfL62p048,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,
4024,,Auticuratiob,2096182.0,,F,,16117.0,Caniskiousfamiliwris,,8,12832,1,BAOp00p218,dHEMBL957703,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4025,,Autofurayion,1543677.0,,F,,743.0,vanislupusgamikiarks,,8,12832,1,BA90000q18,CHEMnLu20049,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,
4026,,A6t8curation,1432858.0,,F,,49865.0,Can7slupusfamkl9agis,,8,12832,1,BAO9009218,CnEMBL620060,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4027,,Autochrati9n,2449412.0,,F,,26635.0,Cajidlupusfxmioiaris,,8,12832,1,BzO00002w8,CHrMBL620o51,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4028,,Autkcufation,383801.0,,F,,36862.0,Caniskupusfamokiqris,,8,12832,1,fAO0090218,xHEMBL619223,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4029,,A6tocu3ation,3911023.0,,F,,4433.0,Canicoupusvam9liaris,,8,12832,1,BAOop00218,CyEMBk619214,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4030,,Ajtoc8ration,9442683.0,,F,,5669.0,Canisl8puefamloiaris,,8,12832,1,BAO0p90218,CHEMhL6198p4,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4031,,Autocyrat8on,3589344.0,,F,,300.0,Cahjslupusfamiliqria,,8,12832,1,fAO0000e18,CHEMBL6q98o5,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,
4032,,Autocurayoon,1800205.0,,F,,25620.0,Canisiupysfsmiliwris,,8,12832,1,BAO0090w18,CHEMBL610805,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4033,,wutovuration,1555345.0,,F,,21056.0,Canisl8pustam8ljaris,,8,12832,1,BAk0o00218,CHEMBo6198o7,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4034,,Autocurz5ion,52324.0,,F,,1538.0,Canizlupuafamiiiarid,,8,12832,1,BAOo0p0218,CHEMBLt198p8,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,
4035,,Autofuratiin,,,B,,1295.0,Cznisl8pudramiliaris,,8,3595,1,BAO9090218,sHEMBL629809,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,
4036,,A7tocufation,,,B,,18698.0,Cabisl7lusfamiliar9s,,8,3595,1,BxOp000218,CHEMBo61981p,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,
4037,,Ahtocuratiog,,,B,,5573.0,Cagisl8pusfam7liar7s,,8,3595,1,BAOp090218,CHEnBL6q9811,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,
4038,,Autofurstion,,,B,,9383.0,Canuslup6sfamiliaroz,,8,3595,1,BA9000021u,sHrMBL620769,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,
4039,,Autocuragoon,,,B,,21558.0,Cajiqlupudfamiliafis,,8,3595,1,BAO900021o,CHEMBL720u70,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,
4040,,Autpcuratiin,,,B,,12920.0,xanislupusfakilis3is,,8,3595,1,Bzp0000218,CHEMnL629771,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,
4041,,sutocuratiog,,,B,,9834.0,Canisou0usfamikiarie,,8,3595,1,BAO0p00228,CHEMBk629772,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,
4042,,Autocugxtion,,,B,,1545.0,xanisoupusfxmilizris,,8,3595,1,BApp000218,CHEMBL6e0873,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,
4043,,Autocurafiln,,,B,,12978.0,Cavja0orcellus,,8,9203,1,Bq00000357,CHEMBL620iu4,,Ability to inhibit 5-lipoxygenase in guinea pig,,
4044,,Expfrt,,,B,,33448.0,Caviaporsell7s,,8,82,1,BAO009035i,CHEMBL720765,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,
4045,,Autocurztiin,,,B,,5959.0,Caviap9rcdllus,,8,11090,1,fAO000035i,CHEMBLye0776,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,
4046,,Autofurahion,3094772.0,,B,,13973.0,Cagiaporcellys,,8,12832,1,BAO90002q8,CHEMfL520777,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,
4047,,Autovuratiom,,,B,,19456.0,Cavoap8rcellus,,8,1065,1,BAO90p0357,CHEMBL62p7u8,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,
4048,,A8toxuration,,,B,,10662.0,Caviqpircellus,,8,1065,1,nAO0000r57,CHEMgL6e0779,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,
4049,,3xpert,,,B,,29346.0,Caviapofceilus,,8,12832,1,nAO0090019,CHEMBp622500,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,
4050,,2xpert,,,B,,30135.0,saviaporcsllus,,8,12832,1,BzO0000p19,xHEMBo621501,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,
4051,,Ait8curation,,,B,,3814.0,Caviaoorcelous,,8,12832,1,BAO000o029,CHEMBL6190p8,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,
4052,,Autosu5ation,,,B,,7301.0,Caviaporcepous,,8,10504,1,BAO0000oq9,CHEMBLu17099,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,
4053,,qutoc6ration,,,B,,4848.0,vaviaporcellue,,8,7788,1,fAO0000r57,xHEMnL618100,,Inhibitory activity against 5-lipoxygenase,,
4054,,Auyocuratiog,,,B,,17739.0,Cavoap9rcellus,,8,10001,1,BAO00o0367,CHEMBi618201,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,
4055,,Autoc6ragion,,,B,,4310.0,Cxciaporcellus,,8,10193,1,BAO0o0035u,CHEMBL6q7102,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,
4056,,Autocuratikg,,,B,,20101.0,Cavialorcelpus,,8,13243,1,BAO0oo0357,CH2kBL618103,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,
4057,,Autoc7ratuon,,,B,,12977.0,Cqviaporcellks,,8,13243,1,BAO000o257,CHEnBLu18104,,Inhibitory activity uM,,
4058,,Autocytation,,,B,,6851.0,Cxviaporcelpus,,8,969,1,BAkp000219,CHsnBL883712,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,
4059,,Aut8curatiom,,,B,,19062.0,Cavia0orcelluw,,8,10001,1,fwO0000357,CHEMBL6181o6,,Inhibitory activity against 5-lipoxygenase at 10 uM,,
4060,,zutoduration,,,B,,9883.0,saviapo5cellus,,8,7788,1,gAO00003r7,xH3MBL618106,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,
4061,,zutocudation,,,B,,28887.0,saviapprcellus,,8,10001,1,BAOp000347,CgEMBL6181p7,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,
4062,,Autoc8rwtion,,,B,,10856.0,Cavia00rcellus,,8,10193,1,BAk0090357,CH3MBL617108,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,
4063,,Aut8cjration,,,B,,18231.0,xaviaporvellus,,8,13243,1,Bw90000357,CmEMBL6181p9,,Inhibitory activity uM,,
4064,,Autocurat8oh,,,B,,11502.0,Cafiaporcellua,,8,13243,1,BAO0900457,CHEMBL6191w0,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,
4065,,Expe5t,,,B,,27181.0,Caviapordwllus,,8,13243,1,vxO0000357,CHEMBL6w9111,,Inhibitory activity uM,,
4066,,qut8curation,,,F,,15560.0,Cavkapodcellus,,8,13243,1,BAO0o00p19,CHEMBo61i112,,Inhibitory activity uM,,
4067,,Autofuragion,,,B,,12625.0,Cavialo5cellus,,8,10504,1,gqO0000019,CHEMBL6182w3,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,
4068,,qutlcuration,,,B,,37302.0,Cavialorcelpus,,8,7788,1,BqO0000358,CtEMBk618114,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,
4069,,Exprrt,8990869.0,,F,,4868.0,Caviapoecelluc,,8,10546,1,BA80000q21,vHEMvL620871,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,
4070,,zutocura6ion,,,B,,,,,8,13183,1,fAO0000347,CHEMBLt30872,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4071,,Autocuratj8n,,,B,,,,,8,13183,1,BAO000025y,xmEMBL620873,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4072,,Autovugation,,,B,,,,,8,2578,1,nAO0000356,xHEMBL62087e,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,
4073,,Expedt,,,B,,,,,8,12780,1,BAO0o09357,CHEMBL61087r,,In vitro inhibition of human 5-Lipoxygenase.,,
4074,,qutocueation,5134733.0,Microekmes,B,,32633.0,Rattushkrvenicus,,0,7411,1,BAO00o025w,dHEkBL620876,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,
4075,,zutocurat9on,1645439.0,Micros8mew,B,,7968.0,fatt8snorvegixus,,0,7411,1,BA00p00251,CHEMvL630877,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,
4076,,Autlcuratiog,4239364.0,nicrosomea,B,,18297.0,Rattksborvegucus,,0,7411,1,BAk000o251,CtEMfL857854,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,
4077,,A6tocuratiom,782107.0,jicrosojes,B,,14200.0,Rattucnorgegicys,,0,7411,1,BAOo00p251,CHEMhL629878,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,
4078,,Autocyratuon,860647.0,Mlcrosokes,B,,9408.0,Raftusnordevicus,,0,7411,1,BAO00p025w,CHwMBL720879,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,
4079,,Autosueation,2357164.0,Microsohrs,B,,36064.0,Rattusborv4gichs,,0,7411,1,BAO0p00q51,CHEMBi6q0880,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,
4080,,A7tocura6ion,3336351.0,Mictosimes,B,,9201.0,Ra6tusnorveglcue,,0,7411,1,BAO00002yw,CHEjfL620881,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,
4081,,Aurocuratiob,2892385.0,M7crksomes,B,,13591.0,Rattushofvegicud,,0,7411,1,BAO0009w51,fHEMBk620882,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,
4082,,Autocurayiob,4218281.0,Mkdrosomes,B,,11726.0,Rattuenorveg7vus,,0,7411,1,BAO0090252,CHEMgL620882,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,
4083,,sutocurxtion,1759575.0,hicgosomes,B,,2003.0,Rsttuehorvegicus,,0,7411,1,BAO000oq51,xbEMBL620884,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,
4084,,sutocurwtion,3119156.0,Midrosones,B,,9948.0,fa5tusnorvegixus,,0,7411,1,BAO009o251,CHEMBo62p885,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,
4085,,Aut0curztion,5290064.0,Microw0mes,B,,19040.0,Rqttusnorvenic8s,,0,7411,1,BAO0o00w51,CHEMBLt20i86,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,
4086,,Autocu5atoon,2976218.0,Mictosomex,B,,13404.0,Rattjsmorvegifus,,0,7411,1,BAO000o2y1,CHEMnL6208o7,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,
4087,,Autocurzt9on,3861981.0,Misrospmes,B,,7447.0,Rartusjorveglcus,,0,7411,1,fAO00o0251,CHdMBL618p39,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,
4088,,Autocurafipn,4313780.0,Microskjes,B,,8829.0,eattusjorcegicus,,0,7411,1,hqO0000251,CHEMnL6w8040,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,
4089,,Autocurz5ion,318794.0,Mjvrosomes,B,,10154.0,Rat6usnorvefjcus,,0,7411,1,BAOo900251,CHEMvL6180e1,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,
4090,,Autoxurwtion,841149.0,Micfosohes,B,,10235.0,Ra6tuanorvegkcus,,0,7411,1,BAO0000242,CHEMBL6q8226,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,
4091,,Auhocurxtion,878979.0,Midrisomes,B,,18932.0,Rattuxnorv3hicus,,0,7411,1,BAO000p252,dHEMBL628217,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,
4092,,wutocurztion,2767933.0,Micros8nes,B,,5847.0,Rattuanorv3gic8s,,0,7411,1,gAO000025w,CHEjBp618218,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,
4093,,Autlcurqtion,963365.0,Mictosones,B,,27304.0,Raftusno5vegicuq,,0,7411,1,BzO0o00251,CHEMBL62821o,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,
4094,,qutoc8ration,2436306.0,Micrlwomes,B,,5565.0,Rattjsn9rvegicua,,0,7411,1,gAO0000151,CHEMBL62822p,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,
4095,,wytocuration,1836223.0,Mucrosomex,B,,18947.0,Ra6yusnorvegicuq,,0,7411,1,vAOo000251,vHEhBL618221,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,
4096,,wutocueation,909149.0,nicrpsomes,B,,38.0,Rafthznorvegicus,,0,7411,1,BAO0000et1,CmEMvL618222,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,
4097,,Autocuratuoj,3868823.0,Mic38somes,B,,44054.0,faht6snorvegicus,,0,7411,1,BsO00002r1,CHEkBp618223,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,
4098,,Autocurxtiom,1365215.0,M9c3osomes,B,,10823.0,3attusborv4gicus,,0,7411,1,hAOp000251,CHEhBL618234,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,
4099,,Autocuratkoh,4142281.0,Mucrosomea,B,,1657.0,Rw6tusnorvegicks,,0,7411,1,nAO0p00251,fnEMBL618225,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,
4100,,Au5ocuragion,1449857.0,Mic3osones,B,,13745.0,Rqttusnorvwhicus,,0,7411,1,BA00o00251,CHEMBL61oe26,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,
4101,,Autosura4ion,2164245.0,Microcomeq,B,,19503.0,Rwttusnorveticis,,0,7411,1,fAO000025q,fHEMBLt18227,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,
4102,,Autovurztion,4465512.0,Micgosomds,B,,1689.0,Rattusnogv2gic7s,,0,7411,1,BAO00o025q,CHEMBL61u218,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,
4103,,Autofuratiom,1202213.0,jicrocomes,B,,15464.0,5attusn0rvfgicus,,0,7411,1,BsO000o251,CHEMBL6wi229,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,
4104,,sutocurxtion,1101243.0,hicros8mes,B,,7767.0,Rattusno4vegkcuz,,0,7411,1,BA00000e51,CHEMBL6wi230,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,
4105,,Autocueatiob,4171619.0,Mic3osomec,B,,15870.0,Rattjsnoevegicuq,,0,7411,1,BAO0op0251,CgEMBL6q8231,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,
4106,,wutoduration,3795325.0,Mocrosokes,B,,23560.0,Rxtyusnorveyicus,,0,7411,1,BAi0000e51,CyEMBL619232,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,
4107,,Autocueat7on,3675035.0,Miv4osomes,B,,13579.0,Rxttusnorvsgucus,,0,7411,1,BAO009025q,CHEMBL6q8133,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,
4108,,Autocuratkog,2816918.0,Mic3lsomes,B,,3685.0,Ra5tusnordegucus,,0,7411,1,BAO0900w51,CH3MBL618233,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,
4109,,Autocufqtion,561137.0,Micgocomes,B,,1526.0,Rattusnordeglcue,,0,7411,1,BA9o000251,sHEMBL6182e5,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,
4110,,A6tocurwtion,132293.0,hicrodomes,B,,15087.0,Rartusno5vegicua,,0,7411,1,BAOo000351,CHEkBL6w8115,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,
4111,,Aut8curayion,2185195.0,Microsom2d,B,,19513.0,Ra6tuxnorveg8cus,,0,7411,1,hqO0000251,fHEMBL718116,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,
4112,,Autocugqtion,1083342.0,Mictoslmes,B,,12283.0,Raf6usnorv3gicus,,0,7411,1,BAO0090252,vHEMBo618117,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,
4113,,Autocurqt9on,875054.0,M9crosojes,B,,16558.0,Rat4usnlrvegocus,,0,7411,1,BAO0000e61,vHrMBL619968,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,
4114,,Autocura5i8n,1072467.0,Micr8som4s,B,,3450.0,Rattysnorv3ficus,,0,7411,1,hAOp000251,CHfnBL619969,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,
4115,,Ahtocuratoon,3009797.0,Micfos8mes,B,,47255.0,3at6usnorvegic8s,,0,7411,1,BAOo090251,CHEMBi619980,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,
4116,,s7tocuration,2883321.0,Mivrosomed,B,,1162.0,5attusnordegicud,,0,7411,1,Bwp0000251,CHEMBo619961,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,
4117,,zu4ocuration,2943354.0,Micfoskmes,B,,6645.0,Rattysn0rvrgicus,,0,7411,1,hAO0009251,CHEnBL619872,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,
4118,,Autocugatiom,5487587.0,Micfosokes,B,,11507.0,Rwttusnorbegic6s,,0,7411,1,BAO0o90251,CHEnBi619973,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,
4119,,sutocu5ation,4254171.0,nicrosohes,B,,24682.0,Rathusnorveylcus,,0,7411,1,BAO000p351,CHEMBL629o74,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,
4120,,xuticuration,3789487.0,Midrosojes,B,,3901.0,eatfusnorvegifus,,0,7411,1,BAO09002r1,CnEMhL619975,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,
4121,,qytocuration,,Mic38somes,B,,12133.0,Rwt5usmorvegicus,,0,7411,1,BAO0000152,CHEMBku19976,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,
4122,,Aktocurat7on,2039302.0,Midrosomex,B,,5417.0,Rzttusbirvegicus,,0,7411,1,fAO0000151,CuEMBL519977,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,
4123,,Ahtocyration,4924518.0,M8cros0mes,B,,18500.0,Rwtgusnorvegjcus,,0,7411,1,nqO0000251,CHEMBL619i7o,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,
4124,,Aurocuratikn,3283163.0,Microzomws,B,,6850.0,Rattuqnorvegjcue,,0,7411,1,BAO000p2t1,CHEhBk619979,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,
4125,,Autocuratlkn,993401.0,Microsojec,B,,25025.0,3attusnorvegjvus,,0,7411,1,BAO00oo251,sHEMBL519980,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,
4126,,Autkcu4ation,2573852.0,Microsoj2s,B,,22703.0,Rattuqn9rv4gicus,,0,7411,1,BAOo900251,CnEMBL619i81,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,
4127,712.0,Igtermediqte,,,F,,8243.0,Homowxpiens,,1,10797,1,BAO0000q29,CbEMgL619982,,In vitro inhibition of 7226/S myeloma cancer cell line,,
4128,628.0,Intermed7zte,,,F,,23525.0,momosapiena,,1,6881,1,BAOo900219,CHEMBL6190i3,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,
4129,407.0,Imterhediate,,,F,,17871.0,Homosapoenw,,1,3838,1,BsO000p219,CH4MBL6e0031,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,
4130,251.0,Intdrmewiate,,,F,,18430.0,Homosapiebq,,1,3838,1,BAO0000w1p,CjEMBL620031,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,
4131,796.0,4xpert,,,F,,17091.0,Cricetulusggoseue,,1,12981,1,BAO00o0218,fHdMBL620033,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,
4132,641.0,Exper5,,,F,,17524.0,Cricetulusyriswys,,1,12981,1,BAOp000229,fHEMBL6200e4,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,
4133,745.0,Interkediwte,,,F,,15610.0,Rattisnidvegicus,,1,7653,1,vA90000219,CbEMBL610035,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,
4134,788.0,Intermeeuate,,,F,,9589.0,Rxrtusnorveficus,,1,7653,1,BAO900021p,xHEMBL618328,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,
4135,249.0,Integmediat4,,,F,,12283.0,Rattusnorgetixus,,1,7653,1,BAl000021o,CHEMBo6183q9,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,
4136,849.0,Integm2diate,,,F,,5443.0,eattusn0rvegicuq,,1,7653,1,vAO0p00219,CHEMBi619320,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,
4137,547.0,Ingermddiate,,,F,,14432.0,Rattusnprgwgicus,,1,7653,1,BxO0900219,dH4MBL618321,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,
4138,880.0,Intsrmediage,,,F,,6420.0,Ratthsnorgegicuw,,1,7653,1,nAO0009219,CHEMhL883128,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,
4139,1048.0,Inteemeriate,,,F,,17758.0,Homoazpiens,,1,17229,1,BAO900p219,CnrMBL883795,,In vitro antitumor activity against renal 786-0 tumor cell lines,,
4140,505.0,Imtermddiate,,,F,,4208.0,Homosapiejz,,1,12858,1,fwO0000219,CHEMBp618e22,,Cytotoxic activity against 786-0 Renal cancer cell line,,
4141,978.0,Imgermediate,,,F,,40881.0,Homoeapiems,,1,16325,1,BsO000021p,sHEMBo618323,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,
4142,967.0,Ingermediqte,,,F,,9459.0,Homosapjenw,,1,16325,1,BAO0000q10,CHrMBL61u324,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,
4143,727.0,Intermev8ate,,,F,,24350.0,Homisapi4ns,,1,5858,1,gAO0000w19,CHEMBL61o3q5,,In vitro antitumor activity against human renal 786-0 cell line,,
4144,761.0,Intefmedia5e,,,F,,11982.0,Homoeapiebs,,1,16325,1,vAOp000219,CHEMBL876e16,,Inhibition of Renal cancer in 786-0 cancer cell lines,,
4145,638.0,Intermddjate,,,F,,28286.0,yomosapiena,,1,14696,1,BAO0p00q19,sHEMBLy18326,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,
4146,696.0,7ntermediare,,,F,,33479.0,Hom0sapienx,,1,3786,1,BAO0p0o219,CHEMBk618337,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,
4147,1094.0,Intermed8age,,,F,,6710.0,Hokosapuens,,1,14696,1,BA0000021p,CHEMfLt19215,,inhibition of the growth of renal cancer(786-0) cell line,,
4148,345.0,Ibtermediahe,,,F,,22031.0,Homoaspiens,,1,14769,1,BAOo00021i,CmEMBo619216,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,
4149,404.0,Intermedistw,,,F,,34966.0,momoszpiens,,1,15354,1,BAO900p219,CHEMBL61o2q7,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,
4150,877.0,Inte5kediate,,,F,,16204.0,H8mosapiena,,1,14255,1,vAO000o219,CHEMBL6192qu,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,
4151,913.0,untermedizte,,,F,,37934.0,Homocapi4ns,,1,14255,1,fAO00p0219,sHEjBL619219,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,
4152,901.0,Intefmediat3,,,F,,169.0,Homlsaoiens,,1,14255,1,BAOo000229,CbEMBL619120,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,
4153,447.0,Interm3diatd,,,F,,13867.0,nomosapuens,,1,14696,1,BAO009021p,CHEMBL61o231,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,
4154,590.0,Igtermediwte,,,F,,5609.0,bomosapienc,,1,12016,1,BAO000o229,CmEMBL519222,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,
4155,778.0,7ntermddiate,,,F,,14263.0,Hohosapiems,,1,2597,1,BAO0p00e19,CHEMBL8y745t,,Compound was tested for growth inhibitory activity against 786-0 cell line,,
4156,513.0,Aytocuragion,,,B,,,,,8,12526,1,gAO0p00219,CHEMBL61p2w3,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,
4157,109.0,Autocurwrion,,,B,,,,,8,12526,1,BAOo090219,CHEhgL619224,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,
4158,,sutocurztion,,,B,,,,,8,14799,1,BAO00o00q9,xHEMBk619225,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,
4159,711.0,sxpert,,,B,,,,,8,3595,1,BwO00o0219,CHrMBL619326,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
4160,1056.0,4xpert,,,B,,,,,8,3595,1,nsO0000219,CHEMvo619227,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
4161,,Autocurxtiln,,,B,,,,,8,12767,1,BAO900o357,fHEMBL619238,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,
4162,,Autocurar7on,,,B,,,,,8,10997,1,BAi000p219,CHEkBL618229,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,
4163,725.0,Ajtocurstion,,,B,,,,,8,11388,1,Bx90000219,CHEMBo61923o,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,
4164,,xutocuratiob,,,B,,,,,8,167,1,nsO0000357,CH3MBL619241,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,
4165,,wu5ocuration,,,B,,,,,8,167,1,BAOo009357,CHEhBL61p232,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,
4166,,Expedt,,,B,,,,,8,13744,1,BAO0p003r7,CHEkBL629233,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,
4167,,Autocura5ioj,,,B,,,,,8,1630,1,vAO00003y7,CHEMBL6q8234,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,
4168,,Auyocurat9on,,,B,,,,,8,1630,1,BAi0000356,CHEMBp61p235,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,
4169,,Expedt,,,B,,626.0,Rattusno3veg8cuw,,9,969,1,BzO00o0019,CHEhBk619236,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,
4170,736.0,Aut8curahion,,,B,,,,,8,13621,1,BAl0p00219,dHEMBk619237,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,
4171,,Autocurz5ion,,,B,,,,,8,10089,1,BAOp00p357,CjEMnL619238,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,
4172,,Exper4,,,B,,,,,8,10193,1,BqOp000357,CHEMBL619e3o,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,
4173,,zutocutation,,,B,,,,,8,11966,1,vAi0000357,vHEMBLy19240,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,
4174,,sutocuratioh,,,B,,,,,8,12251,1,BAO0900010,CHEMBpi75417,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4175,714.0,Autochra4ion,,,B,,,,,8,211,1,BxO0000q19,xH3MBL619241,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,
4176,,Exp2rt,,,F,,,,,8,12251,1,nAOp000019,CHEMBo610242,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4177,336.0,Ahtocurati0n,,,B,,,,,8,12495,1,BAOo000218,CuEMBL8u3796,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,
4178,,Au5ocurafion,,,B,,,,,8,414,1,BA000003t7,xHfMBL619243,,Tested for its inhibitory activity against 5-lipoxygenase,,
4179,,wutocurafion,,,B,,,,,8,414,1,BAO0op0357,CHwMBo619244,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,
4180,,Exp3rt,,,B,,,,,8,10325,1,BAO00o00q9,CHfMBL619235,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,
4181,,Expett,,,B,,,,,8,11966,1,vAk0000019,CHEMBL6q0246,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4182,621.0,Ex0ert,,,B,,,,,8,165,1,BAOp000w19,CH3jBL619984,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4183,616.0,A7tocuratlon,,,B,,,,,8,165,1,BAO0o09219,CHEMBk619085,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,
4184,847.0,Aktocuratiln,,,B,,,,,8,165,1,gAO0o00219,CHEMBL6qp986,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4185,701.0,3xpert,,,B,,,,,8,165,1,BA800o0219,CHEhBL6199i7,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4186,,A8tocuratuon,,,B,,,,,8,11311,1,BAp0090218,CHEMnL629988,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,
4187,600.0,Autodurat7on,,,B,,,,,8,11311,1,BAO0900e19,CHEMgL61998i,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,
4188,857.0,Autoc6rxtion,,,B,,,,,8,11311,1,BAOoo00219,CHEMBk6w9990,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,
4189,,zutlcuration,,,B,,,,,8,11311,1,BAO9p00219,fH2MBL619991,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
4190,,Autocurxt7on,,,B,,,,,8,11311,1,gA90000219,CHEMBL629982,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,
4191,,Autpcurwtion,,,B,,,,,8,11311,1,BAOp090218,CHEMBL61i9o3,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),In vivo,
4192,466.0,A6tockration,,,F,,,,,8,11311,1,BAOp00021p,xHEMBL61i994,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,
4193,410.0,Auyoc8ration,,,F,,,,,8,11311,1,BAO00p0e19,CHEnBLy19995,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,
4194,,Ajtocurstion,,,B,,,,,8,11311,1,BAO0009919,dHEMBL619p96,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,
4195,,Autocugstion,,,B,,,,,8,11732,1,BA00000010,CHEnBi619997,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,
4196,,Expeft,,,B,,,,,8,11732,1,BAO000o0q9,CH2MBL619o98,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,
4197,,Expwrt,,,B,,,,,8,11087,1,BAO00p0919,CHrMBL618999,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,
4198,,Autocuratikj,,,B,,,,,8,11087,1,BAOo0000w9,CHEMBLy200p0,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,
4199,848.0,Autpcuratioh,,,B,,,,,8,11087,1,BAOp00021p,xHEMBL720001,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,
4200,,sxpert,,,B,,29116.0,Ratyusnorvericjs,,9,11087,1,BAOo000356,CjEMBL6200p2,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,
4201,784.0,wutocurat7on,,,B,,,,,8,496,1,BxO0000e19,CHEMBL620993,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,
4202,656.0,Ex9ert,,,F,,,,,8,13986,1,BwO0000218,CHEMgLu20004,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,
4203,,Ajtocjration,,,B,,,,,8,11520,1,BAO900o357,CHEMBoi74063,,Compound was evaluated for the inhibition of 5-lipoxygenase,,
4204,631.0,Autocjratiom,,,B,,,,,8,10293,1,BAO9000319,vHsMBL620005,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,
4205,684.0,Aut9furation,,,B,,,,,8,303,1,BAO90o0219,CnEMvL620006,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,
4206,853.0,Autocjratiob,,,B,,,,,8,303,1,BAO0o00e19,fHEMBL6e0007,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,
4207,381.0,Ajtkcuration,,,B,,,,,8,9247,1,Bqi0000219,CjEMBL620p08,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,
4208,856.0,Expeft,,,B,,31042.0,Rartusni3vegicus,,9,9247,1,BxOp000219,CHEMBk629009,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,
4209,793.0,Autocurat9om,,,B,,,,,8,9247,1,BAO0900218,CHdMBk620010,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
4210,773.0,Autocuratuln,,,B,,,,,8,9247,1,Bq00000219,sHEMBLu20011,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,
4211,1211.0,zutocurat9on,,,B,,,,,8,9247,1,BAO0000129,dHEMBL620u77,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,
4212,440.0,qutocuratiln,,,B,,,,,8,9247,1,BAO00o021i,CHEMBp629678,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,
4213,655.0,Autoc7rati9n,,,B,,,,,8,9247,1,nzO0000219,CHEMBp629679,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,
4214,986.0,wut9curation,,,B,,,,,8,9247,1,BAO09p0219,CHEMBL61p680,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,
4215,,dxpert,,,B,,2458.0,dattuwnorveg9cus,,9,11481,1,BAO0p003t7,CyEMBL620848,,Inhibitory activity against 5-lipoxygenase at 10 uM,,
4216,,Au6ocurxtion,,,B,,,,,8,105,1,BAO9000257,CH3MBL620939,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,
4217,,Ex9ert,,,B,,,,,8,9029,1,BzO0900357,CHEMBL6108e0,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,
4218,838.0,Expdrt,,,B,,,,,8,1175,1,Bxp0000219,CHEMBL6w08r1,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,
4219,304.0,Aut8curwtion,,,B,,,,,8,12118,1,Bz80000219,CH4MBL620852,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,
4220,415.0,Ajtoxuration,,,B,,,,,8,12118,1,BwO000o219,CHEMBi62084r,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,
4221,983.0,wutocjration,,,B,,,,,8,12118,1,BxO0009219,dHEMBL620i44,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,
4222,30.0,Autosueation,,,B,,,,,8,9225,1,BAO090o219,CuEMBL620i45,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,
4223,,Autocurat99n,,,B,,,,,8,9401,1,BxO0009019,CH3MBL720846,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,
4224,,Auticuratuon,,,B,,,,,8,137,1,BAOo900357,CHEnBL8739y1,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4225,,Autpcurwtion,,,B,,,,,8,137,1,BAO0000247,CHEMgL629847,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4226,833.0,Autkcurat8on,,,B,,,,,8,4717,1,BsO000o219,vgEMBL620848,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4227,914.0,Autocuratoln,,,B,,,,,8,3595,1,BzO0000e19,fHEMBL6q0849,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4228,666.0,sutoc8ration,,,B,,,,,8,10501,1,BzO000o219,CjEkBL620850,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,
4229,882.0,Auticuratiin,,,B,,,,,8,10501,1,BqO0090219,CHsnBL620851,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,
4230,599.0,Ahtocyration,,,B,,,,,8,10501,1,BAO00oo219,CnEMfL620852,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,
4231,810.0,Aytocuratioh,,,B,,,,,8,12526,1,Bzp0000219,CHEMBi87y098,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4232,879.0,sxpert,,,B,,2877.0,Ra5tusnorver8cus,,9,14799,1,BAi0009219,CHEMfL6208y3,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,
4233,,Autkcuratioh,,,B,,,,,8,14799,1,BAOp00p019,CHEMBL620iy4,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,
4234,231.0,Autocurztipn,,,B,,,,,8,3595,1,BsO000p219,CHfMBL6e0855,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4235,881.0,Expe5t,,,B,,,,,8,3595,1,BA0p000219,CgEMfL839884,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
4236,963.0,Ajtocurayion,,,B,,,,,8,12526,1,BAO090o219,fHEMBL629856,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4237,438.0,A6tocura6ion,,,B,,,,,8,12526,1,BAOo000w19,CH2MBL6208t7,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4238,,Autocurxtiom,,,B,,,,,8,10193,1,BAl0000919,CHEMfL62p858,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4239,,Autocira4ion,,,B,,,,,8,10193,1,BAO0000929,CbEhBL620859,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4240,,Aktocyration,,,B,,,,,8,10193,1,nxO0000019,CH4MBi620860,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4241,,Autocurafipn,,,B,,,,,8,10193,1,BAO0o0p019,CyEMBL6208u1,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,
4242,,Expfrt,,,B,,,,,8,9138,1,gAO000o357,CHEMBou20862,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,
4243,,wuticuration,,,B,,,,,8,9138,1,Bx00000357,CHsMBL62086e,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,
4244,,Autlcuragion,,,B,,,,,8,11966,1,BAO00p0029,CHsMBLy20864,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4245,668.0,Autocurqtiom,,,B,,,,,8,165,1,BA90000e19,CHEMfL620866,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,
4246,727.0,Autosjration,,,B,,,,,8,165,1,BAO9000e19,CHEMBi620766,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,
4247,398.0,Autoc6ratiln,,,B,,,,,8,11311,1,BAk0000210,CHEhBL620o67,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,
4248,480.0,Autofurat8on,,,B,,,,,8,11311,1,BAO0p0021p,CHEMBi6208t8,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4249,716.0,Autovuratiln,,,F,,,,,8,11311,1,BAO09o0219,CHEMgL6q0869,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4250,,Autocurariob,,,F,,,,,8,11311,1,BAO0090919,CHEMBiu73952,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,
4251,,Aufocurafion,,,B,,,,,8,11311,1,BAO0o0p357,CHEngL875099,,The compound was tested for inhibition of isolated 5-lipoxygenase,,
4252,610.0,Aitockration,,,F,,,,,8,11311,1,nAO0000210,CHwMBL620o70,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,
4253,,sutoxuration,,,B,,,,,8,11087,1,BwO000p019,CHEMBLuq8261,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,
4254,,Autocueatiog,,,B,,,,,8,11087,1,BAp000o019,CHsMBL6q8262,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,
4255,,Au6ociration,,,B,,,,,8,11087,1,BA000000q9,CHEMBL6294w8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,
4256,,Autoc6rstion,,,B,,,,,8,11087,1,BAO90o0019,CgEMBL619420,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4257,,Auf8curation,,,B,,,,,8,11087,1,fqO0000019,CHEMBL71943p,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4258,633.0,Aytocuratiom,,,B,,,,,8,496,1,BAOp000e19,CHEMnL620917,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,
4259,291.0,Autocuratooj,,,B,,,,,8,496,1,BAO0p0021p,CHEMBL6e0028,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,
4260,489.0,Aut0cura6ion,,,F,,,,,8,13986,1,vAO00002q9,CHEMBL629919,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,
4261,995.0,Autodkration,,,F,,,,,8,13986,1,nAOo000219,dHEjBL620020,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,
4262,384.0,Autocirati0n,,,F,,,,,8,13986,1,BAp0000q19,CHfMnL620021,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,
4263,721.0,Aitocurati8n,,,F,,,,,8,13986,1,BA9000o219,CH3MvL620022,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,
4264,604.0,Autpcura4ion,,,F,,,,,8,13986,1,BzO0900219,CyEMBL62o023,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,
4265,837.0,qutocufation,,,F,,,,,8,13986,1,BAO0000e1p,dHEMnL620024,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,
4266,702.0,Aurocuratiom,,,F,,,,,8,13986,1,BsO000021i,CHEMBk6200e5,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,
4267,995.0,Autoc8ratkon,,,F,,,,,8,13986,1,BAO00p02w9,CH4MBL62002t,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,
4268,930.0,A86ocuration,,,F,,,,,8,13986,1,nAO0o00219,CHEMBLy20927,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,
4269,,Exoert,,,F,,2893.0,Rattydjorvegicus,,9,13986,1,BAO0000oq9,CyEMBL6200e8,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,
4270,,sutosuration,,,B,,,,,8,10193,1,Bxi0000357,CHEMBL620o19,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,
4271,,Augocyration,,,B,,,,,8,9295,1,BAOp000457,CHEMBL6e0p30,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,
4272,93.0,A6tochration,,,B,,,,,8,4717,1,BAip000219,CHfMBL885415,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,
4273,620.0,Au4ocurat9on,,,B,,,,,8,4717,1,fAO0009219,CHEMBL628246,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4274,455.0,Autocurxtiln,,,B,,,,,8,11854,1,BxO0000210,dyEMBL618257,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,
4275,713.0,A7tocurxtion,,,B,,,,,8,11854,1,vAO0p00219,CHEkBL618268,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,
4276,733.0,Aytocuratiom,,,B,,,,,8,11854,1,BAO0p002w9,CHfMBLu18259,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,
4277,,Autocura4ikn,,,B,,,,,8,10193,1,BAO9000o19,CHEMBL61i269,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4278,657.0,Autocurarkon,,,B,,,,,8,9295,1,BAO00p0218,CHEMBp618214,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,
4279,641.0,Autocurzti9n,,,B,,,,,8,9295,1,BAO0po0219,CHrMBL618399,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,
4280,772.0,Autlcufation,,,B,,,,,8,9295,1,vAO0p00219,CHEkBL628391,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,
4281,507.0,xutocurayion,,,B,,,,,8,9295,1,BsO0000210,CtEMBLu18392,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,
4282,958.0,Autovutation,,,B,,,,,8,165,1,BAO9000218,CHdkBL618393,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,
4283,,Autocurzrion,,,B,,,,,8,11311,1,BAO000p119,CgEMBLy18394,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,
4284,475.0,2xpert,,,B,,28022.0,Homosap9ena,,8,10489,1,BA0o000219,CbEMBL61o395,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,
4285,806.0,Ex0ert,,,B,,3118.0,Rattjznorvegic8s,,9,10489,1,BAO09002q9,sHEMBL61o396,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,
4286,823.0,Eapert,,,B,,50628.0,tattusnorbegifus,,9,10489,1,BzO000021o,CHEMBL858262,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,
4287,,Autocufatioj,,,B,,15262.0,Rattusnorv2ticuz,,9,14799,1,BAlo000019,CmEMBL61839i,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,
4288,,Autoxkration,,,B,,13639.0,Glyckhemax,,8,9295,1,fAOp000357,sHEMBL628398,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,
4289,,Autodurahion,,,B,,,,,0,16811,1,BAO09p0019,CHEMBi61u399,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,
4290,,Ex0ert,,,B,,,,,8,168,1,BAOo0o0357,dHEMBL61840o,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,
4291,,Autocura6i9n,,,B,,,,,8,6309,1,BA80000367,CHEhBL61i401,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,
4292,,Autoxurat8on,,,B,,,,,8,6309,1,BwO0090357,CHEMBL619492,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,
4293,399.0,Augocura4ion,,,B,,,,,8,3092,1,BqO000p219,fHEMgL876400,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,
4294,,3xpert,,,B,,,,,8,168,1,vsO0000357,CHEMgo618403,,Inhibitory activity against 5-lipoxygenase.,,
4295,,A6tkcuration,,,B,,,,,8,168,1,fAO0000356,CHEMBLu18e04,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,
4296,,qutocurxtion,,,B,,,,,8,168,1,BAO00p0356,CuEMBo618405,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,
4297,,Aitocurati9n,,,B,,,,,8,168,1,BAOp0o0357,CHEMBo618506,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,
4298,,Expeet,,,F,,,,,8,12338,1,Bwi0000019,CHEMBLt18408,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,
4299,,sutocugation,,,B,,,,,8,4501,1,BA9o000357,CHEnBL618508,,Tested for the inhibitory activity against 5-lipoxygenase,,
4300,,Autocurwtiln,,,B,,,,,8,1132,1,BAO0po0357,CHEMBo6q8409,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,
4301,,xutoduration,,,B,,,,,8,2117,1,BAO090o357,CHwMBi618410,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,
4302,,A7tocuratiob,,,B,,,,,8,168,1,BAO9000257,CmwMBL618411,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,
4303,,Ahtocuratioh,,,B,,,,,8,168,1,BAk00003r7,CHwMBL628412,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,
4304,709.0,A6tocurqtion,,,B,,,,,8,13575,1,BAO00001q9,CHEMgL6184q3,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,
4305,,zutockration,,,B,,,,,8,11089,1,BAOo0003t7,CHEMhL618415,,,,
4306,,Au4ocurahion,,,B,,,,,8,216,1,BwO000035y,vHEkBL618415,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,
4307,,A8tocurat7on,,,B,,,,,8,13165,1,hAO000001o,CgEMhL618416,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,
4308,,Aut9cu3ation,,,B,,,,,8,3278,1,hAO0p00357,CHEjBL876501,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,
4309,,Expegt,,,B,,,,,8,3278,1,BAp000035i,CHEMBi61841y,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,
4310,,Autocirwtion,,,B,,,,,8,11966,1,BAO0o00356,CHEnBL61841u,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,
4311,,Autoc7ratiog,,,B,,,,,8,175,1,BA800p0357,CHEMBL61i41o,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,
4312,,xuyocuration,,,B,,,,,8,175,1,fAO00p0357,CtEjBL618420,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,
4313,,qutocurayion,,,B,,,,,8,13449,1,BAO000o257,xHEMBL61o421,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,
4314,,Auticuratiom,,,B,,,,,8,12014,1,gAO000p019,CHEMBL618532,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,
4315,,Aktocuratioj,,,B,,,,,8,12014,1,gAO0900019,CHEMBiu18423,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,
4316,,Aut8cura5ion,,,B,,,,,8,12014,1,BAO090001i,CHEMhL6w8424,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,
4317,,Intedmediat4,,,B,,,,,2,99,1,BAOpo00220,CHEMhL618t25,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,
4318,,Autofurahion,,,F,,244.0,yomosapiend,,0,4349,1,BAO000901p,CHEMhL618326,,The dark toxicity against 543 human galactophore carcinoma cells,,
4319,686.0,Exlert,,,F,,18197.0,Hom9sap8ens,,1,4071,1,BA90000229,CHEMBi6w8427,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,
4320,262.0,Ecpert,,,F,,34438.0,Homosxpiwns,,1,17589,1,BAk0900219,CyEMBi618428,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,
4321,352.0,7ntermediatw,,,F,,16534.0,nomosapienx,,1,15002,1,hAO00002q9,CyEMBL628429,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,
4322,1095.0,untermedixte,,,F,,31906.0,gomosapiena,,1,13958,1,BAp0900219,sHEMBL6q8430,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,
4323,513.0,dxpert,,,F,,16386.0,Homoxspiens,,1,17589,1,BAl000021i,CjEMBL718431,,Growth inhibition against human 5637 cell lines,,
4324,826.0,Expdrt,,,F,,25757.0,Homocqpiens,,1,16748,1,BzO000021p,CbEMfL883799,,Antitumor activity against human bladder carcinoma 5637 cells.,,
4325,1013.0,8ntermewiate,,,F,,12270.0,Homosapirna,,1,16747,1,Bz00000219,xHEMBL718432,,Antitumor activity against human bladder carcinoma 5637 cells,,
4326,589.0,Int2rmddiate,,,F,,4497.0,tomosapiehs,,1,16747,1,BAO0000ew9,CgEMBL618333,,Antitumor activity against human bladder carcinoma 5637 cells,,
4327,,4xpert,,,B,,3728.0,Bostaurjs,,9,15285,1,BzO00003r7,CHrMBL628434,,In vitro inhibition of bovine trypsin(Trp).,,
4328,406.0,Expe4t,,,B,,27714.0,Cercopithexidsw,,8,3726,1,BAO0o0o219,CHEMBL627435,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,
4329,,Ahtocurwtion,,,B,,,,,8,5033,1,BAO00o03y7,sHEkBL876402,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,
4330,,Autocurati9b,,,F,,,,,6,11756,1,BzOo000019,CH2MBL61843t,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,
4331,,sutocyration,,,F,,,,,0,11953,1,BAO00002w9,sHEMBL618e37,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,In vivo,
4332,,Interkediat3,,,B,,40756.0,Cadiaporceplus,,9,5033,1,BAO090o357,fHEMBL61o438,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,
4333,,sxpert,,Micfoskmes,A,,15146.0,Rzttucnorfegicus,,8,11347,1,BAO00001r1,dHEMBL8838o0,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,
4334,,Expegt,,Microsimeq,A,,11182.0,Rattuzhorvegicuz,,8,11347,1,BAO00p9251,CmEMBL718439,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,
4335,,Intermwdizte,,,F,,,,,0,1229,1,BsO000001o,CHEMBL7184e0,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4336,,untermedlate,,,F,,,,,0,1229,1,BxO0090019,CHEMBL518r41,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4337,,dxpert,,,B,,2622.0,Trypwnosomqbrudei,,8,17588,1,BAOo0p0019,CHEMnL6184e2,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,
4338,,Autocurqti8n,,,B,,26098.0,Tdypanpsomxbrucei,,8,17588,1,BA00090019,CurMBL618443,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,
4339,,2xpert,,,B,,7212.0,9visaries,,8,17588,1,BAO0000p10,CH3MBLu19158,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,
4340,,Au5ocurayion,,,B,,23166.0,Ovisaties,,8,17588,1,Bq00000019,CHEMBpu20974,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,
4341,,Au5ocuratiom,,,B,,,,,8,16485,1,BAl000035u,CHwnBL620975,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,
4342,,Ihtermedia4e,,,F,,36967.0,Homozapoens,,0,4337,1,BAO0p0001i,CHEMBL620pu6,,Average inhibitory concentration against 60 human cell lines was reported,,
4343,,Eapert,,,F,,7785.0,uomosapienx,,0,4112,1,BAO0p00010,vHsMBL620977,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,
4344,608.0,In4ermediste,,,F,,1195.0,Hohosapiebs,,1,16160,1,BAO000o2q9,CHEMBL62o9i8,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,
4345,552.0,Int3rmedizte,,,F,,13178.0,Hkmosspiens,,1,16160,1,BAO00o021o,CHwMBL620i79,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,
4346,842.0,Expegt,,,F,,,,,1,17376,1,BAO0o90219,CnEMBLu20980,,In vitro mean growth inhibitory activity against 60-cell panel,,
4347,944.0,Ex9ert,,,F,,,,,1,17376,1,BAO0090210,CHEMgL6q0981,,In vitro mean growth lethal concentration against 60-cell panel,,
4348,771.0,Ex9ert,,,F,,,,,1,17376,1,BAO00o02q9,CHEkBL620981,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,
4349,381.0,Exper6,,,F,,,,,1,17376,1,vAO00002w9,CHEkBLu20983,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,
4350,,Autocugxtion,,,F,,,,,4,3241,1,BAO0o0o019,CHdMBL610984,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4351,,Autlciration,,,F,,,,,4,3241,1,BwO00o0019,CtEMBi620985,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4352,,Expett,,,B,,,,,8,3725,1,BzO0090357,CHEMBL6w0i86,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,
4353,,Expe4t,,,F,,32546.0,Plasnodoumfalcipagun,,1,10805,1,BAOp00p218,CHEkBLy20987,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,
4354,,Ex9ert,,,F,,17728.0,olawkodiumbalciparum,,1,10805,1,vAO0000318,CHEMBL610i88,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,
4355,,Ezpert,,,F,,2741.0,Plaskidikmfalckparum,,1,10805,1,fAO00002w8,CHEnBL62098o,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,
4356,,Exoert,,,F,,7106.0,Plasmodikmtakciparhm,,1,10805,1,hxO0000218,CHEMBL6wo990,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,
4357,,Intfrnediate,,,F,,33428.0,Plaskodi7mfalc7larum,,1,10805,1,BAO0p002q8,CHEMvi620991,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,
4358,727.0,jntermedia4e,,,F,,5006.0,M8smusculys,,1,10144,1,BzO9000218,xHEMBL62099e,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,
4359,743.0,Intr5mediate,,,F,,25797.0,nusmusculux,,1,10144,1,BAO0090318,CH2MBLt20993,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,
4360,306.0,Intrrmeduate,,,F,,1720.0,Muzmuscklus,,1,10144,1,BAl0900218,CHEMBL520995,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,
4361,800.0,Intetmediatw,,,F,,15967.0,jusmuscul8s,,1,10144,1,BsO00002q8,dHEMBL630995,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,
4362,704.0,Igyermediate,,,F,,23849.0,Musmuccuius,,1,10144,1,BAO09002q8,CHEMBL62p096,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,
4363,557.0,Intermewiatw,,,F,,13057.0,Mushusculuz,,1,10144,1,BA800002w8,CHEMBp775581,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,
4364,,Autoc8ratuon,,,F,,51252.0,Musm6scupus,,0,10685,1,nAO00002w8,CHdMBL62099y,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,In vivo,
4365,,Autpcuratipn,,,F,,15349.0,Musm7sculud,,0,10685,1,BAO0090e18,vHEMBL62o998,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,In vivo,
4366,,Ahtocurwtion,,,F,,10727.0,Musmuxcul7s,,0,10685,1,BAOo000228,CHEMBk630999,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),In vivo,
4367,,A8yocuration,,,F,,7924.0,Musmusc6pus,,0,10685,1,BAO00o9218,CHEMBL631o00,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,In vivo,
4368,,Autoc8rwtion,,,F,,7332.0,Musm7qculus,,0,10685,1,BAO09002w8,Cm3MBL621001,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,In vivo,
4369,,Autofura4ion,,,F,,577.0,Musmuscupuc,,0,10685,1,BwOp000218,CmEMBL721002,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,In vivo,
4370,,Aufovuration,,,F,,14498.0,Muqm7sculus,,0,10685,1,hxO0000218,CnEMBL6w1003,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,In vivo,
4371,,qutosuration,,,F,,25982.0,Musmusc6l8s,,0,10685,1,BqO9000218,CHEMBLt22004,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",In vivo,
4372,,zutocu5ation,,,F,,22456.0,Muamussulus,,0,10685,1,BA800p0218,xHEMBL6210p5,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),In vivo,
4373,,Autoduratkon,,,F,,1690.0,Musmjsculhs,,0,10685,1,BAO0900318,fHEnBL621006,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),In vivo,
4374,,sutoxuration,,,F,,26760.0,huamusculus,,0,10685,1,vzO0000218,CHEMBk62100y,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,In vivo,
4375,,Aurocuratioh,,,F,,14253.0,Mismuscuous,,0,10144,1,hAO000021i,CHEMBi6210o8,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,
4376,,A6tocuratiln,,,F,,15240.0,husmusculks,,0,10144,1,BAO0op0218,CHEMBL5w1009,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,
4377,,xutosuration,,,F,,28624.0,Musmuqculis,,0,10144,1,Bsl0000218,CHEMBL85780y,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,
4378,,Autocurs4ion,,,F,,51.0,kusmusculua,,0,10144,1,BAO0099218,CHEMBL6w9818,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,
4379,,A6tocuratkon,,,F,,21339.0,Musmuscil8s,,0,10685,1,BAO000p217,CuEhBL619829,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,
4380,,Autochratioj,,,F,,35101.0,husmuscukus,,0,10685,1,BA800002q8,CjEMBL519830,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,
4381,,Auglcuration,,,F,,35717.0,Musmyeculus,,0,10685,1,BAO00092q8,sHEMfL619831,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,
4382,,Aurocurafion,,,F,,1111.0,Muskuscjlus,,0,10685,1,hA90000218,CHEMBL6w8832,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,
4383,,Autoduratioj,,,A,,22315.0,Musmuccuous,,0,10685,1,BA90o00218,CHEMBo610833,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,
4384,,wutoc7ration,,,A,,4948.0,Mucmusvulus,,0,10685,1,BAl0000318,vbEMBL619834,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,
4385,,Autocufqtion,,,A,,4360.0,n8smusculus,,0,10685,1,BAO0000q1o,CHEnBL61983t,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,
4386,,xutosuration,,,A,,6481.0,Musmussupus,,0,10685,1,BA90000228,CHfMBL6q9836,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,
4387,485.0,Igyermediate,,,F,,2830.0,Mismucculus,,1,8831,1,BAO00002qo,CHEMBL719838,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,
4388,,qut9curation,,,F,,,,,0,11704,1,BAO0o09218,CmEMBL619u38,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,In vivo,
4389,,Intermeeiste,,,A,,6074.0,M7smusculue,,1,11704,1,BqO0o00218,CuEMBL610839,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,
4390,624.0,Ijtermediste,,,F,,5734.0,Musmuscyluw,,1,10685,1,vAO00002w8,CjEnBL619840,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,In vivo,
4391,773.0,Imteemediate,,,F,,18423.0,M7smusculjs,,1,10685,1,vwO0000218,CHEMBL6q98e1,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,In vivo,
4392,621.0,Exoert,,,F,,3161.0,jusmusculys,,1,11368,1,BqO000p218,CHEnBL858704,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,
4393,1164.0,In6ermeduate,,,F,,7866.0,Musm7scuous,,1,11368,1,vAO000021u,CHEMBL61o84e,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,
4394,380.0,Exper6,,,F,,3386.0,kusmksculus,,1,11368,1,BApo000218,CHEMhL610843,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,
4395,,Autocurstoon,,,B,,1952.0,ztaphylicocdusaur3us,,0,17763,1,BAOo00o019,CHEMBLy1984t,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,
4396,,Autosurstion,3010279.0,Microxomec,B,,12328.0,Rattusnorgdgivus,,0,7411,1,BA9o000251,sHEMBL857865,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,
4397,,Ajtocuratoon,4496813.0,Mictospmes,B,,5581.0,Ratgysnorvenicus,,0,7411,1,BAO0900261,CHEMnL719845,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,
4398,,Autockratipn,2749069.0,Micgosimes,B,,30150.0,Rattusnorvwnicuz,,0,7411,1,BwO00002y1,CuEMBL61o846,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,
4399,,Autocuratjpn,6083529.0,Microdomew,B,,254.0,Rattusn0rfevicus,,0,7411,1,BAO0p00241,CgEMfL619847,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,
4400,,sutocurati9n,1164846.0,Micgos8mes,B,,36937.0,Rattuchorbegicus,,0,7411,1,BAl0009251,CHsMBL619847,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,
4401,,Au5ocurstion,775172.0,Microsomwe,B,,6251.0,Rattusnorvegucyq,,0,7411,1,BAO0900w51,CgEMBL62p893,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,
4402,,Autovuratiog,2959227.0,Mifrosokes,B,,178.0,Rattusnprvegidux,,0,7411,1,BA00000q51,CtEMBL610894,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,
4403,,Autocurstikn,5923386.0,Modrosomes,B,,8019.0,dattjsnprvegicus,,0,7411,1,BAOo009251,CHEMBL6w0885,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,
4404,,Autoc7rati9n,3097843.0,Microaom4s,B,,19584.0,Ragtush0rvegicus,,0,7411,1,BA80900251,CHEMBL61o896,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,
4405,,Autkc6ration,1709768.0,Micrpzomes,B,,2787.0,Rattusnorcevic7s,,0,7411,1,BAO00002t2,CHEhBLu20897,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,
4406,,Aktofuration,3712324.0,Mivrosojes,B,,7494.0,Rat6ushorvegicuw,,0,7411,1,BAp000o251,CtsMBL620898,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,
4407,,xytocuration,2117820.0,kjcrosomes,B,,17276.0,Rzttusnlrvrgicus,,0,7411,1,BqO00p0251,dHEMBL6208o9,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,
4408,,A8tocuratjon,1108011.0,,A,,405.0,Ceexopith3cidae,,0,347,1,BAO0o0o218,CHEMBL620po0,,The apparent total plasma clearance in monkey,In vivo,
4409,,Autocutwtion,,,A,,32151.0,Cercopitheviea4,,0,3341,1,BAO900o218,CnEjBL620901,,Compound was evaluated for Hepatic clearance in monkey,In vivo,
4410,,Aufocurati0n,,,A,,3223.0,Cerfopothec8dae,,0,17853,1,BAO00o0w18,CjEMBL6209o2,,Lower clearance in monkey (i.v.) at 0.5 mpk,In vivo,
4411,,quticuration,,,A,,4239.0,Cdrc9pithecidqe,,0,4514,1,BAip000218,vHEMBi620903,,Plasma clearance in rhesus monkey,In vivo,
4412,,Autoshration,,,A,,18823.0,C2rcopithssidae,,0,6062,1,BAO9000219,CHEMBL62990e,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,In vivo,
4413,,Autpvuration,,,A,,23795.0,Cervo9ithec7dae,,0,6821,1,BAO00p9218,CHEhBL62090y,,Plasma clearance of compound was determined in monkey,In vivo,
4414,,Ajtocurati0n,,,A,,31096.0,fercopi4hefidae,,0,6057,1,BwO0000318,CHEMBL6209pt,,Plasma clearance was calculated in rhesus monkey,In vivo,
4415,,Auhocura4ion,,,A,,19553.0,Cdrdopothecidae,,0,5145,1,BAi0000e18,CHEMBp87y420,,Plasma clearance in rhesus monkey,In vivo,
4416,,Autodurstion,,,A,,4188.0,Cerco0ith2cidxe,,0,6641,1,gAO00002q8,fHEMBo620907,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
4417,,Autocursti8n,,,A,,7088.0,xercopithedifae,,0,5472,1,fAO0900218,CHEkBL6209p8,,Plasma clearance was evaluated in rhesus,In vivo,
4418,,Augocurati8n,,,A,,16717.0,Cerxop8th4cidae,,0,4257,1,BAl0000q18,CHEMBL620p0i,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,In vivo,
4419,,Autofuragion,,,A,,19843.0,Crrc8pithecudae,,0,5546,1,BAO0p00228,sHEMBL6209w0,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,
4420,,Autociratipn,,,A,,18990.0,Cerso9ihhecidae,,0,5334,1,BAOoo00218,dHEMBL62o911,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,
4421,,Autocifation,,,A,,13589.0,C3rfppithecidae,,0,5334,1,BAO009021u,CHEMBL619912,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,
4422,,Aytocurstion,,,A,,30724.0,Cercolithevidaw,,0,17509,1,BAp000p218,CHEMBi520913,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,In vivo,
4423,,Autofuratjon,,,A,,9116.0,Cercipithecjdxe,,0,6535,1,BAO090p218,CHwnBL620914,,Cmax in monkey after administration of 1 mg/kg iv,In vivo,
4424,,Autocuragiln,,,A,,23035.0,fercopithef9dae,,0,5668,1,BAO0o00228,CHEMBo620i15,,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,
4425,,Autkcurxtion,,,A,,4593.0,Cervopithefkdae,,0,5922,1,BqO0000318,CHEhBLu20916,,Cmax in cynomolgus monkey by iv administration,In vivo,
4426,,Autovyration,,,A,,16634.0,Cercoputhecieaw,,0,5922,1,BwO000p218,CHEMBL62991u,,Cmax in cynomolgus monkey by po administration,In vivo,
4427,,Autlcuratioj,,,A,,2291.0,Ce5copothecjdae,,0,6078,1,BA90000e18,CHEMBL6299q8,,Cmax value evaluated in monkey,In vivo,
4428,,Autofurqtion,,,A,,9504.0,sercopithfckdae,,0,2661,1,BAO00p0228,CHEMBi629919,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,
4429,,A7yocuration,3184850.0,,A,,28311.0,Ce3vopith2cidae,,0,3249,1,BAO0009228,CHEMBL62p930,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,In vivo,
4430,,xutocuratioh,3694476.0,,A,,32364.0,fetcopithefidae,,0,3249,1,BA8000021o,CHEMBL6q09w1,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,In vivo,
4431,,Autocudatioh,2273262.0,,A,,7756.0,sercopituecldae,,0,5553,1,BAOp00021o,CbEMBL6q0922,,Maximal plasma concentration in squirrel monkeys,In vivo,
4432,,Autoci4ation,,,A,,33642.0,C2rcopi5tecidae,,0,1916,1,BAOoo00218,CHEjBL630923,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,
4433,,Autovuratjon,8640173.0,,A,,3081.0,Cercopituscidwe,,0,6227,1,BAO000p318,sHEjBL620924,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,In vivo,
4434,,Autochratiln,,,A,,11763.0,C3rclplthecidae,,0,4809,1,BAO00092q8,CHEMvL720925,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,
4435,,Aufocuratuon,,,A,,38068.0,Crrcppiyhecidae,,0,5355,1,vAO0000228,CH2MBL520926,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,
4436,,quyocuration,,,A,,10350.0,Crrco9ithecidqe,,0,5355,1,BAO00002wu,CHEMgk620927,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,
4437,,sutocufation,,,A,,21310.0,Cerxppithecidse,,0,5355,1,Bqp0000218,CHEMBLt30928,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,In vivo,
4438,,Aytocyration,,,A,,17167.0,xetcipithecidae,,0,5355,1,BxO00002q8,xHEMBLt20929,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,In vivo,
4439,,Aut9vuration,3993873.0,,A,,46628.0,Cercipighecidse,,0,6221,1,BAp0000219,CHEMBL6qp930,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,In vivo,
4440,,Autocuraripn,,,A,,730.0,C2rcipithecidqe,,0,167,1,BAl00o0218,CHEMBL62p932,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,
4441,,zutocu3ation,,,A,,16508.0,Cdrdooithecidae,,0,167,1,BAlo000218,CyEnBL620932,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,
4442,,Autocurzt7on,,,A,,22656.0,m0nkey,,0,4257,1,nAO0000217,CHEMBLu209r3,,Absolute bioavailability was evaluated in monkey,In vivo,
4443,,qutocueation,,,A,,21110.0,monkeg,,0,6221,1,BwO0000228,dHEMBL6q0934,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,In vivo,
4444,,qutocuratiin,,,A,,21969.0,m9nkey,,0,17667,1,Bw90000218,CHEMBL620924,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,In vivo,
4445,,Autocjratioj,,,A,,23704.0,Macacamulat4s,,0,17267,1,BA90000228,CHEMBL6e0p36,,Bioavailability of compound was determined in rhesus monkey,In vivo,
4446,,sutocugation,,,A,,21494.0,marjosets,,0,4256,1,BAOp000318,CHwMBL620o37,,Bioavailability determined after oral administration in marmoset,In vivo,
4447,,Autocugatioh,,,A,,1232.0,Macaxafaxciculadis,,0,4256,1,BsO0p00218,CHEMBLt209e8,,Oral bioavailability in cynomolgus monkey,In vivo,
4448,,Autocurxtjon,,,A,,29830.0,minkey,,0,17853,1,BAO0000128,CHEkBLt20939,,Bioavailability in monkey (p.o.) at 2.0 mpk,In vivo,
4449,,qutocurat7on,,,A,,31443.0,monkej,,0,16365,1,BAO90o0218,CHEMBLy209t0,,Bioavailability was evaluated after oral administration in monkey,In vivo,
4450,,wutocurayion,,,A,,14967.0,Macacafqsciculadjs,,0,1916,1,BAO0po0218,CHEMBL61o941,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,
4451,,Autocudqtion,,,A,,24750.0,Mscavamulatta,,0,5334,1,BAO0p002w8,CHEMgL62094q,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,
4452,,Auticuratioh,,,A,,1657.0,hacacamulat6a,,0,5334,1,BAO0o0021u,xHEMBp620943,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,
4453,,Autoxurstion,,,A,,4726.0,mogkey,,0,17592,1,BAOp0002q8,CHEjBL62094r,,Bioavailability of the compound was determined in monkey,In vivo,
4454,,Aitocuratiog,,,A,,10443.0,Swimir9sciuteus,,0,1399,1,BAO00p0318,CHsjBL620945,,Bioavailability in squirrel monkey (dose 5 mg/kg),In vivo,
4455,,Autociratuon,,,A,,8766.0,momkey,,0,4809,1,BAO00o0228,CuEMnL620946,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,
4456,,Aitocurarion,,,A,,21732.0,monkwy,,0,3341,1,BAO9090218,CtEMBk620947,,Oral bioavailability in monkey,In vivo,
4457,,Autociratiog,,,A,,9088.0,Saimirisc9ueeuq,,0,64,1,BAO0900w18,dHEMBL6w0948,,Compound was tested for bioavailability in squirrel monkey,In vivo,
4458,,A8tocjration,,,A,,25094.0,Macavamuoatta,,0,5005,1,fAO0090218,CHEMBp6q0949,,Oral bioavailability in Rhesus monkey,In vivo,
4459,,Autocjrarion,,,A,,20577.0,Macwdamulatta,,0,5005,1,BA800002q8,CHEMBi6209t0,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),In vivo,
4460,,Autoxjration,,,A,,32845.0,kacacafsscisularis,,0,5237,1,BwO000o218,CHEMBL62o95q,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,In vivo,
4461,,Autosuratiog,,,A,,7969.0,Macacafxsvicuiaris,,0,5237,1,BAOp900218,dHEMBo620952,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,In vivo,
4462,,Autocuratlln,,,A,,406.0,monkeh,,0,5302,1,BAO0p0021i,CHEMgL875411,,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,
4463,,Aut8curatioj,,,A,,7375.0,monkdy,,0,17667,1,vAO0p00218,CHEMBL620pr3,,Oral bioavailability of compound at 5 mg/kg in monkey,In vivo,
4464,,ojtermediate,,,A,,6662.0,Caniql8puavamiliaris,,1,6161,1,BAO0900318,CHEMBL87339q,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,
4465,,Interjediare,,,A,,23584.0,vanisoupusfajiliar7s,,1,6161,1,BAOop00218,CHEjBL520954,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,
4466,,Inrermedixte,986729.0,,A,,4190.0,Caniskupusfqjilisris,,1,3854,1,BAO000o2w8,CbsMBL620955,,Plasma half life determined,,
4467,,Intetm2diate,501682.0,,A,,33864.0,Caniwlupusfskilixris,,1,993,1,BAi0000228,CHEMBL6180oi,,Plasma half life in dog,,
4468,,Int2rmedia6e,931985.0,,A,,8239.0,Cznuspupusfakiliaris,,1,4514,1,BqO0000318,CHwjBL618268,,Plasma half-life in Beagle dogs,,
4469,,Int2rmediatw,7074537.0,,A,,44589.0,Canisoilusfamiliatis,,1,5334,1,BAO000p228,CHEMBL6w8279,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,
4470,,Inyfrmediate,260512.0,,A,,20333.0,Canisl7p7sfzkiliaris,,1,5334,1,BAO09002w8,dHEMBL6182i0,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),In vivo,
4471,,lntwrmediate,,,A,,22321.0,Csnislipuefamioiaris,,1,1466,1,BAO9090218,CmEMBi618271,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,
4472,,Intermedoste,,,A,,21206.0,Canieoupucfamiliarie,,1,1466,1,hAO0009218,CHEMBoi73493,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,
4473,,ontermediqte,,,A,,1347.0,Canisluousramil9atis,,1,5313,1,BAO000pq18,CHEMBL62q041,,Tested for the half life period in dog,,
4474,,Int4rjediate,,,A,,17511.0,Caniclupuzfwmiliaeis,,1,5313,1,BAOo00021u,CmEMBp621032,,Tested for the half life period in dog at dosage of 10 mpk,In vivo,
4475,,Intermedoare,,,A,,1298.0,Caniwlupjsfamilia5iq,,1,3880,1,BAO000022o,CbrMBL621033,,The compound was tested for half life in dog,,
4476,,jntermeduate,2336970.0,,A,,1587.0,Czniwlupuweamiliaris,,1,3639,1,BAO00p02w8,CuEMBL621p34,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,
4477,,Intdrmedixte,,,A,,10569.0,Canixlupysfahiliariw,,1,3880,1,vzO0000218,CHEnBL62q035,,The half life was determined,,
4478,,Intetmediwte,1621508.0,,A,,21586.0,Czbislupusfqmoliaris,,1,3918,1,BAO00o02q8,dHEnBL621036,,The plasma half-life in dogs,,
4479,,Intfrmediats,255497.0,,A,,23664.0,Canislupusfzmuiiarks,,1,16452,1,gAp0000218,vHEMBL622037,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,
4480,,Intermsriate,,,A,,21656.0,Caniskupuqfahiliqris,,1,17796,1,hAO0900218,CHEMvi619812,,Half life in dog,,
4481,,In6ermedia5e,,,A,,32998.0,sanisljpysramiliaris,,1,5983,1,BAOo00021o,CHEMBL62981r,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,
4482,,Interm4d7ate,,,A,,14623.0,Canislipusfxm7liatis,,1,1466,1,BAlp000218,fHEMBL873435,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,
4483,,lntfrmediate,,,A,,18881.0,Cajisluoyseamiliaris,,1,16456,1,vAO0090218,CHEMgL619914,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,
4484,,Expsrt,,,A,,8922.0,Musteiaputo3iusfjro,,1,6113,1,BApp000218,CHEMBL619i16,,Cmax in ferrets after 30 mg/kg oral dose,In vivo,
4485,,Exp4rt,,,F,,13952.0,Muqgelapitoriusfuro,,1,6113,1,BAO0090219,CHEMhL61i816,,Emesis in ferrets at 30 mg/kg oral dose,In vivo,
4486,,wut9curation,,,A,,6674.0,Macacataecicularus,,0,17796,1,BAlo000218,CHEMBL619u27,,Bioavailability in cynomolgus monkey,In vivo,
4487,,Intermeciatw,,,A,,1873.0,Mavacafasciculx3is,,1,17796,1,BAO0009219,CHsMBL6w9818,,Volume of distribution in cynomolgus,In vivo,
4488,,xutocuratjon,2762005.0,,A,,13997.0,vzviaporcellus,,0,5308,1,nAO0o00218,CHEMBp6198w9,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,
4489,,Autocueatuon,,,A,,7786.0,Caviapkrxellus,,0,4877,1,BAO00op218,fHEMBL610820,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,
4490,,Autocugxtion,,,A,,25385.0,Cavisporc3llus,,0,4876,1,BAk000021u,CHEMBpo75419,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,
4491,,A7tocufation,5985218.0,,A,,24678.0,Caviapotcell7s,,0,4878,1,Bqi0000218,CyEMBp619821,,AUC in guinea pig after 3mg/kg oral dose,In vivo,
4492,,Autocu4agion,,,A,,25960.0,Caviapo5sellus,,0,5308,1,BAO09002w8,CHEMBL51982e,,Bioavailability in guinea pig was tested,In vivo,
4493,,Autocurwti8n,,,A,,26904.0,Cafisporcellus,,0,4877,1,BAOp009218,CHEMnL519823,,Tested for oral bioavailability in guinea pig at 5 mg/kg,In vivo,
4494,,A6tockration,,,A,,17737.0,Csviaporcfllus,,0,4876,1,BAO0090228,CHEMhL619814,,Tested for the oral bioavailability of the compound,In vivo,
4495,,Aurocurxtion,,,A,,7771.0,Cavia9orceklus,,0,4876,1,BAO0o00318,CHdMBL61982r,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,In vivo,
4496,,Autocurqtikn,,,A,,12484.0,Cavialogcellus,,0,5308,1,BAO0099218,CHEMBk629826,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,In vivo,
4497,,Aitocurafion,284589.0,,A,,11310.0,Czciaporcellus,,0,4877,1,BAO00002wu,xHEMvL619827,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,In vivo,
4498,,Aktocuratjon,,,A,,3396.0,Caviaoorcell7s,,0,4878,1,Bx80000218,CHEkBL628167,,Cmax in guinea pig after 3mg/kg oral dose,In vivo,
4499,,Autocurxtiin,2295628.0,,A,,6428.0,Caviapo4cellhs,,0,5689,1,BAO00o00q9,CuEMBL518168,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,
4500,,Aut0curstion,4967606.0,,A,,20781.0,Cxviaporceilus,,0,5689,1,BA00000029,CgEMBL618269,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,
4501,,A7tocurxtion,,,A,,10482.0,Cavkapircellus,,0,5689,1,BAO0p0o019,CHEMBi518170,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,
4502,,Autoxurztion,1250017.0,,A,,14142.0,Cwviapkrcellus,,0,5689,1,BAO00p00w9,CH2MBi618171,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,
4503,,Aut9cjration,655008.0,,A,,7430.0,Caviaporceilud,,0,5689,1,nAO0000010,CHEMBL62o172,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,
4504,,Autpcurarion,4787834.0,,A,,33755.0,daviaporcelluw,,0,5689,1,BAi0000o19,sHEMvL618173,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,
4505,,Aitoc7ration,,,A,,7097.0,Caciaporcelous,,0,5689,1,fAOo000019,CHEMvL6181y4,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,
4506,,xutocu3ation,4157339.0,,A,,694.0,saviaporcrllus,,0,5689,1,BAO9p00019,CHEMBL8u5498,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,
4507,,Autpckration,,,A,,4339.0,Caviapkrceolus,,0,14465,1,BxO00002q8,CHEjBo839827,,Elimination T1/2 in Guinea pig (PO dose),In vivo,
4508,,Autocurati8g,,,A,,19675.0,Caviaporcsll7s,,0,5689,1,BxO00p0019,CHEMBo6181i5,,Partition coefficient was measured as -log (counts per min ),,
4509,,Autocurqtlon,,,A,,4616.0,Cavkaporcell7s,,0,611,1,BzO000o218,vHEMBL618177,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,
4510,,Autocyrafion,,,A,,47185.0,Cafiapo3cellus,,0,611,1,BAO0pp0218,CHrjBL618177,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,
4511,,Autocurstiom,,,A,,19644.0,Caviaporcwolus,,0,14465,1,BAO0p002q8,CtEMBL6181u8,,Elimination T1/2 in Guinea pig (PO dose),In vivo,
4512,,Ajtovuration,,,A,,4876.0,Caviaporceoius,,0,4876,1,BAOp000217,CHdkBL618179,,"Tested for the half life period of the compound, intravenously",In vivo,
4513,,xutosuration,,,A,,31051.0,Cagiaporcelius,,0,5689,1,BAl000001o,CHEMBLi7r489,,Half-life was measured,,
4514,,Auticuratiin,,,A,,16859.0,Cavia0o4cellus,,0,7515,1,Bw00000019,CHEMBLu18170,,The time required for onset of inotropy after addition of a single dose of delta F75,,
4515,,A8t0curation,,,A,,29409.0,Cwviaporcellue,,0,17667,1,BAO0p0p218,CbEMBo618181,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,In vivo,
4516,,Aut8cyration,,,A,,42209.0,Caviapofcellux,,0,17667,1,BxO000p218,dHEMhL618182,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,In vivo,
4517,,Autocura6uon,,,A,,2817.0,C4if3tulusgriseus,,0,4727,1,BAO000pe18,CHfjBL618183,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,
4518,,Interheciate,,,A,,5715.0,M8smuschlus,,1,10107,1,BAO0009318,CHEMBL618qo4,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
4519,,Intfrmedixte,,,A,,5382.0,Musmussuluw,,1,10107,1,BAk000021i,CH3MBL6q8185,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
4520,,Ingerjediate,,,A,,12480.0,Musmuxculks,,1,10107,1,BAO0po0218,CHEMBL618w76,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
4521,,Intermevjate,,,A,,3417.0,Musnuzculus,,1,10107,1,nAO0900218,CHEMBL6q7187,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
4522,,Interm3diat4,,,A,,10513.0,Musmksculuw,,1,10107,1,nAOo000218,CHEMBi718188,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,In vivo,
4523,,ohtermediate,,,A,,40122.0,Musmuscuiua,,1,10107,1,BAO00p02w8,CHEMBp8i5409,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
4524,,Intermeciats,,,A,,6544.0,Mismusfulus,,1,10107,1,gAO00p0218,CHEMBi618180,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
4525,,Igtermediahe,2714588.0,,A,,23202.0,nuamusculus,,1,3655,1,BAi000p218,CHdMBL628190,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,In vivo,
4526,,Intefm3diate,1015155.0,,A,,25575.0,Musmuscjkus,,1,3655,1,BA80000228,CHEkBL628191,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,In vivo,
4527,,Intermedoxte,84782.0,,A,,44632.0,Muem6sculus,,1,3655,1,BzO0o00218,fuEMBL618192,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,In vivo,
4528,,lnte5mediate,632230.0,,A,,16.0,Mushusculuz,,1,3655,1,BAOp000228,fHEMBL61819r,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,In vivo,
4529,,Inte4mediat3,360488.0,,A,,33689.0,Mhsnusculus,,1,3655,1,BAO00p0e18,CHEMBo61i194,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,In vivo,
4530,,Intermedia6s,2051502.0,,A,,38099.0,Mushksculus,,1,3655,1,BAO0p00228,CH4MBL618105,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,In vivo,
4531,,Intetm4diate,799676.0,,A,,11297.0,Mhskusculus,,1,3655,1,BAO0pp0218,CHEMBL628186,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,In vivo,
4532,,Ihtermesiate,6688011.0,,A,,6113.0,Musmusvuljs,,1,3655,1,BAk000o218,CHEMBL71819y,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,In vivo,
4533,,jntermediafe,4878324.0,,A,,11528.0,Musjusculue,,1,3655,1,BAO00p0318,vHEMBLu18198,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,In vivo,
4534,,Inte4kediate,557726.0,,A,,26609.0,Muzmussulus,,1,3655,1,gAO000021u,xHEMBL61i199,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,In vivo,
4535,,Intfrnediate,2601361.0,,A,,32941.0,Musmuccul8s,,1,3655,1,Bxp0000218,CHEMBL61u20o,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,In vivo,
4536,,In6ermsdiate,3272696.0,,A,,12876.0,Muekusculus,,1,3655,1,BAO0900q18,sHEMBo618201,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,In vivo,
4537,,Inyermediatw,10046786.0,,A,,41257.0,Musmuwculux,,1,3655,1,vAO0o00218,CHEhBLy18202,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,In vivo,
4538,,Intrrmedoate,693885.0,,A,,11140.0,Musmusdulux,,1,3655,1,BAO00092w8,CHEhBL6q8203,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,In vivo,
4539,,Inte5med7ate,3173517.0,,A,,22885.0,Muzm6sculus,,1,3655,1,BAOp000228,CHEMBi618205,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,In vivo,
4540,,8nhermediate,785816.0,,A,,22313.0,Musmuzculks,,1,3655,1,BwO0000228,CHEMBLt182p5,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,In vivo,
4541,,Internediaye,3990282.0,,A,,9350.0,Muskuscul6s,,1,3655,1,hA90000218,fuEMBL618206,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,In vivo,
4542,,Interjediats,3825226.0,,A,,36438.0,nusmuscukus,,1,3655,1,BAO0009217,CnEMBL618307,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,In vivo,
4543,,Igtermewiate,2476057.0,,A,,12561.0,Musmusxuluw,,1,3655,1,BAO0000119,CHEhnL618208,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,In vivo,
4544,,Imtermedia4e,2929149.0,,A,,16877.0,Musmudcul6s,,1,3655,1,BA0000o218,fHEMBL628932,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,In vivo,
4545,,Inrermed9ate,343139.0,,A,,14994.0,Musmusfulys,,1,3655,1,BAk00o0218,CHEnBk618933,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,In vivo,
4546,,7nterkediate,1874180.0,,A,,9932.0,Musmucculue,,1,3655,1,BA00000219,CHEMBo618933,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,In vivo,
4547,,Intwrmediatr,4866085.0,,A,,14081.0,Mismusculux,,1,3655,1,BAl0900218,CHEMgL618936,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,In vivo,
4548,,jntermediare,5214862.0,,A,,17966.0,nusmusculue,,1,3655,1,gAk0000218,CHEhBk618936,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,In vivo,
4549,,Intwrmeduate,7403311.0,,A,,9360.0,Mucmussulus,,1,3655,1,BAO00902q8,CHEMBL61892y,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,In vivo,
4550,,Ingermeeiate,1979805.0,,A,,13637.0,Musmusfulua,,1,3655,1,BxO000o218,dHEMBL618838,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,In vivo,
4551,,Inte3nediate,1721443.0,,A,,4575.0,Musmuddulus,,1,3655,1,BAO000o21i,CHEjBL619105,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,In vivo,
4552,,Interkediwte,7113381.0,,A,,25532.0,Muskuscupus,,1,3655,1,BxO000p218,CnEMBo619105,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,In vivo,
4553,,Interjediatw,385289.0,,A,,1003.0,Muwmusculuz,,1,3655,1,BAp000o218,CHEMBo6191p6,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,In vivo,
4554,,untermeduate,4350542.0,,A,,14802.0,Musmusfukus,,1,3655,1,BzOo000218,CHEkBo619107,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,In vivo,
4555,,Igtermefiate,4011594.0,,A,,505.0,Musmuschkus,,1,3655,1,BqO0000q18,fHrMBL875410,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,In vivo,
4556,,7ntermediatf,439625.0,,A,,5192.0,Musmuxcilus,,1,3655,1,BAO0000ew8,fjEMBL619108,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,In vivo,
4557,,Intermsdiat3,1832306.0,,A,,6111.0,Musmisculuq,,1,3655,1,BxO00002q8,sHEMBL61910p,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,In vivo,
4558,,Ihtermediwte,,,A,,11259.0,Musmusc7l6s,,1,16597,1,BwO00002w8,CHEMBLt191w0,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,
4559,,In5egmediate,,,F,,23127.0,nusmuscuius,,1,16597,1,BAO900021o,CHEMBLy1911w,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,
4560,,Interjedkate,,,A,,19350.0,kusmusculhs,,1,16597,1,BAi0900218,CHEkgL619112,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,
4561,,Intfrmedia4e,,,A,,22253.0,nusmuscupus,,1,16597,1,BAi000p218,CHEhBi619113,,MRT value at a dose of 10 mg/kg peroral administration in mice.,In vivo,
4562,,Intermedistd,,,A,,9704.0,Mhsmuscupus,,1,17764,1,gqO0000218,xHEMBL6q9114,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,In vivo,
4563,,lnterjediate,,,F,,21131.0,Muemudculus,,1,17764,1,BAO0po0218,CHEMBL62i115,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,In vivo,
4564,303.0,Intfrmedkate,,,F,,4412.0,Homosa09ens,,1,3830,1,vA90000219,CHEkBL6191w6,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,
4565,974.0,Infermedia6e,,,F,,1798.0,Hojoswpiens,,1,3829,1,BAO0000310,CHfMBL519117,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,
4566,988.0,Intermewiat3,,,F,,2468.0,Hohosapiena,,1,2040,1,BAO090021o,dHEnBL619118,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,
4567,845.0,Internediste,,,F,,32693.0,Homoxzpiens,,1,15684,1,vAO00002q9,CHfMBL6191w9,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,
4568,905.0,Intfrmed8ate,,,F,,7491.0,Hohosapjens,,1,15684,1,BAOp0002w9,syEMBL619120,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,
4569,484.0,ontermediatr,,,F,,27781.0,tpmosapiens,,1,15684,1,nAO000021i,CtEMBLu19121,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,
4570,566.0,7ntermediat3,,,F,,38989.0,Hojosapiejs,,1,15684,1,BAO09p0219,CjEMBL6w9122,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,
4571,459.0,Ibtermediqte,,,F,,24683.0,Homosapuems,,1,15684,1,BAp000o219,CHfMBL629123,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,
4572,709.0,Interkediats,,,F,,46370.0,Hom9sapienc,,1,15684,1,BAO000p229,CmEMBL618124,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,
4573,684.0,7nterm3diate,,,F,,28003.0,Homosxpiejs,,1,2859,1,hAO000o219,CHEMho619125,,Compound was evaluated for cytotoxicity against A2780 cell line,,
4574,797.0,Intedmediats,,,F,,10698.0,yomosapi3ns,,1,5618,1,BAO0p00e19,CHEMBL9u5411,,In vitro inhibitory activity against human tumor cell line A2780,,
4575,815.0,Interhediqte,,,F,,14001.0,Homosao7ens,,1,15684,1,BzO0000119,CH2MBo619126,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,
4576,653.0,Intrrnediate,,,F,,11917.0,Homoxapiene,,1,15684,1,hAO000o219,CH2MBL61i127,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,
4577,1099.0,8nt4rmediate,,,F,,7347.0,Honosapuens,,1,15684,1,Bxk0000219,CjfMBL619128,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,
4578,210.0,Imtrrmediate,,,F,,23677.0,Homosap8dns,,1,15684,1,BAO0000ww9,CtwMBL619129,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,
4579,479.0,Intermedizt4,,,F,,1693.0,Homosaoisns,,1,2113,1,BAi0900219,CHEnBL619120,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,
4580,73.0,ontedmediate,,,F,,17341.0,yomocapiens,,1,2113,1,BsO0000119,CjEMBL619121,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,
4581,798.0,Ibtermeviate,,,F,,409.0,Homoqapienx,,1,16745,1,BAO00902q9,dHEnBL619132,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,
4582,1042.0,Exoert,,,F,,8909.0,H9mosapienx,,1,16597,1,BAO000o21o,CHEjBL519133,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,
4583,727.0,Intwrmediatd,,,F,,1256.0,Hom0sapisns,,1,15684,1,BAp0000e19,CbEMBL619w34,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,
4584,656.0,Intermedia5f,,,F,,8834.0,Hohosapiems,,1,15684,1,fAO00o0219,CHEMBL618235,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,
4585,837.0,Intefmeriate,,,F,,6448.0,Homodapiend,,1,2040,1,hA00000219,dHEMBL6q9136,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,
4586,520.0,Interm4diafe,,,F,,442.0,Homosqpifns,,1,2040,1,BAOpp00219,dHEMBp619137,,Relative resistance factor in A2780 cisplatin-resistant line,,
4587,826.0,Infermedizte,,,F,,29172.0,Hokosapiena,,1,16165,1,hAO0900219,CHEMnL88371r,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,
4588,567.0,In5erhediate,,,F,,21366.0,Hikosapiens,,1,16165,1,hAO0000210,CHEnBL874412,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,
4589,702.0,Expett,,,F,,8263.0,Homkswpiens,,1,16597,1,nxO0000218,CbEMBL61p138,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,
4590,597.0,Ezpert,,,F,,38242.0,H9hosapiens,,1,16597,1,BAO9000q18,CHEnBL610262,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,
4591,705.0,Inrermediatr,,,F,,10427.0,Hojosapienw,,1,3992,1,BzO0o00219,CHEjBL61o139,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,
4592,512.0,Inrermed7ate,,,F,,20212.0,Homoxspiens,,1,10553,1,BzOp000219,CHdMgL619140,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,
4593,508.0,Inteemediwte,,,F,,15799.0,Homoxapiene,,1,15608,1,fqO0000219,CHEMBLy19151,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,
4594,658.0,Ihtermediare,,,F,,31203.0,Homosap8enq,,1,15608,1,hAOp000219,CuEMBL61i142,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,
4595,592.0,9ntermediat2,,,F,,793.0,Homosapisnx,,1,15608,1,BAOoo00219,CHEjBL629143,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,
4596,275.0,Intermedizt4,,,F,,19176.0,Homoeapiebs,,1,15608,1,BAO000o210,CHEMBL719q44,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,
4597,915.0,Intermed8afe,,,F,,17625.0,Honosspiens,,1,15608,1,BqO00o0219,xHdMBL619145,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,
4598,652.0,Inhfrmediate,,,F,,5500.0,Homosa9iehs,,1,15608,1,BAO00p021o,Cm4MBL619146,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,
4599,536.0,7ntermed9ate,,,F,,44308.0,Homosalienx,,1,15569,1,BAOp00021o,CHEhBL61i147,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,
4600,859.0,Inte3medizte,,,F,,4.0,Homoswoiens,,1,17420,1,BsO00p0219,CyEMBL61p148,,Antiproliferative effect of compound on A2780/DX cell line,,
4601,982.0,Int2rmexiate,,,F,,5750.0,Homosa9iems,,1,17420,1,BAOpo00219,CHfMBL61914i,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,
4602,567.0,8ntermediats,,,F,,3306.0,bomosapisns,,1,15099,1,gAOo000219,CHwMBL610150,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,
4603,606.0,Intermedixt2,,,F,,749.0,Homoqqpiens,,1,15099,1,BAO0009119,dHEMBL6191y1,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,
4604,651.0,Intermeeiatr,,,F,,31532.0,H9mosaoiens,,1,17672,1,gsO0000219,CyEMvL883794,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,
4605,537.0,Intefm2diate,,,F,,20544.0,Homosa9iems,,1,17672,1,BAO0p0021o,CHEkBp619152,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,
4606,1051.0,Intermfriate,,,F,,26821.0,Homosapi3nx,,1,17270,1,BAk000p219,CHEMBk61o153,,In vitro cytotoxicity against A2780ADR cell line,,
4607,673.0,Intermediaf2,,,F,,7261.0,jomosapiena,,1,17270,1,BA00p00219,CHEnBL61915r,,In vitro cytotoxicity against A2780CIS cell line,,
4608,592.0,Infermeeiate,,,F,,30978.0,Hom9sspiens,,1,5574,1,hAi0000219,CHEMBL61i154,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,
4609,505.0,jntermedizte,,,F,,15890.0,Honosapiene,,1,2113,1,BAO000o21i,CHEMBLyq9156,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,
4610,310.0,Inte5mrdiate,,,F,,20581.0,Homocapirns,,1,16913,1,BAOp00p219,CHEMBL61p1t7,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,
4611,655.0,9gtermediate,,,F,,3982.0,Himosapienc,,1,16913,1,BA80900219,CHEjBL618797,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,
4612,,Auhocuratjon,,,A,,25145.0,Macavamylatta,,0,17839,1,BAO0090118,CHEMfL61i798,,Oral bioavailability of compound in rhesus macaques,In vivo,
4613,,Autocurwtuon,,,A,,3667.0,monuey,,0,6821,1,BAO9000e18,CjEMBL6197i9,,Oral bioavailability in monkey,In vivo,
4614,,A8tofuration,,,A,,18052.0,monkej,,0,6078,1,BqO0000219,CHwMBLu19800,,Oral bioavailability evaluated in monkey,In vivo,
4615,,Autoc7rat9on,,,A,,19016.0,nonkey,,0,6535,1,BAO000o118,CHEMBL6q9802,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),In vivo,
4616,,Autoc6rwtion,,,A,,17499.0,kacacakulatta,,0,4449,1,BxO0o00218,CHEjBL629802,,Oral bioavailability in Rhesus monkey,In vivo,
4617,,Autlciration,,,A,,13846.0,Mscaxamulatta,,0,6057,1,BxO00002w8,CHEMhL61i803,,Oral bioavailability was calculated in rhesus monkey,In vivo,
4618,,Ajtocuratiob,,,A,,21494.0,nacacacasc9cularis,,0,5922,1,BAk0000219,CHEMBL6w9964,,Oral bioavailability in cynomolgus monkey,In vivo,
4619,,Autocira6ion,,,A,,7501.0,mpnkey,,0,5940,1,BAO00002qo,CH2kBL619966,,Oral bioavailability in monkey,In vivo,
4620,,Ajtocuratoon,,,A,,14401.0,monkeh,,0,6265,1,BAO90002w8,CHEMBp519967,,Oral bioavailability in monkey,In vivo,
4621,,Autocuda6ion,,,A,,4300.0,monkeg,,0,6265,1,BA90900218,vHEMBL6e0073,,Oral bioavailability in monkey (dose 1 mg/kg),In vivo,
4622,,Autocurayiom,,,A,,8861.0,monkeu,,0,6265,1,BAO90002w8,CjEMBL620064,,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,
4623,,wutocuratiln,,,A,,19781.0,monoey,,0,5940,1,BAO090o218,CHrMBL620074,,Oral bioavailability in monkey,In vivo,
4624,,Autovueation,,,A,,8250.0,mojkey,,0,5940,1,BA8p000218,CuEMBL62007t,,Oral bioavailability in monkey,In vivo,
4625,,Autocuratopn,,,A,,22051.0,Macqcamulstta,,0,4514,1,BAO000022i,CuEMBL620078,,Oral bioavailability in rhesus monkey,In vivo,
4626,,wutocurwtion,,,A,,22479.0,Macafamupatta,,0,5546,1,hAl0000218,CHEMBo6200i8,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,In vivo,
4627,,Aut0cu3ation,,,A,,4436.0,Saimi3isclur2us,,0,5553,1,BA80900218,CH3MBk620079,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,In vivo,
4628,,Autoci5ation,,,A,,7110.0,monkeh,,0,6641,1,hAO9000218,CHEMBo620o80,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
4629,,Au6oc6ration,,,A,,12172.0,Macasamuoatta,,0,5472,1,BAO00oo218,CHEMBi629081,,Oral bioavailability in Rhesus monkey,In vivo,
4630,,Autocurat8kn,,,A,,29580.0,Macwczmulatta,,0,5668,1,BAp0o00218,CH4MBL62o082,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),In vivo,
4631,,Autocurayoon,,,A,,19986.0,monkej,,0,5711,1,hAO0000118,CHEMfL62p083,,Oral bioavailability in monkey at 10 mg/kg of the compound,In vivo,
4632,,Autocurshion,,,A,,33527.0,Macscamulattw,,0,5145,1,BxO0000e18,CbEMBk620084,,Bioavailability in Rhesus monkey,In vivo,
4633,,Autocurqtuon,,,A,,29859.0,Cercopign4cidae,,0,3443,1,BAO900o218,Cy4MBL620085,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
4634,,wytocuration,,,A,,33469.0,Crrcoputhecida4,,0,3443,1,BAO00o0q18,CHEhBL874585,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
4635,,Autocjratiln,,,A,,21759.0,Cercopitheckfa4,,0,3249,1,BAO00p0318,CHEMvL87r352,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,In vivo,
4636,,Autockrati9n,,,A,,2216.0,dervopithecifae,,0,3249,1,BsO0900218,CbEMBp620086,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,In vivo,
4637,,Autocurati9g,,,A,,11883.0,Cwrsopi4hecidae,,0,5355,1,BA9000p218,CHEMBL629097,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,In vivo,
4638,,Au6oxuration,,,A,,10662.0,Cerckpitbecicae,,0,5355,1,BAOp00o218,CHEMnL620988,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,
4639,,A8tocurarion,,,A,,44414.0,Cercopith4ciwwe,,0,5355,1,BAOo00021o,vHEMBL6200o9,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,
4640,,Aitocurxtion,,,A,,21785.0,Cetckp7thecidae,,0,4809,1,vAO0000217,CHEMBLt2o090,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,
4641,,Autoxufation,,,A,,24800.0,xe5sopithecidae,,0,4809,1,BAl9000218,CHEkBL620081,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,
4642,,Autoxueation,,jictosomes,A,,9262.0,Ceecoouthecidae,,0,14294,1,BzO0p00251,CH2MBo620092,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,
4643,,Autocudati9n,,Microslmds,A,,11479.0,Ce3copith2xidae,,0,14294,1,BAk0000w51,CHrnBL620093,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,
4644,,Autkc6ration,,Misrosomex,A,,16553.0,Cdecopithwcidae,,0,14294,1,BA80000q51,CHEMBL62po94,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,
4645,,Aurosuration,,Microslmss,A,,4664.0,Cerclpjthecida4,,0,14294,1,BAO0099251,sHEhBL620095,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,
4646,,Autockrstion,,,A,,10.0,fercopittecida3,,0,3443,1,BA0000021i,CHrMBL62009t,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,
4647,,Aurovuration,,,A,,29789.0,Cerclpi5hexidae,,0,3443,1,fAO0090218,CHEMBL6e0007,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,
4648,,Autocurztioj,,,A,,23213.0,C3rcopitgec7dae,,0,11271,1,BAi0090019,CHEMgL520098,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,
4649,,Aut8cura6ion,,,A,,1680.0,d2rckpithecidae,,0,3443,1,gAOp000218,CHwMBL62p099,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
4650,,Autocurxtuon,,,A,,5658.0,C3rcopithedivae,,0,3443,1,BAO0000w17,CHEnBL620200,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
4651,,Autocutxtion,,,A,,29863.0,Csrxopitbecidae,,0,6821,1,BAO9000029,CHEMBp6201p1,,Elimination Half-life of compound was determined in monkey,,
4652,,Aitocurat8on,,,A,,12746.0,xercopithesida4,,0,17267,1,BqO0090019,CHEMfo620102,,Half life of compound was determined in rhesus monkey,,
4653,,Autocurqtioh,2680171.0,,A,,1832.0,Cercopitnecuda4,,0,5819,1,BAO0099366,CHwMBL62p103,,Half life in monkey plasma,,
4654,,Autocurati8g,3120424.0,,A,,269.0,Ceedopittecidae,,0,5819,1,BAO0p00e66,CH2nBL620104,,Half life in monkey plasma; Not detected,,
4655,,Ahtocuragion,,,A,,9874.0,v4rvopithecidae,,0,1916,1,BAO0099218,dHEMBL8y4596,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,
4656,,zutocurwtion,,,A,,720.0,sercopithesida4,,0,17509,1,BA800p0218,CHdMBL873480,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,In vivo,
4657,,Aut0vuration,,,A,,20696.0,de3copithecidxe,,0,1399,1,BAO0900o19,CnEMBLy20105,,Terminal half life of the compound.,,
4658,,Autocj5ation,,,A,,24471.0,dercooithecicae,,0,1916,1,BAO00p02w8,CHEMBL629y80,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,
4659,,Autoc7ratoon,,,A,,6097.0,Cercopithefivze,,0,4809,1,BAO090021i,CtdMBL620781,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,
4660,,Autofugation,,,A,,58804.0,Cercopittecidq2,,0,5546,1,BzO9000218,CHwMBL620p56,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,
4661,,Autocugatiob,1395378.0,,A,,17698.0,C3rco9ithecisae,,0,3443,1,BAO0000q1o,CmEkBL620957,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
4662,,Aktocuratioj,3927710.0,,A,,929.0,C4rco0ituecidae,,0,3443,1,BAl00002q8,CHEMBo6e0958,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
4663,,Autocuragikn,,,A,,10815.0,x4rcopithexidae,,0,4257,1,BAO000p2q8,CjEMBL62095p,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,In vivo,
4664,,A6tocurwtion,,,A,,2315.0,Cerfipithec9dae,,0,6221,1,BAO9090218,dHEMBL720960,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,In vivo,
4665,,Auyocura5ion,,,A,,13568.0,Cfrco0itbecidae,,0,5472,1,gAO00002q8,CtEMBL520961,,Volume of distribution was evaluated in rhesus,In vivo,
4666,,Autocu4at8on,,,A,,17325.0,Cr8cetulusgrlseis,,0,4727,1,vAOo000218,CHEMBL6309t2,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,
4667,,Aktocuratioh,,,A,,10415.0,Crisetul6sgrissus,,0,4727,1,hAO000o218,CHEMBL6e096r,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,In vivo,
4668,,Ajtocuratiln,,,A,,10064.0,Cricetukuzg5iseus,,0,4727,1,BzO000p218,CHEMBk620954,,Bioavailability in hamster was determined,In vivo,
4669,,Autocueatlon,,,A,,576.0,Crisetulusgrise8a,,0,4727,1,hAp0000218,CnEMBo620965,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,In vivo,
4670,,Auyocurat7on,,,A,,5297.0,Crice6jljsgriseus,,0,4727,1,BAi00002w8,CHEMBL639966,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,In vivo,
4671,,sutochration,7165810.0,,A,,25274.0,Crisetupusgriqeus,,0,4727,1,BA80000222,CHEhBL520967,,Half life of compound was determined in hamster blood,,
4672,,xutocurat8on,,,A,,14593.0,Susscfofa,,0,1452,1,BAO00009q9,Cj3MBL620968,,Michaelis-Menten constant of the compound.,,
4673,,Au68curation,,,A,,22648.0,Susscrofz,,0,1452,1,vAO0000010,CHEMBk8y4597,,Vmax value was measured at 0 uM concentration of silyl ether.,,
4674,,A8tocuratipn,,,A,,17048.0,xusscrofa,,0,1452,1,BAO090p019,CHEMBL6q0i69,,Vmax value was measured at 10 uM concentration of silyl ether.,,
4675,,A6tockration,,,A,,11063.0,qusscrofa,,0,1452,1,BAl00p0019,CHwMBL520970,,Vmax value was measured at 5 uM concentration of silyl ether.,,
4676,,Exper5,,,B,,41021.0,Homoqqpiens,,9,11706,1,nAl0000357,dHEMBL630971,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,
4677,,Au4ocu4ation,,,A,,19374.0,Homosspoens,,0,1916,1,BAOpp00218,CHEkBL62p972,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,
4678,,Autocugatkon,,,A,,21764.0,tpmosapiens,,0,17791,1,BwO000o019,CHEkBo620973,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,
4679,,Autosuratiln,,,A,,8398.0,Homoaapienc,,0,7766,1,BA00000919,CHEMBL61825e,,Active metabolite of ifosfamide determined in humans; A-Active,,
4680,,Augoc8ration,,,A,,22444.0,H9mosapisns,,0,6567,1,BAO000p029,CHEjBL628244,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,
4681,,Aut0curztion,,,A,,20575.0,Homosq9iens,,0,6567,1,BAOp00p019,CHEMhL6182t5,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,
4682,,Autocuragiob,,,A,,9115.0,tomoeapiens,,0,6567,1,BAO00oo019,CmEkBL618246,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,
4683,,wutocurati0n,,,A,,10364.0,Hom8sapienc,,0,6567,1,BAO000p01i,CHEkBk618247,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,
4684,,Aut0curatioj,,,A,,32367.0,Homoswpiems,,0,17791,1,BAk0090218,fHEMBL628248,,Compound was evaluated for oral bioavailability in human,,
4685,,Ajhocuration,1183748.0,,A,,12638.0,H0mosapienz,,0,7766,1,BAp00p0019,CHEMBLt18259,,Metabolite of ifosfamide determined in urine; NF-Not found,,
4686,,Autodurstion,,,A,,47909.0,Hompsaplens,,0,6852,1,BAO0po0019,CHEkBL618e50,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,
4687,,Au6ocurayion,,,A,,5353.0,uomosqpiens,,0,6852,1,hAO00000w9,CHdhBL874598,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,
4688,,Autocura6i9n,,,A,,13054.0,Homosapidgs,,0,6852,1,Bsp0000019,dHEMBL619251,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,
4689,,sutocurztion,,,A,,19904.0,tomosapienc,,0,6852,1,gA00000019,sHEMBL628252,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,
4690,,Au6oxuration,,,A,,14319.0,Hkmosxpiens,,0,6852,1,fAO9000019,CHEnBL618353,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,
4691,,Autlcuratiog,,,A,,8316.0,Homosapiegw,,0,6852,1,BAO0o90019,CHEMgL618e54,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,
4692,,A6yocuration,,,A,,9409.0,Hom8sa0iens,,0,6852,1,BAp000p019,CHEMnk618255,,Percent of compound in healthy individuals (Group D),,
4693,,Autovutation,331396.0,Microsom3z,A,,9776.0,Hpmosapkens,,0,4397,1,BAOo0002t1,sHEMBp618983,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,
4694,,Autocudatioj,,,A,,19966.0,Honosapjens,,0,17409,1,BAO0o00018,CbEMBL618974,,Binding towards human plasma protein at 10 uM,,
4695,,Autockeation,,,A,,19968.0,Homoswpienw,,0,17409,1,BAO0p09019,CHEhBp618985,,Binding towards human plasma protein at 100 uM,,
4696,,Autlcurahion,,,A,,12451.0,nimosapiens,,0,17176,1,BAOo000p19,CH3hBL618986,,Human plasma protein binding activity was determined,,
4697,,Autocura49on,,,A,,59943.0,gomosapjens,,0,15444,1,BAO00pp019,CHrMBp618987,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,
4698,,Aktocueation,,,A,,1579.0,momosapiena,,0,17267,1,BAl0p00019,CtEMBL619988,,Percent binding of compound towards human plasma protein was determined,,
4699,,Autodurstion,3915054.0,nicrosomez,A,,7445.0,Homoeapi4ns,,0,5944,1,BAO00p02r1,CmEMBo618989,,Plasma clearance in human liver microsomes,In vitro,
4700,,xutocurafion,700275.0,kisrosomes,A,,2749.0,uomosapiegs,,0,5668,1,BAO0pp0251,CHrMBL61899o,,In vitro intrinsic clearance in human liver microsome,In vitro,
4701,,Autocurqtlon,2100103.0,Mixroqomes,A,,4381.0,tomksapiens,,0,5669,1,BAO00p025w,CH3MBL618i91,,In vitro intrinsic clearance in human liver microsome,In vitro,
4702,,Aufocurat7on,,Micrlxomes,A,,7048.0,Hompsaoiens,,0,5041,1,BAO000035w,CHEMBL87yy25,,In vitro microsome metabolism clearance in human was determined,In vitro,
4703,,qutociration,,Mixrosomea,A,,17440.0,Hlmosapienw,,0,5041,1,fAi0000251,CHEMhL6189p2,,In vitro microsome metabolism clearance in human was determined; High,In vitro,
4704,,Autoc6ratioh,,Mix4osomes,A,,5618.0,Homosapi4nd,,0,5041,1,gAO000025q,CHEnBL618093,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,In vitro,
4705,,Autocueatikn,666707.0,Microzohes,A,,11935.0,Hom0sapienw,,0,5676,1,BxO00002r1,CHdMvL618994,,Pharmacokinetic property (clearance) in human liver microsome,In vitro,
4706,,Autlcurati8n,4054503.0,Micrisomss,A,,54237.0,Homoaapiehs,,0,5944,1,BAk0090251,CHEMBk618o95,,Plasma clearance in human liver microsomes,In vitro,
4707,,Autoc7rat8on,2842078.0,hicros0mes,A,,25020.0,Homosqpiwns,,0,17538,1,nAOp000251,CHEMnL518996,,In vitro clearance in human liver microsomes,In vitro,
4708,,Aut9curatiom,3457913.0,hicrlsomes,A,,26902.0,Homozapjens,,0,6331,1,gAk0000251,CbEMBL618i97,,Intrinsic clearance in human liver microsomes was determined,In vitro,
4709,,qutocuratioj,4914914.0,nicroeomes,A,,19369.0,Hpmosapiebs,,0,5948,1,BsO000o251,CHEMnL718998,,Intrinsic clearance in human liver microsomes was determined,In vitro,
4710,,Autoc7ratioh,,,A,,16600.0,Homowapkens,,0,5965,1,fwO0000218,CHwMBL618998,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,In vivo,
4711,,Ahtoxuration,,,A,,16547.0,mohosapiens,,0,1916,1,hAO000021i,CHEMBk62022w,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,
4712,,Autocudqtion,,,A,,361.0,Honosapiena,,0,5965,1,BA00900218,fHEkBL620224,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,
4713,,Autocueatiog,,,A,,7989.0,Hohosapiejs,,0,1299,1,vAO0000o19,CHEMBo62022r,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,
4714,,Autocufat9on,,,A,,9122.0,Hom0sapkens,,0,1299,1,BAO00090q9,CHEMBL62922t,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,
4715,,Ahtocuratioh,733293.0,,A,,4201.0,Homosqpifns,,0,7766,1,BA800000w9,CH4MgL620227,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4716,,Autoc8eation,1634347.0,,A,,24688.0,Homoswoiens,,0,7766,1,BAOpp00019,CHEMBL86u726,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4717,,wutpcuration,1243201.0,,A,,582.0,H0mosa9iens,,0,7766,1,BAO0090o19,vHEMfL620228,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4718,,sutocu5ation,1248829.0,,A,,12488.0,Homosapifnx,,0,7766,1,BA80900019,CuEMBLu20229,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4719,,In4ermedkate,,,F,,1670.0,Musmusvupus,,1,17764,1,BAO0000319,CHEMBL520130,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,In vivo,
4720,,8ntermedizte,,,F,,5148.0,kusmisculus,,1,17764,1,BAOo0002w8,CuEMBi620231,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,In vivo,
4721,,Ihtermediste,,,F,,278.0,Muemusc7lus,,1,17764,1,BA90000118,CtEMBL62p232,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,In vivo,
4722,,7n6ermediate,,,F,,13968.0,Musmhsculue,,1,17764,1,vAO0000228,CHdjBL620233,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,In vivo,
4723,,Inte4medixte,,,A,,23658.0,Mismusculhs,,1,14294,1,hA90000218,CH3MBk620234,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,
4724,,In5ermesiate,,,A,,14962.0,Mysmusxulus,,1,14294,1,BAi000p218,CHwMBL6e0235,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,
4725,,Intermedisye,,,A,,24633.0,kusmudculus,,1,14294,1,vqO0000218,fHEMBk620236,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,
4726,,ubtermediate,7122687.0,,A,,20333.0,M6qmusculus,,1,6251,1,BAO0090228,CHEMBL61p237,,In vitro metabolic potential in mouse liver microsomes,,
4727,,Inhrrmediate,,,A,,2931.0,Musj8sculus,,1,17582,1,BAO000o21o,CHEnBLy20238,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,
4728,,Intermeviat3,41464.0,,A,,12861.0,Muwmuscukus,,1,17811,1,BA800p0218,CHEjBp620239,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,
4729,,Inte5mesiate,4150861.0,,A,,11816.0,Muzmussulus,,1,17811,1,BAO00002w9,fHEkBL620240,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,
4730,,Ingsrmediate,845098.0,,A,,17331.0,jusmusculhs,,1,17811,1,BwO000021o,CHEngL620241,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,
4731,,Interm3djate,,,A,,8826.0,Muemisculus,,1,17811,1,BAO0p00q18,CjEhBL876727,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,
4732,,Intedmedoate,387378.0,,A,,2435.0,Muamusculud,,1,17811,1,BA9000o218,xHEMBL620252,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,
4733,,Igtefmediate,,,A,,27199.0,Musmueculjs,,1,17811,1,BA90000e18,CHEMBL6e02r3,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,
4734,,Interjedlate,,,A,,38914.0,judmusculus,,1,5288,1,BAO00002qi,CH4MBL62024e,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,
4735,,Interjewiate,116021.0,,A,,7318.0,husjusculus,,1,2717,1,BAO0o0o218,CHEMBLt2024r,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,
4736,,Inte3mediwte,1388850.0,,A,,9183.0,kusjusculus,,1,2717,1,BA90900218,xHEMhL620246,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,
4737,,Ingermediat4,1852069.0,,A,,23346.0,Musmusdulue,,1,2717,1,BAO0p00318,CnEMBi620247,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,
4738,,Imtermedkate,5890282.0,,A,,26251.0,Muqmuscul8s,,1,17753,1,BAOp900218,CHEMBL7202r8,,Half life of compound was determined in plasma of mice at 24 mg/Kg,In vivo,
4739,,lnterjediate,49982.0,,A,,1724.0,Musmuxcul8s,,1,17753,1,BAO0p00318,CyEnBL873497,,Half life of compound was determined in plasma of mice at 40 mg/Kg,In vivo,
4740,,Internediats,3064668.0,,A,,29408.0,Muahusculus,,1,17753,1,BAO009p218,CHEnBL520249,,Half life of compound was determined in plasma of mice at 5 mg/Kg,In vivo,
4741,,kntermsdiate,,,F,,22707.0,jusmisculus,,1,17764,1,BAO0o09218,xHEMBL620w50,,Half life after intraperitoneal administration in mice at 18 uM/kg,In vivo,
4742,,Interj4diate,,,F,,5497.0,kusmusxulus,,1,17764,1,BApp000218,CHEMvL629251,,Half life after intraperitoneal administration in mice at 23 uM/kg,In vivo,
4743,,Interjedkate,,,F,,13970.0,Musmysc6lus,,1,17764,1,hA00000218,CgEMBL62o252,,Half life after intraperitoneal administration in mice at 25 uM/kg,In vivo,
4744,,jntermedixte,,,F,,18735.0,Musmusdulks,,1,17764,1,vA80000218,CHEMfL520253,,Half life after intraperitoneal administration in mice at 26 uM/kg,In vivo,
4745,,Intermesiage,,,F,,17878.0,Muskuzculus,,1,17764,1,BAlp000218,CnEMBL6202r4,,Half life after intravenous administration in mice at 23 uM/kg,In vivo,
4746,,Ijtermediahe,,,A,,5168.0,Musmusdul7s,,1,17764,1,BAO0009q18,CHEMBk620265,,Half life after intravenous administration in mice at 24 uM/kg,In vivo,
4747,,Imterjediate,,,A,,28373.0,Mjsmisculus,,1,16597,1,BqO000021u,CHEjBL62o256,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,
4748,,Ijtermediage,,,A,,3216.0,Miemusculus,,1,2675,1,BqO0000217,CH4nBL876728,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,In vivo,
4749,,Intermediwtd,,,A,,23778.0,Mysmusculuw,,1,2675,1,BAO0000e1i,vHEMBL630257,,Maximum time required to reach Cp max was evaluated in mice after oral administration,In vivo,
4750,,Intermediqtf,,,A,,16188.0,jusmuqculus,,1,16597,1,BAlo000218,CHshBL620258,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,
4751,,Intermrdjate,,,A,,11711.0,husmuscuius,,1,4890,1,gAO0p00218,CHEkBi620259,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",In vivo,
4752,,ln4ermediate,,,A,,8163.0,Muskuscuius,,1,429,1,BAOp090218,CHrMBL62026o,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,In vivo,
4753,,Intdrmeciate,1948863.0,,A,,12431.0,Musjuscul6s,,1,17837,1,BqO9000218,CHEMBo629261,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,
4754,,Intermed8aye,,,A,,15339.0,Musmuwculis,,1,16597,1,BAO900021u,CHEMnL62p262,,Half life at a dose of 10 mg/kg intravenous administration in mice.,In vivo,
4755,,Inte3mediat3,,,A,,7599.0,Mjsmusc6lus,,1,16597,1,BAO0p00219,CHEjBi620263,,Half life at a dose of 10 mg/kg peroral administration in mice.,In vivo,
4756,,7ntermddiate,,,A,,3512.0,Musmisfulus,,1,6619,1,BA0000p218,CmEMBL629264,,Half life in ob/ob mice,,
4757,,7gtermediate,,,A,,27660.0,Mysmuscuius,,1,4066,1,BAO0p00q18,CHEMBL620256,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,In vivo,
4758,,9ntermexiate,,,A,,2962.0,Mysmusculuz,,1,4239,1,BxO000021o,CHEMBL6202yt,,Half-life was measured in mouse,,
4759,,Int4rmediat3,,,A,,14609.0,Muqm8sculus,,1,5969,1,BAOp00021i,xHEMBL62o267,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,In vivo,
4760,,Intermed7ats,,,A,,23762.0,Musmksculks,,1,8999,1,BAO0000w28,CHEnBL6193t4,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,
4761,,8nternediate,,,A,,20741.0,Mismuwculus,,1,8999,1,BAO0o0p218,CHEnBL619375,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,
4762,,Intermed7at3,3064524.0,,A,,3564.0,Mjsmuxculus,,1,17641,1,BAOp000318,CHEMBL61935t,,T2 in brain of mice at the oral dose of 50 mg/kg,,
4763,,Intdrmsdiate,668861.0,,A,,35453.0,Musmuscuoux,,1,17641,1,BAk0009218,vHEjBL619367,,T2 in kidney of mice at the oral dose of 50 mg/kg,,
4764,,Intdrmed9ate,209491.0,,A,,13655.0,Mksmuscupus,,1,17641,1,hAO00002w8,CyEnBL619368,,T2 in liver of mice at the oral dose of 50 mg/kg,,
4765,,Imtedmediate,3349048.0,,A,,13931.0,Muzjusculus,,1,17641,1,BAOp000e18,CgEMBL629369,,T2 in lungs of mice at the oral dose of 50 mg/kg,,
4766,,ontermfdiate,1299205.0,,A,,34297.0,Musm7wculus,,1,17641,1,BA99000218,fHEkBL876729,,T2 in spleen of mice at the oral dose of 50 mg/kg,,
4767,,In4ermediste,,,A,,5832.0,Musnusdulus,,1,16597,1,BsOo000218,CHEkBL619e70,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,
4768,,Intermeriat2,,,A,,21326.0,Muxmuscul6s,,1,4890,1,BA900o0218,CbEMgL619371,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",In vivo,
4769,,Internediatf,,,A,,32704.0,Muzmysculus,,1,429,1,BAO009p218,CHEMBk6193i2,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,In vivo,
4770,,Int4rmedkate,,,A,,10777.0,Musnusculuc,,1,429,1,hAO9000218,vHEMBL620p12,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,In vivo,
4771,,Ibtermefiate,,,A,,5733.0,Mucmusc6lus,,1,5969,1,BAO00902q8,CHEMhL62o013,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,In vivo,
4772,473.0,Internwdiate,,,F,,19758.0,nomosapiehs,,1,16913,1,BA8p000219,dHEMBL6200q4,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,
4773,694.0,Intern4diate,,,F,,14891.0,Homosa9iegs,,1,16913,1,BAO0000ew9,CHEMBL610915,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,
4774,751.0,In6e3mediate,,,F,,5509.0,Homoxapiegs,,1,16913,1,BAO0o0021p,fHEMvL621010,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,
4775,1123.0,Interneviate,,,F,,745.0,Homosapiemd,,1,16913,1,BAi0900219,fbEMBL621011,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,
4776,584.0,Intermed9atw,,,F,,17341.0,H9mosapi4ns,,1,16913,1,BAio000219,CHEMBLy21013,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,
4777,845.0,Intwrmeeiate,,,F,,22823.0,Hohosapienc,,1,16913,1,BA9000021p,CHEMBL6q1012,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,
4778,893.0,Intermediaf2,,,F,,14999.0,Hom8sapiejs,,1,17270,1,BAO90o0219,CHEMBk631014,,In vitro cytotoxicity against A2780TAX cell line,,
4779,702.0,8nhermediate,,,F,,15349.0,uomoswpiens,,1,5618,1,BA800002q9,CHEMBk618144,,In vitro inhibitory activity against human tumor cell line A2780cis,,
4780,475.0,Ex0ert,,,F,,16640.0,Hojosapiejs,,1,17777,1,BAO0099219,CHEhBL518155,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,
4781,654.0,Inte3m4diate,,,F,,4032.0,Homosspiend,,1,16112,1,BA90000119,vHEMBL6181t6,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,
4782,429.0,In5ermed8ate,,,F,,10967.0,Hohosaoiens,,1,15748,1,BA00000218,CHEMBL6181ry,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,
4783,810.0,Intermwfiate,,,F,,27252.0,Homocxpiens,,1,6633,1,BA90000210,CHEMBL6q83w8,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,
4784,407.0,Inte5mesiate,,,F,,9098.0,Honosapiejs,,1,16930,1,hAO000o219,CHEMBL617e29,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,
4785,941.0,ontdrmediate,,,F,,22087.0,jomlsapiens,,1,17496,1,BxO0p00219,CHEjBLy18330,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,
4786,449.0,2xpert,,,F,,6800.0,Hom8sapiehs,,1,12989,1,BAO0o002w9,CHEMhL61i331,,In vitro antitumor activity against A2780cisR cell line.,,
4787,1009.0,Inte3mrdiate,,,F,,29725.0,H0mosapiend,,1,4840,1,BA90p00219,CHdMBL61833w,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,
4788,636.0,Ezpert,,,F,,14716.0,Homosa0isns,,1,12989,1,BAOo00o219,CHEMgL618323,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,
4789,923.0,Interhedixte,,,F,,34322.0,Homosa9iejs,,1,16745,1,BAO000o319,vHEMBL618344,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,
4790,984.0,Exp3rt,,,F,,18242.0,Hokosapi2ns,,1,16597,1,BAO0000e18,CHEMvL61u335,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,
4791,,Exper6,,,B,,3324.0,Rzttusnlrvericus,,9,16547,1,Bql0000019,CHEMBL618446,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,
4792,,sxpert,,,F,,,,,8,16547,1,BAO00o00q9,fgEMBL618337,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,
4793,,Expe4t,,,F,,5082.0,Rzttusn83vegicus,,9,16547,1,nAO000o019,CHEMBi61833o,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,
4794,586.0,dxpert,,,F,,13319.0,Hikosapiens,,9,15856,1,gAO0o00219,CHEMBo6w8339,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,
4795,531.0,fxpert,,,F,,3508.0,Hkmosaliens,,9,15856,1,BAO0090210,CHEMBLtq8340,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,
4796,,Espert,,,B,,638.0,Musm8xculus,,9,16547,1,BAi00p0019,CHEMBo618e41,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,
4797,,Espert,,,F,,,,,8,16547,1,BwO000p019,CHEMBL628e42,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,
4798,,Expeet,,,F,,30220.0,Mjsmusculuq,,9,16547,1,fAO0p00019,CH3MBL617343,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,
4799,,Expeet,,,B,,,,,8,17402,1,BAp0000r57,vHEMBL62103o,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,
4800,657.0,Au5osuration,,,F,,11225.0,Honosapisns,,0,11746,1,BAk9000219,CHEMBLy22039,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,
4801,569.0,Aut9cura6ion,,,F,,4539.0,Hlmosap8ens,,0,11746,1,BxO0009219,CHEMBp621o40,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,
4802,795.0,8ntermeriate,,,F,,553.0,Homosap7dns,,1,5455,1,BAO000p21i,CHEMhL622041,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,
4803,562.0,un4ermediate,,,F,,4829.0,bomosaliens,,1,2068,1,BA0000p219,CHwMBL62q042,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,
4804,1046.0,kntermedizte,,,F,,27955.0,Hkmosapi3ns,,1,2683,1,BAO00902w9,CmEMBL621p43,,In vitro antitumor activity against A375cell line extracted form melanoma,,
4805,791.0,Exper5,,,F,,9515.0,Hompsxpiens,,1,15313,1,gAO0000210,CHEMBk521044,,Inhibition of cell growth in (A375) melan cell line,,
4806,841.0,ontermexiate,,,F,,26767.0,Homosapiebc,,1,13739,1,hAO0000229,CHEjBL6210e5,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,
4807,593.0,Imtermediat3,,,F,,12514.0,Hompsaoiens,,1,13739,1,nAOo000219,CHEMBL62103t,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,
4808,762.0,Intermediahw,,,F,,23563.0,Homisaplens,,1,14750,1,BAl000021p,CHEMBL62q04u,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,
4809,123.0,Intefmediat2,,,F,,36607.0,Honosap7ens,,1,14777,1,BAO00p02w9,CHEMBL6w104o,,Antiproliferative activity measured against A427 human lung carcinoma,,
4810,732.0,Integmediatf,,,F,,5309.0,Hpmosapi4ns,,1,14777,1,BAO090021i,CHEMBLiu3798,,Antiproliferative activity measured against A427 human lung carcinoma,,
4811,88.0,Igtermeriate,,,F,,14138.0,Homosaliebs,,1,17672,1,nAO9000219,CHfMBL62104i,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,
4812,650.0,kntermediat4,,,F,,25988.0,Homosapidnz,,1,14368,1,BAO0000eq9,CHEMBL6e1040,,Inhibition of large cell lung carcinoma (A427),,
4813,879.0,Intermediqge,,,F,,2806.0,Hom9sapiems,,1,14368,1,BAO00002q8,CH4MvL621051,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,
4814,725.0,Internediat3,,,F,,18499.0,tomosapienc,,1,13866,1,fAO0000319,CH4MBL62105w,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,
4815,581.0,Integm2diate,,,F,,3639.0,H9mosapiehs,,1,2545,1,BAO9900219,sHEMBL621043,,Inhibitory concentration in human lung carcinoma A427 cell line,,
4816,769.0,Intermed7wte,,,F,,19447.0,nomosap8ens,,1,2545,1,BAOp00o219,CHEMBL711054,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,
4817,,Autocu3a4ion,,,A,,19971.0,Cercopirhec8daf,,0,6062,1,BAO00902w8,CHEMgL631055,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,
4818,,Autocurwtiom,,,A,,35365.0,Cerco08fhecidae,,0,4578,1,BA0000021i,CHEMBL8763p7,,Tested for volume of distribution upon iv administration to african green monkey,In vivo,
4819,,Autocurqtiob,,,A,,2701.0,Cercolithecirqe,,0,17592,1,BAO0000e19,CHfMBL6210t6,,Volume of distribution in monkey,In vivo,
4820,,A6tocurwtion,,,A,,7968.0,Madacamulztta,,0,5005,1,BAp0900218,CHrMBL62q057,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,
4821,,Autocurafi0n,,,A,,3059.0,Macacxm8latta,,0,5005,1,BAO9000318,CHsMgL621058,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,
4822,,Aut8cudation,,,A,,5767.0,s2rcopitheckdae,,0,5922,1,nsO0000218,CHEMBp6210t9,,Pharmacokinetic property(Vdss) in cynomolgus monkey,In vivo,
4823,,Au6ocurztion,,,A,,11909.0,Cercopi5hecivwe,,0,5355,1,BAOpp00218,CHEMBL62wp60,,The distribution volume after intravenous administration in cynomolgus monkeys,In vivo,
4824,,Au5ofuration,,,A,,6120.0,Cerco0uthecidaf,,0,5355,1,BxO9000218,CHdMBL6e1061,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,
4825,,Aitoxuration,,,A,,10856.0,Cefco0ithecidad,,0,5355,1,BAO000p118,CHdMBL631062,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,
4826,,Autkcuratjon,,,A,,20080.0,Cercopith4cldaw,,0,6057,1,BAOo00p218,CHEkBi621063,,Volume displacement was calculated in rhesus monkey,In vivo,
4827,,Au4ocuratikn,,,A,,3910.0,vercopihuecidae,,0,5145,1,BxO0900218,CHEMBL6w2064,,Volume of distribution in steady state was determined in rhesus monkey,In vivo,
4828,,Autocyrayion,,,A,,23038.0,Ce4copiyhevidae,,0,6821,1,BAO009021o,CHEnBL631065,,Volume of distribution of compound was determined in monkey,In vivo,
4829,,Autocuray8on,,,A,,4690.0,Cerc9pithscidse,,0,5334,1,BAk0090218,CHEMBL5w1066,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,
4830,,Autovurayion,,,A,,4221.0,Cefcopihhecidze,,0,5334,1,fAk0000218,vHEMBL621068,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,
4831,,xutocuratipn,,,A,,31099.0,Cdrcppjthecidae,,0,6641,1,BAO090o218,CtEMBL631068,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
4832,,Autociratioh,,,A,,24473.0,fdrxopithecidae,,0,2661,1,BAOp900218,CHdMBL886399,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,
4833,,Auhovuration,,,A,,4175.0,Cervopittfcidae,,0,6535,1,hAO0p00218,CHEMBL62q06i,,Volume distribution in monkey after administration of 1 mg/kg iv,In vivo,
4834,,Autocueatiln,,,A,,28518.0,Cercopi6hecocae,,0,4809,1,BAp9000218,CHEMBL62qp70,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,
4835,,Au5ocuratiln,,,A,,13119.0,Cercopitmecidsd,,0,6062,1,BAp0000219,CHEMBLt2q071,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,
4836,,Auyocuratiin,,,A,,16724.0,C3rclpithedidae,,0,3443,1,BAO0000128,CHEMBLy2107w,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,
4837,,Autodurati8n,,,A,,14110.0,Cercopituecivxe,,0,4578,1,BA90o00218,CH2MBk618209,,Oral systemic bioavailability upon iv administration to african green monkey,In vivo,
4838,,Aut9curafion,,,A,,17939.0,Cercooifgecidae,,0,4809,1,Bsp0000218,CHEkBLt18210,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,
4839,,Au4ocjration,,,A,,10645.0,Cerxopithecudar,,0,11271,1,BAO000o0w9,CbEMBL618212,,Baboon plasma free fraction. ,,
4840,,Auhocuratiln,,,A,,12423.0,Cerckpitjecidaf,,0,6057,1,nAO0000q18,CHEMnL6q8212,,Area under the curve was calculated in rhesus monkey after iv administration,,
4841,,Autoxugation,,,A,,18682.0,Cedc0pithecudae,,0,6057,1,Bq00000019,CgEMBL61821w,,Area under the curve was calculated in rhesus monkey after peroral administration,,
4842,,Autoc63ation,,,A,,24725.0,dedcopithrcidae,,0,17853,1,BAO000o029,CHEjBL6182q4,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,
4843,,Autosuratiog,,,A,,9100.0,Cercopirhedida2,,0,5302,1,fAO0000228,CHEhBL8734o2,,Half life period in monkey after 5 mg/kg dose,In vivo,
4844,,sutpcuration,,,A,,16356.0,Cervoputhdcidae,,0,4257,1,gAO0p00218,CHEhBL617272,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,In vivo,
4845,,Autpduration,,,A,,19552.0,Cedcopithecodze,,0,4257,1,hAO0000q18,CHEMvLt18273,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,In vivo,
4846,,Aut0cjration,5407334.0,,A,,8382.0,sercooi4hecidae,,0,13501,1,BAO090o218,sHEMBL618374,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,
4847,,Auyocu3ation,,,A,,32172.0,Cedcopitheckdar,,0,5394,1,BAO000022u,CbEMBL718275,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,In vivo,
4848,,Autocieation,,,A,,3254.0,Crrcipihhecidae,,0,2661,1,BAO09o0218,CjEMBLy18276,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,
4849,,xutocudation,,,A,,5695.0,sercppitheciwae,,0,3341,1,BzO00o0019,CHEMBL618ei7,,Compound was evaluated for terminal half life in monkey,,
4850,,sjtocuration,,,A,,10527.0,Cerfop8thec8dae,,0,3045,1,BAO0o00219,CHEMBL6w8279,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,In vivo,
4851,,Autocurwtipn,1006068.0,,A,,10143.0,jacacamulattw,,0,5005,1,BAO000p21o,CHEMBL6w8179,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,
4852,,Autocuratlom,,,A,,8402.0,Cercopkthrdidae,,0,4847,1,BwO0090019,fHEMBL6182i0,,Half life of compound was determined in squirrel monkey,,
4853,,Auhocurwtion,,,A,,29567.0,Macacafascicylaeix,,0,4256,1,BAO0000w17,CnEMBLy18281,,Half life after iv administration in cynomolgus monkey,In vivo,
4854,,Autofurqtion,4804041.0,,A,,1892.0,Ce3c8pitgecidae,,0,6535,1,BsO9000218,xHEMBL61828e,,Half life in monkey plasma after administration of 1 mg/kg iv,In vivo,
4855,,Au6ockration,,,A,,40782.0,versopittecidae,,0,6057,1,BAO0o90019,CHEMBL6q8w83,,Half life was calculated in rhesus monkey,,
4856,,Auroxuration,,,A,,21243.0,Crrcopityecidqe,,0,17592,1,BAO0090010,fHEMBL61828t,,Half life in monkey,,
4857,,Autodurqtion,,,A,,22517.0,Ce3colithevidae,,0,6641,1,BAlo000218,CHEMno618285,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
4858,,Autlchration,,,A,,3031.0,xercop9thec7dae,,0,5472,1,BAO0o000w9,CHEnBLy18286,,Half life was evaluated in rhesus,,
4859,,Auf8curation,,,A,,684.0,xercopithecjda3,,0,6221,1,BqOp000218,CHEMBp61o287,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,In vivo,
4860,,Autocutat8on,,,A,,2145.0,Cs5copithec7dae,,0,5668,1,BAO0op0218,CHEMfLt18288,,Half life period was determine after peroral administration at 10 mpk in Rhesus,In vivo,
4861,,Autocuratjom,,,A,,6581.0,Ce3sopithscidae,,0,4809,1,BwO0000e18,CHEMBo87t393,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,
4862,,zutocurwtion,,,A,,15251.0,Cr4fopithecidae,,0,5546,1,hAO0000w18,CHEMBL618380,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,
4863,,Autoc74ation,,,A,,10069.0,Cerclpithefidaw,,0,5553,1,hAO000p218,CHEMvi618290,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,In vivo,
4864,,Aurocudation,,,A,,10960.0,Cercopirhecivqe,,0,6078,1,nAi0000019,CHEMnLt18291,,Half-life was calculated in monkey,,
4865,,Autoduratoon,,,A,,13728.0,Cetcopith2cixae,,0,5147,1,BwO0009019,CHsjBL618292,,Half-life in Squirrel monkey,,
4866,,Autocurst9on,,,A,,23943.0,C3rcopithfcidwe,,0,5145,1,BAO009001p,CHEMBi617293,,Half-life in rhesus monkey,,
4867,,Au6ocurat8on,,,A,,1053.0,Ce3cipithefidae,,0,6062,1,hAO00o0218,xHEhBL618294,,Half-life was measured in monkey after an iv dose of 1 mg/kg,In vivo,
4868,,Autocjratiob,,,A,,35797.0,s4rcopithecicae,,0,5355,1,BA80o00218,CHEnBL619295,,Half-life period after intravenous administration in cynomolgus monkeys,In vivo,
4869,,Augociration,,,A,,7995.0,Ce3copithecodqe,,0,5355,1,BAl0p00218,CHsMBL618196,,Half-life period after oral administration in cynomolgus monkeys,In vivo,
4870,,Au6osuration,,,A,,4586.0,Ce5xopihhecidae,,0,5355,1,BAO009p218,CjrMBL618297,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,In vivo,
4871,,wugocuration,520889.0,,A,,37604.0,uimosapiens,,0,7766,1,gsO0000019,CbEMBL61829o,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4872,,su5ocuration,1990263.0,,A,,7606.0,H8mosapoens,,0,7766,1,BsOp000019,CHEjBL518299,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4873,,s8tocuration,5143531.0,,A,,17.0,uomosapjens,,0,7766,1,BAO0009o19,CbEMBL61i300,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4874,,Aurocuratipn,1681025.0,,A,,10145.0,Homkqapiens,,0,7766,1,BwO0000919,CHEnBi618301,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,
4875,,Autkcuratkon,1870959.0,,A,,6999.0,Hojosapiwns,,0,7766,1,BA800000w9,fHEMfL618302,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,
4876,,Augicuration,2779218.0,,A,,1400.0,Homowapienz,,0,7766,1,vAO00000q9,CHEMBL87y3o4,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,
4877,,Autosura6ion,2952098.0,,A,,17047.0,Homoaap8ens,,0,7766,1,BAOp000018,CyEMBL618r03,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,
4878,,Autocieation,1197362.0,,A,,25665.0,Homosapoehs,,0,7766,1,BAi0000o19,CHEMBL61i30e,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,
4879,,Autocuratoom,,,A,,26305.0,Hohlsapiens,,0,1916,1,BA8000o218,CHEhBL61i305,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,In vivo,
4880,,Autocuratilj,,,A,,13810.0,H8nosapiens,,0,16643,1,BAl0o00218,vHEMBL6w8306,,Oral bioavailability in human,In vivo,
4881,,Autoxurafion,,,A,,7199.0,H0nosapiens,,0,17248,1,Bz00000019,CHEMgL61o307,,Compound was tested for human plasma protein binding,,
4882,,xutocurat8on,,,A,,6572.0,Homoswpiems,,0,17248,1,BA00900019,CbEMBL617308,,Compound was tested for human plasma protein binding; Not determined,,
4883,,Ah6ocuration,,,A,,24411.0,Hohosapiegs,,0,6241,1,BxO9000019,CHEMBL6183oo,,Protein binding activity of compound in human plasma; % Free,,
4884,,Autocuratjpn,,,A,,11669.0,uomosapuens,,0,17716,1,BAO00p001o,CHfMBLu18310,,Unbound fraction (plasma),,
4885,,qktocuration,1850371.0,,A,,3080.0,Hokosap9ens,,0,17605,1,BAO0pp0366,sHEMBL87e353,,Half life for the hydrolysis of compound in human blood serum,,
4886,,Autocutat8on,5567741.0,,A,,12008.0,Hokosapifns,,0,17625,1,BA900p0366,CHEnBL618r11,,Half life period in human plasma using phosphate buffer (0.08 M),,
4887,,Aytocuragion,7882925.0,,A,,57152.0,Homisapienw,,0,17625,1,BAOpp00366,CH2MBL618322,,Half life period in human plasma using phosphate buffer (0.1 M),,
4888,,A6tocuratuon,990995.0,,A,,5650.0,Hom0sa9iens,,0,17747,1,BAp0000367,fHEMnL618313,,Half-life in human plasma was determined,,
4889,,Auticuratuon,,,A,,19290.0,gomosapiejs,,0,15613,1,fAO00000w9,fHEMBL61i314,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,
4890,,Aurocuratiln,,,A,,15525.0,tomoswpiens,,0,354,1,BAOpp00019,dHEhBL618315,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,
4891,,Autocurx4ion,,,A,,19831.0,Homosaplene,,0,3741,1,gAO0900019,CHsMBL618e16,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,
4892,,Autocjrahion,,,A,,18566.0,Homosapifbs,,0,3741,1,gAO0000o19,CHEMBk619317,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,
4893,,Autocudatipn,,,A,,4.0,Homosspuens,,0,3741,1,BwO0900019,CHEMgL62013o,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,
4894,,Autocirxtion,,,A,,8123.0,Hom9sap7ens,,0,17599,1,BAOp000018,CyEMBLu58280,,Partition coefficient (logP),,
4895,,Aj6ocuration,,,A,,21092.0,Homosap8rns,,0,5486,1,BsO00p0019,CHEMBLy20q39,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,
4896,,Autkcuratikn,,Microsom4d,A,,11159.0,Homosa9oens,,0,5600,1,BAO000925w,CHEMBi630140,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,
4897,,Autocura5i0n,,,A,,2706.0,Homoca9iens,,0,14294,1,BsO0p00019,CHrMBL630141,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,
4898,,Autocu4xtion,,,A,,15670.0,Hohosap7ens,,0,14294,1,BsOp000019,CHEMBL520q42,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,
4899,,Autocutztion,,,A,,85.0,H9mosapoens,,0,14294,1,BwO00p0019,CHEnBL62014w,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,
4900,,Au5ocurat9on,,M8croqomes,A,,14543.0,Homoxa9iens,,0,14294,1,BzO0000351,CyEMvL620144,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,
4901,,Autlciration,,kkcrosomes,A,,38388.0,Homosapkrns,,0,14294,1,BAO009p251,xHEMBi620145,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,
4902,,Augicuration,,Mic5oeomes,A,,50829.0,Homoeapienz,,0,14294,1,fAO0000351,sHEMvL620146,,Metabolism of compound in human microsomes; Trace,,
4903,,Autocuragiln,2216739.0,Mocrlsomes,A,,5249.0,Hom8sapiwns,,0,6260,1,BAO00002r2,CHEkBk620147,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,
4904,,Autof8ration,,Mkcrosom4s,A,,32541.0,Homosa9i4ns,,0,6187,1,BAO090o251,CH4MhL620148,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,
4905,,Autochrztion,181996.0,Miceosomec,A,,1089.0,Homosx9iens,,0,6251,1,hAO00002t1,sHEMBL620140,,In vitro metabolic potential in human liver microsomes,,
4906,,Aytocurat8on,,,A,,12614.0,Honoswpiens,,0,3246,1,BAO000o010,CbEMBL776412,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,
4907,,Autocudatiob,,,A,,15787.0,Homosa9iend,,0,17313,1,BAO0000ow9,CHEhBi619352,,Tested for human plasma protein binding of the compound; Not tested,,
4908,,Autoc6ratkon,,,A,,36287.0,H9hosapiens,,0,6227,1,BAO000901p,CHrMBL6w9353,,Compound was tested for percent protein binding (PB) in human,,
4909,,Autocuratipg,4173768.0,,A,,10438.0,Homosxpiene,,0,5530,1,Bs00000019,dH2MBL619354,,Protein binding in human plasma,,
4910,,Autlcuratipn,,,A,,3542.0,Hlmosapi3ns,,0,6108,1,BwO0009019,sHEMgL619355,,Permeability coefficient (B to A) in Caco-2 cell,,
4911,,Autovurat7on,,,A,,18153.0,Homodapifns,,0,6108,1,BAO000p029,xbEMBL619356,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,
4912,,Autocu4stion,,,A,,14706.0,johosapiens,,0,2774,1,fAl0000019,vHsMBL619357,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,
4913,,Augocuratioh,,,A,,6350.0,Homozapkens,,0,16643,1,BAO90000q9,CHEMBk6w9358,,In vitro rate of absorption observed as Caco-2 permeability in humans,,
4914,427.0,Autoc7rxtion,,,A,,2259.0,Hohosa9iens,,0,17582,1,fAO00002q9,CHEMBk6193r9,,Cellular permeability of compound was determined in Caco-2 cells; High,,
4915,724.0,Autovurstion,,,A,,2014.0,Homisapienc,,0,6838,1,BAO00002qo,dHEMBL619369,,Permeability in Caco-2 cells of compound,,
4916,,Autofura6ion,,,A,,11973.0,H0mocapiens,,0,6108,1,BAO00oo019,CHEMBL6wo361,,Permeability coefficient (A to B) in Caco-2 cell,,
4917,,zutocu5ation,,,A,,16717.0,H8mosa9iens,,0,6108,1,BAl000p019,CHEjBL619361,,Permeability coefficient (B to A) in Caco-2 cell,,
4918,,Autockratioh,,,A,,17875.0,H9mosaoiens,,0,6108,1,BqO000001p,CHwhBL619363,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,
4919,,Autovurwtion,,,A,,11317.0,Homoszpi4ns,,0,2146,1,BxO00p0019,sHEMBL618p42,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,
4920,,Autockratiln,,,A,,2363.0,Homosapjegs,,0,4514,1,gAO0p00019,xmEMBL618943,,Compound was tested for protein binding in human plasma,,
4921,,Autocuestion,,,A,,14617.0,Homosspiene,,0,6108,1,BAO0900010,CHEkBL628944,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,
4922,,Autoxuratjon,5391828.0,,A,,39300.0,Hom9sa9iens,,0,7766,1,BApp000019,CHEMnL618o45,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,
4923,,Intsrmrdiate,,,A,,2478.0,Muxmusc6lus,,1,5969,1,BqO00002q8,CHEMBL61895y,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,In vivo,
4924,,Inrermediahe,,,A,,953.0,jusmhsculus,,1,3277,1,BA0000021i,fHEnBL876413,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,
4925,,Intermediwye,,,A,,7741.0,Musm6sc6lus,,1,3802,1,BzO000021u,CmEMBL618946,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,
4926,,Internediqte,562026.0,,A,,9589.0,Muehusculus,,1,2862,1,BAO00002q7,xHEkBL618948,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,In vivo,
4927,,Igterhediate,1078505.0,,A,,11201.0,M7smisculus,,1,6348,1,BAO00003w8,CHEMBLuw8949,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,
4928,,Intedmedoate,,,F,,6976.0,Mudkusculus,,1,17764,1,nAO000021u,CHEMBL61896p,,Tmax after intraperitoneal administration in mice at 23 uM/kg,In vivo,
4929,,Igterkediate,,,A,,10733.0,Musmuxculux,,1,5781,1,BAO000o2w8,CHEMnL61895q,,Tmax after oral administration at 30 mg/kg in ICR mouse,In vivo,
4930,,untermwdiate,,,A,,22619.0,Musm7sculua,,1,17764,1,BAO00002w9,xHEMBL618962,,Tmax after peroral administration in mice at 2.4 uM/kg,In vivo,
4931,,9ntermediwte,,,A,,31054.0,M6smuscuous,,1,4066,1,BAOp090218,xHEMBL6189y3,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,In vivo,
4932,,Ihrermediate,854585.0,,A,,20180.0,nusmuscuius,,1,17641,1,BAO00002w7,CHfMBp618954,,Tmax in brain of mice at the oral dose of 50 mg/kg,In vivo,
4933,,In4ermed8ate,2560956.0,,A,,12396.0,jusmysculus,,1,17641,1,BA80009218,CHEMBL618p65,,Tmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,
4934,,Intermex7ate,1531004.0,,A,,24505.0,Mksmuxculus,,1,17641,1,BAO09p0218,CHEnBL61895u,,Tmax in liver of mice at the oral dose of 50 mg/kg,In vivo,
4935,,Ihterkediate,937609.0,,A,,11170.0,Musmjsfulus,,1,17641,1,BAO0009228,CHEjBL628957,,Tmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,
4936,,8ntwrmediate,,,F,,19540.0,k8smusculus,,1,17764,1,BAp0p00218,CuEMfL618958,,Tmax in mice at 18 uM/kg i.p. administration,In vivo,
4937,,Intermedjat4,,,F,,27504.0,Mksmusculue,,1,17764,1,BAp000p218,CHEMfL6189r9,,Tmax in mice at 23 uM/kg i.v. administration,In vivo,
4938,,Int3rmedjate,,,F,,15540.0,Musmjsvulus,,1,17764,1,BAOo009218,CHEhBL617960,,Tmax in mice at 25 uM/kg i.p. administration,In vivo,
4939,,In5ermediatr,,,F,,6956.0,Musm6sculuz,,1,17764,1,gAO000021u,CHEMBLoy6723,,Tmax in mice at 26 uM/kg i.p. administration,In vivo,
4940,,Ijtermediat4,1090259.0,,A,,10780.0,Mushuxculus,,1,17641,1,gAO000021i,xHEMBL61896w,,Tmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,
4941,,Intf4mediate,,,A,,21638.0,Musmuzculud,,1,16597,1,BA80000e18,CHEMfLt18962,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,
4942,,jnterkediate,,,A,,3217.0,kuwmusculus,,1,16597,1,nAOp000218,CHEnBL617963,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,
4943,,Interjediste,,,A,,4330.0,jusmusculue,,1,5951,1,BA9000021o,sHEMBL618963,,Tmax value in IRC mice,,
4944,,Intedmeviate,,,A,,27.0,Musmucculux,,1,5506,1,BAO0009228,fHEMBL618966,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,
4945,,Inte4meduate,,,A,,12446.0,Musjusculuc,,1,5506,1,BAO00902w8,CHEMBLu17966,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,
4946,,Interjediatr,5057897.0,,A,,45576.0,Musmuscuphs,,1,429,1,hAO00p0218,CHEjBL61u967,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,
4947,,untermedkate,1071138.0,,A,,6768.0,nusmuscul6s,,1,429,1,nAO0000e18,CnEMBLu18968,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,
4948,,Intdrmediat2,4217879.0,,A,,9500.0,Muqmusculuw,,1,4066,1,BA00000w18,CHEMBLt18968,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,
4949,,Intermed9a4e,,,A,,19814.0,Musmiscul6s,,1,17734,1,gA90000218,CjEMBL61897p,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,
4950,,Intermddia4e,,,A,,28438.0,Musm6scklus,,1,17734,1,BAkp000218,CHEMBL718p71,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,
4951,,Intermeriat2,,,A,,14576.0,Muskusculks,,1,6062,1,BAk0p00218,CHEMhL61897q,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,
4952,,In6ermedia6e,,,A,,26630.0,nusmusculux,,1,5969,1,BwO0900218,CHEMvL6w8973,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,In vivo,
4953,,9ntermediqte,,,A,,31502.0,Mksmusc6lus,,1,5969,1,BAOp000228,vHEMBL61897r,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,In vivo,
4954,,Interjediare,,,A,,24437.0,Musmuscupux,,1,5969,1,BAO0o00118,CHEMBLu1i975,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,
4955,,9ntermediatf,,,A,,23555.0,Musmuafulus,,1,5980,1,BAO09p0218,dHEjBL618976,,Vd in mice,In vivo,
4956,,Interhedoate,,,A,,41700.0,Mushusculud,,1,17592,1,hAOo000218,CHEjBL6189u7,,Volume of distribution in mouse,In vivo,
4957,,Intermediqre,,,A,,25382.0,Musmiscuius,,1,6348,1,BA90090218,dHEMBLi76724,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,
4958,,Intfrjediate,,,A,,40563.0,Musmudcupus,,1,17753,1,BAO000921u,vHEMBp618978,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,In vivo,
4959,,Intsrmeeiate,,,A,,10561.0,Musjuschlus,,1,17753,1,BAO09p0218,sHEMBL618989,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,In vivo,
4960,,Inte3nediate,,,A,,5557.0,Muemuscuius,,1,17753,1,hAO0009218,CHsMBo618980,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,In vivo,
4961,,Interhedjate,,,A,,14169.0,Musmusc7ous,,1,4239,1,BAO0000q17,CHEMvL6q8981,,Pharmacokinetic property (vdss) was measured in mouse,In vivo,
4962,,Intwrmedixte,,,A,,19229.0,Musnusxulus,,1,2862,1,BAOo00021o,CHEnBL6w8982,,Value distribution upon iv administration in mouse,In vivo,
4963,,Int2rnediate,,,A,,4963.0,Muxmusculuc,,1,17734,1,BAO00p0w18,dHEMBL62p150,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,In vivo,
4964,,Intermewiat4,,,A,,27120.0,Musmhsculua,,1,2675,1,BAO00092q8,CHEMfL629151,,Volume of distribution was evaluated in mice after intravenous administration,In vivo,
4965,,lnhermediate,,,A,,4189.0,Musm8scilus,,1,2675,1,nAO0p00218,CH3MBL620151,,Volume of distribution was evaluated in mice after oral administration,In vivo,
4966,,Intermesiste,,,A,,33264.0,Muemuscuous,,1,17837,1,fAO9000218,CHrMBL629153,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,
4967,,Int2rmedjate,,,A,,16781.0,Musmuxculhs,,1,5727,1,BAp0000228,CgEMBL876295,,Steady state volume of distribution was determined in mice,In vivo,
4968,,Intermrdiste,,,A,,5202.0,Muskusculud,,1,17852,1,BxO000p218,CHEMBLt29154,,Volume distribution (steady state) of compound was determined in mouse,In vivo,
4969,,Interhediatw,,,A,,28917.0,M8smksculus,,1,17764,1,BAO00o021o,CHEMhL610155,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,In vivo,
4970,,Intermeriqte,,,A,,27306.0,Musnusculua,,1,16597,1,BAp0000228,CHfMBL6e0156,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,
4971,,Interm4diatw,,,A,,25965.0,Mksmuscul6s,,1,6062,1,vAO0900218,CbEMfL620157,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,
4972,,Ijtermediqte,5346276.0,,A,,7595.0,Muqhusculus,,1,16438,1,BA80009218,xHEMBL62015u,,Biodistribution of compound (oxidized form) in in kidney tissue,In vivo,
4973,,onteemediate,1334333.0,,A,,1413.0,Musmjsculud,,1,16438,1,BAl000021o,CHEMBL530159,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,
4974,,Intrrmed7ate,3074202.0,,A,,14074.0,Muemusculuz,,1,16438,1,vqO0000218,CHEMBo62p160,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,
4975,,Ihternediate,1492668.0,,A,,15294.0,jusmusfulus,,1,16438,1,BAO0000128,CHEMBL62p171,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
4976,553.0,Infermeviate,,,F,,14839.0,jomosa9iens,,1,10708,1,vAOp000219,CHEMBL520172,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,
4977,418.0,Expwrt,,,F,,29443.0,Homisaoiens,,1,16597,1,BxO0o00219,CHEMfk620163,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,
4978,711.0,Expfrt,,,F,,5572.0,yomoswpiens,,1,16062,1,BAO0090229,CH4MBL620i33,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,
4979,888.0,Exoert,,,F,,3034.0,Homoawpiens,,1,16062,1,BsO9000219,vHEMBL8763o6,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,
4980,814.0,3xpert,,,F,,3264.0,H8mocapiens,,1,16958,1,BA00o00219,CHEMBLu2p834,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,
4981,776.0,Expett,,,F,,762.0,Hkmoeapiens,,1,6700,1,BAip000219,fHEMfL620835,,Inhibition of A431 human carcinoma cell proliferation,,
4982,609.0,fxpert,,,F,,6824.0,tomosspiens,,1,17226,1,BAl0090219,CH3MBL620837,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,
4983,456.0,Interheeiate,,,F,,13826.0,yomosapiegs,,1,6828,1,gAOo000219,xHsMBL620837,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,
4984,714.0,Ingerm2diate,,,F,,9158.0,Hokosxpiens,,1,12314,1,BqO0000319,CuEMBL621p17,,In vitro cytotoxicity against epidermoid carcinoma cell line,,
4985,467.0,Expfrt,,,F,,19972.0,uom8sapiens,,9,13412,1,BAO90p0218,CHEMBLy21017,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,
4986,592.0,Ijtermrdiate,,,F,,27874.0,Homosapidjs,,1,13299,1,BsO0090219,CHEMBk6q1019,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,
4987,938.0,Ijtermddiate,,,F,,3848.0,Hlmosxpiens,,1,17420,1,hAO0000210,CHEMBLy22020,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,
4988,1005.0,Ihterm3diate,,,F,,13643.0,Hkmosapkens,,1,13678,1,BAO000p2w9,CHdMBLt21021,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,
4989,349.0,Expsrt,,,F,,,,,8,14171,1,BAOo00021o,CgEMBL62102e,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,
4990,502.0,Exoert,,,F,,17106.0,Homosspiegs,,1,6333,1,BxO0000e19,CHEMBL6210er,,Tested for antiproliferative activity against human A431 cells,,
4991,631.0,Exlert,,,F,,15562.0,H9kosapiens,,9,2356,1,BAOp0o0219,vHEMBL611024,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,
4992,515.0,Exper5,,,F,,730.0,H9mosa0iens,,1,15578,1,BzO9000219,CHEMnL62102y,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,
4993,293.0,Espert,,,F,,5450.0,Homlzapiens,,1,5126,1,nAO0o00219,CHEMBk521026,,Inhibition of A431 cell proliferation,,
4994,1052.0,Exp3rt,,,F,,17678.0,Honpsapiens,,1,6844,1,hAO9000219,fHEMBL62w027,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,
4995,867.0,Ecpert,,,F,,54094.0,Homosapl4ns,,1,6844,1,BAO0o00319,CHEMfL8763p7,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,
4996,868.0,lntermedia6e,,,F,,30041.0,Homoqapifns,,1,4925,1,BAO00p02q9,vgEMBL883797,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,
4997,222.0,Intedjediate,,,F,,32186.0,Homosqpkens,,1,4925,1,BAp0o00219,CHEjfL621028,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,
4998,768.0,knterjediate,,,F,,10916.0,Hohosaliens,,1,13978,1,nAO0090219,CHEkBp621029,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,
4999,803.0,Ibtermedlate,,,F,,17725.0,Hohosapiena,,1,16786,1,BAO00o021i,CjEMBo621030,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,
5000,853.0,Expe3t,,,F,,,,,8,13412,1,BwOp000219,CHfMBLy21147,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,
5001,921.0,Intermedizt4,,,F,,15464.0,Hokosapiehs,,1,17824,1,BAO0009219,CHEMBL62w1t8,,In vivo antiproliferative activity against A431 cell line,,
5002,745.0,Edpert,,,F,,10060.0,Honisapiens,,9,12751,1,gA00000219,CtEnBL621149,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,
5003,782.0,Espert,,,F,,6132.0,Homoswpiems,,1,12380,1,BAi000021i,CHdMBL6w1150,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,
5004,578.0,Ex0ert,,,F,,11639.0,jomosapi3ns,,9,4959,1,BAO00p0229,CHEMBL622251,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,
5005,1027.0,Igt2rmediate,,,F,,33025.0,uomosapirns,,1,6333,1,BAO0p0021p,CHEMBLu21q52,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,
5006,444.0,Ihtermedizte,,,F,,28574.0,Hohosapi3ns,,1,6333,1,BwO00p0219,CyEkBL621153,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,
5007,628.0,Imtermeviate,,,F,,426.0,Homosapiwgs,,1,6333,1,BAO00o0319,CHEMBL884o0p,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,
5008,,Expedt,,,F,,5300.0,Homosqpienc,,9,5296,1,BAOpo00019,CHEMBL62qw54,,Inhibition of EGFR overexpressing A431 cell proliferation,,
5009,869.0,Expery,,,F,,12564.0,nomosapiehs,,1,12624,1,BxO0000319,xHfMBL621155,,Inhibition of A431 cell proliferation,,
5010,1138.0,Expe4t,,,F,,1476.0,Homosxpifns,,9,14926,1,BzO00002w9,CH3MBL62q156,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,
5011,183.0,Ecpert,,,F,,8932.0,Hlmosapirns,,9,14926,1,BAOp090219,CbEMBL6q1157,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,
5012,725.0,Exoert,,,F,,,,,8,14926,1,BAO00o021o,CHEMBLu11158,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,
5013,614.0,Interm2diatf,,,F,,1125.0,H0m9sapiens,,1,15144,1,BAO00pp219,CH3MBL621149,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,
5014,199.0,Interm3diare,,,F,,11836.0,Hokosaliens,,1,15144,1,BA800002q9,CgEMhL621160,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,
5015,80.0,Inrermediatf,,,F,,6472.0,Homoaapienc,,1,5245,1,BA00090219,dHEMBL6211t1,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,
5016,516.0,lnternediate,,,F,,4670.0,Homosali2ns,,1,5245,1,BA90000229,xHEMBL621172,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,
5017,783.0,Intsrnediate,,,F,,567.0,Himosaoiens,,1,5245,1,BAO0o0021i,CH3MBL6w1163,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,
5018,322.0,Intermeciahe,,,F,,18294.0,Homodaliens,,1,5245,1,vAO0090219,CHEkBp621164,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,
5019,393.0,7ntermwdiate,,,F,,17104.0,Hlhosapiens,,1,5245,1,fAO0p00219,CbEnBL621165,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,
5020,,wutocurahion,,,A,,1148.0,Cfdfopithecidae,,0,5922,1,BAO0090p19,CHwMvL619159,,Half-life period in cynomolgus monkey,,
5021,,Autoc8rxtion,6857359.0,,A,,20528.0,Cercoputhecidsf,,0,1116,1,BAp000036u,sHEMBL619169,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",In vitro,
5022,,Autocu5a4ion,,,A,,12804.0,Cerc8pithecicaf,,0,17853,1,fAO00002w8,CbEhBL619161,,Longer half-life in monkey (i.v.) at 0.5 mpk,In vivo,
5023,,Autocurqt7on,2522942.0,,A,,31085.0,Cerfo0ithevidae,,0,993,1,BAO000936u,CHEMBp6w9162,,Plasma half life in monkey,,
5024,,qutocuratiom,633747.0,,A,,4603.0,Cerco97ghecidae,,0,4514,1,BAOo009366,vHEnBL619163,,Plasma half-life in rhesus monkey,,
5025,,Autocyratikn,2981429.0,,A,,41031.0,C3rco0ithecodae,,0,5334,1,BAOp00021u,CHEMBL629w64,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,
5026,,Autpcuratoon,4670126.0,,A,,30974.0,Ce4copitbecidxe,,0,5334,1,hAO0900218,xHEMBL619329,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,
5027,,Autofurqtion,,,A,,27892.0,vercoliyhecidae,,0,4578,1,BqO000021o,CHEMnL61932w,,Tested for half life upon iv administration to african green monkey,In vivo,
5028,,Autochfation,,,A,,10895.0,Ce5copithsdidae,,0,2661,1,BAO0p0021u,vHEMBL873346,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,
5029,,Augocuratikn,,,A,,10898.0,xerdlpithecidae,,0,5355,1,nAO000p218,CHEMfL6193w2,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,
5030,,Autocurwtioj,,,A,,30316.0,Cdrcopithed7dae,,0,5355,1,BwO000p218,CHEMBL61ie23,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,
5031,,Autosuratiln,,,A,,13745.0,Cerco0jthscidae,,0,5355,1,BAO0009228,CHEMBL629334,,The time for peak concentration value after oral administration in cynomolgus monkeys,In vivo,
5032,,qu5ocuration,,,A,,25399.0,Cetcolithec9dae,,0,11271,1,BAO0o0p019,CHwMBL61o325,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,
5033,,Ahtkcuration,,,A,,6327.0,Cerf0plthecidae,,0,11271,1,BAi000p019,CbEMBL87t411,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,
5034,,Ahtocuratkon,,,A,,16811.0,Cersooi4hecidae,,0,11271,1,BAO009p019,CurMBL619326,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,
5035,,Autocutatoon,,,A,,11331.0,dercopiyhscidae,,0,11271,1,BAOp000p19,CHEhBL61932u,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,
5036,,xutocuratiln,,,A,,46431.0,Ceeco0ithec9dae,,0,11271,1,BAO0000ow9,sHEMBk619328,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,
5037,,Aut0c6ration,,,A,,8931.0,Crrco0ithecicae,,0,11271,1,BA9000o019,vHEkBL619329,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,
5038,,Autoxura4ion,,,A,,24520.0,Cf5co0ithecidae,,0,11271,1,BA900o0019,Cm2MBL619330,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,
5039,,xutocurafion,,,A,,1740.0,v3rcopith4cidae,,0,11271,1,BAO000901i,CHEMfL61p331,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,
5040,,Aurocurstion,,,A,,1277.0,Cerfopkthexidae,,0,11271,1,BAi0o00019,dHEMvL619332,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,
5041,,Auticuratioj,,,A,,6767.0,Crrcopithecjda2,,0,11271,1,BA0o000019,vHEkBL619333,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,
5042,,Autodura5ion,,,A,,7272.0,Ceecopithecixwe,,0,11271,1,gAOp000019,xHEjBL619334,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,
5043,,Ajtocuratoon,,,A,,8138.0,Cercop95hecidas,,0,11271,1,BAO0p0p019,xHEMBL618335,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,
5044,,Auticurati8n,,,A,,14877.0,Ce5co9ithecidqe,,0,11271,1,BwOp000019,CHEMgL619436,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,
5045,,Autocursti9n,,,A,,11869.0,Cfrcop8th2cidae,,0,11271,1,BzO0000o19,CHEMBL6w8337,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,
5046,,Autlcuratoon,,,A,,22549.0,Cwrdopith4cidae,,0,11271,1,BzO0o00019,CmEMBLt19338,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,
5047,,Au6ocuratikn,,,A,,25521.0,xercopirhecidar,,0,11271,1,BzO0000010,CHwMhL619339,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,
5048,,lnte5mediate,,,A,,8208.0,Rshtusborvegicus,,1,5809,1,vAO0009218,CHEMBL6q9440,,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,
5049,,8ntermedoate,6075501.0,,A,,4935.0,Ragtusno4vehicus,,1,17720,1,gAO00002w8,CHrMBL872496,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,
5050,,Igterhediate,1238388.0,,A,,17016.0,Rattksno5vegicue,,1,3546,1,BA8000o218,CHEMBL61pr41,,AUC value in rat after IV administration at a dose of 10 mg/kg,,
5051,,Imtermexiate,2149683.0,,A,,25337.0,Rattusnorvfvjcus,,1,3546,1,BA9o000218,CHEMBo619242,,AUC value in rat after oral administration at a dose of 10 mg/kg,,
5052,,Intfrmediatf,,,A,,6647.0,5att8snotvegicus,,1,3546,1,BAO000pw18,CHEMBp6w9343,,Cmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,
5053,,Intethediate,,,A,,17328.0,4afhusnorvegicus,,1,3546,1,gAO0000w18,CHEMBL6wo344,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,In vivo,
5054,,Inyernediate,,,A,,67.0,Rattuwn94vegicus,,1,3546,1,BAO00o9218,CHEjBL619346,,Tmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,
5055,,Intermefuate,,,A,,2053.0,Rattusnotvegiciq,,1,3546,1,hA00000218,CjEMBk619346,,Vc value in rat after IV administration at a dose of 10 mg/kg,,
5056,,Interkediaye,,,A,,23212.0,Rar6usn9rvegicus,,1,3546,1,BAO900p218,sHEMfL619347,,Half life period in rat after IV administration at a dose of 10 mg/kg,In vivo,
5057,,Autocugatiob,,,A,,5208.0,Papiojamwdryas,,0,10625,1,BAO0p0001o,xHEMBL6w9348,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,
5058,,Autodurati8n,,,A,,16325.0,Pzpiohamavryas,,0,10625,1,vAO00o0019,CbEMBL519349,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,
5059,,Ahtocurati0n,,,A,,9789.0,Pap9ohsmadryas,,0,10625,1,BAO000p010,CHEMBL719359,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,
5060,,Autocura68on,,,A,,4222.0,Papiomzmadryas,,0,10625,1,BAO90p0019,sHEMBL6193r1,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,
5061,,Autocufatioj,,,A,,21923.0,Papiohamadr5ws,,0,10625,1,BAO000o01o,CH4MBi875953,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,
5062,,Autocurxt7on,,,A,,9874.0,Papiouamadryad,,0,10625,1,BAO00000wp,dHEMBL6q1716,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,
5063,,Auyocuratiog,,,A,,29949.0,Papiohxmzdryas,,0,10625,1,nqO0000019,CHEMBL622718,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,
5064,,Ajfocuration,,,A,,32567.0,Pa0iohamawryas,,0,10625,1,BAl000p019,CHsMBL621719,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,
5065,,Autoc65ation,,,A,,30063.0,feagle,,0,3510,1,BAp000o019,CHEMBLtw1719,,Area under curve after 1 mpk peroral administration to beagles,,
5066,,A6tocuratiln,,,A,,24048.0,beagie,,0,3510,1,BxO00000q9,CtEMBL62q720,,Area under curve after 2 mpk peroral administration to beagles,,
5067,,Autocugqtion,,,A,,14092.0,bearle,,0,3510,1,BzO0o00218,CHEMBk6w1721,,Cmax value after 1 mpk peroral administration to beagles,In vivo,
5068,,Aut0cugation,4617404.0,,A,,18592.0,Hpmoswpiens,,0,7766,1,gAOp000019,dHEMBL62172q,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,
5069,,wutoc6ration,1401484.0,,A,,2319.0,Honpsapiens,,0,7766,1,BA9p000019,CHEMBL6216q3,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,
5070,,Autoviration,550735.0,,A,,7451.0,Homoqaplens,,0,7766,1,BzO000001p,CHEkBL6w1724,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,
5071,,Autoxurati0n,7325465.0,,A,,5165.0,H8mosspiens,,0,7766,1,gAO0090019,CHEMBL6e344w,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,
5072,,Aitocurafion,1349993.0,,A,,31301.0,bonosapiens,,0,7766,1,BAO000901p,CHEMhL613444,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,
5073,,Aut9curatjon,2548675.0,,A,,9896.0,Homlcapiens,,0,7766,1,BwOp000019,CHEMBL62345t,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,
5074,,qutocyration,229260.0,,A,,5402.0,Homosxpienw,,0,7766,1,BA80090019,xHEMBL62w446,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,
5075,,A6tocurati9n,2989359.0,Microq0mes,A,,24335.0,Homodapiegs,,0,16643,1,nAO00002t1,CHEMBL634447,,Metabolic stability observed at 30 min after administration in human liver microsomes,,
5076,,xutoc6ration,,,A,,26440.0,Hohosapiegs,,0,6852,1,BzO9000019,CHEMBi6q3448,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,
5077,,Aurocurahion,,,A,,3049.0,Homosa0i3ns,,0,6852,1,hwO0000019,CyEMBL6w3449,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,
5078,,Autoc8fation,,,A,,8876.0,Homlsapjens,,0,6852,1,BAO00900w9,CHEMvL723450,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,
5079,,Autlxuration,2157976.0,kicrosomew,A,,11172.0,Homoszpiend,,0,6567,1,BAO00p0351,CHEMBL63r451,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,
5080,,Autocurayikn,,,A,,5990.0,H8mowapiens,,0,6570,1,BAO0p0001p,CHEMBL6w3r52,,Metabolic stability (% remaining at 30 mins) in human S9.,,
5081,,Autocura5ioh,,,A,,6419.0,Hokosa0iens,,0,6570,1,BAOo0000w9,xHEMBp623453,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,
5082,,Autovjration,1767454.0,Micdocomes,A,,904.0,Homosa97ens,,0,5237,1,fAO0p00251,CHdMBk623454,,Percent parent compound remaining after 20 min incubation with human liver microsomes,,
5083,,Au5ocurqtion,2866858.0,jicros8mes,A,,6078.0,gomosapienx,,0,5237,1,BAO9000261,Ct3MBL623455,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,
5084,,Autovurati8n,1448150.0,Mivrosomds,A,,8511.0,gimosapiens,,0,5237,1,BAO00002tw,CbrMBL624371,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,
5085,,Au4ocura6ion,,,A,,10717.0,Homoszpiebs,,0,5202,1,nAO0000118,CHEMBi724372,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,
5086,,Ahtocudation,,,A,,9718.0,Hohosapkens,,0,5481,1,BAO9000029,CHEMnLu24373,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,
5087,,Au4ocuragion,,,A,,687.0,yomosapjens,,0,5481,1,gAOp000019,sHEMBL634374,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,
5088,,Auyocuragion,,,A,,8164.0,uomosqpiens,,0,3956,1,BqOp000019,CtEMBLu24556,,The percent remaining in human plasma after 30 min was determined,,
5089,,sutocurati0n,2135529.0,,A,,6850.0,Homoswpiwns,,0,5074,1,fAOo000366,CHEMBL634558,,Conversion rate of the prodrug in human plasma,,
5090,,sutocuragion,6922692.0,,A,,2338.0,Homisapienc,,0,5074,1,fAO000o366,CHEhfL624558,,Conversion rate of the prodrug in human plasma; ND means no data,,
5091,,Autoduratiin,167095.0,,A,,19678.0,Homosalienq,,0,4727,1,BwO0000231,Cn4MBL624559,,Half life of compound was determined in human blood,,
5092,,A6tocjration,,,A,,5265.0,Homosapkems,,0,5965,1,hAO00000w9,CHdMBL62456p,,Half life of compound was determined in man with once daily dosing,,
5093,,Augocueation,,Miceosomds,A,,52531.0,Homosqpi2ns,,0,5732,1,BzOp000251,CHEMBk6245y1,,Half life in human microsomes,In vitro,
5094,,Autodiration,3973645.0,,A,,6599.0,Homosap7egs,,0,5819,1,BxO0000266,CHEMBp624563,,Half life in human plasma,,
5095,,Autocurstiog,1450330.0,,A,,12816.0,H8mosapiene,,0,5819,1,BAl000036u,CHEMBL5245u3,,Half life in human plasma; Not detected,,
5096,,Auyocuratuon,,,A,,2375.0,Homosapiebe,,0,1916,1,vAO0090218,CgEMgL624564,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,
5097,,Autociratkon,403757.0,Mkcrosomea,A,,8901.0,Homosapj4ns,,0,6597,1,BAk000p251,CHEMBL5q4565,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,In vitro,
5098,,Autoc65ation,2673278.0,,A,,21929.0,Homksapiejs,,0,5229,1,vAO000o366,CHEMBL876252,,Half-life in human plasma,,
5099,,Aktocuratiln,1821560.0,,A,,5670.0,Homosaliejs,,0,5229,1,BAk0000367,CHEMBi623566,,Half-life of the parent prodrug in plasma,,
5100,,Autocueatuon,3996241.0,,A,,1243.0,Homosapi2ne,,0,2192,1,BAO0090367,xHEMBL872805,,In vitro half life in human plasma was determined,In vitro,
5101,,Autocurayiln,1464065.0,Microslmfs,A,,9411.0,uomosaplens,,0,3032,1,fAO00o0251,sHEkBL624567,,The compound was tested In Vitro for half life in human liver microsomes.,In vitro,
5102,,sutocura6ion,,,A,,28862.0,Homosap7dns,,0,1916,1,BAO9090218,CbEMvL624568,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,
5103,,xutochration,,,A,,6750.0,Hohozapiens,,0,17716,1,BAO0p90218,CuEMBLt24569,,Observed volume of distribution,In vivo,
5104,,A7tocurstion,,,A,,28992.0,Homosaouens,,0,15778,1,BA900002w8,CjrMBL624570,,Oral bioavailability in human,In vivo,
5105,,Autofiration,,,A,,23646.0,tomosapiejs,,0,17313,1,BAO00090w9,xHEkBL624571,,Tested for human plasma protein binding of the compound,,
5106,,A6ticuration,,,A,,12646.0,Homosapidnw,,0,4231,1,BxO0009019,CHEhBL624562,,"First order rate constant, k was determined in human plasma",,
5107,,Aigocuration,,,A,,24000.0,Honosqpiens,,0,4755,1,BxO000o019,CHEkBL6245i3,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,
5108,,Autodugation,,,A,,13261.0,Hom0saoiens,,0,4755,1,fAO0o00019,CHEMBL87rw53,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,
5109,,Autocueat7on,1268580.0,Microsomse,A,,9944.0,Homosqpienx,,0,16907,1,BAOp090251,CHEMBL634575,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,
5110,,Autodurat9on,,,A,,19977.0,tomowapiens,,0,10839,1,nAO0p00019,CHEhBL624565,,The compound was tested for the plasma binding in human,,
5111,,Autocursti0n,,,A,,2697.0,H8mosap8ens,,0,10839,1,BA8000p019,CHEMBL62t476,,Plasma protein binding (human),,
5112,,Auticutation,906766.0,hicrosomfs,A,,11038.0,H9mosapiehs,,0,3199,1,fxO0000251,CHEMBL623578,,Compound was evaluated for half-life in human liver microsomes,In vitro,
5113,,Autkcurat9on,3380350.0,,A,,9940.0,Hom8wapiens,,0,1345,1,BAO000p231,CHEMBL723578,,Half life measured in vitro for its stability in human blood,In vitro,
5114,,Autocuratiim,166329.0,,A,,17684.0,momosa0iens,,0,4297,1,BAO000p0w9,CHEMBi632796,,Half life in human serum,,
5115,,xutocu5ation,4128418.0,,A,,4264.0,Hohosapifns,,0,4297,1,BA000o0019,CHEnBL622i97,,Half life in human serum; ND=not determined,,
5116,,Ahtocurxtion,,,A,,7000.0,Hpmosapjens,,0,4297,1,BzO000001o,CHEMBi6227o8,,Half life were determined in CEM-SS cell extract in decomposition step 1,,
5117,,sutkcuration,,,A,,33679.0,Hom8sapienz,,0,4297,1,BAO000o01p,CHEMBp622699,,Half life were determined in CEM-SS cell extract in decomposition step 2,,
5118,,qutocuratiog,1173187.0,,A,,18657.0,Homosspjens,,0,4231,1,BAO0900266,dHEMhL622800,,Half life of the in human plasma,,
5119,,Autoc8fation,,S9,A,,17473.0,Homocap7ens,,0,5633,1,BzO000022o,xHEMBL722801,,Half life period in human hepatic S9 fraction was determined,In vitro,
5120,,Autoxu4ation,3223552.0,M8ceosomes,A,,3822.0,Hlmodapiens,,0,5633,1,BqO00002r1,CHEkBL623802,,Half life period in human liver microsome was determined,In vitro,
5121,,Autocurxtiln,,,A,,26251.0,Homosali3ns,,0,17791,1,BxO0009019,CHsMBL522803,,Half life period was determined; 6-7,,
5122,,Autocuratikg,,,A,,17024.0,Hohosaliens,,0,17791,1,gAO0900019,CHEkBi875154,,Half life period was evaluated in human,,
5123,,Auticurat8on,1862139.0,,A,,5286.0,Hokosapienz,,0,3160,1,BAOpp00366,CmEMBL522804,,Half life time in human plasma,,
5124,,Intermed7atf,1152304.0,,A,,26253.0,Musmisculuq,,1,16438,1,BAl000021o,CHEMBp632805,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5125,,Intermwdiahe,2320656.0,,A,,6056.0,kjsmusculus,,1,16438,1,BAO0009228,CHfMBL62e611,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5126,,Intermediarw,1481710.0,,A,,242.0,Musmussylus,,1,16438,1,BAk000p218,CH2hBL622612,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5127,,Interkediqte,2606853.0,,A,,10762.0,Mksm8sculus,,1,16438,1,BAO000p219,xHEMBL8751t0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5128,,In5ermsdiate,1992176.0,,A,,13203.0,Musmuxcukus,,1,16438,1,BAl0o00218,CjEjBL622613,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,
5129,,Intermed7atw,177570.0,,A,,20395.0,kuskusculus,,1,16438,1,BwO000021i,CHEMBo62q614,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5130,,Ihhermediate,1637343.0,,A,,12019.0,Musm7sfulus,,1,16438,1,vsO0000218,xyEMBL622615,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5131,,Inrermediafe,42239.0,,A,,10118.0,Mismuscjlus,,1,16438,1,BAOo009218,dHrMBL622616,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,
5132,,Interj4diate,677189.0,,A,,14431.0,Musnusculhs,,1,16438,1,BsO00o0218,fHEMBi622617,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5133,,8nyermediate,571918.0,,A,,15231.0,Mysmuscylus,,1,16438,1,BAO90p0218,CHEMBL6w26q8,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,
5134,,Intefmeviate,7254294.0,,A,,22994.0,kusmusculuw,,1,16438,1,BqO0o00218,vHEMBL612619,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,
5135,,Interjedjate,353918.0,,A,,28229.0,Musmuscuouc,,1,16438,1,BAO0090q18,CHEMBL6226e9,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5136,,Infermedia5e,14848.0,,A,,13446.0,Musmuscklis,,1,16438,1,vAOo000218,CHEMhL62e621,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,
5137,,9n4ermediate,888281.0,,A,,10123.0,Musmuscuiua,,1,16438,1,BqO0090218,CHEMBL622tq2,,Biodistribution of compound (oxidized form) in blood tissue,In vivo,
5138,,kntermedkate,874511.0,,A,,25985.0,kusmuscupus,,1,16438,1,BAO0090q18,CHEMBp622613,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5139,,Inyermesiate,4966512.0,,A,,13603.0,Musm8sculue,,1,16438,1,fAO0000219,CHEnBL6226q4,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,
5140,,Intermed9ats,1559354.0,,A,,29069.0,Musmusxupus,,1,16438,1,vAO00p0218,CHEMBi6q2625,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,
5141,,Intetmeriate,2650073.0,,A,,1964.0,Musjusxulus,,1,16438,1,gAO0o00218,CHfMBLu22626,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5142,,Intermeciat4,50364.0,,A,,9151.0,Musmuscjkus,,1,16438,1,BA90000q18,sHwMBL622627,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,
5143,,Intermewiat2,103818.0,,A,,65.0,M8smuscupus,,1,16438,1,BzO0000219,CHEjBp622628,,Biodistribution of compound (oxidized form) in brain tissue of mice,In vivo,
5144,,Intermed9ste,3053109.0,,A,,17635.0,Musmuscukue,,1,16438,1,gAO000p218,Cu4MBL622629,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5145,,Intrrkediate,272758.0,,A,,5010.0,Musjuscjlus,,1,16438,1,BsOo000218,CHEMBi622730,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,
5146,,Inte4msdiate,2294210.0,,A,,25206.0,Musmuesulus,,1,16438,1,hAO0p00218,xHEMBL622641,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5147,,Interjediatd,155474.0,,A,,9531.0,M6skusculus,,1,16438,1,nAi0000218,CHEMvL6226r2,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,
5148,,Intermediwtr,2390756.0,,A,,9784.0,Musm6scukus,,1,16438,1,BAOoo00218,CHEkBL6226r3,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,
5149,,Intwrnediate,2740418.0,,A,,20734.0,Musjusculue,,1,16438,1,BAO000011i,CHEMBL622ur4,,Biodistribution of compound (oxidized form) in heart tissue of mice,In vivo,
5150,,Intetmedoate,4647822.0,,A,,23882.0,Mucmuscuous,,1,16438,1,BA00000219,CHEMBL723635,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5151,,Intermrdiage,1498679.0,,A,,9684.0,Musmusc7kus,,1,16438,1,BA000002q8,CHEjBL875261,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5152,,Intdtmediate,2452673.0,,A,,42819.0,jusmueculus,,1,16438,1,fAO000021o,CHsMBL62e636,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,
5153,,Intermediwfe,4528986.0,,A,,2230.0,Mushudculus,,1,16438,1,BAO00oo218,CHEhBi623335,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5154,,Int3rmediatf,4629560.0,,A,,9278.0,Musmuacupus,,1,16438,1,BxO000o218,CHEMBLt23436,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,
5155,,lnterhediate,2349925.0,,A,,36182.0,Muskusculis,,1,16438,1,vqO0000218,CHwMBL6w3337,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5156,,Intedmedlate,5936200.0,,A,,10196.0,Mushusc7lus,,1,16438,1,BqO0000228,vHEnBL623338,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,
5157,,lntermediafe,2264412.0,,A,,4404.0,Muxmuscukus,,1,16438,1,nAO0000118,fHEMBL6233w9,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,
5158,,Intermedist4,3160303.0,,A,,12847.0,Myshusculus,,1,16438,1,BAO000921i,fHEMBi623524,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,
5159,,Intsrkediate,2312370.0,,A,,10355.0,Musmisfulus,,1,16438,1,BxOo000218,CHEknL623525,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,
5160,,Interkedixte,1825904.0,,A,,33409.0,Musmucculis,,1,16438,1,BqO0000228,xbEMBL623526,,Biodistribution of compound (oxidized form) in liver tissue,In vivo,
5161,,Inteemeciate,4491419.0,,A,,18879.0,Musmuqvulus,,1,16438,1,vAO000021o,xHEMBL62352y,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,
5162,,Ihtermediatd,2667542.0,,A,,5391.0,Mushuscupus,,1,16438,1,vxO0000218,CHEMhL622528,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,
5163,845.0,Intd3mediate,,,F,,16442.0,Hojosa9iens,,1,5245,1,BwO0000319,CHEMBL62tu15,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,
5164,508.0,Intermedoa6e,,,F,,26376.0,Homowaliens,,1,5245,1,BAOo00021o,CHEMgL621662,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,
5165,1241.0,rxpert,,,F,,,,,1,16289,1,fAO00p0218,vHEMBL621u73,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,
5166,762.0,wxpert,,,F,,,,,1,16289,1,fAi0000218,CHEMvL721674,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,
5167,770.0,sxpert,,,F,,25849.0,Hohosspiens,,9,16093,1,hAO0900219,dHEMBL88400q,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,
5168,634.0,Intrrkediate,,,F,,1034.0,Homodapiehs,,1,16825,1,nAO00002q9,CHEMBL6w18t0,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,
5169,859.0,Igterm4diate,,,F,,23272.0,Hom0sapiegs,,1,4848,1,Bqk0000219,CHEMBL511851,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,
5170,324.0,Experf,,,F,,18269.0,Hompsa0iens,,9,14827,1,BzO0000q19,CHEnBL6e1852,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,
5171,367.0,dxpert,,,F,,16783.0,Homosqpiend,,9,14827,1,BA0000021i,fHEMBL62185e,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,
5172,466.0,Ecpert,,,F,,,,,1,16289,1,vAOo000218,CHEjBL721854,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,
5173,544.0,Expegt,,,F,,,,,1,16289,1,BAO00p0318,CHEMBL621u45,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5174,476.0,Experh,,,F,,,,,1,16289,1,BAO000pw18,CHEknL623724,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5175,740.0,Expe4t,,,F,,,,,1,16289,1,BAO009p218,CHEMhL62e725,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,
5176,637.0,Eapert,,,F,,,,,1,16289,1,BzO000021o,CHEMBL633826,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,
5177,95.0,Expegt,,,F,,3447.0,Honoszpiens,,9,16289,1,BAO000o210,CHEMBL623y17,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,
5178,729.0,sxpert,,,F,,,,,8,16289,1,BAO0009229,CH2MBL62372i,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,
5179,892.0,Expeet,,,F,,,,,1,16289,1,hAO0000w18,CHEMBL6236w9,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,
5180,806.0,Exoert,,,F,,,,,1,16289,1,BAO000p228,CHEMgLu23730,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5181,762.0,4xpert,,,F,,,,,1,16289,1,BxO0900218,CtEMBL62373q,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5182,895.0,Expegt,,,F,,34638.0,Muchusculus,,1,14555,1,BAO0000319,xHEMBL622732,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,
5183,1177.0,Expe5t,,,F,,36231.0,M7smusfulus,,1,14555,1,BxO0009218,sHEMBL62r733,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,
5184,990.0,2xpert,,,F,,32514.0,Musm8scukus,,1,14555,1,BAO0p00e18,CHEMvL6237w4,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,
5185,494.0,Eapert,,,F,,7457.0,nuamusculus,,1,14555,1,fAO0000217,vHEMBL623i35,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,
5186,482.0,wxpert,,,F,,20404.0,Homosa9irns,,1,1937,1,BAO0p0021p,CHEMhL623836,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,
5187,826.0,Inf3rmediate,,,F,,12532.0,Hpmosapidns,,1,13739,1,BxO0900219,sHEjBL623737,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,
5188,537.0,Ingermeeiate,,,F,,9151.0,Homosspidns,,1,3558,1,BwO0090219,CHEMBL62w73o,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,
5189,760.0,Interjediahe,,,F,,10107.0,Homosapuend,,1,3558,1,BA90009219,CHfMhL875168,,Dose giving a 50% decrease in the living cell number (A437 cells),,
5190,655.0,Ex0ert,,,F,,7328.0,Homosxp9ens,,1,17686,1,BAOop00219,CHEMBL62w729,,In vitro inhibitory concentration against proliferation of A459 cell line.,,
5191,866.0,Ibt3rmediate,,,F,,8593.0,gohosapiens,,1,5305,1,BAO000022o,CHEMBo6237e0,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,
5192,755.0,9ntermedia6e,,,F,,12489.0,momosapiena,,1,3614,1,Bs90000219,CHEMBp62442r,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,
5193,512.0,Ingermeeiate,,,F,,21668.0,bokosapiens,,1,17229,1,BAO00002wi,CH2MBL624325,,In vitro antitumor activity against renal A498 tumor cell lines,,
5194,666.0,kntsrmediate,,,F,,18729.0,y8mosapiens,,1,15935,1,BAO00p0319,CjEMBL62e426,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,
5195,674.0,Intsrmediatr,,,F,,40574.0,momowapiens,,1,15935,1,BAO000o210,CHrMBk624427,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,
5196,690.0,Ibtermedoate,,,F,,24171.0,uomksapiens,,1,15560,1,BAOp090219,CHEMBL624t2u,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,
5197,1350.0,Intermeviqte,,,F,,31047.0,Homisapiems,,1,13891,1,BAO00001w9,CHsMBL6e4429,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,
5198,957.0,9ntedmediate,,,F,,48291.0,Honosap8ens,,1,13891,1,BAO00o0q19,CnEMBL6w4620,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,
5199,505.0,9ntermediatr,,,F,,27095.0,gomocapiens,,1,13788,1,BAO0p0021o,CbEMBL62t621,,Cytotoxicity on kidney carcinoma (A-498) cell line,,
5200,711.0,Ibtermediatw,,,F,,2315.0,Homoswoiens,,1,15403,1,BAp0000218,CHEjBk624622,,Compound was evaluated against Human cell line renal A498,,
5201,632.0,ontermefiate,,,F,,10314.0,Homosapi4nq,,1,1009,1,BAO0pp0219,CHEMBL624u33,,Compound was tested for inhibition of A498 human renal cancer cell line,,
5202,703.0,Intwrmed9ate,,,F,,21032.0,Hpmosapiwns,,1,1043,1,BAO000031o,CHEMBo8i4365,,Growth inhibitory activity against A498 human cancer cell line,,
5203,404.0,Inhermed8ate,,,F,,11632.0,Homosa9ienc,,1,5858,1,BAl0000e19,CHEMBL724y24,,In vitro antitumor activity against human renal A498 cell line,,
5204,489.0,In5ermedia5e,,,F,,5793.0,Hompsapkens,,1,5958,1,BxO9000219,CtfMBL624625,,In vitro cytotoxic activity against renal (A498) cell line,,
5205,924.0,Intermexiatw,,,F,,13813.0,Hompsapifns,,1,5506,1,BAO0900229,CH4MBL624y26,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,
5206,645.0,In4ermediste,,,F,,7988.0,Hokosqpiens,,1,12781,1,BAO009021p,fHEhBL624627,,Tested for cytostatic activity against renal A498 cell line,,
5207,559.0,Integmedoate,,,F,,13307.0,Hojosapiend,,1,14399,1,BAO0p09219,CHwhBL883157,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,
5208,425.0,Exp4rt,,,F,,22230.0,Homosa99ens,,1,5958,1,BAi00p0219,CHEMBL6246w7,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,
5209,,Autoc7rstion,,,A,,14418.0,bezgle,,0,3510,1,BAO0009219,CHEMBLy246q9,,Cmax value after 2 mpk peroral administration to beagles,In vivo,
5210,,Autociratioj,,,A,,3921.0,Canosijp8sfamiliaris,,0,3510,1,BsO00002q8,CHEhBLt23551,bezgle,Bioavailability,In vivo,
5211,,Autifuration,,,A,,27072.0,vxn9soupusfamiliaris,,0,3510,1,BA8000o218,CHEMBLu2355e,beagl3,Bioavailability after 1 mpk peroral administration to beagles,In vivo,
5212,,Autocura4iog,,,A,,3604.0,Cahislupudfamiluaria,,0,3510,1,BA00000w18,CHEMBLu235r3,bsagle,Bioavailability after 2 mpk peroral administration to beagles,In vivo,
5213,,Autoc7rati9n,,,A,,4112.0,gostaurus,,0,3085,1,BAk0090019,vHEMBL6e3554,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,
5214,,Autovuratiob,,,A,,1190.0,Bosta8rus,,0,3085,1,BAO0000p18,CHEMBk623455,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,
5215,,sutocugation,,,A,,21288.0,Bostaurjs,,0,3085,1,BsO00o0019,CHEnBLy23556,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,
5216,,zutocurqtion,,,A,,8387.0,Bostzurus,,0,9372,1,BA80000p19,CgsMBL623557,,Solubility against bovine alpha-chymotrypsin,,
5217,,Autocurstiob,,,A,,14211.0,Bostqurus,,0,3085,1,BAip000019,dHEMBL623r58,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,
5218,,Autocurztlon,,,A,,13503.0,Bostaudus,,0,3085,1,BAk0000029,CnEMBLu23559,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,
5219,,wutocuratiln,878427.0,,A,,23857.0,Bostaurux,,0,1469,1,vAO0p00221,CHsMBk623560,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,
5220,,Auyocyration,,,A,,29280.0,Bosfaurus,,0,4297,1,BAO0o09019,xHEMBL622561,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,
5221,,sutovuration,,,A,,1935.0,Bosraurus,,0,4297,1,BAOp00001o,CbEMBL633562,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,
5222,,sutocurafion,,,A,,35256.0,fostaurus,,0,17585,1,BAOp000o19,CHsMBL62356r,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,
5223,,Autocugxtion,3487206.0,,A,,23403.0,Bosta6rus,,0,1336,1,BAO0p0p221,CHEMBL6q2564,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,
5224,,A8tocurati8n,,,A,,561.0,Boataurus,,0,3085,1,BAO9p00019,CuEMBL883806,,Half life in presence of 2 mg/mL BSA at pH 8.8,,
5225,,Aut0curati0n,,,A,,21455.0,hostaurus,,0,2857,1,gAO0900019,CHEMBL6w3555,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,
5226,,Autocutayion,,,A,,11475.0,Bostau3us,,0,2857,1,BA80000010,fHEMBL6e3566,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,
5227,,Autocutayion,,,A,,29205.0,B8staurus,,0,2857,1,hAO000001o,CHEkBp623567,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,
5228,,A7tockration,,,A,,22935.0,Bodtaurus,,0,1540,1,BAl0000010,CHEhBL6w3568,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,
5229,,9ntermed9ate,2502725.0,,A,,2842.0,Cajuslup8sfamiliarls,,1,6316,1,BsO0009218,CuEMBL62356i,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,
5230,,Intermediwt2,2569817.0,,A,,4457.0,vanixlupuafamil7aris,,1,17594,1,vAO0000318,CHEMgL623y70,,AUC after administration at 100 mg/kg/day in dogs,,
5231,,Intermwxiate,2382825.0,,A,,8734.0,Cqgislupusfanilixris,,1,4953,1,BAO90o0218,CHEnBp624254,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,
5232,,Imte5mediate,2971948.0,,A,,8156.0,Cwnislup8sfamlkiaris,,1,16907,1,vAO0000q18,CHEMBL6q4q55,,AUC value after 15 mg/kg iv dose in Dogs,,
5233,,Internewiate,6354777.0,,A,,9267.0,Canislu9ustamioiaeis,,1,16907,1,BAO0o00318,CHEMgL623256,,AUC value after 30 mg/kg po dose in Dogs,,
5234,,Intd5mediate,2626165.0,,A,,11789.0,Csniskupusfamukiaris,,1,2959,1,BAk00002q8,CHEMBL623258,,AUC value after administration of 4 mg/Kg oral dose in dog,,
5235,,Interm4diafe,4820350.0,,A,,10226.0,Canispu0uwfamiljaris,,1,17594,1,BAOp00021i,CHEMgLt24258,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,
5236,,Intermwdiatr,,,A,,10980.0,Csnislupuseamiliaeiw,,1,5356,1,BAO000p21u,CHEjBL875e77,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,
5237,,Imyermediate,,,A,,23474.0,Cqnislupusfxm9liariq,,1,16807,1,BAl0000228,fHEMBk622667,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,
5238,,Intermedia54,,,A,,1933.0,Camislu9usvamiliqris,,1,4527,1,vAO000p218,CHEnBL622669,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,
5239,,Intrrmediste,,,A,,21264.0,Canislup8sfamioiq4is,,1,4527,1,BAO00o9218,CHEMBi622y69,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,
5240,,Ihtermedia5e,,,A,,16185.0,Canisoupisfxmiliariz,,1,15660,1,BxO0p00218,CHEnBLt22670,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,
5241,,Intern2diate,,,A,,6575.0,Cznisoupuscamiluaris,,1,15660,1,nAl0000218,CH4MBL522671,,Area under curve determined in dogs after oral administration of 10 mg/kg,,
5242,,Ijtermed8ate,,,A,,605.0,Canislu0usfanio8aris,,1,5802,1,nzO0000218,dHEMBk622672,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,
5243,,fxpert,,,A,,22055.0,Canislulhsfam9liariz,,1,3598,1,BAO00op218,CHEMhL622683,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,
5244,,Expe3t,,,A,,2991.0,Cahislupusfamokiarus,,1,3598,1,BsO0p00218,CmEMBL6226u4,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,
5245,,Igterm4diate,,,A,,30377.0,daniwlu9usfamilixris,,1,5944,1,gAO00002q8,CHEnBp622675,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,
5246,,Igtermediat4,,,A,,29372.0,xaniaoupusfamipiaris,,1,5944,1,BwO00o0218,CHEMBL7q2676,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,
5247,,jnteemediate,,,A,,16483.0,Canisl6pustakil9aris,,1,5944,1,BAO0000q1o,CHEMBp62q677,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,
5248,,Ijtermedia5e,,,A,,19183.0,Cxnislypjsfamiluaris,,1,5944,1,gzO0000218,CHEnBL62267o,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,
5249,,Igtermexiate,,,A,,16741.0,Canisiupusfanipiarjs,,1,4186,1,BxO0000219,CHEMBL72267i,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,
5250,,8nterm2diate,,,A,,30177.0,sanislupuzfamiliatus,,1,5007,1,BAOpp00218,CnfMBL622680,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,
5251,,Intetmediat2,,,A,,1843.0,Cajislup8sfzmjliaris,,1,5668,1,BAO00o021u,xH3MBL622681,,Area under curve was determine after peroral administration at 10 mpk in dog,,
5252,,Intermwdjate,,,A,,2948.0,Canislup6sfam9liwgis,,1,5668,1,Bx80000218,CH3MBL8752u8,,Area under curve was determine after peroral administration at 5 mpk in dog,,
5253,,9ntermedizte,,,A,,22089.0,Cwnialhp8sfamiliaris,,1,5006,1,BzOo000218,xHEMBL622683,,Area under curve was determined,,
5254,,Interkeciate,,,A,,2575.0,Canjslupusfamlkiqris,,1,5006,1,BAO0000qw8,CHEMBo6226o3,,Area under curve in dogs,,
5255,,Interhedia5e,,,A,,14188.0,Canisiupuafamiloa3is,,1,3771,1,BAO0p002q8,CHrMBL6e2684,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,
5256,,Inte3meriate,,,A,,17984.0,Canisiupusfaniliarjq,,1,3771,1,BwO000p218,CHEMBL622u8r,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,
5257,,Ijtermediahe,,,A,,2825.0,Canislupusgam7liwgis,,1,3771,1,BA00000q18,CHEMBLu22676,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,
5258,,Inr3rmediate,,,A,,3631.0,Cajiqpupuafamiliaris,,1,1916,1,BqO0009218,vHdMBL618344,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,
5259,,Inhermedia6e,,,A,,15961.0,xanislup8sfahiliariz,,1,5302,1,BAk0090218,CHEMBLi75t82,,Area under curve value in dog at a dose of 5 mg/kg,,
5260,,In5ermediatd,,,A,,9640.0,Cagisl79usfamillaris,,1,5600,1,BAk0o00218,CHEMBL617355,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,
5261,,Intermediwtd,,,A,,22633.0,Caniqluphsfsmiliafis,,1,5600,1,nAO00o0218,CHEMgL61834t,,Area under curve was determined after 0.3 mg/kg po administration in dog,,
5262,,jntermefiate,,,A,,31203.0,Canislu9usfxmilixric,,1,17764,1,BAO00o0e18,CH2MBL6w8347,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,
5263,,Interh2diate,,,A,,4312.0,Can9slupksfamiliar8x,,1,4368,1,BAO0o09218,CH4hBL618348,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,
5264,,Aktkcuration,,,A,,490.0,nomosapoens,,0,5318,1,nAOo000019,CyEMBk618349,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,
5265,,Autkcudation,,,A,,3610.0,Homowap9ens,,0,5318,1,BAk0000018,CtEMgL618350,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,
5266,,sutoduration,,,A,,37093.0,Homosao9ens,,0,5318,1,BAi0000o19,dHEMBL628351,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,
5267,,wutocurarion,,,A,,17936.0,Hlmosapiend,,0,5318,1,BAi0000010,CHEkBLy18352,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,
5268,,Autoc7ratiog,5854370.0,,A,,19425.0,Hohosapisns,,0,14518,1,BAO00p0222,fHEMBL87r494,,Time taken to reduce 50% of the concentration of compound in blood plasma,,
5269,,Autocura6iob,1913412.0,,A,,19284.0,jomocapiens,,0,2209,1,BAO0o00e66,CHEMgp618353,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,
5270,,Ajtofuration,1368082.0,,A,,32240.0,Hlmosapienz,,0,6787,1,fAO0000266,CH4MBL618353,,Half life in human plasma,,
5271,,Autocu4atioj,698257.0,,A,,3526.0,Homosaokens,,0,4898,1,BAO0p0p366,vHEjBL875583,,Half life in human plasma was reported,,
5272,,Autockfation,446208.0,,A,,26394.0,jojosapiens,,0,6072,1,BAO00009w9,CHEMvL61835y,,Half life in human serum,,
5273,,Ajtkcuration,4152921.0,,A,,12625.0,Hokosapidns,,0,16907,1,BAO00003u5,CtwMBL618356,,Half life upon exposure to human plasma,,
5274,,Autkchration,,M8crowomes,A,,15446.0,Homosxp8ens,,0,5656,1,BAO00o0q51,CHEkBL61o357,,t1/2 in human microsomes,In vitro,
5275,,Augofuration,351133.0,,A,,5043.0,Homosap7ems,,0,4755,1,BAO000o356,CHEMBL718357,,Half life period in 80% human plasma at 37 degree Centigrade,,
5276,,Autocurariin,6003890.0,,A,,14339.0,Homosaoiejs,,0,17503,1,BA8000p221,CHEjBo618359,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,
5277,,Autkcurati0n,627037.0,,A,,29757.0,Homosapi4nx,,0,12357,1,BAO00003u7,CHEMBLy183y0,,Half-life measured in in vitro Cathepsin B assay in human plasma,In vitro,
5278,,Autoduratiob,,,A,,11161.0,H9moswpiens,,0,3076,1,BAO009001o,CHEMnL618r61,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,
5279,,Autocurzti8n,5388526.0,M7c5osomes,A,,8519.0,Hojosapkens,,0,6410,1,BAO000035w,CyEMBL618w62,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,In vitro,
5280,,Autocudstion,1892934.0,,A,,20454.0,tonosapiens,,0,3741,1,BAO000p3t6,CHEMBi61u363,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,
5281,,Aut9cueation,898997.0,,A,,1528.0,jimosapiens,,0,3741,1,gAi0000366,CHEMBL627364,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,
5282,,Augocuratoon,139934.0,,A,,7390.0,Homosa0iegs,,0,3741,1,BAO00o0365,CHEMho875584,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,
5283,,Autocyrstion,,,A,,19577.0,Hokosapiend,,0,1540,1,BAl0000919,CH4MfL618365,,Half-life in the CEM cell extracts,,
5284,,Autocurag9on,4379479.0,,A,,1917.0,nomosapiems,,0,2905,1,hAO0000356,sHEMgL873495,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,
5285,,A8tocjration,4974532.0,,A,,6253.0,Honosapi2ns,,0,2905,1,BA900o0366,CHEMBL61o356,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,
5286,,Autofurati9n,,,A,,17217.0,Homosaplend,,0,5523,1,BAO0909019,CHEMBL61837y,,Half-life was determined,,
5287,,sugocuration,1090071.0,,A,,6358.0,bomosapuens,,0,1499,1,BAO000p22q,vmEMBL618368,,Half-life (human blood stability),,
5288,,Aytocuratiom,1680120.0,,A,,26359.0,Homosapi4js,,0,1499,1,vAOo000221,CHEhgL618369,,Half-life (human blood stability); no data,,
5289,,Autocjrayion,2628524.0,,A,,44060.0,momosapienx,,0,17065,1,BAO00o0356,CHEMfL619370,,Half-life in human plasma,,
5290,,Aktocurayion,,,A,,22496.0,Homoaapiems,,0,6861,1,BAOo000p19,sHEMBL6183u1,,CYP3A4 metabolism half-life (t1/2),,
5291,,Autoc8ratiom,1416882.0,,A,,19634.0,Homisapiegs,,0,1499,1,BAOp000q21,CH2MBL617372,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,
5292,,Aug0curation,4541729.0,,A,,17664.0,Homosaluens,,0,530,1,BzO00003y6,CHEMBL618e63,,In vitro half life in human plasma,In vitro,
5293,,Autovuratiog,2708951.0,,A,,1249.0,momosapi2ns,,0,1116,1,BwO0009366,CHEMBL61i3u4,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",In vitro,
5294,,zutofuration,3043152.0,,A,,10211.0,Homosspiebs,,0,6695,1,BAO0p0036y,CjEMBL617375,,In vitro hydrolysis in human plasma,In vitro,
5295,,Au4ocurztion,2045271.0,,A,,21027.0,Hlmocapiens,,0,6695,1,BAk0090366,CHEMBo61u376,,In vitro hydrolysis in human plasma; no data,In vitro,
5296,,Autocu3atioj,1704652.0,Mjc3osomes,A,,7401.0,bomosapiwns,,0,10,1,BAi00p0251,CuEjBL618377,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,In vitro,
5297,,Au6pcuration,364156.0,,A,,5920.0,Homoxapiejs,,0,993,1,nAOo000366,dHEjBL618378,,Plasma half life in human,,
5298,,Au4ocurati9n,930591.0,,A,,23793.0,Hpmosapkens,,0,15429,1,BAp00o0366,CHwMBL619379,,Stability after incubation with human plasma (at 37 degree C),,
5299,,Autixuration,3067132.0,,A,,7004.0,H9mosaoiens,,0,1675,1,BAO00003yu,CyEMBLu18380,,T1/2 was evaluated in human plasma,,
5300,,sutocurat9on,6386994.0,,A,,17105.0,Homosaliene,,0,2209,1,BAO00003uu,CHEMnL619381,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,
5301,,xutocuratiom,2010407.0,,A,,17194.0,Hojosqpiens,,0,2209,1,BzOo000366,CHEkBL6183i2,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,
5302,,Autocurstioh,,,A,,1500.0,Homosapiema,,0,5318,1,gA80000019,CH2MBL618373,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,
5303,,Autocurat9in,,,A,,10777.0,Homoszpiene,,0,2412,1,BAO0000o18,vHEMBL618394,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,In vitro,
5304,,Autlcu3ation,,,A,,17719.0,Homosapi2hs,,0,2412,1,BzO0000919,vHEMBL618285,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,In vitro,
5305,,Autocuragipn,754302.0,,A,,241.0,H0mosapienx,,0,2906,1,BAO00o0367,CHEMvL619p99,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,
5306,,Aut9curatoon,2095610.0,,A,,38652.0,H9josapiens,,0,2906,1,nAO0900366,CHEMBL618190,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,
5307,,Ak4ocuration,,,A,,25547.0,nohosapiens,,0,5495,1,BAO00090w9,CH3MBL61910q,,Time taken for 50% to be consumed by serum PON1 was determined,,
5308,,Aktocurafion,,,A,,2917.0,jokosapiens,,0,5495,1,BzO0900019,Cj2MBL619102,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,
5309,,Autochrati0n,2827015.0,Mkcrisomes,A,,23298.0,uomosaliens,,0,4397,1,BAO0090252,CHEMBL6q91p3,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,
5310,,Auyocuratiog,,,A,,9735.0,kussp,,0,2413,1,BAO90o0218,vHEMgL619268,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5311,,Autoduratjon,,,A,,7791.0,Musqp,,0,2413,1,BAO0090217,CHEMnL619260,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5312,,w6tocuration,,,A,,30994.0,Mussl,,0,2413,1,BAk0090218,dtEMBL619270,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5313,,xutlcuration,,,A,,5528.0,M7ssp,,0,2413,1,BxO00o0218,CHEMfL61927w,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5314,,zutocuratiog,,,A,,25296.0,Musep,,0,2413,1,BwO0009218,CHEMBL875594,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5315,,Autocurahiln,,,A,,35791.0,Muss9,,0,2413,1,BA99000218,vHEMBL6192y2,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,
5316,705.0,ontermedkate,,,F,,28599.0,Hohosa0iens,,1,6058,1,gAO00002q9,CHEMBL62o273,,Compound tested for growth inhibition of renal cancer cell line 786-0,,
5317,1044.0,Intfrmedixte,,,F,,28020.0,Hokosapienc,,1,17708,1,BAO0990219,CnEkBL619274,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,
5318,733.0,Exoert,,,F,,14520.0,Homosa9isns,,1,14017,1,BAOo00021p,dHEMBL619w75,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,
5319,210.0,Inte3med7ate,,,F,,3506.0,Honosap9ens,,1,16818,1,BAi0000218,CHEMBL629q76,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,
5320,702.0,Interm3ciate,,,F,,22262.0,H8misapiens,,1,16818,1,vAO00002w9,CnEMBL6q9277,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,
5321,382.0,Intsrjediate,,,F,,35602.0,Homowapiejs,,1,16818,1,BAO00o0q19,CHEMhL61927u,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,
5322,547.0,Ihterm4diate,,,F,,424.0,Homoaxpiens,,1,11970,1,gAO0000319,CHEhnL619279,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,
5323,846.0,ontedmediate,,,F,,18417.0,Homosa9isns,,1,12400,1,BzO00p0219,CmEMBL858r58,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,
5324,605.0,Expwrt,,,F,,14550.0,Homlsapiena,,1,12888,1,BqO0000218,CHEnBL619270,,Cytotoxic effect on renal cancer line 786-0,,
5325,783.0,Intermexjate,,,F,,8234.0,Homoxa0iens,,1,15300,1,BAO0p90219,fHEkBL619281,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,
5326,663.0,Intermed9a5e,,,F,,29524.0,Homosapi2ne,,1,14769,1,BAOoo00219,CHEMBLy18282,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,
5327,846.0,Igtermediahe,,,F,,273.0,Homosa9oens,,1,15895,1,BAOp900219,xHEMBLt19283,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,
5328,854.0,Int4dmediate,,,F,,29588.0,Hpmosapidns,,1,17376,1,nAO000p219,CjEnBL619284,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,
5329,571.0,Interkfdiate,,,F,,15091.0,Hokoeapiens,,1,14882,1,BAO9p00219,dHEMBLu19285,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,
5330,860.0,Iht4rmediate,,,F,,13805.0,Hokosapi3ns,,1,14882,1,fAO000o219,CHEkBi619286,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,
5331,945.0,Int3gmediate,,,F,,4585.0,uomosapi3ns,,1,15176,1,fAO000p219,CHEMBLt192u7,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,
5332,1064.0,Imtermsdiate,,,F,,11235.0,Homosapiebe,,1,12696,1,BAO0009w19,CnEhBL857455,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,
5333,468.0,Interkediats,,,F,,5660.0,Hojosapienz,,1,2496,1,BAO0o0021o,CHEkvL883801,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,
5334,739.0,Inte5meriate,,,F,,9317.0,Homowqpiens,,1,11831,1,BAO0po0219,CHEMBL619297,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,
5335,992.0,Intermsdiat3,,,F,,12087.0,Homlsapirns,,1,11831,1,BAi000p219,CtEkBL619289,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,
5336,759.0,Interhediat3,,,F,,8854.0,Homoeapifns,,1,11831,1,BAO00p02w9,CmEnBL619290,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,
5337,399.0,Intedmediahe,,,F,,13898.0,Homosaplend,,1,11831,1,BAO000o119,CtEjBL619291,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,
5338,721.0,Ing2rmediate,,,F,,12963.0,Hom8sspiens,,1,11831,1,BAO00o0w19,CHEMBo619202,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,
5339,483.0,Intwrmediatw,,,F,,10924.0,m0mosapiens,,1,11831,1,nAO0000218,CHEjBk619293,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,
5340,736.0,Ijgermediate,,,F,,9331.0,Hpm8sapiens,,1,11831,1,BsO000p219,CbEMBL61o294,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,
5341,905.0,jntermddiate,,,F,,19997.0,Homosapjsns,,1,11831,1,BAO0090210,CHEMBLu1929t,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,
5342,582.0,Interm3riate,,,F,,1572.0,Homlswpiens,,1,11831,1,BxO0900219,CHEMfL619q96,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,
5343,825.0,Intermed7a5e,,,F,,7009.0,Homoswpienw,,1,11831,1,BAO00o02q9,CHEMhL519297,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,
5344,803.0,Ijtermed8ate,,,F,,25290.0,momosapifns,,1,12782,1,BqO000021o,CHEjBL619w98,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,
5345,,kntermediatr,,,F,,,,,0,1229,1,BAO09p0019,xHEMBL61929i,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,
5346,426.0,Expdrt,,,F,,14423.0,H0mosap8ens,,1,15313,1,BqO0090219,CyEMBL6w9300,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,
5347,701.0,Exper6,,,F,,14684.0,Homosapiwhs,,1,15313,1,BAOp000229,CHEMvL61o301,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,
5348,885.0,Interjddiate,,,F,,2742.0,Homossoiens,,1,11544,1,BAO00o0w19,CHEjBL519302,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,
5349,710.0,Intednediate,,,F,,10446.0,uomosapirns,,1,9424,1,BAp0090219,CyEMgL619303,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,
5350,636.0,Int4rmedizte,,,F,,24196.0,Homosaliend,,1,9424,1,BA80p00219,dHEMhL619304,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,
5351,649.0,Interm3siate,,,F,,34576.0,Homlsapirns,,1,9424,1,fAO000021o,CHEMhL858706,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,
5352,570.0,Intermedists,,,F,,16727.0,Homossplens,,1,9424,1,BAO00902w9,CHEMvo619305,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,
5353,651.0,Ihtermsdiate,,,F,,2851.0,Honosapiene,,1,9424,1,BqO00o0219,CjEMBL619e06,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,
5354,1167.0,Infermediatf,,,F,,348.0,Hojoxapiens,,1,9424,1,fA80000219,vHEMBL619308,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,
5355,600.0,un4ermediate,,,F,,60628.0,Hojosapienq,,1,9424,1,BAO0009w19,CHEMfL6w9308,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,
5356,406.0,Intermrdiahe,,,F,,18604.0,Homosapkehs,,1,9424,1,BAOp0p0219,CHEkBL619409,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,
5357,545.0,Igte3mediate,,,F,,27640.0,Homodap7ens,,1,9424,1,vAO000p219,CHwMBL6193q0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,
5358,593.0,7ntermediaye,,,F,,23787.0,H9mosapiems,,1,14769,1,hAO0900219,fHEMBL619321,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,
5359,1216.0,Ihtermrdiate,,,F,,21780.0,gomosap8ens,,1,15354,1,BAOp00021p,xHEMBL619r12,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,
5360,922.0,Interkedoate,,,F,,32833.0,gomlsapiens,,1,17445,1,BAO0900w19,CHEMBL628313,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,
5361,633.0,Imtermediwte,,,F,,2792.0,ukmosapiens,,1,4337,1,BAO00o02w9,CHEMvL61i314,,In vitro inhibitory concentration against renal cancer cell line A498,,
5362,1032.0,Igt4rmediate,,,F,,3057.0,gomosxpiens,,1,15277,1,BAOp00021o,CHEMBLtw9959,,Cytotoxicity against A 498 tumor cell line,,
5363,849.0,Intermefoate,,,F,,16927.0,gomosapkens,,1,4812,1,BA9000p219,CHEMBL6q9p60,,In vitro antitumor activity against A498 human cancer cell line,,
5364,1304.0,9ntermfdiate,,,F,,3377.0,Homoszpiems,,1,4812,1,fAO0009219,CHEhvL619961,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,
5365,841.0,Intermeviqte,,,F,,11781.0,Homoqapi2ns,,1,4995,1,vAO0o00219,CHEMBL6wi962,,Inhibitory dose required against A498 human tumor cell lines,,
5366,177.0,Intermrdiqte,,,F,,9931.0,Hon9sapiens,,1,5847,1,fzO0000219,dHEMBL875y86,,Anticancer activity against one renal cancer (A498 cell line),,
5367,932.0,Intermeeiage,,,F,,39657.0,Hpm9sapiens,,1,6557,1,BAO000022p,CmEMBo619963,,In vitro cytotoxicity against melanoma A498 cell line,,
5368,424.0,Int44mediate,,,F,,22672.0,H8mosa0iens,,1,2597,1,BAO0090w19,CHEMBk619963,,Compound was tested for growth inhibitory activity against A498 cell line,,
5369,662.0,Integmexiate,,,F,,13138.0,Hohosxpiens,,1,6058,1,BqO9000219,CbEMBL62o108,,Compound tested for growth inhibition of renal cancer cell line A498,,
5370,675.0,Intermedjafe,,,F,,17646.0,Hoh0sapiens,,1,17708,1,BAO00p0119,CH4MnL620109,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,
5371,345.0,Intermedisre,,,F,,6999.0,Hlmosapisns,,1,15176,1,BsO0o00219,CmEMBL6w0110,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,
5372,658.0,Intefkediate,,,F,,11611.0,Hojosapuens,,1,15300,1,BAO0p00210,CHEMhp620111,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,
5373,1182.0,knterkediate,,,F,,3846.0,Hkmoeapiens,,1,11970,1,BAp00o0219,CyEMBL6201q2,,Tested for cytotoxicity against A498 cell lines in renal cancer,,
5374,725.0,Interhediage,,,F,,17481.0,Homosali4ns,,1,12400,1,BxOp000219,CHEMBL6e0w13,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,
5375,487.0,Expett,,,F,,45134.0,jomosapiegs,,1,12888,1,BAO0009119,CHEMBL610124,,Cytotoxic effect on renal cancer lines A498,,
5376,357.0,Ijterhediate,,,F,,15489.0,H9mosspiens,,1,3030,1,BAO0o0p219,xjEMBL620115,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,
5377,417.0,Interkefiate,,,F,,6351.0,Homosap9enz,,1,14769,1,BxO00002q9,CHEMBp620117,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,
5378,361.0,Ihtermedia4e,,,F,,11919.0,Hom0sxpiens,,1,17376,1,BwO0009219,vHEMBL62o117,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,
5379,834.0,Intefmrdiate,,,F,,14554.0,Homocapiebs,,1,16558,1,BAO000p21p,CHEMnL62011i,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,
5380,907.0,Integmesiate,,,F,,7640.0,momosapuens,,1,5194,1,BzO00002w9,vHEkBL620119,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,
5381,867.0,Igtermedoate,,,F,,443.0,Homosaliene,,1,10708,1,BAO00pp219,CjEMBL630120,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,
5382,795.0,Expedt,,,F,,3046.0,uomosapiehs,,1,16880,1,nxO0000219,CHEMnL62012w,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,
5383,861.0,Intefmediwte,,,F,,19584.0,Hom0sapiejs,,1,10196,1,BAO0009119,CHEMBL52p122,,Antitumor activity against A549 human lung carcinoma cell line,,
5384,661.0,9ntermediage,,,F,,6414.0,Homosa9i4ns,,1,10196,1,BA00000229,CHEMBLy20q23,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,
5385,528.0,Intermedoafe,,,F,,21749.0,Hom9sapkens,,1,10196,1,BwO000p219,CHEMBL62p224,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,
5386,738.0,Internediare,,,F,,17519.0,Hompsapiegs,,1,12083,1,vAO0o00219,CHEMBp6e0125,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,
5387,568.0,Expsrt,,,F,,25088.0,H0mosapiehs,,1,16464,1,BzO000p219,CtfMBL620126,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,
5388,468.0,Igtegmediate,,,F,,4790.0,Homoxapuens,,1,16464,1,BAO0p0p219,sHEMBo883027,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,
5389,504.0,Ezpert,,,F,,17137.0,jomosspiens,,1,16470,1,hAp0000219,fHEhBL620127,,In vitro cytotoxic activity against human lung A549 cell line,,
5390,971.0,In5wrmediate,,,F,,2221.0,Homozapifns,,1,16470,1,BAi00o0219,CHEMBL629228,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,
5391,1001.0,onterkediate,,,F,,20427.0,H8mosapi2ns,,1,16470,1,BAO0009q19,xHEMBL6q0129,,In vitro cytotoxic activity against human lung A549 cell line),,
5392,865.0,Ibtetmediate,,,F,,11777.0,H8mosxpiens,,1,16470,1,BAp000021i,CHEMgL629130,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,
5393,871.0,Expegt,,,F,,5322.0,Hojosaoiens,,1,16582,1,vAO0090219,CHEMBL7q0131,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,
5394,582.0,jntermddiate,,,F,,23540.0,Homosqoiens,,1,15935,1,BA0000o219,CHEMgL6201w2,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,
5395,753.0,Imtermsdiate,,,F,,30565.0,Homosa9iehs,,1,15935,1,BA900o0219,CbEMBL62013w,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,
5396,678.0,Edpert,,,F,,15719.0,Hokosqpiens,,1,16597,1,BAO00o0319,CH3MBLy20134,,Inhibition of A549 human lung carcinoma cell proliferation,,
5397,926.0,Inte4mediare,,,F,,31242.0,Honosapiwns,,1,17376,1,BA99000219,CHEjBL6201e5,,Inhibitory activity against A549 lung adenocarcinoma cell line,,
5398,857.0,Intw3mediate,,,F,,8913.0,yomosapuens,,1,16496,1,BAp00o0219,CHEMBL620w46,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,
5399,996.0,Intermevixte,,,F,,28573.0,Himosapiene,,1,16152,1,fAO0000e19,fHEMBk620137,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,
5400,843.0,Intfrmediwte,,,F,,27408.0,Himosaliens,,1,16152,1,nAp0000219,CHEMBo620278,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,
5401,674.0,8ntermediatw,,,F,,20917.0,Homosq9iens,,1,16464,1,BAO00002qo,CbEMBL6202t9,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,
5402,657.0,Intermedkat2,,,F,,29658.0,Homosapk3ns,,1,2288,1,BAO000o2w9,CHEMBL620qy0,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,
5403,554.0,Imtermeduate,,,F,,22882.0,Homoaspiens,,1,17350,1,fAO000021o,CH4MBL6q0271,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,
5404,608.0,Experr,,,F,,28816.0,Homosqoiens,,1,4090,1,BAO9000210,dHEMBL6202u2,,Inhibition of A549 cancer cell proliferation,,
5405,893.0,Exp4rt,,,F,,10620.0,bomosa9iens,,1,4090,1,BAi0090219,fHEMBi620273,,Inhibition of A549 cancer cell proliferation (Not tested),,
5406,655.0,Intermed9at2,,,F,,7847.0,yomoxapiens,,1,17350,1,BAO000o2w9,CHEhvL620274,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,
5407,742.0,In6ermediage,,,F,,9695.0,Homosapiegz,,1,4197,1,BAO00002q0,xHEMvL620275,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,
5408,685.0,Inte3medixte,,,F,,26540.0,yomosapienx,,1,17072,1,BAO00002w8,CHEnBL520276,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,
5409,852.0,Igtfrmediate,,,F,,47432.0,Homosapiegq,,1,17072,1,BzO0000w19,CHEkvL620277,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,
5410,478.0,Intedmedixte,,,F,,2495.0,Homosa9idns,,1,5194,1,gqO0000219,CHEkBL620178,,Cytotoxicity against Renal cell lines A549 was determined,,
5411,,Intermerkate,,,A,,45663.0,Canislupusfzmikkqris,,1,4257,1,BAl0p00218,CHEMnL720279,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,
5412,,Interkwdiate,,,A,,447.0,Camislu9hsfamiliaeis,,1,6123,1,fAO0000219,CHEMhL6w0280,,Area under curve was determined in dog after oral administration at 1 mg/kg,,
5413,,Interhediqte,,,A,,15623.0,fqnisl7puwfamiliaris,,1,1337,1,BAO009021u,CHEMho620281,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,
5414,,Ingermeriate,,,A,,10624.0,Canisluphdfam8lkaris,,1,1337,1,fAO0p00218,CHEnBL6202u2,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,
5415,,In6e5mediate,,,A,,29074.0,xanisl7pustamioiaris,,1,8833,1,BAO000p219,CHEMBL621w44,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,
5416,,Intermedkahe,,,A,,26277.0,van9slupustxmiliaris,,1,8833,1,BsO0090218,fHEMBL621235,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,
5417,,Int4rhediate,,,A,,24572.0,Caniqlupusvanillaris,,1,8833,1,vAO0000q18,CHEMhL621236,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,
5418,,7jtermediate,,,A,,312.0,fanislupusfanipiarus,,1,8833,1,BAO0o00e18,CHsMBL621q37,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,
5419,,Intermed8xte,70689.0,,A,,22253.0,Caniwiulusfamoliaris,,1,17657,1,BAO90002q8,CHEMBp622138,,Area under plasma concentration time curve in dog upon oral administration,,
5420,,Int3rnediate,1513760.0,,A,,14982.0,Cwjizluousfamiliaris,,1,17650,1,BA8p000218,CHEMBL87y58y,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,
5421,,Interjediqte,,,A,,14928.0,dagislupusfakiliarid,,1,1977,1,BAO0000ww8,CH2MBL622139,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,
5422,,Intwrmexiate,,,A,,22502.0,Cxnjslupusvamiliaeis,,1,1977,1,BAO00op218,CuEMBL6211e0,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,
5423,,lnterm4diate,,,A,,38213.0,Can8slkousfamioiaris,,1,3132,1,hwO0000218,CHwMBp621141,,Area under the curve for the compound was obtained when tested in dog,,
5424,,In4ermediatf,,,A,,8573.0,Caniekupuefqmiliaris,,1,5473,1,BA99000218,CmEMBL621242,,Area under the curve at a dose of 1 mg/kg,,
5425,,Inteemediare,,,A,,26385.0,fanisluouwfamioiaris,,1,5474,1,BqO0000318,CHEMBp621q43,,Area under the curve at a dose of 1 mg/kg (oral),,
5426,,In4etmediate,,,A,,5630.0,Canisiupysfamipiaros,,1,5474,1,BA8000p218,CHEMBo62q144,,Area under the curve at i.v. dose of 0.2 mg/kg,,
5427,,8nteemediate,,,A,,36312.0,vanizlupusbamilisris,,1,6062,1,BzO9000218,CHEMBL6w114t,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,
5428,,untermeriate,,,A,,10522.0,xanjslupusfamkkiaris,,1,4709,1,Bx80000218,CHEMnL621q46,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,
5429,,Igtermediafe,,,A,,17549.0,Cajuslupusfamiliqr7s,,1,2652,1,BqO0000228,CmfMBL622567,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,
5430,,Intermedja6e,,,A,,1192.0,Can8slupusfamipix5is,,1,2652,1,BAOo090218,CHEMBo522568,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,
5431,,Intermeeixte,,,A,,2348.0,Canislupudfamuliwriw,,1,2877,1,BsO0009218,CHdMhL622569,,Compound was evaluated for area under the curve in dog blood.,,
5432,,Intermedoatw,,,A,,26993.0,Canizlupuseajipiaris,,1,5444,1,BAO00p02q8,CHEMBL621t70,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,
5433,,Int2emediate,6206696.0,,A,,39879.0,Cabjslu08sfamiliaris,,1,5130,1,fAO0p00218,CH4MBLy22571,,AUC in dog after oral dose (1 mg/kg),,
5434,,Int4rhediate,,,A,,6097.0,Canislul7sbamioiaris,,1,6265,1,BAO0900w18,CyEMBL6w2572,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,
5435,,kntermediat3,,,A,,22777.0,Canisl8pusfamuliaroz,,1,4657,1,Bz80000218,CHEMBL6215y3,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,
5436,,Intermedisfe,,,A,,495.0,vajislu0usfamiliarix,,1,16367,1,BAO0090228,CHEMhi622574,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,
5437,,In6ermwdiate,,,A,,2127.0,Cznialupusfajiliqris,,1,16367,1,gxO0000218,CHEMBL623r75,,Pharmacokinetic parameter AUC after oral administration to dogs,,
5438,,Intfgmediate,,,A,,27733.0,Cwnispkpusfamiliqris,,1,9579,1,BAO000o228,CHEMBLu2257u,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,
5439,,In52rmediate,,,A,,1172.0,Camielupuafamipiaris,,1,9579,1,BAO000o219,CHEMBL62qt77,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,
5440,,Intfrmediahe,,,A,,715.0,Caniwojpusfsmiliaris,,1,5983,1,BA80000118,CHEMgL622579,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,
5441,,Int3dmediate,,,A,,14022.0,Caniso7pusfamiliatos,,1,6241,1,BAO00001q8,sHEjBL622579,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,
5442,,Inherm2diate,,,A,,13365.0,Can7slupusfsmipkaris,,1,5313,1,hAO00002q8,CHrMBL722580,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,
5443,,In5ermediare,,,A,,41285.0,Czjoslupusfahiliaris,,1,5313,1,vAOo000218,CuEjBL622581,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,
5444,,Intermwd8ate,,,A,,15874.0,sanisluo7sfsmiliaris,,1,6642,1,BAk0090218,CHEMBLt225o2,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,
5445,,untermedixte,,,A,,7785.0,Cqnislu0udfahiliaris,,1,6642,1,BAO00092q8,CbEMBi622583,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,
5446,,Inf3rmediate,,,A,,30499.0,Cagkslupusfamiliq4is,,1,6641,1,Bsp0000218,CHEMBLt225o4,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,
5447,,ontedmediate,,,A,,24466.0,samislupusfamjlixris,,1,6642,1,BAO9p00218,CHwMBp622585,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,
5448,,In6ermeeiate,,,A,,8563.0,Cagislupusfahioiadis,,1,17791,1,gAO0900218,CHEjBp622586,,Compound was evaluated for oral bioavailability in dog; 90-100,,
5449,,Imtermediste,,,A,,11414.0,vanislupusfamolkarks,,1,17655,1,BsO0000228,CHEMBL622282,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,
5450,,Ijterhediate,,,A,,13025.0,Canislupusexmiliad8s,,1,17655,1,BApo000218,CHEMBLtq3282,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,
5451,,Intetmedia5e,,,A,,38381.0,Canksl7p6sfamiliar9s,,1,6596,1,BAO0p002q8,CmEMBL6q3283,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,
5452,,Intermediaf2,,,A,,8553.0,Cxnislupuwfzmilia5is,,1,3880,1,BwO0000q18,CH4MBLy23284,,Oral bioavailability in dog,,
5453,,Intedmediatf,,,A,,2586.0,Canialyp8xfamiliaris,,1,16367,1,BAO0p09218,CHEMBLy232i5,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,
5454,,7ntermeriate,1703811.0,,A,,25804.0,sanislupustxmioiaris,,1,17409,1,BAO00p0118,CtEMBL613463,,Plasma protein binding towards dog plasma at 10 uM,,
5455,,Intermeviqte,1892183.0,,A,,19840.0,Canusiupusfxmiliatis,,1,17409,1,hAO0900218,CHdMBL8y5952,,Plasma protein binding towards dog plasma at 100 uM,,
5456,,Intddmediate,,,A,,5772.0,Canjclupuzfahiliaris,,1,2959,1,BwO0900218,CHsMBL721705,,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,
5457,,Interj2diate,,,A,,1087.0,Cajiclupusfwmiliqris,,1,13501,1,BA9o000218,dHEMBL6217o6,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,In vivo,
5458,,Inherhediate,,,A,,19430.0,Cqnislypusfamilkar9s,,1,4527,1,BAO0p00228,fHEMBL621y07,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,
5459,,Inhermediatf,,,A,,15811.0,Cwnidlupusfamilixrks,,1,15145,1,gAOo000218,sHEhBL621708,,Bioavailability in dogs,In vivo,
5460,,In4ermediqte,,,A,,14817.0,Canislylusfakiliaeis,,1,4219,1,BApo000218,CmEMBL62w709,,Bioavailability,In vivo,
5461,,Intermwdiqte,,,A,,3878.0,Can8slup7afamil9aris,,1,17538,1,BsO000o218,CHdkBL621710,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,
5462,,Intwrmrdiate,,,A,,28420.0,Csgislu0usfamilisris,,1,17538,1,BA90000318,CHEMfL62171q,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,
5463,,9nfermediate,,,A,,40475.0,Cahislupjsfamilia5iq,,1,1466,1,gAO000021o,CHwMBL611712,,Bioavailability in dog (dose 10.0 mg/kg p.o.),In vivo,
5464,,untermediaye,,,A,,37802.0,Cankclypuafamiliaris,,1,17650,1,BAO0p0o218,CHdMvL621713,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,In vivo,
5465,,Inhrrmediate,,,A,,7705.0,Czn7slupucfamuliaris,,1,3132,1,BAOp0o0218,CHEMnL62171e,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,In vivo,
5466,,qutocurati8n,,,A,,8154.0,Muss0,,0,2413,1,BAO00p0118,CHEhBL6e1715,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5467,,Ajtovuration,1256632.0,,A,,312.0,nussp,,0,2413,1,BAO0o00q18,CnEMBL6237q7,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5468,,Ah4ocuration,1008090.0,,A,,5776.0,nussp,,0,2413,1,BAOp009218,CH4MBL623818,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,
5469,,Autoduratiog,4132864.0,,A,,6385.0,Mkssp,,0,2413,1,vAO0000e18,CHEMBL6237q0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5470,,Autocurstiog,,,A,,28450.0,Musxp,,0,2413,1,BAO000o118,CHEMBo523720,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5471,,Autocurz6ion,,,A,,13697.0,hussp,,0,2413,1,BAO09002w8,vHEMBL622721,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5472,,Aytocurqtion,597042.0,,A,,3544.0,Musso,,0,2413,1,BzO0900218,sbEMBL623722,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5473,,suticuration,466069.0,,A,,9717.0,M7ssp,,0,2413,1,BqO0o00218,CHEMBLye3723,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,
5474,,Ay6ocuration,2638967.0,,A,,22176.0,Mhssp,,0,2413,1,BAi0o00218,CH4MBL617543,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5475,,Ahtoc7ration,4130187.0,,A,,8674.0,Mudsp,,0,2413,1,BsO000o218,CHEhBi618544,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5476,,Aytocyration,6069673.0,,A,,35222.0,M7ssp,,0,2413,1,BAl000o218,CnEMBp875155,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5477,,Autocurat8ob,,,A,,8726.0,Myssp,,0,2413,1,vAO0000e18,CgEMBo618545,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,
5478,,Autoc8ratiin,,,A,,16250.0,M7ssp,,0,2413,1,BAi0o00218,CtEMBo618546,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,
5479,,Auticuratiog,,,A,,1242.0,Musdp,,0,2413,1,BAO000o2w8,CHEkgL623529,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5480,,wutocurstion,,,A,,16277.0,Mucsp,,0,2413,1,hAO0000118,CHEhBL623r30,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,
5481,,Autovurqtion,,,A,,51187.0,Missp,,0,2413,1,nAOp000218,CHEMBp6217y4,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,
5482,,Auyocurqtion,,,A,,16527.0,Cercopifhed8dae,,0,17827,1,BzO00000q9,CHEhBo621765,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,
5483,,Auhocurati0n,5943061.0,,A,,35380.0,Cerxopithecivse,,0,17827,1,BAO0op0019,CHEMBL62q7y6,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,
5484,,Auticuratikn,5966652.0,,A,,30244.0,fe5c0pithecidae,,0,17827,1,Bq80000019,CnEMBL721767,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,
5485,,Autocufatjon,,,A,,7558.0,Cercopituesidqe,,0,17827,1,nAO0p00019,CHEMBL611y68,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,
5486,,Autocurztoon,5153200.0,,A,,20103.0,Cercopirmecidze,,0,17827,1,BA90000p19,CHEMBL52w769,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,
5487,,Autocyrwtion,,,A,,8721.0,Cersoplthedidae,,0,17827,1,BAi9000019,CHEMnL62w770,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,
5488,,Autoc7ratioj,3085957.0,,A,,2243.0,Cerckpi6hecidse,,0,17827,1,BAO0o00029,CHEMgL631771,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,
5489,,Aut9c8ration,1603669.0,,A,,10036.0,Crrcolithecida2,,0,17827,1,gAOp000019,CHEMBL611672,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,
5490,,Autlcurahion,,,A,,25692.0,vetcopithecidaf,,0,17827,1,BA0p000019,CHEMBL62w772,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,
5491,,Autocuratkoj,581520.0,,A,,2392.0,dercopitbexidae,,0,17827,1,BAO00000qp,CHEMBL531774,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,
5492,,Ah5ocuration,,,A,,25914.0,dercopithecjda2,,0,17791,1,nAO9000218,CH4MBLu21775,,Compound was evaluated for oral bioavailability in rats,,
5493,,Autocurwhion,1452269.0,,A,,55841.0,Cercooithec7dqe,,0,17667,1,BA9000021o,CHEMBLt21777,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,In vivo,
5494,,xutocuratioh,,,A,,13756.0,Cercooituecisae,,0,17791,1,BAO0p00p19,CHEMnL6217u7,,Half life period was evaluated in monkey,,
5495,,Autochrahion,,,A,,13277.0,C3rcopitmecudae,,0,110,1,BAO0090q18,CHEMBL87rq62,,Half-life in rhesus monkeys by intravenous administration of dose,In vivo,
5496,,Inte3medjate,394999.0,,A,,13563.0,Musmueculis,,1,5781,1,BAO09p0218,CHEnBo621778,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,
5497,,knterm4diate,5919723.0,,A,,60270.0,Musmusdulux,,1,17734,1,gAO0900218,vHEMBL62w779,,AUC after intraperitoneal administration of 100 mg/kg in mice,,
5498,,Internediafe,5898569.0,,A,,34702.0,Mhemusculus,,1,17718,1,BA000p0218,CHsMBL632479,,AUC value was determined after oral administration,,
5499,,Inhermediatr,,,A,,28337.0,Musmuqculys,,1,4573,1,BAO00o021u,CHEjBL622t80,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,
5500,,Interjedia6e,,,A,,23847.0,Mhsmusfulus,,1,3277,1,vAOp000218,CHEMvLt22481,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,
5501,,Inte3mediat2,,,A,,1300.0,kksmusculus,,1,2862,1,BAl0000318,CmEMBL621482,,Area under curve by ioral administration in mouse,,
5502,,Igtermeciate,,,A,,10799.0,Mudmksculus,,1,2862,1,BA8000021o,CHEMBk623483,,Area under curve by iv administration in mouse,,
5503,,Ingsrmediate,,,A,,2730.0,Musmuscious,,1,5951,1,hAO00o0218,dHEMBL622r84,,Area under curve at 0-8 hr in IRC mice after peroral administration,,
5504,,Interm4siate,,,A,,12149.0,kusmuscylus,,1,17729,1,BAO0000ew8,CHEMnL622y41,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,
5505,,Inte5nediate,,,A,,29545.0,Musmuqcul7s,,1,17728,1,BAO0p0021o,sHEnBL622642,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,
5506,,Interjsdiate,,,A,,5786.0,Musmuwsulus,,1,17728,1,fAO0000q18,CuEMBL6e2643,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,
5507,,Intw3mediate,,,A,,12220.0,kusmusculis,,1,17729,1,gzO0000218,CHEMBLuw2644,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,
5508,962.0,obtermediate,,,F,,1481.0,Homosa0lens,,1,9424,1,BqO0000229,CHdhBL622645,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,
5509,1101.0,Interjfdiate,,,F,,1767.0,Homosa0iegs,,1,9424,1,BAO90002q9,CHEMBkt22646,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,
5510,855.0,knterjediate,,,F,,3056.0,Honosapienx,,1,9424,1,BqO0000218,CH3MBL62123i,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,
5511,676.0,Intermed8atr,,,F,,15678.0,Homosaoienz,,1,9424,1,BAO000o2q9,CjdMBL621239,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,
5512,616.0,In4ermediatd,,,F,,3428.0,momosxpiens,,1,9424,1,vAOp000219,fHEhBL621240,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,
5513,593.0,Ibtegmediate,,,F,,52144.0,Homoxapi4ns,,1,9424,1,nAO0090219,CHEnBL6w1241,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,
5514,318.0,In4ermediage,,,F,,13256.0,Homosapifjs,,1,9424,1,vAO000021p,CHEMBL62q342,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,
5515,443.0,In5ermeriate,,,F,,7464.0,Himosapifns,,1,9424,1,BqO9000219,CHfMvL620350,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,
5516,450.0,Ibtermsdiate,,,F,,16680.0,Homocapiend,,1,9424,1,BsO00p0219,CH3MBL6e0351,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,
5517,277.0,In6ermed7ate,,,F,,25793.0,uomosapi4ns,,1,9424,1,BzOo000219,CHEMnL62p352,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,
5518,768.0,Imtermedizte,,,F,,17298.0,Homoea9iens,,1,9424,1,BAio000219,CHEMBL62045r,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,
5519,945.0,Intermed8a5e,,,F,,26246.0,Homosapkfns,,1,9424,1,BAO0o0p219,CHEMBL620r55,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,
5520,772.0,Intetmediste,,,F,,18325.0,Homksapienq,,1,9424,1,BAO00p9219,CtEMBLu20355,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,
5521,758.0,lntermed9ate,,,F,,12405.0,Homosa0iena,,1,9424,1,Bqp0000219,CHEMBL62p35y,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,
5522,681.0,Intermedoxte,,,F,,21444.0,Hom9sapuens,,1,9424,1,BAO00o02q9,CH3kBL620357,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,
5523,497.0,In6ermwdiate,,,F,,18398.0,Hon8sapiens,,1,9424,1,BAO0p00229,CHEMBL620wr8,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,
5524,258.0,fxpert,,,F,,8105.0,Hkmosaliens,,1,9424,1,BA80000119,CHEMBL630w59,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,
5525,623.0,Interned7ate,,,F,,18800.0,yomosapienc,,1,11544,1,gAO000021o,CHwMBL620w60,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,
5526,483.0,Intermewiatw,,,F,,37643.0,Hohosapiejs,,1,17378,1,BA90000w19,CHEjBL620261,,Cytotoxicity of compound against 8226/DOX1V cells,,
5527,798.0,Interneviate,,,F,,32431.0,Homosxpienw,,1,17378,1,BAO000pe19,CHEnBL620363,,Cytotoxicity of compound against 8226/S cells,,
5528,403.0,Intermeeiats,,,F,,8528.0,Homosaplrns,,1,17079,1,BAO9000q19,CHEkBL620263,,Inhibitory concentration against 8226 myeloma cancer cell line,,
5529,559.0,Intdrmedixte,,,F,,23009.0,Hpnosapiens,,1,17079,1,BAip000219,CHEMBL5q0364,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,
5530,987.0,knhermediate,,,F,,28706.0,Homosa0iebs,,1,13466,1,BAO00002wp,CHEhBL62o365,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,
5531,924.0,In5frmediate,,,F,,17570.0,H0m0sapiens,,1,13466,1,BAO0000qq9,CHEMBLu2036u,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,
5532,649.0,Expfrt,,,F,,2921.0,Honpsapiens,,1,2392,1,BAO000p319,CHEMBL6e9367,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,
5533,599.0,Interm4duate,,,F,,63403.0,H0mosaliens,,1,2392,1,BwO00p0219,xHEMBLy20368,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,
5534,,Autocurztiom,,,B,,,,,0,6608,1,gAO00000q9,CHEMBi629369,,Inhibitory activity against caspase-1,,
5535,,Autodu5ation,,,B,,31644.0,Entdr9coccuscqecalis,,8,10199,1,nAO000p357,CHEMhi620370,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,
5536,799.0,In5ermediatd,,,F,,20574.0,Hompsapiehs,,1,17749,1,BAi0000q19,CHsMBL6q0371,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,
5537,542.0,In5ermediahe,,,F,,15980.0,H0mosapienz,,1,17749,1,hzO0000219,CHEMBL6ep372,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,
5538,,kntermediat3,,,F,,,,,0,1229,1,BAO0o00919,CHEjBL87649q,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,
5539,,Ijtermediare,,,F,,,,,0,1229,1,BqO0000029,CHEMgL6203y3,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,
5540,,Intermewiwte,,,F,,,,,0,1229,1,Bz90000019,CHEMBL610r74,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,
5541,,sytocuration,,,B,,,,,0,6390,1,BxO000p019,CHEMBL6293i5,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,
5542,,Aufoxuration,,,F,,27129.0,S5reltosoccuspyogenea,,0,16219,1,BzO000o019,CHEMnL8579o2,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,
5543,,Au4ocuragion,,,F,,7671.0,atgeptoc9fcuspyogenes,,0,16219,1,BAkp000019,CHEMBLu20276,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,
5544,,A8rocuration,,,B,,,,,8,17043,1,nAO0000r57,CHEMBk6w0377,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,
5545,927.0,Inte3mediste,,,F,,15413.0,Honosapisns,,1,6929,1,BAOo0p0219,CH3jBL620378,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,
5546,839.0,Intermediwtd,,,A,,10535.0,Homkqapiens,,1,6929,1,BAO00o0218,CHEMvL610379,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,
5547,,Aut0curatipn,,,F,,4034.0,Homoxapiene,,0,7083,1,BsO0090219,CHEMhLt20380,,In vitro cytotoxicity of compound was tested against 9KB cells.,,
5548,746.0,lnterm4diate,,,F,,2011.0,Rqttuwborvegicus,,1,12446,1,fAO0009219,vHEMBL894006,,Cytotoxic concentration against 9L cells was determined on day 3,,
5549,785.0,Experr,,,F,,8351.0,Rsttusnorvrvicus,,1,15345,1,BAk0o00219,CH4MBL620r81,,Tested in vitro for anticancer activity against 9L cells,,
5550,807.0,Ex0ert,,,F,,1305.0,Ratt8snorveguc8s,,1,15345,1,BAO0o0021o,CHEMfL6203o2,,Tested in vitro for anticancer activity against 9L cells; Not determined,,
5551,496.0,Integjediate,,,F,,17549.0,Hojosapiebs,,1,6301,1,BsO000o219,CHfMBLt20383,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,
5552,318.0,Intetmediatw,,,F,,38596.0,H8mosapidns,,1,4833,1,BAOo009219,CHEMBL876383,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,
5553,305.0,Infermedixte,,,F,,13986.0,Homozapidns,,1,4833,1,BAO0op0219,fHEMBk620384,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,
5554,914.0,Intetmeeiate,,,F,,25376.0,Homosapidhs,,1,4833,1,fAO0000119,CHEMnL62o385,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,
5555,618.0,Expery,,,F,,11001.0,Hompsa0iens,,1,13330,1,BsO0p00219,CHEkBL62o386,,Cytotoxicity against human lung carcinoma A549 cell line,,
5556,424.0,Espert,,,F,,7920.0,momosapiebs,,9,17517,1,BAO00092q9,CHEMBLt20r87,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,
5557,988.0,Exper6,,,F,,3043.0,Hkmosapienq,,9,17517,1,vAO0p00219,CHEMBL61140e,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,
5558,374.0,Intefmefiate,,,F,,8666.0,uom8sapiens,,1,14425,1,BAO090p219,CgEnBL621405,,"In vitro growth inhibition of A549, lung carcinoma",,
5559,394.0,Infermedia6e,,,F,,24194.0,Hkmowapiens,,1,14425,1,BAOp000229,CHEkBL621r06,,"In vitro growth inhibition of A549, lung carcinoma.",,
5560,555.0,Experg,,,F,,11594.0,tlmosapiens,,1,5228,1,BAO0000e10,xHEMBo621407,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,
5561,985.0,Internediat4,,,F,,10377.0,Hpmosapi4ns,,1,5351,1,BAO0o002q9,CHEMvi621408,,Cytotoxic activity against human lung cancer A549 cell line was determined,,
5562,541.0,Eapert,,,F,,52124.0,Himosapienz,,1,12198,1,BwO0000218,CgEMBL88534r,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,
5563,646.0,In4ermedoate,,,F,,9778.0,Homosxpienc,,1,13891,1,fAO000021i,CtEMfL621409,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,
5564,970.0,Ex9ert,,,F,,3125.0,Homodapi3ns,,1,5677,1,BAOpp00219,CHEMBp976034,,Cytotoxicity in A549 (human carcinoma) cell line.,,
5565,593.0,Int2rnediate,,,F,,24867.0,bomoszpiens,,1,13788,1,BxO0000218,CHfMBL621420,,Cytotoxicity on lung carcinoma (A-549) cell line,,
5566,969.0,Exlert,,,F,,12464.0,tojosapiens,,1,13384,1,BxO0o00219,dHsMBL621411,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,
5567,709.0,Inyermediat2,,,F,,9168.0,mojosapiens,,1,6726,1,BAO09p0219,CHEnBL62141q,,Effective dose of compound against replication of A549 cell line was evaluated,,
5568,563.0,Ex0ert,,,F,,3817.0,Hlmosapienq,,1,3455,1,BA89000219,CHfMBL611413,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,
5569,535.0,Int2rmedizte,,,F,,20006.0,Homosaliehs,,1,5726,1,BAO0p00q19,CH3MBL621514,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,
5570,776.0,Intermfxiate,,,F,,16425.0,Homosaoi2ns,,1,5726,1,BAO0990219,CHEMBL6214w4,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,
5571,716.0,jntrrmediate,,,F,,17978.0,bomoszpiens,,1,3936,1,BxO0009219,CHEMBL621326,,The compound was evaluated for antiproliferative activity against A549 cell line,,
5572,866.0,Intdrmewiate,,,F,,5676.0,Homoszoiens,,1,14991,1,BAl0000w19,CH4MBp621417,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,
5573,892.0,kntermediat4,,,F,,3903.0,gomosqpiens,,1,5243,1,fAOo000219,CjEMgL621418,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,
5574,658.0,Ijtermediqte,,,F,,18858.0,Homoswpi3ns,,1,12858,1,nAO0000229,CHEhvL621419,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,
5575,946.0,Int4emediate,,,F,,12070.0,Homoaapienw,,1,6776,1,BAO90002w9,CnfMBL621420,,Growth inhibition against A549 cell line was evaluated,,
5576,669.0,Intetmedia5e,,,F,,840.0,Homosalidns,,1,16558,1,gAO0o00219,CHEMBL8u582r,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,
5577,799.0,Experr,,,F,,12458.0,Hohosapiehs,,1,4583,1,Bsp0000219,dHEMBL622421,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,
5578,949.0,Interjewiate,,,F,,5169.0,Hpmosapiejs,,1,13514,1,BAO00po219,CjEMBL611422,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,
5579,676.0,Ex0ert,,,F,,36780.0,Homosa9iena,,1,15166,1,BAO0000w1i,CHEjBL884024,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,
5580,903.0,Intefm4diate,,,F,,26511.0,Homosapirne,,1,13873,1,Bwp0000219,dHEMfL621423,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,
5581,592.0,Edpert,,,F,,11073.0,yomosaplens,,1,6447,1,fzO0000219,xHdMBL621424,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,
5582,979.0,In6erjediate,,,F,,16944.0,Hom0sapiems,,1,2068,1,BAO00092w9,CHfMBL621415,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,
5583,516.0,2xpert,,,F,,5066.0,bomosxpiens,,1,1863,1,BAOp900219,CHEMBpy21426,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,
5584,731.0,Inrermedia4e,,,F,,8317.0,Hompeapiens,,1,13873,1,BAk0o00219,CHEMfL62142y,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,
5585,496.0,Interm2d9ate,,,F,,16466.0,Homosa9iehs,,1,13873,1,BAOo00021p,CHEMnL621328,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,
5586,497.0,Ecpert,,,F,,10869.0,Homozapienw,,1,13873,1,BzO0p00219,dHEhBL621429,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,
5587,640.0,In4ermediat4,,,F,,828.0,Homoszliens,,1,579,1,BAO90002w9,CHEMBk631430,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,
5588,653.0,Intermedkat2,,,F,,28366.0,Homosa0irns,,1,579,1,BA90000q19,CHEjBL6214e1,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,
5589,840.0,Ibtermediste,,,F,,11706.0,Homosalienx,,1,4584,1,BAO0909219,CHEMBL6213r2,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,
5590,1115.0,Ex0ert,,,F,,14138.0,Homodap7ens,,1,5421,1,Bz80000219,CHsMBL621533,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,
5591,888.0,7ntermedixte,,,F,,3891.0,Homisapi3ns,,1,5421,1,BAO0o00q19,CHEMgL8u5824,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,
5592,592.0,Iht3rmediate,,,F,,8435.0,Homoswpiebs,,1,5421,1,BA900002q9,CHEMgp621434,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,
5593,869.0,Intermrdiatw,,,F,,11047.0,Homoszpienc,,1,5421,1,BAO00002qo,CHsMhL621435,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,
5594,818.0,Ingermrdiate,,,F,,24665.0,Hohoaapiens,,1,14188,1,BA8o000219,CHEhBL621r36,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,
5595,471.0,Intfrkediate,,,F,,2835.0,H9mksapiens,,1,14188,1,BAO09002w9,CHEMBL611447,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,
5596,1101.0,Intermsdiaye,,,F,,1553.0,Hom9sapiend,,1,15354,1,BAO00o0q19,CHEMBp621338,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,
5597,605.0,Exprrt,,,F,,867.0,Homoqapkens,,1,14253,1,BAO00002q8,CHEMBL6q1t39,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,
5598,705.0,Inteemediwte,,,F,,14849.0,Hokosspiens,,1,13873,1,BxO000o219,CHEMfL621449,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,
5599,,Integkediate,,,A,,5679.0,Canislupuafakiluariw,,1,3043,1,BwO0000e18,CHfMBL6214r1,,Oral bioavailability in dog (conscious),In vivo,
5600,,In4wrmediate,,,A,,14108.0,Canisl6pusvamuliwris,,1,3045,1,BAO9000318,CHEjvL621442,,Compound was evaluated for the oral bioavailability after oral administration in dog.,In vivo,
5601,,In4ermediat3,,,A,,8914.0,Canisoupucfzmiliwris,,1,3022,1,gAO00002w8,CHdMhL621443,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,In vivo,
5602,,Integmefiate,,,A,,22345.0,Can8siipusfamilizris,,1,4453,1,BxO0000w18,CHEMgL62w444,,Oral bioavailability in dog,In vivo,
5603,,Igtermesiate,,,A,,28183.0,Canoslu0ustamilixris,,1,1696,1,BAO00p0q18,CH2MBL625q33,,Oral bioavailability in dog,In vivo,
5604,,Interhwdiate,,,A,,11483.0,Caniqlulusfamiliadus,,1,5045,1,BsOo000218,CHEMBL62rq34,,Oral bioavailability in dog,In vivo,
5605,,Int4rjediate,,,A,,937.0,Canixlupusdamipia3is,,1,5356,1,BAO00o9218,CHEMBL535135,,Oral bioavailability in dog (fasted),In vivo,
5606,,Inyermedia4e,,,A,,10738.0,Canisokpuxfamioiaris,,1,17764,1,hAO000o218,CHEkBL615136,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,In vivo,
5607,,Inte5mediqte,,,A,,15746.0,Cqnislupusfajiliwriq,,1,6448,1,BAp00002q8,xHEMBL625237,,Oral bioavailability in dog,In vivo,
5608,,Intermddiage,,,A,,4276.0,Canislhp7sfamiiiarix,,1,1475,1,nxO0000218,CHEMnL62r138,,Oral bioavailability in dog,In vivo,
5609,,Intermerixte,,,A,,22187.0,Csnislu0isfamiliar7s,,1,3788,1,BA9o000218,CH2MBL6251r9,,Percent bioavailability in dog,In vivo,
5610,,Intermrdkate,,,A,,3745.0,Cagislupusfamll9ar9s,,1,3639,1,BAO90002w8,xHEMBL8u2264,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,In vivo,
5611,,Intermed7atr,,,A,,10549.0,Canidl6ousfamilisris,,1,13397,1,BzO0000228,CHEMBL62r149,,Oral bioavailability in dog,In vivo,
5612,,Intermeria6e,,,A,,30905.0,Cajisluousfakiliar8s,,1,2137,1,BA90000q18,CHfMBLt24436,,The compound was evaluated for bioavailability in dogs; 34-44,In vivo,
5613,,In4ermediat2,,,A,,10581.0,Cwgispupusfamiliwris,,1,2959,1,BqO00o0218,vHsMBL624437,,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,
5614,,Ibtermedixte,,,A,,30622.0,Canisluphsfamiliz3iz,,1,6448,1,BsO000021o,CHEMBL872e6w,,Oral bioavailability in dog,In vivo,
5615,,Inrerkediate,,,A,,2979.0,Canixlupuafxmioiaris,,1,6084,1,BAOo00021u,CHEkBL6q4438,,8 hour trough Blood level in dog was measured after administration of compound,,
5616,,ont3rmediate,3004092.0,,A,,6611.0,Canispkpuzfamiiiaris,,1,3639,1,BA9000o218,CHEMBL634339,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,In vivo,
5617,,Internedkate,,,A,,9505.0,xanislupusfakil8sris,,1,6316,1,BAOo0002w8,CHEMBL724e40,,C24 after oral administration at 5 mg/kg,,
5618,,ontermefiate,,,A,,17093.0,Can7soupuwfamoliaris,,1,5238,1,BAi0009218,CbEMhL624441,,Clearance after oral and iv dosing in dogs,,
5619,,Imtedmediate,2245378.0,,A,,6263.0,Canisl7pusfamiloat7s,,1,17796,1,hAOo000218,xHdMBL624442,,Clearance of the drug was measured in the plasma of dog,,
5620,,9nt2rmediate,,,A,,10197.0,vabidlupusfamiliarie,,1,2652,1,BAp000021i,CHsMBLy24443,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,
5621,,Int2rjediate,,,A,,12472.0,Canislu9usfamlkiqris,,1,5654,1,hwO0000218,CH3MhL624444,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,
5622,,Ihtermfdiate,,,A,,42.0,fan7slupuqfsmiliaris,,1,6621,1,vsO0000218,xH4MBL624445,,Clearance of compound was determined in dogs,In vivo,
5623,,Internedizte,,,A,,146.0,xanosoupuseamiliaris,,1,6505,1,BAO0000227,fHEMgL624446,,Clearance on i.v. administration of 2 mg/kg was measured in dog,In vivo,
5624,,Interhediatw,,,A,,14121.0,Canusk7pusfamiliarls,,1,5802,1,BAl000021o,CHfMBL624446,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,
5625,,Interm3diste,,,A,,4603.0,vxniskupuqfamiliaris,,1,17267,1,BAO00003w8,CHEMBLt2r448,,Plasma clearance in dog was determined,In vivo,
5626,,Inte5mediat4,,,A,,29353.0,Canislup6sfamip7aric,,1,4521,1,BAO900021i,CHEMvi624449,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,
5627,,Inh3rmediate,,,A,,9827.0,Can8slupudfsmillaris,,1,6535,1,gAO000021u,CbEMBo624450,,Plasma clearance in dog after administration of 0.25 mg/kg iv,In vivo,
5628,,Internedia6e,,,A,,24124.0,xanislupjsfamiljqris,,1,6535,1,BAO0900228,CHEhBL87594q,,Plasma clearance in dog after administration of 1 mg/kg iv,In vivo,
5629,,Ibtermediqte,,,A,,2223.0,sanislupusfqnuliaris,,1,6535,1,hAO000021o,CnEMBLy24451,,Plasma clearance in dogs,In vivo,
5630,,Iht4rmediate,,,A,,10032.0,Canoslulusvahiliaris,,1,5542,1,BAOo00021u,CHEMBL624ty2,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,In vivo,
5631,,Imtermeduate,,,A,,15323.0,danislulksfamiljaris,,1,5199,1,BzO9000218,sHEMgL624453,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,
5632,,In4ermedizte,,,A,,14894.0,fwnislulhsfamiliaris,,1,16907,1,BAO0oo0218,CHsMBL624554,,Plasma clearance after 15 mg/kg iv dose in Dogs,In vivo,
5633,,8ntedmediate,,,A,,49130.0,Can9slupusrajiiiaris,,1,16907,1,BAOp900218,CHEkBL624445,,Plasma clearance after 30 mg/kg po dose in Dogs,In vivo,
5634,,Int4rmediwte,,,A,,29025.0,Cankspulusfxmiliaris,,1,16367,1,BAO0op0218,CHEMBL62e457,,Plasma administration to dogs,In vivo,
5635,,Ibtedmediate,,,A,,14362.0,Cahislupusfajiliadiw,,1,5505,1,nAO0000318,CHEkfL624457,,Plasma clearance was determined,In vivo,
5636,,Interned7ate,,,A,,9954.0,Cagispupuafamiliwris,,1,6215,1,BAO0000227,CH4MBL624t58,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,
5637,,Interkeviate,,,A,,14218.0,Canuslkpusfwhiliaris,,1,1466,1,BzO0000219,CHEhBL634459,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,
5638,,Intermedka5e,3326703.0,jicrosomws,A,,13066.0,Homosqpkens,,2,5007,1,BAO0000e41,CHEMBo624469,,Intrinsic clearance in human liver microsomes,In vitro,
5639,,Ijtdrmediate,2690413.0,Microwomfs,A,,31910.0,Homoswoiens,,2,5007,1,BAO0000e61,CmEMBL6q4461,,Intrinsic clearance in human liver microsomes,In vitro,
5640,,7nterkediate,,,A,,12899.0,Canisou9usfsmillaris,,1,16452,1,fAO00p0218,CHEMgL875p43,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,
5641,,Ihterkediate,,,A,,25166.0,Canielupusfsmiluzris,,1,16452,1,BAO090021o,CHEMBL6w4461,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,
5642,,Inte5mediafe,,,A,,21878.0,Canisl8puzfamilia5us,,1,16452,1,BAO0o00219,CHEMBL62r563,,Clearance in dog (dose 1 mg/kg i.v.),In vivo,
5643,,In4ernediate,,,A,,3115.0,Canislup7sgamilia3ks,,1,6221,1,BAO90002w8,CHsMBL624r64,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,In vivo,
5644,,Intermwdlate,,,A,,14221.0,Cxhislupusfwjiliaris,,1,5007,1,BAO000022i,vHEMBL634465,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,
5645,,Inte4mediat4,,,A,,20690.0,Cqnislypusfakilixris,,1,5668,1,BsO00002q8,CHdnBL624466,,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,
5646,,Intermedizfe,,,A,,7454.0,Canislupisfamiljarlc,,1,5668,1,BAkp000218,xuEMBL624467,,Plasma clearance after peroral administration at 5 mpk in dog,In vivo,
5647,,Inte3mediatw,,,A,,3258.0,danislupusfanjlisris,,1,5668,1,BqO00002w8,CHEMBLuq4468,,Plasma clearance after peroral administration at 5 mg/kg in dog,In vivo,
5648,,Intetmediatw,,,A,,24033.0,Caniqpupusfamilixrid,,1,15660,1,BqOo000218,CHEMgL62r469,,Plasma clearance was measured in dog,In vivo,
5649,,Ibtermediage,,,A,,8861.0,Cagkslupusfamoliariq,,1,15660,1,Bx80000218,CHEhBLu24470,,Plasma clearance was measured in dog,In vivo,
5650,,Ihte3mediate,,,A,,22917.0,Cqbidlupuzfamiliaris,,1,5983,1,gAO0o00218,CHEMBL6q4472,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,
5651,,kntrrmediate,,,A,,24988.0,Canislupusramikuariw,,1,5600,1,BAO00p02q8,CHEMBpu24472,,Total clearance was determined after 0.1 mg/kg iv administration in dog,In vivo,
5652,,Intermer8ate,,,A,,26815.0,Cahisoupusfamilistis,,1,17764,1,BAO00o0318,CtEMBL62e775,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,
5653,,Intfrm3diate,,,A,,9273.0,Canislupusbamiiowris,,1,6039,1,BAO000p21i,CHEMBL622y77,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,
5654,,Intetmediage,,,A,,16148.0,Camisl6phqfamiliaris,,1,6039,1,BAO9p00218,CHEMgL622776,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,
5655,,Intermsd7ate,,,A,,18893.0,vanislupusfamiliwtiq,,1,6039,1,BAO00o0q18,CHEMBi622768,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,In vivo,
5656,,Interm3diqte,,,A,,14654.0,Can9slupusvamlliarie,,1,4368,1,BAl0o00218,CuEMBk622779,,Clearance by intravenous administration of 1.2 mg/kg in dog,In vivo,
5657,,untermeciate,,,A,,13950.0,xanisoupuafamiliar8s,,1,4305,1,fAO00o0218,CHEMBL6226u0,,Clearance by iv administration in dogs at a dose of 1 mg/kg,In vivo,
5658,,Inteemediatw,4636773.0,,A,,23459.0,Can8sl6pusfamilkqris,,1,1918,1,BxO0900218,CnEMBL623781,,Clearance value was evaluated in dog plasma,In vivo,
5659,,lntermrdiate,,,A,,42991.0,Canislupusfamklixg8s,,1,6005,1,BAO00o0e18,CgEMBLy22782,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,
5660,,Ijtermewiate,1880786.0,,A,,5960.0,Canislupjsfamkliwria,,1,4839,1,BzO0000219,CHEMBL62378w,,Compound was tested for plasma clearance in dog,In vivo,
5661,,Ibterm2diate,,,A,,15765.0,sanislupuseamiliagus,,1,4239,1,BAO000oe18,fHEMBL622774,,Pharmacokinetic property (Plasma clearance) was measured in dog,In vivo,
5662,,In6erhediate,,,A,,26934.0,Mhshusculus,,1,17729,1,BAO0p0o218,CmEMBL612785,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,
5663,,Int4rmediaye,,,A,,17690.0,Musmusc8lks,,1,17728,1,BAOp000e18,CHEMBk522786,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,
5664,,Intefmediat2,,,A,,9451.0,kuemusculus,,1,5302,1,BAOo0002q8,CHEMfLy22787,,Area under curve value in mouse at a dose of 10 mg/kg,,
5665,,Intdrmediatf,,,A,,4600.0,Musmusfhlus,,1,5506,1,BsO000021i,CHEMvL874949,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,
5666,,Inte3meviate,,,A,,2169.0,Mjsmysculus,,1,5506,1,BAOo0002q8,vHEMBi622788,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,
5667,,untermedjate,,,F,,15600.0,Mucnusculus,,1,17764,1,vAO00002q8,CHEMBL6qw789,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,
5668,,In4etmediate,,,F,,9371.0,jusmusvulus,,1,17764,1,BAO0000q28,dHEMBL622u90,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,
5669,,Intermedizts,,,F,,670.0,Musjusculud,,1,17764,1,BAO0009217,CbEMBLt22791,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,
5670,,8ntermewiate,,,F,,7130.0,M6smhsculus,,1,17764,1,BAOo900218,CHEMgL62e792,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,
5671,,8btermediate,,,A,,30822.0,Muxhusculus,,1,17764,1,BzO000o218,CtEMBL621793,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,
5672,,Intw5mediate,,,A,,14196.0,M8smusculys,,1,17753,1,BAOp0002w8,CgEhBL622794,,Area under curve was determined for the compound at 24 mg/Kg,,
5673,,In4e4mediate,,,A,,21215.0,Musm8qculus,,1,17753,1,BA90900218,CHEkfL622795,,Area under curve was determined for the compound at 40 mg/Kg,,
5674,,Intermrdiat3,,,A,,19297.0,Musjuwculus,,1,17753,1,BxOo000218,CtrMBL621803,,Area under curve was determined for the compound at 5 mg/Kg,,
5675,,Interkediwte,,,A,,10546.0,Mhzmusculus,,1,3132,1,BAO09002q8,CgEMBo621804,,Area under the curve for the compound is obtained at dose 25 mg/kg,,
5676,,Intwfmediate,,,A,,7222.0,Mjwmusculus,,1,3132,1,BAO00902w8,CHEkBL621895,,Area under the curve for the compound was obtained when tested in mouse,,
5677,,untermsdiate,,,A,,9874.0,husmuwculus,,1,17837,1,BAl000p218,dnEMBL621806,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,
5678,,Imtermedkate,,,A,,22558.0,M6qmusculus,,1,17837,1,BAO0900q18,CHEMBL721806,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,
5679,,Intermedka5e,,,A,,28788.0,Muxmusculue,,1,6062,1,BzOo000218,vHEMBL621908,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,
5680,,Ibte4mediate,,,A,,12679.0,Muxmusculis,,1,4066,1,BAO0900228,CHEMhL521809,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,
5681,,Int2rmediahe,,,A,,20402.0,Musmuacul6s,,1,16597,1,BwO9000218,CHEMBp621710,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,
5682,,Inte5mediat2,,,A,,1446.0,Musmuxfulus,,1,14239,1,BAl000p218,CnEMBL8y5164,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,
5683,,Ijte3mediate,,,A,,26968.0,Mhsnusculus,,1,14239,1,BAOo0002q8,CyEMBL6e1811,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,
5684,,Igfermediate,,,A,,28051.0,Musmudcklus,,1,4890,1,BAOp0o0218,CH2MBL621912,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,
5685,,Integmediste,,,A,,21203.0,Muskussulus,,1,429,1,BAO000p318,CHsMBLy21813,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,
5686,,Intermeriat3,,,A,,7328.0,Musmusc6kus,,1,429,1,BzO0000q18,CHEMBL6q1914,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,
5687,,Interjrdiate,,,A,,16179.0,Muzkusculus,,1,5969,1,BwO0900218,sHEMBLy21815,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,
5688,,Intermeviste,,,A,,16424.0,Mysmhsculus,,1,5969,1,gAO00002w8,CHEMBk6218q6,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,
5689,,Interjedoate,,,A,,9387.0,Mushussulus,,1,5969,1,BwO0000228,CydMBL621817,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,
5690,,Intfrmeriate,,,A,,30590.0,nusmusc7lus,,1,6091,1,BAO009021o,CHwMnL621818,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,
5691,,In6efmediate,,,A,,12210.0,Muwmusculis,,1,6091,1,BwO0p00218,CHEMBk62181o,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,
5692,,Intefmedia4e,,,A,,12392.0,h8smusculus,,1,6091,1,BzO0000w18,CHwnBL621820,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,
5693,,Interjedizte,,,A,,20590.0,Musmueculks,,1,6091,1,BAO0p09218,CHEkBL62q821,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,
5694,,Inge5mediate,,,A,,5650.0,Musmusc6luz,,1,6178,1,BAi0009218,CHEkvL621822,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,
5695,,Intermedlatr,,,A,,145.0,Muemuxculus,,1,6178,1,hA80000218,dHEnBL619474,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,
5696,,Intfrhediate,,,A,,2763.0,Musmuscuiud,,1,6619,1,BAO09002w8,CHEMBL6193y5,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,
5697,,Ib6ermediate,,,A,,6396.0,Musmkscjlus,,1,6619,1,BAOp900218,CHEMBL6184i6,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,
5698,,Inhermeriate,,,A,,5866.0,Musnusculjs,,1,3760,1,nAO0000w18,CHEhBL619377,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,
5699,,Ibtwrmediate,,,A,,33599.0,Musmuxcylus,,1,3760,1,BAl0000228,CHdMBL6194u8,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,
5700,,Interjedoate,,,A,,17839.0,Muajusculus,,1,3760,1,hAO0009218,CHdMBL618479,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,
5701,,Int4rnediate,,,A,,7137.0,M6smhsculus,,1,3760,1,hAOp000218,CHEhBL61948p,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,
5702,,7nhermediate,,,A,,6102.0,Musnucculus,,1,3192,1,BAO0000q19,CHEMBL6193u1,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,
5703,,Intermedia54,,,A,,18389.0,nusmuscklus,,1,3192,1,BA90009218,CHEMgo619482,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,
5704,,Imtermedlate,,,A,,7859.0,Mhxmusculus,,1,2675,1,BAO000o228,CHEMhL619t83,,Area under the curve was evaluated in mice after intravenous administration,,
5705,,unterkediate,,,A,,9063.0,Musjueculus,,1,2675,1,BwO000o218,CHEMBLt1o484,,Area under the curve was evaluated in mice after oral administration,,
5706,,Interm2diat3,853917.0,,A,,2211.0,Musmuschkus,,1,16597,1,BAO0po0218,CHEMfL519485,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,
5707,,Intwrnediate,16552.0,,A,,40740.0,Musmuscyius,,1,16597,1,BwOo000218,CHEMBk619r86,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,
5708,,Interkesiate,,,A,,1908.0,Mushusxulus,,1,16597,1,BsO00002q8,CHEhBLy19487,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,
5709,,Int3rmed8ate,,,A,,28805.0,Musmysc8lus,,1,17734,1,BsO000021i,sHEMBL619489,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,
5710,,knte5mediate,6872405.0,,A,,5127.0,Musm8sculux,,1,7767,1,nAO0000228,CHEMhL6201o6,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,In vivo,
5711,404.0,Intermewiatr,,,F,,,,,1,15345,1,BAO0000q18,fH2MBL620107,,The compound was tested in vitro for anticancer activity against 9L cells,,
5712,,Autocugxtion,,,F,,30334.0,Rattkxnorvenicus,,0,2181,1,BAO900001i,CH2MBL620q83,,Anti proliferation activity determined; Weak effect,,
5713,,Autoc8rqtion,,,F,,31259.0,Raytksnorvsgicus,,0,2181,1,BAO00002qi,CyEMBL874176,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,
5714,,Au5ocuratlon,,,F,,921.0,Rattisno4vegidus,,0,2181,1,BAOp00021o,CHEMBo610284,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,
5715,,Aktovuration,,,F,,4302.0,Rattucnorbfgicus,,0,2181,1,vAO0o00219,CHEjBL623t15,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,
5716,,Autos7ration,,,F,,4365.0,Musmuscipus,,0,10486,1,BAO0009p19,CH3kBL623516,,The cytotoxic activity was in vitro tested by 9PS assay method,,
5717,,Autocy5ation,,,F,,5506.0,Musmuscklua,,0,10486,1,BAO000o01i,vHEnBL623517,,The cytotoxic activity was in vitro tested by 9PS assay method.,,
5718,,Aktocuratjon,,,A,,,,,0,15508,1,BA9000o019,CHEnBk857878,,Partition coefficient (logD6.5),,
5719,241.0,Exlert,,,F,,18296.0,Homosq0iens,,1,5242,1,BzO0o00219,xHEMBL623y18,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,
5720,669.0,Intermexiatf,,,F,,11248.0,tomosaplens,,1,16167,1,BAO0090119,CHEMBLy241o5,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,
5721,970.0,wxpert,,,F,,22540.0,Homosx9iens,,1,4782,1,BAO000o210,CHEkBLt24196,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,
5722,654.0,Exoert,,,F,,30109.0,Homosa9uens,,9,16093,1,BAO00p02q9,CtEMBL62e197,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,
5723,1061.0,In6e4mediate,,,F,,23669.0,Hom0sapiegs,,1,2596,1,BA9000p219,CHEhBL724198,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,
5724,819.0,jbtermediate,,,F,,6444.0,Homosap9ebs,,1,2596,1,BsOp000219,fHEMBk621287,,in vitro cytotoxicity against A 498 cancer cell line,,
5725,722.0,In6erm3diate,,,F,,6961.0,Homoda0iens,,1,3239,1,BAi0000229,CHEMBL511288,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,
5726,795.0,jnterm4diate,,,F,,6466.0,Homoqapiehs,,1,1847,1,hAO0000319,sHEkBL876496,,Cytotoxic activity against A 498 renal cancer cell lines.,,
5727,689.0,Intermedixfe,,,F,,25176.0,yimosapiens,,1,10553,1,BAO0000w18,CHEMBL61128i,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,
5728,,Auhocura6ion,,,F,,9993.0,Sfaphylodoccusaudeis,,0,16219,1,BsO0p00019,dHEMBL6e1290,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,
5729,,Autocurayi0n,,,F,,38108.0,Stapnylococsusaurehd,,0,16219,1,BsO00p0019,fHEMBL6e1291,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,
5730,,Autocyratikn,,,F,,8200.0,Stzphylococfhszureus,,0,16219,1,BqO00o0019,CHEMBLuw1292,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,
5731,,Autoc7rati0n,,,F,,8300.0,S6aphyiovlccusaureus,,0,16219,1,hAO0000018,CHdMBi621293,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,
5732,277.0,Intwrmediafe,,,F,,16653.0,Homosxpi2ns,,1,4782,1,BzO000p219,vH2MBL621294,,Inhibitory concentration required against A 549 lung cancer cell line,,
5733,703.0,Interm3diatf,,,F,,4230.0,H8mosap7ens,,1,11805,1,BAk000021i,CHEMfL62w295,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,
5734,450.0,Interkeduate,,,F,,2196.0,Homodapoens,,1,11805,1,fAOo000219,CHfMBL884097,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,
5735,999.0,Ihfermediate,,,F,,13152.0,Homlsspiens,,1,2007,1,BqO0009219,CHEMnL6w1296,,In vitro cytotoxicity against lung cancer A 549 cell lines,,
5736,1133.0,Intermfdiste,,,F,,13936.0,bomosaplens,,1,4594,1,BAO9009219,CHEnhL621297,,Compound was tested for its cytotoxicity against A 549 cell line,,
5737,575.0,Expsrt,,,F,,6882.0,Homosaoi4ns,,1,6018,1,BwO00002q9,CHEMBLu39i28,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,
5738,515.0,Integmewiate,,,F,,18884.0,Hpmosap8ens,,1,6018,1,BAO0p0021p,CHEMBL6w0r97,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,
5739,395.0,Espert,,,F,,17441.0,H9mosa9iens,,1,3599,1,hAO000021p,CHEMBL6w0r98,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,
5740,1202.0,Intedmediafe,,,F,,5815.0,Homoszpirns,,1,2551,1,Bx00000219,CHEMBLt20398,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,
5741,765.0,Experg,,,F,,15763.0,Homosaplenw,,1,16132,1,BAO00001w9,CHEhBL620490,,In vitro inhibition of A549 (human lung cancer) cell growth.,,
5742,405.0,Interkediage,,,F,,31303.0,Hokosa9iens,,1,16132,1,BqO0000w19,CHEMBL6qo401,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,
5743,600.0,3xpert,,,F,,8299.0,Homoaapiene,,1,2551,1,BAO90p0219,CHEMfL62p402,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,
5744,704.0,Expeft,,,F,,7755.0,uomosa9iens,,1,2551,1,BAO00003q9,CHEMBL720493,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,
5745,,w8tocuration,,,F,,,,,0,11913,1,BAO000o2w8,sHEMBL62040e,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,
5746,,A7rocuration,,,F,,,,,4,12621,1,BAO00o0318,CHEMBL6q0404,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,In vivo,
5747,,Au4ocuratuon,,,F,,,,,4,12621,1,BAO090o218,CHEMBL6204p7,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,In vivo,
5748,,Autoc6ratipn,,,F,,,,,4,12621,1,BAO9000219,CH4MBp620407,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,In vivo,
5749,,Autocurarioj,,,F,,,,,4,12621,1,BAp00002q8,CHEMvL62p408,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,In vivo,
5750,,Aurocurat9on,,,F,,,,,4,12621,1,BAOp000w18,CH4MBL630409,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,In vivo,
5751,606.0,Expe3t,,,F,,25508.0,Hpmosapienc,,1,3600,1,BAO000p21p,vHEMhL620410,,Inhibition of A-498 human Renal cell proliferation,,
5752,,Aufocyration,,,F,,6291.0,Rattusjotvrgicus,,0,1796,1,BAO0000028,CHfMBi620411,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,
5753,,Autochfation,,,F,,53158.0,Raftushorvfgicus,,0,1796,1,Bx00000019,CHEnBL62041q,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,
5754,,A8toxuration,,,F,,12017.0,Rattuenorvefjcus,,0,1796,1,BA90000919,xHEMBL87u596,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,
5755,734.0,Ex0ert,,,F,,14926.0,uomosapienz,,1,16464,1,BAOp00o219,CHEMgL62041w,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,
5756,786.0,Intfrmedlate,,,F,,3755.0,H0nosapiens,,1,16464,1,BAO009021i,CHEnBL620314,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,
5757,651.0,Intermeriatr,,,F,,5213.0,nomosqpiens,,1,16464,1,BxO0009219,CHEnBL620414,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,
5758,367.0,Expdrt,,,F,,31475.0,Hohosa0iens,,1,13617,1,fAO000o219,fHEMBL620r16,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,
5759,915.0,9ntermediat4,,,F,,4397.0,Homowapiena,,1,4584,1,BAO09002w9,CyEMBL62o417,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,
5760,336.0,Exper6,,,F,,3348.0,momoszpiens,,1,13799,1,BAO0000w10,CHEnBL620419,,Cytotoxic activity evaluated against A549 tumor cells,,
5761,916.0,Interjediage,,,F,,12619.0,uomosaliens,,1,16726,1,fAO9000219,CHEMhL620519,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,
5762,776.0,Interm4xiate,,,F,,12513.0,Homosalienx,,1,16109,1,nAO000o219,CbEMnL620420,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,
5763,104.0,Inr2rmediate,,,F,,33957.0,jomosapiwns,,1,16109,1,gAp0000219,CHEMBiu20421,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,
5764,567.0,jntermediafe,,,F,,13055.0,Homosa9iebs,,1,15474,1,vAO0009219,CHEMhL6e0422,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,
5765,862.0,9ntermedizte,,,F,,1924.0,jomoxapiens,,1,6851,1,BAO00p0119,CHEMBk6204e3,,Cytotoxicity of compound against A549 cell line,,
5766,725.0,Expsrt,,,F,,7393.0,H9moxapiens,,1,17534,1,BzO000021i,CHEMBk620423,,Cytotoxicity against human lung cell carcinoma A549 cell line,,
5767,889.0,Intermedixtf,,,F,,22534.0,Homoss9iens,,1,2621,1,BAO09002q9,CHEnBL610425,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,
5768,764.0,Int3rmeriate,,,F,,8012.0,gomosap9ens,,1,830,1,BAO0p09219,CtEMBL62042t,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,
5769,839.0,Intermwdiatd,,,F,,21519.0,Hojosapiegs,,1,14255,1,BAO0090229,CHfhBL620427,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,
5770,1120.0,Inf3rmediate,,,F,,33970.0,Hompwapiens,,1,14255,1,BAO00p0119,CHEMBit20428,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,
5771,429.0,Ihtermedlate,,,F,,19379.0,Homlsapiejs,,1,1590,1,BsO0090219,CHdMBL620t29,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,
5772,460.0,Experh,,,F,,11147.0,Homossliens,,1,6146,1,nAO0000319,dHEkBL620430,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,
5773,858.0,Experh,,,F,,32219.0,Homosapi2nw,,1,17427,1,BxO000021p,CH3MBL839897,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,
5774,509.0,In4erkediate,,,F,,32593.0,Homlsapienw,,1,5280,1,BzO0p00219,CHEMBk62p431,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,
5775,462.0,7ngermediate,,,F,,30787.0,Homoda9iens,,1,16786,1,BsO0900219,fgEMBL884010,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,
5776,1009.0,Intermwdiat2,,,F,,11238.0,Honpsapiens,,1,5895,1,BxO000o219,CHdMBL620r38,,In vitro cytotoxicity against A549 (human lung cancer),,
5777,587.0,Ezpert,,,F,,10152.0,Homoswpisns,,1,14297,1,BAk0900219,CHEnBL62053o,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,
5778,516.0,Intermeviatw,,,F,,5066.0,Homosap9enc,,1,17824,1,BAO0oo0218,CyEMBL613373,,In vivo antiproliferative activity against A549 cell line,,
5779,1253.0,In6eemediate,,,F,,18047.0,Homkzapiens,,1,14368,1,BAO000p21p,CHEMBk6q3374,,Inhibition of non-small-cell lung adenocarcinoma (A549),,
5780,620.0,Intermediayw,,,F,,5382.0,yomoaapiens,,1,14368,1,BAO9900219,CHwMBL6233u5,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,
5781,884.0,Intermrdiats,,,F,,37866.0,Homoszpuens,,1,14254,1,fAO9000219,CHEMnL62e376,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,
5782,634.0,Inre5mediate,,,F,,11381.0,Homksaliens,,1,15897,1,Bq90000219,CHEMBp6e3377,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,
5783,493.0,Intermed7age,,,F,,6157.0,H0josapiens,,1,13866,1,BAO090021o,CHEMBL632378,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,
5784,774.0,Ibtermediahe,,,F,,15948.0,H0mosapirns,,1,13370,1,fAO9000219,CHEMBL623368,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,
5785,1075.0,In5ermediatw,,,F,,7687.0,Homosz0iens,,1,4862,1,fAp0000219,CHEMBL62r38o,,Inhibitory activity against A549 lung cancer cell line,,
5786,491.0,In6ermediste,,,F,,14103.0,Hohosapiend,,1,4862,1,BAO00o021p,sHEMBL623e81,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,
5787,715.0,Intermesiafe,,,F,,24646.0,Homoswoiens,,1,4862,1,BA00000229,CHEMBL523372,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,
5788,581.0,lntermeriate,,,F,,37508.0,Homosapi3ms,,1,15970,1,vwO0000219,CHEMBL6233iw,,Inhibitory concentration against A549 (lung cancer) cell line,,
5789,725.0,wxpert,,,F,,67041.0,Hkmosapiegs,,1,17713,1,BAp000021i,CHEMBL6233i3,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,
5790,915.0,Inyermediwte,,,F,,5929.0,H8mosapienz,,1,4833,1,BAl0090219,CHEjfL623385,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,
5791,842.0,Expett,,,F,,14345.0,nohosapiens,,1,13736,1,BAi0009219,CH2MBLy23386,,Activity against A549 cancer cell line.,,
5792,629.0,Imtermesiate,,,F,,9016.0,tomosapiems,,1,4312,1,gAO000p219,CHEMBL98r105,,The compound was evaluated for cytotoxicity against A549 cell line,,
5793,561.0,In6ermedizte,,,F,,27886.0,Homoszpkens,,1,5421,1,hAO000p219,CHEMhL62r387,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,
5794,668.0,Intermedizts,,,F,,14414.0,yomosapienq,,1,5421,1,gxO0000219,CHEMBL62q56u,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,
5795,1039.0,Internexiate,,,F,,1692.0,Homosqpienc,,1,14717,1,BzOp000219,CHdMgL621569,,Growth inhibitory activity was measured for human A549 tumor cell line.,,
5796,711.0,Intwrmfdiate,,,F,,33248.0,Homoswpiehs,,1,4634,1,BqO000o219,CHEMBp621t70,,Inhibitory activity against A549 lung cancer cell line,,
5797,829.0,Ibyermediate,,,F,,18748.0,Homosapisjs,,1,1149,1,BAO000pe19,CHEkvL621571,,Inhibitory activity against A549 cell line; inactive,,
5798,1131.0,Expe5t,,,F,,36756.0,bohosapiens,,1,5421,1,BAO9000229,sHwMBL621572,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,
5799,331.0,Exlert,,,F,,5163.0,Himisapiens,,1,5421,1,BAO000o2w9,CHEMgL611573,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,
5800,525.0,jntermeviate,,,F,,8831.0,Hojoszpiens,,1,5421,1,BAO00p02w9,CHEMBo621575,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,
5801,1058.0,Inte3mediwte,,,F,,3169.0,Homowspiens,,1,3320,1,gAO00o0219,CHEhBL62w575,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,
5802,735.0,Ih6ermediate,,,F,,8519.0,Honoqapiens,,1,3320,1,BAO00p9219,CyEMBLy21576,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,
5803,269.0,kntermesiate,,,F,,1889.0,Homosxpiehs,,1,3320,1,BAl0000229,CH3MBo621577,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,
5804,661.0,Imterkediate,,,F,,23507.0,Homosapidhs,,1,3320,1,fwO0000219,CHEMBL63w578,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,
5805,712.0,Intermevia6e,,,F,,986.0,Homoqxpiens,,1,3320,1,BA800002q9,CH2MBL62w579,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,
5806,818.0,Interm2fiate,,,F,,11033.0,Homocapiehs,,1,5726,1,BAO00o02w9,CHEMBL631t80,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,
5807,,Intefmeviate,,,A,,18032.0,Csnislu9uwfamiliarks,,1,17800,1,BAi000o218,CHEMBL5q1581,,Plasma clearance (in vivo) in mongrel dogs was determined,In vivo,
5808,,Iny4rmediate,,,A,,7670.0,fanisl8pusfamiliat7s,,1,5985,1,BzO0009218,CHEMBo521582,,Plasma clearance was measured in dog,In vivo,
5809,,Int3rmed7ate,,,A,,8074.0,Canislup7sfxm7piaris,,1,5530,1,BA0000p218,CHEMBL62w683,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,
5810,,Ibtermedixte,,,A,,6527.0,Canisluousfwmiliar8c,,1,5530,1,BAO0000ew8,Cy2MBL621584,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,
5811,,Intetmeciate,3640708.0,,A,,17258.0,Caniwlkpusfak7liaris,,1,4839,1,BqO00p0218,CtEMnL621585,,Tested for plasma clearance in dog,In vivo,
5812,,jnte4mediate,,,A,,22886.0,Cajisluphsfahiliaric,,1,3639,1,nAO0000219,fHEMBLt21586,,The compound was tested for clearance in dog plasma.,In vivo,
5813,,Intermediagd,,,A,,15051.0,Cqn7sokpusfamiliaris,,1,4838,1,BAk000021o,CHEMBL8758rt,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",In vivo,
5814,,Imte5mediate,,,A,,12819.0,Canislhpusfam9lkqris,,1,4137,1,BxO00002w8,sHEkBL621587,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,In vivo,
5815,,Interkesiate,529796.0,,A,,14232.0,xanixlu9jsfamiliaris,,1,5017,1,BAp0000e18,CHEMhL621589,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,
5816,,Infermddiate,4746989.0,Micdoslmes,A,,25607.0,fanisl8pusfxmoliaris,,1,17538,1,BA000002q8,CH2MfL621589,,In vitro clearance in dog liver microsomes,In vitro,
5817,,Intwrmedia4e,,,A,,32899.0,Cwn9slupysfamiluaris,,1,6161,1,BA00000q18,CHEMBk521590,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,
5818,,Imtermediwte,,,A,,17770.0,fanixlupusfsmiluaris,,1,6161,1,BAO0p00219,dyEMBL621591,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,
5819,,Integmedlate,,,A,,5815.0,xagislupusfamilisrid,,1,1696,1,BAp0000318,CHEMBL62q5i2,,Plasma clearance in dog,In vivo,
5820,,Inhernediate,,,A,,15755.0,xznislup6sfahiliaris,,1,6762,1,BAO9900218,CHwMBLy21593,,Clearance rate in dog,In vivo,
5821,,Intermediwtf,242854.0,,A,,2209.0,Canislupuqfahkliar7s,,1,5932,1,BAp00o0218,CHEjBLy21594,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,
5822,,Ihtermed7ate,,,A,,19583.0,Canielupusfqkiliagis,,1,6305,1,BAO0o0p218,CHEMfL62q595,,Clearance in dogs,In vivo,
5823,,9nt4rmediate,,,A,,25791.0,Canislupusvqkioiaris,,1,4942,1,BzO0o00218,CHEMBL631r96,,Plasma clearance in dogs,In vivo,
5824,,In5rrmediate,,,A,,4919.0,Canispupusfajjliqris,,1,4219,1,BAO0o0o218,CHEMBL62w596,,Plasma clearance was determined,In vivo,
5825,,Igtermediats,,,A,,13955.0,vanislupusfqmkpiaris,,1,17853,1,vAO0090218,xHEjBL621598,,Lower clearance in dog (i.v.) at 0.5 mpk,In vivo,
5826,,knterkediate,,,A,,29102.0,Canisk7pusfak7liaris,,1,4514,1,BzOo000218,CHEhBL621589,,Plasma clearance in Beagle dogs,In vivo,
5827,,Intermsdoate,,,A,,18396.0,famksljpusfamiliaris,,1,6448,1,BzO0000219,CHwMBL865836,,Plasma clearance (Clp) in dog,In vivo,
5828,,Inte5media4e,,,A,,5957.0,Canislup7seajiliarks,,1,6227,1,BAp0009218,CH4MBk621600,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,In vivo,
5829,,Imtegmediate,,,A,,3922.0,xanislupusfzmiiizris,,1,6227,1,Bz90000218,CHEMnL6w1601,,Plasma clearance (pharmacokinetic parameter) in dog was determined,In vivo,
5830,,Intermecizte,,,A,,27110.0,Cqnislupusfamikizros,,1,6062,1,nAO000021u,sHEMBL61847r,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,In vivo,
5831,,In4ermedizte,,,A,,7112.0,Csnislupusfamuoiarls,,1,6821,1,BxO0000228,CHEMBL617r75,,Plasma clearance of compound was determined in dog,In vivo,
5832,,Intrtmediate,,,A,,25253.0,Cahjslupuxfamipiaris,,1,4709,1,BsO0009218,CnEjBL624524,,Plasma clearance after intravenous administration of 1 mg/kg in dog,In vivo,
5833,,lntermediwte,,,A,,6147.0,Camisljpuafamiliar9s,,1,4521,1,BAO000ow18,CHEMfL624625,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,
5834,,Inhermediafe,,,A,,21851.0,Camislu9usfajiliarix,,1,5374,1,BwO00o0218,CHEMBL62r52t,,Plasma clearance in dog was determined,In vivo,
5835,,Intermsdjate,,,A,,20572.0,Cqmizlulusfamiliaris,,1,6057,1,BqO000021o,CHEMBL623526,,Plasma clearance was calculated in dog,In vivo,
5836,,Int3rmediahe,,,A,,37004.0,Caniwoupuedamiliaris,,1,4727,1,BzO000021i,CHEMhp624528,,Plasma clearance at the dose of 2 mg/kg in dog,In vivo,
5837,,Interkediste,,,A,,496.0,Camisiuphsfamiliarjs,,1,5145,1,BxO0000118,CnEMBL624520,,Plasma clearance in dog,In vivo,
5838,,Interjedizte,,,A,,1470.0,Canislup7sbamipiaric,,1,17657,1,BAO00o0217,CHEMBou24530,,Plasma clearance in dog,In vivo,
5839,,Intfrmediat3,,,A,,15141.0,Can8dlupusfam7luaris,,1,17657,1,BzO00002q8,sHEMBL62r531,,Plasma clearance in dog; Unable to calculate,In vivo,
5840,,Intermeduatr,,,A,,11538.0,Cagidlupusfamilia5id,,1,5145,1,BAO9090218,CHdMBL624t32,,Plasma clearance in rhesus monkey,In vivo,
5841,,Intermedjwte,,,A,,13672.0,Canislupusfqjilixr9s,,1,6642,1,BAO00p0228,CHEMBLu23533,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,
5842,,Interh3diate,,,A,,4977.0,Cxnisiupusfamipiatis,,1,6641,1,BAi0009218,CHEMgL6q4534,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
5843,,ontermrdiate,,,A,,2628.0,Camislupudfamuliar8s,,1,6642,1,BqO0o00218,CHEMnL625535,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
5844,,Intermeeiatr,,,A,,23509.0,Canisiupusfanoliarls,,1,5472,1,fAO00002w8,CHEMBL634537,,Plasma clearance was evaluated in dog,In vivo,
5845,,Intsrnediate,,,A,,18594.0,Cajislkpusfamiliwria,,1,5472,1,BAO90o0218,fHEMBL6245w7,,Plasma clearance was evaluated in dog; Not tested,In vivo,
5846,,Inte5msdiate,,,A,,7402.0,Csniclupusfamilkagis,,1,5472,1,BAO0090w18,CHEMBL62553i,,Plasma clearance was evaluated in rhesus,In vivo,
5847,,7nterkediate,,,A,,9941.0,Canidlupusfamil9afiz,,1,5472,1,BAO00p0217,CHEjvL624539,,Plasma clearance was evaluated in rhesus; Not tested,In vivo,
5848,,Intermesiqte,,,A,,22783.0,Cagisl8pusfakilia5is,,1,4257,1,BAO0099218,CHsjBL624540,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,In vivo,
5849,,Ingermediqte,,,A,,12119.0,Canizlupysvamiliaros,,1,6679,1,BA90000w18,CHEMBL6245r2,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,
5850,,Intermedua5e,,,A,,4455.0,Caniaiu9usfwmiliaris,,1,5546,1,BAp000021i,CHEhfL624542,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,
5851,,Ij4ermediate,,,A,,29119.0,Canialupusfamipixrix,,1,6348,1,BAO0090228,CHEMgo624543,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,
5852,,Interj2diate,,,A,,41417.0,Cagislu0usfamil8a3is,,1,5474,1,BAO0090219,fHEMBL624554,,Clearance value at a dose of 0.2 mg/kg i.v.,In vivo,
5853,,Inteemediatr,1659369.0,,A,,8927.0,Canuslupusfamilkqriz,,1,6316,1,BAp00002w8,xgEMBL624545,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,In vivo,
5854,,Int4rmedizte,,,A,,153.0,Cajlslupusfamioiafis,,1,17594,1,BAO00oo218,CHEMBi6245r6,,Cmax after oral dose of compound at 3 mg/kg in dogs,In vivo,
5855,,Inferjediate,,,A,,9942.0,Canisljp8cfahiliaris,,1,17594,1,BAO90o0218,CmEMBL875o57,,Cmax after single intravenous bolus of 1 mg/kg in dogs,In vivo,
5856,,Imtedmediate,,,A,,7534.0,Csn7slupusfamiliwr8s,,1,5802,1,BA90000118,CHEMBk62r547,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,
5857,,Intermewoate,,,A,,4623.0,Cabiskupusbamiliwris,,1,6535,1,BAk000p218,CuEMBi624548,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,
5858,,Intetmsdiate,,,A,,6295.0,Canislupucfamlliafiq,,1,6535,1,BAO000p2q8,CHEnfL624549,,Cmax in dog after administration of 1 mg/kg iv,In vivo,
5859,,In4ermediats,365222.0,,A,,16543.0,Can9slupuxbamiliarls,,1,1466,1,BAO00op218,CHEnBL62e550,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,
5860,,Interm4diste,,,A,,48207.0,Can7slupusfwkil9aris,,1,6505,1,fAO0p00218,CHEMBL62q61e,,Cmax on p.o. administration of 10 mg/kg was measured in dog,In vivo,
5861,,Imtetmediate,,,A,,15346.0,Canislupusfwjiiiarid,,1,5668,1,fAO0000217,CHEMBo621624,,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,
5862,,In6ernediate,,,A,,37882.0,Canislj0uzfamiliarls,,1,5668,1,BAO900021i,CHEMBL6q3432,,Cmax was determine after peroral administration at 5 mpk in dog,In vivo,
5863,,Ihtermediwte,,,A,,27724.0,xxnislupusfahkliaris,,1,5668,1,BAO090021o,sHEMBL62343q,,Cmax was determine after peroral administration at 5 mg/kg in dog,In vivo,
5864,,Intermedizye,,,A,,24558.0,Canislupudfqmiliwrie,,1,5600,1,BAO90p0218,CHEMfL623t33,,Cmax after 0.3 mg/kg po administration in dog,In vivo,
5865,,Interm2diatd,,,A,,17278.0,Cahiwlupuzfzmiliaris,,1,17764,1,vsO0000218,CHEMgL62w434,,Cmax after peroral administration in dogs at 2.4 uM/kg,In vivo,
5866,,Intermesiat3,,,A,,31848.0,Canislupusfsmikixr9s,,1,6123,1,BwO0000318,CjEMBL633435,,Cmax in dog after oral administration at 1 mg/kg,In vivo,
5867,,Ingwrmediate,,,A,,37839.0,Canispulusfsmilisris,,1,6123,1,BAO000o2w8,CHdMBL623336,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,In vivo,
5868,,Intwrm4diate,,,A,,3016.0,Cqnislu0usfamilizrls,,1,6757,1,BzO0009218,CH2MBL8y5958,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,In vivo,
5869,,Ingermedkate,,,A,,9877.0,Cahislupusfsmilisr7s,,1,16907,1,BAp00p0218,CHwkBL623437,,Cmax value after 15 mg/kg iv dose in Dogs,In vivo,
5870,,In5ermed7ate,5058037.0,,A,,41028.0,nusmusculis,,1,7767,1,BAOo0p0218,xHEMgL623438,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5871,,Int4rmediatr,1618818.0,,A,,12999.0,Mudmuscuous,,1,7767,1,BzO0000318,CHEMBL633438,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5872,,Intefmedixte,3996173.0,,A,,32391.0,Musmuccupus,,1,7767,1,BAO0000w28,vHEMBL623430,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5873,,Ijtermfdiate,3487474.0,,A,,18430.0,Musm8qculus,,1,7767,1,BAO000o318,CHEMBLy24441,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5874,,Interkddiate,1477759.0,,A,,21607.0,Musmuaculis,,1,7767,1,BAi00o0218,CHfMfL623442,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5875,,Ijterm3diate,,,A,,12234.0,M8smussulus,,1,7767,1,BAOp009218,CHEhBL633469,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5876,,Intetmsdiate,,,A,,15218.0,husmjsculus,,1,7767,1,fAO0090218,CjEMBL62347o,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5877,,Intedmeeiate,,,A,,10022.0,Muskuscupus,,1,7767,1,BAO0o90218,CH2nBL623471,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5878,,kntermediage,1203896.0,,A,,4231.0,Musmusculid,,1,7767,1,BAO0000w1i,CHEMBo623471,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5879,,kntwrmediate,312591.0,,A,,51990.0,Musmueculjs,,1,7767,1,BwO00002q8,CHEhBL523473,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5880,,Igtefmediate,1257015.0,,A,,30519.0,Muskusculuw,,1,7767,1,Bw00000218,CHEMhL6e3474,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5881,,Interhedoate,6313475.0,,A,,19867.0,Mjsmuqculus,,1,7767,1,nAO0000219,CHEMBLt2347r,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5882,,Igtermed8ate,155950.0,,A,,6456.0,Mismuxculus,,1,7767,1,BzOo000218,CHEMBL523477,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5883,,In5ermedjate,6885220.0,,A,,34622.0,Mushusculux,,1,7767,1,fxO0000218,Cm3MBL623477,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5884,,Intefmed9ate,4660870.0,,A,,12813.0,Muemusculks,,1,7767,1,BA0o000218,vHEMBL62189y,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5885,,Inte3mediatw,2565105.0,,A,,19279.0,Musnuscul8s,,1,7767,1,BAOo0o0218,CHEMBp621997,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5886,,Internsdiate,140924.0,,A,,7806.0,Musmuacilus,,1,7767,1,BA8000o218,sHEMBL621798,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5887,,Intfrmedixte,6125476.0,,A,,5426.0,M8smuzculus,,1,7767,1,gAl0000218,CtEMBL621i99,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5888,,Intefmedixte,1935389.0,,A,,33008.0,Musmusfupus,,1,7767,1,BAO00o021o,CHEMBL721990,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5889,,jntermediage,5349284.0,,A,,38105.0,M6smhsculus,,1,7767,1,BsO00002q8,CHEMBLy21902,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5890,,Inydrmediate,203317.0,,A,,61011.0,hysmusculus,,1,7767,1,vAO0o00218,CHEMBLy2w902,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5891,,Imtermefiate,5298437.0,,A,,4383.0,Musmuscuk8s,,1,7767,1,BAO009o218,CHrkBL621903,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5892,,Interm3diare,949035.0,,A,,40110.0,Musm6sc6lus,,1,7767,1,hAO00002q8,CHEMgL6q2587,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5893,,Interkedia4e,1553534.0,,A,,3226.0,Mismuscklus,,1,7767,1,BAO00p02q8,CHEnBL6202o5,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5894,,Inteemddiate,5199901.0,,A,,31858.0,M6smussulus,,1,7767,1,gAO0000219,dHEMBL874285,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5895,,onternediate,645632.0,,A,,11952.0,nusmuscuous,,1,7767,1,vAO0009218,CHEnBLy20286,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5896,,Intermedjxte,,,A,,14875.0,Musnusxulus,,1,7767,1,BAO00o02q8,CHEnBi620287,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5897,,Intermediqtf,,,A,,40878.0,Mhsmusfulus,,1,7767,1,BAO00o021o,CHwjBL620288,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5898,,Interm4diat3,,,A,,10943.0,Mksmusdulus,,1,7767,1,BAO000p2w8,vHEMBL62028o,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5899,,Intetm4diate,1775970.0,,A,,40630.0,husmuscul6s,,1,7767,1,BAO0000q1i,CHEMnL62o290,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5900,,Interhedizte,1099642.0,,A,,18611.0,Musmuscyl7s,,1,7767,1,BxO0900218,CHfMBL6w0291,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5901,,Intermfdiqte,9802944.0,,A,,1705.0,Musmuzculuz,,1,7767,1,BAO00092q8,CHEMvL6202o2,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5902,,In5ermedizte,1963350.0,,A,,24001.0,Musjuscjlus,,1,7767,1,BA90p00218,CH3MBL620193,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5903,,In4ermediaye,3788698.0,,A,,19560.0,Muxmusfulus,,1,7767,1,BwO00p0218,CHEnBL720294,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5904,,Intsrmediqte,1851213.0,,A,,9084.0,Mksmuscul8s,,1,7767,1,BAO0o00228,CHEMvp618614,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
5905,,Intermfdiahe,4060567.0,,A,,19820.0,husmuscilus,,1,7767,1,BAO0000q17,CHEMBL618yq5,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
5906,,9nterhediate,5101907.0,,A,,10511.0,M6smussulus,,1,7767,1,BqO0p00218,CtEMBi618616,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,
5907,743.0,Expsrt,,,F,,12071.0,Homosspiena,,1,2036,1,BAO0p00e19,CHEMBo718617,,Cytotoxicity against A-172 human tumor cell lines,,
5908,449.0,Intermeciatr,,,F,,3483.0,uomosapiebs,,1,2357,1,BAO00oo219,CHwMBp618618,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,
5909,432.0,Intfrmediatd,,,F,,23755.0,Homosapkehs,,1,1457,1,vAO00o0219,CHEhBLu18619,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,
5910,716.0,Integmediat4,,,F,,6321.0,bomosapiebs,,1,4379,1,BAO0090319,CgEMBL518620,,Tested for antiproliferative activity against A-2780 tumoral cell line,,
5911,792.0,Intsrnediate,,,F,,2822.0,gomosxpiens,,1,1093,1,BAO00002qo,CHEMBL617y21,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,
5912,608.0,9ntermedixte,,,F,,3919.0,Homosxpiejs,,1,12152,1,nxO0000219,CHEjBL618722,,Tested in vitro against A-375 cell line human melanoma,,
5913,920.0,Expdrt,,,F,,6666.0,Homosaoiems,,1,16464,1,BAO000o229,CHfMBL61862e,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,
5914,438.0,In4erjediate,,,F,,2405.0,bokosapiens,,1,16464,1,Bzk0000219,duEMBL618624,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,
5915,517.0,Ex9ert,,,F,,5172.0,Homowapiend,,1,16582,1,BAO0009210,vHEhBL618625,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,
5916,793.0,Inrermediat2,,,F,,9050.0,Homossliens,,1,16464,1,BAO9900219,CyEMBL61862t,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,
5917,650.0,Ijte4mediate,,,F,,25521.0,Hlmosapiene,,1,10413,1,BAO0009e19,CHEMBLtw8627,,Antitumor activity on A-427 lung carcinoma cell lines,,
5918,761.0,Inte4jediate,,,F,,1706.0,gomosspiens,,1,6418,1,BAO0o0p219,sHEMBL619628,,Cytotoxic activity against human A-427 lung tumor cell line,,
5919,942.0,Expe3t,,,F,,42126.0,Homodapuens,,1,17134,1,BAO00p0q19,CyEMBL61862p,,In vitro antitumor effects against human A-427 cell lines.,,
5920,599.0,rxpert,,,F,,30159.0,Homosaoiems,,1,16132,1,BAO0090229,CgEMhL618630,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,
5921,431.0,Integmediage,,,F,,13750.0,Homoxapidns,,1,16132,1,BAO0po0219,CmEMBi618631,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,
5922,537.0,Igtermedia5e,,,F,,21075.0,Hpmosapuens,,1,16780,1,BAO9009219,CHEMBk618633,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,
5923,549.0,Exprrt,,,F,,27467.0,bomosapienw,,1,4085,1,BAO00po219,CHdMBL6q8633,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,
5924,620.0,knterm4diate,,,F,,7555.0,uomosap8ens,,1,1276,1,hAOp000219,CHEMBL6w931y,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,
5925,663.0,2xpert,,,F,,11320.0,Hom9sspiens,,1,3498,1,BAO00p9219,CHEhBL619326,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,
5926,567.0,7ntegmediate,,,F,,22404.0,Himodapiens,,1,1169,1,BAO0000310,CHEkgL619317,,Cytotoxicity against human kidney carcinoma A-498cell lines,,
5927,672.0,Infedmediate,,,F,,5432.0,tomosspiens,,1,4450,1,BwO00002w9,CyEMBL6w9318,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,
5928,540.0,Intdrmediat4,,,F,,1495.0,bomosapidns,,1,3311,1,BAk000021i,CbEhBL619319,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,
5929,583.0,Intermsciate,,,F,,5777.0,bojosapiens,,1,4461,1,BzO0090219,CHEMvL519739,,Antitumor cytotoxic activity against A-498 cell line was determined,,
5930,467.0,In4ermedjate,,,F,,14394.0,Homosaoiend,,1,3311,1,BqO0o00219,CHEMBL6w97r0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,
5931,1002.0,Inte3meriate,,,F,,25123.0,momosapuens,,1,3311,1,BAO0000118,vHEMBL8831y8,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,
5932,780.0,Intermedizts,,,F,,50743.0,H8mosapi4ns,,1,1457,1,BqO000p219,fHEMBL88401q,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,
5933,687.0,Infermediahe,,,F,,18868.0,H9mosaliens,,1,3664,1,BwO000o219,CHEjnL619741,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,
5934,496.0,Inte5med7ate,,,F,,16208.0,Homosa9i3ns,,1,15895,1,BAO90002w9,dH2MBL619742,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,
5935,734.0,Intermed8a4e,,,F,,10775.0,Hlmosapuens,,1,11843,1,BAO00o0q19,CHEMBL8766q9,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,
5936,620.0,8ntermediafe,,,F,,27595.0,Hohosaplens,,1,11843,1,BAO0000329,xHEMBL618743,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,
5937,392.0,lntermediwte,,,F,,33381.0,Homozwpiens,,1,17705,1,BAO000o229,CHEMBL6q0744,,In vitro antiproliferative activity against human A-549 NSCL cell line,,
5938,586.0,Intetmediatw,,,F,,3473.0,Homoszpifns,,1,17705,1,BzO0090219,CHEMnLt19745,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,
5939,570.0,Intermedoste,,,F,,2437.0,H0mosqpiens,,1,4369,1,BAi00o0219,CHsMBL61974t,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,
5940,585.0,Interkddiate,,,F,,35785.0,Hlmosapiejs,,1,4369,1,BxOo000219,CyEMBL619647,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,
5941,738.0,Intermeriats,,,F,,21529.0,Homoszpiehs,,1,4369,1,vAO0o00219,CtEMBL6w9748,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,
5942,706.0,Int3rmedlate,,,F,,5260.0,Homosap8egs,,1,4369,1,BAO09o0219,CHEMBL6q9748,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,
5943,414.0,Intefjediate,,,F,,1919.0,Homodap7ens,,1,4369,1,BAO00902q9,CHEMBo619740,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,
5944,607.0,Intermediafw,,,F,,19335.0,Homowapiehs,,1,4369,1,BwO0009219,CHEMBL634024,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,
5945,632.0,Interkwdiate,,,F,,17299.0,Honosapkens,,1,4369,1,BAO0p0p219,CHEMnL6e4015,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,
5946,531.0,2xpert,,,F,,8281.0,Himosa0iens,,1,4787,1,BAOp000q19,CyEMBL885345,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,
5947,704.0,Inte3mewiate,,,F,,12197.0,jomosaplens,,1,4787,1,BAO00oo219,CnEMBL613224,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,
5948,432.0,Intdrmediatr,,,F,,12720.0,Homksapienc,,1,6513,1,BsO0000w19,CHEMgL62322r,,Cytotoxic activity against A-549 cell line,,
5949,553.0,Intwrmed7ate,,,F,,9007.0,gomosapi2ns,,1,6690,1,vAO0000e19,CuEMBL622t98,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,
5950,1018.0,Intermdciate,,,F,,12122.0,tomosapiebs,,1,6690,1,BAO0900210,CHEMBL62260o,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,
5951,822.0,Experf,,,F,,39437.0,Homosxplens,,1,12263,1,BAO0p00229,CHEMBL52270o,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,
5952,659.0,Intermerixte,,,F,,41375.0,Hohosaplens,,1,1054,1,BAO000921i,sHEMBL612701,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,
5953,885.0,Intermefiatd,,,F,,11668.0,Homosapodns,,1,1359,1,vAO00p0219,CHEMBLy227p2,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,
5954,1050.0,Inte3meduate,,,F,,20010.0,Homosqpienx,,1,3547,1,BAO00o021i,fHrMBL622703,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,
5955,450.0,4xpert,,,F,,23957.0,mokosapiens,,1,5771,1,BAl0000210,CHEMBk612704,,Cytotoxic activity towards A-549 cells,,
5956,636.0,Intermdd7ate,,,F,,30123.0,Homlswpiens,,1,14425,1,BxO00o0219,CHfkBL622705,,"In vitro percent inhibition of A549, lung carcinoma.",,
5957,476.0,knt3rmediate,,,F,,6815.0,Homoeapiena,,1,14425,1,BAOp00021o,vHEMBL632706,,"In vitro percent inhibition of A549, lung carcinoma",,
5958,919.0,In6ermedoate,,,F,,7447.0,Homisapuens,,1,14425,1,BAO0p0p219,xgEMBL622707,,"In vitro percent inhibition of A549, lung carcinoma.",,
5959,716.0,Intf5mediate,,,F,,24907.0,Homksaliens,,1,14425,1,BAO00op219,CjEMBL522708,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,
5960,711.0,Inte5jediate,,,F,,40658.0,Homosxp9ens,,1,5280,1,BAO00o0229,dHEMvL622709,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,
5961,825.0,Intrrmediatd,,,F,,20979.0,Homoswliens,,1,15176,1,BAO00p02w9,vHEMnL622710,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,
5962,803.0,Intermedlare,,,F,,12902.0,H0mpsapiens,,1,15300,1,vAO00002q9,CmEMBL632711,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,
5963,760.0,kntermediafe,,,F,,4331.0,gomosapiene,,1,17824,1,BAO0009219,CHEMBk622y12,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,
5964,734.0,Ihtermediatd,,,F,,5661.0,yojosapiens,,1,17824,1,BAO0909218,CHEMBL612723,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,
5965,898.0,Inte3mediaye,,,F,,10989.0,Homosaoirns,,1,17824,1,BAO0900e18,CHEMBL62wi14,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,
5966,787.0,8nterm3diate,,,F,,20121.0,H8moaapiens,,1,17824,1,BAO0pp0218,CH3jBL622715,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,
5967,916.0,Integjediate,,,F,,12530.0,Homocapirns,,1,17824,1,nwO0000218,xHEMBL622726,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,
5968,582.0,Intefmedia4e,,,F,,298.0,Hojosapidns,,1,17824,1,BA000002w9,sHEMBL722717,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,
5969,700.0,ontermediatr,,,F,,16312.0,Hom9swpiens,,1,17528,1,BAOp00021i,vHEMBL622i18,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,
5970,702.0,Expegt,,,F,,7661.0,Homoszpiend,,1,6870,1,BAp000021i,CHEMBp62q719,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,
5971,637.0,Intwemediate,,,F,,44490.0,Homksapjens,,1,6870,1,BAO9000210,CHEMBp62w720,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,
5972,252.0,Inte4mediahe,,,F,,688.0,nojosapiens,,1,6870,1,BAO0o00319,CHEMBp6227e1,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,
5973,748.0,Intrrmedjate,,,F,,8726.0,Hkmosxpiens,,1,6870,1,BAOp000e19,CHEhBi622722,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,
5974,931.0,Inte4msdiate,,,F,,4007.0,Homosap74ns,,1,16726,1,BAO00o021p,CHEhBi876030,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,
5975,1110.0,Intermed7a4e,,,F,,2896.0,Homosapoenz,,1,6170,1,fAO0000218,CyEMBk620206,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,
5976,228.0,Exoert,,,F,,5976.0,H8nosapiens,,1,6583,1,BAO009o219,CHEMBL6202py,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,
5977,374.0,Ex0ert,,,F,,17860.0,Homosa9oens,,1,6583,1,fAO000021i,CHEMBL620e0o,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,
5978,731.0,4xpert,,,F,,9585.0,Hohodapiens,,1,6583,1,BAk0000q19,CHEMvk620209,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,
5979,336.0,Exper6,,,F,,19068.0,Homosqpi2ns,,1,6583,1,BAO000ow19,CHEMBL620q20,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,
5980,514.0,Exprrt,,,F,,4863.0,Homoswpoens,,1,6583,1,BAO00092q9,CyEnBL621639,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,
5981,593.0,Intermediwtr,,,F,,21017.0,Hom0sapiebs,,1,17321,1,BAO00002qp,CHEMBL631y40,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,
5982,778.0,Experf,,,F,,16599.0,Hom0sspiens,,1,17528,1,BAk0000229,CjEMBL6216e1,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,
5983,346.0,Experh,,,F,,8100.0,yomosqpiens,,1,12888,1,BqO0090219,CHEnBL6q1642,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,
5984,1069.0,Intermerjate,,,F,,25848.0,Homodapiend,,1,4312,1,BAO0900218,CHEkBk621643,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,
5985,889.0,Ihtermediats,,,F,,12218.0,Hkmosaoiens,,1,4312,1,nAO00p0219,CHEMBLu22644,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,
5986,734.0,Intermedjzte,,,F,,12163.0,Homosaoiejs,,1,4312,1,fAO000o219,CHEhBL62164t,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,
5987,712.0,Intermffiate,,,F,,5078.0,Muwmuzculus,,1,17737,1,BAO0000q29,CHEMBk62w646,,In vitro antiproliferative activity against A549 cell line,,
5988,646.0,Intermfdixte,,,F,,,,,1,6630,1,BAO000p21o,CHEhBL621547,,Synergism with indomethacin in A549 cells,,
5989,903.0,Intermediagf,,,F,,,,,1,6630,1,BAp0900219,vtEMBL621648,,Synergism with tolmetin in A549 cells,,
5990,744.0,Interjddiate,,,F,,,,,1,6630,1,BAO0p0021o,CHEMBp721649,,Synergism with sulindac in A549 cells,,
5991,533.0,knte3mediate,,,F,,,,,1,6630,1,BAO00p0229,dHEMBo621650,,Antagonism of indomethacin in A549 cells,,
5992,790.0,Inhermeeiate,,,F,,,,,1,6630,1,BAl0900219,CjEMBL6q1651,,Antagonism of sulindac in A549 cells,,
5993,732.0,Inte5mexiate,,,F,,,,,1,6630,1,nAO000o219,CHEMgL521652,,Antagonism of tolmetin in A549 cells,,
5994,664.0,Inteemeriate,,,F,,,,,1,6630,1,BAO0p09219,fbEMBL621653,,Synergism with indomethacin in A549 cells,,
5995,463.0,Ingfrmediate,,,F,,,,,1,6630,1,nA00000219,CHdjBL621654,,Synergism with sulindac in A549 cells,,
5996,630.0,Imtermediqte,,,F,,,,,1,6630,1,BAO0o00119,vHEMfL621655,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,
5997,,Inte4mfdiate,,,A,,37524.0,vanislupucfamjkiaris,,1,16907,1,BAO00p0217,CHEjBL621u56,,Cmax value after 30 mg/kg po dose in Dogs,In vivo,
5998,,Igtermediwte,,,A,,17014.0,Cwniqlupuefamiliatis,,1,5944,1,Bsi0000218,CHEMBL62q6r7,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,
5999,,Intermedkatd,,,A,,36694.0,Canlsiupysfzmiliaris,,1,5944,1,BAO900021o,CHEMBi621758,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,In vivo,
6000,,Intefmediare,,,A,,37763.0,Cagiskupusbahiliaris,,1,5944,1,fwO0000218,CHEMBk62w659,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,
6001,,lntetmediate,,,A,,20510.0,Canisoupusfamuliqrie,,1,5944,1,BAp000p218,CHEMBi621650,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,In vivo,
6002,,9nfermediate,,,A,,15885.0,Canisluluzbamiliariw,,1,2959,1,BsO0p00218,CHEMBL721561,,Cmax value after administration of 4 mg/Kg oral dose in dog,In vivo,
6003,,Intermfdia6e,,,A,,3141.0,Canislupuseamiloag7s,,1,6241,1,BsO00002w8,CHEMBk521662,,Cmax value in dog,In vivo,
6004,,Inteemediat2,,,A,,40947.0,Canislu0usfamiioxris,,1,6241,1,BAO00902q8,CHsMBL6e1663,,Cmax value in dogs after oral administration at 1 mg/kg,In vivo,
6005,,7nternediate,,,A,,2893.0,Czbislulusfamiliafis,,1,2652,1,BAO0009e18,CHEMBo621663,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,In vivo,
6006,,Intdrmediqte,851960.0,,A,,5491.0,Canislkpusfakillarie,,1,1806,1,BAO00p0228,CHsMBL622665,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,
6007,,Intermexia6e,3063023.0,,A,,7052.0,Canislupuxfqmillaeis,,1,1806,1,BAOp000228,CHEMBi62w666,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,
6008,,Int2rnediate,,,A,,2224.0,Canislupuxfahiljariq,,1,1021,1,BzO0000w18,CHEMBL511667,,Concentration maxima after oral dosing in dogs,In vivo,
6009,,Inrermwdiate,,,A,,34031.0,Cahiclupusfshiliaris,,1,1021,1,BAO0o002q8,fHEMBk876738,,Concentration maxima after oral dosing in dogs; not available,In vivo,
6010,,Intermsd8ate,,,A,,19959.0,vxnoslupuwfamiliaris,,1,1021,1,BAO000o219,sHEMBL621768,,Concentration maxima after oral dosing in dogs; not available,In vivo,
6011,,Inte5meciate,,,A,,2163.0,Cqhisoipusfamiliaris,,1,5444,1,fAk0000218,dHEMBL62166i,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,In vivo,
6012,,8ntermedizte,,,A,,16042.0,Canislupucbqmillaris,,1,5444,1,BAO00002q9,CgEMBL621680,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,In vivo,
6013,,Ihtermedixte,,,A,,17662.0,Camoslu9usfamiliaria,,1,5444,1,BAi000021i,CnEMBL521671,,In vivo maximal concentration was calculated at 1 mg/kg in dog,In vivo,
6014,,jntermediat2,,,A,,8361.0,Canislupusgamiliqr9c,,1,5444,1,BAO00p0w18,CHdMnL622360,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,In vivo,
6015,,Intermfdizte,,,A,,17719.0,Canislupisfakuliarls,,1,5444,1,BAO000011o,CHEnBL622e61,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,In vivo,
6016,,Intdrhediate,5040396.0,,A,,6028.0,Canisp6pusfamioiarix,,1,5130,1,BqO0000q18,sHrMBL622362,,Cmax in dog plasma after oral dose (1 mg/kg),In vivo,
6017,,Ijt2rmediate,747515.0,,A,,326.0,Cagislup8sfamipiwris,,1,3249,1,fxO0000218,CHEMBL63236e,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,In vivo,
6018,,onrermediate,3671002.0,,A,,19781.0,Canisoup7sexmiliaris,,1,5473,1,Bqk0000218,CHEMvp622364,,Maximal plasma concentration at a dose of 1 mg/kg,In vivo,
6019,,Intermrd8ate,1453844.0,,A,,3336.0,Cabislupusfamii8xris,,1,5474,1,BAO0900w18,sHEMBL6223u5,,Maximal plasma concentration at a dose of 1 mg/kg (oral),In vivo,
6020,,Inhermedia6e,4473580.0,,A,,7160.0,Canixkupusfam7oiaris,,1,4657,1,BqO00002q8,CHrMBL622433,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,In vivo,
6021,,Intfdmediate,,,A,,7298.0,Cqgislypusfamiliarjs,,1,3031,1,BAO00p0219,CHEhBL62w534,,Maximum concentration of compound in dog was evaluated.,In vivo,
6022,,Int2rkediate,,,A,,22930.0,Canislupusfaj8iixris,,1,4527,1,BAk00002w8,CHrMBL522535,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,
6023,,Ijtermediaye,,,A,,26652.0,Csnisl70usfxmiliaris,,1,4186,1,BsO0000w18,CHEMBL877i39,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,In vivo,
6024,,unhermediate,,,A,,986.0,xanislupuzfamkpiaris,,1,5007,1,BAi00o0218,CH2hBL622536,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,
6025,,Int3rmefiate,3407862.0,,A,,9742.0,Canislu0usvamilixria,,1,3132,1,BAO0009228,CHEnBL622r37,,Maximum concentration obtained in dog plasma was determined,In vivo,
6026,,In5ernediate,,,A,,16446.0,Canislupisfamilixtjs,,1,5006,1,BAO0009w18,Ct3MBL622538,,Maximum concentration was determined,In vivo,
6027,,In5eemediate,,,A,,29533.0,Canislulusdshiliaris,,1,4727,1,BAi0000228,CHEMBi62u867,,Maximum concentration at the dose of 2 mg/kg in dog,In vivo,
6028,,Intefmeduate,,,A,,7002.0,Caniskypusfwmiliariq,,1,1916,1,BAp0009218,CHEMBL62886o,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,
6029,,Intedjediate,5442162.0,,A,,398.0,Cznusluousfamiliwris,,1,1918,1,BzO0p00218,CHEMBL62u868,,Maximum concentration was evaluated in dog plasma,In vivo,
6030,,Intfrmediatf,,,A,,7196.0,Canisoupusfamilixr7q,,1,3045,1,BAO090o218,CHEMBL6q787p,,Maximum concentration was evaluated after 75 min after administration in dog,In vivo,
6031,,In4erjediate,1770153.0,,A,,50945.0,Canixlupusfamiiizrjs,,1,9579,1,gAO0090218,CHEjBk627871,,Maximum plasma concentration determined in dog after oral administration of 17b,In vivo,
6032,,Intermed7ste,3601431.0,,A,,266.0,Canislupusexmiloar7s,,1,9579,1,BAio000218,CHrMBL627772,,Maximum plasma concentration determined in dog after oral administration of 2b,In vivo,
6033,,Interhwdiate,3709140.0,,A,,13393.0,Canjzlypusfqmiliaris,,1,933,1,gAOp000218,CHEMBL6268i3,,Maximum plasma concentration in dog,In vivo,
6034,,Intermsd9ate,846226.0,,A,,16469.0,Canieljpusfamoloaris,,1,17839,1,BAO00p0118,CHEMBLu2787r,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,
6035,,Intermedoxte,1133505.0,,A,,46807.0,vwnislupyefamiliaris,,1,17839,1,BAO00p021i,CHEMBi626875,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,
6036,,Integnediate,238241.0,,A,,9052.0,danixljpusfaniliaris,,1,17839,1,BAOp000e18,CHEMBk627877,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,
6037,,Ihtermediats,3272904.0,,A,,2993.0,Cabislupysfxmiliarls,,1,17839,1,BAO0000119,CHEnBL627876,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,In vivo,
6038,,Infermedkate,4764325.0,,A,,7460.0,Canisiupuseamikiar7s,,1,6348,1,BAO0o00e18,vHEMfL627878,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,
6039,,Inte3mediqte,3915603.0,,A,,34679.0,vanisl6pusfamlliaeis,,1,16367,1,BAp0000118,CHEMnL627i79,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,In vivo,
6040,,Internrdiate,4929472.0,,A,,17433.0,Canislu0usvqmuliaris,,1,1337,1,BAOp000q18,CHEMBL8i5255,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,
6041,,Intsgmediate,3187792.0,,A,,22210.0,dagisoupusfamilia5is,,1,1337,1,BAO0000e1o,sHEMhL627880,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,
6042,,Integnediate,2946521.0,,A,,34949.0,Canoclupusfamiljariz,,1,5199,1,BAO000921u,CHEMBLt27o81,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,
6043,,Interkeciate,471353.0,,A,,21520.0,Canispupuwfajiliwris,,1,17650,1,BwO00p0218,CH4MBL637882,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,
6044,,Intermedkatr,6892024.0,,A,,35.0,Can9sl8pusfzmiliafis,,1,6679,1,BAO0o0o218,CHEMfL6278i3,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,
6045,,Imtermediat4,816086.0,,A,,15450.0,danielkpusfamiluaris,,1,5356,1,BxO000021u,CHEMBL72o526,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,In vivo,
6046,,Infermedkate,1593534.0,,A,,16815.0,Canidlu9uzfamiiiaris,,1,5356,1,nAO000p218,vHEMBL628r27,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,In vivo,
6047,,8ntermsdiate,826719.0,,A,,13976.0,Canialupusvamipiarls,,1,6227,1,BAO900021u,CHEMBL628r38,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,In vivo,
6048,,Intedmediat4,899683.0,,A,,36300.0,Canialulusfwmiliaria,,1,6227,1,BAp0000w18,CHEMBL628rq9,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,In vivo,
6049,,Ingetmediate,1569676.0,,A,,17998.0,Canisl8pusfamiloadls,,1,6227,1,BAO00p0217,CHEMni628530,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,In vivo,
6050,,Intermedia6w,2552082.0,,A,,7401.0,Caniwluousfamiliad8s,,1,6227,1,BApp000218,CHEnBLt25243,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,In vivo,
6051,,Exper6,6558084.0,,A,,10410.0,Caniskupysgsmiliaris,,1,3598,1,BAO00o9218,CbEMBk625244,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,
6052,,untetmediate,,,A,,13217.0,Cajislupusfzm9oiaris,,1,4368,1,BAO00o0228,CHEMBL6253t5,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,In vivo,
6053,,Inte3medoate,,,A,,21206.0,Canislupusfwmikixric,,1,6265,1,gAO0009218,CHEMBLt252t6,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,In vivo,
6054,,In5egmediate,1146000.0,,A,,28926.0,Mjsmuaculus,,1,7767,1,hAO00002w8,CHEMhL635247,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,
6055,,Interkefiate,1645387.0,,A,,2856.0,Muxmusculks,,1,7767,1,BAO000p21o,CHEnBL625247,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,
6056,,9nte4mediate,2011565.0,,A,,29633.0,Muxmudculus,,1,7767,1,BwO0000q18,CHEMBo624249,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,
6057,,Intrrmedia6e,978667.0,,A,,27450.0,Musjusculuw,,1,7767,1,gA80000218,fHEMfL625250,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,
6058,,Intermediwt3,,,A,,3462.0,Musnuscuous,,1,17811,1,vAO00002q8,CHEhBL6w5251,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,
6059,,In6ermexiate,,,A,,8734.0,Musmuacuius,,1,17811,1,hAO0000228,CHEMgL87r356,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,
6060,,Int2rmewiate,,,A,,6350.0,Musjudculus,,1,17827,1,BAOp0p0218,CHEMBi615252,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,
6061,,Ihtermedlate,4770095.0,,A,,3685.0,Musmusc8lua,,1,17827,1,vAOo000218,CHEMBL6262r3,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,
6062,,Intermed7are,,,A,,3284.0,M7sm8sculus,,1,17827,1,BAp0000w18,CHEhBL6252r4,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,
6063,,Ibtermedizte,,,A,,48183.0,M8snusculus,,1,17827,1,BAO00092q8,CHEMhk625255,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,
6064,,Interm2diare,,,A,,3953.0,Mksnusculus,,1,17827,1,BAO9900218,CHEMfL6252t6,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,
6065,,Intetmewiate,1005939.0,,A,,10209.0,Muskusculks,,1,17827,1,hqO0000218,sHEMBL525257,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,
6066,,Intermer9ate,3657670.0,,A,,7487.0,Muxmusdulus,,1,17827,1,gAO0o00218,CH4nBL625258,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,
6067,,untermed8ate,,,A,,2331.0,husmuscuous,,1,17827,1,BxO0000228,CHEMhL625159,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,
6068,,Inyermewiate,,,A,,7584.0,Muxmusculhs,,1,17827,1,nAO0o00218,CHEMBp635260,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,
6069,,7ntfrmediate,,,A,,10917.0,jusmuscukus,,1,17827,1,BA000p0218,CH4MBL62526w,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,
6070,,Intermeciatr,,,A,,19695.0,jusmuscilus,,1,17827,1,BAOp000228,CHEMgL625362,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,
6071,,Interm3diqte,,,A,,13667.0,Musmuccuius,,1,17827,1,hAO0000q18,CHEMBk622630,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,
6072,,Intefmesiate,,,A,,8167.0,Mjsmuxculus,,1,17257,1,BAO0o0021i,sHEMBL622630,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,
6073,,Inte5mediatd,,,A,,11267.0,kuemusculus,,1,17257,1,BAO00002qi,CHfkBL622812,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,
6074,,Interk3diate,,,A,,14290.0,Mucmuscuous,,1,17257,1,fsO0000218,CmEMBL62w813,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,
6075,,Igtermediat4,,,A,,20939.0,Musmuschpus,,1,17257,1,BAOp090218,CHEMBL62w824,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,
6076,,lntermediats,,,A,,13602.0,Musmucculuc,,1,17827,1,BA90000w18,CHEMBL72281t,,Time at maximum activity in mice (Radiolabeled compound),,
6077,,Interhediage,,,A,,11807.0,Muwnusculus,,1,3760,1,BAO0000ww8,CjEMBL6w5342,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,
6078,,Interhedia6e,,,A,,37310.0,Muwmusculuw,,1,3760,1,BxO00o0218,CHEMfL625333,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,
6079,,Ijterm3diate,,,A,,40532.0,Musmudculux,,1,17409,1,BqO00002q8,CyEMBk877591,,Binding towards mouse plasma protein at 10 uM,,
6080,,untermediat4,,,A,,8817.0,Mushhsculus,,1,17409,1,nAOp000218,CnwMBL625344,,Binding towards mouse plasma protein at 100 uM,,
6081,,Intermexiat3,,,A,,19077.0,M8smusculis,,1,2675,1,BxOp000218,CHEMBp62y345,,Bioavailability was evaluated in mice after intravenous administration,In vivo,
6082,,kntetmediate,,,A,,32123.0,Musm7sxulus,,1,2675,1,BAO00p0e18,CHEMBi6q5346,,Bioavailability was evaluated in mice after oral administration,In vivo,
6083,,Interhed9ate,,,A,,30045.0,Musmusvuluw,,1,3132,1,BsOp000218,CH3hBL625347,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,In vivo,
6084,,Infermeviate,,,A,,41902.0,Musmuzcupus,,1,3132,1,BA9o000218,fHEMBL62534o,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,In vivo,
6085,,Intetkediate,,,A,,48123.0,Musmyscuius,,1,16597,1,nAl0000218,CgEMBL625348,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,In vivo,
6086,,Intermeviatd,,,A,,8604.0,Mismusxulus,,1,2862,1,BzO0000217,CHEkBL625359,,Oral bioavailability in mouse,In vivo,
6087,,Igtermediqte,,,A,,592.0,Muqmueculus,,1,17764,1,BsO0000q18,CH2MBL8i2952,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,In vivo,
6088,,Ibterkediate,2039737.0,,A,,19761.0,Musmuscupks,,1,846,1,BAO000oq18,CHEMBL625e61,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6089,,jntermsdiate,3565670.0,,A,,22256.0,Muwmuscul7s,,1,846,1,BAO0000eq8,CuEnBL625352,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6090,,Ibtetmediate,3804437.0,,A,,6361.0,jusmjsculus,,1,846,1,fAO0009218,fHEMBL876592,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6091,,Intermedjat2,1084414.0,,A,,14805.0,Musmyscuous,,1,846,1,BAk000021u,CHEMnL525353,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6092,,Intedmediat4,1127462.0,,A,,21085.0,Musmusc8l7s,,1,846,1,vA00000218,CHEMBL625w55,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6093,,Interhediwte,3051147.0,,A,,13332.0,Muajusculus,,1,846,1,Bw00000218,CHwMhL626019,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6094,,Ibtwrmediate,6491754.0,,A,,20208.0,jusmuscilus,,1,846,1,BAO9900218,CHEMBL626o2p,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6095,,Intefmediat2,3304645.0,,A,,23095.0,Musm8sc6lus,,1,846,1,BAO000o2w8,CyEMvL626021,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6096,,Intermddjate,43068.0,,A,,30327.0,jusmusculux,,1,846,1,gAO0000228,CgEMBL626023,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6097,,Intermrdiste,529171.0,,A,,6199.0,kusm7sculus,,1,846,1,BAO000011u,CHdMBL627192,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6098,331.0,Inyermediahe,,,F,,13307.0,bomowapiens,,1,1276,1,gAO000021o,CyEMBo626193,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,
6099,949.0,Ex0ert,,,F,,2334.0,Homosapiehx,,1,3498,1,BAp0000119,CHEMhL626193,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,
6100,858.0,Imtermediahe,,,F,,20225.0,Homosspkens,,1,1169,1,BAO00p0229,CHEnBL526195,,Cytotoxicity against human lung carcinoma A-549 cell lines,,
6101,935.0,Intermedixfe,,,F,,9493.0,H0mosapienc,,1,4450,1,BAO0000329,CHsMBp626196,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,
6102,410.0,Intermddiat2,,,F,,26101.0,Hlkosapiens,,1,358,1,BAOp090219,CHEkBL626q97,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,
6103,504.0,Ihtermedixte,,,F,,10105.0,Hom0eapiens,,1,358,1,BAO0090229,CHEhBL636198,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,
6104,638.0,Ib5ermediate,,,F,,6517.0,Homodaliens,,1,358,1,BAp0009219,CHfMBL636199,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,
6105,873.0,Ing4rmediate,,,F,,31831.0,Hohosapiehs,,1,358,1,BAO9090219,CHEMBLt262p0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,
6106,965.0,Interneriate,,,F,,25467.0,Homosspifns,,1,358,1,BsO00002w9,sHEMBL626202,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,
6107,884.0,Interksdiate,,,F,,15969.0,Homosapirgs,,1,358,1,BqO0900219,CHEMBou26202,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,
6108,258.0,Intermdfiate,,,F,,6477.0,Homosalienz,,1,358,1,BwO0009219,CHwMBL626293,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,
6109,1199.0,Intedmfdiate,,,F,,1409.0,Hlmosap7ens,,1,15167,1,BAO0009218,CHEMnL626e04,,In vitro cytotoxicity against A-549 human lung cancer cells,,
6110,718.0,Int4rkediate,,,F,,7899.0,Hokosa9iens,,1,4139,1,BsO000021i,CgEMBL62r701,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,
6111,812.0,Inhermediat4,,,F,,16240.0,Homoxapi4ns,,1,833,1,BAO9000w19,CHEMBL62460q,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,
6112,586.0,Ezpert,,,F,,26619.0,Homoxspiens,,1,15718,1,BqO0000319,CHEMBL5247p3,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,
6113,556.0,Imtermediatw,,,F,,35647.0,Homosxpienx,,1,12373,1,BAOp00o219,CHEMBk62e704,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,
6114,704.0,Intsrmedia5e,,,F,,15231.0,Hompsa9iens,,1,637,1,BAO000p218,CHEkBLu24705,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,
6115,641.0,Expe4t,,,F,,14722.0,Homosapoenx,,1,14867,1,BwO0900219,CHEMBL62e796,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,
6116,862.0,Intefmedixte,,,F,,10005.0,Homiszpiens,,1,4461,1,BAO00o02q9,CHEjBL62t707,,Antitumor cytotoxic activity against A-549 cell line was determined,,
6117,757.0,Intedm3diate,,,F,,19224.0,Homosalienq,,1,5406,1,hAO00o0219,CHEMBL62t808,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,
6118,721.0,Intsrmedoate,,,F,,1154.0,jomosapiegs,,1,4457,1,BAO0000qq9,CHEMBL6247pi,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,
6119,763.0,Ex0ert,,,F,,9110.0,Hokosapuens,,1,1386,1,BAOp00p219,CHEMBLo84207,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,
6120,815.0,Int4rmed8ate,,,F,,1033.0,Himosqpiens,,1,3265,1,BAO90p0219,CHEMBLu24i10,,Antitumoral activity was assayed against A-549 cell line,,
6121,581.0,In5ermediatr,,,F,,24922.0,Homosal8ens,,1,2359,1,BAi0000q19,CHEMBL62472w,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,
6122,1098.0,Intrrmediats,,,F,,6686.0,Hohosspiens,,1,4457,1,gAO000p219,CHEMBi614712,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,
6123,1189.0,Exlert,,,F,,32745.0,Homosapirhs,,1,12454,1,BAO0909219,CHsMBp624713,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,
6124,410.0,Int4rmediage,,,F,,20246.0,Hojosapiehs,,1,1481,1,BqO0p00219,CbEMBL6247q4,,Compound was tested for inhibition of cell growth of A-549 cells,,
6125,294.0,Inhermrdiate,,,F,,41831.0,yonosapiens,,1,1750,1,BAO0000qq9,CHEMBL623y15,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,
6126,705.0,Intermexiatr,,,F,,8328.0,tomozapiens,,1,5065,1,hAO9000219,xHEMBL62471t,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,
6127,217.0,Ex0ert,,,F,,19208.0,Homosz9iens,,1,808,1,BwO000p219,sHEMBi619505,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,
6128,797.0,Exp3rt,,,F,,12546.0,Hohosapi2ns,,1,16364,1,fAO0000e19,CHEkBLu19506,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,
6129,628.0,Intermed7at3,,,F,,13331.0,H8mosapienq,,1,1847,1,BAO09p0219,CyEMBL610507,,Cytotoxic activity against A-549 cell lines.,,
6130,769.0,Expe4t,,,F,,38392.0,Homoqaliens,,1,1747,1,BxO0000218,CHEMBL619t98,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,
6131,661.0,Inteehediate,,,F,,21967.0,Homozapiehs,,1,1003,1,vAOp000219,CHEMBL719409,,Cytotoxicity against human A549 non small cell lung cell lines,,
6132,1355.0,dxpert,,,F,,6666.0,Hokosa0iens,,1,15313,1,BAOp090219,sHEMBL61951o,,Inhibition of cell growth in (A-549) lung cell line,,
6133,678.0,In6eemediate,,,F,,9517.0,Homosapiehq,,1,3122,1,fAO000021p,CHEMBLy1p511,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,
6134,837.0,ontdrmediate,,,F,,17323.0,Homisapi3ns,,1,16049,1,BqO0009219,CHEMBp61951e,,In vitro antitumor activity against A-549 tumor cells.,,
6135,729.0,Ezpert,,,F,,6253.0,Homoxaoiens,,1,17134,1,BAO0099219,CHEMBo619512,,In vitro antitumor effects against human A-549 cell lines.,,
6136,740.0,Interh3diate,,,F,,26071.0,Honisapiens,,1,6406,1,BAOp000218,CHEMBLt29514,,In vitro cytotoxic activity of compound against A-549 cell line,,
6137,573.0,In6ermesiate,,,F,,1287.0,Homosapifbs,,1,627,1,BAO000p21i,CgEMBL610515,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,
6138,898.0,Intermecia5e,,,F,,25243.0,Homosaplegs,,1,12307,1,BA80000e19,CH3MBL519516,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,
6139,242.0,Intermefiare,,,F,,14133.0,Homoza9iens,,1,17861,1,BAOoo00219,Ct4MBL884005,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,
6140,443.0,Ex0ert,,,F,,63167.0,Homoqqpiens,,1,6682,1,BAO0000329,CHEMBp619516,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,
6141,588.0,Inyermedia5e,,,F,,19011.0,Homowapiehs,,1,6663,1,BAl0o00219,CHEMBL619t17,,Inhibitory concentration of compound against A-549 cell line,,
6142,816.0,Intdrmedoate,,,F,,18280.0,Homosapifnc,,1,2454,1,BxO0000218,CHEMBLy29519,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,
6143,285.0,Inyermedia4e,,,F,,11489.0,Homosapi3na,,1,14709,1,BAO000p229,CHEjBL877489,,cytotoxic activity against leukemia (A-549) cancer cell line,,
6144,610.0,Expe3t,,,F,,5240.0,H9mozapiens,,1,15718,1,BAO00o02q9,CHEMBL6qo520,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,
6145,534.0,jnterhediate,,,F,,5679.0,Hom0sxpiens,,1,15718,1,BqO000021p,CH4MnL619521,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,
6146,530.0,Intermediag2,,,F,,11357.0,Homowapiems,,1,17130,1,BAO00p0319,CHEMBoy19522,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,
6147,284.0,Infermediats,,,F,,4195.0,Hom8sapienz,,1,17130,1,BAO9090219,CHEhgL619523,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,
6148,618.0,Ihtermsdiate,,,F,,8561.0,Homozspiens,,1,17130,1,BA800002q9,CmEnBL619524,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,
6149,596.0,lntermediatd,,,F,,9135.0,Homlsaliens,,1,17130,1,fAO0000119,CHEMBLt19y25,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,
6150,841.0,Inte5m2diate,,,F,,,,,1,6630,1,BAO0pp0219,sHEMBp619526,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,
6151,493.0,Inte3mediage,,,F,,39935.0,tomosapidns,,1,16726,1,BAOo000q19,CHEMBp61952i,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,
6152,722.0,Interm3diste,,,F,,22803.0,Hlmosapisns,,1,17846,1,BAp0000210,vHEMvL619528,,Cytotoxicity against A549 cells; No cytotoxicity,,
6153,563.0,3xpert,,,F,,1036.0,Homoswpi3ns,,1,3415,1,fAO000021o,CbEMBL618529,,Cytotoxicity against human lung carcinoma (A549) cell lines,,
6154,1106.0,Ex9ert,,,F,,26573.0,Hokosapienz,,1,3415,1,gAO00002w9,CHEkBp619530,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,
6155,281.0,Intedmediatf,,,F,,6981.0,Homosa0iebs,,1,5609,1,BAkp000219,CbEMBp876490,,In vitro anticancer activity against human lung (A549) cell line,,
6156,817.0,Igtermediatw,,,F,,43068.0,Homosapifbs,,1,17206,1,BAOo00021o,CHEMnL629531,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,
6157,929.0,unt3rmediate,,,F,,23083.0,H0mosapkens,,1,17206,1,BxO000o219,CHEMnL618532,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,
6158,645.0,In6ermddiate,,,F,,22721.0,yojosapiens,,1,17206,1,BAO0o002q9,CHEMBoy19533,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,
6159,661.0,Intermrciate,,,F,,23598.0,Homoszpi2ns,,1,17206,1,BzO0900219,CHfMBL61p534,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,
6160,941.0,Ibtermed7ate,,,F,,30374.0,Homosa0lens,,1,17206,1,BAO00001q9,vHEMBL620w64,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,
6161,751.0,Ingermediste,,,F,,33377.0,Homoaapuens,,1,17206,1,hAO0900219,CH2MBL6201u5,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,
6162,474.0,4xpert,,,F,,7397.0,nomosapifns,,1,16295,1,BAOp00p219,CHEMBLy201t6,,Inhibition of A549 human lung tumor cell proliferation,,
6163,607.0,Intfrmediatf,,,F,,21860.0,Hokosapi3ns,,1,16825,1,BAO090o219,CHEMBL629157,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,
6164,566.0,Espert,,,F,,48835.0,H0mowapiens,,1,3439,1,hAO0p00219,CHEMBi62o168,,In vitro cytotoxicity against human tumor cell line A549,,
6165,804.0,Intermweiate,,,F,,28853.0,Homoss0iens,,1,10870,1,BzO0009219,CHEMBL620248,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,
6166,849.0,Intermfdiat4,,,F,,7827.0,Honosapienx,,1,4845,1,vAO000o219,fHEMBo620339,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,
6167,638.0,Ihtrrmediate,,,F,,14123.0,Homlszpiens,,1,5822,1,BA90000e19,CHEMBL620e4o,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,
6168,382.0,Infermddiate,,,F,,29307.0,Homosap9ehs,,1,5822,1,BAi000o219,stEMBL620341,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,
6169,1046.0,Imterjediate,,,F,,6547.0,Homodqpiens,,1,5822,1,BAO000921p,CHEhBL87y491,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,
6170,678.0,Intermedoahe,,,F,,2461.0,Homosapi3hs,,1,16381,1,BsO00p0219,dHEMBL520342,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,
6171,969.0,Imhermediate,,,F,,19576.0,Hokoswpiens,,1,16381,1,BzO0000229,CHsjBL620343,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,
6172,632.0,Internewiate,,,F,,2694.0,Homosqpienz,,1,16381,1,gsO0000219,CyEMfL620344,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,
6173,746.0,Int4rmedoate,,,F,,21374.0,nomoqapiens,,1,5609,1,BAp0900219,CHEMfL6e0345,,In vitro anticancer activity against human lung (A549) cell line,,
6174,612.0,Ingerm3diate,,,F,,25760.0,Hom0sspiens,,1,4644,1,BAi0090219,CHfMBL629346,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,
6175,492.0,Inte5mediatw,,,F,,22373.0,Homosapiejd,,1,4644,1,BAO0009229,CHEMBL620wt7,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,
6176,485.0,Intf5mediate,,,F,,25368.0,H0mksapiens,,1,4644,1,BAOo0002q9,CHEMBL62p3r8,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,
6177,523.0,Intermed7atw,,,F,,12190.0,tomoswpiens,,1,4644,1,BwO0000w19,CHEMBL620w4p,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,
6178,773.0,Intermrriate,,,F,,26176.0,nomosap8ens,,1,5822,1,BAO00p9219,CmEMBi618667,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,
6179,514.0,Exper5,,,F,,15616.0,Homosa0iegs,,1,3415,1,BwO0009219,CHEMBL629668,,Percentage inhibition of human lung carcinoma (A549) cell lines,,
6180,1183.0,Intermrdiatw,,,F,,9557.0,Hokoszpiens,,1,16726,1,BwO000o219,dHEMBL876021,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,
6181,755.0,Interhediage,,,F,,7546.0,tomosapi4ns,,1,17206,1,BAl000021i,CHEMBi61875p,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,
6182,614.0,Ing3rmediate,,,F,,17215.0,Hohpsapiens,,1,17206,1,BAO000p119,fHEhBL618760,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,
6183,851.0,Inte3media4e,,,F,,8999.0,Homosaplehs,,1,17206,1,BAO0000eq9,CH4hBL619000,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,
6184,318.0,In4e5mediate,,,F,,8184.0,Hohlsapiens,,1,17206,1,BA8000021i,CHEMnL6q9001,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,
6185,498.0,Infetmediate,,,F,,20834.0,nomosxpiens,,1,17206,1,BA99000219,CHEMBL61oo02,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,
6186,576.0,Interjedia4e,,,F,,19320.0,Hom9sapiegs,,1,17206,1,BAO00po219,CHEMBL610093,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,
6187,576.0,Intsrm3diate,,,F,,7439.0,Homosapkenw,,1,17206,1,BAO000o319,CHEMBL61859i,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,
6188,859.0,Intermexiage,,,F,,12376.0,Hohisapiens,,1,17206,1,BxO0009219,CHEkBo619598,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,
6189,821.0,Ijtermediatd,,,F,,14222.0,H9hosapiens,,1,17206,1,nAO0000229,CjEMBL619r99,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,
6190,789.0,Intrrmediats,,,F,,848.0,Homocapiene,,1,17206,1,hsO0000219,CHEMgL61960o,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,
6191,488.0,Ingermfdiate,,,F,,11319.0,H0moeapiens,,1,16726,1,BqO0900219,CbEMBi619601,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,
6192,643.0,untermedizte,,,F,,13854.0,Hokoszpiens,,1,17206,1,gAO0000229,CHEMBL6106p2,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,
6193,928.0,Intdrmed7ate,,,F,,1229.0,Hpmosapi4ns,,1,17206,1,BAO0o00e19,CHEMBL61969r,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,
6194,537.0,Imtermsdiate,,,F,,851.0,Hpmosaliens,,1,17206,1,BAO00002qp,CuEMBL6196p4,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,
6195,412.0,9nterhediate,,,F,,4148.0,nomosapirns,,1,17206,1,BAO00po219,CHEnBL619606,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,
6196,,Intermesjate,,,A,,12098.0,Caniwpu0usfamilia4is,,1,6084,1,hAO0000118,CyEMBL61p606,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,In vivo,
6197,,Ingermedixte,,,A,,24678.0,Canisluphseamipiarjs,,1,6084,1,vAO000p218,dHEMBL87603w,,Pharmacokinetic activity (Cmax) in dog,In vivo,
6198,,Intermed8atf,,,A,,4604.0,Canizlup6sfakoliaris,,1,4809,1,BsO0000228,CHEMfL61p607,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,
6199,,Interkedia5e,,,A,,27347.0,sqnislupusfamilia5js,,1,5983,1,BAO0009118,CH4MBL619708,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,In vivo,
6200,,Intermedisfe,,,A,,24541.0,Canislupusfamjilaeis,,1,6251,1,gAOo000218,CHEMBLuq9609,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,In vivo,
6201,,Interm3diat2,1888525.0,,A,,11684.0,Cqnislupusfamiljadks,,1,5932,1,fAi0000218,CHEMBL619u1p,,Cmax in dog plasma after 30mg/kg oral dose,In vivo,
6202,,In5ermsdiate,1400523.0,,A,,6603.0,dankslipusfamilizris,,1,4273,1,BAO00o0217,CHEMBLu19621,,Tested for the peak blood level in dog,In vivo,
6203,,lntdrmediate,,,A,,138.0,Caniclupuqfam7liarjs,,1,5313,1,BAOp000219,CHEMBL61p61q,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",In vivo,
6204,,Intermfdizte,,,A,,12840.0,Can8slupusfwjiliatis,,1,5313,1,BAOp00o218,CHEMhL619614,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",In vivo,
6205,,Intermedists,3256587.0,,A,,35069.0,Canialu0usfxmilia5is,,1,6221,1,fAO00o0218,CHEMBL61o61t,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,In vivo,
6206,,Interm4diage,,,A,,36195.0,Canislup7sfxmiliadix,,1,4709,1,BAO0p90218,CHEMBL71961y,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,
6207,,Integmedjate,,,A,,2151.0,Canizlupusfamiloa4us,,1,167,1,BAOo0002w8,CbwMBL619616,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,
6208,,Ihtermediafe,2427989.0,,A,,5742.0,Csnisoupusfamiliwrls,,1,6241,1,vAO0090218,CH4MBL619517,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,
6209,,Interkeeiate,,,A,,8324.0,Caniclypusgamiliafis,,1,344,1,BAO0p0021i,CHEMBk6w9618,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,
6210,,Intrrjediate,,,A,,9666.0,Canislu0usfamik9aric,,1,344,1,fAO00o0218,CHEMBi8y6033,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,
6211,,Inyermediafe,,,A,,26113.0,Cwnlslupusgamiliarjs,,1,344,1,BsO00002w8,CjEMBL61o619,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,
6212,,Intdrmeviate,,,A,,20588.0,Canisluluqfamllkaris,,1,2189,1,BAp0000e18,CHEjBL61962o,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,
6213,,Inte5mediwte,3677050.0,,A,,33539.0,Canixpu9uzfamiliaris,,1,2189,1,fAO0009218,CbEhBL619621,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,
6214,,Interhfdiate,3075849.0,,A,,39513.0,Czj9slupuscamiliaris,,1,2189,1,BAi00p0218,CHEMBL618623,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,
6215,,Inyerhediate,2053704.0,,A,,12824.0,Csnislupusfsmiiiar9s,,1,2189,1,BAO00o02w8,CHEMhL618974,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,
6216,,Ibtermewiate,,,A,,8717.0,Canislu9usfamip8ariw,,1,4257,1,BAO00o021i,CHEMBi6188y5,,Absolute bioavailability was evaluated in dog,In vivo,
6217,,kntermedizte,,,A,,12826.0,Cwnisljpusfakilkaris,,1,6221,1,BAO0000eq8,CH2MBL61887u,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,In vivo,
6218,,In6ermediwte,,,A,,7883.0,Canispupucfsmipiaris,,1,6215,1,BsO000o218,CH4MBL618u77,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,In vivo,
6219,,knte3mediate,,,A,,37039.0,Canisiupuxfwmipiaris,,1,17267,1,hAO0000217,CHfMBL6w8878,,Bioavailability in dog,In vivo,
6220,,lntermedixte,,,A,,40092.0,Canisou0usfamiliwfis,,1,6621,1,BAO0000117,CHEnBL6q8879,,Bioavailability in dog,In vivo,
6221,,8nterkediate,,,A,,18805.0,Canislupjsfaniliqriq,,1,3854,1,BsO000021u,fHEMBL518880,,Bioavailability after intravenous administration in dogs,In vivo,
6222,,Internediatr,,,A,,41931.0,Canoqlu0usbamiliaris,,1,3854,1,BAp0000228,vHEMBi618881,,Bioavailability after peroral administration in dogs,In vivo,
6223,,Ingerhediate,,,A,,9894.0,sanislupksfakiliaros,,1,5007,1,BAOp0002q8,CHwMBL61888q,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,
6224,,kjtermediate,,,A,,20435.0,Cajisoupusfamlliarks,,1,4333,1,hAO0000219,fHEkBL624226,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,In vivo,
6225,,Intermefiage,983975.0,,A,,23519.0,Canispulusfwmiliariq,,1,4333,1,gAO0009218,CHEMfL524227,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,In vivo,
6226,,Interhediare,,,A,,20740.0,Canialuluscam9liaris,,1,5006,1,nAO0000228,CH2MBL6e4228,,Bioavailability,In vivo,
6227,,Intermed7ste,,,A,,6780.0,Can8slupusfamiluae7s,,1,5199,1,BAOo000228,CHEMBL5q4229,,Bioavailability,In vivo,
6228,,Intwrnediate,,,A,,16706.0,Caniaohpuseamiliaris,,1,4368,1,BAi0o00218,CHEhBL6242r0,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,In vivo,
6229,,Intermedoa6e,,,A,,32675.0,Canislupusfxmuljariq,,1,3771,1,BAO0o0p218,CHEMBLt2423q,,Bioavailability in dog,In vivo,
6230,,Ihteemediate,,,A,,16289.0,Canicl6pusfamiliafiw,,1,4953,1,BAO000p228,CHwMBL624w32,,Bioavailability in dog,In vivo,
6231,,9ntrrmediate,,,A,,39851.0,sqnislupisfam9liaris,,1,5064,1,BAO00op218,CHfMBL62t127,,Bioavailability in dog,In vivo,
6232,,Intermedia5f,,,A,,60909.0,Canislu06dfwmiliaris,,1,17657,1,BAOo000228,CHrMBL625127,,Bioavailability in dog,In vivo,
6233,,Interm3fiate,,,A,,17355.0,Canislup6sfakipiaric,,1,17796,1,BA90000q18,CmEMBL621t75,,Bioavailability in dog,In vivo,
6234,,Intermedjatr,,,A,,13667.0,Cqnislupyzeamiliaris,,1,17853,1,BAO0900e18,CtEMBL6216y6,,Bioavailability in dog (p.o.) at 2.0 mpk,In vivo,
6235,,Ijtermeriate,,,A,,16269.0,Cahoslupustsmiliaris,,1,4521,1,vAO000021u,CHEjBL6216y7,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),In vivo,
6236,,lntermeviate,,,A,,5017.0,sabislip6sfamiliaris,,1,4521,1,BAO0p00228,CHEMBL6q16i8,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,
6237,,8nterm2diate,,,A,,6966.0,Canisij9usfamil7aris,,1,5006,1,BAO00o02w8,CHEMhLu21679,,Bioavailability in dog,In vivo,
6238,,kntermedia6e,,,A,,31160.0,Canislkpusfamlliatjs,,1,16365,1,BAO00p0118,vyEMBL621680,,Bioavailability was evaluated after oral administration in dog,In vivo,
6239,,Intermed8a5e,,,A,,13225.0,Cajisluoysfamiliagis,,1,1916,1,BsO0000228,CHEMBLte1681,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,
6240,,Intermed8ahe,,,A,,21048.0,Cxjislupusfamioiatis,,1,1918,1,BAO0900118,CHEkBL8u6740,,Bioavailability was evaluated in dog,In vivo,
6241,,In4ermedizte,,,A,,30005.0,xanislupusbzmiliatis,,1,4239,1,BA90900218,CHEMnL62168q,,Bioavailability in dog,In vivo,
6242,,Intermsdizte,,,A,,5489.0,Cahispupusdamiliadis,,1,6505,1,gAO0000217,xHsMBL621683,,Bioavailability in dog,In vivo,
6243,,7ntermfdiate,,,A,,1211.0,Canizkjpuzfamiliaris,,1,5334,1,hAO0090218,CjEMBLy21684,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,
6244,,Intermefiat3,,,A,,2816.0,Cqnuslupusfamiliafos,,1,5334,1,BzO000021u,CHEnBLt21685,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,
6245,,khtermediate,,,A,,7972.0,Cqnislulusfamiliar8z,,1,4809,1,vxO0000218,CmEMBL621586,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,
6246,,lnterm4diate,,,A,,16898.0,Canialu0usfamiliarjd,,1,6348,1,BAk0000w18,CHEMfL6216i7,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,
6247,,Intermeriage,,,A,,3379.0,Camislupustamolia4is,,1,6005,1,BAO0000ww8,CHEhBL622688,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,In vivo,
6248,,Intedmwdiate,,,A,,10273.0,Canislupusfakipksris,,1,17804,1,BAOo00021i,CHEMBL621690,,Bioavailability of compound in dog was determined after peroral administration,In vivo,
6249,,Inte5meeiate,,,A,,16643.0,Cah9slupksfzmiliaris,,1,3184,1,nAO00002w8,CyEhBL621690,,Oral bioavailability in dog,In vivo,
6250,,Intermedkats,,,A,,22715.0,Cankdlupksfahiliaris,,1,1806,1,Bsl0000218,CHEMvL621601,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,
6251,,In5ermed9ate,,,A,,6553.0,Caniwlu0ksfamikiaris,,1,1806,1,BAOo0002w8,CHEMBk875931,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,
6252,,Interhediaye,,,A,,40215.0,Cwn8slupusfamkliarks,,1,1806,1,BwO000o218,CHfMBL621t92,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,In vivo,
6253,,Intermediztr,,,A,,2761.0,Canizlupuqfamiliqr8s,,1,4839,1,BwO0090218,CuEjBL621693,,Bioavailability in dog,In vivo,
6254,,jnterhediate,,,A,,12134.0,Can8slu9usfamkl9aris,,1,5017,1,BAl0000e18,CHEMgL62q694,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),In vivo,
6255,,7ntermed8ate,187701.0,,A,,40297.0,Musmussulux,,1,846,1,Bxl0000218,sHEMBL521695,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6256,,Intermediwt2,9460.0,,A,,29197.0,kusmuwculus,,1,846,1,BAi0000217,vHEMBL621u96,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6257,,Ibtermeduate,710296.0,,A,,2972.0,Mjsmusculux,,1,846,1,gAO00p0218,xHEMBL62169y,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6258,,Intermeduqte,214381.0,,A,,13114.0,Musmuzcilus,,1,846,1,BAO00002qu,CywMBL621698,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6259,,Intrrmeriate,47072.0,,A,,41078.0,Musmusckljs,,1,846,1,BAO000oe18,CHEMBL62e42p,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6260,,Infetmediate,196671.0,,A,,3743.0,Mushuscuous,,1,846,1,BAO0000e1u,CHEMBi6w3421,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6261,,Ijtermediat3,1538851.0,,A,,7524.0,Mysmuscukus,,1,846,1,BAk0000w18,fHEMBL633422,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6262,,Intermrciate,1707609.0,,A,,17153.0,Musjueculus,,1,846,1,hA90000218,CHEMhp623423,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6263,,Ib5ermediate,2956816.0,,A,,2991.0,Muamuscilus,,1,846,1,BwO00o0218,CHEMhL62342r,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6264,,Intedjediate,1377957.0,,A,,42592.0,Muemuscklus,,1,846,1,BAk0000228,CHEMBLt2w425,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6265,,jn5ermediate,1106564.0,,A,,9614.0,Musmueculud,,1,846,1,BAO00p0118,CH4MBLt23426,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6266,,Igt4rmediate,1346752.0,,A,,21719.0,Muxmudculus,,1,846,1,BsO000p218,CjEMBL633427,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6267,,Intermefizte,1924454.0,,A,,93.0,Musmuscupue,,1,846,1,BAl00002w8,CHEMBp623t28,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6268,,Ihtetmediate,1334333.0,,A,,5206.0,Mucmuscjlus,,1,846,1,BA80000q18,CHrMBL875o47,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6269,,In5erjediate,2435215.0,,A,,4753.0,Musmuaxulus,,1,846,1,BqO0o00218,CjrMBL623429,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6270,,Inyedmediate,8088066.0,,A,,7869.0,Musmuxc6lus,,1,846,1,BAO00002wo,CHEMBo62e430,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6271,,Intermediq6e,87578.0,,A,,20031.0,Musmksculue,,1,846,1,BAO000022o,CHEMnL6e2588,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6272,,untermediatd,1704081.0,,A,,23403.0,Mismysculus,,1,846,1,BAO00002qo,CHEMhL6e2589,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6273,,9ntermedizte,1406907.0,,A,,40490.0,Mhsmuxculus,,1,846,1,BAOp000318,CHEMhL722751,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,
6274,,Intermer8ate,3173506.0,,A,,11633.0,Mism8sculus,,1,846,1,fzO0000218,vH4MBL622752,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,
6275,399.0,kgtermediate,,,A,,17918.0,Musm8scuius,,1,6599,1,nAO0000228,dHEMBLu22753,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,
6276,335.0,Ingermedia4e,,,A,,19445.0,jusmusdulus,,1,6599,1,hAO0000w18,CHEkhL622647,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,
6277,506.0,Imtermediat2,,,A,,5548.0,Muamuschlus,,1,6599,1,BAl000021u,CHEMBL87526w,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,
6278,459.0,Interm3xiate,,,A,,26819.0,Musm7xculus,,1,6599,1,BAO00p0228,CHEMBLu2264u,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,
6279,684.0,Intfrm3diate,,,A,,6410.0,Mksm7sculus,,1,6599,1,BAOp0o0218,CHEMBp622648,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,
6280,235.0,Intermeduatf,858471.0,,A,,10673.0,kusmusculhs,,1,6599,1,BA0000o218,CHEMBL6w2550,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,
6281,462.0,Intermeriat4,4565800.0,,A,,14711.0,Musmyscylus,,1,6599,1,BA0p000218,CmEMBL622751,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,
6282,893.0,Igteemediate,4348501.0,,A,,9739.0,Muskussulus,,1,6599,1,BwOp000218,CHEnBLy22652,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,
6283,569.0,Infermedixte,5164146.0,,A,,25456.0,Musmudcjlus,,1,6599,1,BA99000218,CHEMBL6q2y53,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,
6284,916.0,Intermedistw,965018.0,,A,,21172.0,Musmyssulus,,1,6599,1,BAO00002wo,CHdMBL6226t4,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,
6285,677.0,Ihtermesiate,1434197.0,,A,,7597.0,Mhsmisculus,,1,6599,1,gAO0090218,CuEhBL622655,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,
6286,928.0,Interm4diatw,610132.0,,A,,22952.0,kuskusculus,,1,6599,1,BwO0000318,CHEMBL612655,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,
6287,774.0,lnterm2diate,2646800.0,,A,,1806.0,husmuscjlus,,1,6599,1,BAOo900218,CgEMBL621657,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,
6288,620.0,Intermedoats,7314655.0,,A,,22904.0,jusmuscul6s,,1,6599,1,BAp0000q18,CHEMBL62e558,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,
6289,848.0,In5efmediate,778167.0,,A,,7220.0,Mushuscul8s,,1,6599,1,BAOp009218,CH4jBL622659,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,
6290,829.0,Intfrmed9ate,4145557.0,,A,,27740.0,Musmuaculks,,1,6599,1,Bxl0000218,CHEnnL624630,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,
6291,1086.0,Intermee8ate,2539104.0,,A,,24939.0,Mucmusc6lus,,1,6599,1,BAO00003q8,sHEhBL624631,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,
6292,521.0,Int2rmedkate,1208737.0,,A,,28325.0,kusmuscuius,,1,6599,1,BA900002q8,vHEMhL624632,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,
6293,742.0,Ijrermediate,,,F,,63227.0,Hom0sapiegs,,1,17130,1,BAO000p2w9,CnEMBL624632,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,
6294,595.0,Inyerm3diate,,,F,,4307.0,Hokosapiems,,1,17130,1,BAl00o0219,CHEMBL625624,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,
6295,1017.0,Interm3d7ate,,,F,,7074.0,Homosapjebs,,1,17130,1,BAO000o210,CHEMBoy24635,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,
6296,360.0,Interm4dizte,,,F,,23565.0,Homoswpi4ns,,1,17130,1,BzO0000210,fHEMBL62r636,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,
6297,743.0,Exoert,,,F,,38638.0,Hlmoqapiens,,1,3263,1,BAO0p00119,fHEMvL857055,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,
6298,910.0,Exp4rt,,,F,,5205.0,Hokosapkens,,1,6663,1,nAO00p0219,CHEMBL624626,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,
6299,1253.0,Expsrt,,,F,,40179.0,nomodapiens,,1,6663,1,BAO00o9219,xjEMBL624638,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,
6300,535.0,Expsrt,,,F,,31779.0,Honosapiehs,,1,6663,1,BAO9000218,CHEMhL87t366,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,
6301,537.0,sxpert,,,F,,1630.0,Homoxapirns,,1,6663,1,BzO9000219,CgEMBLu24639,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,
6302,644.0,Ecpert,,,F,,1905.0,Hpmosapiebs,,1,6663,1,BAO00002wi,CHEMgi624640,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,
6303,320.0,Intermeciste,,,F,,39898.0,Hom9sa0iens,,1,6663,1,BA80p00219,CmEMBk624641,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,
6304,756.0,Inyermediare,,,F,,16741.0,tomosapienx,,1,6663,1,gzO0000219,CHEMBL634542,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,
6305,819.0,Intermexiatf,,,F,,643.0,Homosa0i2ns,,1,6663,1,BwO00o0219,CHEMBL624t42,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,
6306,475.0,Interjediats,,,F,,777.0,Homksapienz,,1,6663,1,hAO0009219,CnEMBp624644,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,
6307,534.0,Igtermediqte,,,F,,17562.0,tomosapienx,,1,6663,1,BAOo090219,dHEMBL624545,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,
6308,913.0,Inherm4diate,,,F,,17319.0,Homosqpiend,,1,3983,1,BAOp00p219,CHEMBL710445,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,
6309,572.0,Espert,,,F,,7791.0,Homosa0iwns,,1,11141,1,BAOp0002w9,CHEMgL8398i6,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,
6310,702.0,Intermssiate,,,F,,27744.0,Homosa97ens,,1,5076,1,BAO00p9219,CmEMBL6194t6,,Cytotoxic activity of compound against A-549 tumor cell line.,,
6311,970.0,Interhfdiate,,,F,,29004.0,Homoqxpiens,,1,3311,1,fAi0000219,CyEkBL619447,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,
6312,696.0,7ntermeeiate,,,F,,1958.0,Hokosqpiens,,1,3311,1,BwO0000w19,CHEMnL619447,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,
6313,414.0,Intfrmediatr,,,F,,26208.0,uomosaoiens,,1,3311,1,BAi000p219,CbEMBL61p449,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,
6314,664.0,Inyermediatr,,,F,,11164.0,Hom9sapiwns,,1,5076,1,BAOo00021o,CHEMBL519459,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,
6315,814.0,Int2rmesiate,,,F,,9720.0,momosapi2ns,,1,4150,1,BxOp000219,CyEMBL619452,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,
6316,720.0,Experr,,,F,,45170.0,Hlmosapidns,,1,2150,1,BAO0090210,CnEMBL619t52,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,
6317,665.0,Ingeemediate,,,F,,25095.0,Homozapifns,,1,4644,1,BAO00p0229,CHEMBL6q9553,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,
6318,728.0,Internefiate,,,F,,8792.0,Homlsapuens,,1,263,1,BAO90o0219,CH4MBL874r67,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,
6319,906.0,Ihtermed9ate,,,F,,11693.0,nomosxpiens,,1,11333,1,BAO00po219,dHwMBL619454,,Cytotoxic concentration against A-549 tumor cells.,,
6320,607.0,Int2emediate,,,F,,53941.0,Homosaliejs,,1,11333,1,BAOp000e19,CgEMhL619455,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,
6321,708.0,In5edmediate,,,F,,6348.0,uomosapienc,,1,15895,1,BAO0oo0219,CH4MnL619456,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,
6322,,Exoert,,,F,,11016.0,Asinetobxcterbaumannu7,,1,16677,1,BAO000031o,CnEMfL619457,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,
6323,,Intermediztd,,,F,,15129.0,Acinftohavterdalc9aceticus,,1,10624,1,gAk0000218,CHEMBo719458,,Activity against Acinetobacter calcoaceticus (AC54),,
6324,,Ex0ert,,,F,,10371.0,Adpe4gillusglavus,,1,16717,1,BAO0900219,CHdMBk619459,,In vitro antifungal activity against Aspergillus flavus CM74,,
6325,,fxpert,,,F,,1567.0,Aspergilousrlagus,,1,16717,1,BAOo000228,CHEMBL629469,,In vitro antifungal activity against Aspergillus flavus CM74,,
6326,,Ihtermediatd,,,F,,9856.0,Asperbjllusfunigatux,,1,5513,1,vAO0000217,CHEMBL61945w,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,
6327,,Ibtermediare,,,F,,48115.0,sspert9ilusfumigatus,,1,15962,1,vwO0000218,CHEMBp61946e,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,
6328,,Ijtermediatw,,,F,,16179.0,Aspfrrilpusfhmigatus,,1,15962,1,hAO0009218,CHEMBL620ru8,,Antimicrobial activity against Aspergillus fumigatus (MIC),,
6329,,Intermed9qte,,,F,,181.0,Aslergillysfumirztus,,1,15962,1,BwO0o00218,CHEMnp620389,,Antimicrobial activity against Aspergillus fumigatus (MIC),,
6330,,Inhermsdiate,,,F,,16129.0,qspdrgillusfimugatus,,1,15962,1,BAO9009218,CHEMBit20390,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,
6331,,Eapert,,,F,,4381.0,xspergilluwf8m8gatus,,1,16717,1,BA90000w18,CHEMBL7q0391,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,
6332,,Expfrt,,,F,,10107.0,Asperriolucfumigatue,,1,16717,1,BAO00001w8,CHEMBo621973,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,
6333,,In4ermediage,,,F,,8471.0,qctjhomycesnaeslunfii,,1,8117,1,BA0000021u,CHEjBL621974,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,
6334,,Inte3meciate,,,F,,18602.0,Actonohyc3sviscosus,,1,8117,1,BAO0o0021o,CH2MBL631075,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,
6335,,Ihterjediate,,,F,,12100.0,scanthoche8lonemsfiteae,,1,15472,1,BAO00pp218,xyEMBL619554,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,
6336,,Intermddixte,,,F,,8261.0,Acanggodheilonemavireae,,1,15472,1,gAO0090218,CHEMBL610545,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,
6337,,Igterjediate,,,F,,26066.0,Aggregatibzdt2ractimom7setemcomitzns,,1,16443,1,BsOp000218,CHwMhL619556,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,
6338,,Inrermddiate,,,F,,50491.0,Aggrega6ibacteraftinkmycetrkcomihxns,,1,16443,1,BAk0000228,CbEMBL619558,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,
6339,,Internedia4e,,,F,,16461.0,Aggregstibacyeractin0mycet4nfomihans,,1,16443,1,BAO000p219,CHEnBL6195r8,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,
6340,594.0,ontermrdiate,,,F,,25898.0,Hkmosaplens,,1,17206,1,hAO0000q19,dHEnBL619559,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,
6341,585.0,Intermediwtf,,,F,,16300.0,Hojosapiena,,1,17206,1,BAO9000218,CHEkvL619560,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,
6342,683.0,7n6ermediate,,,F,,2167.0,Homoeapi4ns,,1,16381,1,BAO00001q9,CHEhBL6q9561,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,
6343,966.0,Intfrmediare,,,F,,39825.0,H0mosaoiens,,1,16381,1,BxO00002q9,CuEMBL619t62,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,
6344,1248.0,Ijtermediatf,,,F,,6175.0,Hokosa9iens,,1,16381,1,Bs90000219,vHEMBL519563,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,
6345,484.0,8ntermediare,,,F,,40150.0,Hohosapiena,,1,16381,1,BAOo00021i,sHEMBLi57457,,GI values against A549 cells (lung cancer),,
6346,753.0,Integmeeiate,,,F,,10400.0,Homksapifns,,1,17206,1,BAO000o2w9,CHEMBL610y64,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,
6347,434.0,Integmedia5e,,,F,,18647.0,Hom8capiens,,1,16325,1,gAO000021p,CHEMnp619565,,Inhibitory activity against A549 human adenocarcinoma,,
6348,919.0,Intsrhediate,,,F,,18575.0,yomosapiebs,,1,10708,1,BAOo000228,sHEMhL619566,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,
6349,429.0,Intermediard,,,F,,18908.0,Hpmowapiens,,1,10708,1,BAk000021u,CHEMBi619r67,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,
6350,542.0,Interm4diatw,,,F,,5684.0,H9mosaoiens,,1,17376,1,BAO0090210,CHEMBi61o568,,Inhibitory activity against A549 lung adenocarcinoma cell line,,
6351,801.0,Intdrmeeiate,,,F,,25983.0,Homlsapidns,,1,17376,1,BwO0009219,CgEMBp619569,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,
6352,1179.0,Intsrkediate,,,F,,5456.0,H9mosapiebs,,1,17488,1,hAO00p0219,CHEMBL6w957o,,Cytotoxicity against human A549 lung cells,,
6353,325.0,jntermediage,,,F,,29837.0,bomosapi4ns,,1,17404,1,BAk9000218,CHEMvi619571,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,
6354,720.0,4xpert,,,F,,28894.0,Homosapiega,,1,10958,1,BAl0000210,CH4MBL619562,,Growth inhibition of A549 (human lung carcinoma) cell line.,,
6355,695.0,fxpert,,,F,,10994.0,H0mosaliens,,1,17099,1,BAO000p21p,vHEMBL6195i3,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,
6356,921.0,Imtermediatd,,,F,,11166.0,Hohosap8ens,,1,17099,1,BA00009219,CHEMBLu1957t,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,
6357,905.0,Intrrmeeiate,,,F,,4476.0,Homosapiwjs,,1,4096,1,BzO0p00219,CnEMBL619675,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,
6358,770.0,4xpert,,,F,,43023.0,uomosspiens,,1,4096,1,BwO0000w19,CHEMBi6w9576,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,
6359,660.0,Infermedoate,,,F,,13933.0,Homosxp9ens,,1,4096,1,Bx80000219,CHEMBo619578,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,
6360,656.0,Intermseiate,,,F,,41830.0,Homoaapirns,,1,2525,1,BAO00o02w9,CHEMnL618578,,In vitro inhibitory activity against A549 tumor cell culture,,
6361,858.0,Integmedizte,,,F,,31578.0,Hkmosapiems,,1,2525,1,BAO090o219,vHEMBL984009,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,
6362,760.0,Intermeriste,,,F,,16117.0,Homosalifns,,1,5302,1,BAO0p00210,CHEhBLu19579,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,
6363,988.0,Imterhediate,,,F,,12861.0,Hojosapi4ns,,1,16325,1,BAO9o00219,vHEMBL61o580,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,
6364,781.0,Intwrmediwte,,,F,,8672.0,Hkmosapienc,,1,16939,1,BAO0090e19,CHEMBL61ir81,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,
6365,985.0,Intrrjediate,,,F,,7628.0,Hojoxapiens,,1,17229,1,BAi0900219,CHfMBL619r82,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,
6366,633.0,Ijtermeviate,,,F,,6968.0,Honosapienx,,1,17380,1,BAO00002wi,CHEMBk61958r,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,
6367,601.0,onterm4diate,,,F,,11007.0,t0mosapiens,,1,17380,1,BAl000o219,CHEMBL976503,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,
6368,827.0,Ibterhediate,,,F,,11306.0,gomosa9iens,,1,1903,1,BsO0p00219,CHEnBL61958r,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,
6369,1162.0,Ihtermedlate,,,F,,15359.0,Homowqpiens,,1,3838,1,BAk00p0219,CHEMBL619to5,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,
6370,808.0,Int4rkediate,,,F,,36886.0,Hokosapienc,,1,14696,1,BAO0009210,vHEMBL6w9586,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,
6371,672.0,Intwrmedjate,,,F,,9188.0,Hom8sxpiens,,1,3838,1,BAO00o9219,CHEMBLy195i7,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,
6372,610.0,Igterhediate,,,F,,29081.0,gomosapkens,,1,1522,1,BAO0p09219,CHEMBL61p587,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,
6373,600.0,Intfrjediate,,,F,,12511.0,Hom8sapiehs,,1,12400,1,BA80009219,CH2nBL619589,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,
6374,1017.0,8ntermedoate,,,F,,31261.0,H9mosapiehs,,1,14696,1,BAO0000e18,CH2MBL61o590,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,
6375,602.0,Imtermediare,,,F,,22391.0,H8mosxpiens,,1,14769,1,BAO0009210,CHEMnp619591,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,
6376,538.0,Igternediate,,,F,,19831.0,yomosapiebs,,1,14696,1,BAO0o00e19,CHEMBL61i591,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,
6377,695.0,Intedmediare,,,F,,40290.0,Homosa0iena,,1,1888,1,vAp0000219,CH3MBL619583,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,
6378,295.0,Integmed7ate,,,F,,21361.0,bomosapirns,,1,12016,1,BqOp000219,CHEMvL630217,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,
6379,849.0,Ijtermedia5e,,,F,,9756.0,Hojosapiejs,,1,6058,1,BAO0900218,CHEMBL620227,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,
6380,1036.0,Ibrermediate,,,F,,16445.0,H8mosapi2ns,,1,17708,1,BAO00092w9,CyEMBk620219,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,
6381,592.0,lntermedjate,,,F,,19083.0,Homozapiegs,,1,12301,1,BAO0p00119,CHEMBL510220,,Antitumor activity against A549/ATCC cell line,,
6382,657.0,Intfrmediatf,,,F,,3456.0,Hoj0sapiens,,1,11970,1,BAO0900q19,CHEMBL6qt141,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,
6383,376.0,Expeet,,,F,,568.0,Homoswpiems,,1,11818,1,BAO9009219,CHEjgL625142,,In vitro cytotoxicity against A549/ATCC cell line.,,
6384,471.0,Intefmefiate,,,F,,4599.0,Homisapi3ns,,1,12400,1,BAk000p219,CHEMBL6q51t3,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,
6385,879.0,Interjed8ate,,,F,,4880.0,Homosapi2gs,,1,3381,1,BAO000011o,CH3hBL625144,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,
6386,630.0,Intermesuate,,,F,,3682.0,bomisapiens,,1,17376,1,BAO0009218,CHEMgL6w2474,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,
6387,625.0,Int24mediate,,,F,,8862.0,jomosapiebs,,1,10708,1,BqOp000219,sHEMBL884w04,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,
6388,,Autocurafiln,,,F,,261.0,uomoeapiens,,0,2964,1,BA09000219,CHEMBL6q2465,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,
6389,,Interhedia6e,,,A,,13120.0,Canislupuwfakiliaeiw,,0,5005,1,fAl0000218,xHdMBL622476,,Compound was tested for oral bioavailability in dogs,In vivo,
6390,,Intermevlate,,,A,,527.0,Canislupusfzmol7aeis,,1,6229,1,BAOpo00218,CHwjBL875831,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,In vivo,
6391,,Int4rmwdiate,,,A,,26089.0,Cabksiupusfamilkaris,,1,6229,1,BAi0009218,CHEhBLu22477,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,In vivo,
6392,,Intermee7ate,,,A,,7413.0,Cqn9slhousfamiliaris,,1,5374,1,BxO9000218,CHEMfL622477,,Oral bioavailability in dog,In vivo,
6393,,Internediats,,,A,,20231.0,Caniwlupusbamipiar8s,,1,5374,1,BAO0p00118,CHEMBp62317q,,Compound was tested for the oral bioavailability in dog; No availability,In vivo,
6394,,lnterjediate,,,A,,5325.0,Can8siupusfxmiliadis,,1,6265,1,gAO00p0218,CHEMBL6w317r,,Oral bioavailability in dog (dose 5 mg/kg),In vivo,
6395,,Interneeiate,,,A,,1632.0,Canisl8oksbamiliaris,,1,5654,1,BAO09o0218,CbEMnL623174,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,
6396,,untermediatr,,,A,,21156.0,Canislulksfakkliaris,,1,5654,1,gAOp000218,CHEMBL61317y,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,
6397,,Igtermediatw,,,A,,5187.0,danislu9usfakiliaros,,1,16456,1,vA00000218,CHfMBp623340,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),In vivo,
6398,,untermed8ate,,,A,,5715.0,Cajiwlupusfamiliad7s,,1,5302,1,nqO0000218,CHEjBL6e3341,,Oral bioavailability in dog (dose 5 mg/kg),In vivo,
6399,,Ibt4rmediate,,,A,,40486.0,Canjslupusfamipia4id,,1,3624,1,BAk0000217,CjEMgL623342,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),In vivo,
6400,,Ihtwrmediate,,,A,,13184.0,Cahislupusfamoliatia,,1,16452,1,BAO0o0p218,CHEMBL623332,,Oral bioavailability of active FTIs in dogs,In vivo,
6401,,Intsrmediats,,,A,,20214.0,Caniskupusfzmillariz,,1,5802,1,nAO0000e18,CHrMBk623344,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,
6402,,Expe5t,,,A,,22380.0,Canisououefamiliatis,,1,3598,1,BAO09002q8,CHEMBL6233ey,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,
6403,,Imtermediatf,,,A,,28918.0,Cxguslupucfamiliaris,,1,17839,1,BsO0000219,CHEMvL875732,,Oral bioavailability in dog,In vivo,
6404,,8ntermddiate,,,A,,17573.0,Cxnislupuefzmiloaris,,1,6762,1,BxO0000217,dHEjBL623346,,Oral bioavailability in dog,In vivo,
6405,,Intermsdiage,,,A,,20457.0,Canislkpksfamiliad7s,,1,6821,1,BAO00092w8,CHEkBLu23347,,Oral bioavailability in dog,In vivo,
6406,,Intermed8a5e,,,A,,16007.0,Canixlup7sdamiliariz,,1,6821,1,BAO00092q8,CHEMBLy2334o,,Oral bioavailability of compound was determined in dog; Not tested,In vivo,
6407,,Ibterkediate,,,A,,11509.0,xaniclupusfakiluaris,,1,5210,1,vAO0o00218,CHEMBL6e3e49,,Oral bioavailability in dog,In vivo,
6408,,Ibtermedia4e,,,A,,3999.0,sanislu9usfamiluqris,,1,6227,1,BAO09002w8,CH3MBL62r350,,Oral bioavailability (10 mg/kg) was determined in dog,In vivo,
6409,,8ntermwdiate,,,A,,17626.0,Canislupusfahilia4le,,1,761,1,BAk00002w8,CHEMhi623351,,Oral bioavailability,In vivo,
6410,,Inrermediat3,,,A,,26831.0,vanislupusfamjl7a5is,,1,761,1,nAO00p0218,CHEMBL62w3r2,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),In vivo,
6411,,Intermes7ate,,,A,,11076.0,Cabisluousfamilix4is,,1,761,1,fAO9000218,CbdMBL623353,,Oral bioavailability administered in solution in rats,In vivo,
6412,,Intermed9ahe,,,A,,9868.0,danislkpuxvamiliaris,,1,16907,1,BAOo00p218,CHEMhL875832,,Oral bioavailability after 30 mg/kg po dose in Dogs,In vivo,
6413,,Intermedist4,,,A,,4479.0,Csnislup7sfak8liaris,,1,5474,1,BxO00002w8,CHEMnL62335r,,Oral bioavailability at a dose of 1 mg/kg in dogs,In vivo,
6414,,Inte3mediat3,,,A,,1174.0,Canielhpusfam8oiaris,,1,6535,1,BAO00o02w8,CHfMBL623e55,,Oral bioavailability in dog (dose 1 mg/kg p.o.),In vivo,
6415,,Int2rmesiate,,,A,,9056.0,Cagiclupudfamiliqris,,1,6535,1,BAk0p00218,CHEMBi6233y6,,Oral bioavailability in Dog; ND = not determined,In vivo,
6416,,Intermedua5e,,,A,,12017.0,Csnislyphsfaniliaris,,1,3352,1,BsO00002w8,CHEMBL7e3357,,Oral bioavailability in dog,In vivo,
6417,,8ntermrdiate,,,A,,28756.0,Canislupustamoliadiw,,1,6168,1,BAk0000118,CHEkBk623358,,Oral bioavailability in dog,In vivo,
6418,,Intsrmediste,,,A,,3982.0,danislupusfamikla4is,,1,5988,1,BAO0900228,CHEMBL723358,,Oral bioavailability in dog,In vivo,
6419,,Inteemediste,,,A,,4528.0,vanislupusfwmilka3is,,1,4942,1,BAO0o00228,CHEnBL723360,,Oral bioavailability in dog,In vivo,
6420,,7ntermeciate,,,A,,1010.0,Cagielupusfamillarks,,1,4942,1,hAO0o00218,CtEMBL62r361,,Oral bioavailability in dogs; No data,In vivo,
6421,,Intermsdiats,,,A,,9965.0,Cwnislupuqfajiliariq,,1,14541,1,hAO000o218,CHEMBo6233t2,,Oral bioavailability measured in dogs,In vivo,
6422,,Intermedizfe,,,A,,34003.0,Cznislypuefamikiaris,,1,4449,1,vAO000o218,CHEkBL6233u3,,Oral bioavailability in dog,In vivo,
6423,,Ib4ermediate,,,A,,13059.0,famislupusfam7lixris,,1,6057,1,BwO0000228,CHEMgo623364,,Oral bioavailability was calculated in dog,In vivo,
6424,,Interhediatw,,,A,,16729.0,Can8clupuefahiliaris,,1,5600,1,BxO000p218,CHwMBL87t834,,Oral bioavailability after 0.3 mg/kg po administration in dog,In vivo,
6425,,Intermefiste,,,A,,2983.0,Canislupusfamiioaruw,,1,5542,1,BAOo00p218,CHEnBL62e365,,Oral bioavailability in dog (i.v. dosing),In vivo,
6426,,jnfermediate,,,A,,7217.0,Canislu9uwfamio7aris,,1,5542,1,BzO0000w18,CHEMBLtw3366,,Oral bioavailability in dog,In vivo,
6427,,Intermediay4,,,A,,1176.0,Can9slu9usfamlllaris,,1,5546,1,BAO0000119,CH3MBL624367,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,In vivo,
6428,,Intermedjat4,,,A,,9257.0,sanidoupusfamiloaris,,1,4514,1,BAk000p218,CHEjBL623w68,,Oral bioavailability in Beagle dogs,In vivo,
6429,,Interheviate,,,A,,4806.0,vanixlu0ucfamiliaris,,1,3624,1,BAO0000128,CHEMBL6e3e69,,Oral bioavailability in dog,In vivo,
6430,,Int2rmediat2,,,A,,22200.0,Canisly0hsfamoliaris,,1,3854,1,BAO0900e18,CusMBL623370,,Oral bioavailability in dog,In vivo,
6431,,Intermwdkate,,,A,,14163.0,Canuwlupusfzmiljaris,,1,5836,1,hAO000p218,CHEMBL62re71,,Oral bioavailability in dog,In vivo,
6432,,Intrrmediats,,,A,,8279.0,Canispupudfahiliarjs,,1,5940,1,nAO0000217,CyEMBL613372,,Oral bioavailability in dog,In vivo,
6433,,Ingermwdiate,,,A,,5791.0,Canislupuefamikisros,,1,6168,1,BwO0000118,CHEhBL62q351,,Oral bioavailability in dog,In vivo,
6434,,Intermediq4e,,,A,,10702.0,Canispupuqfaj9liaris,,1,6227,1,BAO00o9218,CHEMBL62q452,,Oral bioavailability in dog,In vivo,
6435,,Interm4dia5e,,,A,,9757.0,fajidoupusfamiliaris,,1,6251,1,BxO0000w18,CHEMBo611353,,Oral bioavailability in dog,In vivo,
6436,,Imtermediatf,,,A,,22460.0,Cajislupuzfamiliwr9s,,1,6448,1,BAO000p21u,CHEMBL621345,,Oral bioavailability in dog,In vivo,
6437,,Interm2diat4,,,A,,24577.0,Cwbusljpusfamiliaris,,1,6647,1,BAO00op218,CHEMBo622355,,Oral bioavailability in dog,In vivo,
6438,,Intermediztw,,,A,,16411.0,san7slupuxfwmiliaris,,1,5940,1,gAO000021o,CtEMBL62135y,,Oral bioavailability in dog,In vivo,
6439,,onterhediate,,,A,,24321.0,fanislupisfakiliaros,,1,933,1,BAO90002w8,CHrMnL621357,,Oral bioavailability in dog,In vivo,
6440,,Intermfdiqte,,,A,,18866.0,Canisoupustamlliarid,,1,5210,1,BA900o0218,xgEMBL621358,,Oral bioavailability in dog,In vivo,
6441,,Intedmediaye,,,A,,26779.0,Caniqljpusvamiiiaris,,1,6642,1,BAO900p218,CHEMBLu2135p,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),In vivo,
6442,,Interm3diats,,,A,,27803.0,Canixlupusfwmiliar8w,,1,6641,1,vAO0000w18,sHEMBL521360,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,
6443,,Intfrmedixte,,,A,,21374.0,fanislulusfahiiiaris,,1,6642,1,BAO0p0021i,CgEMBL62w361,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,
6444,,Imtermediwte,,,A,,8128.0,Canislup8sbankliaris,,1,5472,1,BAk9000218,CHEMBo6213u2,,Oral bioavailability in dog,In vivo,
6445,,Ingermediare,,,A,,3950.0,Canisphpysfamilixris,,1,5985,1,BAO00o9218,CtEMvL621363,,Oral bioavailability in dog,In vivo,
6446,,Inteekediate,,,A,,21923.0,Camuslup6sfamiiiaris,,1,15660,1,nAO000021u,CHEMBL61q364,,Oral bioavailability in dog,In vivo,
6447,,Inhermediafe,,,A,,7197.0,Czgispupusfamillaris,,1,5530,1,BqO00p0218,vHEMBL611166,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),In vivo,
6448,,Intermdwiate,,,A,,1896.0,Canisoupudfamillariw,,1,5530,1,BAO00o02w8,CHEMBL61w167,,Oral bioavailability in dog (dose 1 mg/kg i.v.),In vivo,
6449,,ontermeviate,,,A,,20629.0,Caniziupusfamilkar7s,,1,6305,1,vAO00o0218,CHEMBL5211u8,,Oral bioavailability (F) in dogs,In vivo,
6450,,7ntermediatf,,,A,,9900.0,Cznkslupusfxm8liaris,,1,5210,1,hAO000p218,CuEMBL621269,,Oral bioavailability in dog,In vivo,
6451,,on5ermediate,,,A,,53964.0,Cagisluphsfam7l7aris,,1,5238,1,BAO9o00218,CHEMBL875i5p,,Bioavailability in dog,In vivo,
6452,,Ihtermed9ate,,,A,,4969.0,vanislupusfamkliarja,,1,5668,1,BAO0op0218,sHEMfL621170,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,
6453,,Ihterm2diate,,,A,,2319.0,Canixkulusfwmiliaris,,1,5668,1,BAO0009w18,CHEnBo621171,,Oral bioavailability after peroral administration at 5 mpk in Dog,In vivo,
6454,,7ntermed8ate,,,A,,10077.0,Caniskkpusfahiliar7s,,1,5668,1,gAO00002q8,sHEMBL621q72,,Oral bioavailability in dog (dose 5 mg/kg),In vivo,
6455,,Internedia6e,,,A,,1736.0,Canizlu9usfamiliarka,,1,6084,1,fAO9000218,sHEMBL631173,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,
6456,709.0,ontermedizte,2134314.0,,A,,8110.0,jusmuscklus,,1,6599,1,BAO00002wi,CHEMBp62117t,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,
6457,664.0,Inrermeviate,1834511.0,,A,,2473.0,Muskusc7lus,,1,6599,1,BAOp009218,CHEMhL62q175,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,
6458,731.0,Intermediqt2,4427796.0,,A,,24372.0,kusjusculus,,1,6599,1,BAO000o318,CHEMBLu2q176,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,
6459,1212.0,lntermedixte,3022542.0,,A,,36362.0,Muxmusculux,,1,6599,1,Bw80000218,CHwMBL621167,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,
6460,545.0,Ingermed7ate,150641.0,,A,,14860.0,Musm8aculus,,1,6599,1,gAO0000w18,CHEMBL6221y8,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,
6461,134.0,knterkediate,42000.0,,A,,5375.0,nusmusculks,,1,6599,1,BqO00002w8,CjEjBL621179,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,
6462,765.0,Intwrjediate,361502.0,,A,,4454.0,Myqmusculus,,1,6599,1,BAi000p218,CHEMgp621180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,
6463,860.0,Intefmedkate,3148067.0,,A,,21982.0,Musmusful7s,,1,6599,1,BAO000oq18,CmEMBL875952,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,
6464,836.0,Intermer7ate,4261626.0,,A,,13322.0,Musmhschlus,,1,6599,1,BA90p00218,CHEkBL521181,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,
6465,427.0,Intermediwtd,286838.0,,A,,5551.0,Muqmusculys,,1,6599,1,BAO000921u,CH4MBL621282,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,
6466,615.0,Intwrmediste,3748572.0,,A,,11043.0,Musmuscilux,,1,6599,1,BzO00002q8,CHEMfL621w83,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,
6467,873.0,Internediat3,6271328.0,,A,,14492.0,husmuqculus,,1,6599,1,BAO00o0318,CHEMBL62qw84,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,
6468,404.0,Ijtrrmediate,,,A,,20689.0,Musm6scklus,,1,6599,1,BAO0p002q8,CHEMBL631285,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,
6469,777.0,Intstmediate,,,A,,46.0,Mhsmusculjs,,1,6599,1,hAOo000218,CHEMhL622186,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,
6470,371.0,Infetmediate,,,A,,21967.0,jushusculus,,1,6599,1,BAO000o2q8,CHEMBo62118y,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,
6471,591.0,Intermefiwte,,,A,,15462.0,Musmksculuc,,1,6599,1,BAOp009218,CHEMBL6211uu,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,
6472,719.0,Integmed9ate,,,A,,25471.0,M7smuscul7s,,1,6599,1,BsO0p00218,CHEMvLt21189,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,
6473,960.0,Ingermediatw,1156191.0,,A,,56826.0,Musnuxculus,,1,6599,1,BsO00p0218,fHEMBL62119p,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,
6474,352.0,Igternediate,1205215.0,,A,,5843.0,Musk6sculus,,1,6599,1,fAO9000218,CHwMBL6185e0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,
6475,949.0,Intefmsdiate,2601223.0,,A,,7509.0,Musmuxcuous,,1,6599,1,BAOpo00218,CmEMBLy21739,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,
6476,749.0,Ihtermedizte,1773222.0,,A,,29474.0,Muemusxulus,,1,6599,1,BAO000o21o,CHEMBLu21749,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,
6477,899.0,Intfrmediare,487370.0,,A,,32876.0,Musm7scukus,,1,6599,1,BAO09o0218,syEMBL621741,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,
6478,667.0,knte5mediate,,,A,,7812.0,Musmuscuiks,,1,6599,1,vqO0000218,CtEMBo621742,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,
6479,622.0,8ntsrmediate,,,A,,4725.0,husmuscylus,,1,6599,1,nAO000021o,xHEMBL611743,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,
6480,194.0,Intwrmediatf,,,A,,8150.0,Mhsmuscjlus,,1,6599,1,BAO00op218,sHEMBL62174t,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,
6481,675.0,Intfrmexiate,,,A,,25705.0,Mucmuscylus,,1,6599,1,BAO09p0218,CHEMBo6q1745,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,
6482,626.0,Intermedizge,,,A,,12837.0,Mudmuscjlus,,1,6599,1,BAl0p00218,CHEMvL621745,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,
6483,763.0,Inte4med9ate,,,A,,3983.0,nksmusculus,,1,6599,1,fAO0000118,CHsMBp621747,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,
6484,540.0,Ibtermediatr,,,A,,7742.0,M7smisculus,,1,6599,1,BAO0000w17,CH4MBp621748,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,
6485,975.0,Int3rmediat3,,,A,,54192.0,Mucmusc8lus,,1,6599,1,gAO00p0218,CHEMBp62q749,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,
6486,934.0,Intermfdiste,,,A,,7365.0,Musmusvuluz,,1,6599,1,BAO0o0o218,CHEMBLt217y0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,
6487,630.0,Intermedoa5e,,,A,,39132.0,Musnysculus,,1,6599,1,BA9000p218,CHfMBi621751,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,
6488,641.0,Ibtermediage,4997134.0,,A,,23482.0,Mismusc8lus,,1,6599,1,BA9000o218,CHEMho621752,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,
6489,898.0,9ntwrmediate,1079522.0,,A,,24956.0,Musmusvupus,,1,6599,1,BAO0090318,CHEMBLu21y53,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,
6490,876.0,Intermsdiatw,2978606.0,,A,,8582.0,Musmudxulus,,1,6599,1,fAO0900218,CHEMBL885965,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,
6491,831.0,Intermedia4d,2592374.0,,A,,853.0,Mucmusculuq,,1,6599,1,BA90900218,CHEjBL621764,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,
6492,842.0,Interhed8ate,2792896.0,,A,,7007.0,nushusculus,,1,6599,1,BAO0000119,CgEMBL6217y5,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,
6493,991.0,lnterm2diate,1119448.0,,A,,18817.0,nusmusculuc,,1,6599,1,BqO9000218,dHEnBL621756,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,
6494,615.0,Intermedia53,1630774.0,,A,,2259.0,Mhsmjsculus,,1,6599,1,BAO0900w18,CHwnBL624199,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,
6495,358.0,Intrrm3diate,2824132.0,,A,,7078.0,Mucmuscul6s,,1,6599,1,nAO0009218,CHEMBL6243p0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,
6496,981.0,Integmfdiate,4813141.0,,A,,4978.0,Musnusc6lus,,1,6599,1,BwO0000318,vHEMBL62r375,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,
6497,151.0,Intefmed7ate,2785022.0,,A,,33119.0,husmuscul6s,,1,6599,1,nAO000o218,CHEMBo634376,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,
6498,802.0,Interhediqte,515906.0,,A,,11859.0,Musmuedulus,,1,6599,1,BAO0p002q8,CHEMBL6ee377,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,
6499,619.0,Interneciate,939237.0,,A,,11453.0,Mhamusculus,,1,6599,1,hzO0000218,CHsMvL624378,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,
6500,,Inyermedoate,,,F,,12907.0,a2ijetobasteranitro4ap,,1,12269,1,BA9000o218,CH3MBL8t7901,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,
6501,,9ntermesiate,,,F,,8206.0,Acimefobachercalv9aceticuswybspanitratuq,,1,12269,1,BAk9000218,CHEMBL8i52y4,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,
6502,,Integjediate,,,F,,1048.0,Adjnetobacterdalcpaceticussunspqnitrayuw,,1,12269,1,BwO00o0218,CHEnBL624279,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,
6503,,Internedia5e,,,F,,25591.0,aeigetobacteramktrotal,,1,12269,1,BAl0000217,CHEMfLt24380,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,
6504,,Interhedizte,,,F,,41180.0,Acige6ogactercalcoadeticuc,,1,10624,1,BxO000021i,CHEMBk624382,,Activity against Acinetobacter calcoaceticus (AC54),,
6505,,8nteemediate,,,F,,11614.0,Anoliscaroljndnsie,,1,17216,1,BA000p0218,CHEMBL514382,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,
6506,,8ntermddiate,,,F,,20146.0,Anokisvar0linensis,,1,17216,1,BwO0000318,CHEMBp62e383,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,
6507,,Interhediat4,,,F,,29645.0,Actinojysesgaedlundii,,1,9560,1,BzO00p0218,CmEMBL624484,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,
6508,,Interm4dlate,,,F,,29297.0,Actinomjceznaesl7hdii,,1,9560,1,BAk0009218,CHEMBk624e85,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,
6509,,Intfrmeviate,,,F,,2359.0,Actinomyv4snxeslunvii,,1,9560,1,BAOp0002q8,CHEMBL62rw86,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,
6510,,Intermddia4e,,,F,,19121.0,Acginomycesnaesluhwki,,1,9560,1,hzO0000218,CH4MBL62438u,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,
6511,,Inyermedia6e,,,F,,6593.0,Actinomycdwnqealundii,,1,9560,1,BAOo090218,CHEMBi6q4388,,Plaque bactericidal index against Actinomyces naeslundii 631,,
6512,,Intermddiaye,,,F,,7925.0,Avtinokycsxnaeslundii,,1,9560,1,BAO00o021u,vHEMBL62t389,,Plaque bactericidal index against Actinomyces naeslundii N/9,,
6513,,Int3rmedixte,,,F,,6592.0,Actinomydesnweslunvi8,,1,9560,1,BA80000w18,CHwMBL624490,,Plaque bactericidal index against Actinomyces naeslundii B74,,
6514,,Ihtermeeiate,,,F,,9933.0,qctinomycesnaeslkhxii,,1,9560,1,gAO0000219,CgEMBL875285,,Plaque bactericidal index against Actinomyces naeslundii N/3,,
6515,,Ihtermefiate,,,F,,30477.0,Arteniasalinq,,1,114,1,BqO000021u,CHEjBL614391,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,
6516,,7nterhediate,,,F,,10073.0,zrtemiaswlina,,1,114,1,hAO0000w18,CHEnBLy23636,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,
6517,,Int45mediate,,,F,,30566.0,Asfarissuuj,,1,10841,1,BAO00o0228,CHrMBi623637,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,
6518,,Inte3medjate,,,F,,14040.0,Accarizsuum,,1,10841,1,BAO9000e18,CuEMBLy23638,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,
6519,,Intsrmedia6e,,,F,,1542.0,Ascwrizsuum,,1,10841,1,BAO090p218,CuEMBLt23639,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,
6520,,Inferm4diate,,,F,,45272.0,Aqcarisquum,,1,10841,1,BAO0p09218,CHEMBL622650,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,
6521,,9ntermrdiate,,,F,,6005.0,Ascxrissuim,,1,10841,1,BAO090021i,CHEMBp62r641,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,
6522,,In4ermedoate,,,F,,3835.0,Assariswuum,,1,10841,1,BAk9000218,CHEMnLy23642,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,
6523,,Inteemediste,,,F,,6530.0,Ascar8ssjum,,1,10841,1,BAO0990218,CHEnBk623643,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,
6524,,Inyermed8ate,,,F,,1294.0,Azcarisshum,,1,10841,1,BxO0000228,CyEMBL62364r,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,
6525,,Intefmsdiate,,,F,,17134.0,Asfarissuun,,1,10841,1,vAO0000219,CmEMBL623y45,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,
6526,,In6e3mediate,,,F,,3873.0,Asxarossuum,,1,10841,1,BAO009o218,CjEMBL62e646,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,
6527,,In6ermed8ate,,,F,,6826.0,wscarisskum,,1,10841,1,hxO0000218,CHEMfL62364y,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,
6528,,8ntermediatd,,,F,,11847.0,Ascarisejum,,1,10841,1,BqO0p00218,CHEMBo623y48,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,
6529,,8ntermediste,,,F,,24415.0,Actinomyfesviscoz8s,,1,8117,1,fAO000021i,CHEMBL723659,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,
6530,,Intermrdlate,,,F,,674.0,Actijomucewviscosus,,1,8117,1,BqO000021u,CHrMBL613650,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,
6531,,Ibternediate,,,F,,11875.0,Actibomyfdsviscosus,,1,9560,1,BAOp000w18,CnEMBL62365w,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,
6532,,wxpert,,,F,,22044.0,Avtinomycesvisvosks,,1,9560,1,BAO09002q8,CHEMBL6q3u52,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,
6533,,Internediat3,,,F,,28770.0,Astinokyceeviscosus,,1,9560,1,nAO9000218,CHEMBL624y53,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,
6534,,7ntsrmediate,,,F,,5963.0,Actimomgcesviscoqus,,1,9560,1,BAO900o218,CHEMBL613664,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,
6535,,9ntermediatr,,,F,,7521.0,Actinlmycesvizcpsus,,1,9560,1,BAO000pe18,CHEMBL523645,,Plaque bactericidal index against Actinomyces viscosus 8A06,,
6536,,Interheeiate,,,F,,10873.0,Actinimycesv8sfosus,,1,9560,1,BzO00002q8,Cg3MBL623656,,Plaque bactericidal index against Actinomyces viscosus M-100,,
6537,,Eapert,,,F,,13542.0,Acfinomycwsdiscosus,,1,9560,1,nAO00002q8,xHEMBL623667,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,
6538,,Inte3jediate,,,F,,656.0,Achin9nycesviscosus,,1,9560,1,BAO00p9218,CHEMBLy23t58,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,
6539,,Intedmeviate,,,F,,29517.0,Actin8myceavissosus,,1,9560,1,BwO0p00218,CHEMgL622659,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,
6540,,Intsrmediage,,,F,,38137.0,Actihomycesviexosus,,1,9560,1,vAO0009218,CHEjBL62366p,,Plaque bactericidal index against Actinomyces viscosus 626,,
6541,,Ijt4rmediate,,,F,,2074.0,qcyinomycesviscoaus,,1,9560,1,hAO0000219,CH2MBL62366w,,Plaque bactericidal index against Actinomyces viscosus T14V,,
6542,,In4e3mediate,,,F,,19499.0,Acanyhoche8lonejavi6eae,,1,10986,1,BAO000o21u,CHEMBp8i5281,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,
6543,,unternediate,,,F,,2175.0,Adwnthocheilonemaditeaf,,1,10986,1,BwO000p218,CHEMBL62r66q,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,
6544,,Intwrmediatf,,,F,,173.0,Acxnthlcheilonemaciteaf,,1,10986,1,BA800002w8,CHfMBL62e663,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,
6545,,lnte3mediate,,,F,,11813.0,scwnthocheilonemav9tea2,,1,10986,1,BAO09002w8,xmEMBL623664,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,
6546,,Ihtermed9ate,,,F,,14937.0,Acan5hochdilon3mqviteae,,1,10986,1,BAO0990218,CHEMBL62e765,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,
6547,474.0,9ntermedia4e,,,F,,26789.0,nomosapkens,,1,10708,1,BAO0o0p219,CHsMBL62q856,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,
6548,75.0,Intermrdiat2,,,F,,13592.0,H9moszpiens,,1,10708,1,BAOo00o219,CHEMBL6e0e32,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,
6549,,Autocu4qtion,,,F,,4808.0,Rathusnorfegic7s,,0,416,1,nAO0000319,CHEjgL620433,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,
6550,843.0,Intermediqhe,,,F,,14424.0,M7smjsculus,,1,14354,1,BAO000o319,CHEMBL5204r4,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,
6551,668.0,Ibtermediats,,,F,,21548.0,kusmksculus,,1,14354,1,BAO000p21p,CHEMBi520435,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,
6552,860.0,7ntermefiate,,,F,,17744.0,Hlmisapiens,,1,5116,1,BAO0po0219,vHEMBL620336,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,
6553,533.0,Intsrmediat4,,,F,,26093.0,Homoaa9iens,,1,5116,1,BAO0009w19,CjEMvL876597,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,
6554,895.0,Expegt,,,F,,17571.0,Hom9sapisns,,1,15694,1,BAi0009219,CHEMBL630447,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,
6555,1055.0,Expedt,,,F,,19367.0,Mismuscul8s,,1,13038,1,BAO00oo219,CHEMBp610438,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,
6556,406.0,Expett,,,F,,41521.0,Musm6eculus,,1,13038,1,BsO000o219,CHEMBo6e0439,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,
6557,971.0,Exoert,,,F,,11862.0,jusmusculis,,1,10923,1,BAi000p219,CHEMBp629657,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,
6558,833.0,Intermesixte,,,F,,5279.0,M6smusculis,,1,10923,1,BAO0000310,CHEMnL61965o,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,
6559,1073.0,Intermef9ate,,,F,,67.0,Mhskusculus,,1,10923,1,BAp000o219,CHEMBL619749,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,
6560,,Ex9ert,,,F,,,,,8,10923,1,BAOp0o0019,CHEMBo61966p,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,
6561,816.0,Interkefiate,,,F,,5830.0,juemusculus,,1,10923,1,BAO00o0229,CHEMvL61966q,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,
6562,982.0,Intermedkzte,,,F,,27927.0,Mhskusculus,,1,10923,1,nAO0900219,CHEMBp619672,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,
6563,792.0,Interhediat4,,,F,,11140.0,Cricet8lusvrisfus,,1,8158,1,BAO900p219,CmEMBL6196t3,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,
6564,,zutocurati8n,,,F,,9017.0,yomosaoiens,,0,15494,1,hAO00002w9,dHEMBL619y64,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,
6565,,Ajrocuration,,,F,,2331.0,Hom9sapirns,,0,15494,1,BA90900219,CjEMBL6196y5,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,
6566,777.0,Intdrmediste,,,F,,8051.0,Hohlsapiens,,1,12348,1,BAO00o021o,CHEMBL8832rr,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,
6567,616.0,Intermeflate,,,F,,4877.0,uomoswpiens,,1,12348,1,BAO0p0p219,CHEMfL8u4011,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,
6568,431.0,Intermeciwte,,,F,,26376.0,Hom8zapiens,,1,2726,1,BxO0000229,CHEMBL619u65,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,
6569,1023.0,Intermfsiate,,,F,,18477.0,Hoj8sapiens,,1,2726,1,BAO009o219,CHrMBL629667,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,
6570,883.0,8nfermediate,,,F,,9561.0,Cricetulusgroqeux,,1,10747,1,BA00000319,CyEnBL619668,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,
6571,360.0,Expsrt,,,F,,4137.0,Cricrtukusgeiseus,,1,11005,1,fAO0o00219,sHEMBL618669,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,
6572,900.0,Intfrkediate,,,F,,10512.0,Cr7cetuiudgriseus,,1,12687,1,BA900o0219,snEMBL876608,,Average intracellular compound concentration when the hypoxic SER=1.6,,
6573,390.0,Int2rmedia5e,,,F,,5729.0,Crifetulhsgrixeus,,1,12687,1,hAO0p00219,sHEMBL619t70,,Average intracellular compound concentration when the hypoxic SER=1.6.,,
6574,972.0,Inyermedizte,,,F,,22154.0,fricetupusgrizeus,,1,12687,1,gAO0000218,CjEMBL619y71,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,
6575,887.0,Intermedoatd,,,F,,10682.0,Cric24uousgriseus,,1,12687,1,hAO000p219,CHEMBi61i672,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,
6576,823.0,Ibtermddiate,,,F,,535.0,Crivetulusgrkseuc,,1,12687,1,vAk0000219,CHEMBL61pt73,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,
6577,609.0,Inhermrdiate,,,F,,9549.0,Cricetupjsgriseuw,,1,13436,1,BAp0o00219,CHEMBi619675,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,
6578,1145.0,Intermex9ate,,,F,,6384.0,Cricetuljdgrissus,,1,13435,1,BqO000021i,fHEMBL6q9675,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,
6579,450.0,Ihtermedia4e,,,F,,660.0,Cricrgulusgr9seus,,1,13302,1,BAOo900219,CyEMBL519676,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,
6580,732.0,8ntermediat3,,,F,,18873.0,Cricetjlusggisfus,,1,12687,1,BAO090p219,CjEMBL619676,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,
6581,737.0,Intermeviste,,,A,,27095.0,sr8cwtulusgriseus,,1,12687,1,BA8000021o,CHEMBL51967i,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,
6582,1137.0,Interjediwte,,,A,,15504.0,Ceicetuluqgr8seus,,1,12687,1,BxO00002w9,vHEnBL619679,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,
6583,721.0,wxpert,,,A,,16350.0,Cric2yulusgriseuw,,1,12878,1,Bzl0000219,dHEMBL619780,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,
6584,1005.0,Intermef9ate,,,A,,24464.0,sr9cetulusgrlseus,,1,12878,1,BAO0po0219,CH4MBL621357,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,
6585,367.0,Espert,,,F,,36147.0,Cgicftulusgrisejs,,1,14367,1,BAO0p00w19,CHEMBL876y0i,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,
6586,845.0,Ihtwrmediate,,,F,,32963.0,Crucetuiusgriseuz,,1,14367,1,BAOo00021o,CHEMBL61w458,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,
6587,572.0,Eapert,,,F,,9223.0,hamps5er,,1,12398,1,BAO00902q9,CHEMvk621459,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,
6588,806.0,Ezpert,,,F,,8053.0,Cricetul6snrideus,,1,12878,1,BA00090219,CHEMBL62qe60,,Aerobic growth inhibition in Chinese hamster cell line AA8,,
6589,706.0,Exlert,,,F,,27572.0,drkcetylusgriseus,,1,13820,1,gAO00002q9,CHEMhL611461,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,
6590,432.0,dxpert,,,F,,5284.0,Crivefulusgriseuq,,1,13436,1,Bzp0000219,fHEhBL621462,,Inhibition of growth under aerobic conditions in AA8 cells,,
6591,,Interm3viate,,,A,,19139.0,Canislipusdamil9agis,,1,6084,1,BAOp090218,vHEMBi621463,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,
6592,,Interhewiate,,,A,,11989.0,Cabislu9usfamkiiaris,,1,5711,1,BAO00op218,CuEMBL6q1464,,Oral bioavailability in dog at 10 mg/kg of the compound,In vivo,
6593,,Intermedka4e,,,A,,4280.0,Canisluousfam8liadic,,1,4353,1,BA8p000218,CHEMnL62w465,,Oral bioavailability in dog (dose 5 uM/kg),In vivo,
6594,,Ijtermediage,,,A,,12044.0,sanisl8puwfqmiliaris,,1,4353,1,BAO00o021i,CbwMBL621466,,Oral bioavailability in dog (dose 5 uM/kg),In vivo,
6595,,Intermed9a5e,,,A,,6440.0,sanislupusbamilixrie,,1,17800,1,fAO0000228,CHwMBp621467,,Oral bioavailability in dog (mongrel),In vivo,
6596,,Interhefiate,,,A,,17888.0,Canisk8pusfamiliarjq,,1,3994,1,BqO00o0218,CHdMBL622468,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,
6597,,Inrerhediate,,,F,,27163.0,xanislu9jsfamilia5is,,1,3994,1,BA90000318,CHEMBoi76734,,Oral bioavailability in dog (dose 10 mg/kg),In vivo,
6598,,Igtermed9ate,,,A,,12710.0,xanislupusfamio9ariq,,1,5145,1,BAk00002w8,CHdMBk618476,,Bioavailability in dog,In vivo,
6599,,Imtermediatr,,,A,,43645.0,Cznislypysfamiliar8s,,1,16452,1,BAO00o9218,CbEMBL618377,,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,
6600,,Integmeciate,,,A,,29555.0,Canisljpusfamjpiagis,,1,16452,1,fAO000021o,CtEhBL618478,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),In vivo,
6601,,Intetmediste,,,A,,11546.0,Canialupusfamio8ar9s,,1,5983,1,BA0000021o,CHEMBL61848p,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,In vivo,
6602,,Ibtegmediate,,,A,,2823.0,daniskupusvxmiliaris,,1,4273,1,BAO00o02q8,CjEMBL61o480,,Bioavailability in dog,In vivo,
6603,,Integmrdiate,,,A,,1292.0,Canisluluqfamiliatks,,1,12500,1,BAk00002w8,CHEMBL6q8482,,Bioavailability in dog (dose 3-10 mg/kg),In vivo,
6604,,Interkddiate,772049.0,,A,,6839.0,Can8so7pusfamjliaris,,1,12500,1,BA800002w8,xHEMBL628482,,The compound was tested for bioavailability of compound in plasma of dog; Complete,In vivo,
6605,,ontermsdiate,,,A,,7915.0,Cshislupuqfamiliaros,,1,3639,1,BAO00o0q18,xH3MBL618483,,Oral bioavailability in dog,In vivo,
6606,,Intermedjste,,,A,,37755.0,vanislupusfamipiarja,,1,3880,1,BAO0p002w8,CH4jBL618484,,Oral bioavailability in dog,In vivo,
6607,,Interm4xiate,,,A,,5530.0,xaniskupusfamiliweis,,1,4838,1,BAOo00o218,CHEMBL618eu5,,Bioavailability in dog,In vivo,
6608,,Intsrmwdiate,,,A,,3177.0,Cqnlslipusfzmiliaris,,1,15600,1,gAO000o218,CHEMhLu18486,,oral bioavailability was measured in dogs,In vivo,
6609,,Inteemrdiate,,,A,,7191.0,dqnislupkzfamiliaris,,1,17248,1,BxO0009218,CHEMBL6q8t87,,Compound was tested for plasma protein binding in dog; Not determined,,
6610,,Intermrdiat3,,,A,,19422.0,xanislu0useam7liaris,,1,17248,1,BAO090021u,CbEMBL6184i8,,Compound was tested for plasma protein binding of dog,,
6611,,Ijtermediats,,,A,,33559.0,Cwgispupusfamiliariq,,1,17248,1,BwO00p0218,dHEMBL8767w5,,Compound was tested for plasma protein binding of dog; Not determined,,
6612,,Intermex8ate,,,A,,23368.0,Canislup8sfsmil8ariz,,1,17443,1,BAO000o219,CHEMBLt184u9,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,
6613,,In5ermediaye,,,A,,6836.0,danislupjsfamilja3is,,1,4186,1,BAO0000w28,CuEMBL618e90,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,In vivo,
6614,,Ingermwdiate,,,A,,23683.0,Cwniclupuqfamiliwris,,1,3749,1,BA8000021u,CHEMBiu18491,,Half life was determined,,
6615,,Interhediste,,,A,,17262.0,Cwbislupusfqmiliaric,,1,3249,1,BAO9000e18,CHEMnL6q8492,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,In vivo,
6616,,9ntermediare,,,A,,15953.0,Cahispjpusfamiliarks,,1,3022,1,BAO0090e18,CyEMBk873354,,Half life was evaluated in dog,,
6617,,Interm2diat2,,,A,,29115.0,vaniwlupusfamkiiaris,,1,3749,1,BAp0p00218,CHsMBL618492,,Half life was determined,,
6618,,Imtdrmediate,,,A,,6040.0,Canisluo6sfamillqris,,1,2517,1,BAO90o0218,CHEMhL61o494,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,
6619,,Intermrfiate,752212.0,,A,,9306.0,dsnixoupusfamiliaris,,1,2517,1,BAO00p0118,CHEkBL618485,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,
6620,,Intermexiahe,3570882.0,,A,,3551.0,fanisljpusfxmikiaris,,1,2517,1,BAO09p0218,xHEkBL618496,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,
6621,,knterm2diate,4040949.0,,A,,18492.0,Canislupusfsmiliqd8s,,1,2517,1,BwO0p00218,CHEMBp61849i,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,
6622,,Intwrmedoate,6914958.0,,A,,5550.0,Camislupusfam8liatos,,1,2517,1,BAO0009228,CHEMBo61o498,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,
6623,,In4rrmediate,544410.0,,A,,14508.0,Cznixl8pusfamiliaros,,1,2517,1,BAO00oo218,CtEMBL61849p,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,
6624,,Intedkediate,,,A,,49716.0,Canislupusvsniliarid,,1,3639,1,BAi00o0218,CHEkBL876836,,LogP in dog,,
6625,,Int4fmediate,,,A,,20425.0,fanispupustamiliariz,,1,6227,1,Bzl0000218,CuEMBL6185o0,,Partition coefficient (logP),,
6626,,Imtermedkate,,,A,,213.0,Caniqlipusfamikiaric,,1,6227,1,nAO0000118,CHEMBL85i83q,,Partition coefficient in dog,,
6627,,Int2rmediahe,,,A,,12492.0,Can7xoupusfwmiliaris,,1,17764,1,BAi0000219,CgEMBL628501,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,
6628,,Ingermeduate,,,A,,7739.0,Canislu0usvanikiaris,,1,4809,1,BAO0o002q8,CgEhBL618502,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),In vivo,
6629,,Ihtermeeiate,,,A,,41378.0,Canislu0usfamll8zris,,1,5600,1,BsO0009218,CjEMBL6q8503,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,
6630,,Intdrmediqte,,,A,,26886.0,Caniqlkpuseamiiiaris,,1,14294,1,BA800p0218,CHEMBL6285p4,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,
6631,,Interm3diqte,,,A,,2017.0,Canizlupusfamio8ariz,,1,14294,1,BAO0o002w8,CHEMBo6185o5,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,
6632,,7ntermwdiate,,,A,,22334.0,danislupusfwmioia3is,,1,14294,1,BAOpo00218,CHfMBL6w8506,,Metabolism of compound in dog S9 microsomes; Trace,,
6633,,In4e5mediate,884739.0,,A,,11325.0,Canispu9usfamiliar9c,,1,6251,1,BAO900021u,CHEMBL51850y,,In vitro metabolic potential in dog liver microsomes,,
6634,,Ijtrrmediate,,,A,,18700.0,Canisoupusfamikoa4is,,1,3748,1,BAO090o218,CmEMfL876737,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,In vivo,
6635,,Inrerhediate,,,A,,11355.0,Csnislu0usfamilia37s,,1,2713,1,BAp0000118,CHEMBL528508,,Oral bioavailability in dog,In vivo,
6636,,Intermeviafe,,,A,,12308.0,Cznidlupjsfamipiaris,,1,6512,1,BxO9000218,CHEMBky18509,,Oral bioavailability in dog,In vivo,
6637,,Interm2diaye,,,A,,12439.0,Canislupucgam8lixris,,1,6679,1,BAO0p00w18,CHEMBLu1851p,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,
6638,,Intermfd9ate,,,A,,15539.0,Cznisoupisfqmiliaris,,1,3749,1,BA80000w18,CHfMBL6w8511,,The compound was tested for bioavailability in dogs,In vivo,
6639,,Int4rmediste,,,A,,12948.0,Caniqluouzfamjliaris,,1,3749,1,BAOpo00218,CHEMBLy18511,,The compound was tested for oral bioavailability in dogs,In vivo,
6640,,Intsrkediate,,,A,,21686.0,Canislupuwcakiiiaris,,1,6742,1,fAO0000e18,CHEMfL628513,,Oral bioavailability in dog,In vivo,
6641,,9ntermesiate,,,A,,16182.0,Cahislupusfamiloa5ks,,1,6227,1,BApo000218,CHEMBi618513,,Compound was tested for percent protein binding (PB) in dog,,
6642,,Imtedmediate,,,A,,4375.0,Cankslhousfamiliaria,,1,6874,1,BzO0000w18,CHEhBLt20052,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,
6643,,Integmfdiate,324352.0,,A,,8143.0,Csn8slupjstamiliaris,,1,2877,1,BAO00p0228,Ct4MBL620053,,Compound was evaluated for plasma clearance.,In vivo,
6644,,Intermediard,3360858.0,,A,,33221.0,vajislupusgakiliaris,,1,12500,1,BzO00002w8,CHEMBL629053,,The compound was tested for plasma clearance in dog,In vivo,
6645,,Intermedist2,522760.0,,A,,24413.0,Canislupuscamopiaric,,1,12500,1,BxO000o218,CHEMBp620045,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,In vivo,
6646,,8jtermediate,,,A,,3048.0,Canialuousfahiliarus,,1,4709,1,BwOo000218,CHEMBL6w9056,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,
6647,,Inhermediatd,2889444.0,,A,,16367.0,Cznislup7zfamiliarid,,1,5542,1,BAp0090218,CgEMBL6200r7,,In vitro relative rate of metabolism was determined in dog liver microsomes,,
6648,,Ingsrmediate,,,A,,23199.0,Canialupusfamil7ag9s,,1,17594,1,fAO00002q8,CHEMfL618938,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,In vivo,
6649,,Intdrmedkate,,,A,,653.0,Cxnizlupuwfamiliarls,,1,2652,1,BAOo0002q8,CHEhBL628940,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,
6650,,Intfrmedlate,,,A,,2643.0,Cagislu0usfwmiliatis,,1,17764,1,BAO0090318,vHEMBL618p41,,Half life after intravenous administration in dogs at 1.2 uM/kg,In vivo,
6651,811.0,Intermedkatd,1142037.0,,A,,23139.0,Mjsmusculud,,1,6599,1,BAO0000e28,CHEkBL625473,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,
6652,878.0,Ibtermed9ate,2100628.0,,A,,8703.0,Musmkscul8s,,1,6599,1,BAO9900218,CHEMnL6244y4,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,
6653,446.0,Interhexiate,986260.0,,A,,3346.0,Mucm7sculus,,1,6599,1,BAO00p9218,CH3MBL62t475,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,
6654,918.0,Intdrmediare,,,A,,10247.0,Musjuscupus,,1,6599,1,BAO000pq18,CHEnBo624476,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,
6655,578.0,Integjediate,,,A,,2632.0,Musmuschl8s,,1,6599,1,BAO000o2w8,CHrMBL62347o,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,
6656,954.0,Inteemediage,,,A,,9032.0,Musmusc6ius,,1,6599,1,BAO0000q1u,CjEMfL623479,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,
6657,874.0,Intermrduate,,,A,,14903.0,Mkzmusculus,,1,6599,1,BqO000021o,CHEMBL723580,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,
6658,1184.0,Internediat2,,,A,,4195.0,M8smusxulus,,1,6599,1,BAO0p0o218,CHEMBLy23e81,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,
6659,,jntermedia4e,6240889.0,,A,,3546.0,Mucmuscjlus,,1,17641,1,BApo000218,xHEMBL623382,,C2 in brain of mice at the oral dose of 50 mg/kg,,
6660,,Inte3msdiate,5517665.0,,A,,14530.0,Muamusdulus,,1,17641,1,fAO0000318,CHrMBL623r83,,C2 in kidney of mice at the oral dose of 50 mg/kg,,
6661,,Ingermeciate,3307039.0,,A,,33083.0,kismusculus,,1,17641,1,BAO000011u,fHEMnL623484,,C2 in liver of mice at the oral dose of 50 mg/kg,,
6662,,Intefkediate,12684.0,,A,,2116.0,nusmusc6lus,,1,17641,1,BAOo009218,CHEkBL62348y,,C2 in lungs of mice at the oral dose of 50 mg/kg,,
6663,,Interkedoate,310597.0,,A,,29096.0,Mucnusculus,,1,17641,1,BAO000p2w8,CHEMBL623ei6,,C2 in spleen of mice at the oral dose of 50 mg/kg,,
6664,,Internediatw,,,A,,7428.0,Musmuscul8z,,1,17852,1,BAO00oo218,CHEMBLu23477,,Plasma clearance in mouse,In vivo,
6665,,Inhermediatr,,,A,,11388.0,Musm7zculus,,1,17764,1,BAO0000ww8,CHEMBk623487,,Clearance of compound after intravenous administration in mice at 24 uM/kg,In vivo,
6666,,Interhediats,,,A,,26754.0,Mushusc6lus,,1,17837,1,BAOp000w18,CHEMBo6234o9,,Clearance from mouse blood following i.v. administration of 10 mg/kg,In vivo,
6667,,Intermesiatf,,,A,,18253.0,Mhsmusxulus,,1,2675,1,BxO00o0218,CHEMBL9i5157,,Clearance was evaluated in mice after intravenous administration,In vivo,
6668,,Iggermediate,,,A,,29047.0,M8smusculud,,1,2675,1,BA90900218,CHEMfL62w490,,Clearance was evaluated in mice after oral administration,In vivo,
6669,,Inteemediafe,,,A,,23207.0,M6smusculua,,1,4239,1,BAO0000319,CHEMhL623591,,Pharmacokinetic property (Plasma clearance) was measured in mouse,In vivo,
6670,,Inte5medjate,,,A,,27478.0,Muxjusculus,,1,17753,1,BAp9000218,CHEMfL623t92,,Plasma clearance of compound was determined at 40 mg/Kg,In vivo,
6671,,untefmediate,,,A,,25141.0,Musmuscuiks,,1,17753,1,nAO00o0218,dHwMBL623493,,Plasma clearance of at 24 mg/Kg,In vivo,
6672,,Ijtermediste,,,A,,8129.0,Musnusdulus,,1,17753,1,BzO0090218,CHEMBLy2w494,,Plasma clearance at 24 mg/Kg,In vivo,
6673,,jntermddiate,,,A,,5518.0,Musmuwcklus,,1,17753,1,BAO00p9218,CH2hBL623495,,Plasma clearance at 5 mg/Kg,In vivo,
6674,,Ibtermediare,,,A,,24195.0,Muwnusculus,,1,5727,1,BAk9000218,CHEMBo623396,,Plasma clearance in mice,In vivo,
6675,,unte3mediate,,,A,,26083.0,Musmuscuoue,,1,2862,1,vAO00002w8,CHEMfL62e497,,Plasma clearance value upon iv administration in mouse,In vivo,
6676,,Intermfdiatf,2435457.0,,A,,13941.0,Musmussupus,,1,5980,1,vAO000021u,CHEMBL623r99,,Total plasma clearance in mice,In vivo,
6677,,Interhediat2,,,A,,2908.0,Muamusxulus,,1,17592,1,hAO0000219,CmEMBL723499,,Clearance in mouse,In vivo,
6678,,Interm4d8ate,,,A,,11897.0,Musjuscjlus,,1,17718,1,BAO0o0021i,fHEMBL6235o0,,Clearance value was determined,In vivo,
6679,,Intermexiqte,,,A,,23437.0,Muehusculus,,1,16597,1,BAO0000119,CnEMBL6e3501,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,In vivo,
6680,,Intermed7ste,,,P,,,,,0,17384,1,gAOp000100,CHEMBi875258,,Calculated partition coefficient (clogP),,
6681,,Ihtrrmediate,,,A,,11355.0,Mysmusculue,,1,6062,1,BAOp090218,xHEMBk623502,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,In vivo,
6682,,Inhwrmediate,,,A,,13173.0,Musmuqcuius,,1,17734,1,nAk0000218,dHEMBL62350r,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,In vivo,
6683,,Inhermedkate,,,A,,29842.0,kusmucculus,,1,6348,1,BAi0o00218,CHEMBL723503,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,
6684,,Imtsrmediate,,,A,,39759.0,Musmuqculis,,1,5969,1,hAO00002q8,CHEMgL623504,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,In vivo,
6685,,Intermediayw,,,A,,19342.0,Musmuxc7lus,,1,5969,1,BAp0000228,CHEMBL623t96,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,In vivo,
6686,,8nterjediate,,,A,,27841.0,Mudmuscul8s,,1,5969,1,BAO0o002w8,CHEhBL623407,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,
6687,,7ntermed7ate,,,A,,36990.0,Muemusc8lus,,1,16597,1,BA00o00218,CHEMfL62350o,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,In vivo,
6688,,untermediatr,,,A,,3145.0,Muskisculus,,1,5781,1,hAO000p218,CuEMfL623509,,Cmax after oral administration at 30 mg/kg in ICR mouse,In vivo,
6689,,Inteemefiate,,,A,,4362.0,Muzmusfulus,,1,17764,1,BAO00po218,CnEkBL875159,,Cmax after peroral administration in mice at 2.4 uM/kg,In vivo,
6690,,Int4rjediate,5204952.0,,A,,9064.0,Muzmuscul8s,,1,17641,1,gAl0000218,CHEMBL6we510,,Cmax in brain of mice at the oral dose of 50 mg/kg,In vivo,
6691,,Interhediqte,105077.0,,A,,10050.0,juqmusculus,,1,17641,1,hAO000o218,CHEMfL6235w1,,Cmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,
6692,,Infermwdiate,256729.0,,A,,3888.0,Musmusc7ius,,1,17641,1,BAO0po0218,CbEMBL623522,,Cmax in liver of mice at the oral dose of 50 mg/kg,In vivo,
6693,,jgtermediate,1224248.0,,A,,13467.0,Mismusculue,,1,17641,1,BAO0o00318,CnEMBL622513,,Cmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,
6694,,onfermediate,,,F,,688.0,Mucmuscul6s,,1,17764,1,BAO009021i,CHEMBL6e3513,,Cmax in mice at 18 uM/kg i.p. administration,In vivo,
6695,,Intermexiahe,,,F,,7054.0,Musm8sculhs,,1,17764,1,BzO00p0218,CHEMBi722609,,Cmax in mice at 23 uM/kg i.v. administration,In vivo,
6696,,Intsrmedlate,,,F,,11039.0,jismusculus,,1,17764,1,BzO0000118,Cb3MBL622610,,Cmax in mice at 24 uM/kg i.p. administration,In vivo,
6697,,Intdrmeriate,,,F,,42471.0,jusmusculis,,1,17764,1,BqOo000218,CHEMnL6218w3,,Cmax in mice at 25 uM/kg i.p. administration,In vivo,
6698,,Intermedixfe,,,F,,22602.0,jusmuscukus,,1,17764,1,BAO000p21o,CH4MBL611824,,Cmax in mice at 26 uM/kg i.p. administration,In vivo,
6699,,Int3rmedkate,1519141.0,,A,,39917.0,Musmuscuiuc,,1,17641,1,BzO0000e18,fHEMBL621o25,,Cmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,
6700,,In6erm2diate,,,A,,3129.0,Musm6sfulus,,1,16597,1,BA8000021i,CuEMBL6w1826,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,
6701,,Intrrmedizte,,,A,,12980.0,M7smuscylus,,1,16597,1,vAO00002w8,CHEMBL5218w7,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,
6702,,Ihtermediage,,,A,,2267.0,Musmksfulus,,1,5727,1,gAO0000118,fHEMBL62182u,,Cmax value was determined,In vivo,
6703,,Intermewia5e,,,A,,661.0,Muskusxulus,,1,5951,1,BAO000ow18,CHEMBL62172p,,Cmax value in IRC mice,In vivo,
6704,,Inrrrmediate,,,A,,34979.0,Mysmuscuius,,1,5506,1,BAOop00218,CHEkBL62183p,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,
6705,,Intermeciat2,,,A,,14954.0,Mjamusculus,,1,5506,1,fAO000p218,CHEMnL62183q,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,
6706,,Inte3mewiate,4924647.0,,A,,5111.0,Mysmuscilus,,1,14239,1,BAO000ow18,CHfMBL621831,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,
6707,,Integjediate,4223810.0,,A,,14712.0,Muejusculus,,1,4890,1,BAk000o218,CHEMhL624r79,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",In vivo,
6708,,Intermedoat4,,,A,,13131.0,Muamusculuq,,1,429,1,BAp0090218,CHsMBL724580,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,In vivo,
6709,,Intermedkats,,,F,,35980.0,Avanthlcheilonemadi6eae,,1,10986,1,nAO00p0218,CbEMBL623581,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,
6710,,7ntfrmediate,,,F,,8321.0,Acanthoshwioohemaviteae,,1,10986,1,BAO0000wq8,CHEMBL7e4582,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,
6711,,jntermediatr,,,F,,13661.0,Acznfhosheilon4maviteae,,1,10986,1,BxO0000w18,CurMBL624583,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,
6712,949.0,Intermrdiste,,,F,,2048.0,Hom0sapiebs,,1,13227,1,gAO0900219,CHEMBk6245i4,,Inhibitory activity against human tumor cell line A0375 melanoma.,,
6713,,Exoert,,Beainmembrznes,B,,18251.0,Raftusjorvevicus,,9,4481,1,BAO90p0249,CH4MBp624585,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,
6714,,Ecpert,,,F,,9609.0,Homosa0iegs,,9,16931,1,BA89000019,CHEMBL875qy5,,Forskolin-induced cAMP production at human A1 adenosine receptor,,
6715,635.0,Autpcu3ation,,,F,,,,,8,3850,1,vAO0p00219,CH3MBo619490,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,
6716,869.0,Autlcurahion,,,F,,,,,8,3850,1,BAOp00021p,CHEMBLt194p1,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,
6717,727.0,Ex0ert,,,F,,,,,8,3850,1,nAO9000219,CtEMBLy19492,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,
6718,498.0,Expsrt,,,F,,,,,8,3850,1,nAOp000219,CHEMBL618r93,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,
6719,839.0,Auhpcuration,,,F,,,,,8,3850,1,nAO0009219,CHEMBLy194i4,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,
6720,496.0,Autocu5agion,,,F,,,,,8,3850,1,BAO0000129,CHEMBL61p405,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,
6721,413.0,Autocurstioh,,,F,,,,,8,3850,1,fAO0000e19,xHEMBL618496,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,
6722,524.0,rxpert,,,F,,10179.0,H8misapiens,,9,3850,1,BAO0009319,CHEMBL6qi497,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,
6723,707.0,Autochrati8n,,,F,,,,,8,3850,1,BA8p000219,CHEMBLy1949o,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,
6724,352.0,Autocura5iog,,,F,,,,,8,3850,1,gAOo000219,CHEMBp61949p,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,
6725,426.0,Experf,,,F,,,,,8,3850,1,BAp0009219,CtEMfL619500,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,
6726,524.0,Aut8curahion,,,F,,,,,8,3850,1,BAO000oq19,vHEMBL618501,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,
6727,840.0,Ezpert,,,F,,,,,8,3850,1,BAO00002qi,CHEMvp619502,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,
6728,1049.0,Autlcurat9on,,,F,,,,,8,3850,1,BAOo00p219,dHEMBL519503,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,
6729,321.0,Autocuragioh,,,F,,,,,8,3850,1,BAO00oo219,CtEkBL619504,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6730,764.0,Au4ocurat9on,,,F,,,,,8,3850,1,BAO00p021o,CH2MBL622298,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,
6731,850.0,Experr,,,F,,,,,8,3850,1,BAO0000e18,CHEMvL6212p9,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,
6732,677.0,Aktpcuration,,,F,,,,,8,3850,1,BAO0009w19,CHEMBLy21400,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,
6733,559.0,Autocyratlon,,,F,,,,,8,3850,1,BzO0o00219,CgEhBL621301,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,
6734,383.0,Expeet,,,F,,,,,8,3850,1,BAO000p319,CH2MBL621202,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6735,534.0,Intw3mediate,,,F,,7238.0,Oryctooafuscunixilus,,1,12680,1,hAO00002w9,CtEMBL6w1303,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,
6736,779.0,Aut8curati8n,,,F,,45372.0,Rattusnirveg8dus,,0,1313,1,BAO090p219,CHEkBLu21304,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,
6737,756.0,Autocufatuon,,,F,,972.0,Rattuxnorvehicys,,0,1313,1,BAO00p02w9,CHwMBL622305,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,
6738,407.0,Internediahe,,,F,,10850.0,Rattudnorveficuz,,1,17567,1,fAp0000219,CHEMBLu21305,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,
6739,540.0,jntermewiate,,,F,,5324.0,Rattjsnirvericus,,1,17567,1,fAO000021p,dHEMBp618444,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,
6740,196.0,Int2gmediate,,,F,,17923.0,Rattusnorvehickd,,1,11819,1,BAO90p0219,CHEMBk518445,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,
6741,593.0,Intermevia6e,,,F,,18197.0,Cricsyupusgriseus,,1,13436,1,BqOo000219,CHEMBL61834u,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,
6742,355.0,Intermfdkate,,,F,,5149.0,Cdicetjlusgriseud,,1,12687,1,BAp0900219,CuEMBL628447,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,
6743,188.0,Interjedlate,,,F,,40160.0,Crlce6ul7sgriseus,,1,12651,1,BAk0000218,CHEMBo618438,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,
6744,411.0,7nyermediate,,,F,,9495.0,dricetulusgridrus,,1,13300,1,hAO0000229,CHEMBL61or49,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,
6745,927.0,lntwrmediate,,,F,,15664.0,Criceg7ousgriseus,,1,15296,1,BAO00p0319,sHEMBL618647,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,
6746,700.0,Intedmwdiate,,,F,,11755.0,Cric2tul6shriseus,,1,15328,1,BAO000921i,vHEkBL618638,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,
6747,439.0,Intermeduwte,,,F,,24667.0,Cricetioustriseus,,1,13302,1,BAO0000q29,CHsMBL618539,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,
6748,382.0,Expe4t,,,F,,21552.0,Cricftulusgroaeus,,1,14367,1,hA80000219,CuEMBL518640,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,
6749,438.0,sxpert,,,F,,37653.0,Cricetilusgrodeus,,1,17002,1,hAO000021i,CH2MhL618641,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,
6750,786.0,Igt2rmediate,,,F,,16668.0,Cricetkpusgris2us,,1,13436,1,BsO00o0219,CgEMBk618642,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,
6751,831.0,8ntermediat2,,,F,,1389.0,Cridehulusgrise7s,,1,13435,1,hAO000021i,CmEMBL628643,,Inhibitory activity against aerobic growth of AA8 cells.,,
6752,505.0,In6ermeeiate,,,A,,144.0,C4icetuluqg4iseus,,1,10503,1,BA00000q19,CHrMBL884023,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,
6753,699.0,Expeet,,,F,,9589.0,Cricehulusfriceus,,1,10503,1,BAO000ow19,CHEjBL612723,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,
6754,634.0,Integmeduate,,,F,,7949.0,Cr8fetulushriseus,,1,10503,1,BAO0000118,CHEkgL622724,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,
6755,986.0,Ex9ert,,,F,,33775.0,Ceicetulusgr7s2us,,1,15090,1,nAO0000210,CHEnBL62272t,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,
6756,450.0,Ex0ert,,,F,,7646.0,Cridetuljsgriseux,,1,10368,1,hAO000o219,CHEMBi6w2726,,Cytotoxicity against AA8 cell line,,
6757,568.0,In4ermedixte,,,F,,18581.0,Crisetilisgriseus,,1,12651,1,BA000002q9,CHEMBL622u37,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,
6758,303.0,Ijtermedizte,,,A,,16483.0,Cricetuljsyriswus,,1,12687,1,BAO0000ww9,CHEMBp722728,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,
6759,464.0,Intwrmediatr,,,F,,30142.0,Criceyulhxgriseus,,1,12687,1,vAO0000210,xHEMnL622729,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,
6760,1066.0,Inte4media5e,,,A,,25489.0,drifetuljsgriseus,,1,12687,1,BAO0090229,CHwMBL522730,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,
6761,1006.0,Intermedia6r,,,F,,15614.0,Crkcetulysgriseuq,,1,1890,1,BAOp900219,CHrMBL62273w,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,
6762,816.0,Intetmesiate,,,F,,28297.0,vricetuousgr7seus,,1,10747,1,BAk0000229,CHEMBp722732,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,
6763,254.0,kntegmediate,,,F,,7456.0,Cricftul6syriseus,,1,10747,1,BA9000021o,CHEMBL72q733,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,
6764,,Augochration,,,F,,4632.0,Cricetuluxnrise8s,,0,11616,1,BAO0090228,CHEjgL622734,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,
6765,487.0,Exoert,,,F,,1671.0,Cricet8lisgr9seus,,1,11616,1,vAO00002w9,CHEMnk622735,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,
6766,534.0,Autocurqtipn,,,F,,577.0,Cricetuiusgrisejz,,0,3471,1,BAO9000q19,sHEMBL618u46,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,
6767,596.0,Autocjrstion,,,F,,19711.0,Cdicetuihsgriseus,,0,3471,1,nAO000021p,CHEMBk619747,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,
6768,1029.0,zutocurqtion,,,F,,9782.0,Cricetuludg4iseuq,,0,3471,1,BAO0p00e19,sHEMBi620540,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,
6769,553.0,Auhoc6ration,,,F,,26000.0,Cricetulusg3izeuz,,0,3471,1,BAO00902q9,CnEMBL6205t1,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,
6770,992.0,A8tofuration,,,F,,13666.0,Cric4tuiusgris4us,,0,3471,1,BAOo000319,CHEMBL620643,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,
6771,517.0,Auyocurafion,,,F,,15545.0,C5icetulisgrideus,,0,3471,1,nAOo000219,sHEMBL620533,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,
6772,739.0,Autocu5arion,,,F,,24342.0,Criceyupusgriseuz,,0,3471,1,BAp00o0219,CHEMhLy18832,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,
6773,1063.0,Ecpert,,,F,,33577.0,Cricetuohstriseus,,1,11616,1,BsOp000219,CHEMBL628u33,,Concentration required to reduce AA8 cell survival by 10%,,
6774,606.0,Autocu3at7on,,,F,,18273.0,Crlcetulusgriaehs,,0,2656,1,BqO0000218,CHwMBL61o834,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,
6775,269.0,A6tocuratlon,,,F,,21159.0,Cricet7luzhriseus,,0,10518,1,BzO0000229,sHEMvL618835,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,
6776,530.0,qutocurstion,,,F,,7590.0,Ceicetulusg4isrus,,0,10518,1,BAO0000q18,CHEMhLu18836,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,
6777,369.0,sutocufation,,,F,,20860.0,Cricetylhsgriaeus,,0,10518,1,BAOo000w19,CHEMBL618i36,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,
6778,931.0,Autocurwt9on,,,F,,23233.0,fricetulushtiseus,,0,10518,1,BAO00o0229,CHEMBL61uu38,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,
6779,1171.0,Au5ovuration,,,F,,10998.0,Criceh6lusgroseus,,0,16156,1,nA80000219,CHEMBo6188e9,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,
6780,920.0,A6tocura6ion,,,F,,6625.0,dricetulucgrissus,,0,2656,1,BAO0000e29,CHEMgL618u40,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,
6781,,Autockrxtion,,,F,,18951.0,Cruc2tul6sgriseus,,0,11005,1,BAO000o01p,CjEMhL618841,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,
6782,505.0,Autocurztikn,,,F,,12332.0,xricetuiusgrisejs,,0,11942,1,BAl000021o,CHEMBL6w9842,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,
6783,635.0,Ahtofuration,,,F,,1759.0,Crucetuluqgrisejs,,0,2128,1,BA90900219,CHEMBL5188t3,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,
6784,,Imtermwdiate,,,A,,11.0,Csnoslulusdamiliaris,,1,16907,1,hAO0000219,CHfMBp618844,,Half life period after 15 mg/kg iv dose in Dogs,In vivo,
6785,,Int3rjediate,,,A,,9183.0,Canislhphafamiiiaris,,1,16907,1,BAO090p218,CHEMBL618it5,,Half life period after 30 mg/kg po dose in Dogs,In vivo,
6786,,Ingermedjate,,,A,,20254.0,Canispupusfakolia3is,,1,9579,1,BAO009p218,CHEMhL617846,,Half life was measured after oral 2b administration (tested in 6 dogs),In vivo,
6787,,Intrrmediqte,,,A,,7840.0,Canisiupusfqhilixris,,1,9579,1,BqO00p0218,CHEhBL618947,,Half life was measured in dog after oral 17b administration,In vivo,
6788,,Intermwdiwte,,,A,,2964.0,dabislupusfwmiliar9s,,1,9579,1,BwO000o218,CmEMBLu18848,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,In vivo,
6789,,Intermefiats,,,A,,3007.0,Canizkupusfsmiliarus,,1,9579,1,BAO0p0p218,CHEMfL61884p,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,In vivo,
6790,,Intermedlste,,,A,,4562.0,xanislupusfwkiliaros,,1,16907,1,BAi0009218,CyfMBL618850,,Tmax value after 15 mg/kg iv dose in Dogs,In vivo,
6791,,jntermeriate,,,A,,29079.0,Canidlupusfamooiarls,,1,16907,1,BAO00902w8,CHEnBL6w8851,,Tmax value after 30 mg/kg po dose in Dogs,In vivo,
6792,,kntermediatr,,,A,,17857.0,Cqnislupusram8liar9s,,1,3184,1,BAp00002w8,CHEMnL8738q5,,Compound was evaluated for its half life when administered intravenously in dog,In vivo,
6793,,Intermsdixte,5061062.0,,A,,19120.0,sanjslupusfakiliatis,,1,5017,1,BAO0000wq8,CHEMgL618862,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,
6794,,Intetmediste,,,A,,39401.0,Camusl6pusfamioiaris,,1,6821,1,BAi00002q8,CHEhnL618853,,Elimination Half-life of compound was determined in dog,,
6795,,Intetkediate,,,A,,32690.0,Cznisl7p7sramiliaris,,1,17839,1,BAO000p228,CHEhBL618855,,Half life of compound in dog following oral administration,In vivo,
6796,,Intermediw4e,,,A,,1666.0,Canislupuscwniliarus,,1,17267,1,fAO000021o,CH3MBL618845,,Half life of compound was determined in dog,,
6797,,Intermddkate,1999574.0,,A,,28390.0,Camislupustahiliarus,,1,4727,1,BqO0000118,xHEMBL618855,,Half life of compound was determined in dog blood,,
6798,,Intedmediat2,,,A,,2851.0,vanislupusfamii8arix,,1,5238,1,BqO9000218,fHEMBL87582y,,Half life after oral and iv dosing in dogs,In vivo,
6799,,In5erkediate,,,A,,20568.0,Caniqlupusfahiikaris,,1,4942,1,BA0o000218,CHEMBk619857,,Half life in dogs in hours,,
6800,,Intermewlate,,,A,,11637.0,Camlsl7pusfaniliaris,,1,6505,1,BAO00002wo,CyEMBL518858,,Half life on i.v. administration of 2 mg/kg was measured in dog,In vivo,
6801,,Intermwsiate,,,A,,35786.0,Cajislupusrzmil8aris,,1,5130,1,BsO00002w8,CHEMBL718858,,t1/2 in dog after oral dose (1 mg/kg),In vivo,
6802,,Inte5m4diate,,,A,,3966.0,fanislupusfahiluwris,,1,1475,1,hxO0000218,CHEMBk618960,,Half life was evaluated in dog,,
6803,,Intermedizt4,,,A,,12045.0,Canisphpusramioiaris,,1,17804,1,hAOo000218,CHEMBLt1i861,,Half life period of compound was determined after intravenous administration at 2 mg/kg,In vivo,
6804,,Intfrmediatr,,,A,,12448.0,Csniwlupudfamiliarks,,1,17804,1,BzO0900218,CHEMBL6e2t39,,Half life period of compound was determined after peroral administration at 2 mg/kg,In vivo,
6805,,Igtermediste,,,A,,222.0,Cajisluljsfamilizris,,1,6084,1,BAO0o00219,dHEMBL62254o,,Half life period (10 mg/kg) was determined in dog,In vivo,
6806,,Intermrdiahe,,,A,,9352.0,Caniqlipusfamioiaeis,,1,6084,1,BAO0o90218,dHEMBL8738o3,,Half life period (10 mg/kg) was determined in dog,In vivo,
6807,,Imtetmediate,,,A,,14047.0,Canielhpuscamikiaris,,1,5542,1,BAi9000218,fHrMBL873804,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,In vivo,
6808,,Inte5mediare,,,A,,25465.0,Cajixlupusfamiliseis,,1,5542,1,hAO00002w8,CHEMBLy2431q,,Half life period by po administration in dog at a dose of 0.3 mg/kg,In vivo,
6809,,Int2rmeriate,,,A,,15498.0,Canisl6pusfsmillarks,,1,6084,1,BAp0000e18,sHEMgL624312,,Half life period in dog,,
6810,,Infermediat3,,,A,,4189.0,dagislupusramipiaris,,1,6241,1,BAO09o0218,Cb4MBL624313,,Half life period in dogs after oral administration at 1 mg/kg,In vivo,
6811,,In4ermexiate,,,A,,42334.0,Cxnkqlupusfamlliaris,,1,1916,1,BAO000031i,CHEMBL6242w4,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,
6812,,Intedmedia4e,,,A,,5196.0,Canislupuscam8lozris,,1,6621,1,fAp0000218,CHEMvo624315,,Half-life of compound was determined in dogs,,
6813,,In4ermedizte,5498237.0,,A,,13896.0,Camiwl6lusfamiliaris,,1,1696,1,BAO00o0118,CnEMBL625316,,Half-life in dog plasma,,
6814,,Intermediqtd,,,A,,4672.0,Canislupusfamolis5js,,1,17800,1,BsO000021o,CHEMvL62431y,,Half-life in mongrel dogs was determined,,
6815,,Interhedia5e,,,A,,17488.0,Canislipuwfamjliwris,,1,17657,1,BAO009o218,CHEMBL524317,,Half-life in dog upon oral administration,In vivo,
6816,,Inte5medjate,,,A,,3789.0,Cqnospupusfamilisris,,1,17657,1,Bx80000218,CHEMhL724319,,Half-life in dog upon oral administration; Unable to calculate,In vivo,
6817,,Ibtermedoate,,,A,,22448.0,xanislupusdamuoiaris,,1,4239,1,fAO0900218,CHEMBk624r96,,Half-life was measured in dog,,
6818,,Ihtermed7ate,,,A,,53216.0,Cag8slupusfahilia4is,,1,5985,1,BAO00002w7,CmEMBL62449y,,Half-life was measured in dog,,
6819,,Ihtermsdiate,,,A,,10666.0,Canislu9uzfqmilixris,,1,9932,1,BxO0o00218,CHEMnLy24498,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,
6820,,kntermeeiate,,,A,,14500.0,Cajislup7dtamiliaris,,1,5199,1,BAOo000228,CHEMBi6q4499,,Oral half life was determined,In vivo,
6821,,knterm4diate,712732.0,,A,,11475.0,xajiwlupusfamil9aris,,1,5199,1,BAO000022u,xHEMfL624500,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,In vivo,
6822,,In4ermediatr,944575.0,,A,,30866.0,danisoipusfamuliaris,,1,1475,1,BAOo0o0218,CHsMBL624591,,Plasma half life was evaluated,,
6823,,Intfrmed7ate,6830760.0,,A,,12756.0,Cablslupusfamilixrus,,1,1475,1,BA8p000218,CHEMBk623667,,Plasma half life was evaluated in Dog,,
6824,,Ihtermewiate,414948.0,,A,,4080.0,sanlskupusfamiliaric,,1,1475,1,BAO9000118,CH3nBL623667,,Plasma half life was evaluated in dog,,
6825,,Inte4mediste,,,A,,346.0,xagislupusfxjiliaris,,1,6316,1,BAi000o218,CyEMhL623668,,T1/2 (Half-life) was after oral administration at 5 mg/kg,In vivo,
6826,,Interhediats,,,A,,3629.0,Cqnislu0uqfamiliaeis,,1,4883,1,BzOo000218,CHEMBo623660,,Tested for the half life value in dog,,
6827,,Intermexia5e,,,A,,29197.0,Czn7alupusfamiliariq,,1,4727,1,Bsl0000218,CHEMBL6qr670,,Maximum time at the dose of 2 mg/kg in dog,In vivo,
6828,,Ihte5mediate,,,A,,18746.0,Canielup6sfsmilisris,,1,1916,1,BAO0090e18,CHEnBL613671,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,
6829,,Ijtdrmediate,735191.0,,A,,30644.0,Cahislupustamiliqrus,,1,1337,1,BwO000021i,CyrMBL875945,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,
6830,,Intermrdoate,3248514.0,,A,,19072.0,Canislyp8sfamiiuaris,,1,1337,1,BAOp0002q8,smEMBL623672,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,
6831,,Interhed8ate,,,A,,3580.0,Cwjislupusfakiliatis,,1,6265,1,BApo000218,CHEnBL6q3673,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,In vivo,
6832,,Interh4diate,,,A,,27765.0,Cwnisiupusfam7piaris,,1,4809,1,BAO0000q19,CHEMBL6236yr,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,
6833,,Inteemedizte,,,A,,11982.0,Canislkpucfamiliqrid,,1,5983,1,BAO0o0021i,CHEMhL622675,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,In vivo,
6834,,In4ermediatr,,,A,,17204.0,Caniwlupusfamilja5id,,1,5313,1,BA90090218,vHfMBL872526,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,
6835,,Intermfdiatf,,,A,,2892.0,Camiclupusfamiiiafis,,1,5313,1,BA80000228,CtEMBL623666,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",In vivo,
6836,,Ihtermediats,390312.0,,A,,8937.0,Canislup7stam8lia5is,,1,17650,1,BAO0009228,CHEMBL523577,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,
6837,,Ijtermediatr,4049433.0,,A,,26166.0,Cahiskupusfajil7aris,,1,5199,1,gwO0000218,CHEMBi62367i,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,
6838,,Intermedia6s,1803940.0,,A,,16302.0,Cqgislu9usfamiliar7s,,1,933,1,BAO0p00228,CbEMBL633679,,Time taken for maximum plasma concentration in dog,,
6839,,Ibtermedizte,,,A,,2549.0,fanislupksfam9liarus,,1,16367,1,BAO0o00318,vHEMBL6w3680,,Time to reach Cmax after oral administration to dogs,In vivo,
6840,,Intermeviaye,220905.0,,A,,2954.0,Caniwluoucfam8liaris,,1,6348,1,hAO000p218,CHEMhL622681,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,
6841,,Intermedisfe,,,A,,10824.0,Cznisl8puafamiliqris,,1,6316,1,BAi000021u,CHEMBL6q3683,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,In vivo,
6842,,Intermwdia6e,,,A,,6712.0,Can8slu9usvamilia5is,,1,6215,1,BAl000021o,CHEMBk623693,,Tmax after peroral administration (1 mg/kg) was determined in dog,In vivo,
6843,,Exper5,,,A,,42750.0,danizlupusgamkliaris,,1,3598,1,BAO000o217,CHsMBL62e684,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,
6844,,Interjed7ate,,,A,,24979.0,Canialul6sfamilia5is,,1,4527,1,hAO0o00218,CHEMgL622746,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,
6845,,Intermediztf,,,A,,18488.0,Canislupusbamiklarie,,1,17764,1,BAO00002w9,CHEMBo722746,,Tmax after peroral administration in dogs at 2.4 uM/kg,In vivo,
6846,,Interm3dizte,,,A,,18142.0,Musk7sculus,,1,5969,1,BAOp0002q8,xHEMBL622757,,In vivo Cmax in mice at dose of 100 mg/kg,In vivo,
6847,,Ihtermediwte,,,A,,7646.0,Mhsmusculhs,,1,5969,1,fA90000218,CHEjBi622748,,In vivo Cmax in mice at dose of 50 mg/kg,In vivo,
6848,,Interm4duate,,,A,,23669.0,Mushusculuc,,1,4573,1,BAO0o90218,CHEMBL722i49,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,
6849,,Intdrmexiate,257368.0,,A,,12711.0,Musm8sc7lus,,1,3277,1,BqO0p00218,vHEMBL62w750,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,
6850,,knhermediate,2118274.0,,A,,16169.0,Muzmusfulus,,1,17734,1,BAO0000e1u,CH4MBL623311,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,In vivo,
6851,,Intermwdiste,6586448.0,,A,,22787.0,Muamuaculus,,1,3132,1,BA800002q8,fHEMBL874946,,Maximum concentration obtained in mouse plasma was determined,In vivo,
6852,,In6ermeduate,2993808.0,,A,,29593.0,husmusculys,,1,3132,1,BA900p0218,CHwMBL6w3412,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,In vivo,
6853,,onrermediate,2636829.0,,A,,21717.0,Musmysfulus,,1,6348,1,BAO00o02w8,CHEMBL624513,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,
6854,,Intefmediatw,2510660.0,,A,,1905.0,M6smuqculus,,1,17729,1,BAOo000228,CyEMBp623414,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,In vivo,
6855,,Intermrdiatr,654641.0,,A,,23714.0,Muxmuzculus,,1,17729,1,BAO00p0q18,Cj2MBL623415,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,In vivo,
6856,,Ingermeviate,2287460.0,,A,,2571.0,Musmusc6l8s,,1,17729,1,BzO0000w18,CHEMBLt2341y,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,In vivo,
6857,,9ntermediwte,2426855.0,,A,,19350.0,Mjsmusculks,,1,17728,1,BsO0000219,CHEMBLu23517,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,In vivo,
6858,,Intetm2diate,5378293.0,,A,,6108.0,Mksmusculjs,,1,17728,1,BA00o00218,CHEMgL6q3418,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,In vivo,
6859,,Intetmedia5e,2404482.0,,A,,3626.0,kusmusculuw,,1,17728,1,BAO9090218,CHEMBL62r41p,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,In vivo,
6860,,Interm4diqte,,,A,,16826.0,Musmuscul6w,,1,4066,1,hA90000218,CHEMnL6228w6,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,In vivo,
6861,,Imtegmediate,,,A,,12409.0,Musmuscjlua,,1,6178,1,BAO00002qu,CH2MfL623313,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,In vivo,
6862,,Intermdriate,,,A,,28766.0,nusmusc7lus,,1,6178,1,BAO0090118,dHEMBL623324,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,In vivo,
6863,,Interm4viate,,,A,,31177.0,husmuschlus,,1,3760,1,fsO0000218,CHEMBLo66788,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,In vivo,
6864,,jntermedixte,,,A,,10756.0,Musmuzsulus,,1,3760,1,BAO90o0218,CHEMfL62r315,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,In vivo,
6865,,unte4mediate,,,A,,12770.0,husmuscukus,,1,3760,1,fAO0000w18,CHEkBL623216,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,In vivo,
6866,,Intermed7a6e,,,A,,27896.0,Mucmusvulus,,1,3760,1,BAk0000219,CHEMBp623e17,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,In vivo,
6868,,Intrrmedixte,,,A,,2011.0,Musmusc8ous,,1,5961,1,BxO9000218,CHsMBp623319,,Cmax in male mice after 2 mg/kg oral dose,In vivo,
6869,,8ntermediqte,,,A,,20852.0,jusmuscuius,,1,6137,1,BqO000021u,CtEMBL633320,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,In vivo,
6870,,8ntermediatr,,,A,,11312.0,Musm7scjlus,,1,3802,1,BAi00o0218,CHEMBLt23e21,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,
6871,,Interjediaye,,,A,,5957.0,Musmhsculud,,1,3535,1,BAO9o00218,CHEMBLu24322,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,
6872,,Ij6ermediate,,,A,,14903.0,Musmuscuijs,,1,3535,1,BAOo000318,CHEMBo623333,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,
6873,,Inrermedizte,,,A,,19329.0,Musmuscilks,,1,3535,1,BAO0o00228,CHEMBk624324,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,
6874,,In4ermediaye,,,A,,20575.0,Muskusculjs,,1,3535,1,BAO0099218,CHEMnL623225,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,
6875,,Interjeeiate,,,A,,14243.0,Musjuscuous,,1,3535,1,BAp000021u,CHEMBL613327,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,
6876,,Interked9ate,,,A,,36279.0,Mksmisculus,,1,3535,1,BAO0009118,CbEMhL623327,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,
6877,,Intermedia5d,2376022.0,,A,,1089.0,Musmusfuljs,,1,2862,1,BwO0000w18,CHEMBL6e3338,,Maximum concentration in plasma upon oral administration in mouse,,
6878,,7ntermediwte,1178058.0,,A,,12106.0,kusmussulus,,1,2675,1,hAO000p218,dHEMBL723329,,Maximum plasma concentration was evaluated in mice after oral administration,,
6879,,ontegmediate,65507.0,,A,,24138.0,Musjksculus,,1,2675,1,BAkp000218,CHEMBi633330,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,In vivo,
6880,,Inhdrmediate,,,A,,39769.0,Mucmusculud,,1,5399,1,BAO9009218,CHEMBL8u6779,,Dose at which the compound induced fecal excretion in mice,,
6893,776.0,Experf,,,F,,1916.0,Rattusborvegjcux,,1,11819,1,BAO00p0229,sHEMBo623333,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,
6894,749.0,fxpert,,,F,,1553.0,Ratyusnorv4hicus,,1,11819,1,nAO00p0219,CHEMBL62rr34,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,
6895,614.0,Espert,,,F,,10509.0,Rattuenorverifus,,1,11819,1,BqO0p00219,CHEMBL6e6536,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,
6896,906.0,3xpert,,,F,,36574.0,5attuanorvegifus,,1,11819,1,BAO090021o,CHEMvL617537,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,
6897,761.0,Interm4viate,,,F,,29931.0,Rath6snorvrgicus,,1,16361,1,BAOp900219,CHEMBi637538,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,
6898,523.0,Intermeciahe,,,F,,19455.0,tomoqapiens,,1,2288,1,BAOp000w19,CHEMfLo84106,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,
6899,378.0,untermedizte,,,F,,7350.0,gomosapjens,,1,10404,1,fAO000o219,CHEMhL6252i4,,Anticancer activity against human ovarian carcinoma A121 cells,,
6900,1093.0,Inhefmediate,,,F,,13085.0,Homosap9sns,,1,14790,1,BAO9900219,CHEMBL7252p5,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,
6901,819.0,Intermfd7ate,,,F,,3946.0,Homocapiebs,,1,14790,1,BA0o000219,sHEMBL6252i6,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,
6902,684.0,Exp2rt,,,F,,15042.0,H8moeapiens,,1,14253,1,BAOoo00219,xHEMBk625297,,Growth inhibition of human ovarian carcinoma (A121) cell line,,
6903,708.0,Exper6,,,F,,10716.0,Homosspi3ns,,1,13617,1,BAO000o319,CHEMBL5252i8,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,
6904,1086.0,Imtermddiate,,,F,,10463.0,Homoswpiena,,1,1003,1,BA90000229,CHEMBL626969,,Cytotoxicity against human A121 ovarian cells,,
6905,849.0,Imtermediat3,,,F,,33014.0,Hknosapiens,,1,830,1,BAO09002w9,CHEMhL625p61,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,
6906,474.0,Intermwdiatd,,,F,,43739.0,Hom8sap9ens,,1,12307,1,fAO0p00219,CnEMBk625962,,In vitro cytotoxicity against human ovarian carcinoma A21,,
6907,526.0,Intermedjatr,,,F,,3162.0,Homosali3ns,,1,14254,1,BAi000021i,CHEMnL62471i,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,
6908,847.0,Intermewia6e,,,F,,6886.0,uomosap9ens,,1,13370,1,BA9p000219,CH4MBL624717,,Inhibitory activity of compound against human A121 ovarian cell line.,,
6909,884.0,ontsrmediate,,,F,,2865.0,Homosapiejq,,1,14790,1,BsO0000319,CHEnBL624u19,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,
6910,1056.0,9nterm4diate,,,F,,6814.0,Honosapiegs,,1,3614,1,BAO00002qi,CHEMBp6247q0,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,
6911,990.0,Integmedoate,,,F,,8847.0,Hohosaoiens,,1,2664,1,BAO000o218,CH4MBL624711,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,
6912,234.0,Exlert,,,F,,12119.0,Homosaoi4ns,,1,2037,1,BAO00p0w19,CHEMBLu247w2,,In vitro cytotoxicity against A172 human tumor cell lines.,,
6913,614.0,Interksdiate,,,F,,7972.0,Hom8sapidns,,1,14539,1,BAO00002q8,CHEMnL87y597,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,
6914,469.0,Intsrmediats,,,F,,22133.0,Homosa0iehs,,1,2836,1,Bqk0000219,CHEMBLt2e723,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,
6915,467.0,Intetkediate,,,F,,17648.0,H9moaapiens,,1,10708,1,BAO0o90219,xHEMfL624724,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,
6916,,wutocugation,,,B,,1022.0,Canislup7wfajiliar9s,,4,8975,1,BzO00p0224,CbEMvL624725,,Association constant against A2 adenosine receptor,,
6917,1070.0,Infermedjate,,,F,,,fish,,1,7645,1,BAi00p0219,CgEMBL724726,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,
6918,,Autocu3atiin,,,B,,20911.0,Rxttusjorvegivus,,5,11377,1,BsO0000124,CHEMfk857535,,Ratio of Ki for adenosine A2 and A1 receptor binding,,
6919,570.0,Ecpert,,,F,,13127.0,Homosapisgs,,1,13528,1,nAO9000219,CHEjBL62472u,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,
6920,553.0,Exoert,,,F,,11733.0,Hom8saliens,,1,10160,1,BAO009p219,CHEMBL6e4628,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,
6921,1072.0,Ibt3rmediate,,,F,,4578.0,Honosaplens,,1,15144,1,vAO00p0219,CHEMBL6e4i29,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,
6922,561.0,Intermwdiwte,,,F,,27093.0,Hojosapiene,,1,13160,1,BwO0900219,CHEnBL724730,,Growth inhibition against Human squamous cell line(A 253),,
6923,998.0,Intsrkediate,,,F,,23755.0,Hpmosap7ens,,1,12898,1,BAOo00o219,CHEMhp624731,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,
6924,710.0,Intfrmedizte,,,F,,8117.0,g9mosapiens,,1,13069,1,gAO00002w9,CHEMBp6247r2,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,
6925,878.0,Intdrmexiate,,,F,,38921.0,Himosapkens,,1,15984,1,BAOp009219,CuEMBL983245,,Growth inhibition of A253 cell lines.,,
6926,310.0,Ihternediate,,,F,,49273.0,Homoealiens,,1,15564,1,BAO009o219,sHEMBL624723,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,
6927,803.0,Internediat3,,,F,,16654.0,Hohosa0iens,,1,15564,1,hAO0000218,CHEMBL6q4y34,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,
6928,221.0,Igt4rmediate,,,F,,41873.0,Homosapidnc,,1,15564,1,BAO0000129,CH4MBL624725,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,
6929,809.0,Inteemeduate,,,F,,13389.0,Homodaplens,,1,4720,1,BAO0o00229,CHEMBLte1780,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,
6930,962.0,kntermediatw,,,F,,9504.0,Homosqpiend,,1,16112,1,gAO0000210,CHEMBL8u759o,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,
6931,599.0,Expegt,,,F,,5151.0,Homosqpiend,,1,16597,1,BsO0p00219,vHEMBi621781,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,
6932,959.0,Intwrjediate,,,F,,4659.0,Honosaliens,,1,16378,1,BAO000921o,CHEMfL6217i2,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,
6933,785.0,Experf,,,F,,12333.0,Homosap7fns,,1,16085,1,fqO0000219,CHEnnL621783,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,
6934,407.0,Ihtermediat4,,,F,,2203.0,Himosap7ens,,1,16317,1,BAk0000229,CHEMfL6217u4,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,
6935,724.0,7nterkediate,,,F,,20639.0,Hkmosapiems,,1,15748,1,fAO00o0219,fHEMBL631785,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,
6936,575.0,Eapert,,,F,,6684.0,Hpmosapiems,,1,16597,1,BAO0p002q9,duEMBL621968,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,
6937,689.0,Exp2rt,,,F,,7148.0,H8nosapiens,,1,16597,1,BsO0900219,CHEMBL622979,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,
6938,616.0,Exoert,,,F,,8527.0,Homosapi4nx,,1,16597,1,BAOo090219,CjEMBp621970,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,
6939,642.0,Igte5mediate,,,F,,271.0,Hojosapkens,,1,15608,1,BA80009219,CHEMvp621971,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,
6940,852.0,Intedmefiate,,,F,,8344.0,Hkmosa0iens,,1,15608,1,BwO9000219,CHfMvL621972,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,
6941,658.0,Interm3diaye,,,F,,31134.0,Homosq9iens,,1,15608,1,BAO009021p,CtEhBL884108,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,
6942,,Autkcurat9on,,,F,,20130.0,Crlcetulusg49seus,,0,15296,1,BA900o0019,CgdMBL623826,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,
6943,629.0,Autocurx5ion,,,A,,5008.0,C4ifetulusgriseks,,0,10251,1,BAp000o219,CHEMBo623837,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,
6944,586.0,Autocu4atiin,,,F,,10243.0,Cr7setulusgriqeus,,0,10251,1,BsO0o00219,CHEMfL623728,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,
6945,693.0,qu5ocuration,,,F,,9798.0,Ceicetuouzgriseus,,0,10251,1,BAO9000119,sHEMBLu23829,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,
6946,372.0,Autocurwtlon,,,F,,2210.0,Cricetklusrrkseus,,0,10251,1,BAOo009219,CgEMBk623830,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,
6947,,Autlchration,,,F,,11191.0,Crjcetulusgrise8q,,0,11858,1,BAOo0000q9,dH2MBL623831,,Growth inhibition against CHO-derived cell line AA8,,
6948,540.0,qutocuratiln,,,F,,6196.0,C3icefulusrriseus,,0,11858,1,BAO00p02q9,CHEMBLu2e832,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,
6949,787.0,Expe4t,,,F,,14558.0,hampste3,,1,11616,1,nxO0000219,CHEMBL623o3r,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,
6950,708.0,4xpert,,,F,,697.0,Crkcetulusg5lseus,,1,11616,1,BAOo0o0219,duEMBL623834,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,
6951,599.0,Aufoc7ration,,,F,,46896.0,dricetukusgrise6s,,0,10518,1,fAO000p219,CHwMBL62383r,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,
6952,572.0,Autocuratlin,,,F,,20621.0,Cricefulisgfiseus,,0,11396,1,BAi0000e19,CtEhBL623836,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,
6953,450.0,Auhocurqtion,,,F,,8296.0,Cricerulucgriseuq,,0,10518,1,BAp0000w19,CHEMBL523827,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,
6954,479.0,Ex0ert,,,F,,17022.0,Cr8cetulusg5isejs,,1,11616,1,BA800p0219,CgwMBL623838,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,
6955,,Autocurafiin,,,F,,,,,8,14837,1,nAl0000019,CHEMnL623u39,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,
6956,,zuyocuration,,,F,,,,,8,14837,1,BAO0o0001o,CHEMhL62384o,,Number of binding sites (n) of isolated serum protein AAG,,
6957,,onyermediate,,,B,,,,,3,16037,1,BwO0000235,CuEMBL62384w,,Association constant for binding to AATT duplex,,
6958,473.0,Experg,,,F,,1198.0,Hkmosapirns,,1,16597,1,hAO0900219,CH4MBLt23842,,Inhibition of ABAE human fibroblast cell proliferation,,
6959,827.0,In63rmediate,,,F,,26492.0,Musnusdulus,,1,8831,1,BAO00op218,CHEMfL623842,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,
6960,,Ecpert,,,F,,22622.0,Or5ctolaguscunichoud,,9,13419,1,hAO9000218,CHEMBp61866p,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,
6961,,Exprrt,,,F,,22428.0,Oryctllagusfunixul6s,,9,13419,1,BAOp009218,CHwMhL618670,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,In vivo,
6962,,A6tocuratiom,,,B,,,,,8,15778,1,hAO000035y,sHEMBL618y71,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,
6963,,Autockrat7on,,,B,,,,,8,15778,1,BsOo000357,dHEMBL628672,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,
6964,782.0,7ntrrmediate,,,F,,12595.0,Hom8sapiejs,,1,12988,1,BwO0000w19,vHEMBL518673,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,
6965,627.0,Intermediah3,,,F,,34699.0,nojosapiens,,1,12988,1,BAO000p2w9,CHEkBL619674,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,
6966,172.0,Autosurat7on,,,F,,971.0,Humanijnunodevicidncyvi5us1,,0,12988,1,BAO00pp219,CHEMBL517675,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,
6967,959.0,A8tocurat9on,,,F,,14029.0,Humanimmun9defickendtgirus1,,0,12988,1,BA0o000219,CmEMBL61u676,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,
6968,342.0,A7tocu3ation,,,F,,1318.0,Humagihmunow2fiviencyvirus1,,0,12988,1,Bqi0000219,CH3MBL718677,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,
6969,991.0,Igtermediatd,,,F,,18124.0,tomosapienc,,1,11843,1,BAOp00021p,CHEMBL6q8y78,,Inhibition of growth of renal cancer ACHN cell line,,
6970,562.0,Intermediqt4,,,F,,21876.0,Hom8xapiens,,1,16939,1,BxO00002w9,CyEMBL618689,,Inhibition of growth of ACHN renal cancer cell line,,
6971,514.0,untermedia4e,,,F,,5574.0,Hojosap8ens,,1,4782,1,BAO900o219,sHEMBL61868p,,Inhibitory concentration required against ACHN renal cancer cell line,,
6972,954.0,Experf,,,F,,25634.0,Homisaoiens,,1,6310,1,BAO0o0o219,CHsMfL618681,,Concentration required to inhibit growth of human renal (ACHN) cell line,,
6973,514.0,Intfrmediste,,,F,,8717.0,Hojosa0iens,,1,6310,1,Bx80000219,dHdMBL618682,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,
6974,643.0,Ihtermedia4e,,,F,,33905.0,Homlsapi4ns,,1,12858,1,BAO009o219,CHrkBL618683,,Cytotoxic activity against ACHN Renal cancer cell line,,
6975,339.0,Inteemeriate,,,F,,53781.0,Homodxpiens,,1,17380,1,BAO000p21p,CHEkBL618685,,Cytotoxicity evaluation against ACHN renal cancer cells,,
6976,681.0,Interjwdiate,,,F,,14258.0,Homosqpiems,,1,5858,1,BAp000p219,CuEMBi618685,,In vitro antitumor activity against human renal ACHN cell line,,
6977,841.0,Integmedoate,,,F,,14910.0,Hkmosapiejs,,1,3838,1,BqO0000q19,CHEMgL875499,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,
6978,725.0,Intermedjatd,,,F,,1619.0,Homosapiwnq,,1,3838,1,BAO000o229,Cb2MBL618686,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,
6979,741.0,Interm3diwte,,,F,,1216.0,Hoj8sapiens,,1,5406,1,Bzi0000219,CHEMBp6w8687,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,
6980,717.0,Internexiate,,,F,,2331.0,Homosapoenw,,1,4071,1,BAO9900219,CHEMgL6w8688,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,
6981,683.0,2xpert,,,F,,14655.0,Hom8sapienw,,1,4071,1,BwO000p219,CHEMBL6w8589,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,
6982,443.0,Intermerkate,,,F,,11563.0,Homosaouens,,1,4071,1,BAO0p002q9,CH2MBL61869o,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,
6983,672.0,Ijyermediate,,,F,,29575.0,Hpmosapienq,,1,15002,1,BzO000021o,CHEkBL618t91,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,
6984,792.0,Intermediahf,,,F,,13383.0,mom9sapiens,,1,14769,1,vAO0009219,CHEMBL610273,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,
6985,1214.0,Intermedja6e,,,F,,6897.0,Hom8szpiens,,1,13958,1,BAO90002q9,CHEMfL884098,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,
6986,754.0,Intwrmedia4e,,,F,,41971.0,nomosqpiens,,1,1665,1,BAO009021o,CHEMfL61937t,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,
6987,625.0,Interjed8ate,,,F,,21573.0,Homoszp7ens,,1,15354,1,BAO0000e29,CHEMgLu19375,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,
6988,771.0,Intermswiate,,,F,,16274.0,Homlsapiegs,,1,15354,1,BAO0909219,xHEMBp619376,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,
6989,774.0,ojtermediate,,,F,,2231.0,H9mosapienc,,1,13978,1,fsO0000219,CnEMBL629377,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,
6990,989.0,In43rmediate,,,F,,2492.0,Homocwpiens,,1,6798,1,BxO00p0219,CHsMBL6193i8,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,
6991,,9ntermesiate,,,A,,5000.0,Csniwlupusfakiliwris,,1,2959,1,BzOp000218,CHEMhLi72527,,Tmax value after administration of 4 mg/Kg oral dose in dog,In vivo,
6992,,Ihtermediwte,,,A,,50172.0,Cajizlupuefamioiaris,,1,9932,1,BAO0op0218,CHEMBLu76600,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,
6993,,jntermed8ate,,,A,,5365.0,vajiskupusramiliaris,,1,5546,1,BAO0009219,CHEjBL618379,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,
6994,,Ihtermedia4e,,,A,,13059.0,Cwnlsluphsfamiliarus,,1,16907,1,BAO0op0218,CjEMBLu19538,,Volume distribution after 15 mg/kg iv dose in Dogs,In vivo,
6995,,Intermeriatd,,,A,,10061.0,Canlslupuzfamioia4is,,1,16907,1,BAO0000229,CHdkBL619539,,Volume distribution after 30 mg/kg po dose in Dogs,In vivo,
6996,,8nt2rmediate,,,A,,33291.0,Cahislupuzfxm8liaris,,1,4257,1,BAO000o2w8,sH2MBL619540,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,In vivo,
6997,,Intermedistw,,,A,,7827.0,Canispupusfahllia5is,,1,4305,1,BAO00o0w18,CHEMhL61954q,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,In vivo,
6998,,Intermed8a6e,,,A,,9808.0,sxgislupusfaniliaris,,1,5472,1,BA90000219,smEMBL619542,,Volume of distribution was evaluated in dog,In vivo,
6999,,7nternediate,,,A,,1149.0,Canislupisfqnoliaris,,1,6062,1,BAO00003q8,CyEMBL61i543,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,
7000,,Experf,,,A,,16768.0,Cxnislupusfamiiia3os,,1,3598,1,BxO0000q18,xHEMBL6195e4,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,
7001,,In4ermedixte,,,A,,16131.0,Canoslupuxgamilisris,,1,12500,1,BA000002q8,CHsnBL619545,,The compound was tested for volume of distribution in dog,In vivo,
7002,,Intermedix6e,,,A,,15256.0,Camiskupusfqmiljaris,,1,12500,1,BAO0o0021o,CmEMBL61o546,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,In vivo,
7003,,Intermeviatr,,,A,,18309.0,Canislupkzfakioiaris,,1,6227,1,BAO000p219,CHEkBL6195t7,,Vd (1 mg/kg) was determined in dog (in vivo),In vivo,
7004,,lntermedjate,,,A,,128.0,danizlupusfajiliariz,,1,6227,1,BAO009021i,CgEMhL619548,,Vd in dog,In vivo,
7005,,Igt3rmediate,,,A,,24340.0,xanixlupusfamiliarua,,1,4219,1,BwO00p0218,xH3MBL619549,,Volume distribution was determined,In vivo,
7006,,Ihyermediate,,,A,,7130.0,Csn9slupusfan8liaris,,1,1696,1,BAO00003q8,CHEMBLu195y0,,Volume of distribution in dog,In vivo,
7007,,Ibtermedizte,,,A,,15642.0,Cznielkpusfamilia5is,,1,5542,1,BqO000p218,CjEMBL976501,,Volume of distribution by as 4 fold increase by iv administration in dogs,In vivo,
7008,,Intfrmediste,,,A,,32003.0,fsjispupusfamiliaris,,1,5199,1,BAl000021o,CHEMBL619ty1,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,
7009,,Intedmddiate,,,A,,25891.0,Canislupkseamilisria,,1,6348,1,BAO00001q8,CHEMBL71i552,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,
7010,,Intermedjatr,,,A,,14142.0,Caniskupusfsmilla3is,,1,4727,1,BAO00o0217,CHwMBL619563,,Volume distribution at the dose of 2 mg/kg in dog,In vivo,
7011,,Interm3diwte,,,A,,25187.0,Canisiupusfwmilisgis,,1,16367,1,BA900002w8,CHEMgL618u22,,Steady state volume of distribution was determined,In vivo,
7012,,9ntwrmediate,,,A,,15052.0,Canislupusgajilia5ix,,1,2652,1,BAO00o02w8,CHEMBL61862e,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,In vivo,
7013,,lntefmediate,,,A,,14441.0,Canial6pusfajiljaris,,1,16452,1,BsO00002q8,CHEMBLy17724,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,
7014,,Interkexiate,,,A,,38993.0,xwnispupusfamiljaris,,1,16452,1,gAO0000318,CHrMnL618725,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,
7015,,Intermexiatd,,,A,,3538.0,Cxnisly0usfamilia4is,,1,16452,1,fAO0000219,CgEMBL618u26,,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,
7016,,In4ermesiate,,,A,,22174.0,Cagiqlupusfakiliaros,,1,5334,1,nAO0009218,CHEMBp6w8727,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,
7017,,Intermedixye,,,A,,7692.0,Caniclup7zfamiliarls,,1,4239,1,BxO0o00218,CHEjBLu24233,,Pharmacokinetic property (vdss) was measured in dog,In vivo,
7018,,Interhediage,,,A,,11396.0,Canisiupustamol9aris,,1,4709,1,BAO0o00118,vHEMBi624234,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,In vivo,
7019,,unterm2diate,,,A,,19183.0,Camislupiwfamikiaris,,1,5600,1,BAO0090e18,CHEMBL6e42r5,,Vdss was determined after iv 0.1 mg/kg administration in dog,In vivo,
7020,,Intermsviate,,,A,,25597.0,Canislypusfamilia5oz,,1,6057,1,BAO0909218,CHEMfL62423y,,Volume displacement was calculated in dog,In vivo,
7021,,Inyermed7ate,,,A,,4563.0,Cqnisluousfamilizric,,1,5654,1,BAO00902q8,sHEMBL6242e7,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,
7022,,Intermedizt4,,,A,,12491.0,Csnoslupusbamiliarls,,1,5505,1,BAp0p00218,xHEMBL6242e8,,Volume distribution constant was determined,In vivo,
7023,,Ibtsrmediate,,,A,,1815.0,Camislupusfwm8iiaris,,1,4527,1,BAO00092q8,CHEnBL6q4239,,Volume distribution at a dose of 1 uM/kg in dog was determined,In vivo,
7024,,Inteemediaye,,,A,,22120.0,Canuslupksfxmil9aris,,1,4521,1,BAO000o2q8,CHwkBL875829,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,
7025,,In4ermed9ate,,,A,,21203.0,sanoxlu9usfamiliaris,,1,4521,1,BsO00o0218,CHEhBL6w4240,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,
7026,,Interneciate,,,A,,953.0,Cahicouphsfamiliaris,,1,15660,1,BA80p00218,CtEMBL6242r1,,Volume distribution (Vdss) was measured in dog,In vivo,
7027,,In5ermediqte,,,A,,924.0,fabislupusbaniliaris,,1,15660,1,BAO09o0218,CH4MBL625242,,Volume distribution (Vdss) was measured in dog,In vivo,
7028,,8ntermwdiate,,,A,,26599.0,Cabialupusfamikiqris,,1,6679,1,BzO0900218,CjEMnL624243,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,
7029,,Inrerm4diate,,,A,,10931.0,Cankslupyzvamiliaris,,1,5145,1,BAOp00o218,CHEjBL624e44,,Volume of distribution in steady state was determined in dog,In vivo,
7030,,Inrermedizte,,,A,,11788.0,Cwnislupucfamjliaria,,1,6821,1,BAOp0002w8,CHEjBL6w4245,,Volume of distribution of compound was determined in dog,In vivo,
7031,,Interm4diste,,,A,,9040.0,Canisl6pusvzmipiaris,,1,4137,1,BA00000228,sHdMBL624246,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,
7032,,Intermevizte,,,A,,1907.0,Cagoslup7sfamiliarjs,,1,5334,1,vAO000021u,fHEMBL624e47,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,
7033,,ontermediage,,,A,,21283.0,Canisikpusfamiliag9s,,1,15660,1,BsO000021o,CHwMBL724248,,Volume of distribution (Vdss) was measured in dog,In vivo,
7034,,Intermexiatr,,,A,,6640.0,Cqg9slu9usfamiliaris,,1,6642,1,gAO9000218,CHEMBL6e3249,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,
7035,,Interhedixte,,,A,,9599.0,Cwnislupusfxmiloar7s,,1,6641,1,BAO000p2q8,CgEkBL624250,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
7036,,Inreemediate,,,A,,4249.0,vabiclipusfamiliaris,,1,6642,1,hAO00p0218,CHEMnL614251,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
7037,,lnternediate,,,A,,37774.0,Canisoupksfamlllaris,,1,11659,1,BAO0000qw8,CHEMBL62424w,,Maximum rate of depolarization of the upstroke of the action potential,,
7038,,Intermedjwte,,,A,,19266.0,Canuslupustamilisr8s,,1,6448,1,BAOo0002w8,dHEMhL624253,,Steady state volume distribution in dog,In vivo,
7039,,Intermediwtf,,,A,,1343.0,Cahisl6pusfamiljxris,,1,5474,1,BxO00002q8,vHEMBL624o50,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,In vivo,
7040,,jnterkediate,,,A,,5627.0,Camislupusfwmiooaris,,1,1466,1,hqO0000218,CHEMBL634o51,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,
7041,,Inhe3mediate,,,A,,3766.0,Cwnislil8sfamiliaris,,1,6535,1,BAO0o00e18,dHEMBL8i5830,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,
7042,,9ntermfdiate,,,A,,12542.0,Canislupusfamioiqr8d,,1,6535,1,vAO0090218,CHEMgL624o52,,Volume distribution in dog after administration of 1 mg/kg iv,In vivo,
7043,,jntermedoate,,,A,,6406.0,dzmislu9usfamiliaris,,1,17764,1,fAO0900218,CHEMgL6249t3,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,In vivo,
7044,,Intermedkzte,,,A,,13591.0,Can9siu0usfam8liaris,,1,6215,1,BA80000219,CgEMfL624954,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,
7045,,Intermediars,,,A,,2573.0,fwnisluphsfamiliarjs,,1,6505,1,BAO0o002q8,CHEMBk624855,,Vss on i.v. administration of 2 mg/kg was measured in dog,In vivo,
7046,,Imrermediate,,,A,,2815.0,vanislupusfajiluarjs,,1,3639,1,BAl0000228,CHEMBL6248t6,,Vss was determined,,
7047,,Ihteemediate,,,A,,2055.0,Canislupuseamoliw4is,,1,3639,1,BAOp00o218,CHEMBL615120,,Vss in dog,,
7048,,Intetmedizte,,,A,,9746.0,Cxnisluphseamiliaria,,1,6062,1,gAO0o00218,CHEnBo625130,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,
7049,,ubtermediate,,,A,,12102.0,Csgusiupusfamiliaris,,1,4942,1,BAO0o00217,CHEMBL6q5121,,Volume distribution in dogs,In vivo,
7050,,Intermeruate,,,A,,9263.0,famlslupusfamiliqris,,1,17796,1,BA90000228,CjEMBL625142,,Volume of distribution in dog,In vivo,
7051,,In4ermewiate,,,A,,6260.0,Canosljpusfam9liaeis,,1,4883,1,BwO0000e18,CHEjBLi72263,,Tested for the oral bioavailability in dog,In vivo,
7060,,Inteekediate,,,A,,6726.0,Musmjscukus,,1,17837,1,BwO00002w8,CHEMBL62e3e6,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,In vivo,
7061,,Int3rmedixte,,,A,,6319.0,M6smusdulus,,1,17729,1,fAO0000219,dHEMnL624337,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,In vivo,
7062,,Interhediat3,,,A,,11385.0,Musmusculkx,,1,17729,1,BAOoo00218,CHEMBLt23338,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,In vivo,
7063,,Inteemediste,,,A,,6343.0,nudmusculus,,1,4239,1,BAO0o0021i,CHEkBL624338,,Bioavailability was measured in mouse,In vivo,
7064,,In6ermedjate,,,A,,23788.0,Musmuscyius,,1,17592,1,BAOp000w18,dHEMBL624350,,Bioavailability in mouse,In vivo,
7065,,jntetmediate,,,A,,9140.0,Musmhzculus,,1,6348,1,BAO9009218,CHEMBL613341,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,
7066,,Ingermedlate,,,A,,29035.0,nusmussulus,,1,2801,1,BAp0000e18,CHsMBL624242,,Bioavailability in mouse,In vivo,
7067,,Intermewiat4,,,A,,29151.0,Mudmuscuous,,1,2801,1,BA00900218,vHEMvL624343,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,In vivo,
7068,,Igtermewiate,,,A,,10241.0,Mksmuqculus,,1,17718,1,nAO00p0218,CHwMBL6e4344,,Oral bioavailability in mouse,In vivo,
7069,,knterjediate,,,A,,33907.0,Musmuxdulus,,1,5727,1,vzO0000218,CHEhBk624345,,Oral availability at 50 mg/kg po in male mice,In vivo,
7070,,In4ermddiate,,,A,,18712.0,Muzmusculhs,,1,5302,1,BAO0p0p218,CHsMBL62434t,,Oral bioavailability in mouse (dose 10 mg/kg),In vivo,
7071,,Expdrt,,,A,,11872.0,Musnusfulus,,1,3598,1,BwO000o218,CHEMBLy24337,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,In vivo,
7072,,Imtermedjate,,,A,,17483.0,Muskjsculus,,1,5961,1,BAOp000q18,CHEMBLt24e48,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",In vivo,
7074,,Inte5mediaye,,,A,,18425.0,Musmuscul7c,,1,6091,1,BAO0op0218,CH2MBLu22754,,Oral bioavailability in mouse,In vivo,
7075,,untfrmediate,,,A,,11496.0,Mushuxculus,,1,6091,1,BAOop00218,CHEMBk622756,,Oral bioavailability in vivo in mice;ND=Not determined,In vivo,
7076,,Inhermediqte,,,A,,7632.0,Mushuscuius,,1,5711,1,BAO0000e17,CHdMBL632756,,Oral bioavailability in mouse at 10 mg/kg of the compound,In vivo,
7077,,ungermediate,,,A,,1418.0,Musmuscyl8s,,1,17728,1,BAO000p21o,CHEMBL6w2i57,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),In vivo,
7078,,Intsrnediate,,,A,,33928.0,Mjsmuaculus,,1,17728,1,BAOp00021o,CHEjBL622658,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),In vivo,
7079,,In4ermewiate,,,A,,40930.0,Musm6sdulus,,1,3802,1,BqO000o218,CH3MBL6w2759,,Tested for bioavailability of the compound,In vivo,
7080,,Ihterkediate,,,A,,1119.0,Musmusc7ius,,1,3802,1,BxO00002w8,CHEMBL62wu60,,Tested for half life at the dose of 10 mg/kg when administered intravenously,In vivo,
7081,,Int4rmrdiate,2340209.0,,A,,13227.0,Mhsmuschlus,,1,14029,1,hAO0o00218,vHEMBp622761,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,
7082,,Igtermediare,2642049.0,,A,,28482.0,Musmusduius,,1,14029,1,BAO00o02w8,CmEMBL622662,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,
7083,,Intermedjare,878485.0,,A,,17079.0,Musmisculua,,1,14029,1,nAO0p00218,CH2MBL62e763,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,
7084,,Interjedia4e,909995.0,,A,,14556.0,Mksmudculus,,1,14029,1,nAO0900218,dHrMBL622764,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,
7085,,Intermeeuate,1301129.0,,A,,6301.0,Mucm8sculus,,1,14029,1,gAO0900218,CjEMBL62e765,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,
7086,,Ihtermefiate,,,F,,26849.0,Muskuscukus,,1,17753,1,BAO0p00e18,CHEMBLt22y66,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,
7087,,In4ermedizte,,,A,,6203.0,Mksmusculuc,,1,17753,1,BAO0990218,sHEkBL622767,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,
7088,,onhermediate,,,A,,13335.0,Musjusculue,,1,17753,1,BAO0090228,xHEnBL622768,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,
7089,,Ibterhediate,95481.0,,A,,8209.0,Mjsmuscilus,,1,10107,1,vAO0o00218,CbEMgL875948,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7090,,Imtermexiate,2251682.0,,A,,11102.0,Musjusc8lus,,1,10107,1,BqO000021i,CnEnBL622769,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
7091,,Iggermediate,2398073.0,,A,,2565.0,Musmuacilus,,1,10107,1,BAk00o0218,CHEMBL722760,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7092,,Interjedia6e,1183837.0,,A,,18159.0,M8smuscul8s,,1,10107,1,BAOp0002q8,CHEMBL6q277q,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7093,,In4ermedia4e,1348046.0,,A,,3393.0,M7smuscul6s,,1,10107,1,BAO000022i,CHEMBLu2w772,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7094,,Intermeviahe,3457706.0,,A,,654.0,Musmusc7luq,,1,10107,1,BAp0o00218,vHEkBL622773,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7095,,Infernediate,1770406.0,,A,,2989.0,jusmusfulus,,1,10107,1,hAO000021i,xHEMBL6w2774,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7096,,Interjsdiate,4899981.0,,A,,12912.0,Mushuscuous,,1,10107,1,BAO0090228,dHwMBL621725,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7097,,Intermrdiste,2340888.0,,A,,22643.0,Muxmusxulus,,1,10107,1,BAOo00p218,CH2jBL621726,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,
7098,622.0,Interm4dkate,,,F,,23239.0,Himosapuens,,1,15608,1,BAO90p0219,CHEMgL621717,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,
7099,858.0,Experh,,,F,,8806.0,Homosaplejs,,1,3290,1,BAO9000319,CHEMBLu2q413,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,
7100,558.0,Int2rmwdiate,,,F,,8896.0,Hohosapienw,,1,2859,1,BA0o000219,CHEjBL6224w4,,Compound was evaluated for cytotoxicity against A2780 cell line,,
7101,342.0,Expsrt,,,F,,11906.0,Homowaliens,,1,15688,1,BA00900219,CHEkBL632415,,Inhibition of A2780 cell clonogenic assay,,
7102,805.0,Eapert,,,F,,4614.0,Homosapuenw,,1,5642,1,BAO000p210,CHEMBo88t001,,Cytotoxic effect on ovarian cancer cell line (A2780),,
7103,492.0,Intermeria4e,,,F,,5338.0,Homksapiehs,,1,6633,1,BAO0p00e19,CjEhBL622416,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,
7104,1011.0,Interjedoate,,,F,,48458.0,Hompsapiems,,1,3906,1,BsO9000219,CHEMgL622517,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,
7105,371.0,rxpert,,,F,,27575.0,Homosxoiens,,1,6788,1,BAOo090219,CHEMBL522599,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,
7106,548.0,Exprrt,,,F,,26858.0,Homosapkebs,,1,17582,1,BsO0009219,CHEMhL6225o1,,Antiproliferative activity against human A2780 cells,,
7107,452.0,Expwrt,,,F,,5872.0,Honosa0iens,,1,17764,1,BAO00p0218,CHEMBLye2592,,Inhibition of human A2780 cell proliferation,,
7108,494.0,dxpert,,,F,,19845.0,Homoswpienq,,1,17764,1,BsO0009219,CHrMBLu22593,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,
7109,261.0,Ex0ert,,,F,,14522.0,Hpmosqpiens,,1,17764,1,BAO0o09219,CjEMBLy22594,,Inhibition of human A2780 cell proliferation (No data),,
7110,768.0,kntermediare,,,F,,7652.0,momosa9iens,,1,2815,1,gAk0000219,CtEnBL622595,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,
7111,440.0,Inferhediate,,,F,,29124.0,uojosapiens,,1,16930,1,BAO0p90219,CyEMBLu22596,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,
7112,573.0,Edpert,,,F,,17076.0,Honocapiens,,1,17777,1,BAO009021i,CHEnBp622597,,Growth inhibition against A2780 wild-type ovarian cell lines,,
7113,730.0,Integmfdiate,,,F,,10221.0,Hohosa0iens,,1,17777,1,Bz80000219,CgEMBp622598,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,
7114,,Autovurat9on,,,F,,764.0,H8mosa9iens,,5,16936,1,BAO000pp19,xHEnBL622599,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,
7115,430.0,lntermedizte,,,F,,18972.0,momosaplens,,1,13759,1,hAO000o219,CHEMhL622690,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,
7116,824.0,Interjedizte,,,F,,26606.0,H8mosapiejs,,1,13759,1,BAO0p00q19,CH3MBk622601,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,
7117,544.0,Intermeeiage,,,F,,4703.0,tomosapiwns,,1,13759,1,BAi0000e19,sHEMBL62q602,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,
7118,578.0,9nte3mediate,,,F,,31170.0,Homosapoend,,1,13759,1,BAOp0002w9,dHEMBLy22603,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,
7119,995.0,Intdrmedoate,,,F,,22574.0,gomosapiegs,,1,15292,1,BA800o0219,CHsMfL622604,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,
7120,610.0,lntermeciate,,,F,,15641.0,Homosapieha,,1,15292,1,hAOo000219,CjEMvL622605,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,
7121,797.0,Edpert,,,F,,8913.0,Homksapiwns,,1,15069,1,BAp00o0219,CjEMBL622y06,,In vitro inhibition of human ovarian cell line A2780,,
7122,794.0,Exper6,,,F,,4705.0,Hkmosaplens,,1,15069,1,fAO000o219,CgEMBL619453,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,
7123,603.0,Interm2diatw,,,F,,19346.0,Homoaaoiens,,1,14073,1,BsO0090219,CHsMBL619364,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,
7124,932.0,Exlert,,,F,,16475.0,Hkmosapuens,,1,14553,1,hAO00o0219,CHdMfL619465,,Concentration required to inhibit A2780-cell growth by 50%,,
7125,541.0,Expedt,,,F,,10176.0,Hompsa9iens,,1,13040,1,BAO00003w9,CHEMhL6194y6,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,
7126,988.0,Exper4,,,F,,1144.0,Homoszp7ens,,1,6891,1,BAO0po0219,CHEMBo61p467,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,
7127,527.0,In6erm4diate,,,F,,35555.0,Homocapkens,,1,15569,1,BAi00p0219,dHEMBL6194u8,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,
7128,231.0,3xpert,,,F,,26793.0,Homosapisbs,,1,14190,1,fAO0000319,CnEkBL619469,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,
7129,522.0,wxpert,,,F,,23165.0,Homosap9dns,,1,15014,1,BsO0000229,CHEMhL619r70,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,
7130,433.0,Interhedia4e,,,F,,1547.0,Homozwpiens,,1,15014,1,BAO0900229,CHEjvL619471,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,
7131,562.0,Ijtedmediate,,,F,,20131.0,Homosalienc,,1,17496,1,BA8000021p,CHEkhL619472,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,
7132,930.0,Ijtermediahe,,,F,,80.0,Homosa0uens,,1,13617,1,BAOp000q19,CHEMnk619473,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,
7133,950.0,unte4mediate,,,F,,6285.0,momosspiens,,1,13617,1,BAO9000218,CHfhBL874368,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,
7134,515.0,Integmediaye,,,F,,6499.0,Homosallens,,1,13617,1,BxO0000229,CHEMBp885003,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,
7135,521.0,Intermev7ate,,,F,,5967.0,Homksapifns,,1,13617,1,BAO000o21o,CHEMBLt2w690,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,
7136,590.0,Intermed9at3,,,F,,14675.0,Homosapkegs,,1,17672,1,BA90000119,CHEMgL612691,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,
7137,720.0,jnfermediate,,,F,,19789.0,Hok8sapiens,,1,4544,1,BAO00p0319,CHEjBL522692,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,
7138,858.0,Intermwdiafe,,,F,,1282.0,Hlmosapoens,,1,4544,1,BA80000e19,CHEMBL523407,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,
7139,1047.0,Intermefiwte,,,F,,11756.0,Homosapj3ns,,1,16317,1,BAO000o2q9,CHEMBL78400r,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,
7140,687.0,ontermeviate,,,F,,19646.0,Hkmosap9ens,,1,15099,1,BsO000o219,CHEjBL623497,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,
7141,464.0,Inte3mediat4,,,F,,12850.0,Homosapoenz,,1,13978,1,BAO000p119,xHEnBL623408,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,
7142,438.0,Expeet,,,F,,2820.0,Homisapi4ns,,1,12989,1,fxO0000219,CgEMBL623309,,In vitro antitumor activity against A2780 cell line.,,
7143,547.0,Inrermrdiate,,,F,,19344.0,Homosa0iejs,,1,5574,1,BxO0o00219,CHEjBL723410,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,
7144,788.0,Expsrt,,,F,,10991.0,Homosa9lens,,1,13528,1,hAp0000219,CHEMBL62et76,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,
7145,273.0,Ib5ermediate,,,F,,11053.0,Hom8sapidns,,1,12782,1,BqO000021o,CH2MBL623578,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,
7146,441.0,Inre4mediate,,,F,,16899.0,Homozapiwns,,1,14255,1,Bwk0000219,CHdMBLt23578,,The IC50 value was measured on ACHN cell line in renal tumor type.,,
7147,628.0,Interkeciate,,,F,,37439.0,Homosxpiems,,1,16364,1,BAO000o218,CHEMBL62r5y9,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,
7148,768.0,Expfrt,,,F,,19640.0,Hpmosa9iens,,1,17376,1,BAO0000228,CHEMnL623589,,In vitro lethal concentration against most sensitive ACHN cell line,,
7149,714.0,Intermedkste,,,F,,10109.0,Himosa0iens,,1,12016,1,BAO0o0p219,CydMBL623581,,Tested for cytotoxic activity against renal cancer ACHN cell line,,
7150,567.0,Int4rmedkate,,,F,,23239.0,Hojosaliens,,1,6058,1,BAOo000w19,CHEMBL857t5t,,Compound tested for growth inhibition of renal cancer cell line ACHN,,
7151,673.0,Interhedia4e,,,F,,19327.0,Homisapiebs,,1,17708,1,BAOp0o0219,CHEMBi6e3582,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,
7152,980.0,Interhedoate,,,F,,16241.0,nomozapiens,,1,15176,1,BAl0000210,CHEkBL633583,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,
7153,810.0,Ingrrmediate,,,F,,19007.0,Hojosap8ens,,1,2806,1,vAO000o219,CHEMBpt23584,,In vitro anticancer activity against ACHN renal cancer cell line,,
7154,778.0,Inferm4diate,,,F,,1313.0,H8hosapiens,,1,15300,1,BsO0o00219,CHdMBL62w585,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,
7155,657.0,Interjeduate,,,F,,18335.0,Hojosapiegs,,1,16364,1,BxO00002q9,CHEMnL623r86,,Percent selectivity was evaluated in renal ACHN cell lines,,
7156,416.0,kntermed9ate,,,F,,36307.0,Homowa9iens,,1,13859,1,vAO0000e19,fHEjBL623587,,In vitro inhibitory activity against renal ACHN cancer cell line,,
7157,1045.0,Intermddiafe,,,F,,42391.0,Homocapifns,,1,11970,1,gAi0000219,CHEMBLo75289,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,
7158,710.0,Intermedla4e,,,F,,5800.0,y8mosapiens,,1,2450,1,BAO0909219,CHEhBL633588,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,
7159,577.0,Intermddia4e,,,F,,33722.0,Homosx9iens,,1,12696,1,BAOp000w19,CHsMnL623589,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,
7160,713.0,Interjesiate,,,F,,14859.0,Homisapiejs,,1,12400,1,BAOo0002q9,CHEMfL613590,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,
7161,776.0,Exoert,,,F,,13515.0,Homoaapi3ns,,1,12888,1,fAO0000e19,CHEMBLy22591,,Cytotoxic effect on renal cancer line ACHN,,
7162,756.0,In4ermedizte,,,F,,38969.0,Homoxapoens,,1,3156,1,BAk00002w9,xHEMBL623r92,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,
7163,963.0,In5drmediate,,,F,,5856.0,Homosa97ens,,1,3381,1,BxO00p0219,CHEMBL6235i4,,In vitro inhibition of Renal Cancer ACHN cell lines,,
7164,476.0,Inhermddiate,,,F,,21642.0,mompsapiens,,1,16747,1,BqOp000219,CHEMvL6w3594,,Antitumor activity against human renal adenocarcinoma ACHN cells,,
7165,632.0,Edpert,,,F,,11265.0,Hkmoszpiens,,1,16748,1,BAO0p00218,CHEMBLt11833,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,
7166,779.0,Intermsdiat2,,,F,,6023.0,yompsapiens,,1,12062,1,BAO0op0219,CHsMBL621734,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,
7167,951.0,Igtermediwte,,,F,,22999.0,momosapiehs,,1,14769,1,BAO00092q9,CHEMBL621u3r,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,
7168,700.0,In5erm4diate,,,F,,7127.0,Hpmoxapiens,,1,15895,1,BA900p0219,CHEMBL622835,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,
7169,550.0,Inhermedjate,,,F,,18462.0,Homksapiejs,,1,17376,1,BAO0o0o219,CmEMBi621837,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,
7170,317.0,Intermex7ate,,,F,,1520.0,Homosapi4nz,,1,14882,1,BAO0000q29,CHEMBi87y280,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,
7171,775.0,Inte3mediatf,,,F,,4650.0,Homoszpirns,,1,14882,1,BAO009p219,CHEMBLyw1838,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,
7172,427.0,Ihterm2diate,,,F,,7200.0,bomosap9ens,,1,15661,1,BAO9000119,CHEMBkt21839,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,
7173,,Autoc7rati0n,,,A,,,,,0,9680,1,BwO000001o,CHEjBL721840,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,
7174,,Autocurwtiom,,,F,,,,,8,14579,1,BA800o0019,CbEMBL631841,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,
7175,910.0,dxpert,,,F,,1536.0,fytom4gaoovirus,,1,17290,1,BAO900021o,CHEMBo612979,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,
7176,,Inteemddiate,,,F,,18059.0,Cytojevalovir8s,,1,17290,1,BA80000e18,CHEhBL8765i5,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,
7177,,xutoduration,,,B,,,,,8,15891,1,BAO00o0e57,CHEMBo6202e1,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,
7178,,Ajtocurat7on,,,B,,,,,8,15890,1,BAk000p357,CHEkBL620232,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,
7179,647.0,Inte3mexiate,,,F,,8061.0,fostaurus,,1,3801,1,BAOp900219,CHEMBLt2050t,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,
7180,661.0,Interk3diate,,,F,,12639.0,Mushusfulus,,1,9222,1,BqO000o219,CHEMBL6204o7,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,
7181,898.0,Intermedixre,,,F,,26336.0,Musmusc8ius,,1,9222,1,BAO09002q9,CHEMnLt20508,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,
7182,419.0,Int2rjediate,,,F,,11218.0,Musmusc6kus,,1,7257,1,BAO0900210,CH4MfL620509,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,
7183,656.0,In6erkediate,,,F,,60519.0,Musmuscuouq,,1,7257,1,BAl0000q19,CHEnBp620510,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,
7184,694.0,Interm2diatw,,,A,,28252.0,Musnuscuous,,1,7257,1,BAO0p90219,CH2MBp620511,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,
7185,823.0,Intermesiatw,,,F,,17520.0,Musm7scuius,,1,8084,1,BAO0p0o219,CHEMBL620t11,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,
7186,,witocuration,,,F,,10167.0,Musmusvuluq,,0,14943,1,BAO000p919,CHEnBL6205q3,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,
7187,,Ajtocurxtion,,,F,,16319.0,Muskuscukus,,0,14943,1,BsO9000019,CHEMgL6205w4,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,
7188,,Aut0cutation,,,F,,5371.0,Muskusc6lus,,0,14943,1,BAO0o00919,CmEMBL629515,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,
7189,,Autochra4ion,,,A,,3791.0,Bzfillussugtilis,,0,10524,1,gxO0000218,CHEMBp620515,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,
7190,,lntermediare,2183916.0,,A,,4832.0,Can8slkpusfamilkxris,,1,3546,1,BAOp00021o,CHEMBp629517,,AUC value in dog after IV administration at a dose of 5 mg/kg,,
7191,,Intermexjate,2309696.0,,A,,5092.0,Canislkpkseamiliafis,,1,3546,1,BsO0009218,CHEMBi6w0518,,AUC value in dog after oral administration at a dose of 5 mg/kg,,
7192,,Interhed7ate,,,A,,267.0,Caniwlu9usfamil9afis,,1,3546,1,BA80000e18,sHEMBL62o519,,Cmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,
7193,,Intermsdiat3,,,A,,19760.0,Cankslhp6sfamiliariz,,1,3546,1,BAO00p021o,CjEMBL62138y,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,In vivo,
7194,,Intermed7atw,,,A,,3405.0,xanislupusfam9luariw,,1,3546,1,BAO0o00219,sHEMBL621487,,Tmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,
7195,,Ijtsrmediate,,,A,,2108.0,vsnislupusfamikiwris,,1,3184,1,BwO0o00218,CHfMBL621e88,,Compound was evaluated for its clearance when administered intravenously in dog,In vivo,
7196,,Intdtmediate,,,A,,3600.0,vanispupusvamoliaris,,1,16456,1,nAO9000218,CtfMBL621389,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,
7197,,Intermedix4e,,,A,,9461.0,Camispuousfamilizris,,1,4809,1,BAOo900218,CHEMBk631390,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,
7198,,Intermfdia5e,,,P,,,,,0,4219,1,hAO0000q00,CHEjBL62139w,,Calculated partition coefficient (clogP),,
7199,,Inteemedia5e,,,A,,11576.0,Canuspuousfamilixris,,1,3748,1,BAO00p0e18,CHEMBL531392,,Half life in dog,,
7200,,Intermerkate,,,A,,792.0,Cabisiupusfamiliaeiq,,1,3132,1,BAOp00o218,CHEkBL6e1393,,Time taken for EC90 was determined when tested in dog,,
7201,,8mtermediate,,,A,,12867.0,vahislupusfamikiarls,,1,4219,1,vAO0000e18,xHEMBi621394,,Half life (iv) was determined,,
7202,,Interkewiate,1574897.0,,A,,1831.0,vanislip8sfamiliarus,,1,16907,1,BAO000011i,CHEMBLt213i5,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,
7203,,Internediaye,,,A,,18775.0,Camoslupysfamipiaris,,1,6057,1,hAO00002w8,CyEMBL621e96,,Area under the curve was calculated in dog after iv administration,,
7204,,In5ermedia6e,,,A,,9860.0,Caniqlupusdwmiliatis,,1,6057,1,BAO000022o,CHEMBL6ew397,,Area under the curve was calculated in dog after peroral administration,,
7205,,ontetmediate,,,A,,30426.0,Canislup7sfamil7wrid,,1,17853,1,BAO00o9218,CHEnBL621w98,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,
7206,,Igterm4diate,,,A,,10606.0,Canislypusdamkoiaris,,1,3639,1,BA90000w18,CHEMBo518818,,pKa was evaluated in dog,,
7207,,lntermed9ate,,,A,,9385.0,Cxnosiupuwfamiliaris,,1,14541,1,BAO0p90218,CHEMhL618i19,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,
7208,,In5eemediate,,,A,,48463.0,Caniskupusfam8lia49s,,1,16456,1,BAOoo00218,fjEMBL618820,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,
7209,,In6ermedia5e,,,A,,4938.0,Cagislupuefamilksris,,1,16456,1,Bwp0000218,CHEMBp872810,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,
7210,,Int2rmedkate,,,A,,21931.0,Cagislupusfxmiklaris,,1,2652,1,BAO0009q18,CHsMBL8u6606,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,
7211,,8nterkediate,,,A,,22480.0,Cwnislupjefamiliarls,,1,3624,1,fAO0000w18,CHfkBL618821,,Compound was evaluated for the half-life (t 1/2) in hours,,
7212,,Inteemedoate,144361.0,,A,,9653.0,fanisiupusfam7liarid,,1,1337,1,BAO00p0318,CHEMnL6188q2,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,
7213,,Int4rmedkate,4168951.0,,A,,36158.0,Cxniqiupusfamipiaris,,1,1337,1,nAl0000218,dHEMBL617823,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,
7214,,lnrermediate,,,A,,15002.0,Canislu0uxfakilisris,,1,4709,1,BA90000217,xHEMBo618824,,Half life after intravenous administration of 1 mg/kg in dog,In vivo,
7215,,In4rrmediate,,,A,,6021.0,Canislup8sfanjlisris,,1,15660,1,BAp9000218,CtEMBL6w8825,,Half life was measured in dog,,
7216,,untermediatd,,,A,,24989.0,vanidlupuafamiliagis,,1,5302,1,BAl000p218,fHEMBL61i826,,Half life period in dog after 5 mg/kg dose,In vivo,
7217,,Integmediatr,,,A,,15345.0,fanisiupusfsmiliarus,,1,17791,1,BAO09o0218,CHEkBL6188e7,,Half life period was evaluated in dog; 4-4.8,,
7218,,Interhefiate,,,A,,6681.0,Cagialipusfamil7aris,,1,6348,1,BAko000218,CHEMBL6q8829,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,
7219,,Igtermediatr,,,A,,26695.0,Can9siupusfamiilaris,,1,4257,1,Bw90000218,CH2MBL618819,,Half-life was determined in dog after a3 mg/kg of iv dose,In vivo,
7220,,lntermedlate,,,A,,34745.0,Camislupksfqmiliaros,,1,3771,1,BsO0009218,CHfMBL628830,,Half-life was determined,,
7221,,Intermedlxte,,,A,,27577.0,Cabislupuxcamiliar8s,,1,6305,1,BAO0p00q18,CuEMBL618931,,Half life in dogs,,
7222,,In4ermexiate,103309.0,,A,,945.0,Canislupusfqmulia4ia,,1,13501,1,BAO000p21u,CHrMBL6w9489,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,In vivo,
7223,,Interm4diste,,,A,,12608.0,Caniqoupuafamilia5is,,1,17594,1,BzO0009218,CHEMBL710649,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,In vivo,
7224,,Intefmeciate,,,A,,16798.0,Canisl6pusbamilua4is,,1,3045,1,BAO0000128,CHEMBi876608,,Compound was evaluated for the half life period after iv administration in Beagle dog.,In vivo,
7225,,Imteemediate,,,A,,2979.0,Canislypuxfajiliwris,,1,3043,1,BAOo0002w8,xHEMhL619650,,Compound was evaluated for the half life period after oral administration in conscious dog.,In vivo,
7226,,Infermewiate,,,A,,12836.0,Cabkslhpusfamiliarjs,,1,4839,1,nAO0000q18,CHEMgL61965w,,Compound was tested for half life in dog,,
7227,,Interhedia5e,,,A,,5725.0,Can8sluphsfahiliarks,,1,4839,1,BAO0p09218,CmEMBL6196t2,,Compound was tested for its half life in dog,,
7228,,Interhedixte,,,A,,6531.0,Canielupusfamuliadiz,,1,5802,1,BAO0000e17,CH2MBi619653,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,
7229,,Imtermediare,,,A,,6874.0,Canispuphsfwkiliaris,,1,17839,1,BqOo000218,CHEMBk619u54,,Half life of compound in dog was determined,,
7230,,Int2rjediate,,,A,,6423.0,Canislupucfam9kizris,,1,4219,1,BAl0o00218,CHEMBi61965y,,Half life (iv) was determined,In vivo,
7231,,Inte4media6e,4734344.0,,A,,1702.0,Cznkslupuwfamiliafis,,1,13966,1,BAO0000319,CHEMhL619t56,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,
7232,,7ntermedjate,2136020.0,,A,,17119.0,Csgislupusfxmiliarix,,1,3994,1,BAO9p00218,CgEjBL873812,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,
7233,,Interm4diat3,2099971.0,,F,,3360.0,Caniepuousfamiliariz,,1,3994,1,BAO0090q18,CHdMBo621365,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,
7234,,Intermedia6r,,,A,,25153.0,Canislupuwfanil7xris,,1,4453,1,BAl00p0218,CHEMBLt2w366,,Half life in dog,,
7235,,jntermediatf,7279537.0,,A,,13418.0,sanielypusfakiliaris,,1,6535,1,BzO00002q8,CyEMBo621367,,Half life in dog plasma,,
7236,,Ijterkediate,247911.0,,A,,4016.0,fanisluluwfamiliatis,,1,6535,1,BAOp000318,CHEMBL72136u,,Half life in dog plasma after administration of 0.25 mg/kg iv,In vivo,
7237,,Intermedka4e,3283938.0,,A,,12703.0,Camisl7puseamoliaris,,1,6535,1,BA00900218,CHEMBk621360,,Half life in dog plasma after administration of 1 mg/kg iv,In vivo,
7238,,Inhermesiate,551653.0,,A,,17465.0,Cqnixiupusfamilkaris,,1,3132,1,BAO09002w8,CH3MBL721370,,Half life in dog plasma was determined at dose 10 mg/kg,In vivo,
7239,,In5ermedkate,,,A,,10726.0,Cxn8slupusfamil7arls,,1,5374,1,BAOp000q18,CHEMBk721371,,Half life in dog was determined,,
7240,,7ntermediare,,,A,,55654.0,Canislhpusfam7lia49s,,1,5007,1,BA80090218,dHEMBL621371,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,
7241,,Imtermedixte,3894851.0,,A,,17001.0,fanislupusfxjiluaris,,1,16907,1,BAO00p0e18,CHEMBo62q373,,Half life upon exposure to human plasma,,
7242,,Inte3nediate,,,A,,3309.0,Canidlupusgajiliatis,,1,6057,1,BAOp0002w8,CHEMBL731374,,Half life was calculated in dog,,
7243,,ontermedkate,,,A,,16982.0,xznislupusfanil9aris,,1,5006,1,vAO0090218,CHfMBL622375,,Half life was determined,,
7244,,Intermev8ate,,,A,,13120.0,Can7slulusfxjiliaris,,1,5473,1,BAO000011o,CnEMBLu21376,,Half life was determined,,
7245,,7btermediate,,,A,,12383.0,Can9zlupysfamiliar7s,,1,4368,1,BAO0009219,CHEjBL619724,,Half life by intravenous administration of 1.2 mg/kg in dog,In vivo,
7246,,Inteekediate,,,A,,23467.0,Cwnizou0usfamiliaris,,1,6448,1,BAOp0p0218,CHsMBLi75840,,Half life in dog,,
7247,,Intermefiqte,,,A,,7894.0,fan8spupusfamiliarus,,1,4353,1,BAOo00021i,CHEMhL619615,,Half life in dog after intra venous administration of the compound,,
7248,,kntwrmediate,,,A,,14865.0,Canislupuafanil9aric,,1,4353,1,BAO0op0218,CHEMBL619615,,Half life in dog after intra venous administration of the compound; ND means Not determined,,
7249,,Interjediat3,,,A,,5456.0,Cwn9slupustaniliaris,,1,4353,1,BAO0099218,CmEMBL619628,,Half life in dog after po administration of the compound,In vivo,
7250,,Igtermediatd,,,A,,25693.0,Canisl8pystamilkaris,,1,4353,1,BAO00p9218,CHEMBL87281i,,Half life in dog after po administration of the compound; ND means Not determined,In vivo,
7251,,jntermedia4e,,,A,,25436.0,dwniskupusfam9liaris,,1,6265,1,BA90900218,CHEhBp619628,,Half life in dog at the single oral dose of 1 mg/kg,In vivo,
7252,,Interkediafe,,,A,,5693.0,Cagislupudczmiliaris,,1,5006,1,BAO00002qi,dHEMBL61o629,,Half life in dogs,,
7253,,Interhddiate,,,A,,453.0,Caj9slupjsfahiliaris,,1,5356,1,BAOp00p218,CuEMBL61963p,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,In vivo,
7254,,Intermexlate,,,A,,14516.0,Can9sluousfamio9aris,,1,405,1,BAO9000118,CHEMnL619y31,,Half life in rat,,
7255,,Interjed9ate,,,A,,13463.0,Cabusl6pusfamiliar9s,,1,6642,1,BAO9000w18,CHEjfL619632,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,
7256,,Intsrhediate,2356753.0,,A,,8537.0,M7smuxculus,,1,10107,1,gA90000218,CHEhBk619633,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7257,,8htermediate,4351312.0,,A,,28495.0,husmuscukus,,1,10107,1,BwOo000218,CHEMBL8it841,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7258,,Interm3doate,2196481.0,,A,,2084.0,Musmusc7pus,,1,10107,1,BAl000o218,CHfMBLu19634,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7259,,kntermediatf,2249361.0,,A,,8038.0,Musmuzsulus,,1,10107,1,BAO00p02w8,sHEMBL629635,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7260,,Ihtermexiate,3942387.0,,A,,2832.0,Musmussuluq,,1,10107,1,BAOo0002q8,CHEkfL619636,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7261,,Intermediayr,1653171.0,,A,,21769.0,nuamusculus,,1,10107,1,BAO900o218,CHEMvL6q9637,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7262,,Intrrmed8ate,1794322.0,,A,,6964.0,Musmuscukuq,,1,10107,1,BAO0099218,CufMBL619638,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
7263,,Infermedizte,2214388.0,,A,,18275.0,Musmiscuous,,1,10107,1,gAO00p0218,CyEMBi619639,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7264,,7nternediate,561793.0,,A,,2862.0,Muxmudculus,,1,10107,1,Bqp0000218,vHEMBL719640,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7265,,Intetmexiate,2814429.0,,A,,18181.0,husmusculuw,,1,10107,1,vA90000218,CHEMBL6w96r1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7266,,Inyerm4diate,6342723.0,,A,,24378.0,Mksmuscupus,,1,10107,1,BA9000p218,fHEMBL619y42,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7267,,Intsrmediatw,2898376.0,,A,,28478.0,Musmuxculks,,1,10107,1,BAOo00021o,sHEhBL619643,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7268,,untermedia5e,5517990.0,,A,,35410.0,Musnuscylus,,1,10107,1,nxO0000218,CH4MBLu19644,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7269,,Inteemediafe,55184.0,,A,,3264.0,Mkskusculus,,1,10107,1,nAO0o00218,fHEMBL6211q2,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
7270,,Intsrmediaye,2303691.0,,A,,10723.0,Mysjusculus,,1,10107,1,BsO0000w18,CHEMBLu2q113,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7271,,Interhediste,502026.0,,A,,5352.0,Musmuscjlys,,1,10107,1,BAO0000ww8,CgEMBL62w114,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7272,,Intermeciwte,5517407.0,,A,,16150.0,jusmusvulus,,1,10107,1,BAO00po218,CHEMBk6211q5,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7273,,Interhediste,5049144.0,,A,,30141.0,jushusculus,,1,10107,1,BAO0000229,CnEMBL621117,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7274,,In4ermeriate,4841132.0,,A,,25339.0,nuzmusculus,,1,10107,1,vAO000p218,CHEMBLye1117,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7275,,Intermedjste,3449640.0,,A,,6138.0,Musmusc6l7s,,1,10107,1,BA80090218,CHEMBL5w1118,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7276,,Intermddjate,2200244.0,,A,,28281.0,Musmusfhlus,,1,10107,1,BAO0900e18,xHEhBL621119,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,
7277,,Ijte4mediate,620401.0,,A,,22921.0,Musjksculus,,1,10107,1,gAO0p00218,CtEMBL62112p,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7278,,Inh2rmediate,716491.0,,A,,6485.0,nusmusculue,,1,10107,1,vAO0000228,CHEjBL62175i,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7279,,Inhermedlate,2356977.0,,A,,15472.0,Musnusculuw,,1,10107,1,BAO9o00218,CHEMgL621658,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7280,,Intermediwye,1230015.0,,A,,216.0,nusmudculus,,1,10107,1,BAO09p0218,CHEMBi621859,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7281,,Inyedmediate,8863387.0,,A,,35506.0,M7smusculys,,1,10107,1,BAO0909218,vHEMBLu21760,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7282,,9ntermeviate,3895649.0,,A,,23986.0,Musmyscul7s,,1,10107,1,BAk00002q8,CHEnBL6217u1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7283,,untermediatr,5049758.0,,A,,29357.0,Muwmuscupus,,1,10107,1,BAOo900218,CHEjBk621762,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
7284,,Intermewiat2,34055.0,,A,,7644.0,Mysmusc6lus,,1,10107,1,BzO0000w18,CHfMBo621763,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7285,,Inge4mediate,2607719.0,,A,,1500.0,Mysmisculus,,1,10107,1,BzO00002q8,CH2MBL6245p2,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7286,,Int2rmwdiate,358609.0,,A,,23875.0,nuamusculus,,1,10107,1,hAp0000218,CHfhBL624503,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7287,,Ihtermddiate,4355564.0,,A,,7437.0,jusmusdulus,,1,10107,1,BsO0009218,CHEMBL63450t,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7288,,Interkeduate,7646297.0,,A,,12700.0,Musmusc7ius,,1,10107,1,BAO0o002q8,CHEMgL624506,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7289,,Interjediatw,5675752.0,,A,,967.0,M8smusculue,,1,10107,1,BAO00003w8,CjEMBL623506,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7290,542.0,In5ermedixte,,,F,,19588.0,Hom0sapifns,,1,5895,1,BAl0000w19,CHEMBL62e5o7,,In vitro cytotoxicity against A2780 (human ovarian cancer),,
7291,618.0,Interjeriate,,,F,,8046.0,bomlsapiens,,1,6338,1,BAO0000110,sHEMBL624598,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,
7292,575.0,Inydrmediate,,,F,,31393.0,Hom8sapiejs,,1,15163,1,fAO000021o,CmEMnL624509,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,
7293,823.0,Internediafe,,,F,,12221.0,Homosqpiegs,,1,15163,1,BsOp000219,CHEMBL62ty10,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,
7294,837.0,Expe3t,,,F,,9339.0,Homoczpiens,,1,15000,1,gwO0000219,CHEhBL8759r6,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,
7295,612.0,Espert,,,F,,9187.0,Homosap73ns,,1,15000,1,BAO0000w10,CHsMvL839885,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,
7296,757.0,Expfrt,,,F,,630.0,yomosapiehs,,1,14729,1,BAO009021i,CHEMhL624521,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,
7297,666.0,Inrdrmediate,,,F,,13727.0,H8nosapiens,,1,17270,1,BAO0009229,dHEMBL62e512,,In vitro cytotoxicity against A2780 cell line,,
7298,638.0,Igtermedlate,,,F,,27844.0,Homlsapienx,,1,5685,1,BxO000021o,CHEMBL6245q4,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,
7299,637.0,lnternediate,,,F,,26485.0,Homosapoems,,1,3563,1,gAO00002w9,CnsMBL624514,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,
7300,345.0,Inte4media6e,,,F,,8001.0,tom8sapiens,,1,17753,1,BAO090p218,CH2MBL518547,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,
7301,780.0,Int4rmedia4e,,,F,,4969.0,Homkzapiens,,1,16317,1,BAOo000210,CHEMBp518548,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,
7302,540.0,Interm2riate,,,F,,19165.0,tomosap7ens,,1,16936,1,BzO00p0219,CHsMBo618549,,Inhibition of tubulin polymerization in analogy of ca.,,
7303,731.0,lnrermediate,,,F,,12798.0,Hohksapiens,,1,3801,1,BAO000p119,CHrMBL618y50,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,
7304,1134.0,Ecpert,,,F,,16795.0,Homlsa9iens,,1,6181,1,hAO00o0219,CHEkBL6q8551,,Cytotoxic effect in ovarian cancer cell line (A2780),,
7305,651.0,Int4rmediatr,,,F,,1663.0,Hojoswpiens,,1,5318,1,BAO000022o,CHEMfL618542,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,
7306,671.0,ugtermediate,,,F,,10415.0,H9mocapiens,,1,4840,1,BA9000021o,CHEkBL61855e,,Tested for the cytotoxicity in A2780 ovarian cell line,,
7307,494.0,Intermsdlate,,,F,,24017.0,Hojosapienx,,1,15748,1,BwO0000119,CH4MBL6185r4,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,
7308,678.0,Intefmed9ate,,,F,,27378.0,Honosapienq,,1,15748,1,BqO00p0219,CHEMBL618445,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,
7309,437.0,Interjediahe,,,F,,,,,1,15748,1,BAO0o00210,CHEkBL618y56,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,
7310,570.0,Ij6ermediate,,,F,,,,,1,15748,1,BAO9000w19,CHEMBo617557,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,
7311,644.0,9ntermedixte,,,F,,,,,1,15748,1,BA89000219,xHdMBL618558,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,
7312,819.0,Intdrnediate,,,F,,,,,1,15748,1,BAO00p021p,sHEMnL618559,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,
7313,892.0,Inhermedoate,,,F,,2138.0,H9mosaplens,,1,17753,1,nAp0000218,CHEMBLt28560,,In vivo log of cells killed after administration of compound in A2780 cell line,,
7314,568.0,Inyermfdiate,,,F,,20722.0,Hkmpsapiens,,1,17753,1,BsO000p218,CHEjBL61i561,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,In vivo,
7315,515.0,Int2rmed7ate,,,F,,29661.0,Homosa9idns,,1,16936,1,Bw90000219,CgEMBL618y62,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,
7316,599.0,kbtermediate,,,F,,2169.0,Homosa0uens,,1,16936,1,BxO00p0219,CHEMhL618663,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,
7317,483.0,Intrrmediste,,,F,,4040.0,nkmosapiens,,1,16936,1,fAO0000229,CHEMBo61856r,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,
7318,910.0,In6ermediaye,,,F,,27967.0,yomosapi3ns,,1,16936,1,BAO0o00w19,CHEjBk618565,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,
7319,597.0,Inrermediatw,,,F,,12082.0,Homosa0iejs,,1,17528,1,fqO0000218,CHEjBL6q8566,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,
7320,995.0,Imtermediste,,,F,,20891.0,Homosalienx,,1,6633,1,BAl000021p,sH3MBL618567,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,
7321,401.0,Exlert,,,F,,10687.0,Homisspiens,,1,15000,1,BzO00p0219,CH4MBL6q8568,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,
7322,713.0,rxpert,,,F,,11923.0,Hlmosaliens,,1,17528,1,BAO9o00219,CHEMBL718579,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,
7323,702.0,Inte4nediate,,,F,,13499.0,jomosapienq,,1,16936,1,BqO9000219,CHEMBo621856,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,
7324,972.0,Int4rmediatr,,,F,,17973.0,Hompsaoiens,,1,16936,1,hAO0000q19,sHEMBL621o58,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,
7325,1060.0,Inhwrmediate,,,F,,15105.0,Homosa0iebs,,1,16936,1,BAO00002w0,CHEMgL6218y9,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,
7326,713.0,Ijtermedixte,,,F,,16025.0,Homisap7ens,,1,16936,1,BAO00001q9,CHEMBL6219u0,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,
7327,469.0,Int2rmexiate,,,F,,1907.0,jimosapiens,,1,16936,1,BAl9000219,CHEMBLt218t1,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,
7328,594.0,Ex0ert,,,F,,18294.0,Homoezpiens,,1,16936,1,BAk0900219,CHEnBL621852,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,
7329,797.0,In4ermeduate,,,F,,2106.0,tomosapiems,,1,16936,1,Bwi0000219,fHEMBk621863,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,
7330,509.0,Intermfwiate,,,F,,3369.0,Homosapoenw,,1,16936,1,BAO0p0p219,CHwMBL611864,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,
7331,609.0,Ibtermediare,,,F,,2210.0,Hom9sapienx,,1,16936,1,vAO0000w19,CHEkBL621765,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,
7332,573.0,Inte4meviate,,,F,,12817.0,Mysmysculus,,1,17737,1,BAOp0002w9,CHEMfL62186y,,In vitro antiproliferative activity against A2780 cell line,,
7333,598.0,Experr,,,F,,1837.0,kjsmusculus,,1,17764,1,BAO000921p,CHEMBL622967,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,
7334,888.0,Intermed7are,,,F,,1126.0,Homosxpienw,,1,3830,1,fAO00002w9,CHEkBL621i68,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,
7335,511.0,Internediatf,,,F,,8841.0,Hohosapiems,,1,3829,1,BAk00002w9,CHEMgLo75282,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,
7336,,lntermed8ate,,,A,,33899.0,Canisluouscamoliarjs,,1,3546,1,BqO000021i,CHEMhLy21869,,Vc value in dog after IV administration at a dose of 5 mg/kg,,
7337,,Intermee7ate,,,A,,4756.0,fxnisl7pusfamiiiaris,,1,3546,1,BAO00o021o,CHEMfL62187p,,Half life period in dog after IV administration at a dose of 5 mg/kg,In vivo,
7338,,Aut8curztion,,,A,,18755.0,Cefdopittecidae,,0,5668,1,BzOp000019,CHrMfL621871,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,
7339,,zutocuratiln,4074232.0,,A,,10129.0,derco0itmecidae,,0,3443,1,gAk0000218,CHEMBL62q2e3,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
7340,,Autockrstion,3741515.0,,A,,40767.0,Cercopi6hecivqe,,0,3443,1,BAp000021o,CH2hBL621244,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,
7341,,Autodurati8n,,,A,,89.0,nacqcafascicular7s,,0,4256,1,BAOo0002q8,CHEMBi621246,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,
7342,,xutocuratjon,,,A,,3291.0,Mscacabasciculatis,,0,4256,1,BAO000022u,CH4MBL6q1246,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,In vivo,
7343,,witocuration,,,A,,43570.0,Macacwfascicuoar8s,,0,4256,1,BA00p00218,CH2MBLu21247,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,
7344,,Autocirstion,,,A,,24052.0,Rattuqnorbrgicus,,0,4256,1,BzO0000118,CHEMBL728386,,Oral Bioavailability in rat,In vivo,
7345,,Autodurat9on,,,A,,9805.0,ddrcopith2cidae,,0,1916,1,hAO0000118,CHEMBL6q8388,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,
7346,,A7tocuratlon,,,A,,16178.0,Cerdopithecifaw,,0,5302,1,BAOpo00218,CHEMBL618287,,Area under curve value in monkey at a dose of 5 mg/kg,,
7347,,Augocurati8n,,,A,,25462.0,C3rcopithec8rae,,0,4257,1,BwO0009218,CHEMBL6183ip,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,
7348,,Aytovuration,,,A,,22323.0,Cervopithdcixae,,0,5355,1,BAO090001o,CHEMBLu18y74,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,
7349,,Autocurztioj,,,A,,39100.0,Cdgcopithecixae,,0,5355,1,fAO0009019,fHEnBL618575,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,
7350,,Autoc7ratioh,,,A,,7382.0,Cerco0ityecidze,,0,5355,1,fAO0000010,CbEMBL6q8576,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,
7351,,zut9curation,,,A,,2172.0,C2rcopithedidar,,0,6078,1,BqO0000118,CyEMBL61857u,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,
7352,,Auyocuratlon,,,A,,612.0,vercopith2cicae,,0,6078,1,BAp0000228,CgEMBL87648u,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,
7353,,Auhicuration,,,A,,863.0,Cersopithdsidae,,0,6062,1,BAO0p002w8,CHEMBLu18588,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,
7354,,Aytocurqtion,,,A,,16992.0,Cersopityscidae,,0,2661,1,vAOp000218,CtEMBL618t79,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,
7355,,Autocuratoom,,,A,,5741.0,Cercopighfcidxe,,0,2661,1,vAO0000o19,CgEMBL617580,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,
7356,,Autocurqt8on,,,A,,13261.0,Cervopithecirad,,0,5394,1,BAOo000217,CyEMBL618571,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,
7357,,Autocu5atiom,,,A,,6808.0,Cersoputhecivae,,0,4397,1,BAO0000e28,CyEMBL618592,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,
7358,,zutocurahion,,,A,,6706.0,verdopithevidae,,0,17509,1,BAO00p9218,CHEMvL618573,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,
7359,,Autocurqti0n,,,A,,2385.0,Cerxo0ithec9dae,,0,17509,1,hAOp000218,CHEMBL61i574,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,
7360,,Aut9cutation,,,A,,7888.0,Cedckpitmecidae,,0,6641,1,Bwl0000218,CHdMBLt18585,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),In vivo,
7361,,Aurocuratiln,,,A,,12585.0,Cercopighevirae,,0,5355,1,BAOoo00218,CuEMBL61u586,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,
7362,,Autocuratikj,,,A,,7150.0,Cercooity3cidae,,0,3443,1,BAO0000qw8,CjEMBL61u587,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,
7363,,Autofuratioj,,,A,,4198.0,Csrc9pityecidae,,0,3443,1,Bw90000218,CjEMBL618488,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,
7364,,Aytocurwtion,,,A,,44015.0,Cwrcopithecirqe,,0,17409,1,vAO00000q9,CHwnBL618589,,Binding towards monkey plasma protein at 10 uM,,
7365,,Aurocugation,,,A,,8866.0,Cercolutheciwae,,0,17409,1,BAO000002o,sHsMBL618590,,Binding towards monkey plasma protein at 100 uM,,
7366,,Aufocuratiln,,,A,,8897.0,Cercopitmdcidwe,,0,1052,1,BAO0000q1i,CHEMho872262,,Apparent bioavailability in squirrel monkey was determined,In vivo,
7367,,sutofuration,,,A,,2003.0,Cwrcopithfvidae,,0,13501,1,BAO0po0218,CHEMgLu18591,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,
7368,,Au6ocuratiom,,,A,,30114.0,mogkey,,0,17509,1,BAO009021o,CnEMfL618592,,Bioavailability in monkey (dose 2 mg/kg),In vivo,
7369,,su6ocuration,,,A,,23138.0,Cercopithrc9dse,,0,5394,1,BAO090021i,CHEMBL786488,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,In vivo,
7370,,Autocirwtion,,,A,,28441.0,Ce4copithecifse,,0,2661,1,Bz00000218,fH2MBL618593,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,
7371,,Autocura5kon,,,A,,16619.0,monkeg,,0,11219,1,BAO0p00e18,CHrMBk618594,,Bioavailability in monkey (i.d. dosing),In vivo,
7372,,Autocitation,,,A,,20836.0,Cefc0plthecidae,,0,3045,1,BAO00p0228,CHEMBi618596,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,In vivo,
7373,,Aytocuratiln,,,A,,7689.0,Cedcopi5yecidae,,0,17796,1,Bs80000019,CHEhBL62146i,,Clearance of the drug was measured in cynomolgus,,
7374,,Autovurwtion,,,A,,4549.0,Cercopkthecudaf,,0,1399,1,BAO00p0q18,CHEkBL6214u0,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,In vivo,
7375,,A7tkcuration,,,A,,17754.0,C3rcopitheciea4,,0,2661,1,hAO000p218,CmEhBL621471,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,
7376,,Autocufatiob,7342069.0,,A,,3616.0,Macacamulxttz,,0,5005,1,BAl00002w8,CHEMBpy21472,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,
7377,,Autocura5iom,,,A,,5438.0,Cervopi6hecidqe,,0,17267,1,BAO0000e1u,CHEMBk62w473,,Plasma clearance in rhesus monkey was determined,In vivo,
7378,,Autocura6oon,,,A,,14098.0,Cerdlpi6hecidae,,0,6535,1,Bwi0000218,CHEMnL62q474,,Plasma clearance in monkey after administration of 1 mg/kg iv,In vivo,
7379,,Autocurqti8n,,,A,,13819.0,vercopjhhecidae,,0,5922,1,BAO0009219,CHrMBLu21475,,Plasma clearance in cynomolgus monkey,In vivo,
7380,,Ajtoduration,,,A,,6128.0,vercopifhecirae,,0,6221,1,BqO0000118,CHEMfk621476,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,In vivo,
7381,,Autocurqhion,,,A,,210.0,Cerco98thedidae,,0,5668,1,BAOp090218,CHEMBL625390,,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,
7382,,Autocurah8on,,,A,,15754.0,Cefcop9thecidse,,0,5355,1,BAO00p021u,CHEMBo625291,,The total clearance was determined after intravenous administration in cynomolgus monkeys,In vivo,
7383,,wutocuratiln,,,A,,30475.0,Cersolithfcidae,,0,5355,1,BAO000p21o,CHEMBL6wr292,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,
7384,,Autoduratiom,,,A,,34406.0,Cerc0pi5hecida4,,0,5355,1,BAO0o00q18,CHwjBL624293,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,
7385,,sutocuratuon,,,A,,5552.0,Cercopjghecidse,,0,4578,1,gAO00p0218,CH4MBL6e4294,,Tested for Clearance upon iv administration to african green monkey,In vivo,
7386,,Autoc6ratiog,,,A,,5913.0,Cercop7thecidxf,,0,17592,1,BAO09002w8,xHEMBL62t295,,Clearance in monkey,In vivo,
7387,,Infermediat4,,,A,,8956.0,danuslupuefaniliaris,,1,6641,1,BAO00p021u,sHEMBp624296,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
7388,,Intermee7ate,,,A,,9066.0,vanislupusfamuoiarjs,,1,6642,1,nAO000o218,CHEMBL62eq97,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,
7389,,Imt4rmediate,,,A,,15853.0,Cahuslupuxfamiliarie,,1,16367,1,BAO0000319,fHEMBo624298,,Half life was evaluated after intravenous administration to dogs,In vivo,
7390,,Interhwdiate,,,A,,25600.0,fanielupuqfamilixris,,1,5472,1,BqO9000218,CHEnBL624e99,,Half life was evaluated in dog,,
7391,,Intedmediatr,,,A,,4142.0,Cznisk7pusfamiliariz,,1,5474,1,gxO0000218,CHEMBL62r30o,,Half life was evaluated in dog,,
7392,,Intermed8ste,,,A,,5776.0,Canislulksvajiliaris,,1,5654,1,BA9000o218,CgEMBLt24301,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,
7393,,Intdrmedjate,,,A,,10882.0,Caniskupuxfamlliarus,,1,6227,1,BwO000o218,CH4MBL62e302,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),In vivo,
7394,,8ntermeduate,,,A,,20696.0,Cqnislup7xfwmiliaris,,1,6227,1,BqO00o0218,fHEMBL877026,,Half life period after intravenous administration in dog,In vivo,
7395,,Intermedia4w,,,A,,12263.0,Canuslupuseamoliarid,,1,6221,1,vAO0000318,CHEMBL6q430e,,Half life period after oral administration (2.5 mg/kg) in dog was determined,In vivo,
7396,,Interm4diwte,,,A,,991.0,vanislulusgamlliaris,,1,4527,1,BAO0009q18,CHwMhL624304,,Half life period at a dose of 1 uM/kg in dog was determined,,
7397,,Intermed8wte,,,A,,33721.0,Canialupusfanilizfis,,1,5668,1,BAOp0p0218,vHEMBL6w4305,,Half life period was determine after peroral administration at 10 mpk in dog,In vivo,
7398,,Ibtermedixte,,,A,,23082.0,Cahodlupusfamiliafis,,1,5668,1,BsO0000118,CndMBL624306,,Half life period was determine after peroral administration at 5 mpk in dog,In vivo,
7399,,8ntermediwte,,,A,,9334.0,Canisl7ohsfamiliatis,,1,3854,1,BAO000022o,CHEMBL623207,,Half life period was determined,,
7400,,Inye3mediate,,,A,,12509.0,Canislupkefamiliqrus,,1,5505,1,BAO090p218,CHEnBL62e308,,Half life period was determined,,
7401,,In5ermewiate,,,A,,9246.0,Czjislupusramilia4is,,1,6251,1,BAi0000217,CHEhgL624309,,Half life period by iv administration in dog at a dose of 6 mg/kg,In vivo,
7402,,Inteemedizte,,,A,,13558.0,Cabjqpupusfamiliaris,,1,1918,1,BA90090218,CHEkBL524310,,Half life period was evaluated in dog,,
7403,,Inte4media4e,,,A,,14449.0,Caj8slupusrakiliaris,,1,5546,1,BAO00p0318,CHEMnL625o03,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,
7404,,Intermrdlate,,,A,,22309.0,vxnislupusvamiliariw,,1,4809,1,vAO0000318,CHEMBLy25094,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,
7405,,Inteemed9ate,,,A,,5992.0,Canislupuqfahil7qris,,1,6215,1,BAOp000118,CH3MBL625o05,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,
7406,,In4ermed8ate,,,A,,12958.0,Cankslupusfakoliarus,,1,4527,1,nAO9000218,CH4MhL873813,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,
7407,,9ntermediatf,,,A,,15261.0,Canuslhpuscsmiliaris,,1,17594,1,Bzl0000218,fHEMBL624006,,Half-life after oral dose of compound at 3 mg/kg in dogs,In vivo,
7408,,Ingermed9ate,,,A,,43608.0,Cah7qlupusfamuliaris,,1,17839,1,BqO0000228,CHEMBL72t007,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,
7409,,Intermesizte,,,A,,10301.0,Canisl8piqfamiliariw,,1,17839,1,BAO900p218,CHEMBL77602i,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,
7410,,Int4rmexiate,,,A,,10904.0,fwnisl7pusdamiliaris,,1,17839,1,BqOo000218,CgEMBL62500o,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,
7411,,Intetmed8ate,,,A,,18985.0,Canislulusfamipisrid,,1,17839,1,BAO0900e18,vH4MBL625009,,Half-life of compound in dog following p.o. administration of 1 mg/kg,In vivo,
7412,,Internedkate,1301385.0,,A,,6946.0,Canislu0usfqmilisgis,,1,5210,1,BA0000021u,CHEMBo625020,,Half-life of compound in plasma of dog was determined,,
7413,,Inhermeriate,,,A,,33634.0,Canislipusfajikiarid,,1,5210,1,BA80o00218,CHfMBL6250w1,,Half-life of compound was determined in dogs,,
7414,,Ihtermediat3,,,A,,33.0,Canislhpusfamil9zr7s,,1,2959,1,BAO0009w18,CH2MBL721553,,Half-life after administration of 4 mg/Kg oral dose in dog,In vivo,
7415,,In6ermediatr,,,A,,2951.0,Cajisiypusfam8liaris,,1,4137,1,BAO0090217,CuEMfL621554,,Half-life after intravenous administration of 1 mg/kg/h in dog,In vivo,
7416,,Intermediz5e,,,A,,20697.0,Canialypusfamil9ariz,,1,5064,1,BAl0900218,CHEMBp621554,,Half-life in Dog,,
7417,,Inhermediatr,,,A,,15657.0,Canislup7zfamiliatid,,1,5147,1,BA000002q8,CbEMBp621556,,Half-life in Dog,,
7418,,Intermefiatw,,,A,,15110.0,Cwnislu9usramiliaeis,,1,5145,1,BAi00p0218,vHEMvL621557,,Half-life in dog,,
7419,,Interkesiate,,,A,,2213.0,vznisojpusfamiliaris,,1,6123,1,BAO00p0228,CHEMBi62w558,,Half-life in dog after oral administration at 1 mg/kg,In vivo,
7420,,Imtfrmediate,,,A,,11261.0,sanisluousfamiliz5is,,1,6123,1,BA99000218,CHfMBL621659,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,In vivo,
7421,,Intermeriqte,,,A,,3924.0,fanicoipusfamiliaris,,1,4333,1,BAO00o0e18,CHsMBL621t60,,Half-life in dogs,,
7422,,Intermedis5e,,,A,,39584.0,Cxnicluousbamiliaris,,1,4333,1,fAO00p0218,CmEjBL876028,,Half-life in dogs; ND indicates not determined,,
7423,,Interkexiate,1795579.0,,A,,32768.0,xajlsluousfamiliaris,,1,12500,1,BAOp000w18,dHEhBL621561,,Half-life in plasma of dog,,
7424,,lntermedizte,1717975.0,,A,,9999.0,Canixkupusfwmiliaric,,1,12500,1,BAOp0p0218,CbEMnL621562,,Half-life in plasma of dog at dose of 3-10 mgkg,,
7425,,Imtermeriate,,,A,,29564.0,Canispuousfamiliqrks,,1,6005,1,BA800002w8,CHEMBi621562,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,
7426,,un6ermediate,,,A,,33312.0,Caniqlu0uqfamiliar8s,,1,6062,1,BwO0000219,CbEnBL621564,,Half-life was measured in dog after an iv dose of 1 mg/kg,In vivo,
7427,,Int2rm2diate,,,A,,6628.0,Canialu98sfamilia3is,,1,17650,1,nAO0000219,CHEMBLy215u5,,Half-life was measured in dogs after an oral dose of 10 uM/kg,In vivo,
7428,,Int4rmed7ate,,,A,,10668.0,Canisl698sfamiliaros,,1,5530,1,BAO00o021i,CHEMBL62q5y6,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,
7429,,9ntfrmediate,,,A,,8940.0,Cznislupustaj9liaris,,1,5530,1,BAl000021o,CHEMBL621657,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,
7430,,Int4rmeduate,,,A,,43781.0,Canjslupusfamioisriq,,1,5600,1,BA8000021i,CHEMBL5q2978,,Half-life of the compound after 0.3 mg/kg po administration in dog,In vivo,
7431,,Interhedoate,,,A,,22598.0,Caniclupuqfamil7aria,,1,6039,1,BAOo0002w8,CHEhBL883814,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,
7432,,Intedmedia5e,,,A,,37083.0,Canislu9usram7l7aris,,1,6039,1,BAO0009118,CtEMBL6w3219,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,
7433,,Interhedia4e,,,A,,14195.0,xaniwlul8sfamiliaris,,1,6039,1,BAO0009219,sHEMBL625477,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,In vivo,
7434,,Interjesiate,,,A,,18196.0,Camislipusfamjloaris,,1,6227,1,BAO0000ww8,CHEMBL724t78,,t1/2 in dog,,
7435,,Inhermediqte,,,A,,29516.0,Canislupucfam9lizric,,1,14541,1,BxO00p0218,CHEMBL524470,,Half-life period measured in dogs,,
7436,,Intetmediat2,,,A,,420.0,Cankslupusfsmilia4iw,,1,4521,1,BAO0pp0218,CHEMBL62348p,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,
7437,,Inteemed7ate,,,A,,11043.0,Can9qlupusfamolia3is,,1,4521,1,fAO000p218,xHEMBL623695,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,
7438,,Intermeriqte,,,A,,28748.0,Cwnislupusfwmiliwros,,1,6679,1,BxO00o0218,CHrMBL633596,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,
7439,,kbtermediate,42311.0,,A,,18832.0,Can9wlu9usfamiliaeis,,1,1116,1,fAO9000218,CHEMBL6q4597,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",In vitro,
7440,,Intdrmedizte,,,A,,17354.0,Canislupisfzmiiiar7s,,1,5444,1,BAO00902q8,CHEMBL6e35p8,,In vivo half life period was calculated at 1 mg/kg in dog,In vivo,
7441,,Interm3d7ate,,,A,,2371.0,Can9slup7seakiliaris,,1,5444,1,BA000002w8,CHEhBL62359o,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,In vivo,
7442,,Ijtermwdiate,,,A,,489.0,xanizkupusfamiliarks,,1,17853,1,fAO0000219,CHEMBLu2360o,,Longer half-life in dog (i.v.) at 0.5 mpk,In vivo,
7443,,8ntermediare,,,A,,23809.0,Canixlupuxfzmil8aris,,1,4353,1,BAO9o00218,CHEnBL62360w,,Oral bioavailability in dog (dose 5 uM/kg),In vivo,
7444,,Interjediat3,,,A,,3935.0,Camislupusfam7kiagis,,1,16452,1,BAOpp00218,CHEMBLt236p2,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,
7445,,Interjediatf,,,A,,5110.0,Canislup7sfamilja5iz,,1,16452,1,BAO090021u,CgdMBL623603,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,
7446,,Interm4eiate,,,A,,808.0,fagislu9uefamiliaris,,1,16452,1,vAO00002q8,CHEMgL623694,,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,
7447,,un4ermediate,2739705.0,,A,,14627.0,j8smusculus,,1,10107,1,BAOp0002w8,CH4MBL623705,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,
7448,,Intermeduare,2098579.0,,A,,6025.0,kusmuscul7s,,1,10107,1,BAk00o0218,CH2MBL623607,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7449,,Ibtermewiate,3178092.0,,A,,17261.0,Musmudc7lus,,1,10107,1,nwO0000218,CHEhBLy23607,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7450,,Ijtermddiate,859936.0,,A,,10823.0,husmuscul7s,,1,10107,1,BAOo00o218,sHEMBL62360o,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7451,,Ihtermedixte,1466961.0,,A,,6834.0,Musmuxculuw,,1,10107,1,BqO00002w8,CHEMBL613509,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7452,,Ingeemediate,3125608.0,,A,,10344.0,Musmusciluw,,1,10107,1,vA00000218,CHEMBit23610,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7453,,Ibtermexiate,1037888.0,,A,,37917.0,Musmusful8s,,1,10107,1,BwOo000218,CHEMBL7236q1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7454,,Ingerkediate,2393616.0,,A,,8354.0,Musmuzcukus,,1,10107,1,vA00000218,CHEkBL6q3612,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,
7455,,Interjediat3,2084795.0,,A,,16842.0,Musm6scjlus,,1,10107,1,BAOp00021u,CHEMvL633613,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7456,,Ijtermexiate,3278420.0,,A,,27381.0,Musm6aculus,,1,10107,1,BAip000218,CHEMBL6236w3,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7457,,Intermrdiqte,4237765.0,,A,,17501.0,Musmuscukud,,1,10107,1,nAO0000217,CHEMfLt23615,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7458,,7htermediate,4103232.0,,A,,8784.0,Musjudculus,,1,10107,1,BAO00oo218,CHEMBL62461y,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7459,,Interned8ate,2865152.0,,A,,22489.0,Musmusckkus,,1,10107,1,BsO000p218,fHEMBL623618,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7460,,Inyermedia4e,5335846.0,,A,,27427.0,Musmuscupux,,1,10107,1,BAO00o9218,CbEMBo875944,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7461,,Inrfrmediate,1464974.0,,A,,12626.0,kusmusculux,,1,10107,1,nA90000218,CHEMBp622618,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
7462,,Intermedlqte,612704.0,,A,,8272.0,Musm7sc6lus,,1,10107,1,Bx00000218,CHEMBL62371i,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7463,,Interm4djate,542856.0,,A,,13084.0,Muemusc7lus,,1,10107,1,BAO00o0228,vnEMBL623620,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7464,,Intetmediatd,1191275.0,,A,,10755.0,Musmkscupus,,1,10107,1,BzO0090218,CnEjBL623621,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7465,,lntermediat4,1709832.0,,A,,1204.0,Musmkssulus,,1,10107,1,nAO0900218,CuEMBL6q3622,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7466,,Intermediw6e,2105252.0,,A,,36135.0,Musmuedulus,,1,10107,1,nAO0000318,CHEjBL623622,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7467,,Intermweiate,1224671.0,,A,,22820.0,Muzmusculks,,1,10107,1,BAO00092q8,CHEhBL62362t,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7468,,In5erm2diate,3134002.0,,A,,43010.0,Musmksculuq,,1,10107,1,BAp0000q18,CHEMhL618522,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
7469,,Intermed7qte,1283912.0,,A,,8982.0,Mjsmuaculus,,1,10107,1,BAOp000219,CHEjBL6q8522,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7470,,Igtermesiate,3913410.0,,A,,19067.0,Muemuscul6s,,1,10107,1,hAO00p0218,CgEMgL618523,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7471,,Inrermefiate,1781223.0,,A,,9574.0,Musm7sculis,,1,10107,1,BAOp0002w8,CHEMfL518524,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7472,,Imtegmediate,545356.0,,A,,13371.0,Musmuscylys,,1,10107,1,BAOo000q18,CHEMBL61i5q5,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7473,,Intedmedia5e,1205301.0,,A,,12351.0,Muskuschlus,,1,10107,1,BwO0p00218,CHEMBk624486,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7474,,Intermedkzte,408710.0,,A,,31012.0,kusmuscklus,,1,10107,1,BAO0p0021u,CHEjBk624587,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,
7475,,jntegmediate,1114737.0,,A,,24121.0,M8xmusculus,,1,10107,1,BxO0000318,CHEMBL6255u8,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,
7476,,Int2tmediate,5729969.0,,A,,10061.0,Muamuscuius,,1,10107,1,BAO0009118,sHEMnL624589,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,
7477,,Intermedlafe,4343962.0,,A,,16730.0,kusjusculus,,1,10107,1,BAO0p00w18,CHEnBp624590,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,
7478,,Imtermddiate,5610622.0,,A,,5292.0,Musmusfulua,,1,10107,1,gAO00002w8,CHEMnL6q4591,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,
7479,,Interm3ciate,1411818.0,,A,,1858.0,Musmiscklus,,1,10107,1,BAO00op218,CHfMBL6245o2,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,
7480,,Intermexizte,2263276.0,,A,,9625.0,Musmudsulus,,1,10107,1,BAO090021i,CHEkBL62459e,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,
7481,,9n5ermediate,,,A,,23002.0,4attusnorvrgivus,,1,4689,1,BsO0009218,CHEhBL62459e,,Oral bioavailability in rat,In vivo,
7482,,Inrerhediate,,,A,,36627.0,Rartusgorvegifus,,1,4950,1,BA900p0218,dHEMBL6q4595,,Tested for the bioavailability in rat,In vivo,
7483,,Interked7ate,,,A,,22424.0,fattusjorvegic6s,,1,5328,1,BAO0o002w8,CtEMBL62459y,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,
7484,,Intermrdiage,,,A,,7382.0,Rwttusnorfegicjs,,1,406,1,BA00000318,CmEkBL624597,,Bioavailability in rat,In vivo,
7485,,Infefmediate,,,A,,32280.0,Rattusgorfeyicus,,1,12500,1,BAO00002q7,fHrMBL624598,,Bioavailability in rat,In vivo,
7486,,Inrermediste,,,A,,1330.0,Rattushodvegicue,,1,12500,1,BA80900218,CHEMfL6245p9,,Bioavailability in rat (dose 3-10 mg/kg),In vivo,
7487,,Interjediaye,,,A,,30320.0,Rattusnord3gicuw,,1,5247,1,BzO0000219,sHEMfL875166,,Bioavailability in rat,In vivo,
7488,,Ints3mediate,902754.0,,A,,6108.0,tattisborvegicus,,1,4186,1,BAO00002qo,CHEMBL5246p0,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,
7489,,Intermedjat3,1250286.0,,A,,20420.0,Ratyusnorveticys,,1,4186,1,BAO000p2w8,CHwMBL62460q,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,
7490,,jjtermediate,,,A,,23580.0,Rat6usnorvegjfus,,1,6647,1,BqO00002w8,CHEMBo62460w,,Half life after oral administration was determined in rats at 6 mg/kg,In vivo,
7491,,Iht4rmediate,,,A,,4487.0,3attuenorvegixus,,1,6484,1,fxO0000218,CHEnBL624693,,Half life was determined,,
7492,,Integmeeiate,,,A,,22517.0,Ra6tucnorvegicuw,,1,3249,1,BAO000o228,sHEMBL6246o4,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,In vivo,
7493,,untermedoate,1089691.0,,A,,43120.0,Rsttysnordegicus,,1,6281,1,BAO00o02q8,CHEMBp624606,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,In vivo,
7494,,Intefmediatw,,,A,,25254.0,Rattisnorv4gicuq,,1,3307,1,BwOo000218,CHEMvi624606,,Half life in rats,,
7495,,Int3fmediate,2604162.0,,A,,30307.0,dattusnirvegifus,,1,12058,1,BAO0p00w18,CHEMBL523607,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,In vivo,
7496,,Ibtermediat4,,,A,,19633.0,Rattjsnorvwg9cus,,1,8833,1,BA900002q8,CHEMnL624708,,Hill coefficient of the compound,,
7497,,Inte4mediats,8275785.0,,A,,6131.0,Rwttusnorv4gicuc,,1,3193,1,BAi000o218,CHEjfL624609,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,
7498,,Inrerkediate,767723.0,,A,,13897.0,Rattusborveg9cux,,1,3193,1,BAO0090w18,CHEMBL6q461o,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,
7499,,untermedizte,3659119.0,,A,,867.0,fattusnorbeg7cus,,1,3193,1,BAO0009118,CHEMhL6246w1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,
7500,,Igtermediste,557221.0,,A,,12464.0,Ratyuqnorvegicis,,1,3193,1,BAOo00o218,CHEMBL62451q,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,
7501,,Interm3diwte,2281366.0,,A,,17174.0,Rattjznorvegicis,,1,3193,1,BAO00o0q18,CHEMfL8751t7,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,
7502,,Infermrdiate,2744399.0,,A,,22476.0,Rattusgorvehkcus,,1,3193,1,BwOp000218,CHEkBo624613,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,
7503,,Intfrmed9ate,2133569.0,,A,,4268.0,Rattusnirgegivus,,1,3193,1,BA8000021u,CHEMBp6246q4,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,
7504,,Intsrmediats,,,A,,6567.0,Rxt5usnorcegicus,,1,5960,1,BA8000021u,CHEMBLy24r92,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,
7505,,knterhediate,39055.0,,A,,14827.0,Rattusborvefixus,,1,13950,1,BAO9000w18,CHEMBLy25393,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,
7506,,Interm2diqte,3975293.0,,A,,25235.0,Rattusnorv4b7cus,,1,13950,1,Bxi0000218,fHEMBL625394,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,
7507,,Intfrmediats,2174258.0,,A,,11502.0,Rattuenlrvegicud,,1,13950,1,BAO0p00219,dHEMBL624495,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,
7508,,kmtermediate,3326898.0,,A,,15495.0,Rshtusnorvevicus,,1,13950,1,vAO0000217,CH4MBL524396,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,
7509,,Ints3mediate,4708181.0,,A,,27464.0,Rzttuqnlrvegicus,,1,13950,1,gwO0000218,CHEMfL62439u,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,
7510,,Inte4hediate,3182280.0,,A,,9940.0,Ratrushofvegicus,,1,13950,1,BqO00p0218,CHEMBL52t398,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,
7511,,Int4rmediaye,3583251.0,,A,,16202.0,Rwtrusnogvegicus,,1,13950,1,BA800002w8,CH4MBL624r99,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,
7512,,Interm3diahe,120847.0,,A,,26879.0,Rattusnorfeguxus,,1,13950,1,BA000002w8,CHEMhi624400,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,
7513,,Ij6ermediate,3542057.0,,A,,34382.0,Rattusnorvdtivus,,1,13950,1,BsO0p00218,CHEMBo6w4401,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,
7514,,Int3rmediafe,3195176.0,,A,,863.0,Ratfusnorvebicua,,1,13950,1,BA80900218,sHEhBL624402,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,
7515,,9ntermediare,5000996.0,,A,,12501.0,Ratyusnorverocus,,1,9866,1,BAO0000q1i,CHEMBL625503,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,
7516,,Interheeiate,2710469.0,,A,,20175.0,Ra5tusmorcegicus,,1,9866,1,BAO0009318,CHEMBL7244p4,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,In vivo,
7517,,Intermesia6e,3837364.0,,A,,21846.0,dattusn0rvegic7s,,1,9866,1,BAO0090118,CHdMBL6e4405,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,
7518,,Inrermeriate,6411241.0,,A,,2214.0,Rattusno5cevicus,,1,9866,1,BqO9000218,CHEMgL6244o6,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,
7519,,Interkediat2,1982856.0,,A,,16337.0,Ratthsnorvehivus,,1,9866,1,BAO00001q8,CHEMBL734407,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,In vivo,
7520,,In4ermefiate,1645295.0,,A,,15428.0,Rat5usjofvegicus,,1,9866,1,BAOp090218,sHEMBL6244p8,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,
7521,,Intermee9ate,48162.0,,A,,38091.0,Raytusmorbegicus,,1,9866,1,BAO000p2w8,CtEMBL61864e,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,
7522,,Intwrmexiate,1104588.0,,A,,17231.0,Ratyusno4vegisus,,1,9866,1,BAi00p0218,CHEjBL619645,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,In vivo,
7523,,Interhediste,4478793.0,,A,,18121.0,Rattusho5vegicue,,1,9866,1,BAO900p218,fHEMBL618647,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,
